FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Suzuki, M
   Shigematsu, H
   Iizasa, T
   Hiroshima, K
   Nakatani, Y
   Minna, JD
   Gazdar, AF
   Fujisawa, T
AF Suzuki, M
   Shigematsu, H
   Iizasa, T
   Hiroshima, K
   Nakatani, Y
   Minna, JD
   Gazdar, AF
   Fujisawa, T
TI Exclusive mutation in epidermal growth factor receptor gene, HER-2, and
   KRAS, and synchronous methylation of nonsmall cell lung cancer
SO CANCER
LA English
DT Article
DE epidermal growth factor receptor gene; mutation; methylation; methylator
   phenotype; lung cancer
ID ABERRANT METHYLATION; PROMOTER METHYLATION; ERBB RECEPTORS;
   BREAST-CANCER; PHENOTYPE; THERAPY; EXPRESSION; GEFITINIB; PROFILE; SPARC
AB BACKGROUND. Both genetic and epigenetic changes in nonsmall cell lung cancer (NSCLC) are known to be a common event.
   METHODS. Mutations in the epidermal growth factor receptor gene (EGFR), HER-2, and KRAS and the methylation profile of 9 genes for NSCLC were analyzed and correlated with clinical and histologic data.
   RESULTS. Thirty-nine EGFR, 4 HER-2, and 6 KRAS mutations were found in 150 NSCLC cases, with the methylation percentages of the genes ranging from 13% to 54%. Most mutations were present in adenocarcinomas, but mutations of the 3 genes were never found to be present in individual tumors. The frequency of methylation for all the genes was correlated with the Methylation Index, a reflection of the overall methylation pattern (all genes, P <=.01), Supporting the presence of the CpG island methylator phenotype (CIMP) in NSCLC. On the basis of the methylation profile, CRBP1 and CDH13 methylation were good indicators of CIMP in NSCLC, and were correlated with a poorer prognosis in adenocarcinomas. Mutations in EGFR, HER-2, and KRAS were found to be present exclusively, whereas methylation tended to be present synchronously. A comparison of mutation and methylation demonstrated that the EGFR mutation had an inverse correlation with methylation of SPARC (secreted protein acidic and rich in cysteine), an extracellular Ca2+-binding matricellular glycoprotein associated with the regulation of cell adhesion and growth, and the p16(INK4A) gene.
   CONCLUSIONS. The findings of the Current study suggest that adenocarcinoma cases with CIMP have a poorer prognosis than adenocarcinoma cases without CIMP, and the EGFR mutation was shown to have an inverse correlation with methylation of SPARC and the p16(INK4A) gene in NSCLC.
C1 Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chuo Ku, Chiba 2608670, Japan.
   Chiba Univ, Grad Sch Med, Dept Basic & Diagnost Pathol, Chiba 2608670, Japan.
   Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA.
C3 Chiba University; Chiba University; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas Dallas
RP Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.
EM smakoto@faculty.chiba-u.jp
RI Gazdar, Adi/F-7496-2010; Minna, John/AAB-1036-2022
CR Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
   An CH, 2005, CLIN CANCER RES, V11, P656
   Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939
   Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564
   Esteller M, 2001, CANCER RES, V61, P3225
   Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091
   Gatzemeier U, 2004, ANN ONCOL, V15, P19, DOI 10.1093/annonc/mdh031
   GAZDAR AF, 1994, ANTICANCER RES, V14, P261
   Gazdar AF, 2004, CHEST, V125, p97S, DOI 10.1378/chest.125.5_suppl.97S-a
   Gomyo Y, 2004, ONCOGENE, V23, P6779, DOI 10.1038/sj.onc.1207381
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909
   Langer CJ, 2004, J CLIN ONCOL, V22, P1180, DOI 10.1200/JCO.2004.04.105
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Minna JD, 2004, SCIENCE, V304, P1458, DOI 10.1126/science.1099578
   Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308
   Roman-Gomez J, 2005, J CLIN ONCOL, V23, P7043, DOI 10.1200/JCO.2005.01.4944
   Sekido Y., 1998, Biochimica et Biophysica Acta, V1378, P21
   Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755
   Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235
   Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055
   Sivridis E, 2004, INT J SURG PATHOL, V12, P1, DOI 10.1177/106689690401200101
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b
   Suzuki M, 2005, BRIT J CANCER, V92, P942, DOI 10.1038/sj.bjc.6602376
   Suzuki M, 2005, LUNG CANCER, V47, P309, DOI 10.1016/j.lungcan.2004.08.006
   Suzuki M, 2005, ONCOGENE, V24, P1302, DOI 10.1038/sj.onc.1208263
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Suzuki M, 2003, CLIN CANCER RES, V9, P5636
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2004, INT J CANCER, V110, P462, DOI 10.1002/ijc.20125
   Toyooka S, 2004, BRIT J CANCER, V91, P771, DOI 10.1038/sj.bjc.6602013
   Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P5438
   Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736
   Ueki T, 2000, CANCER RES, V60, P1835
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Wakeling AE, 2002, CANCER RES, V62, P5749
NR 42
TC 107
Z9 115
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2006
VL 106
IS 10
BP 2200
EP 2207
DI 10.1002/cncr.21853
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 039CR
UT WOS:000237278300015
PM 16598760
DA 2025-01-12
ER

PT J
AU Sato, H
   Nakamura, Y
   Motokura, T
AF Sato, Hiroyuki
   Nakamura, Yukari
   Motokura, Toru
TI Differential 14-3-3σ DNA methylation and expression in c-<i>myc</i>- and
   activated H-<i>ras</i>-transformed cells under <i>r</i>- and
   <i>K</i>-selection
SO CANCER LETTERS
LA English
DT Article
DE DNA methylation; 14-3-3; natural selection; multistep tumorigenesis;
   stratifin
ID 5' CPG ISLAND; PANCREATIC ADENOCARCINOMA; CANCER EPIGENETICS;
   BREAST-CANCER; HYPERMETHYLATION; INACTIVATION; GENE; PROGRESSION;
   APOPTOSIS; PATHWAY
AB We cloned rat 14-3-3 sigma, a mediator of p53 tumor suppressor, as a target of K-selection. 14-3-3 sigma expression is suppressed with DNA methylation in breast cancers while its overexpression with hypomethylation is frequent in pancreatic cancers. These opposite findings were recapitulated through r- and K-selection of transformed rat embryo fibroblasts. 14-3-3 sigma expression was suppressed with DNA methylation after r-selection and the gene was overexpressed and demethylated in K-selected cells. 5-aza-2'-deoxycytidine recovered 14-3-3 sigma expression in r-selected cells. The presence of heterogeneous methylation patterns and expression levels before selection suggests that different 14-3-3 sigma expression levels play a role as a prerequisite for selection and clonal evolution. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Tokyo, Dept Hematol & Oncol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Motokura, T (通讯作者)，Univ Tokyo, Dept Hematol & Oncol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM motokura-tky@umin.ac.jp
RI Motokura, Toru/X-3682-2019
CR Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Chikatsu N, 2002, ONCOGENE, V21, P3043, DOI 10.1038/sj.onc.1205413
   Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Guweidhi A, 2004, CARCINOGENESIS, V25, P1575, DOI 10.1093/carcin/bgh159
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9
   Ide M, 2004, CANCER LETT, V207, P241, DOI 10.1016/j.canlet.2003.11.009
   Jones PA, 1996, CANCER RES, V56, P2463
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751
   Kitamura T, 2000, METH MOL B, V134, P143
   LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854
   Logsdon CD, 2003, CANCER RES, V63, P2649
   MAC ARTHUR ROBERT H., 1967
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206
   Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754
   Onishi M, 1996, EXP HEMATOL, V24, P324
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1
   RANNIGER K, 1966, RADIOLOGY, V86, P470, DOI 10.1148/86.3.470
   Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200
   Suzuki H, 2000, CANCER RES, V60, P4353
   Uchimaru K, 1997, BLOOD, V89, P965, DOI 10.1182/blood.V89.3.965
   Uchimaru K, 1998, LEUKEMIA RES, V22, P413, DOI 10.1016/S0145-2126(98)00004-6
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826
   Ushijima T, 2003, GENOME RES, V13, P868, DOI 10.1101/gr.969603
   Zhang Y, 2004, J BIOL CHEM, V279, P34353, DOI 10.1074/jbc.M401300200
NR 37
TC 1
Z9 2
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 8
PY 2006
VL 236
IS 1
BP 105
EP 114
DI 10.1016/j.canlet.2005.05.004
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 044NP
UT WOS:000237679600014
PM 15979784
DA 2025-01-12
ER

PT J
AU Tokunaga, E
   Oki, E
   Nishida, K
   Koga, T
   Yoshida, R
   Ikeda, K
   Kojima, A
   Egashira, A
   Morita, M
   Kakeji, Y
   Maehara, Y
AF Tokunaga, Eriko
   Oki, Eiji
   Nishida, Kojiro
   Koga, Tadashi
   Yoshida, Rintaro
   Ikeda, Keisuke
   Kojima, Aya
   Egashira, Akinori
   Morita, Masaru
   Kakeji, Yoshihiro
   Maehara, Yoshihiko
TI Aberrant hypermethylation of the promoter region of the <i>CHFR</i> gene
   is rare in primary breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE aberrant hypermethylation; breast cancer; CFHR; methylation-specific
   PCR; taxane
ID MITOTIC STRESS CHECKPOINT; TAXOL-INDUCED APOPTOSIS; EPIGENETIC
   INACTIVATION; MICROSATELLITE INSTABILITY; CPG ISLAND; PACLITAXEL;
   SENSITIVITY; MUTATIONS
AB Taxanes are among the most active agents and they are now known to be an indispensable component in chemotherapy for breast cancer. However, some patients are resistant to taxanes and the identification of the molecular characteristics that can predict the sensitivity to taxanes would be useful in selecting the most appropriate patients to receive taxane therapy. Taxanes are antimicrotubular agents that promote microtubular assembly and stabilize microtubules by preventing depolymerization. They interfere with normal mitotic transition and causes cell cycle arrest in the G2-M metaphase. CHFR (checkpoint with forkhead-associated and ring finger) is a recently identified gene, which functions as an important checkpoint protein early in G2-M transition. Its activation delays the cell cycle in prophase and promotes cell survival in response to the mitotic stress induced by either nocodazole or taxane. CHFR is frequently downregulated in human cancers, mostly owing to the hypermethylation of its promoter region. CHFR downregulation has been found in primary cancers or in the established tumor cells of various origins, such as the lung, colon, esophagus, and stomach. The aberrant hypermethylation of CHFR promoter appears to be a good molecular marker to predict sensitivity to taxanes in gastric, lung, and colon cancer. A downregulation of CHFR was observed in breast cancer cells, however, no apparent promoter hypermethylation has yet been reported. In addition, an alteration of the CHFR expression or aberrant promoter hypermethylation in primary breast cancer has not been fully investigated. In this study, we examined the methylation status of the promoter region of CHFR gene in 110 primary breast cancers. We observed the hypermethylation of the CHFR promoter region in only one case (0.9%). We herein show that the aberrant hypermethylation of this region is quite a rare event in primary breast carcinoma.
C1 Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan.
C3 Kyushu University
RP Tokunaga, E (通讯作者)，Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM eriko@surg2.med.kyuhsu-u.ac.jp
RI Oki, Eiji/AFO-6423-2022; Maehara, Yoshihiko/A-4867-2010; Kojima,
   Aya/B-4100-2012
CR Bertholon J, 2003, ONCOGENE, V22, P8956, DOI 10.1038/sj.onc.1207078
   Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058
   Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831
   Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688
   Cheung HW, 2005, MOL CARCINOGEN, V43, P237, DOI 10.1002/mc.20106
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Crown J, 2004, ONCOLOGIST, V9, P24, DOI 10.1634/theoncologist.9-suppl_2-24
   DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041
   Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161
   GELMON K, 1994, LANCET, V344, P1267, DOI 10.1016/S0140-6736(94)90754-4
   Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118
   Honda T, 2004, BRIT J CANCER, V90, P2013, DOI 10.1038/sj.bjc.6601849
   Huang Y, 1997, LEUKEMIA, V11, P253, DOI 10.1038/sj.leu.2400557
   *JAP BREAST CANC S, 2001, GEN RUL CLIN PATH RE
   Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1
   Kang HC, 2004, ONCOL REP, V12, P129
   Mariatos G, 2003, CANCER RES, V63, P7185
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   Nowak AK, 2004, LANCET ONCOL, V5, P372, DOI 10.1016/S1470-2045(04)01494-9
   Satoh A, 2003, CANCER RES, V63, P8606
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695
   Shichiri M, 2002, CANCER RES, V62, P13
   Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013
   Takahashi T, 2004, CLIN CANCER RES, V10, P6126, DOI 10.1158/1078-0432.CCR-04-0579
   TANG C, 1994, LEUKEMIA, V8, P1960
   Tokunaga E, 2000, ONCOLOGY-BASEL, V59, P44, DOI 10.1159/000012136
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4
NR 29
TC 14
Z9 18
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2006
VL 97
IS 2
BP 199
EP 203
DI 10.1007/s10549-005-9112-9
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 051VU
UT WOS:000238190600012
PM 16502017
DA 2025-01-12
ER

PT J
AU Zhao, W
   Liu, HY
   Liu, W
   Wu, YW
   Chen, W
   Jiang, B
   Zhou, Y
   Xue, R
   Luo, C
   Wang, L
   Jiang, JD
   Liu, JW
AF Zhao, W
   Liu, HY
   Liu, W
   Wu, YW
   Chen, W
   Jiang, B
   Zhou, Y
   Xue, R
   Luo, C
   Wang, L
   Jiang, JD
   Liu, JW
TI Abnormal activation of the synuclein-gamma gene in hepatocellular
   carcinomas by epigenetic alteration
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE synuclein-gamma; DNA methylation; liver cancer; liver cirrhosis;
   metastasis
ID BREAST-CANCER CELLS; EXPRESSION PROFILES; ABERRANT EXPRESSION; CPG
   ISLAND; PROMOTES; HYPERMETHYLATION; IDENTIFICATION; STIMULATION;
   METHYLATION; METASTASIS
AB Liver cancer is the fifth most common neoplastic disease and the fourth leading cause of cancer-related death. Identification of the key molecular tat-gets involved in hepatocarcinogenesis has significant therapeutic implications. In this study, by conducting immunohistochemistry, we show that the neuronal protein, synuclein-gamma (SNCG), is abnormally expressed in a high percentage of liver cancer (46/70, 65.7%). The expression of SNCG in liver cancer exhibits a clear stage-specific pattern of low expression in stage I (1/19, 5.3%) and high expression in stages III to IV (44/50, 88%). Importantly, all patients with metastatic diseases expressed SNCG in their primary tumors (15/15, 100%). Consistent with the IHC results, RT-PCR assays demonstrate that SNCG mRNA is highly expressed in the tumor tissue of advanced hepatocellular carcinomas. Analyses of the methylation status of the CpG island of the SNCG gene by methylation-specific PCR confirmed that all tumor samples contained the demethylated gene. To determine whether demethylation of SNCG is an early event of genetic abnormality in the process of hepatocarcinogenesis, we examined the methylation status of SNCG in 70 non-malignant cirrhotic liver samples and showed that 64.3% cirrhotic liver samples contained the partially or completely demethylated gene. We further show that SNCG expression in liver cancer is not restricted to HBV- and HCV-infected tumors, implying the involvement of other hepatocarcinogenic risk factors in SNCG gene reactivation. Utilizing human hepatoma-derived cell line HepG2 as an in vitro model, we demonstrate that hepatic carcinogens aflatoxin B1 and N-nitrosodirnethylamine (DMN) are strong inducers of SNCG expression. Collectively, these new findings suggest that SNCG protein expression in primary tumors is a strong indicator of distant metastasis and demethylation of SNCG CpG island is an early sign of genetic abnormality in liver cirrhosis preceding hepatocarcinogenesis. Our studies also suggest that inducing demethylation of SNCG by hepatocarcinogens may represent one underlying mechanism for the aberrant expression of SNCG in HCC.
C1 VA Palo Alto Hlth Care Syst, Dept Vet Affairs, Palo Alto, CA 94304 USA.
   Second Hosp Nanjing City, Nanjing, Peoples R China.
   First Hosp Nanjing City, Nanjing, Peoples R China.
   Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100037, Peoples R China.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Palo Alto Health Care System; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Institute of Medicinal Biotechnology -
   CAMS
RP VA Palo Alto Hlth Care Syst, Dept Vet Affairs, 3801 Miranda Ave, Palo Alto, CA 94304 USA.
EM jingwen.liu@med.va.gov
RI Liu, Jingwen/J-5058-2019; wu, yiwen/KLY-8477-2024
OI chang, Jie/0000-0003-1788-0334
CR Borlak J, 2005, ONCOGENE, V24, P1809, DOI 10.1038/sj.onc.1208196
   Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9
   Esteller M, 2000, CANCER RES, V60, P4366
   Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R
   Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880
   Gupta A, 2003, CANCER RES, V63, P664
   Harris AJ, 2004, MUTAT RES-FUND MOL M, V549, P79, DOI 10.1016/j.mrfmmm.2003.11.014
   Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0
   Ito Y, 2001, BRIT J CANCER, V84, P1377, DOI 10.1054/bjoc.2000.1580
   Ji HJ, 1997, CANCER RES, V57, P759
   Jia TL, 1999, CANCER RES, V59, P742
   Jiang YF, 2003, CANCER RES, V63, P3899
   Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650
   Kazachkov Y, 1996, CARCINOGENESIS, V17, P2207, DOI 10.1093/carcin/17.10.2207
   Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792
   Liew CT, 1999, INT J CANCER, V81, P319, DOI 10.1002/(SICI)1097-0215(19990505)81:3<319::AID-IJC1>3.0.CO;2-K
   Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089
   Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012
   Lu AP, 2002, J BIOL CHEM, V277, P31364, DOI 10.1074/jbc.M201060200
   Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668
   Masumoto A, 1999, HEPATOLOGY, V29, P68, DOI 10.1002/hep.510290146
   McKillop IH, 1997, HEPATOLOGY, V26, P1484
   Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417
   Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200
   Park WS, 2005, EXP MOL MED, V37, P276, DOI 10.1038/emm.2005.37
   Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P
   Qin BM, 2005, CELL RES, V15, P212, DOI 10.1038/sj.cr.7290289
   Sharma RA, 2004, CLIN CANCER RES, V10, P4901, DOI 10.1158/1078-0432.CCR-04-0098
   Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196
   Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944
   Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920
   Yamamoto H, 1997, INT J CANCER, V74, P251, DOI 10.1002/(SICI)1097-0215(19970620)74:3<251::AID-IJC3>3.3.CO;2-K
   Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107
   Yu J, 2003, CELL RES, V13, P319, DOI 10.1038/sj.cr.7290177
NR 34
TC 44
Z9 55
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2006
VL 28
IS 5
BP 1081
EP 1088
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 034FM
UT WOS:000236914400006
PM 16596223
DA 2025-01-12
ER

PT J
AU Bellosillo, B
   Tusquets, I
AF Bellosillo, Beatriz
   Tusquets, Ignacio
TI Pitfalls and caveats in BRCA sequencing
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE BRCA1; BRCA2; breast cancer; familial cancer; hereditary cancer;
   molecular pathology
ID BREAST-CANCER FAMILIES; MISSENSE MUTATIONS; INCREASED RISK; EARLY-ONSET;
   TRANSCRIPTIONAL ACTIVATION; GENOMIC REARRANGEMENTS; CHEK2 GENE; OVARIAN;
   SUSCEPTIBILITY; PENETRANCE
AB Between 5 and 10% of breast cancer cases are considered to result from hereditary predisposition. Germ-line mutations in BRCA1 and BRCA2 are responsible for an inherited predisposition of breast and ovarian cancer. Direct nucleotide sequencing is considered the gold standard technique for mutation detection for genes such as BRCA1 and BRCA2. In many laboratories that analyze BRCA1 and BRCA2, previous to direct sequencing, screening techniques to identify sequence variants in the PCR amplicons are performed. The mutations detected in these genes may be frameshift mutations ( insertions or deletions), nonsense mutations, or missense mutations. The clinical interpretation of the mutation as the cause of the disease may be difficult to establish in the case of missense mutations. Only in 30-70% of the families in which a hereditary component is suspected, a mutation in BRCA1 and/or BRCA2 is detected. Negative results may be due to: wrong selection of the proband; mutations in the regulatory portion of the genes; gene silencing due to epigenetic phenomena; or large genomic rearrangements that produce deletions of whole exons. Another possibility that explains the lack of detection of alterations in BRCA1 or BRCA2 is the presence of mutations in undiscovered genes or in genes that interact with BRCA1 and/or BRCA2, which may be low-penetrance genes, like CHEK2.
C1 Univ Pompeu Fabra, Hosp del Mar, Lab Cytogenet & Mol Biol,IMAS, Dept Pathol,Serv Patol,Unitat Consell Genet, Barcelona 08003, Spain.
   Hosp del Mar, IMAS, Unitat Consell Genet, Serv Oncol, Barcelona, Spain.
C3 Hospital del Mar Research Institute; Hospital del Mar; Pompeu Fabra
   University; Hospital del Mar Research Institute; Hospital del Mar
RP Bellosillo, B (通讯作者)，Univ Pompeu Fabra, Hosp del Mar, Lab Cytogenet & Mol Biol,IMAS, Dept Pathol,Serv Patol,Unitat Consell Genet, Passeig Maritim,25-29, Barcelona 08003, Spain.
EM bbellosillo@imas.imim.es
CR Begg CB, 2002, J NATL CANCER I, V94, P1221
   Bellosillo B, 2005, CANCER GENET CYTOGEN, V161, P93, DOI 10.1016/j.cancergencyto.2005.01.016
   Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004
   BODIAN CA, 1993, CANCER, V71, P3896, DOI 10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I
   Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
   Casilli F, 2002, HUM MUTAT, V20, P218, DOI 10.1002/humu.10108
   Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0
   Chen JJ, 1999, CANCER RES, V59, p1752S
   Chen YM, 1996, CANCER RES, V56, P3168
   Coleman MP., 1993, TRENDS CANC INCIDENC
   Domchek SM, 2003, J CLIN ONCOL, V21, P593, DOI 10.1200/JCO.2003.07.007
   Dufault MR, 2004, INT J CANCER, V110, P320, DOI 10.1002/ijc.20073
   Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843
   Easton DF, 1997, AM J HUM GENET, V61, P120, DOI 10.1086/513891
   Edwards SM, 2003, AM J HUM GENET, V72, P1, DOI 10.1086/345310
   Eng C, 2001, J MED GENET, V38, P824, DOI 10.1136/jmg.38.12.824
   Evans DGR, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.9.e107
   FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Gad S, 2002, ONCOGENE, V21, P6841, DOI 10.1038/sj.onc.1205685
   Gad S, 2001, J MED GENET, V38, P388, DOI 10.1136/jmg.38.6.388
   GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404
   Hakansson S, 1997, AM J HUM GENET, V60, P1068
   Hofmann Wera, 2003, Hum Mutat, V22, P103, DOI 10.1002/humu.9154
   Hogervorst FBL, 2003, CANCER RES, V63, P1449
   Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X
   KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112
   Lahti-Domenici J, 2001, CANCER GENET CYTOGEN, V129, P120, DOI 10.1016/S0165-4608(01)00437-X
   Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mirkovic N, 2004, CANCER RES, V64, P3790, DOI 10.1158/0008-5472.CAN-03-3009
   Montagna M, 2003, HUM MOL GENET, V12, P1055, DOI 10.1093/hmg/ddg120
   Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595
   Nagy R, 2004, ONCOGENE, V23, P6445, DOI 10.1038/sj.onc.1207714
   Nathanson KL, 2001, HUM MOL GENET, V10, P715, DOI 10.1093/hmg/10.7.715
   Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114
   Nordling M, 1998, CANCER RES, V58, P1372
   Offit Kenneth, 2003, BMC Med Genet, V4, P1, DOI 10.1186/1471-2350-4-1
   Osorio A, 2004, INT J CANCER, V108, P54, DOI 10.1002/ijc.11414
   PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   Puget N, 1999, CANCER RES, V59, P455
   Rajkumar Thangarajan, 2003, Asian Pac J Cancer Prev, V4, P203
   Schubert EK, 1997, AM J HUM GENET, V60, P1031
   Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4
   Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605
   Serova OM, 1997, AM J HUM GENET, V60, P486
   ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242
   SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101
   SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602
   Tancredi M, 2004, EUR J HUM GENET, V12, P775, DOI 10.1038/sj.ejhg.5201223
   Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333
   Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358
   Thull DL, 2004, ONCOLOGIST, V9, P13, DOI 10.1634/theoncologist.9-1-13
   Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179
   Unger MA, 2000, AM J HUM GENET, V67, P841, DOI 10.1086/303076
   Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943
   Vallon-Christersson J, 2001, HUM MOL GENET, V10, P353, DOI 10.1093/hmg/10.4.353
   Wang JP, 2004, J NATL CANCER I, V96, P616, DOI 10.1093/jnci/djhs105
   Wang T, 2001, GENE CHROMOSOME CANC, V31, P91, DOI 10.1002/gcc.1110
   Weber BL, 2000, EUR J CANCER, V36, P1193, DOI 10.1016/S0959-8049(00)00082-4
NR 64
TC 11
Z9 16
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 1521-0758
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD MAY-JUN
PY 2006
VL 30
IS 3
BP 229
EP 235
DI 10.1080/01913120500521281
PG 7
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy; Pathology
GA 061TJ
UT WOS:000238895200012
PM 16825125
DA 2025-01-12
ER

PT J
AU Rasooly, A
   Jacobson, J
AF Rasooly, A
   Jacobson, J
TI Development of biosensors for cancer clinical testing
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE cancer diagnostics; biosensors; point of care testing; molecular
   signatures; ligands
ID PARAFFIN-EMBEDDED TISSUES; IMMUNOMAGNETIC CELL ENRICHMENT;
   POLYMERASE-CHAIN-REACTION; RT-PCR ANALYSIS; PROMOTER HYPERMETHYLATION;
   BREAST-CANCER; BONE-MARROW; TUMOR-CELLS; COLORECTAL-CANCER; DNA
   METHYLATION
AB Biosensors are devices that combine a biochemical recognition/binding element (ligand) with a signal conversion unit (transducer). Biosensors are already used for several clinical applications, for example for electrochemical measurement of blood glucose concentrations. Application of biosensors in cancer clinical testing has several potential advantages over other clinical analysis methods including increased assay speed and flexibility, capability for multi-target analyses, automation, reduced costs of diagnostic testing and a potential to bring molecular diagnostic assays to community health care systems and to underserved populations. They have the potential for facilitating Point of Care Testing (POCT), where state-of-the-art molecular analysis is carried out without requiring a state-of-the-art laboratory. However, not many biosensors have been developed for cancer-related testing. One major challenge in harnessing the potential of biosensors is that cancer is a very complex set of diseases. Tumors vary widely in etiology and pathogenesis. Oncologists rely heavily on histological characterization of tumors and a few biomarkers that have demonstrated clinical utility to aid in patient management decisions. New genomic and proteomic molecular tools are being used to profile tumors and produce "molecular signatures." These signatures include genetic and epigenetic signatures, changes in gene expression, protein profiles and post-translational modifications of proteins. These molecular signatures provide new opportunities for utilizing biosensors. Biosensors have enormous potential to deliver the promise of new molecular diagnostic strategies to patients. This article describes some of the basic elements of cancer biology and cancer biomarkers relevant for the development of biosensors for cancer clinical testing, along with the challenges in using this approach. (c) 2006 Elsevier B.V. All rights reserved.
C1 NCI, NIH, CDP, Rockville, MD 20852 USA.
   US FDA, Div Biol Sci, Off Sci & Engn Labs, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); US Food & Drug Administration (FDA)
RP NCI, NIH, CDP, 6130 Execut Blvd EPN,6035A, Rockville, MD 20852 USA.
EM rasoolya@mail.nih.gov
RI Rasooly, Avraham/AAH-4518-2021
CR Abrahamsen HN, 2003, J MOL DIAGN, V5, P34, DOI 10.1016/S1525-1578(10)60449-7
   Abrantes M, 2001, ANAL CHEM, V73, P2828, DOI 10.1021/ac0100042
   Allan AL, 2005, CYTOM PART A, V65A, P4, DOI 10.1002/cyto.a.20132
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   Baller MK, 2000, ULTRAMICROSCOPY, V82, P1, DOI 10.1016/S0304-3991(99)00123-0
   Bannister AJ, 2004, METHOD ENZYMOL, V376, P269
   Bielawski K, 2001, INT J MOL MED, V8, P573
   Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   CHANG CY, 2005, MOL ENDOCRINOL
   Choesmel V, 2004, BREAST CANCER RES, V6, pR556, DOI 10.1186/bcr898
   Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814
   Collett JR, 2005, ANAL BIOCHEM, V338, P113, DOI 10.1016/j.ab.2004.11.027
   Cunningham JM, 1998, CANCER RES, V58, P3455
   Diaz-Cano SJ, 1997, DIAGN MOL PATHOL, V6, P342, DOI 10.1097/00019606-199712000-00006
   Dlubek D, 2002, EUR J HAEMATOL, V68, P281, DOI 10.1034/j.1600-0609.2002.01682.x
   Dong CK, 2005, CRIT REV ONCOL HEMAT, V54, P85, DOI 10.1016/j.critrevonc.2004.12.005
   Dumur CI, 2003, GENOMICS, V81, P260, DOI 10.1016/S0888-7543(03)00020-X
   EASTON D, 1993, CANCER SURV, V18, P95
   EELES RA, 1994, EUR J CANCER, V30A, P1383, DOI 10.1016/0959-8049(94)90190-2
   Emmert-Buck MR, 2000, AM J PATHOL, V156, P1109, DOI 10.1016/S0002-9440(10)64979-6
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2000, CANCER RES, V60, P2368
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Famulok M, 1998, CURR OPIN CHEM BIOL, V2, P320, DOI 10.1016/S1367-5931(98)80004-5
   Feuerer M, 2001, INT J CANCER, V92, P96, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q
   Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316
   Furdui VI, 2004, LAB CHIP, V4, P614, DOI 10.1039/b409366f
   GALLIE BL, 1984, OPHTHALMOLOGY, V91, P666
   Gloghini A, 2004, J MOL DIAGN, V6, P290, DOI 10.1016/S1525-1578(10)60524-7
   Goldsworthy SM, 1999, MOL CARCINOGEN, V25, P86, DOI 10.1002/(SICI)1098-2744(199906)25:2<86::AID-MC2>3.0.CO;2-4
   Gulliksen A, 2005, LAB CHIP, V5, P416, DOI 10.1039/b415525d
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hansen KM, 2001, ANAL CHEM, V73, P1567, DOI 10.1021/ac0012748
   Hashimoto K, 2001, LAB CHIP, V1, P61, DOI 10.1039/b103851f
   Hu XC, 2003, ONCOLOGY-BASEL, V64, P160, DOI 10.1159/000067776
   Huang Jing, 2004, Human Genomics, V1, P287
   Ikeda K, 1998, J HISTOCHEM CYTOCHEM, V46, P397, DOI 10.1177/002215549804600314
   Jones  LK, 2002, BRIT J HAEMATOL, V118, P714, DOI 10.1046/j.1365-2141.2002.03586.x
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Kalebic T, 2003, ANN NY ACAD SCI, V983, P278, DOI 10.1111/j.1749-6632.2003.tb05982.x
   Kielhorn E, 2002, CANCER, V94, P205, DOI 10.1002/cncr.10193
   Kraemer PS, 2004, CYTOM PART A, V60A, P1, DOI 10.1002/cyto.a.20041
   Krivacic RT, 2004, P NATL ACAD SCI USA, V101, P10501, DOI 10.1073/pnas.0404036101
   Kurita R, 2002, LAB CHIP, V2, P34, DOI 10.1039/b108803n
   Lara O, 2004, EXP HEMATOL, V32, P891, DOI 10.1016/j.exphem.2004.07.007
   Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655
   Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825
   Liang GG, 2002, METHODS, V27, P150, DOI 10.1016/S1046-2023(02)00068-3
   Ligler FS, 2003, ANAL BIOANAL CHEM, V377, P469, DOI 10.1007/s00216-003-1992-0
   Macgregor PF, 2002, CLIN CHEM, V48, P1170
   MCSHANE LM, 2005, J CLIN ONCOL
   Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961
   MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251
   Mitchell P, 2001, NAT BIOTECHNOL, V19, P717, DOI 10.1038/90754
   Mohamed H, 2004, IEEE T NANOBIOSCI, V3, P251, DOI 10.1109/TNB.2004.837903
   Mondello C, 2004, BIOCHEM CELL BIOL, V82, P498, DOI 10.1139/O04-048
   Nath N, 2001, J AM CHEM SOC, V123, P8197, DOI 10.1021/ja015585r
   Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598
   Opitz OG, 2005, CURR MOL MED, V5, P219, DOI 10.2174/1566524053586626
   Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5
   Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598
   Ransohoff DF, 2003, SCIENCE, V299, P1679, DOI 10.1126/science.1083158
   Reid LH, 1996, CANCER RES, V56, P1214
   Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563
   Rosenberg R, 2002, CYTOMETRY, V49, P150, DOI 10.1002/cyto.10161
   Shaikh KA, 2005, P NATL ACAD SCI USA, V102, P9745, DOI 10.1073/pnas.0504082102
   Shibutani M, 2000, LAB INVEST, V80, P199, DOI 10.1038/labinvest.3780023
   Shukla GS, 2005, ONCOL REP, V13, P757
   Specht K, 2000, J MOL MED-JMM, V78, pB27
   Stanta G, 1998, METH MOL B, V86, P23
   Stokes DL, 2001, FRESEN J ANAL CHEM, V369, P295, DOI 10.1007/s002160000660
   Strate LL, 2005, CANCER CAUSE CONTROL, V16, P201, DOI 10.1007/s10552-004-3488-4
   Taitt CR, 2005, BIOSENS BIOELECTRON, V20, P2470, DOI 10.1016/j.bios.2004.10.026
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Torres FE, 2004, P NATL ACAD SCI USA, V101, P9517, DOI 10.1073/pnas.0403573101
   Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272
   Ukraintseva SV, 2004, ANN NY ACAD SCI, V1019, P200, DOI 10.1196/annals.1297.032
   Ulmer A, 2004, CLIN CANCER RES, V10, P531, DOI 10.1158/1078-0432.CCR-0424-03
   Varma MM, 2004, OPT LETT, V29, P950, DOI 10.1364/OL.29.000950
   Wang HY, 2005, GENOME RES, V15, P276, DOI 10.1101/gr.2885205
   Wang PC, 2002, J CHROMATOGR A, V942, P115, DOI 10.1016/S0021-9673(01)01399-1
   Weihrauch MR, 2002, CLIN EXP METASTAS, V19, P617, DOI 10.1023/A:1020988227349
   Weihrauch MR, 2002, J CLIN ONCOL, V20, P4338, DOI 10.1200/JCO.2002.02.152
   Weirich G, 1997, MOL BIOTECHNOL, V8, P299, DOI 10.1007/BF02760783
   Woelfle U, 2005, J IMMUNOL METHODS, V300, P136, DOI 10.1016/j.jim.2005.03.006
   Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856
   Yeates TO, 2002, CELL, V111, P5, DOI 10.1016/S0092-8674(02)01010-3
   Yu YH, 2003, ANN NY ACAD SCI, V983, P268, DOI 10.1111/j.1749-6632.2003.tb05981.x
   Zhen Cai, 2004, Genomics Proteomics & Bioinformatics, V2, P152
   Zieglschmid V, 2005, ANTICANCER RES, V25, P1803
   Zigeuner RE, 2000, J UROLOGY, V164, P1834, DOI 10.1016/S0022-5347(05)67116-9
   Zigeuner RE, 2003, J UROLOGY, V169, P701, DOI 10.1016/S0022-5347(05)63996-1
NR 100
TC 149
Z9 180
U1 1
U2 99
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD APR 15
PY 2006
VL 21
IS 10
BP 1851
EP 1858
DI 10.1016/j.bios.2006.01.003
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 032EG
UT WOS:000236756100002
PM 16458498
DA 2025-01-12
ER

PT J
AU Gumy-Pause, F
   Wacker, P
   Maillet, P
   Betts, DR
   Sappino, AP
AF Gumy-Pause, F
   Wacker, P
   Maillet, P
   Betts, DR
   Sappino, AP
TI <i>ATM</i> alterations in childhood non-Hodgkin lymphoma
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; MANTLE CELL LYMPHOMA;
   ATAXIA-TELANGIECTASIA GENE; BREAST-CANCER; MISSENSE MUTATIONS;
   DNA-DAMAGE; FUNCTIONAL CONSEQUENCES; PROTEIN EXPRESSION; PATHOGENIC
   ROLE; RARE VARIANTS
AB ATM gene alterations and impaired ATM protein expression have been described in various adult lymphoproliferative malignancies, suggesting that ATM contributes to lymphomagenesis. The present study investigated the prevalence of ATM gene and ATM protein expression alterations in sporadic childhood non-Hodgkin lymphoma (NHL). Twenty-seven cases of NHL were screened for ATM mutations by denaturing high-performance liquid chromatography (DHPLC). Direct and indirect criteria, including in silico tools, were used to classify the gene alterations. The methylation status of the ATM promoter CpG island was determined in 25 samples; ATM protein expression was assessed by Western blot in 9 lymphomas. ATM alterations were detected in 12 NHLs (44%). Ten different heterozygous base Substitutions were identified in 10 NHLs (37%). Five samples (19%) were found to harbor a gene alteration considered to be a mutation or a rare variant potentially pathogenic. In one case, an ATM mutation was found in the germline. Four NHLs (44%) showed reduced or absent ATM protein expression. Except for one sample, no definite genetic or epigenetic alteration was identified to account for impaired ATM protein expression. These observations document a high prevalence of ATM gene and protein expression alterations, suggesting that ATM is involved in childhood NHL. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Hosp Geneva, Dept Pediat, Unit Hematooncol, Geneva, Switzerland.
   Univ Hosp Geneva, Dept Oncol, Lab Oncol 5216, CH-1211 Geneva 4, Switzerland.
   Univ Childrens Hosp, Dept Oncol, Zurich, Switzerland.
C3 University of Geneva; University of Geneva; University Children's
   Hospital Zurich
RP Gumy-Pause, F (通讯作者)，Univ Hosp Geneva, Dept Pediat, Unit Hematooncol, Geneva, Switzerland.
EM Fabienne.GumyPause@medecine.unige.ch
CR Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3
   Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368
   Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0
   Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482
   Bretsky P, 2003, CANCER EPIDEM BIOMAR, V12, P733
   Broeks A, 2000, INT J RADIAT BIOL, V76, P693, DOI 10.1080/095530000138367
   Bullrich F, 1999, CANCER RES, V59, P24
   Camacho E, 2002, BLOOD, V99, P238, DOI 10.1182/blood.V99.1.238
   Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775
   Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616
   Castellví-Bel S, 1999, HUM MUTAT, V14, P156, DOI 10.1002/(SICI)1098-1004(1999)14:2<156::AID-HUMU7>3.0.CO;2-E
   Chasman D, 2001, J MOL BIOL, V307, P683, DOI 10.1006/jmbi.2001.4510
   Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P952
   Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205
   Chim CS, 2002, HEMATOL ONCOL, V20, P167, DOI 10.1002/hon.694
   Chim CS, 2005, LEUKEMIA, V19, P880, DOI 10.1038/sj.leu.2403676
   Coutinho G, 2004, AM J MED GENET A, V126A, P33, DOI 10.1002/ajmg.a.20570
   Cuneo A, 2000, J CLIN ONCOL, V18, P2607, DOI 10.1200/JCO.2000.18.13.2607
   DENDUNNEN J, NOMENCLATURE DESCRIP
   Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516
   Dörk T, 2001, CANCER RES, V61, P7608
   Fang NY, 2003, P NATL ACAD SCI USA, V100, P5372, DOI 10.1073/pnas.0831102100
   Gronbæk K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382
   Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200
   Gumy-Pause F, 2004, LEUKEMIA, V18, P238, DOI 10.1038/sj.leu.2403221
   Gutiérrez-Enriquez S, 2004, GENE CHROMOSOME CANC, V40, P109, DOI 10.1002/gcc.20025
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X
   Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874
   LARSON GP, 1997, GENET TEST, P165
   Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020
   Liberzon E, 2004, BRIT J CANCER, V90, P522, DOI 10.1038/sj.bjc.6601522
   Liberzon E, 2004, GENE CHROMOSOME CANC, V39, P161, DOI 10.1002/gcc.10306
   Lossos IS, 2002, LEUKEMIA LYMPHOMA, V43, P1079, DOI 10.1080/10428190290021623
   Luo LP, 1998, CANCER RES, V58, P2293
   Maillet P, 2002, J MED GENET, V39, P751, DOI 10.1136/jmg.39.10.751
   Offit K, 2002, CLIN CANCER RES, V8, P3813
   Oguchi K, 2003, BLOOD, V101, P3622, DOI 10.1182/blood-2002-02-0570
   Pause FG, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9140
   Pecker I, 1996, GENOMICS, V35, P39, DOI 10.1006/geno.1996.0320
   PERCY CL, 1999, SEER PEDIAT MONOGRAP
   Perkins SL, 2000, PEDIATR DEVEL PATHOL, V3, P374, DOI 10.1007/s100249910052
   PETERSON RDA, 1992, LEUKEMIA, V6, P8
   Platzer M, 1997, GENOME RES, V7, P592, DOI 10.1101/gr.7.6.592
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Rodriguez C, 2002, GENE CHROMOSOME CANC, V33, P141, DOI 10.1002/gcc.1222
   Sandlund JT, 1996, NEW ENGL J MED, V334, P1238, DOI 10.1056/NEJM199605093341906
   Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997
   Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753
   Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011
   Sommer SS, 2003, CANCER GENET CYTOGEN, V145, P115, DOI 10.1016/S0165-4608(03)00119-5
   Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161
   Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300
   Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4
   Starczynski J, 2003, AM J PATHOL, V163, P423, DOI 10.1016/S0002-9440(10)63672-3
   Starostik P, 1998, CANCER RES, V58, P4552
   Stilgenbauer S, 1999, BLOOD, V94, P3262, DOI 10.1182/blood.V94.9.3262.421a33_3262_3264
   Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155
   Stoppa-Lyonnet D, 2000, BLOOD, V96, P374, DOI 10.1182/blood.V96.1.374a.013k56e_374_377
   Szabo CI, 2004, CANCER RES, V64, P840, DOI 10.1158/0008-5472.CAN-03-2678
   Takagi M, 2004, BLOOD, V103, P283, DOI 10.1182/blood-2003-01-0094
   Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423
   Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G
   Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141
   Thorstenson YR, 2003, CANCER RES, V63, P3325
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96
   Vorechovsky I, 1996, CANCER RES, V56, P4130
   Xi T, 2004, GENOMICS, V83, P970, DOI 10.1016/j.ygeno.2003.12.016
   Yuille MR, 2002, BLOOD, V100, P603, DOI 10.1182/blood.V100.2.603
   ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8
NR 71
TC 10
Z9 13
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD APR 15
PY 2006
VL 166
IS 2
BP 101
EP 111
DI 10.1016/j.cancergencyto.2005.09.005
PG 11
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 037VA
UT WOS:000237174400002
PM 16631465
DA 2025-01-12
ER

PT J
AU Hou, P
   Ji, MJ
   Yang, B
   Chen, ZZ
   Qiu, JJ
   Shi, X
   Lu, ZH
AF Hou, P
   Ji, MJ
   Yang, B
   Chen, ZZ
   Qiu, JJ
   Shi, X
   Lu, ZH
TI Quantitative analysis of promoter hypermethylation in multiple genes in
   osteosarcoma
SO CANCER
LA English
DT Article
DE osteosarcoma; multiple genes; hypermethylation; quantitative
   methylation-specific polymerase chain reaction
ID ABERRANT P16 METHYLATION; DNA METHYLATION; CANCER PATIENTS;
   BREAST-CANCER; LUNG-CANCER; PCR ASSAY; TUMORS; RASSF1A; KINASE; AGENTS
AB BACKGROUND. Osteosarcoma is the most common solid malignant diseases of childhood, Occurring in approximately 6 children per million annually; however, to the authors' knowledge to date, the cause of osteosarcoma has remained mostly unknown. Genetic alterations of genes that are specific for osteosarcoma have not been identified. Genetic alternations in the status of DNA methylation, known as epigenetic alterations, are the most common molecular alterations in human neoplasia. Aberrant methylation in the promoter region of tumor-related genes is associated closely with epigenetically mediated gene silencing, which is a common feature in human tumors.
   METHODS. The authors analyzed CpG islands of 5 different gene loci for aberrant methylation profiles in 30 pairs of osteosarcoma and corresponding normal tissues by using the quantitative methylation-specific polymerase chain reaction method. The objectives of this study were to characterize the methylation changes in osteosarcoma more extensively and to identify epigenetic biomarkers that may be useful in the diagnosis and prevention of osteosarcoma.
   RESULTS. For the Ras effector homologue (RASSFIA), tissue inhibitor of metalloproteinase 3 (TIMP3), O-6-methylguanine DNA methyltransferase (MGMT), and death-associated protein kinase 1 (DAPK1) genes, significant differences were observed in the degree of hypermethylation between tumors and normal tissues (P < 0.01 and P < 0.001, respectively). Measurement of the cumulative multiple promoter hypermethylation revealed striking differences between tumor specimens and normal tissues (t= 7.31; P <.001). There also was a significant difference in the levels of DNA methylation between the metastatic and nonmetastatic high-grade osteosarcomas (t = 4.57; P <.01). In addition, the methylation levels were associated closely with gender (t = 6.44; P <.001).
   CONCLUSIONS. The results indicated that turner tissues from patients with osteosarcoma had a significantly higher incidence of hypermethylation for several genes compared with corresponding normal tissues. The epigenetic changes observed in this study may have prognostic importance for patients with osteosarcoma.
C1 Southeast Univ, Dept Biol Sci & Med Engn, Chienshiung Wu Lab, Nanjing 210096, Peoples R China.
   Jingling Hosp, Dept Orthoped, Nanjing, Peoples R China.
C3 Southeast University - China
RP Southeast Univ, Dept Biol Sci & Med Engn, Chienshiung Wu Lab, Nanjing 210096, Peoples R China.
EM zhlu@seu.edu.cn
RI Hou, Peng/H-8073-2015; Chen, Zaozao/AAS-6111-2021; Lu,
   Zuhong/A-5448-2013
OI Chen, Zaozao/0000-0001-8922-370X; Lu, Zuhong/0000-0003-3332-2615
CR Bachman KE, 1999, CANCER RES, V59, P798
   Benassi MS, 2001, CANCER-AM CANCER SOC, V92, P3062, DOI 10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X
   Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D
   Birch JM, 2003, EUR J CANCER, V39, P2622, DOI 10.1016/j.ejca.2003.08.006
   Brock MV, 2003, CLIN CANCER RES, V9, P2912
   Buller A, 2000, MOL DIAGN, V5, P239, DOI 10.2165/00066982-200005030-00011
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cotterill SJ, 2004, PEDIATR BLOOD CANCER, V42, P59, DOI 10.1002/pbc.10437
   Eads CA, 1999, CANCER RES, V59, P2302
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2001, CANCER RES, V61, P3225
   Fackler MJ, 2003, J MAMMARY GLAND BIOL, V8, P75, DOI 10.1023/A:1025735405628
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Grimer RJ, 2005, LANCET ONCOL, V6, P85, DOI 10.1016/S1470-2045(05)01734-1
   Gustafson KS, 2004, CANCER CYTOPATHOL, V102, P259, DOI 10.1002/cncr.20425
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Hou P, 2005, BIOCHEM GENET, V43, P1, DOI 10.1007/s10528-005-1062-8
   Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599
   Jerónimo C, 2002, UROLOGY, V60, P1131
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lehmann U, 2001, LAB INVEST, V81, P635, DOI 10.1038/labinvest.3780272
   Lim S, 2003, ONCOL REP, V10, P897
   Lo YMD, 1999, CANCER RES, V59, P3899
   Melki JR, 1999, CANCER RES, V59, P3730
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Park TJ, 2001, CANCER, V92, P2760, DOI 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8
   PEGG AE, 1990, CANCER RES, V50, P6119
   Rosas SLB, 2001, CANCER RES, V61, P939
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268
   Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Warnecke PM, 2000, CURR OPIN ONCOL, V12, P68, DOI 10.1097/00001622-200001000-00012
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zou HZ, 2002, CLIN CANCER RES, V8, P188
NR 46
TC 39
Z9 45
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD APR 1
PY 2006
VL 106
IS 7
BP 1602
EP 1609
DI 10.1002/cncr.21762
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 024KI
UT WOS:000236193500023
PM 16502411
OA Bronze
DA 2025-01-12
ER

PT J
AU Banwell, CM
   MacCartney, DP
   Guy, M
   Miles, AE
   Uskokovic, MR
   Mansi, J
   Stewart, PM
   O'Neill, LP
   Turner, BM
   Colston, KW
   Campbell, MJ
AF Banwell, CM
   MacCartney, DP
   Guy, M
   Miles, AE
   Uskokovic, MR
   Mansi, J
   Stewart, PM
   O'Neill, LP
   Turner, BM
   Colston, KW
   Campbell, MJ
TI Altered nuclear receptor corepressor expression attenuates vitamin D
   receptor signaling in breast cancer cells
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID LIGAND-BINDING DOMAIN; HISTONE DEACETYLASE; 1-ALPHA,25-DIHYDROXYVITAMIN
   D-3; 1,25-DIHYDROXYVITAMIN D-3; GROWTH-INHIBITION; GENE-EXPRESSION;
   CYCLIN D1; ALPHA; ANALOGS; INDUCTION
AB Purpose: We hypothesized that deregulated corepressor actions, with associated histone deacetylation activity, epigenetically suppressed vitamin D receptor (VDR) responsiveness and drives resistance towards 1 alpha,25-dihydroxyvitamin D-3.
   Experimental Design: Profiling, transcriptional, and proliferation assays were undertaken in 1 alpha,25(OH)(2)D-3-sensitive MCF-12A nonmalignant breast epithelial cells, a panel of breast cancer cell lines, and a cohort of primary breast cancer tumors (n = 21).
   Results: Elevated NCoR1 mRNA levels correlated with suppressed regulation of VDR target genes and the ability of cells to undergo arrest in G, of the cell cycle. A similar increased ratio of corepressor m RNA to VDR occurred in matched primary tumor and normal cells, noticeably in estrogen receptor alpha- negative (n = 7) tumors. 1 alpha,25(OH)(2)D-3 resistance in cancer cell lines was targeted by cotreatments with either 1 alpha,25(OH)(2)D-3 or a metabolically stable analogue (RO-26-2198) in combination with either trichostatin A (TSA; histone deacetylation inhibitor) or 5-aza-2'-deoxycytidine (DNA methyltransferase inhibitor). Combinations of vitamin D-3 compounds with TSA restored VDR antiproliferative signaling (target gene regulation, cell cycle arrest, and antiproliferative effects in liquid culture) to levels which were indistinguishable from MCF-12A cells.
   Conclusions: Increased NCoR1 mRNA is a novel molecular lesion in breast cancer cells, which acts to suppress responsiveness of VDR target genes, resulting in 1 alpha,25(OH)(2)D-3 resistance and seems to be particularly associated with estrogen receptor negativity. This lesion provides a novel molecular diagnostic and can be targeted by combinations of vitamin D-3 compounds and low doses of TSA.
C1 Univ Birmingham, Sch Med, Inst Biomed Res Endocrinol & Metab, Birmingham, W Midlands, England.
   Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham, W Midlands, England.
   Hoffmann La Roche Inc, Nutley, NJ 07110 USA.
   Univ London St Georges Hosp, Sch Med, Dept Clin Biochem, London SW17 0RE, England.
C3 University of Birmingham; University of Birmingham; Roche Holding; City
   St Georges, University of London; St Georges University London
RP Univ Birmingham, Sch Med, Inst Biomed Res Endocrinol & Metab, Wolfson Dr, Birmingham, W Midlands, England.
EM m.j.campbell@bham.ac.uk
OI Campbell, Moray/0000-0002-3355-0928; Macartney-Coxson,
   Donia/0000-0002-1051-537X
CR Agadir A, 1999, CARCINOGENESIS, V20, P577, DOI 10.1093/carcin/20.4.577
   Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4
   Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127
   Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985
   Banwell CM, 2004, J STEROID BIOCHEM, V89-90, P245, DOI 10.1016/j.jsbmb.2004.03.081
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888
   Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972
   Campbell MJ, 1997, J CELL BIOCHEM, V66, P413, DOI 10.1002/(SICI)1097-4644(19970901)66:3<413::AID-JCB13>3.3.CO;2-0
   Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015
   Carlberg C, 2004, J STEROID BIOCHEM, V89-90, P227, DOI 10.1016/j.jsbmb.2004.03.112
   Ciesielski F, 2004, J STEROID BIOCHEM, V89-90, P55, DOI 10.1016/j.jsbmb.2004.03.109
   ELSTNER E, 1995, CANCER RES, V55, P2822
   Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806
   Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4
   FOGELMAN Y, 1995, ISRAEL J MED SCI, V31, P221
   Getzenberg RH, 1997, UROLOGY, V50, P999, DOI 10.1016/S0090-4295(97)00408-1
   Girault I, 2003, CLIN CANCER RES, V9, P1259
   Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901
   Guy M, 2004, CLIN CANCER RES, V10, P5472, DOI 10.1158/1078-0432.CCR-04-0206
   Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610
   Hayashi SI, 2003, ENDOCR-RELAT CANCER, V10, P193, DOI 10.1677/erc.0.0100193
   Hermanson O, 2002, NATURE, V419, P934, DOI 10.1038/nature01156
   Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6
   Hiatt RA, 1998, J NATL CANCER I, V90, P461, DOI 10.1093/jnci/90.6.461
   Jeon JH, 2005, CANCER RES, V65, P4485, DOI 10.1158/0008-5472.CAN-04-2271
   Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7
   Jepsen K, 2002, J CELL SCI, V115, P689
   Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200
   Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302
   Khanim FL, 2004, ONCOGENE, V23, P6712, DOI 10.1038/sj.onc.1207772
   Kollara A, 2001, BREAST CANCER RES TR, V67, P245, DOI 10.1023/A:1017938608460
   Kurebayashi J, 2000, CLIN CANCER RES, V6, P512
   Lal A, 1999, CANCER RES, V59, P5403
   Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C
   Nagy L, 2004, TRENDS BIOCHEM SCI, V29, P317, DOI 10.1016/j.tibs.2004.04.006
   PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323
   Planas-Silva MD, 2001, CANCER RES, V61, P3858
   Qin CH, 2003, CANCER RES, V63, P958
   Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4
   Rashid SF, 2001, ONCOGENE, V20, P1860, DOI 10.1038/sj.onc.1204269
   Raval-Pandya M, 2001, MOL ENDOCRINOL, V15, P1035, DOI 10.1210/me.15.6.1035
   Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X
   Schöndorf T, 2003, ONCOLOGY-BASEL, V64, P154, DOI 10.1159/000067767
   Shao Z, 1996, Chin Med Sci J, V11, P142
   Stathopoulos EN, 2005, ANN ONCOL, V16, P240, DOI 10.1093/annonc/mdi043
   Uskokovic MR, 2001, STEROIDS, V66, P463, DOI 10.1016/S0039-128X(00)00226-9
   Väisänen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/j.jmb.2005.04.057
   Vertino AM, 2005, J BIOL CHEM, V280, P14130, DOI 10.1074/jbc.M410720200
   Vienonen A, 2003, EUR J ENDOCRINOL, V148, P469, DOI 10.1530/eje.0.1480469
   Welsh JE, 2003, J NUTR, V133, p2425S, DOI 10.1093/jn/133.7.2425S
   Weyts FA, 2004, BIOCHEM PHARMACOL, V67, P1327, DOI 10.1016/j.bcp.2003.12.006
   Xu XC, 1997, CANCER RES, V57, P4992
   Yang XQ, 1998, BREAST CANCER RES TR, V48, P33, DOI 10.1023/A:1005929714900
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   ZHANG Z, 2005, CANC LETT       0711
   Zhu WG, 2001, CANCER RES, V61, P1327
   ZINSER GM, 2004, MOL ENDOCRINOL
NR 61
TC 71
Z9 76
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 1
PY 2006
VL 12
IS 7
BP 2004
EP 2013
DI 10.1158/1078-0432.CCR-05-1218
PN 1
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 034BI
UT WOS:000236899000011
PM 16609009
OA Bronze
DA 2025-01-12
ER

PT J
AU Dolinoy, DC
   Weidman, JR
   Waterland, RA
   Jirtle, RL
AF Dolinoy, DC
   Weidman, JR
   Waterland, RA
   Jirtle, RL
TI Maternal genistein alters coat color and protects <i>A<SUP>vy</SUP></i>
   mouse offspring from obesity by modifying the fetal epigenome
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE developmental origins of adult disease; DNA methylation; epigenetics;
   viable yellow agouti (A(vy)) mouse
ID BREAST-CANCER RISK; DNA METHYLATION; GENE; ISOFLAVONES; AMERICAN;
   PATTERNS; EXPOSURE; PHYTOESTROGENS; MECHANISMS; EXPRESSION
AB Genistein, the major phytoestrogen in soy, is linked to diminished female reproductive performance and to cancer chemoprevention and decreased adipose deposition. Dietary genistein may also play a role in the decreased incidence of cancer in Asians compared with Westerners, as well as increased cancer incidence in Asians immigrating to the United States. Here, we report that maternal dietary genistein supplementation of mice during gestation, at levels comparable with humans consuming high-soy diets, shifted the coat color of heterozygous viable yellow agouti (A(vy)/a) offspring toward pseudoagouti. This marked phenotypic change was significantly associated with increased methylation of six cytosine-guanine sites in a retrotransposon upstream of the transcription start site of the Agouti gene. The extent of this DNA methylation was similar in endodermal, mesodermal, and ectodermal tissues, indicating that genistein acts during early embryonic development. Moreover, this genistein-induced hypermethylation persisted into adulthood, decreasing ectopic Agouti expression and protecting offspring from obesity. Thus, we provide the first evidence that in utero dietary genistein affects gene expression and alters susceptibility to obesity in adulthood by permanently altering the epigenome.
C1 Duke Univ, Ctr Med, Dept Radiat Oncol, Durham, NC 27710 USA.
   Duke Univ, Univ Program Genet & Genom, Durham, NC 27710 USA.
   Duke Univ, Integrated Toxicol Program, Durham, NC 27710 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Duke University; Duke University; Duke University; Baylor College of
   Medicine; Baylor College of Medicine
RP Duke Univ, Ctr Med, Dept Radiat Oncol, Box 3433, Durham, NC 27710 USA.
EM jirtle@radonc.duke.edu
FU NCI NIH HHS [CA 25921, R01 CA025951] Funding Source: Medline; NIEHS NIH
   HHS [T32 ES007031, T32 ES 07031, R01 ES008823, ES 13053, R21 ES013053,
   ES 08823] Funding Source: Medline
CR AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   Badger TM, 2002, J NUTR, V132, p559S, DOI 10.1093/jn/132.3.559S
   Barker DJP, 2004, J AM COLL NUTR, V23, p588S, DOI 10.1080/07315724.2004.10719428
   Barker DJP, 1997, ACTA PAEDIATR, V86, P178
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brown NM, 2001, LAB INVEST, V81, P735, DOI 10.1038/labinvest.3780282
   Chang CC, 2001, RADIAT RES, V155, P201, DOI 10.1667/0033-7587(2001)155[0201:AHBECT]2.0.CO;2
   Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1
   Cooney Craig A, 2002, J Nutr, V132, p2393S, DOI 10.1093/jn/132.8.2393S
   COWARD L, 1993, J AGR FOOD CHEM, V41, P1961, DOI 10.1021/jf00035a027
   Cruz-Correa M, 2004, GASTROENTEROLOGY, V126, P964, DOI 10.1053/j.gastro.2003.12.051
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   Degen GH, 2002, TOXICOL LETT, V128, P145, DOI 10.1016/S0378-4274(02)00009-7
   DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59
   Fritz WA, 2002, MOL CELL ENDOCRINOL, V186, P89, DOI 10.1016/S0303-7207(01)00663-3
   *GENBANK, 2005, SEARCH GENB
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200
   Hong T, 2004, BIOCHEM BIOPH RES CO, V317, P259, DOI 10.1016/j.bbrc.2004.03.041
   Jirtle RL, 2004, GASTROENTEROLOGY, V126, P1190, DOI 10.1053/j.gastro.2004.02.026
   Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S
   LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2
   Li SF, 2003, ANN NY ACAD SCI, V983, P161, DOI 10.1111/j.1749-6632.2003.tb05971.x
   LYNCOOK BD, 1995, P SOC EXP BIOL MED, V208, P116
   Miltenberger RJ, 1997, J NUTR, V127, pS1902, DOI 10.1093/jn/127.9.1902S
   Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490
   Naaz A, 2003, ENDOCRINOLOGY, V144, P3315, DOI 10.1210/en.2003-0076
   Naciff JM, 2004, ENVIRON HEALTH PERSP, V112, P1519, DOI 10.1289/ehp.6848
   Nagao T, 2001, REPROD TOXICOL, V15, P399, DOI 10.1016/S0890-6238(01)00141-1
   Peeters PHM, 2003, BREAST CANCER RES TR, V77, P171, DOI 10.1023/A:1021381101632
   PRICE KR, 1985, FOOD ADDIT CONTAM A, V2, P73, DOI 10.1080/02652038509373531
   Rakyan VK, 2001, BIOCHEM J, V356, P1, DOI 10.1042/0264-6021:3560001
   Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9
   Souzeau E, 2005, AM J PHYSIOL-HEART C, V289, pH715, DOI 10.1152/ajpheart.00061.2005
   Valachovicova T, 2004, MINI-REV MED CHEM, V4, P881, DOI 10.2174/1389557043403387
   Wang HB, 2005, P NATL ACAD SCI USA, V102, P9960, DOI 10.1073/pnas.0501632102
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   WEI HC, 1993, NUTR CANCER, V20, P1, DOI 10.1080/01635589309514265
   Zhu KM, 2003, CANCER CAUSE CONTROL, V14, P827, DOI 10.1023/B:CACO.0000003823.97506.be
   ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819
NR 44
TC 689
Z9 785
U1 1
U2 90
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD APR
PY 2006
VL 114
IS 4
BP 567
EP 572
DI 10.1289/ehp.8700
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 030QX
UT WOS:000236650500042
PM 16581547
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Shukla, S
   Mirza, S
   Sharma, G
   Parshad, R
   Gupta, SD
   Ralhan, R
AF Shukla, Shruti
   Mirza, Sameer
   Sharma, Gayatri
   Parshad, Rajinder
   Gupta, Siddhartha Datta
   Ralhan, Ranju
TI Detection of <i>RASSF1A</i> and RARβ Hypermethylation in Serum DNA from
   Breast Cancer Patients
SO EPIGENETICS
LA English
DT Article
DE Breast Cancer; RASSF1A; RAR beta; Methylation; Serum
ID TUMOR-SUPPRESSOR GENE; ABERRANT PROMOTER METHYLATION; CPG ISLAND;
   MULTIPLE GENES; HIGH-FREQUENCY; PLASMA; EXPRESSION; FLUID; ASSOCIATION;
   EPIGENETICS
AB Breast cancer is fast emerging as the leading cancer amongst females, especially in young females in metropolitan cities in India. The epigenetic alterations involved in the onset and progression of breast cancer may serve as biomarkers for early detection and prognosis of the disease. Furthermore, using body fluids such as serum offers a noninvasive method to procure multiple samples for such analyses. In this study, we examined methylation status of two normally unmethylated but biologically significant cancer genes, RAS association domain family protein 1A (RASSF1A) and retionic acid receptor beta (RAR beta) by methylation specific PCR (MSP) in invasive ductal carcinomas of the breast and paired serum DNA. RASSF1A was found to be methylated in 17 of 20 (85%) breast tumors; while sera from 15 of 20 (75%) of the patients showed concordant methylated RASSF1A, with a sensitivity of 88%. RAR beta was methylated in 2/20 (10%) breast tumors. A gene unmethylated in the tumor DNA was always found to be unmethylated in the matched serum DNA for both RASSF1A and RAR beta genes; hence specificity was 100%. Immunohistochemical analysis of RAR beta protein in 15 breast carcinoma patients harboring unmethylated RAR beta in tumors and serum DNA showed the expression of RAR beta protein in tumors and paired normal breast tissues, confirming the MSP findings, suggesting that RAR beta promoter is functional in these cases. This study underscores the potential utility of DNA methylation based screening of serum, a readily accessible body fluid, as a surrogate marker for early detection of breast cancer.
C1 [Shukla, Shruti; Mirza, Sameer; Sharma, Gayatri; Ralhan, Ranju] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   [Parshad, Rajinder] All India Inst Med Sci, Dept Surg, New Delhi 110029, India.
   [Gupta, Siddhartha Datta] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; All India
   Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of
   Medical Sciences (AIIMS) New Delhi
RP Ralhan, R (通讯作者)，All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
EM ralhanr@rediffmail.com
FU Department of Biotechnology, India
FX We are grateful to Department of Biotechnology, India, for providing the
   financial support to conduct this study. S. M. is grateful to University
   Grant Commission for award of Junior Research Fellowship. The authors
   thank Dr. Cecile Rochette Egly for the kind gift of RAR beta monoclonal
   antibody.
CR Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Chopra R, 2001, J CLIN ONCOL, V19, p106S
   Dammann R, 2001, CANCER RES, V61, P3105
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 1999, CANCER RES, V59, P67
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fujiwara K, 2005, CLIN CANCER RES, V11, P1219
   Gal S, 2004, BRIT J CANCER, V90, P1211, DOI 10.1038/sj.bjc.6601609
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   *GLOBOCAN, 2005, 5 GLOBOCAN IARC
   Grunt TW, 2005, BIOCHEM BIOPH RES CO, V329, P1253, DOI 10.1016/j.bbrc.2005.02.104
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hibi K, 1998, CANCER RES, V58, P1405
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Ichikawa D, 2004, ANTICANCER RES, V24, P2477
   *IND COUNC MED RES, 2001, REP NAT CANC REG PRO, P22
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Klein PM, 2002, ENVIRON MOL MUTAGEN, V39, P127, DOI 10.1002/em.10061
   Koike H, 2005, HEPATO-GASTROENTEROL, V52, P1293
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   LEON SA, 1977, CANCER RES, V37, P646
   Leung WK, 2005, BRIT J CANCER, V92, P2190, DOI 10.1038/sj.bjc.6602636
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Marshall Fray F, 2005, J Urol, V173, P1918, DOI 10.1097/01.ju.0000161195.11300.49
   Martens JWM, 2005, CANCER RES, V65, P4101, DOI 10.1158/0008-5472.CAN-05-0064
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Mitka M, 2003, JAMA-J AM MED ASSOC, V290, P450, DOI 10.1001/jama.290.4.450
   Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088
   Müller HM, 2003, CANCER RES, V63, P7641
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Ralhan R, 2006, INT J CANCER, V118, P1077, DOI 10.1002/ijc.21483
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Saxena Sunita, 2005, World J Surg Oncol, V3, P67, DOI 10.1186/1477-7819-3-67
   Shao ZM, 2002, ANTI-CANCER DRUG, V13, P353, DOI 10.1097/00001813-200204000-00003
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Silva JM, 1999, CANCER RES, V59, P3251
   Sirchia SM, 2002, CANCER RES, V62, P2455
   SOBIN LH, 1988, CANCER, V61, P2310, DOI 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X
   Swanton C, 2004, LANCET ONCOL, V5, P653, DOI 10.1016/S1470-2045(04)01604-3
   Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
   Yeo W, 2005, PATHOLOGY, V37, P125, DOI 10.1080/00313020500058623
NR 59
TC 54
Z9 61
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD APR-JUN
PY 2006
VL 1
IS 2
BP 88
EP 93
DI 10.4161/epi.1.2.2679
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA V04MS
UT WOS:000207063100005
PM 17998817
OA Bronze
DA 2025-01-12
ER

PT J
AU Mogal, A
   Abdulkadir, SA
AF Mogal, A
   Abdulkadir, SA
TI Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA)
   on the expression of housekeeping genes
SO MOLECULAR AND CELLULAR PROBES
LA English
DT Article
DE housekeeping genes; Histone Deacetylase Inhibitor (HDACi); trichostatin
   A (TSA); ribosomal highly basic 23-kDa protein (rb 23-kDa; RPL13A);
   quantitative RT-PCR; epigenetic; normalization
ID GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; MESSENGER-RNA; RIBOSOMAL-RNA;
   BETA-ACTIN; RT-PCR; TISSUES; CELLS; TRANSCRIPTION; VARIABILITY;
   INITIATION
AB In quantitative RT-PCR (qRT-PCR), analysis of gene expression is dependent on normalization using housekeeping genes such as 18S rRNA, GAPDH and beta actin. However, variability in their expression has been reported to be caused by factors like drug treatment, pathological states and cell-cycle phase. An emerging area of cancer research focuses on identifying the role of epigenetic alterations such as histone modifications and DNA methylation in the initiation and progression of cancer. Historic acetylation is the best studied modification so far and has been probed through the use of histone deacetylase inhibitors (HDACi). Further, modulation of histone acetylation is currently being explored as a therapeutic strategy in the treatment of cancer and HDACis have shown promise in inhibiting tumorigenesis and metastasis. Trichostatin-A (TSA) is the most widely used HDACi. Therefore, we were driven to identify a suitable internal control for RT-PCR following TSA treatment. We performed quantitative RT-PCR analysis using mouse prostate tissue explants, human prostate cancer (LNCaP) cells and human breast cancer (T-47D and ZR-75-1) cells following TSA treatment. Expression of housekeeping genes including 18S rRNA, beta actin. GAPDH and ribosomal highly-basic 23-kDa protein (rb 23-kDa, RPL13A) were compared in vehicle versus TSA treated samples. Our results showed marked variations in 18S rRNA, actin mRNA and GAPDH mRNA levels in mouse prostate explants and a human prostate cancer (LNCaP) cell line following TSA treatment. Furthermore, in two human breast cancer cell lines (T-47D and ZR-75-1) 18S rRNA, actin mRNA and GAPDH mRNA levels varied significantly. However, RPL13A mRNA levels remained constant in all the conditions tested. Therefore, we recommend use of RPL13A as a standard for normalization during TSA treatment. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA.
C3 Vanderbilt University
RP Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA.
EM sarki.abdulkadir@vanderbilt.edu
FU NCI NIH HHS [CA94858] Funding Source: Medline
CR Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002
   Ailenberg M, 2002, BIOCHEM BIOPH RES CO, V298, P110, DOI 10.1016/S0006-291X(02)02420-8
   BHATIA P, 1994, ANAL BIOCHEM, V216, P223, DOI 10.1006/abio.1994.1028
   Blanquicett C, 2002, ANAL BIOCHEM, V303, P209, DOI 10.1006/abio.2001.5570
   CALVO EL, 1991, PANCREAS, V6, P150, DOI 10.1097/00006676-199103000-00004
   Cohen LA., 1991, CANC PREV, V26, P1
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   EDWARDS DR, 1985, EXP CELL RES, V157, P127, DOI 10.1016/0014-4827(85)90157-0
   FINNEGAN MCM, 1993, LEUKEMIA LYMPHOMA, V10, P387, DOI 10.3109/10428199309148565
   FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Jesnowski R, 2002, PANCREATOLOGY, V2, P421, DOI 10.1159/000065091
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3
   Matyas JR, 1999, CONNECT TISSUE RES, V40, P163, DOI 10.3109/03008209909005280
   NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273
   OIKARINEN A, 1991, BIOCHIM BIOPHYS ACTA, V1089, P40, DOI 10.1016/0167-4781(91)90082-W
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   RAO GN, 1990, J BIOL CHEM, V265, P19393
   Rubie C, 2005, MOL CELL PROBE, V19, P101, DOI 10.1016/j.mcp.2004.10.001
   SCHEK N, 1988, CANCER RES, V48, P6354
   Selvey S, 2001, MOL CELL PROBE, V15, P307, DOI 10.1006/mcpr.2001.0376
   Serazin-Leroy V, 1998, MOL CELL PROBE, V12, P283, DOI 10.1006/mcpr.1998.0182
   Solanas M, 2001, ANAL BIOCHEM, V288, P99, DOI 10.1006/abio.2000.4889
   Tatton WG, 2000, ADV RES NEURODEGENER, V8, P77
   Wu YY, 2000, ACTA DERM-VENEREOL, V80, P2
   Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P835, DOI 10.1006/bbrc.1997.6198
   Yuen BSJ, 1999, J ENDOCRINOL, V163, pR1, DOI 10.1677/joe.0.163R001
   Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815
NR 30
TC 56
Z9 68
U1 0
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0890-8508
J9 MOL CELL PROBE
JI Mol. Cell. Probes
PD APR
PY 2006
VL 20
IS 2
BP 81
EP 86
DI 10.1016/j.mcp.2005.09.008
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Cell Biology
GA 028RH
UT WOS:000236505500002
PM 16326072
DA 2025-01-12
ER

PT J
AU Katoh, M
   Katoh, M
AF Katoh, M
   Katoh, M
TI Bioinformatics for cancer management in the post-genome era
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE bioinformatics; oncogenomics; epigenetics; oncoproteomics; Microarray;
   array CGH; biomarker; personalized medicine
ID GENE-EXPRESSION PATTERNS; GASTRIC-CANCER; BREAST-CANCER; CDNA
   MICROARRAY; DNA MICROARRAY; SUSCEPTIBILITY GENE; COMPLEMENTARY-DNA;
   HORMONE-THERAPY; PROSTATE-CANCER; OVARIAN-CANCER
AB Human cancer is caused by multiple factors, such as genetic predisposition, chronic persistent inflammation, environmental factors, life style, and aging. Dysregulated proliferation, dysregulated adhesion, resistance to apoptosis, resistance to senescence, and resistance to anti-cancer drugs are features of cancer cells. Accumulation of multiple epigenetic changes and genetic alterations of cancer-associated genes during multi-stage carcinogenesis results in more malignant phenotypes. Post-genome science is characterized by omics data related to genome, transcriptome, proteome, metabolome, interactome, and epigenome as well as by high-throughput technology, such as whole-genome tiling oligonucleotide array, array CGH with 32,433 overlapping BAC clones, transcriptome microarray, mass spectrometry, tissue-based expression array, and cell-based transfection array. Benchtop oncology supplies Desktop oncology with large amounts of omics data produced by high-throughput technology. Desktop oncology establishes knowledge on Gancer-related biomarkers, such as predisposition markers, diagnostic markers, prognostic markers, and therapeutic markers, by using bioinformatics and human intelligence of experts for data mining and text mining Bedside oncology applies the knowledge established by Desktop oncology to determine therapeutics for cancer patients. Antibody drugs (Trastuzumab/Herceptin, Cetuximab/Erbitux, Bevacizumab/Avastin, et cetera), small molecule inhibitors for tyrosine kinases (Gefitinib/Iressa, Erlotinib/Tarceva, Imatinib/Gleevec, etcetera), conventional cytotoxic drugs, and anti-hormonal drugs are used for cancer chemotherapy. Biomarker monitoring contributes to therapeutic optional choice and drug dosage determination for cancer patients. Knowledge on biomarkers is feedforwarded from desktop to bedside in the translational research, and then biomarker monitoring is feedbacked from bedside to desktop in the reverse translational research. Desktop oncology is indispensable for cancer research in the post-genome era Combination of genetic screening for cancer predisposition in the general population and precise selection of therapeutic options during cancer management could contribute to the realization of personalized prevention and to dramatically improve the prognosis of cancer patients in the future.
C1 M&M Med Bioinformat, Hongo 1130033, Japan.
   Natl Canc Ctr, Res Inst, Genet & Cell Biol Sect, Tokyo 1040045, Japan.
C3 National Cancer Center - Japan
RP Katoh, M (通讯作者)，M&M Med Bioinformat, Hongo 1130033, Japan.
EM mkatoh@ncc.go.jp
CR Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685
   Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388
   BRUIX J, 1989, LANCET, V2, P1004
   Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758
   Callagy G, 2005, J PATHOL, V205, P388, DOI 10.1002/path.1694
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   DeRisi J, 1996, NAT GENET, V14, P457
   Eng C, 2001, ANNU REV MED, V52, P371, DOI 10.1146/annurev.med.52.1.371
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Garciadiego-Cázares D, 2004, DEVELOPMENT, V131, P4735, DOI 10.1242/dev.01345
   Gharib TG, 2002, NEOPLASIA, V4, P440, DOI 10.1038/sj.neo.7900257
   Gruvberger S, 2001, CANCER RES, V61, P5979
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   Hasegawa S, 2002, CANCER RES, V62, P7012
   Hyman E, 2002, CANCER RES, V62, P6240
   Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307
   Kakiuchi S, 2004, HUM MOL GENET, V13, P3029, DOI 10.1093/hmg/ddh331
   Kallioniemi OP, 2001, ANN MED, V33, P142, DOI 10.3109/07853890109002069
   Katoh M, 2003, INT J ONCOL, V22, P1375
   Katoh M, 2004, INT J ONCOL, V24, P757
   Katoh M, 2003, INT J ONCOL, V23, P525
   Katoh M, 2003, INT J MOL MED, V11, P683
   Katoh M, 2003, INT J ONCOL, V23, P235
   Katoh M, 2003, INT J ONCOL, V22, P1369
   Katoh M, 2003, INT J MOL MED, V12, P3
   Katoh M, 2002, INT J MOL MED, V10, P677
   Katoh M, 2005, INT J MOL MED, V16, P1103
   Katoh M, 2002, INT J MOL MED, V10, P683
   Katoh M, 2003, INT J MOL MED, V12, P643
   Katoh M, 2004, CANCER BIOL THER, V3, P566, DOI 10.4161/cbt.3.6.936
   Katoh M, 2002, INT J ONCOL, V21, P1269
   Katoh M, 2003, INT J MOL MED, V12, P45
   Katoh M., 1993, GASTRIC CANCER, P196
   Katoh Y, 2005, CANCER BIOL THER, V4, P1050, DOI 10.4161/cbt.4.10.2184
   Khan J, 1998, CANCER RES, V58, P5009
   Kihara C, 2001, CANCER RES, V61, P6474
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889
   Liu ET, 2003, CURR OPIN GENET DEV, V13, P97, DOI 10.1016/S0959-437X(03)00008-X
   Lyons-Weiler J, 2003, GENOME RES, V13, P503, DOI 10.1101/gr.104003
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   McDonald SL, 2004, CANCER BIOL THER, V3, P110, DOI 10.4161/cbt.3.1.662
   MEISELS A, 1983, PATHOL ANNU, V18, P277
   Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889
   Need AC, 2005, NAT GENET, V37, P671, DOI 10.1038/ng1593
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603
   Persidis A, 1999, NAT BIOTECHNOL, V17, P828, DOI 10.1038/11793
   Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073
   Rosty C, 2005, METH MOLEC MED, V103, P189
   Sagara N, 2000, CANCER RES, V60, P5959
   Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0
   Sgroi DC, 1999, CANCER RES, V59, P5656
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009
   Stam RW, 2003, BLOOD, V101, P1270, DOI 10.1182/blood-2002-05-1600
   SUGIMURA T, 1992, ENVIRON HEALTH PERSP, V98, P5, DOI 10.2307/3431242
   Swain Rajeeb Kumar, 2005, Cell Commun Signal, V3, P12, DOI 10.1186/1478-811X-3-12
   Tsurutani J, 2005, CANCER RES, V65, P8423, DOI 10.1158/0008-5472.CAN-05-0058
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vlahou A, 2001, AM J PATHOL, V158, P1491, DOI 10.1016/S0002-9440(10)64100-4
   Wellmann A, 2002, INT J MOL MED, V9, P341
   Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424
   Wong YF, 2003, CLIN CANCER RES, V9, P5486
   YAZIDIBELKOURA IE, 2002, TECHNOL CANCER RES T, V1, P287
   Zembutsu H, 2002, CANCER RES, V62, P518
   Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308
   Zweiger G, 1999, TRENDS BIOTECHNOL, V17, P429, DOI 10.1016/S0167-7799(99)01359-1
NR 74
TC 40
Z9 42
U1 1
U2 16
PU ADENINE PRESS
PI SCHENECTADY
PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA
SN 1533-0346
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD APR
PY 2006
VL 5
IS 2
BP 169
EP 175
DI 10.1177/153303460600500208
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 034BJ
UT WOS:000236899100010
PM 16551136
DA 2025-01-12
ER

PT J
AU Knowles, DW
   Sudar, D
   Bator-Kelly, C
   Bissell, MJ
   Lelièvre, SA
AF Knowles, DW
   Sudar, D
   Bator-Kelly, C
   Bissell, MJ
   Lelièvre, SA
TI Automated local bright feature image analysis of nuclear protein
   distribution identifies changes in tissue phenotype
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE 3D automated nuclear segmentation; breast cancer; nuclear organization;
   NuMA; quantitative imaging
ID SCANNING LASER MICROSCOPY; BREAST EPITHELIAL-CELLS; MAMMARY EPITHELIUM;
   MATRIX PROTEINS; LIVING CELLS; CAJAL BODY; IN-VIVO; DIFFERENTIATION;
   CYTOMETRY; NUMA
AB The organization of nuclear proteins is linked to cell and tissue phenotypes. When cells arrest proliferation, undergo apoptosis, or differentiate, distribution of nuclear proteins changes. Conversely, forced alteration of the distribution of nuclear proteins modifies cell phenotype. Immunostaining and fluorescence microscopy have been critical for such findings. However, there is increasing need for quantitative analysis of nuclear protein distribution to decipher epigenetic relationships between nuclear structure and cell phenotype and to unravel the mechanisms linking nuclear structure and function. We have developed imaging methods to quantify the distribution of fluorescently stained nuclear protein NuMA in different mammary phenotypes obtained using 3D cell culture. Automated image segmentation of DAPI-stained nuclei was generated to isolate thousands of nuclei from 3D confocal images. Prominent features of fluorescently stained NuMA were detected by using a previously undescribed local bright feature analysis technique, and their normalized spatial density was calculated as a function of the distance from the nuclear perimeter to its center. The results revealed marked changes in the distribution of the density of NuMA bright features when nonneoplastic cells underwent phenotypically normal acinar morphogenesis. Conversely, we did not detect any reorganization of NuMA during formation of tumor nodules by malignant cells. Importantly, the analysis also discriminated proliferating nonneoplastic from proliferating malignant cells, suggesting that these imaging methods are capable of identifying alterations linked not only to the proliferation status but also to the malignant character of cells. We believe that this quantitative analysis will have additional applications for classifying normal and pathological tissues.
C1 Lawrence Berkeley Natl Lab, Dept Biophys, Div Life Sci, Berkeley, CA 94720 USA.
   Lawrence Berkeley Natl Lab, Dept Canc Biol, Div Life Sci, Berkeley, CA 94720 USA.
   Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
   Purdue Univ, Ctr Canc, W Lafayette, IN 47907 USA.
C3 United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; United States Department of Energy (DOE); Lawrence Berkeley
   National Laboratory; Purdue University System; Purdue University; Purdue
   University System; Purdue University
RP Lawrence Berkeley Natl Lab, Dept Biophys, Div Life Sci, MS 84R0171,1 Cyclotron Rd, Berkeley, CA 94720 USA.
EM lelievre@purdue.edu
RI BISSELL, MINA/ABR-7886-2022
OI LELIEVRE, Sophie/0000-0001-6606-2501; Sudar, Damir/0000-0002-2510-7272
FU NCI NIH HHS [R33 CA118479] Funding Source: Medline
CR Ancin H, 1996, CYTOMETRY, V25, P221
   [Anonymous], 2003, Morphological Image Analysis: Principles and Applications
   ANTONIOU M, 1993, J CELL BIOL, V123, P1055, DOI 10.1083/jcb.123.5.1055
   Beil M, 2002, CYTOMETRY, V47, P217, DOI 10.1002/cyto.10077
   Beliën JAM, 2002, CYTOMETRY, V49, P12, DOI 10.1002/cyto.10138
   Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016
   Bissell MJ, 1999, CANCER RES, V59, p1757S
   Briand P, 1996, CANCER RES, V56, P2039
   BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578
   Cammas F, 2002, J CELL SCI, V115, P3439
   Castleman K.R., 1996, Digital image processing
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3
   Eckert RC, 2004, CYTOM PART A, V59A, P182, DOI 10.1002/cyto.a.20052
   Eils R, 2003, J CELL BIOL, V161, P477, DOI 10.1083/jcb.200302097
   Eils R, 2000, MOL BIOL CELL, V11, P413, DOI 10.1091/mbc.11.2.413
   Gerlich D, 2001, NAT CELL BIOL, V3, P852, DOI 10.1038/ncb0901-852
   Gil J, 2003, CANCER INVEST, V21, P950, DOI 10.1081/CNV-120025097
   Gribbon C, 2002, EUR J CELL BIOL, V81, P557, DOI 10.1078/0171-9335-00275
   Gudjonsson T, 2003, METHODS, V30, P247, DOI 10.1016/S1046-2023(03)00031-8
   Irinopoulou T, 1997, CYTOMETRY, V27, P99
   Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1
   JAHNE B, 2002, DIGITAL IMAGING PROC
   Kyan MJ, 2001, IEEE T BIO-MED ENG, V48, P1306, DOI 10.1109/10.959326
   Lelièvre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711
   Lelièvre SA, 2000, CRIT REV EUKAR GENE, V10, P13
   Lieb JD, 2000, GENETICS, V156, P1603
   Lin G, 2003, CYTOM PART A, V56A, P23, DOI 10.1002/cyto.a.10079
   Mancini MA, 1996, J CELL BIOCHEM, V62, P158, DOI 10.1002/(SICI)1097-4644(199608)62:2<158::AID-JCB3>3.3.CO;2-M
   Marr D., 1982, VISION
   Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29
   Merdes A, 1998, J CELL SCI, V111, P71
   PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Platani M, 2000, J CELL BIOL, V151, P1561, DOI 10.1083/jcb.151.7.1561
   Powers MJ, 2002, TISSUE ENG, V8, P499, DOI 10.1089/107632702760184745
   RIGAUT JP, 1991, CYTOMETRY, V12, P511, DOI 10.1002/cyto.990120608
   Russ J.C., 1992, The Image Processing Handbook
   Schüpp S, 2001, ANAL QUANT CYTOL, V23, P257
   Shumaker DK, 2003, CURR OPIN CELL BIOL, V15, P358, DOI 10.1016/S0955-0674(03)00050-4
   Sodja C, 1997, BIOCHEM CELL BIOL, V75, P399, DOI 10.1139/bcb-75-4-399
   Swedlow JR, 2003, SCIENCE, V300, P100, DOI 10.1126/science.1082602
   Tvaruskó W, 1999, P NATL ACAD SCI USA, V96, P7950, DOI 10.1073/pnas.96.14.7950
   Voss TC, 2004, BIOTECHNIQUES, V36, P240, DOI 10.2144/04362BI01
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Weaver VM, 1996, J CELL SCI, V109, P45
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430
   Zweyer M, 1997, EXP CELL RES, V230, P325, DOI 10.1006/excr.1996.3415
NR 49
TC 38
Z9 44
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 21
PY 2006
VL 103
IS 12
BP 4445
EP 4450
DI 10.1073/PNAS.0509944102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 026SN
UT WOS:000236362600024
PM 16537359
OA Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Liu, Y
   Liu, HL
   Han, BG
   Zhang, JT
AF Liu, Y
   Liu, HL
   Han, BG
   Zhang, JT
TI Identification of 14-3-3σ as a contributor to drug resistance in human
   breast cancer cells using functional proteomic analysis
SO CANCER RESEARCH
LA English
DT Article
ID SHOCK PROTEIN HSP27; PANCREATIC ADENOCARCINOMA; EPIGENETIC INACTIVATION;
   MULTIDRUG-RESISTANCE; LUNG CANCERS; SIGMA GENE; EXPRESSION;
   OVEREXPRESSION; CARCINOMA; HYPERMETHYLATION
AB Multidrug resistance (MDR) is a major obstacle to successful cancer treatment. To understand the mechanism of MDR, many cancer cell lines have been established, and various mechanisms of resistance, such as ATP-hinding cassette (ABC) transporter-mediated drug efflux, have been discovered. Previously, a MDR cell line MCF7/AdVp3000 was selected from breast cancer cell line MCF7 against Adriamycin, and overexpression of ABCG2 was thought to cause MDR in this derivative cell line. However, ectopic overexpression of ABCG2 in MCF7 cells could not explain the extremely high drug resistance level of the selected MCF7/AdVp3000 cells. We hypothesized that MCF7/AdVp3000 cells must have other resistance mechanisms selected by Adriamycin. To test this hypothesis, we compared the global protein profiles between MCF7 and MCF7/AdVp3000 cells. Following two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry analysis, 17 protein spots with differential levels between the two cell lines were identified. Although 14-3-3 sigma, keratin 18, keratin 19, ATP synthase beta, protein disulfide isomerase, heat shock protein 27, cathepsin D, triose-phosphate isomerase, peroxiredoxin 6, and electron transfer flavoprotein were increased, nm23/H1, peroxiredoxin 2, nucleophosmin 1/B23, and inorganic pyrophosphatase were decreased in MCF7/AdVp3000 cells. The differential levels of these proteins were validated using Western blot. Furthermore, functional validation showed that the elevated 14-3-3 sigma expression contributes considerably to the observed drug resistance in MCF7/AdVp3000 cells. We, thus, conclude that these proteins likely contribute to the resistance selected in the MCF7/AdVp3000 cells, and their altered expression in tumors may cause clinical resistance to chemotherapy.
C1 Indiana Univ, Sch Med, IU Canc Ctr, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Pharmacol & Toxicol,Walther Canc Inst, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis; Walther
   Cancer Institute; Indiana University System; Indiana University
   Indianapolis
RP Indiana Univ, Sch Med, IU Canc Ctr, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.
EM jianzhan@iupui.edu
RI Zhang, Jian-Ting/L-8334-2015
OI Zhang, Jian-Ting/0000-0002-2803-9914
FU NCI NIH HHS [CA94961] Funding Source: Medline
CR Anderson JM, 1996, CLIN CANCER RES, V2, P97
   Arts HJG, 1999, INT J CANCER, V84, P234, DOI 10.1002/(SICI)1097-0215(19990621)84:3<234::AID-IJC6>3.0.CO;2-9
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   CHEN YN, 1990, J BIOL CHEM, V265, P10073
   Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652
   Cress AE, 1996, CANCER METAST REV, V15, P499, DOI 10.1007/BF00054015
   Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   Falson P, 2004, BBA-BIOENERGETICS, V1658, P133, DOI 10.1016/j.bbabio.2004.05.008
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Ferguson AW, 1996, CANCER RES, V56, P2931
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   Gasco M, 2002, CANCER RES, V62, P2072
   Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256
   HAN B, 2006, IN PRESS MOL CANC TH
   Hustinx SR, 2005, CANCER BIOL THER, V4, P596, DOI 10.4161/cbt.4.5.1748
   Iizuka N, 2000, BRIT J CANCER, V83, P1209, DOI 10.1054/bjoc.2000.1436
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Lage H, 2004, PATHOL RES PRACT, V200, P105, DOI 10.1016/j.prp.2004.02.003
   Langdon SP, 1995, CLIN CANCER RES, V1, P1603
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   Lee JS, 1997, J CELL BIOCHEM, V65, P513, DOI 10.1002/(SICI)1097-4644(19970615)65:4<513::AID-JCB7>3.0.CO;2-R
   Litman T, 2000, J CELL SCI, V113, P2011
   Liu Y, 2005, MOL PHARMACOL, V68, P430, DOI 10.1124/mol.105.011015
   Liu Y, 2004, J PROTEOME RES, V3, P728, DOI 10.1021/pr034127+
   Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292
   Logsdon CD, 2003, CANCER RES, V63, P2649
   Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291
   Moreira JMA, 2005, MOL CELL PROTEOMICS, V4, P555, DOI 10.1074/mcp.M400205-MCP200
   Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5
   Nadin SB, 2003, CELL STRESS CHAPERON, V8, P361, DOI 10.1379/1466-1268(2003)008<0361:DADIBD>2.0.CO;2
   OESTERREICH S, 1993, CANCER RES, V53, P4443
   Papazisis KT, 1997, J IMMUNOL METHODS, V208, P151, DOI 10.1016/S0022-1759(97)00137-3
   Perathoner A, 2005, CLIN CANCER RES, V11, P3274, DOI 10.1158/1078-0432.CCR-04-2207
   Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   Rodriguez JA, 2005, WORLD J SURG, V29, P297, DOI 10.1007/s00268-004-7843-0
   Rosenquist M, 2003, BRAZ J MED BIOL RES, V36, P403, DOI 10.1590/S0100-879X2003000400001
   Simpson PT, 2004, J PATHOL, V202, P274, DOI 10.1002/path.1530
   Sinha P, 1999, ELECTROPHORESIS, V20, P2952, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H
   Suzuki H, 2000, CANCER RES, V60, P4353
   Tager M, 1997, EXP HEMATOL, V25, P601
   van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134
   Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z
   Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200
   Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755
   Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93
   Yatabe Y, 2002, ONCOGENE, V21, P8310, DOI 10.1038/sj.onc.1206014
NR 49
TC 93
Z9 116
U1 1
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2006
VL 66
IS 6
BP 3248
EP 3255
DI 10.1158/0008-5472.CAN-05-3801
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 022ZA
UT WOS:000236093500047
PM 16540677
DA 2025-01-12
ER

PT J
AU Lo, PK
   Mehrotra, J
   D'Costa, A
   Fackler, MJ
   Garrett-Mayer, E
   Argani, P
   Sukumar, S
AF Lo, Pang-Kuo
   Mehrotra, Jyoti
   D'Costa, Anisha
   Fackler, Mary Jo
   Garrett-Mayer, Elizabeth
   Argani, Pedram
   Sukumar, Saraswati
TI Epigenetic suppression of secreted frizzled related protein 1 (SFRP1)
   expression in human breast cancer
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE sFRP1; Wnt antagonist; DNA methylation; histone deacetylation; breast
   cancer
ID METHYLATION-SPECIFIC PCR; HISTONE DEACETYLASE INHIBITION; CARCINOMA
   IN-SITU; PROMOTER HYPERMETHYLATION; COLORECTAL-CANCER; DNA METHYLATION;
   UP-REGULATION; BETA-CATENIN; WNT PATHWAY; GENES
AB Expression of Secreted frizzled related protein 1 (SFRP1), a recently identified tumor suppressor gene encoding a WNT signaling antagonist, has been found to be frequently down-regulated in breast cancer and is associated with disease progression and poor prognosis. Here, we investigated the role of epigenetic silencing of SFRP1 in breast cancer cell lines and primary breast tumors. Through analyses by methylation-specific PCR and bisulfite sequencing, promoter methylation of SFRP1 was detected in 88% (7/8) of breast cancer cell lines, 17% (1/6) of grade 1 of ductal carcinoma in situ ( DCIS), 69% (9/13) of grade 2 and 3 of DCIS, 68% (19/28) of invasive ductal carcinomas (IDC) and 33% (6/18) of lobular carcinomas but not in any (0/14) of normal mammoplasty specimens and mammary epithelial organoids examined. Real-time RT-PCR studies indicated that loss or downregulation of SFRP1 expression in tumors is frequently associated with promoter hypermethylation. In addition, breast cancer cell lines with SFRP1 promoter hypermethylation reexpressed SFRP1 mRNA after treatment with 5-azaC, implying that DNA methylation is the predominant epigenetic mechanism for SFRP1 gene silencing. These findings suggest that frequent downregulation of SFRP1 expression in breast cancer can be attributed, in large part, to aberrant promoter hypermethylation in conjunction with or without histone deacetylation. Based on the frequency of tumor-specific hypermethylation in this gene, SFRP1 could provide a valuable marker for breast cancer.
C1 Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr,Breast Canc Pro, Baltimore, MD 21231 USA.
   Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University
RP Sukumar, S (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr,Breast Canc Pro, 1650 Orleans St,BBCRB 410, Baltimore, MD 21231 USA.
EM saras@jhmi.edu
OI Garrett-Mayer, Elizabeth/0000-0003-4709-0333
FU NCI NIH HHS [P50 CA88843] Funding Source: Medline
CR Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128
   BERGSTRAESSER LM, 1993, CANCER RES, V53, P2644
   Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Dale TC, 1996, CANCER RES, V56, P4320
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   HUGUET EL, 1994, CANCER RES, V54, P2615
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kirikoshi H, 2001, INT J ONCOL, V19, P1221
   Klopocki E, 2004, INT J ONCOL, V25, P641
   LEJEUNE S, 1995, CLIN CANCER RES, V1, P215
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polakis P, 2000, GENE DEV, V14, P1837
   Polyak K, 2002, CURR OPIN ONCOL, V14, P92, DOI 10.1097/00001622-200201000-00016
   Porter D, 2003, MOL CANCER RES, V1, P362
   Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Zou HZ, 2005, INT J CANCER, V116, P584, DOI 10.1002/ijc.21045
NR 38
TC 78
Z9 95
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD MAR
PY 2006
VL 5
IS 3
BP 281
EP 286
DI 10.4161/cbt.5.3.2384
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 043NU
UT WOS:000237608800015
PM 16410723
OA Bronze
DA 2025-01-12
ER

PT J
AU Bibikova, M
   Lin, ZW
   Zhou, LX
   Chudin, E
   Garcia, EW
   Wu, B
   Doucet, D
   Thomas, NJ
   Wang, YH
   Vollmer, E
   Goldmann, T
   Seifart, C
   Jiang, W
   Barker, DL
   Chee, MS
   Floros, J
   Fan, JB
AF Bibikova, M
   Lin, ZW
   Zhou, LX
   Chudin, E
   Garcia, EW
   Wu, B
   Doucet, D
   Thomas, NJ
   Wang, YH
   Vollmer, E
   Goldmann, T
   Seifart, C
   Jiang, W
   Barker, DL
   Chee, MS
   Floros, J
   Fan, JB
TI High-throughput DNA methylation profiling using universal bead arrays
SO GENOME RESEARCH
LA English
DT Article
ID TELOMERASE REVERSE-TRANSCRIPTASE; TIME PCR ASSAY; BREAST-CANCER;
   GENE-EXPRESSION; CPG METHYLATION; LUNG-CANCER; CELL LINES; EPIGENETICS;
   HYPERMETHYLATION; ASSOCIATION
AB We have developed a high-throughput method for analyzing the methylation status of hundreds of preselected genes simultaneously and have applied it to the discovery of methylation signatures that distinguish normal from cancer tissue samples. Through an adaptation of the GoldenGate genotyping assay implemented on a BeadArray platform, the methylation state of 1536 specific CpG sites in 371 genes (one to nine CpG sites per gene) was measured in a single reaction by multiplexed genotyping of 200 ng of bisulfite-treated genomic DNA. The assay was used to obtain a quantitative measure of the methylation level at each CpG site. After validating the assay in cell lines and normal tissues, we analyzed a panel Of lung cancer biopsy samples (N = 22) and identified a panel of methylation markers that distinguished lung adenocarcinomas from normal lung tissues with high specificity. These markers were validated in a second sample set (N = 24). These results demonstrate the effectiveness of the method for reliably profiling many CpG sites in parallel for the discovery of informative methylation markers. The technology should prove useful for DNA methylation analyses in large populations, with potential application to the classification and diagnosis of a broad range of cancers and other diseases.
C1 Illumina Inc, San Diego, CA 92121 USA.
   Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.
   Penn State Univ, Coll Med, Dept Pediat & Hlth Evaluat Sci, Hershey, PA 17033 USA.
   Penn State Univ, Coll Med, Dept Obstet & Gynecol, Hershey, PA 17033 USA.
   Res Ctr Borstel, Clin & Expt Pathol, D-23845 Borstel, Germany.
   Univ Marburg, Dept Internal Med, Div Resp Med, D-35043 Marburg, Germany.
   Burnham Inst, La Jolla, CA 92037 USA.
C3 Illumina; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health; Leibniz Association; Forschungszentrum Borstel; Philipps
   University Marburg; Sanford Burnham Prebys Medical Discovery Institute
RP Illumina Inc, San Diego, CA 92121 USA.
EM jfan@illumina.com
RI ; Goldmann, Torsten/E-5906-2010
OI Jiang, Wei/0000-0002-2309-9571; Goldmann, Torsten/0000-0002-1621-560X;
   Thomas, Neal/0000-0002-7991-7510
FU NCI NIH HHS [R44 CA097851, R43 CA097851, 2 R44 CA097851-02] Funding
   Source: Medline; PHS HHS [R37 NL-34788] Funding Source: Medline
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   Akama TO, 1997, CANCER RES, V57, P3294
   Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224
   Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107
   Barker DL, 2003, P SOC PHOTO-OPT INS, V4966, P1, DOI 10.1117/12.483434
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cottrell SE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh008
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Dennis C, 2003, NATURE, V421, P686, DOI 10.1038/421686a
   Dupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fan JB, 2003, COLD SPRING HARB SYM, V68, P69, DOI 10.1101/sqb.2003.68.69
   FAN JB, 2006, IN PRESS METHODS ENZ
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Galinsky VL, 2003, BIOINFORMATICS, V19, P1832, DOI 10.1093/bioinformatics/btg260
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Grunau C, 2002, J NUTR, V132, p2435S, DOI 10.1093/jn/132.8.2435S
   Gunderson KL, 2004, GENOME RES, V14, P870, DOI 10.1101/gr.2255804
   HANADA M, 1993, BLOOD, V82, P1820
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KAWAI J, 1994, MOL CELL BIOL, V14, P7421, DOI 10.1128/MCB.14.11.7421
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079
   Liu L, 2004, GENE CHROMOSOME CANC, V41, P26, DOI 10.1002/gcc.20058
   Lomas J, 2004, CANCER GENET CYTOGEN, V148, P148, DOI 10.1016/S0165-4608(03)00244-9
   Martens JWM, 2005, CANCER RES, V65, P4101, DOI 10.1158/0008-5472.CAN-05-0064
   Melnikov AA, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni092
   Ogama Y, 2004, INT J ONCOL, V25, P685
   Paz MF, 2003, CANCER RES, V63, P1114
   Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080
   Singal R, 2001, CANCER RES, V61, P4820
   SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P687, DOI 10.1093/nar/18.3.687
   Tomaszewski M, 2004, HYPERTENSION, V44, P689, DOI 10.1161/01.HYP.0000143844.81979.61
   Tost J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng050
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   WANG RYH, 1980, NUCLEIC ACIDS RES, V8, P4777, DOI 10.1093/nar/8.20.4777
   Widschwendter A, 2004, GYNECOL ONCOL, V93, P407, DOI 10.1016/j.ygyno.2004.01.036
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122
NR 57
TC 509
Z9 633
U1 4
U2 63
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD MAR
PY 2006
VL 16
IS 3
BP 383
EP 393
DI 10.1101/gr.4410706
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 018CZ
UT WOS:000235742700012
PM 16449502
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Wu, JY
   Vlastos, AT
   Pelte, MF
   Caligo, MA
   Bianco, A
   Krause, KH
   Laurent, GJ
   Irminger-Finger, I
AF Wu, JY
   Vlastos, AT
   Pelte, MF
   Caligo, MA
   Bianco, A
   Krause, KH
   Laurent, GJ
   Irminger-Finger, I
TI Aberrant expression of <i>BARD1</i> in breast and ovarian cancers with
   poor prognosis
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE BARD1; BRCA1; breast cancer; lung cancer; ovarian cancer; p53
ID CLEAR-CELL CARCINOMA; DISTINCT-HISTOLOGIC-TYPE; TUMOR-SUPPRESSOR;
   LUNG-CANCER; FAMILIAL BREAST; UBIQUITIN LIGASE; GENE-EXPRESSION; BRCA1
   GENE; DNA-REPAIR; P53
AB Mutations in tumor-suppressor gene BARD1 have been found in inherited and spontaneous breast, ovarian and uterine cancers. BARD1 plays a critical role in DNA repair and ubiquitination as binding partner of BRCA1, with which it colocalizes to nuclear dots. Independently of BRCA1, BARD1 can induce p53-dependent apoptosis in response to genotoxic stress. Therefore, BARD1 or p53 might be defective in cancer cells spared from apoptosis. We investigated BARD1 and p53 expression in ovarian, breast and non-small-cell lung cancers. BARD1 expression was highly upregulated and cytoplasmic in most cancer cells, while weak nuclear staining was observed in the surrounding normal tissue. Maximal BARD1 expression was associated with the most malignant ovarian cancer, clear cell carcinoma. In breast cancer, BARD1 expression was correlated with poor differentiation and large tumor size, established factors of poor prognosis, as well as short disease-free survival. In contrast to breast and ovarian cancers, no correlation of BARD1 expression with either grade or stage could be determined for lung cancer. RT-PCR, performed on 10 ovarian cancers, revealed absence of the 5' portion of the BARD1 transcript in 7 tumors, and sequencing of the remaining 3 identified a missense mutation (A1291G) resulting in an amino acid change of glutamine 406 to arginine. These data suggest that genetic and epigenetic changes might lead to elevated cytoplasmic expression of BARD1 and that cytoplasmic BARD1 might be a poor prognostic factor for breast and ovarian cancers. (c) 2005 Wiley-Liss, Inc.
C1 Univ Hosp Geneva, Dept Geriatr, Biol & Aging Lab, Geneva, Switzerland.
   Univ Hosp Geneva, Dept Obstet & Gynecol, Geneva, Switzerland.
   Univ Hosp Geneva, Dept Clin Pathol, Geneva, Switzerland.
   Univ Pisa, Dept Oncol Transplants & New Technol Med, Div Pathol, Pisa, Italy.
   SUN, Dept Cardiothorac & Resp Sci, Naples, Italy.
   UCL, Ctr Resp Dis, London, England.
C3 University of Geneva; University of Geneva; University of Geneva;
   University of Pisa; Universita della Campania Vanvitelli; University of
   London; University College London
RP Irminger-Finger, I (通讯作者)，Univ Geneva, Dept Geriatr, Biol Aging Lab, Chemin Petit Bel Air 2, CH-1225 Geneva, Switzerland.
EM irmgard.irminger@medecine.unige.ch
RI Krause, Karl-Heinz/E-8030-2011; Caligo, Maria/K-4289-2018
OI Caligo, Maria/0000-0003-0589-1829
CR American Joint Committee on Cancer, 2002, AJCC CANC STAG HDB T
   [Anonymous], 2003, WHO CLASSIFICATION T
   Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123
   Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6
   Bali A, 2004, CLIN CANCER RES, V10, P5168, DOI 10.1158/1078-0432.CCR-03-0751
   Bartley AN, 2002, ARCH PATHOL LAB MED, V126, P456
   BODNER SM, 1992, ONCOGENE, V7, P743
   Boulton SJ, 2004, CURR BIOL, V14, P33, DOI 10.1016/j.cub.2003.11.029
   Campling BG, 2003, MOL BIOTECHNOL, V24, P141, DOI 10.1385/MB:24:2:141
   Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200
   Esposito V, 2004, J CLIN PATHOL, V57, P58, DOI 10.1136/jcp.57.1.58
   Fabbro M, 2004, EXP CELL RES, V298, P661, DOI 10.1016/j.yexcr.2004.05.004
   Faleiro-Rodrigues C, 2004, ANN ONCOL, V15, P1535, DOI 10.1093/annonc/mdh387
   Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002
   FEKI A, 2004, BIOL REPROD
   Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223
   Goff BA, 1996, GYNECOL ONCOL, V60, P412, DOI 10.1006/gyno.1996.0065
   GORAI I, 1995, GYNECOL ONCOL, V57, P33, DOI 10.1006/gyno.1995.1097
   Greenman J, 1998, GENE CHROMOSOME CANC, V21, P244, DOI 10.1002/(SICI)1098-2264(199803)21:3<244::AID-GCC9>3.0.CO;2-#
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200
   Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3
   Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329
   Ishitobi M, 2003, CANCER LETT, V200, P1, DOI 10.1016/S0304-3835(03)00387-2
   Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427
   Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288
   Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075
   Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098
   Karppinen SM, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.020669
   Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576
   Maciel MD, 2002, BREAST CANCER RES TR, V71, P193, DOI 10.1023/A:1014403613747
   MAKAR AP, 1995, GYNECOL ONCOL, V56, P175, DOI 10.1006/gyno.1995.1027
   McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003
   Ménard S, 2001, ONCOLOGY-BASEL, V61, P67, DOI 10.1159/000055404
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Narayan G, 2003, ONCOGENE, V22, P3489, DOI 10.1038/sj.onc.1206432
   Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a
   Reinholz MM, 2004, BREAST CANCER RES TR, V86, P75, DOI 10.1023/B:BREA.0000032926.74216.7d
   Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302
   Roth JA, 1999, ONCOLOGY-NY, V13, P148
   Schäfer R, 2003, ADV ENZYME REGUL, V43, P379, DOI 10.1016/S0065-2571(02)00040-7
   Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6
   Silverberg SG, 2000, INT J GYNECOL PATHOL, V19, P7, DOI 10.1097/00004347-200001000-00003
   Spahn L, 2002, CANCER RES, V62, P4583
   Steels E, 2001, EUR RESPIR J, V18, P705, DOI 10.1183/09031936.01.00062201
   Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5
   Tammela J, 1998, EUR J GYNAECOL ONCOL, V19, P438
   Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   Tsutsui S, 2001, Breast Cancer, V8, P194, DOI 10.1007/BF02967508
   Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430
   Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4
   Zuco V, 2003, BIOCHEM PHARMACOL, V65, P1281, DOI 10.1016/S0006-2952(03)00079-0
NR 53
TC 62
Z9 72
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 1
PY 2006
VL 118
IS 5
BP 1215
EP 1226
DI 10.1002/ijc.21428
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 008QP
UT WOS:000235056100018
PM 16152612
OA Bronze
DA 2025-01-12
ER

PT J
AU Wu, Z
   Siadaty, MS
   Riddick, G
   Frierson, HF
   Lee, JK
   Golden, W
   Knuutila, S
   Hampton, GM
   El-Rifai, W
   Theodorescu, D
AF Wu, Z.
   Siadaty, M. S.
   Riddick, G.
   Frierson, H. F., Jr.
   Lee, J. K.
   Golden, W.
   Knuutila, S.
   Hampton, G. M.
   El-Rifai, W.
   Theodorescu, D.
TI A novel method for gene expression mapping of metastatic competence in
   human bladder cancer
SO NEOPLASIA
LA English
DT Article
DE bladder neoplasms; metastasis; gene expression; comparative genomic
   hybridization; karyotype
ID COMPARATIVE GENOMIC HYBRIDIZATION; TRANSITIONAL-CELL CARCINOMA; HUMAN
   BREAST-TUMORS; CHROMOSOMAL IMBALANCES; NUMBER; MICROARRAYS; PROGRESSION;
   OVEREXPRESSION; AMPLIFICATION; EPIGENETICS
AB Expression profiling by DNA microarray analysis has provided insights into molecular alterations that underpin cancer progression and metastasis. Although differential expression of microarray-defined probes can be related to numerical or structural chromosomal alterations, it is unclear if such changes are also clustered in distinct chromosomes or genomic regions and whether chromosomal alterations always reflect changes in gene expression. Here we apply the dChip algorithm and a novel technique to test the hypothesis that expression changes occurring as a function of tumor progression and metastasis are nonrandomly distributed. Expression profiling of a human xenograft model of lung metastasis phenotype indicates that chromosomes 2, 11, and 20 contain higher percentages of differentially expressed genes ( P <.05). Furthermore, we show that a number of differentially expressed probes mapped to chromosome 17q, defining the existence of an expression "hot spot'' corresponding to an area of gain determined by comparative genomic hybridization (CGH). Interestingly, other areas of gains detected by CGH were not associated with expression hot spots. In summary, we show that gene expression changes during bladder cancer lung metastasis occur nonrandomly in specific chromosomes and intrachromosomal locations.
C1 Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol, Charlottesville, VA 22903 USA.
   Univ Virginia, Hlth Sci Ctr, Dept Publ Hlth Sci, Div Biostat, Charlottesville, VA 22903 USA.
   Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22903 USA.
   Univ Helsinki, Haartman Inst, Dept Pathol & Mol Ctyogenet, FIN-00014 Helsinki, Finland.
   Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.
   Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Ingram Vanderbilt Canc Ctr, Nashville, TN USA.
C3 University of Virginia; University of Virginia; University of Virginia;
   University of Helsinki; Novartis; Novartis USA; Vanderbilt University;
   Vanderbilt University
RP Theodorescu, D (通讯作者)，Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol, Box 422, Charlottesville, VA 22903 USA.
EM dt9d@virginia.edu
OI Theodorescu, Dan/0000-0002-8708-8206
FU NCI NIH HHS [CA075115, R29 CA075115, R01 CA075115] Funding Source:
   Medline
CR ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   Andersen PK, 1993, STAT MODELS BASED CO
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bohringer S., 2002, ONL J BIOINFORM, V1, P51
   Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO;2-L
   Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044
   DALBAGNI G, 1993, DIAGN MOL PATHOL, V2, P4, DOI 10.1097/00019606-199303000-00002
   Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061
   El-Rifai W, 2000, AM J PATHOL, V156, P871, DOI 10.1016/S0002-9440(10)64956-5
   El-Rifai W, 1997, LAB INVEST, V77, P699
   ElRifai W, 1996, CANCER RES, V56, P3230
   Gildea JJ, 2000, GENE CHROMOSOME CANC, V27, P252, DOI 10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Guo ZM, 2004, NAT MED, V10, P374, DOI 10.1038/nm1010
   IWABUCHI H, 1995, CANCER RES, V55, P6172
   Jain N, 2003, BIOINFORMATICS, V19, P1945, DOI 10.1093/bioinformatics/btg264
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156
   Koon N, 2004, NEOPLASIA, V6, P143, DOI 10.1593/neo.03385
   Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567
   Masayesva BG, 2004, P NATL ACAD SCI USA, V101, P8715, DOI 10.1073/pnas.0400027101
   Modlich O, 2004, CLIN CANCER RES, V10, P3410, DOI 10.1158/1078-0432.CCR-03-0134
   Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Phillips JL, 2001, CANCER RES, V61, P8143
   Platzer P, 2002, CANCER RES, V62, P1134
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1
   Sanchez-Carbayo M, 2003, AM J PATHOL, V163, P505, DOI 10.1016/S0002-9440(10)63679-6
   SCHLEGEL J, 1995, CANCER RES, V55, P6002
   Schneider BF, 1998, CANCER GENET CYTOGEN, V105, P145, DOI 10.1016/S0165-4608(98)00030-2
   Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320
   Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065
   SolinasToldo S, 1996, CANCER RES, V56, P3803
   Su AI, 2001, CANCER RES, V61, P7388
   Thykjaer T, 2001, CANCER RES, V61, P2492
   TROWSDALE J, 1993, TRENDS GENET, V9, P117, DOI 10.1016/0168-9525(93)90205-V
   Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861
   Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496
NR 41
TC 19
Z9 19
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD MAR
PY 2006
VL 8
IS 3
BP 181
EP 189
DI 10.1593/neo.05727
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 067DV
UT WOS:000239282800003
PM 16611411
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Britschgi, C
   Rizzi, M
   Grob, TJ
   Tschan, MP
   Hügli, B
   Reddy, VA
   Andres, AC
   Torbett, BE
   Tobler, A
   Fey, MF
AF Britschgi, C
   Rizzi, M
   Grob, TJ
   Tschan, MP
   Hügli, B
   Reddy, VA
   Andres, AC
   Torbett, BE
   Tobler, A
   Fey, MF
TI Identification of the p53 family-responsive element in the promoter
   region of the tumor suppressor gene hypermethylated in cancer 1
SO ONCOGENE
LA English
DT Article
DE HIC1; p53; transcriptional target; HIC1.PRE; p73
ID HUMAN BREAST-CANCER; DNA-BINDING; COLORECTAL-CANCER; HIC-1; P73;
   EXPRESSION; CELLS; SITE; PCR; TUMORIGENESIS
AB The tumor suppressor gene hypermethylated in cancer 1 (HIC1), located on human chromosome 17p13.3, is frequently silenced in cancer by epigenetic mechanisms. Hypermethylated in cancer 1 belongs to the bric a brac/ poxviruses and zinc-finger family of transcription factors and acts by repressing target gene expression. It has been shown that enforced p53 expression leads to increased HIC1 mRNA, and recent data suggest that p53 and Hic1 cooperate in tumorigenesis. In order to elucidate the regulation of HIC1 expression, we have analysed the HIC1 promoter region for p53-dependent induction of gene expression. Using progressively truncated luciferase reporter gene constructs, we have identified a p53-responsive element (PRE) 500 bp upstream of the TATA-box containing promoter P0 of HIC1, which is sequence specifically bound by p53 in vitro as assessed by electrophoretic mobility shift assays. We demonstrate that this HIC1 p53-responsive element ( HIC1. PRE) is necessary and sufficient to mediate induction of transcription by p53. This result is supported by the observation that abolishing endogenous wild-type p53 function prevents HIC1 mRNA induction in response to UV-induced DNA damage. Other members of the p53 family, notably TAp73 beta and Delta Np63 alpha, can also act through this HIC1. PRE to induce transcription of HIC1, and finally, hypermethylation of the HIC1 promoter attenuates inducibility by p53.
C1 Inselspital Bern, CH-3010 Bern, Switzerland.
   Univ Bern, Dept Clin Res, Bern, Switzerland.
   Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA.
   Univ Bern, Dept Clin Res, Tiefenau Labs, Bern, Switzerland.
C3 University of Bern; Scripps Research Institute; University of Bern
RP Inselspital Bern, CH-3010 Bern, Switzerland.
EM martin.fey@insel.ch
RI Grob, Tobias/KHT-8187-2024; Rizzi, Mattia/ABE-3996-2021
OI Britschgi, Christian/0000-0001-8831-1564; Grob,
   Tobias/0000-0002-6298-9796; Tschan, Mario P./0000-0001-5897-3647; Rizzi,
   Mattia/0000-0001-6987-0678
FU NIAID NIH HHS [AI49165] Funding Source: Medline
CR Ahuja N, 1997, CANCER RES, V57, P3370
   Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176
   Bahia H, 2002, INT J ONCOL, V20, P489
   Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136
   Bénard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   CHEN W, 2005, P AM ASSOC CANC RES, V46, P114
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030
   de Almodóvar CR, 2004, J BIOL CHEM, V279, P4093, DOI 10.1074/jbc.M311243200
   Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831
   Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
   ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45
   Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Galimi F, 2002, BLOOD, V100, P2732, DOI 10.1182/blood-2002-04-1245
   Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962
   Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200
   Issa JPJ, 1997, CANCER RES, V57, P1678
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004
   Liu XG, 2004, CANCER RES, V64, P5078, DOI 10.1158/0008-5472.CAN-04-1195
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154
   Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316
   Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861
   Moll UM, 2004, MOL CANCER RES, V2, P371
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731
   Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163
   Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524
   Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200
   Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504
   Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974
   Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270
   Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wölcke J, 2003, J BIOL CHEM, V278, P32587, DOI 10.1074/jbc.M303615200
   Wu GJ, 2005, CANCER RES, V65, P758
NR 42
TC 44
Z9 47
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR
PY 2006
VL 25
IS 14
BP 2030
EP 2039
DI 10.1038/sj.onc.1209240
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 026RL
UT WOS:000236359700006
PM 16301995
DA 2025-01-12
ER

PT J
AU Swift-Scanlan, T
   Blackford, A
   Argani, P
   Sukumar, S
   Fackler, MJ
AF Swift-Scanlan, T
   Blackford, A
   Argani, P
   Sukumar, S
   Fackler, MJ
TI Two-color quantitative multiplex methylation-specific PCR
SO BIOTECHNIQUES
LA English
DT Article
ID REAL-TIME PCR; DNA-METHYLATION; MESSENGER-RNA; PROMOTER
   HYPERMETHYLATION; BREAST-CANCER; RT-PCR; EPIGENETICS; ASSAY;
   CARCINOGENESIS; CYTOSINES
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, CRB Room 416,1650 Orleans St, Baltimore, MD 21231 USA.
EM mfackler@jhmi.edu
FU NCI NIH HHS [P50CA88843] Funding Source: Medline; NINR NIH HHS [F31
   NR008311-01A1] Funding Source: Medline
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035
   Barcellos-Hoff MH, 2001, J MAMMARY GLAND BIOL, V6, P213, DOI 10.1023/A:1011317009329
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cottrell SE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh008
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Grace MB, 2003, CLIN CHEM, V49, P1467, DOI 10.1373/49.9.1467
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hindiyeh M, 2005, J CLIN MICROBIOL, V43, P589, DOI 10.1128/JCM.43.2.589-595.2005
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Simi L, 2004, LUNG CANCER, V45, P171, DOI 10.1016/j.lungcan.2004.01.014
   Thomassin H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh166
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 23
TC 23
Z9 38
U1 0
U2 3
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 0736-6205
EI 1940-9818
J9 BIOTECHNIQUES
JI Biotechniques
PD FEB
PY 2006
VL 40
IS 2
BP 210
EP 219
DI 10.2144/000112097
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 012QX
UT WOS:000235355300013
PM 16526411
OA Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Cheng, YW
   Shawber, C
   Notterman, D
   Paty, P
   Barany, F
AF Cheng, YW
   Shawber, C
   Notterman, D
   Paty, P
   Barany, F
TI Multiplexed profiling of candidate genes for CpG island methylation
   status using a flexible PCR/LDR/Universal Array assay
SO GENOME RESEARCH
LA English
DT Article
ID DNA METHYLATION; COLORECTAL-CANCER; BREAST-CANCER; PCR ASSAY;
   HYPERMETHYLATION; MICROARRAY; MUTATIONS; PHENOTYPE; TUMOR; EPIGENETICS
AB DNA methylation in CpG islands is associated with transcriptional silencing. Accurate determination of cytosine methylation status ill promoter CpG dinucleotides may provide diagnostic and prognostic value for human cancers. We have developed a quantitative PCR/LDR/Universal Array assay that allows parallel evaluation of methylation status of 75 CpG dinucleotides in the promoter regions of 15 tumor Suppressor genes (CDKN2B, CDKN2A, CDKN2D, CDKN1A, CDKN1B, TP53, BRCA1, TIMP3, APC, RASSF1, CDH1, MGMT, DAPK1, GSTP1, and RARB). When compared with an independent pyrosequencing method at a single promoter, the two approaches gave good correlation. In a study using 15 promoter regions and seven blinded tumor cell lines, Our technology was capable of distinguishing methylation profiles that identified cancer cell lines derived from the same origins. Preliminary studies using 96 colorectal tumor samples and 73 matched normal tissues indicated CpG methylation is a gene-specific and nonrandom event in colon cancer. This new approach is suitable for clinical applications where sample quantity and purity can be limiting factors.
C1 Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
   Columbia Univ, Med Ctr, Dept OB GYN, New York, NY 10032 USA.
   Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08901 USA.
   Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet, New Brunswick, NJ 08901 USA.
   Mem Sloan Kettering Canc Ctr, Colorectal Surg Serv, Dept Surg, New York, NY 10021 USA.
C3 Cornell University; Weill Cornell Medicine; Columbia University; Rutgers
   University System; Rutgers University New Brunswick; Rutgers University
   Biomedical & Health Sciences; Rutgers University System; Rutgers
   University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Memorial Sloan Kettering Cancer Center
RP Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
EM barany@med.cornell.edu
RI Cheng, Yingwen/B-2202-2012
FU NCI NIH HHS [P01 CA065930, P01-CA65930] Funding Source: Medline
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   Balog RP, 2002, ANAL BIOCHEM, V309, P301, DOI 10.1016/S0003-2697(02)00294-4
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Boyd VL, 2004, ANAL BIOCHEM, V326, P278, DOI 10.1016/j.ab.2003.11.020
   Chen JY, 2004, MAR BIOTECHNOL, V6, P1, DOI 10.1007/s10126-002-0115-9
   CHEN TR, 1995, CANCER GENET CYTOGEN, V81, P103, DOI 10.1016/0165-4608(94)00225-Z
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Deng GR, 1999, CANCER RES, V59, P2029
   Dupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007
   Esteller M, 2001, CANCER RES, V61, P3225
   Favis R, 2000, NAT BIOTECHNOL, V18, P561, DOI 10.1038/75452
   Favis R, 2004, HUM MUTAT, V24, P63, DOI 10.1002/humu.20069
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2001, NAT GENET, V27, P9, DOI 10.1038/83825
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Khanna M, 1999, ONCOGENE, V18, P27, DOI 10.1038/sj.onc.1202291
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8
   Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3071, DOI 10.1093/nar/24.15.3071
   Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4
   Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Uhlmann K, 2002, ELECTROPHORESIS, V23, P4072, DOI 10.1002/elps.200290023
   Warnecke PM, 2000, CURR OPIN ONCOL, V12, P68, DOI 10.1097/00001622-200001000-00012
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9
   Yan PS, 2003, CANCER RES, V63, P6178
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122
   Zirvi M, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e41
NR 41
TC 32
Z9 44
U1 0
U2 9
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD FEB
PY 2006
VL 16
IS 2
BP 282
EP 289
DI 10.1101/gr.4181406
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 009OP
UT WOS:000235122000016
PM 16369045
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Takahashi, K
   Kohno, T
   Ajima, R
   Sasaki, H
   Minna, JD
   Fujiwara, T
   Tanaka, N
   Yokota, J
AF Takahashi, K
   Kohno, T
   Ajima, R
   Sasaki, H
   Minna, JD
   Fujiwara, T
   Tanaka, N
   Yokota, J
TI Homozygous deletion and reduced expression of the <i>DOCK8</i> gene in
   human lung cancer
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE DOCK; lung cancer; homozygous deletion; epigenetic alteration; tumor
   suppressor gene
ID TUMOR-SUPPRESSOR GENE; CELL CARCINOMA; CHROMOSOME 9P; IDENTIFICATION;
   ARRAY; DNA; CARCINOGENESIS; ACTIVATOR; PROTEINS; REVEALS
AB A homozygous deletion of the DOCK8 (dedicator of cytokinesis 8) locus at chromosome 9p24 was found in a lung cancer cell line by array-CGH analysis. Cloning of the full-length DOCK8 cDNA led us to define that the DOCK8 gene encodes a protein consisting of 2,099 amino acids. DOCK8 was expressed in a variety of human organs, including the lungs, and was also expressed in type II alveolar, bronchiolar epithelial and bronchial epithelial cells, which are considered as being progenitors for lung cancer cells. DOCK8 expression was reduced in 62/71 (87%) primary lung cancers compared with normal lung tissue, and the reduction occurred irrespective of the histological type of lung cancer. 5-aza-2'-deoxy-cytidine and/or Trichostatin A treatments induced DOCK8 expression in lung cancer cell lines with reduced DOCK8 expression. Therefore, epigenetic mechanisms, including DNA methylation and histone deacetylation, were indicated to be involved in DOCK8 down-regulation in lung cancer cells. Further screening revealed homozygous deletions of the DOCK8 gene in a gastric and a breast cancer cell line. DOCK family proteins have been shown to play roles in regulation of migration, morphology, adhesion and growth of cells. Thus, the present results suggest that genetic and epigenetic inactivation of DOCK8 is involved in the development and/or progression of lung and other cancers by disturbing such regulations.
C1 Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan.
   Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 1040045, Japan.
   Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Houston, TX 77030 USA.
   Okayama Univ, Grad Sch Med & Dent, Dept Surg, Okayama 7008558, Japan.
   Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan.
C3 National Cancer Center - Japan; National Cancer Center - Japan;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; Okayama University; Okayama University
RP Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5-Chome, Tokyo 1040045, Japan.
EM jyokota@gan2.ncc.go.jp
RI Kohno, Takashi/M-8823-2013; Minna, John/AAB-1036-2022
FU NCI NIH HHS [P50CA70907] Funding Source: Medline
CR Albertson DG, 2003, HUM MOL GENET, V12, pR145, DOI 10.1093/hmg/ddg261
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Côté JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219
   Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X
   Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N
   Heidenblad M, 2004, CANCER RES, V64, P3052, DOI 10.1158/0008-5472.CAN-03-3159
   Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x
   Ishizuka T, 2002, BIOCHEM BIOPH RES CO, V296, P152, DOI 10.1016/S0006-291X(02)00836-7
   Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307
   Jänne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329
   Kim SK, 1997, CANCER RES, V57, P400
   Kishimoto M, 2005, CLIN CANCER RES, V11, P512
   Kobayashi K, 2004, ONCOGENE, V23, P3089, DOI 10.1038/sj.onc.1207433
   Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403
   KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125
   Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835
   Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2
   Nishioka M, 2002, P NATL ACAD SCI USA, V99, P12269, DOI 10.1073/pnas.192445899
   Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009
   Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587
   Ruusala A, 2004, FEBS LETT, V572, P159, DOI 10.1016/j.febslet.2004.06.095
   Sanchez-Cespedes M, 2003, LUNG CANCER, V40, P111, DOI 10.1016/S0169-5002(03)00033-3
   Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200
   Shan ZH, 2004, ONCOGENE, V23, P6612, DOI 10.1038/sj.onc.1207857
   Tani M, 2004, GENE CHROMOSOME CANC, V40, P146, DOI 10.1002/gcc.20027
   Wiest JS, 1997, CANCER RES, V57, P1
   Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7
   Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x
NR 28
TC 43
Z9 46
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2006
VL 28
IS 2
BP 321
EP 328
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 004NF
UT WOS:000234758800005
PM 16391785
DA 2025-01-12
ER

PT J
AU Hunter, K
AF Hunter, K
TI Opinion - Host genetics influence tumour metastasis
SO NATURE REVIEWS CANCER
LA English
DT Article
ID BREAST-CANCER METASTASIS; GENES; MOUSE; MICE; SUSCEPTIBILITY;
   IDENTIFICATION; PROGRESSION; SIGNATURE; CARCINOMA; DIAGNOSIS
AB The complexity of the metastatic process has made it difficult to gain a full understanding of the origins of this most lethal aspect of cancer. Many factors probably have an important role, including somatic mutation, epigenetic modulations, interactions with normal stroma, and environmental stimuli. Additionally, recent evidence implies a significant role for germline polymorphisms in cancer progression. The existence of inherited metastasis risk factors ( or prospective metastatic biomarkers) has potentially significant implications for our models of metastasis, clinical prognosis and the development of tailored treatment. Further investigations into the inherited components of metastasis might help resolve many of the questions that remain about tumour progression.
C1 NCI, Lab Populat Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP NCI, Lab Populat Genet, Ctr Canc Res, NIH, Bldg 41,Room D702,41 Lib Dr, Bethesda, MD 20892 USA.
EM hunterk@mail.nih.gov
FU Intramural NIH HHS Funding Source: Medline
CR Bammler T, 2005, NAT METHODS, V2, P351, DOI 10.1038/nmeth0605-477a
   Ben-Eliyahu S, 2003, BRAIN BEHAV IMMUN, V17, pS27
   Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a
   Bystrykh L, 2005, NAT GENET, V37, P225, DOI 10.1038/ng1497
   Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518
   Cheung ST, 2002, CANCER RES, V62, P4711
   Conrods TP, 2003, EXPERT REV MOL DIAGN, V3, P411, DOI 10.1586/14737159.3.4.411
   Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345
   Demicheli R, 1996, BREAST CANCER RES TR, V41, P177, DOI 10.1007/BF01807163
   Dragani TA, 2000, JPN J CANCER RES, V91, P1142, DOI 10.1111/j.1349-7006.2000.tb00897.x
   Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469
   Eppig JT, 2005, NUCLEIC ACIDS RES, V33, pD471, DOI 10.1093/nar/gki113
   Fidler IJ, 2003, NAT GENET, V34, P23, DOI 10.1038/ng0503-23a
   Gould KA, 1996, GENETICS, V144, P1777
   Harris M, 2005, LANCET ONCOL, V6, P301, DOI 10.1016/S1470-2045(05)70166-2
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Hunter K, 2003, NAT GENET, V34, P23, DOI 10.1038/ng0503-23b
   Hunter KW, 2001, CANCER RES, V61, P8866
   Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756
   Larkin JE, 2005, NAT METHODS, V2, P337, DOI 10.1038/nmeth757
   Li RH, 2005, GENETICS, V169, P1699, DOI 10.1534/genetics.104.033993
   Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8
   Malins DC, 2004, P NATL ACAD SCI USA, V101, P11428, DOI 10.1073/pnas.0404572101
   Park YG, 2005, NAT GENET, V37, P1055, DOI 10.1038/ng1635
   Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242
   Rabino I, 2003, SCI TECHNOL HUM VAL, V28, P365, DOI 10.1177/0162243903028003002
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101
   Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502
   Ruggiero M, 1998, ONCOL RES, V10, P43
   Samuelson DJ, 2003, CARCINOGENESIS, V24, P1455, DOI 10.1093/carcin/bgg112
   Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434
   TALMADGE JE, 1982, SCIENCE, V217, P361, DOI 10.1126/science.6953592
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100
   Yang HY, 2004, CLIN EXP METASTAS, V21, P719, DOI 10.1007/s10585-004-8251-4
   Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843
NR 38
TC 99
Z9 125
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-175X
EI 1474-1768
J9 NAT REV CANCER
JI Nat. Rev. Cancer
PD FEB
PY 2006
VL 6
IS 2
BP 141
EP 146
DI 10.1038/nrc1803
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 005SL
UT WOS:000234844000012
PM 16491073
DA 2025-01-12
ER

PT J
AU Li, CM
   Margolin, AA
   Salas, M
   Memeo, L
   Mansukhani, M
   Hibshoosh, H
   Szabolcs, M
   Klinakis, A
   Tycko, B
AF Li, CM
   Margolin, AA
   Salas, M
   Memeo, L
   Mansukhani, M
   Hibshoosh, H
   Szabolcs, M
   Klinakis, A
   Tycko, B
TI <i>PEG10</i> is a c-MYC target gene in cancer cells
SO CANCER RESEARCH
LA English
DT Article
ID IMPRINTED GENE; REGULATORY GENES; GENOMIC TARGETS; BREAST-CANCER;
   EXPRESSION; IDENTIFICATION; AMPLIFICATION; TRANSCRIPTION; ACTIVATION;
   CARCINOMA
AB The product of the imprinted gene paternally expressed gene-10 (PEG10) has been reported to support proliferation in hepatocellular carcinomas, but how this gene is regulated hat; been an open question. We rind that MYC knockdown by RNA interference suppresses PEG10 expression in Panel pancreatic carcinoma and HepG2 hepatocellular carcinoma cells and that knockdown of PEG10 inhibits the proliferation of Panc1, HepG2, and Hep3B cells. Conversely, PEG10 was up-regulated by inducing c-MYC expression in a B-lymphocyte cell line. Chromatin immunoprecipitation from Panel cells showed c-MYC bound to an E-box-containing region in the PEG10 first intron and site-directed mutagenesis showed that the most proximal E-box is essential for promoter activity. In a mouse mammary tumor virus (MMTV)-MYC transgenic mouse model of breast cancer, most but not all of the mammary carcinomas had strongly increased Peg10 mRNA compared with normal mammary gland. By immunohistochemistry. normal human breast and prostate epithelium was negative for the major isoform [reading frame-1 (RF1)] of PEG10 protein, but this cytoplasmic protein was strongly expressed in a subset of breast carcinomas in situ and invasive ductal carcinomas (similar to 30%) and in a similar percentage of prostate cancers. As in the mouse model, we found positive, but not absolute, correlations between PEG10 and c-MYC in tissue arrays containing 161 human breast cancers (P < 0.002) and 30 prostate cancers (P = 0.014). Immunostaining of human placenta showed PEG10 and c-MYC proteins coexpressed in proliferating cytotrophoblast and coordinately lost in postmitotic syncytiotrophoblast. These findings link cancer genetics and epigenetics by showing that a classic protooncogene, MYC, acts directly upstream of a proliferation-positive imprinted gene, PEG10.
C1 Columbia Univ, Med Ctr, Inst Canc Genet, New York, NY 10032 USA.
   Columbia Univ, Med Ctr, Gen Ctr, New York, NY 10032 USA.
   Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University
RP Columbia Univ, Med Ctr, Inst Canc Genet, 1150 St Nicholas Ave, New York, NY 10032 USA.
EM bt12@columbia.edu
OI Memeo, Lorenzo/0000-0003-4251-7203
CR Aulmann S, 2002, BREAST CANCER RES TR, V74, P25, DOI 10.1023/A:1016061327812
   CARDIFF RD, 1991, AM J PATHOL, V139, P495
   Courjal F, 1997, CANCER RES, V57, P4360
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003
   Glöckner S, 2001, LAB INVEST, V81, P565, DOI 10.1038/labinvest.3780265
   Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653
   Haig D, 2004, ANNU REV GENET, V38, P553, DOI 10.1146/annurev.genet.37.110801.142741
   Hu CS, 2004, CELL MOL IMMUNOL, V1, P280
   Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2
   Lux A, 2005, J BIOL CHEM, V280, P8482, DOI 10.1074/jbc.M409197200
   Manktelow E, 2005, NUCLEIC ACIDS RES, V33, P1553, DOI 10.1093/nar/gki299
   Okabe H, 2003, CANCER RES, V63, P3043
   Ono R, 2003, GENOME RES, V13, P1696, DOI 10.1101/gr.906803
   Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494
   Smallwood A, 2003, BIOL REPROD, V69, P286, DOI 10.1095/biolreprod.102.013078
   Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528
   Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676
   Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010
   Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323
   Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69
   Zhang DY, 2004, HEPATOLOGY, V39, P954, DOI 10.1002/hep.20135
NR 22
TC 82
Z9 100
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 15
PY 2006
VL 66
IS 2
BP 665
EP 672
DI 10.1158/0008-5472.CAN-05-1553
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 006RQ
UT WOS:000234915100013
PM 16423995
OA Bronze
DA 2025-01-12
ER

PT J
AU Birgisdottir, V
   Stefansson, OA
   Bodvarsdottir, SK
   Hilmarsdottir, H
   Jonasson, JG
   Eyfjord, JE
AF Birgisdottir, Valgerdur
   Stefansson, Olafur A.
   Bodvarsdottir, Sigridur K.
   Hilmarsdottir, Holmfridur
   Jonasson, Jon G.
   Eyfjord, Jorunn E.
TI Epigenetic silencing and deletion of the <i>BRCA1</i> gene in sporadic
   breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID GERM-LINE MUTATION; PROMOTER HYPERMETHYLATION; OVARIAN-CANCER;
   EXPRESSION PROFILES; METHYLATION; TUMORS; CARCINOMAS; REGION;
   INACTIVATION; CHROMOSOME
AB Introduction BRCA1 or BRCA2 germline mutations increase the risk of developing breast cancer. Tumour cells from germline mutation carriers have frequently lost the wild-type allele. This is predicted to result in genomic instability where cell survival depends upon dysfunctional checkpoint mechanisms. Tumorigenic potential could then be acquired through further genomic alterations. Surprisingly, somatic BRCA mutations are not found in sporadic breast tumours. BRCA1 methylation has been shown to occur in sporadic breast tumours and to be associated with reduced gene expression. We examined the frequency of BRCA1 methylation in 143 primary sporadic breast tumours along with BRCA1 copy number alterations and tumour phenotype.
   Methods Primary sporadic breast tumours were analysed for BRCA1 a promoter methylation by methylation specific PCR and for allelic imbalance ( AI) at BRCA1 and BRCA2 loci by microsatellite analysis and TP53 ( also known as p53) mutations by constant denaturing gel electrophoresis. The BRCA1 methylated tumours were analysed for BRCA1 copy alterations by fluorescence in situ hybridisation and BRCA1 expression by immunostaining.
   Results BRCA1 methylation was found in 13/143 (9.1%) sporadic breast tumours. The BRCA1 methylated tumours were significantly associated with estrogen receptor ( ER) negativity P = 0.0475) and displayed a trend for BRCA1 AI ( P = 0.0731) as well as young-age at diagnosis (<= 55; P = 0.0898). BRCA1 methylation was not associated with BRCA2 AI ( P = 0.5420), although a significant association was found between BRCA1 AI and BRCA2 AI ( P < 0.0001).
   Absent/markedly reduced BRCA1 expression was observed in 9/13 BRCA1 methylated tumours, most of which had BRCA1 deletion. An elevated TP53 mutation frequency was found among BRCA1 methylated tumours (38.5%) compared with non-methylated tumours (17.2%). The BRCA1 methylated tumours were mainly of tumour grade 3 (7/13) and infiltrating ductal type (12/13). Only one methylated tumour was of grade 1.
   Conclusion BRCA1 methylation is frequent in primary sporadic breast tumours. We found an indication for BRCA1 methylation to be associated with AI at the BRCA1 locus. Almost all BRCA1 methylated tumours with absent/markedly reduced BRCA1 expression (8/9) displayed BRCA1 deletion. Thus, epigenetic silencing and deletion of the BRCA1 gene might serve as Knudson's two 'hits' in sporadic breast tumorigenesis. We observed phenotypic similarities between BRCA1 methylated and familial BRCA1 tumours, based on BRCA1 deletion, TP53 mutations, ER status, young age at diagnosis and tumour grade.
C1 Iceland Canc Soc, Mol & Cell Biol Res Lab, Reykjavik, Iceland.
   Univ Iceland, Dept Med, Reykjavik, Iceland.
   Iceland Canc Registry, Reykjavik, Iceland.
   Univ Hosp, Dept Pathol, Reykjavik, Iceland.
C3 University of Iceland; Landspitali National University Hospital
RP Eyfjord, JE (通讯作者)，Iceland Canc Soc, Mol & Cell Biol Res Lab, Reykjavik, Iceland.
EM jorunn@krabb.is
OI Jonasson, Jon G./0000-0002-2635-5032; Bodvarsdottir, Sigridur
   Klara/0000-0001-8799-8018; Hilmarsdottir, Holmfridur/0000-0003-1040-8125
CR Alvarez S, 2005, CLIN CANCER RES, V11, P1146
   Arver B, 2000, SEMIN CANCER BIOL, V10, P271, DOI 10.1006/scbi.2000.0325
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Bergthorsson JT, 1998, HUM MUTAT, pS195
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   COLLINS N, 1995, ONCOGENE, V10, P1673
   Eisinger F, 1996, CANCER RES, V56, P471
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2001, CANCER RES, V61, P3225
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Greenblatt MS, 2001, CANCER RES, V61, P4092
   Gudlaugsdottir S, 2000, DIAGN CYTOPATHOL, V22, P268, DOI 10.1002/(SICI)1097-0339(200005)22:5<268::AID-DC2>3.0.CO;2-X
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396
   Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453
   Johnson SM, 2002, INT J CANCER, V98, P205, DOI 10.1002/ijc.10197
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138
   Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238
   Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.3.CO;2-E
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000
   SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128
   Staff S, 2000, GENE CHROMOSOME CANC, V28, P432, DOI 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J
   Staff S, 2003, CANCER RES, V63, P4978
   Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117
   Turner N, 2005, CURR OPIN PHARMACOL, V5, P388, DOI 10.1016/j.coph.2005.03.006
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
NR 37
TC 186
Z9 222
U1 1
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2006
VL 8
IS 4
AR R38
DI 10.1186/bcr1522
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 087UI
UT WOS:000240767500012
PM 16846527
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Galliher, AJ
   Schiemann, WP
AF Galliher, Amy J.
   Schiemann, William P.
TI β<sub>3</sub> Integrin and Src facilitate transforming growth factor-β
   mediated induction of epithelial-mesenchymal transition in mammary
   epithelial cells
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; TGF-BETA;
   BREAST-CANCER; SIGNAL-TRANSDUCTION; SURVIVAL SIGNALS; C-SRC; RECEPTOR;
   EXPRESSION; MIGRATION
AB Introduction Transforming growth factor (TGF)-beta suppresses breast cancer formation by preventing cell cycle progression in mammary epithelial cells (MECs). During the course of mammary tumorigenesis, genetic and epigenetic changes negate the cytostatic actions of TGF-beta, thus enabling TGF-beta to promote the acquisition and development of metastatic phenotypes. The molecular mechanisms underlying this conversion of TGF-beta function remain poorly understood but may involve signaling inputs from integrins.
   Methods beta(3) Integrin expression or function in MECs was manipulated by retroviral transduction of active or inactive beta(3) integrins, or by transient transfection of small interfering RNA ( siRNA) against beta(3) integrin. Altered proliferation, invasion, and epithelial-mesenchymal transition (EMT) stimulated by TGF-beta in control and beta(3) integrin manipulated MECs was determined. Src involvement in beta(3) integrin mediated alterations in TGF-beta signaling was assessed by performing Src protein kinase assays, and by interdicting Src function pharmacologically and genetically.
   Results TGF-beta stimulation induced alpha(v)beta(3) integrin expression in a manner that coincided with EMT in MECs. Introduction of siRNA against beta(3) integrin blocked its induction by TGF-beta and prevented TGF-beta stimulation of EMT in MECs. beta(3) integrin interacted physically with the TGF-beta receptor (T beta R) type II, thereby enhancing TGF-beta stimulation of mitogen-activated protein kinases (MAPKs), and of Smad2/3-mediated gene transcription in MECs. Formation of beta(3) integrin: T beta R-II complexes blocked TGF-beta mediated growth arrest and increased TGF-beta mediated invasion and EMT. Dual beta(3) integrin: T beta R-II activation induced tyrosine phosphorylation of T beta R-II, a phosphotransferase reaction mediated by Src in vitro. Inhibiting Src activity in MECs prevented the ability of beta(3) integrin to induce T beta R-II tyrosine phosphorylation, MAPK activation, and EMT stimulated by TGF-beta. Lastly, wild-type and D119A beta(3) integrin expression enhanced and abolished, respectively, TGF-beta stimulation of invasion in human breast cancer cells.
   Conclusion We show that beta(3) integrin alters TGF-beta signaling in MECs via Src-mediated T beta R-II tyrosine phosphorylation, which significantly enhanced the ability of TGF-beta to induce EMT and invasion. Our findings suggest that beta(3) integrin interdiction strategies may represent an innovative approach to reestablishing TGF-beta mediated tumor suppression in progressing human breast cancers.
C1 UCHSC, Dept Pharmacol, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Schiemann, WP (通讯作者)，UCHSC, Dept Pharmacol, Fitzsimons Campus,Mail Stop 8303,RC1 S Tower,Rm L, Aurora, CO 80045 USA.
EM Bill.Schiemann@uchsc.edu
FU NCI NIH HHS [R01 CA114039, R01 CA095519] Funding Source: Medline
CR ALBINI A, 1987, CANCER RES, V47, P3239
   Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100
   Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200
   Bakin AV, 2002, J CELL SCI, V115, P3193
   Berry M G, 2003, Breast Cancer, V10, P214, DOI 10.1007/BF02966720
   Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003
   Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200
   Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Bose R, 2006, CURR OPIN CELL BIOL, V18, P206, DOI 10.1016/j.ceb.2006.02.005
   Böttinger EP, 1997, CANCER RES, V57, P5564
   Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001
   CARY LA, 1999, FRONT BIOSCI, V4, P102
   Dabrowska K, 2004, ACTA VIROL, V48, P241
   DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939
   Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634
   Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853
   Furger KA, 2003, MOL CANCER RES, V1, P810
   Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334
   Gui GPH, 1996, EUR J SURG ONCOL, V22, P254, DOI 10.1016/S0748-7983(96)80013-8
   Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490
   Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   IGNOTZ RA, 1989, J BIOL CHEM, V264, P389
   Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850
   Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4
   Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700
   Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011
   LOFTUS JC, 1994, J BIOL CHEM, V269, P25235
   Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241
   Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970
   Maeda M, 2006, J BIOL CHEM, V281, P59, DOI 10.1074/jbc.M503304200
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5
   Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x
   MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215
   Murillo MM, 2005, ONCOGENE, V24, P4580, DOI 10.1038/sj.onc.1208664
   Park SS, 2004, ONCOGENE, V23, P6272, DOI 10.1038/sj.onc.1207856
   Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019
   Piek E, 1999, J CELL SCI, V112, P4557
   Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132
   Scaffidi AK, 2004, J BIOL CHEM, V279, P37726, DOI 10.1074/jbc.M403010200
   Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001
   Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861
   Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200
   SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361
   Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517
   Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208
   Sokol JP, 2005, BREAST CANCER RES, V7, pR844, DOI 10.1186/bcr1312
   Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899
   Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200
   Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658
   Valdés F, 2004, EXP CELL RES, V292, P209, DOI 10.1016/j.yexcr.2003.08.015
   Wakahara K, 2004, J CELL BIOCHEM, V93, P437, DOI 10.1002/jcb.20160
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3
   Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333
   Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366
   Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398
   Zhou SY, 1999, PROG BIOPHYS MOL BIO, V71, P359, DOI 10.1016/S0079-6107(98)00045-5
NR 68
TC 201
Z9 223
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2006
VL 8
IS 4
AR R42
DI 10.1186/bcr1524
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 087UI
UT WOS:000240767500016
PM 16859511
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Martin, MD
   Hilsenbeck, SG
   Mohsin, SK
   Hopp, TA
   Clark, GM
   Osborne, CK
   Allred, DC
   O'Connell, P
AF Martin, MD
   Hilsenbeck, SG
   Mohsin, SK
   Hopp, TA
   Clark, GM
   Osborne, CK
   Allred, DC
   O'Connell, P
TI Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1)
   protein have high recurrence risks but enhanced responses to systemic
   therapies
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE breast cancer; MTA1; prognostic and predictive biomarker; recurrence
   risk
ID METASTASIS-ASSOCIATED PROTEIN-1; MESSENGER-RNA; CANCER; EXPRESSION;
   GENE; IMMUNOHISTOCHEMISTRY; RECEPTOR; HETEROZYGOSITY; SECTIONS; SAMPLES
AB Nuclear metastasis-associated 1(MTA1) protein is an estrogen receptor co-repressor that regulates transcription via chromatin remodeling, and MTA1 messenger ribonucleic acid (mRNA) levels are elevated in several kinds of locally advanced and metastatic tumors relative to non-metastatic tumors. Previous studies in our laboratory mapped MTA1 into a region showing significantly lower LOH (loss of heterozygosity) in primary breast cancers with metastases compared to node-negative tumors, suggesting that epigenetic alterations of MTA1 affect metastatic potential. The present study examined immunohistochemical expression of the MTA1 protein in treated and untreated primary human breast cancers to study the relationship between MTA1 expression and clinical outcome. Node-negative tumors that overexpress MTA1 protein had recurrence risks similar to node-positive tumors. In multivariate analysis of untreated node-negative tumors, highest expression of MTA1 was associated with increased relapse risk (hazard ratio (HR)=2.72, p=0.0003 for multivariate analysis). Tamoxifen and/or anthracylcene-based chemotherapies eliminated all MTA1 associations with clinical outcome, suggesting MTA1 overexpression predicts early disease relapse, but sensitizes breast tumors to systemic therapies.
C1 Virginia Commonwealth Univ, Sch Med, Dept Human Genet, Richmond, VA 23298 USA.
   Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
C3 Virginia Commonwealth University; Baylor College of Medicine; Baylor
   College of Medicine; Baylor College of Medicine; Baylor College of
   Medicine
RP Virginia Commonwealth Univ, Sch Med, Dept Human Genet, 1101 E Marshall St,POB 980033, Richmond, VA 23298 USA.
EM poconnell@vcu.edu
RI mohsin, syed/KPB-4897-2024
FU NCI NIH HHS [CA30195, CA58183] Funding Source: Medline
CR Allred DC, 1998, MODERN PATHOL, V11, P155
   ALLRED DC, 1993, J HISTOTECHNOL, V16, P117, DOI 10.1179/his.1993.16.2.117
   Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213
   Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8
   Grambsch PM, 1995, BIOMETRICS, V51, P1469, DOI 10.2307/2533277
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Hofer MD, 2004, CANCER RES, V64, P825, DOI 10.1158/0008-5472.CAN-03-2755
   Iguchi H, 2000, INT J ONCOL, V16, P1211
   Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889
   LAMPKIN SR, 1990, J HISTOTECHNOL, V13, P121, DOI 10.1179/his.1990.13.2.121
   Martin MD, 2001, CANCER RES, V61, P3578
   Mohsin SK, 2004, MODERN PATHOL, V17, P1545, DOI 10.1038/modpathol.3800229
   NERI A, 1982, JNCI-J NATL CANCER I, V68, P507
   O'Connell P, 1999, J NATL CANCER I, V91, P1391, DOI 10.1093/jnci/91.16.1391
   OCONNELL P, 1994, BREAST CANCER RES TR, V32, P5, DOI 10.1007/BF00666201
   Sasaki H, 2002, LUNG CANCER-J IASLC, V35, P149, DOI 10.1016/S0169-5002(01)00329-4
   Sasaki H, 2001, CANCER LETT, V174, P159, DOI 10.1016/S0304-3835(01)00704-2
   Therneau T.M., 2000, Modeling Survival Data: Extending the Cox Model
   Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H
   Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274
   TOH Y, 1994, J BIOL CHEM, V269, P22958
   Wenger CR, 1998, BREAST CANCER RES TR, V51, P255, DOI 10.1023/A:1006188512927
NR 22
TC 47
Z9 55
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2006
VL 95
IS 1
BP 7
EP 12
DI 10.1007/s10549-005-9016-8
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 011ZC
UT WOS:000235307000002
PM 16244788
DA 2025-01-12
ER

PT J
AU Tang, D
   Sivko, GS
   DeWille, JW
AF Tang, D
   Sivko, GS
   DeWille, JW
TI Promoter methylation reduces C/EBPδ (CEBPD) gene expression in the
   SUM-52PE human breast cancer cell line and in primary breast tumors
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE breast cancer; CCAAT/Enhancer binding protein delta; C/EBP delta; CEBPD;
   epigenetic promoter methylation
ID MAMMARY EPITHELIAL-CELLS; GROWTH ARREST; DNA METHYLATION; BINDING
   PROTEINS; BASE SEQUENCE; ALPHA; TRANSCRIPTION; PATHWAY; PROGRESSION;
   INHIBITION
AB CCAAT/Enhancer Binding Proteins (C/EBPs) are a highly conserved family of leucine zipper proteins that regulate cell growth and differentiation. C/EBP delta functions in the initiation and maintenance of mammary epithelial cell Go growth arrest and 'loss of function' alterations in C/EBP delta gene expression have been reported in human breast cancer and in rodent carcinogen-induced mammary tumors. The molecular mechanism underlying reduced C/EBP delta gene expression in mammary tumorigenesis, however, is unknown. In this report we demonstrate that C/EBP delta gene expression is undetectable in the SUM-52PE human breast cancer cell line and that silencing of SUM-52PE C/EBP delta gene expression is due to epigenetic promoter hypermethylation (26/27 CpGs methylated). The hypermethylated SUM-52PE C/EBP delta gene promoter is associated with reduced levels of acetylated Histone H4, consistent with a closed, transcriptionally inactive chromatin conformation. Treatment with 5'-aza-cytidine and trichostatin A (TSA) re-activates cytokine-induced SUM-52PE C/EBP delta gene expression. C/EBP delta gene expression is reduced to virtually undetectable levels in 32% (18/57) of primary human breast tumors. Site-specific CpG methylation was observed in 33% (6/18) of the low C/EBP delta expressing primary breast tumors. CpG methylation adjacent to the C/EBP delta proximal promoter Sp1 site was associated with reduced C/EBPb expression in a primary breast cancer sample. Electromobility shift assays (EMSA) demonstrated a significant reduction in binding to oligos containing the CpG methylation 5' to the Sp1 binding site. These results demonstrate a direct. link between C/EBP delta gene promoter hyper- and site specific-methylation and reduced C/EBP delta gene expression in breast cancer cell lines and primary breast tumors.
C1 Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA.
   Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University System of Ohio; Ohio State
   University
RP Ohio State Univ, Dept Vet Biosci, 1925 Coffey Rd, Columbus, OH 43210 USA.
EM dewille.1@osu.edu
CR Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108
   Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465
   D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479
   Ethier SP, 1996, CANCER RES, V56, P899
   Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159
   Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306
   Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3
   Halmos B, 2002, CANCER RES, V62, P528
   Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200
   Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200
   Hutt JA, 2002, MOL CANCER THER, V1, P601
   Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002
   Kerangueven F, 1997, CANCER RES, V57, P5469
   Klochendler-Yeivin A, 2001, BBA-REV CANCER, V1551, pM1, DOI 10.1016/S0304-419X(01)00021-X
   Kuramoto T, 2002, CANCER RES, V62, P3592
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   MANCINIDINARDO DN, 2001, ONCOGENE, V20, P5331
   Nagaoka M, 2001, NUCLEIC ACIDS RES, V29, P4920, DOI 10.1093/nar/29.24.4920
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582
   O'Rourke JP, 1999, BIOCHEM BIOPH RES CO, V262, P696, DOI 10.1006/bbrc.1999.1256
   ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291
   Paz MF, 2003, CANCER RES, V63, P1114
   Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007
   Porter D, 2003, MOL CANCER RES, V1, P362
   Porter DA, 2001, CANCER RES, V61, P5697
   Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508
   Ron D, 1997, CURR TOP MICROBIOL, V220, P131
   Sanford DC, 2005, PROSTATE, V63, P143, DOI 10.1002/pros.20159
   Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439
   Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4
   Sivko GS, 2004, J CELL BIOCHEM, V93, P844, DOI 10.1002/jcb.20224
   Sivko GS, 2004, J CELL BIOCHEM, V93, P830, DOI 10.1002/jcb.20223
   Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Tang DH, 2003, MOL CELL PROBE, V17, P11, DOI 10.1016/S0890-8508(02)00112-3
   Tenen DG, 2001, LEUKEMIA, V15, P688, DOI 10.1038/sj.leu.2402088
   Timchenko NA, 1999, MOL CELL BIOL, V19, P2936
   Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275
   VEGESAN V, 2001, LEUKEMIA RES, V26, P451
   Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002
   Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930
   Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   WOOD S, 1995, CYTOGENET CELL GENET, V70, P188, DOI 10.1159/000134030
   Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 48
TC 40
Z9 45
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2006
VL 95
IS 2
BP 161
EP 170
DI 10.1007/s10549-005-9061-3
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 034XV
UT WOS:000236965100010
PM 16322893
DA 2025-01-12
ER

PT J
AU Tryndyak, VP
   Kovalchuk, O
   Pogribny, IP
AF Tryndyak, VP
   Kovalchuk, O
   Pogribny, IP
TI Loss of DNA methylation and histone H4 lysine 20 trimethylation in human
   breast cancer cells is associated with aberrant expression of DNA
   methyltransferase 1, Suv4-20h2 histone methyltransferase and
   methyl-binding proteins
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE DNA hypomethylation; breast cancer; DNA methyltransferases; histone
   methylation; histone methyltransferases; tumor progression
ID HUMAN-TUMORS; CPG ISLANDS; GLOBAL DNA; HYPOMETHYLATION; EPIGENETICS;
   INSTABILITY; GENE; HETEROCHROMATIN; CARCINOGENESIS; HYPERMETHYLATION
AB Cancer cells are characterized by epigenetic dysregulation, including global genome hypomethylation, regional hypo- and hypermethylation, altered histone modifications, and disturbed genomic imprinting. Despite the long-established fact that global DNA hypomethylation is a common feature of tumors, very little is known about evolution of this and other epigenetic alterations during tumor progression. The present study was undertaken to characterize the status of epigenetic dysregulation in three human breast cancer cell lines (MCF-7, MDA-MB-231 and MDA-MB-231(S30) that represent different stages of human breast cancer. Our data show that breast cancer cells are characterized by significant alterations in cellular epigenetic status compared to non-tumorigenic MCF-10-2A epithelial breast cells. Interestingly, more malignant MDA-MB-231 human breast cancer cells have a more prominent loss of DNA methylation accompanied by altered expression of maintenance DNA methyltransferase DNMT1, methyl-binding proteins MeCP2 and MBD2, decreased trimethylation of lysine 20 of histone H4 and hyperacetylation of histone H4 compared to MCF-7 cells. The decrease in trimethylation of lysine 20 of histone H4 in MDA-MB-231 cells was accompanied by diminished expression of Suv4-20h2 histone methyltransferase. The results of present study demonstrate that MDA-MB-231 cells have more extensive epigenenic alterations than MCF-7. These results demonstrate that human breast cancer cells are characterized by prominent epigenetic alterations which are associated with increased malignant properties of cancer cells. Such epigenetic dysregulation may contribute to and may be indicative of the formation of a more aggressive tumor phenotype during tumor progression.
C1 Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 US Food & Drug Administration (FDA); University of Lethbridge
RP Natl Ctr Toxicol Res, Div Biochem Toxicol, 3900 NCTR Rd, Jefferson, AR 72079 USA.
EM ipogribny@nctr.fda.gov
OI Tryndyak, Volodymyr/0000-0002-8319-2954
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Armenante F, 1999, BIOCHEM BIOPH RES CO, V258, P644, DOI 10.1006/bbrc.1999.0566
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841
   CHEKHUN VF, 2005, IN PRESS CANC LETT
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Ellsworth DL, 2004, LANCET ONCOL, V5, P753, DOI 10.1016/S1470-2045(04)01653-5
   Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   FLATAU E, 1983, CANCER RES, V43, P4901
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Gupta A, 2003, CANCER RES, V63, P664
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Karpinets TV, 2005, CARCINOGENESIS, V26, P1323, DOI 10.1093/carcin/bgi079
   Kim KC, 2003, CANCER RES, V63, P7619
   Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545
   LIN CH, 2001, CANCER RES, V61, P239
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107
   Nakagawa T, 2005, J UROLOGY, V173, P243, DOI 10.1097/01.ju.0000141577.98902.49
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Rajapakse N, 2005, ENVIRON MOL MUTAGEN, V45, P397, DOI 10.1002/em.20104
   Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009
   Sarg B, 2004, J BIOL CHEM, V279, P53458, DOI 10.1074/jbc.M409099200
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Vilain A, 1999, FEBS LETT, V460, P231, DOI 10.1016/S0014-5793(99)01358-7
   Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238
   Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
NR 52
TC 102
Z9 139
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JAN
PY 2006
VL 5
IS 1
BP 65
EP 70
DI 10.4161/cbt.5.1.2288
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 022GW
UT WOS:000236044500019
PM 16322686
DA 2025-01-12
ER

PT J
AU Fiegl, H
   Millinger, S
   Goebel, G
   Müller-Holzner, E
   Marth, C
   Laird, PW
   Widschwendter, M
AF Fiegl, H
   Millinger, S
   Goebel, G
   Müller-Holzner, E
   Marth, C
   Laird, PW
   Widschwendter, M
TI Breast cancer DNA methylation profiles in cancer cells and tumor
   stroma:: Association with HER-2/neu status in primary breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; EXPRESSION; GENE; OVEREXPRESSION;
   AMPLIFICATION; CHEMOTHERAPY; MICROARRAYS; CARCINOMAS; MUTATIONS
AB The HER-2/neu gene is amplified and overexpressed in 20% to 30% of invasive breast carcinomas and is associated with increased metastatic potential and less tamoxifen sensitivity. We generated the DNA methylation profiles of 143 human breast tumors and found significant differences in HER-2/neu expression and DNA methylation of five genes. For three of these five genes [PGR (coding for the progesterone receptor), HSD17B4 (coding for type 4 17-beta-liydroxysteroid dehydrogenase, an enzyme that mainly degrades active 17-beta-estradiol into inactive metabolites), and CDH13 (coding for H-cadherin)] it higher prevalence of DNA methylation in HER-2/neu-positive cancers was confirmed lit an independent set of microdissected primary breast cancers. DNA methylation was not only present in cancer cells but also in the tumor stroma fraction. Of the isolated fractions in HER-2/neu-positive versus -negative cancers, 27.1% versus 10.5%, respectively, showed DNA methylation of the five genes (P = 0.011, Fisher's exact test.). lit Her-2++/+++. breast cancers, HSD17B4 mRNA expression was inversely associated with HSD17B4 methylation (P = 0.04). These data support the view that lit addition to HER-2/neu-associated signaling, epigenetic changes in cancer as well as lit tumor stroma cells might attribute to the specific biological features of HER-2/neu-positive cancers.
C1 UCL, Inst Womens Hlth, Dept Gynaecol Oncol, EGA Hosp, London WC1E 6DH, England.
   Innsbruck Med Univ, Dept Obstet & Gynecol, Innsbruck, Austria.
   Innsbruck Med Univ, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
   Univ So Calif, Dept Biochem, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.
   Univ So Calif, Dept Biol Mol, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.
   Univ So Calif, Dept Surg, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.
C3 University of London; University College London; Medical University of
   Innsbruck; Medical University of Innsbruck; University of Southern
   California; University of Southern California; University of Southern
   California
RP Widschwendter, M (通讯作者)，UCL, Inst Womens Hlth, Dept Gynaecol Oncol, EGA Hosp, 2nd Floor,Huntley St, London WC1E 6DH, England.
EM M.Widschwendter@ucl.ac.uk
RI Zeimet, Alain/AFK-2441-2022; Goebel, Georg/P-6909-2015; LAIRD, PETER
   W/G-8683-2012; Fiegl, Heidi/K-4445-2017
OI Widschwendter, Martin/0000-0002-7778-8380; LAIRD, PETER
   W/0000-0001-9117-3641; Fiegl, Heidi/0000-0002-1236-6806
FU NIEHS NIH HHS [R21 ES011672] Funding Source: Medline
CR BERLUCCI F, 2004, ONCOGENE, V23, P2564
   Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032
   Dressman MA, 2003, CANCER RES, V63, P2194
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808
   FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Galiè M, 2005, CARCINOGENESIS, V26, P1868, DOI 10.1093/carcin/bgi158
   Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Kauraniemi P, 2001, CANCER RES, V61, P8235
   Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142
   Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013
   Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2
   Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Ménard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E
   Müller HM, 2003, BRIT J CANCER, V89, P1934, DOI 10.1038/sj.bjc.6601392
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5
   Yan PS, 2001, CANCER RES, V61, P8375
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 26
TC 145
Z9 157
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2006
VL 66
IS 1
BP 29
EP 33
DI 10.1158/0008-5472.CAN-05-2508
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 001JN
UT WOS:000234529500005
PM 16397211
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Rivenbark, AG
   Jones, WD
   Risher, JD
   Coleman, WB
AF Rivenbark, Ashley G.
   Jones, Wendell D.
   Risher, J. Devon
   Coleman, William B.
TI DNA Methylation-Dependent Epigenetic Regulation of Gene Expression in
   MCF-7 Breast Cancer Cells
SO EPIGENETICS
LA English
DT Article
DE epigenetics; epigenomics; DNA methylation; MCF-7 cells; breast cancer;
   CpG island; 5-aza-2 '-deoxycytidine; trichostatin A
AB To identify epigenetically-regulated genes in breast cancer, MCF-7 cells were exposed to 250 nM 5-aza or 5-aza + 50 nM TSA for three weeks followed by a five week recovery period after treatment withdrawal and gene expression patterns were examined by microarray analysis. We identified 20 genes that are associated with a >= 2-fold increase in expression in response to the demethylating treatment but returned to control levels after treatment withdrawal. RT-PCR verified that the genes identified were expressed at low or undetectable levels in control MCF-7 cells, but increased expression in treated cells. Most of these putative epigentically-regulated genes in MCF-7 cells do not contain CpG islands. In fact, these genes could be classified based upon their promoter CpG features, including genes with: (1) typical CpG features (CpG islands), (2) intermediate CpG features (weak CpG islands), and (3) atypical CpG features (no CpG islands). Prototype genes from each class (including CpG-deficient genes) were shown to be methylation-sensitive (subject to CpG methylation and responsive to demethylating agents), suggesting that not all gene targets of DNA methylation in breast cancer will contain a CpG island. Based upon the results of the current study and observations from the literature, we propose expansion of the current model for methylation-dependent regulation of gene expression to include genes lacking typical CpG islands. The expanded model we propose recognizes that all promoter CpG dinucleotides represent legitimate targets for DNA methylation and that the methylation of specific CpG dinucleotides in critical domains of regulatory regions can result in gene silencing.
C1 [Rivenbark, Ashley G.; Risher, J. Devon; Coleman, William B.] Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27599 USA.
   [Rivenbark, Ashley G.; Coleman, William B.] Univ N Carolina, Curriculum Toxicol, Sch Med, Chapel Hill, NC 27599 USA.
   [Rivenbark, Ashley G.; Risher, J. Devon; Coleman, William B.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA.
   [Jones, Wendell D.] Express Anal, Durham, NC USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill
RP Coleman, WB (通讯作者)，Univ N Carolina, Dept Pathol & Lab Med, Sch Med, 515 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.
EM william.coleman@pathology.unc.edu
RI Jones, Wendell/JAC-5247-2023
OI Jones, Wendell/0000-0002-9676-5387
FU G. Komen Breast Cancer Foundation [BCTR0100575]; National Cancer
   Institute [CA78343]; Medical Alumni Endowment Fund of the University of
   North Carolina at Chapel Hill
FX This work was supported by grants from the Susan G. Komen Breast Cancer
   Foundation (BCTR0100575), the National Cancer Institute (NIH grant
   CA78343), and the Medical Alumni Endowment Fund of the University of
   North Carolina at Chapel Hill. The authors would like to thank Dr. Randy
   Jirtle (Duke University, Durham, NC) for providing details of the
   bisulfite sequencing procedure.
CR Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Bender CM, 1998, CANCER RES, V58, P95
   Benson JR, 2004, LANCET ONCOL, V5, P229, DOI 10.1016/S1470-2045(04)01426-3
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038
   Dammann R, 2001, CANCER RES, V61, P3105
   Deng GR, 2004, CANCER RES, V64, P2692, DOI 10.1158/0008-5472.CAN-03-3000
   Eggert A, 2001, CANCER RES, V61, P1314
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   Friedman JB, 2004, INT J CANCER, V111, P72, DOI 10.1002/ijc.20235
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang C, 2003, CURR OPIN GENET DEV, V13, P246, DOI 10.1016/S0959-437X(03)00054-6
   Jones MV, 1999, J INT MARKETING, V7, P15, DOI 10.1177/1069031X9900700403
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   KEPPLER D, 2005, CANC LETT IN PRESS
   LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O
   Liang G, 2002, CANCER RES, V62, P961
   Lux W, 2005, J THROMB HAEMOST, V3, P1009, DOI 10.1111/j.1538-7836.2005.01276.x
   Mank-Seymour AR, 1998, CLIN CANCER RES, V4, P2003
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   Nan XS, 1996, MOL CELL BIOL, V16, P414
   NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Paz MF, 2003, CANCER RES, V63, P1114
   Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970
   PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636
   RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5
   RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Salisbury JL, 2001, J MAMMARY GLAND BIOL, V6, P203, DOI 10.1023/A:1011312808421
   Sathyanarayana UG, 2004, CANCER RES, V64, P1425, DOI 10.1158/0008-5472.CAN-03-0701
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P6395
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P6389
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P2665
   Sato N, 2003, CANCER RES, V63, P3735
   Shimamoto T, 2005, LEUKEMIA RES, V29, P653, DOI 10.1016/j.leukres.2004.11.014
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Ueki T, 2001, INT J CANCER, V91, P673, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1113>3.0.CO;2-U
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
   Yan PS, 2003, CANCER RES, V63, P6178
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zhang H, 2004, CELL RES, V14, P283, DOI 10.1038/sj.cr.7290229
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
   Zhang L, 2003, NAT BIOTECHNOL, V21, P818, DOI 10.1038/nbt836
NR 66
TC 38
Z9 43
U1 0
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD JAN-MAR
PY 2006
VL 1
IS 1
BP 32
EP 44
DI 10.4161/epi.1.1.2358
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA V04MP
UT WOS:000207062800006
PM 17998816
OA Bronze
DA 2025-01-12
ER

PT J
AU Shi, B
   Vinyals, A
   Alia, P
   Broceño, C
   Chen, FS
   Adrover, M
   Gelpi, C
   Price, JE
   Fabra, A
AF Shi, B
   Vinyals, A
   Alia, P
   Broceño, C
   Chen, FS
   Adrover, M
   Gelpi, C
   Price, JE
   Fabra, A
TI Differential expression of MHC class II molecules in highly metastatic
   breast cancer cells is mediated by the regulation of the CIITA
   transcription -: Implication of CIITA in tumor and metastasis
   development
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE RAP-PCR; differential expression metastasis; MHC class II; CIITA; INF
   gamma; 5-Aza-CR; epigenetic
ID MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSACTIVATOR PROMOTER-III;
   POLYMERASE CHAIN-REACTION; GENE-EXPRESSION; LUNG-CANCER; T-CELLS;
   TROPHOBLAST CELLS; MELANOMA-CELLS; GLIOMA-CELLS; MODEL
AB We analyzed the differential gene expression between variants of MDA-MB-435 human breast cancer cell line that share an identical genetic background but have different metastatic ability. The major histocompatibility complex class II was found down-regulated in highly metastatic cells and correlated with MHC transactivator (CIITA) expression. Constitutive CIITA expression observed in poorly metastatic is driven by promoters III and IV of CIITA gene. Conversely, both promoters were ineffective in highly metastatic cells. The MHC class II and CIITA expression was restored in these cells upon stimulation with IFN gamma or by the treatment with a hypomethylating agent. Both treatments induced USF-1 and IRF binding complexes to promoter IV but only IFN gamma induced the binding of 435-Lung2 nuclear proteins to an ARE-I site at the promoter III. Neither Southern blot nor bisulfite sequencing of promoter IV demonstrated strong hypermethylation of this promoter at the IFN gamma-responsive elements Such as GAS, E-box or IRF-1. We suggest that partial or hemimethylation of promoter IV is sufficient to silence the CIITA expression in highly metastatic cells and that this epigenetic mechanism is responsible for the lack of MHC-II expression. Forced CIITA expression restored the MHC-II antigen expression in 435-Lung2 cells and abrogates spontaneous lung metastasis in both SCID and nude mice but also affected the tumorigenicity in nude mice. The increase in NK cell infiltration in nude mice bearing CIITA-tumors correlated with sign of tumor cell apoptosis and the increase in the number of NK cells in the spleens, suggesting that NK cells might be responsible for the observed antitumor activity. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Hosp Llobregat, Hosp Duran & Reynals, IDIBELL, Barcelona 08907, Spain.
   Hosp Santa Creu & Sant Pau, Serv Immunol, Barcelona, Spain.
   Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran
   i Reynals; Hospital of Santa Creu i Sant Pau; University of Texas
   System; UTMD Anderson Cancer Center
RP Hosp Llobregat, Hosp Duran & Reynals, IDIBELL, Autovida Castelldefels Km 2-7, Barcelona 08907, Spain.
EM afabra@iro.es
OI Vinyals, Antonia/0000-0003-3925-0050; Shi, Bo/0000-0002-0780-0372
CR BASKAR S, 1994, CELL IMMUNOL, V155, P123, DOI 10.1006/cimm.1994.1106
   Bertucci F, 2002, ANN NY ACAD SCI, V975, P217, DOI 10.1111/j.1749-6632.2002.tb05954.x
   Beutler AS, 1999, HUM GENE THER, V10, P95, DOI 10.1089/10430349950019228
   Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5
   BRIGHT JJ, 1995, IMMUNOLOGY, V85, P638
   Cao MY, 2005, CANCER IMMUNOL IMMUN, V54, P229, DOI 10.1007/s00262-004-0582-0
   Chapoval AI, 1998, J IMMUNOL, V161, P6977
   Croce M, 2003, ONCOGENE, V22, P7848, DOI 10.1038/sj.onc.1207054
   DADMARZ R, 1995, CANCER IMMUNOL IMMUN, V40, P1
   FIDLER IJ, 1992, CONTRIB ONCOL, V44, P13
   Garrido F, 1991, Semin Cancer Biol, V2, P3
   Gobin SJP, 1998, IMMUNITY, V9, P531, DOI 10.1016/S1074-7613(00)80636-6
   Goodwin BL, 2001, CELL GROWTH DIFFER, V12, P327
   GORELIK E, 1993, CLIN EXP METASTAS, V11, P439, DOI 10.1007/BF00054935
   HANNA N, 1984, BIOCHIM BIOPHYS ACTA, V780, P213, DOI 10.1016/0304-419X(85)90004-6
   Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000
   Holling TM, 2004, BIOCHEM PHARMACOL, V68, P1209, DOI 10.1016/j.bcp.2004.03.046
   Holling TM, 2002, J IMMUNOL, V168, P763, DOI 10.4049/jimmunol.168.2.763
   Kluger HM, 2004, LAB INVEST, V84, P320, DOI 10.1038/labinvest.3700044
   Landmann S, 2001, J EXP MED, V194, P379, DOI 10.1084/jem.194.4.379
   Lee H, 2003, INT J CANCER, V107, P528, DOI 10.1002/ijc.11428
   LeibundGut-Landmann S, 2004, EUR J IMMUNOL, V34, P1513, DOI 10.1002/eji.200424964
   Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202
   MAIORANA A, 1995, CLIN EXP METASTAS, V13, P43, DOI 10.1007/BF00144017
   Martin BK, 1999, J IMMUNOL, V162, P6663
   Martin BK, 1997, IMMUNITY, V6, P591, DOI 10.1016/S1074-7613(00)80347-7
   Masternak K, 2000, Rev Immunogenet, V2, P267
   Mattsson R, 1998, AM J REPROD IMMUNOL, V40, P383, DOI 10.1111/j.1600-0897.1998.tb00422.x
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Morris AC, 1998, AM J REPROD IMMUNOL, V40, P385, DOI 10.1111/j.1600-0897.1998.tb00423.x
   Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143
   MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851
   Nozell S, 2004, J BIOL CHEM, V279, P38577, DOI 10.1074/jbc.M403738200
   OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068
   Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E
   Pai RK, 2002, J IMMUNOL, V169, P1326, DOI 10.4049/jimmunol.169.3.1326
   PERUCHO M, 1995, METHOD ENZYMOL, V254, P275
   Piskurich JF, 1999, MOL CELL BIOL, V19, P431
   PRICE JE, 1990, CANCER-AM CANCER SOC, V66, P1313, DOI 10.1002/1097-0142(19900915)66:14+<1313::AID-CNCR2820661403>3.0.CO;2-4
   PRICE JE, 1994, INT J ONCOL, V5, P459
   Radosevich M, 2004, INVEST OPHTH VIS SCI, V45, P3185, DOI 10.1167/iovs.04-0111
   Sierra A, 1997, LAB INVEST, V77, P357
   Sloan DD, 2004, AM J PATHOL, V164, P315, DOI 10.1016/S0002-9440(10)63121-5
   Soos JM, 2001, GLIA, V36, P391, DOI 10.1002/glia.1125
   Sotiriadou R, 2001, BRIT J CANCER, V85, P1527, DOI 10.1054/bjoc.2001.2089
   Steimle V, 1996, ADV IMMUNOL, V61, P327, DOI 10.1016/S0065-2776(08)60870-6
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Takamura Y, 2004, GLIA, V45, P392, DOI 10.1002/glia.10343
   Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7
   van der Stoep N, 2002, INT J CANCER, V97, P501, DOI 10.1002/ijc.1623
   Walter W, 2000, BRIT J CANCER, V83, P1192, DOI 10.1054/bjoc.2000.1415
   Warabi M, 2000, PATHOL RES PRACT, V196, P807, DOI 10.1016/S0344-0338(00)80080-1
   Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9
   Warren HS, 1999, IMMUNOL CELL BIOL, V77, P64, DOI 10.1046/j.1440-1711.1999.00790.x
   Welch DR, 2004, BREAST CANCER RES, V6, P61, DOI 10.1186/bcr736
   WELSH J, 1995, MUTAT RES-DNAGING G, V338, P215, DOI 10.1016/0921-8734(95)00026-3
   Yano S, 1997, CANCER RES, V57, P784
   Yazawa T, 1999, J PATHOL, V187, P191, DOI 10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3
   Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8
   Zajchowski DA, 2001, CANCER RES, V61, P5168
   ZHANG RD, 1991, INVAS METAST, V11, P204
NR 61
TC 39
Z9 47
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PY 2006
VL 38
IS 4
BP 544
EP 562
DI 10.1016/j.biocel.2005.07.012
PG 19
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 017PI
UT WOS:000235705100008
PM 16343978
DA 2025-01-12
ER

PT J
AU Paluszczak, J
   Baer-Dubowska, W
AF Paluszczak, Jaroslaw
   Baer-Dubowska, Wanda
TI Epigenetic diagnostics of cancer - the application of DNA methylation
   markers
SO JOURNAL OF APPLIED GENETICS
LA English
DT Article
DE cancer diagnostics; DNA hypermethylation; DNA hypomethylation;
   epigenetics; methylation markers
ID ABERRANT PROMOTER METHYLATION; NONSMALL CELL LUNG; TUMOR-SUPPRESSOR
   GENES; COLORECTAL-CANCER; PROSTATE-CANCER; BREAST-CANCER;
   MOLECULAR-DETECTION; PROGNOSTIC MARKER; DRUG-RESISTANCE; MULTIPLE GENES
AB In recent years it has become apparent that epigenetic events are potentially equally responsible for cancer initiation and progression as genetic abnormalities. DNA methylation is the main epigenetic modification in humans. Two DNA methylation lesions coexist in human neoplasms: hypermethylation of promoter regions of specific genes within a context of genomic hypomethylation. Aberrant methylation is found at early stages of carcinogenesis and distinct types of cancer exhibit specific patterns of methylation changes. Tumor specific DNA is readily obtainable from different clinical samples and methylation status analysis often permits sensitive disease detection. Methylation markers may also serve for prognostic and predictive purposes as they often reflect the metastatic potential and sensitivity to therapy. As current findings show a great potential of recently characterised methylation markers, more studies in the field are needed in the future. Large clinical studies of newly developed markers are especially needed. The review describes the diagnostic potential of DNA methylation markers.
C1 Univ Med Sci, Dept Pharmaceut Biochem, PL-60780 Poznan, Poland.
RP Baer-Dubowska, W (通讯作者)，Univ Med Sci, Dept Pharmaceut Biochem, Grunwaldzka 6, PL-60780 Poznan, Poland.
EM baerw@amp.edu.pl
RI Baer-Dubowska, Wanda/AGN-3671-2022; Paluszczak, Jaroslaw/IZE-4347-2023
OI Baer-Dubowska, Wanda/0000-0002-6625-5343; Paluszczak,
   Jaroslaw/0000-0002-6187-7549
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224
   Anacleto C, 2005, ONCOL REP, V13, P325
   Anzola M, 2004, SCAND J GASTROENTERO, V39, P246, DOI 10.1080/00365520310008124
   Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2
   Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103
   Battagli C, 2003, CANCER RES, V63, P8695
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Blanc JL, 2004, J NEURO-ONCOL, V68, P275, DOI 10.1023/B:NEON.0000033385.37098.85
   Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455
   Chan EC, 2002, CLIN CANCER RES, V8, P3741
   Chang HW, 2002, CANCER, V94, P386, DOI 10.1002/cncr.10211
   Chang YS, 2002, CLIN CANCER RES, V8, P3669
   Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204
   Chim CS, 2001, J CLIN ONCOL, V19, P2033, DOI 10.1200/JCO.2001.19.7.2033
   Cho BS, 2003, BIOCHEM BIOPH RES CO, V307, P52, DOI 10.1016/S0006-291X(03)01121-5
   Cottrell SE, 2004, CLIN BIOCHEM, V37, P595, DOI 10.1016/j.clinbiochem.2004.05.010
   Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Esteller M, 2004, ONCOGENE, V23, P1, DOI 10.1038/sj.onc.1207316
   Esteller M, 2001, CANCER RES, V61, P3225
   Feng QH, 2005, JNCI-J NATL CANCER I, V97, P273, DOI 10.1093/jnci/dji041
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Fiegl H, 2004, CANCER EPIDEM BIOMAR, V13, P882
   Field JK, 2005, INT J ONCOL, V27, P105
   Fujiwara K, 2005, CLIN CANCER RES, V11, P1219
   Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750
   Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732
   González-Quevedo R, 2004, INT J ONCOL, V24, P349
   Gonzalgo ML, 2004, CLIN CANCER RES, V10, P7276, DOI 10.1158/1078-0432.CCR-03-0692
   Graziano F, 2004, CLIN CANCER RES, V10, P2784, DOI 10.1158/1078-0432.CCR-03-0320
   Grunau C, 2005, GENE CHROMOSOME CANC, V43, P11, DOI 10.1002/gcc.20155
   Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384
   Henrique R, 2004, EUR UROL, V46, P660, DOI 10.1016/j.eururo.2004.06.014
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   House MG, 2003, J GASTROINTEST SURG, V7, P1004, DOI 10.1016/j.gassur.2003.08.002
   Itano O, 2002, ONCOGENE, V21, P789, DOI 10.1038/sj.onc.1205124
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jahr S, 2001, CANCER RES, V61, P1659
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7
   Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077
   Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485
   Kimura N, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni046
   Koul S, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-16
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Leung WK, 2005, BRIT J CANCER, V92, P2190, DOI 10.1038/sj.bjc.6602636
   Levenson VV, 2004, PHARMACOGENOMICS, V5, P699, DOI 10.1517/14622416.5.6.699
   Lofton-Day C, 2003, DIGEST DIS, V21, P299, DOI 10.1159/000075352
   Maier S, 2005, AM J PHARMACOGENOMIC, V5, P223, DOI 10.2165/00129785-200505040-00003
   Marchevsky AM, 2004, J MOL DIAGN, V6, P28, DOI 10.1016/S1525-1578(10)60488-6
   Martens JWM, 2005, CANCER RES, V65, P4101, DOI 10.1158/0008-5472.CAN-05-0064
   Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088
   Müller HM, 2003, EXPERT REV MOL DIAGN, V3, P443, DOI 10.1586/14737159.3.4.443
   Nakayama H, 2003, INT J CANCER, V105, P491, DOI 10.1002/ijc.11117
   Olopade OI, 2003, CANCER CELL, V3, P417, DOI 10.1016/S1535-6108(03)00111-9
   Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059
   Plumb JA, 2000, CANCER RES, V60, P6039
   Roman J, 2001, BRIT J HAEMATOL, V113, P329, DOI 10.1046/j.1365-2141.2001.02764.x
   Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291
   Rosenbaum E, 2005, CLIN CANCER RES, V11, P8321, DOI 10.1158/1078-0432.CCR-05-1183
   Russo AL, 2005, CLIN CANCER RES, V11, P2466, DOI 10.1158/1078-0432.CCR-04-1962
   Sathyanarayana UG, 2004, CANCER RES, V64, P1425, DOI 10.1158/0008-5472.CAN-03-0701
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P6395
   Satoh A, 2003, CANCER RES, V63, P8606
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Siu LLP, 2003, BRIT J HAEMATOL, V122, P70, DOI 10.1046/j.1365-2141.2003.04396.x
   Tokumaru Y, 2004, CLIN CANCER RES, V10, P5518, DOI 10.1158/1078-0432.CCR-04-0108
   Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3
   Tsou JA, 2005, LUNG CANCER, V47, P193, DOI 10.1016/j.lungcan.2004.08.003
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Wang J, 2004, CLIN CANCER RES, V10, P6119, DOI 10.1158/1078-0432.CCR-04-0652
   Widschwendter A, 2004, INT J CANCER, V109, P163, DOI 10.1002/ijc.11706
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200
NR 85
TC 82
Z9 95
U1 0
U2 19
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1234-1983
EI 2190-3883
J9 J APPL GENET
JI J. Appl. Genetics
PY 2006
VL 47
IS 4
BP 365
EP 375
DI 10.1007/BF03194647
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 113AB
UT WOS:000242568400011
PM 17132902
DA 2025-01-12
ER

PT J
AU Tischoff, I
   Wittekind, C
   Tannapfel, A
AF Tischoff, Iris
   Wittekind, Christian
   Tannapfel, Andrea
TI Role of epigenetic alterations in cholangiocarcinoma
SO JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY
LA English
DT Article
DE cholangiocarcinoma; tumor suppressor genes; DNA methylation
ID TUMOR-SUPPRESSOR GENE; CPG ISLAND METHYLATION; PROMOTER
   HYPERMETHYLATION; BILIARY-TRACT; BREAST-CANCER; INTRAHEPATIC
   CHOLANGIOCARCINOMA; MICROSATELLITE INSTABILITY; DNA HYPERMETHYLATION;
   CHROMOSOME 3P21.3; SEMAPHORIN 3B
AB Intrahepatic cholangiocarcinomas are rare malignant epithelial liver tumors arising from intrahepatic bile ducts. The prognosis of affected patients is poor. Several risk factors, including hepatolithiasis, liver fluke infection, and anatomical abnormalities associated with inflammation of the biliary tract have been described. At present, little is known about the cellular and molecular mechanisms leading to the development of cholangiocarcinoma. In recent years, in addition to genetic alterations, epigenetic inactivation of (tumor suppressor) genes by promoter CpG island hypermethylation has been recognized as an important and alternative mechanism in tumorigenesis. This review discusses the epigenetic inactivation of different tumor suppressor genes in cholangiocarcinoma.
C1 Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany.
C3 Leipzig University
RP Tischoff, I (通讯作者)，Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany.
CR Abraham SC, 2002, MODERN PATHOL, V15, P1309, DOI 10.1097/01.MP.0000038461.80167.34
   Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243
   Ahrendt SA, 1999, J SURG RES, V84, P88, DOI 10.1006/jsre.1999.5615
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
   Caca K, 2002, INT J CANCER, V97, P481, DOI 10.1002/ijc.1639
   Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101
   Chen YJ, 2005, WORLD J GASTROENTERO, V11, P1333, DOI 10.3748/wjg.v11.i9.1333
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Endo K, 2001, J PATHOL, V193, P310, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH816>3.0.CO;2-K
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2001, CANCER RES, V61, P3225
   Feinberg A. P., 2001, METABOLIC MOL BASES, P525
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Hahn SA, 1998, CANCER RES, V58, P1124
   Harder J, 2002, Praxis (Bern 1994), V91, P1352
   Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407
   Ishikawa A, 2004, HUM PATHOL, V35, P1505, DOI 10.1016/j.humpath.2004.08.014
   Issa JPJ, 2001, CANCER RES, V61, P3573
   Jang TJ, 2001, INT J CANCER, V93, P629, DOI 10.1002/ijc.1394
   Kang YK, 1999, LAB INVEST, V79, P477
   Kawaki J, 2000, INT J CANCER, V88, P228, DOI 10.1002/1097-0215(20001015)88:2<228::AID-IJC13>3.0.CO;2-8
   KIM HG, 1994, AM J PATHOL, V145, P148
   Klump B, 2003, CLIN CANCER RES, V9, P1773
   Koga Y, 2005, ANN SURG ONCOL, V12, P354, DOI 10.1245/ASO.2005.07.020
   KUBO S, 1995, WORLD J SURG, V19, P637, DOI 10.1007/BF00294744
   Kuroki T, 2003, CANCER RES, V63, P3352
   Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9
   Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197
   Limpaiboon T, 2005, CANCER LETT, V217, P213, DOI 10.1016/j.canlet.2004.06.020
   LIPSETT PA, 1994, ANN SURG, V220, P644, DOI 10.1097/00000658-199411000-00007
   LIU C, 2002, WORLD J GASTROENTERO, V2, P10
   Liu D, 2002, INT J CANCER, V102, P366, DOI 10.1002/ijc.10726
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   Liu XQ, 2003, INT J CANCER, V106, P60, DOI 10.1002/ijc.11166
   OKA H, 1993, CANCER RES, V53, P1696
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Oliveira C, 1998, AM J PATHOL, V153, P1211, DOI 10.1016/S0002-9440(10)65665-9
   QUI GH, 2004, ONCOGENE, V23, P4793
   Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134
   RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9
   RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T
   ROSEN CB, 1991, ANN SURG, V213, P21, DOI 10.1097/00000658-199101000-00004
   SANCHEZCESPEDES M, 2000, CANCER RES, V60, P829
   Shin HR, 1996, INT J EPIDEMIOL, V25, P933, DOI 10.1093/ije/25.5.933
   Shiraishi K, 2001, ONCOLOGY-BASEL, V60, P151, DOI 10.1159/000055313
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   Taniai M, 2002, GASTROENTEROLOGY, V123, P1090, DOI 10.1053/gast.2002.36021
   Tannapfel A, 2000, DIGEST DIS SCI, V45, P317, DOI 10.1023/A:1005412626515
   Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721
   Tannapfel A, 2002, J PATHOL, V197, P624, DOI 10.1002/path.1139
   Tchou JC, 2000, INT J ONCOL, V16, P663
   Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Tozawa T, 2004, CANCER SCI, V95, P736, DOI 10.1111/j.1349-7006.2004.tb03254.x
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Watanapa P, 1996, BRIT J SURG, V83, P1062, DOI 10.1002/bjs.1800830809
   Watanapa P, 2002, BRIT J SURG, V89, P962, DOI 10.1046/j.1365-2168.2002.02143.x
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wittekind C., 1995, Prognostic factors in cancer, P88
   Wong N, 2002, J HEPATOL, V37, P633, DOI 10.1016/S0168-8278(02)00269-6
   Yang B, 2005, MODERN PATHOL, V18, P412, DOI 10.1038/modpathol.3800287
   YOSHIDA S, 1995, CANCER RES, V55, P2756
NR 67
TC 35
Z9 39
U1 1
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0944-1166
EI 1436-0691
J9 J HEPATO-BILIARY-PAN
JI J. Hepato-Biliary-Pancreatic Surg.
PY 2006
VL 13
IS 4
BP 274
EP 279
DI 10.1007/s00534-005-1055-3
PG 6
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA 082UA
UT WOS:000240411500002
PM 16858537
DA 2025-01-12
ER

PT J
AU Giacinti, L
   Claudio, PP
   Lopez, M
   Giordano, A
AF Giacinti, Laura
   Claudio, Pier Paolo
   Lopez, Massimo
   Giordano, Antonio
TI Epigenetic information and estrogen receptor alpha expression in breast
   cancer
SO ONCOLOGIST
LA English
DT Article
DE breast cancer; gene expression regulation; estrogen receptors;
   anticancer drug combinations
ID HISTONE DEACETYLASE INHIBITOR; CPG-ISLAND METHYLATION; TUMOR-SUPPRESSOR
   GENES; H3 LYSINE 9; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION;
   RETINOBLASTOMA PROTEIN; SIGNALING PATHWAYS; MCF-7 CELLS; EARLY EVENT
AB In industrialized countries, breast cancer is the most common tumor in women. The tumor expression of estrogen receptors (ERs) is a very important marker for prognosis and a marker that is predictive of response to endocrine therapy. The loss of ER expression portends a poor prognosis and, in a significant fraction of breast cancers, this repression is a result of the hypermethylation of CpG islands within the ER-alpha promoter. Hypermethylation is one of the best known epigenetic events in mammalian cells. Over the last few years, many studies have found that other epigenetic events, such as deacetylation and methylation of histones, are involved in the complex mechanism that regulates promoter transcription. The exact interplay of these factors in transcriptional repression activity is not yet well understood. Inhibitors of some of these are currently being studied as new drugs able to restore ER-alpha protein expression in ER-alpha-negative breast cancer cells and to promote apoptosis and differentiation. Demethylating agents and histone deacetylase (HDAC) inhibitors are candidates for becoming potent new drugs in cancer therapy. This paper reviews the current understanding of the role of epigenetic information in the development of cancer and its significance in breast cancer as predictive markers of ER status and as new targets of anticancer therapy.
C1 Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA.
   Regina Elena Inst Canc Res, Div Med Oncol B, Rome, Italy.
   Dept Human Pathol & Oncol, Lab Biomed Technol & Oncol, Siena, Italy.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina
   Elena
RP Giordano, A (通讯作者)，Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, BioLife Sci Bldg 333,1900 N 12th St, Philadelphia, PA 19122 USA.
EM giordano@temple.edu
RI Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010
OI Claudio, Pier Paolo/0000-0001-7790-1622; Giordano,
   Antonio/0000-0002-5959-016X
CR Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Bouchain G, 2003, CURR MED CHEM, V10, P2359, DOI 10.2174/0929867033456585
   Bouchain G, 2003, J MED CHEM, V46, P820, DOI 10.1021/jm020377a
   Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404
   Castro-Galache MD, 2003, INT J CANCER, V104, P579, DOI 10.1002/ijc.10998
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895
   Driggers PH, 2002, TRENDS ENDOCRIN MET, V13, P422, DOI 10.1016/S1043-2760(02)00634-3
   El-Osta A, 2000, GENE EXPRESSION, V9, P63
   Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493
   Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Hanstein B, 2004, EUR J ENDOCRINOL, V150, P243, DOI 10.1530/eje.0.1500243
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Iwase Hirotaka, 2003, Breast Cancer, V10, P89, DOI 10.1007/BF02967632
   Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Koeller KM, 2003, CHEM BIOL, V10, P397, DOI 10.1016/S1074-5521(03)00093-0
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O
   Ling Y, 2004, NUCLEIC ACIDS RES, V32, P598, DOI 10.1093/nar/gkh195
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Marchion DC, 2004, J CELL BIOCHEM, V92, P223, DOI 10.1002/jcb.20045
   Marks PA, 2004, CELL CYCLE, V3, P534
   Marks Paul A, 2004, Novartis Found Symp, V259, P269
   Martin MB, 2004, J ENDOCRINOL, V180, P487, DOI 10.1677/joe.0.1800487
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   Munster PN, 2001, CANCER RES, V61, P8492
   Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Said TK, 2001, BREAST CANCER RES, V3, P122, DOI 10.1186/bcr284
   Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002
   Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742
   Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003
   Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001
   Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475
   WEIGEL RJ, 1993, CANCER RES, V53, P3472
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
NR 71
TC 148
Z9 178
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JAN
PY 2006
VL 11
IS 1
BP 1
EP 8
DI 10.1634/theoncologist.11-1-1
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 056CF
UT WOS:000238498000001
PM 16401708
OA Bronze
DA 2025-01-12
ER

PT J
AU Kwon, MS
   Kim, SJ
   Lee, SY
   Jeong, JH
   Lee, ES
   Kang, HS
AF Kwon, MS
   Kim, SJ
   Lee, SY
   Jeong, JH
   Lee, ES
   Kang, HS
TI Epigenetic silencing of the sulfotransferase 1A1 gene by
   hypermethylation in breast tissue
SO ONCOLOGY REPORTS
LA English
DT Article
DE sulfotransferase; methylation; breast cancer
ID DNA METHYLATION; CPG ISLAND; SULFATION; PROMOTER; BIOLOGY
AB Sulfotransferase 1A1 (SULT1A1) is reported to be involved in the conjugation with sulfate, resulting in the inactivation of estrogens. Aberrant methylation of promoter CpG islands is known to be responsible for the alteration and silencing of the gene in cancers. This study was intended to evaluate the methylation status and transcriptional activity of SULT1A1 in breast cancer tissue (n=56), benign breast tissue (n=20) and morphologically normal breast tissue (n=20), examined by bisulfite genomic sequencing and reverse transcription (RT)-PCR. As a result, the methylation of the proximal promoter (P1) was identified in 64.3% of breast carcinomas, 15% of normal and 20% of benign breast tissues. In terms of the distal promoter (PO), 32 of 56 cancer tissues (57.1%) were methylated, while 4 normal (20%) and 6 benign tissues (30%) were methylated. Breast cancer tissue showed a higher methylation rate of SULT1A1 than normal and benign tissue at both P1 (p=0.001) and PO (p=0.006) promoters with statistical significance. Furthermore, cancer tissue showed a higher methylation density rate than normal and benign breast tissue at both P1 and P0 promoters (P1, p=0.001; P0, p=0.001). The tissues that showed aberrant methylation of SULTIA1 did not express mRNA significantly, compared with the unmethylated cases (P1, p=0.003; P0, p=0.023). Although the number of samples was relatively small, our results suggest that DNA methylation in the SULT1A1 gene appears to be present in breast tissue including cancer and methylation significantly impacts transcriptional silencing of the gene. In addition, it can be suggested that progressive SULT1A1 methylation within the promoter area of the gene occurs during breast carcinogenesis.
C1 Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea.
   Dongguk Univ, Dept Biol, Seoul 100715, South Korea.
C3 National Cancer Center - Korea (NCC); Dongguk University
RP Natl Canc Ctr, Res Inst Hosp, Ctr Breast Canc, Goyang 411769, Gyeonggi, South Korea.
EM rorerr@ncc.re.kr
RI kang, han/KIC-4795-2024; kim, sun/T-1013-2019
CR CHOU HC, 1995, CANCER RES, V55, P525
   Coughtrie MWH, 1996, HUM EXP TOXICOL, V15, P547, DOI 10.1177/096032719601500701
   Coughtrie MWH, 1998, CHEM-BIOL INTERACT, V109, P3, DOI 10.1016/S0009-2797(97)00117-8
   Dooley TP, 2000, BIOCHEM BIOPH RES CO, V277, P236, DOI 10.1006/bbrc.2000.3643
   Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843
   Falany CN, 1997, FASEB J, V11, P1
   GILISSEN RAHJ, 1994, CARCINOGENESIS, V15, P39, DOI 10.1093/carcin/15.1.39
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Hempel N, 2004, MOL PHARMACOL, V66, P1690, DOI 10.1124/mol.104.003350
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004
   OSBORNE MP, 1993, J NATL CANCER I, V85, P1917, DOI 10.1093/jnci/85.23.1917
   Raftogianis RB, 1997, BIOCHEM BIOPH RES CO, V239, P298, DOI 10.1006/bbrc.1997.7466
   Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381
   Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160
   Yan PS, 2003, CANCER RES, V63, P6178
   Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89
NR 20
TC 14
Z9 16
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2006
VL 15
IS 1
BP 27
EP 32
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 996NW
UT WOS:000234181800005
PM 16328031
DA 2025-01-12
ER

PT J
AU Saito, K
   Uzawa, K
   Endo, Y
   Kato, Y
   Nakashima, D
   Ogawara, K
   Shiba, M
   Bukawa, H
   Yokoe, H
   Tanzawa, H
AF Saito, K
   Uzawa, K
   Endo, Y
   Kato, Y
   Nakashima, D
   Ogawara, K
   Shiba, M
   Bukawa, H
   Yokoe, H
   Tanzawa, H
TI Plasma membrane Ca<SUP>2+</SUP> ATPase isoform 1 down-regulated in human
   oral cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE plasma membrane Ca2+ ATPase; oral squamous cell carcinoma; DNA
   methylation; real-time quantitative RT-PCR; Western blot analysis;
   immunohistochemistry; tumor suppressor gene
ID SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; EXPRESSION; CALCIUM; GENE; PUMP;
   HEAD; NECK
AB The plasma membrane Ca2+ ATPase (PMCA) is an essential regulator of free intracellular calcium. Recent studies have reported aberrant expression of the PMCA1 gene, a member of the PMCA family, in several cancer cell types. To elucidate the contribution of PMCA1 to oral carcinogenesis, we analyzed genetic and epigenetic changes and mRNA and protein expression in primary oral squamous cell carcinomas (OSCCs), oral premalignant lesions (OPLs), and OSCC-derived cell lines. The PMCA1 gene was epigenetically inactivated, but not mutated in the eight OSCC-derived cell lines tested. In clinical samples, frequent down-regulation of PMCA1 protein expression was found not only in primary OSCCs (43%), but also in OPLs (40%). Real-time quantitative reverse transcriptase-polymerase chain reaction data were consistent with the protein expression status. These results suggest that inactivation of the PMCA1 gene is a frequent and early event during oral carcinogenesis, and gene expression may be regulated by an epigenetic mechanism.
C1 Chiba Univ, Dept Clin Mol Biol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan.
   Chiba Univ, COE Program Century 21, Grad Sch Med, Chiba 2608670, Japan.
   Chiba Univ Hosp, Div Dent & Oral Maxillofacial Surg, Div Dent, Chuo Ku, Chiba 2608670, Japan.
C3 Chiba University; Chiba University
RP Chiba Univ, Dept Clin Mol Biol, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.
EM uzawak@faculty.chiba-u.jp
OI Uzawa, Katsuhiro/0000-0002-7036-0859
CR Benkwitz C, 1999, BIOCHEM BIOPH RES CO, V261, P515, DOI 10.1006/bbrc.1999.1064
   Chan AS, 2002, ONCOGENE, V21, P3029, DOI 10.1038/sj.onc.1205460
   Chiba I, 1996, ONCOGENE, V12, P1663
   Delgado-Coello B, 2003, MOL CELL BIOCHEM, V247, P177, DOI 10.1023/A:1024119831983
   Endo Y, 2004, INT J CANCER, V110, P225, DOI 10.1002/ijc.20118
   Gruber AD, 1999, CANCER RES, V59, P5488
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   HERMANEK P, 1987, TNM CLASSIFICATION M, P16
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kotelnikov VM, 1997, CLIN CANCER RES, V3, P95
   Lee WJ, 2002, CELL SIGNAL, V14, P1015, DOI 10.1016/S0898-6568(02)00049-9
   Lipskaia L, 2004, BIOL CELL, V96, P55, DOI 10.1016/j.biolcel.2003.11.001
   LIU LH, 1999, HUM MOL GENET, V8, P1621
   Maeda A, 2000, CANCER RES, V60, P1914
   Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91
   Miracca EC, 1999, BRIT J CANCER, V81, P677, DOI 10.1038/sj.bjc.6690747
   Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6
   Nie L, 1997, CELL CALCIUM, V22, P75, DOI 10.1016/S0143-4160(97)90107-X
   Palakurthi SS, 2000, CANCER RES, V60, P2919
   Rosado JA, 2004, HAEMATOLOGICA, V89, P1142
   Saito Y, 1998, INT J ONCOL, V12, P293
   Scully C, 2003, HEAD NECK CANC EMERG, P117, DOI 10.1016/b978-012239990-9/50010-2
   Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1
   STAUFFER TP, 1993, J BIOL CHEM, V268, P25993
   STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184
   Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21
   Tanaka C, 2003, J DENT RES, V82, P607, DOI 10.1177/154405910308200807
   Usachev YM, 2001, J NEUROCHEM, V76, P1756, DOI 10.1046/j.1471-4159.2001.00169.x
   UZAWA K, 1995, INT J ONCOL, V7, P895
   WAHI PN, 1971, INT HISTOLOGICAL CLA, V4
   Yamamoto N, 2001, BRIT J CANCER, V84, P754, DOI 10.1054/bjoc.2000.1656
   Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017
NR 32
TC 38
Z9 40
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2006
VL 15
IS 1
BP 49
EP 55
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 996NW
UT WOS:000234181800007
PM 16328033
DA 2025-01-12
ER

PT J
AU Li, SY
   Rong, MN
   Iacopetta, B
AF Li, SY
   Rong, MN
   Iacopetta, B
TI Germ-line variants in methyl-group metabolism genes and susceptibility
   to DNA methylation in human breast cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE breast cancer; methyl group metabolism; DNA methylation; polymorphism
ID METHYLENETETRAHYDROFOLATE REDUCTASE GENE; THYMIDYLATE SYNTHASE; MTHFR
   POLYMORPHISMS; RISK; 5-FLUOROURACIL; CELLS; PROMOTER; COLON
AB Aberrant CpG island hypermethylation in gene promoter regions may be an important epigenetic event in human neoplasias, including breast cancer. Dietary and genetic factors that alter DNA methylation levels in normal and tumour tissues could therefore influence both the susceptibility to this disease and tumour phenotype, respectively. In the present study of 227 breast cancers, we investigated whether common polymorphisms in 6 key genes involved in methyl group metabolism (thymidylate synthase, methylene tetrahydrofolate reductase, cystathione beta-synthase, DNA methyltransferase 3B, methylene tetrahydrofolate dehydrogenase, and methionine synthase) were associated with major pathological features of this disease or the frequency of CpG island hypermethylation. No associations were observed between any of the polymorphisms and patient age, tumour size, histological grade or patient outcome. However, tumours from patients who were homozygous for the methionine synthase A2756G polymorphism showed strikingly lower estrogen and progesterone hormone receptor concentrations compared to wild-type homozygotes. Moreover, patients who were homozygous for the methylene tetrahydrofolate dehydrogenase G1958A polymorphism showed a significantly higher frequency of tumour CpG island hypermethylation compared to wild-type homozygotes. Our results show that polymorphisms in two genes involved in methyl group metabolism are associated with hormone receptor content and DNA methylation frequency in breast cancer, however these observations are unlikely to be linked.
C1 Univ Western Australia, Sch Surg & Pathol, Nedlands, WA 6009, Australia.
C3 University of Western Australia
RP Univ Western Australia, Sch Surg & Pathol, M507, Nedlands, WA 6009, Australia.
EM bjiac@cyllene.uwa.edu.au
CR Bièche I, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-37
   Campbell IG, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr457
   Chen J, 2004, INT J CANCER, V110, P617, DOI 10.1002/ijc.20148
   Etienne MC, 2004, BRIT J CANCER, V90, P526, DOI 10.1038/sj.bjc.6601523
   Grieu F, 2004, ANTICANCER RES, V24, P3215
   Grieu F, 2004, ONCOL REP, V11, P501
   Kang S, 2005, GYNECOL ONCOL, V96, P173, DOI 10.1016/j.ygyno.2004.09.031
   Langsenlehner U, 2003, BREAST CANCER RES TR, V81, P169, DOI 10.1023/A:1025752420309
   Le Marchand L, 2004, CANCER EPIDEM BIOMAR, V13, P2071
   LI SY, IN PRESS CANC LETT
   Mariadason JM, 2003, CANCER RES, V63, P8791
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Paz MF, 2002, CANCER RES, V62, P4519
   Shannon B, 2002, GUT, V50, P520, DOI 10.1136/gut.50.4.520
   Sharp L, 2004, AM J EPIDEMIOL, V159, P423, DOI 10.1093/aje/kwh066
   Shen HB, 2002, CANCER RES, V62, P4992
   Shrubsole MJ, 2004, CANCER EPIDEM BIOMAR, V13, P190, DOI 10.1158/1055-9965.EPI-03-0273
   Sohn KJ, 2004, JNCI-J NATL CANCER I, V96, P134, DOI 10.1093/jnci/djh015
   Soong R, 1997, INT J CANCER, V74, P642, DOI 10.1002/(SICI)1097-0215(19971219)74:6<642::AID-IJC15>3.0.CO;2-7
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Takechi T, 2001, JPN J CANCER RES, V92, P696, DOI 10.1111/j.1349-7006.2001.tb01150.x
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 22
TC 23
Z9 25
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2006
VL 15
IS 1
BP 221
EP 225
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 996NW
UT WOS:000234181800033
PM 16328059
DA 2025-01-12
ER

PT J
AU Steele, VE
   Kelloff, GJ
AF Steele, VE
   Kelloff, GJ
TI Development of cancer chemopreventive drugs based on mechanistic
   approaches
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE chemoprevention; drug development; anticancer; antimutagenesis;
   chemoprotection
ID PROSTAGLANDIN-H SYNTHASE-2; SURROGATE END-POINTS; INTRAEPITHELIAL
   NEOPLASIA; BREAST-CANCER; AROMATASE INHIBITORS; THERAPEUTIC ACTIVITY;
   MESSENGER-RNA; COLON-CANCER; TUMOR-CELLS; CELECOXIB
AB One of the most important medical practices of the 21st century is the chemoprevention of cancer, Much progress has been made in this new emerging field, but much work remains before widespread use and practice of cancer prevention becomes commonplace. Cancer chemoprevention includes the concepts of inhibition, reversal, and retardation of the cancer process, The process of carcinogenesis requires 20-40 years to reach invasive cancer, This process follows multiple, diverse. and complex pathways in a stochastic process, called clonal evolution. Many of these pathways appear amenable to inhibition. reversal, or retardation at various points. It is urgent that we identify key pathways in the evolution of the cancer cell. which can be exploited to prevent this carcinogenesis process. Basic researchers are identifying many genetic lesions and epigenetic processes associated with the progression of precancer to invasive disease, These precancer lesions are also called intraepithelial neoplasia (IEN). Many of these early precancerous lesions favor cell division over quiescence and protect cells against apoptosis when signals are present. Many oncogenes, which are active during early development, are reactivated in adulthood by aberrant gene promoting errors. Normal regulatory genes can become mutated, making them insensitive to normal regulatory signals. Tumor suppressor genes are deleted or mutated rendering them inactive, These are several of a wide range of defects in cellular machinery, which can lead to evolution of the cancer phenotype. Errors may not have to appear in a defined order for cells to progress along the cancer pathway. To conquer this diverse disease, it is necessary to attack multiple key pathways at once for a predetermined period of time. Agent combination prevention strategies are. therefore, essential to decrease cancer morbidity. Each cancer type, organ location, or individual genetic background may require a custom combination of prevention strategies to be successful. Published by Elsevier B.V.
C1 NCI, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP NCI, NIH, EPN 2108,MSC 7322,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM vsly@nih.gov
CR Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   BOONE CW, 1992, CANCER RES, V52, P1651
   Brueggemeier RW, 2005, ENDOCR REV, V26, P331, DOI 10.1210/er.2004-0015
   CHEN G, 1994, IMMUNOL INVEST, V23, P269, DOI 10.3109/08820139409066823
   CHEN YQ, 1994, CANCER RES, V54, P1574
   Cho KH, 2000, EUR J CANCER, V36, P2146, DOI 10.1016/S0959-8049(00)00300-2
   Cohen LA, 2001, CANCER RES, V61, P8683
   Dardes RC, 2002, CLIN CANCER RES, V8, P1995
   Dobbs SP, 1997, BRIT J CANCER, V76, P1410, DOI 10.1038/bjc.1997.571
   DUBOIS RN, 1994, AM J PHYSIOL, V266, P822
   Egner PA, 2001, P NATL ACAD SCI USA, V98, P14601, DOI 10.1073/pnas.251536898
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fischer SM, 2003, CARCINOGENESIS, V24, P945, DOI 10.1093/carcin/bgg046
   GAO X, 1995, UROLOGY, V46, P223
   Garcia SB, 2000, INT J EXP PATHOL, V81, P89, DOI 10.1046/j.1365-2613.2000.00142.x
   Grubbs CJ, 2000, CANCER RES, V60, P5599
   Harris RE, 2000, CANCER RES, V60, P2101
   Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X
   HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971
   Huang Y, 2005, ANTI-CANCER DRUG, V16, P229, DOI 10.1097/00001813-200503000-00002
   Kale TA, 2003, CURR TOP MED CHEM, V3, P1043, DOI 10.2174/1568026033452087
   Kelloff G.J., 2004, Cancer Chemoprevention: Volume 1: Promising Cancer Chemopreventive Agents, V1
   Kelloff GJ, 1998, CANCER EPIDEM BIOMAR, V7, P65
   KELLOFF GJ, 1995, CANCER EPIDEM BIOMAR, V4, P1
   Kelloff GJ, 2000, ADV CANCER RES, V78, P199
   Kelloff GJ, 2004, CLIN CANCER RES, V10, P3908, DOI 10.1158/1078-0432.CCR-03-0789
   Kelloff GJ, 2000, CANCER EPIDEM BIOMAR, V9, P127
   Kelloff GJ, 2005, CANC CHEMOPREVENTION, V2
   KENSLER TW, 1992, CANCER CHEMOPREVENTION, P205
   NEWMARK HL, 1984, JNCI-J NATL CANCER I, V72, P1323
   O'Shaughnessy JA, 2002, CLIN CANCER RES, V8, P314
   Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2
   Reddy BS, 2004, ENVIRON MOL MUTAGEN, V44, P26, DOI 10.1002/em.20026
   Reddy BS, 2000, CANCER RES, V60, P293
   RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769
   Robertson JFR, 2001, J STEROID BIOCHEM, V79, P209, DOI 10.1016/S0960-0760(01)00138-8
   Scharovsky OG, 2000, J BIOMED SCI, V7, P292, DOI 10.1159/000025462
   Sharma S, 2001, ANTICANCER RES, V21, P3829
   Shi WG, 2002, CARCINOGENESIS, V23, P131, DOI 10.1093/carcin/23.1.131
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Steele VE, 2002, CANCER RES, V62, P6506
   Steele VE, 2000, CARCINOGENESIS, V21, P63, DOI 10.1093/carcin/21.1.63
   Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5
   Tao LH, 2002, MOL CARCINOGEN, V35, P93, DOI 10.1002/mc.10078
   Voest EE, 1996, ANTI-CANCER DRUG, V7, P723, DOI 10.1097/00001813-199609000-00001
   WARGOVICH MJ, 1983, CARCINOGENESIS, V4, P1205, DOI 10.1093/carcin/4.9.1205
   Wickerham DL, 2003, RECENT RES CANCER, V163, P87
   WOLF CR, 1996, IARC SCI PUBL, V139, P165
   Wu XJ, 2005, MUTAT RES-REV MUTAT, V589, P81, DOI 10.1016/j.mrrev.2004.11.001
NR 49
TC 33
Z9 34
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD DEC 11
PY 2005
VL 591
IS 1-2
BP 16
EP 23
DI 10.1016/j.mrfmmm.2005.04.018
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 993OK
UT WOS:000233963200004
PM 16083917
DA 2025-01-12
ER

PT J
AU Rody, A
   Holtrich, U
   Solbach, C
   Kourtis, K
   von Minckwitz, G
   Engels, K
   Kissler, S
   Gätje, R
   Karn, T
   Kaufmann, M
AF Rody, A
   Holtrich, U
   Solbach, C
   Kourtis, K
   von Minckwitz, G
   Engels, K
   Kissler, S
   Gätje, R
   Karn, T
   Kaufmann, M
TI Methylation of estrogen receptor β promoter correlates with loss of ER-β
   expression in mammary carcinoma and is an early indication marker for
   premalignant lesions
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
ID HUMAN BREAST-CANCER; GENE-EXPRESSION; DNA METHYLATION; TRANSCRIPTION
   FACTOR; REPRESSES TRANSCRIPTION; COLORECTAL-CANCER; TYROSINE KINASE;
   CPG-ISLANDS; HUMAN-CELLS; TUMORS
AB The function of estrogen receptor beta (ER-beta) in mammary tissue is not completely understood. While early observations were often conflicting, more recent data suggest an important role as a tumor-suppressor gene. A decrease of ER-beta expression has been observed in ductal carcinoma in situ and invasive carcinoma as compared with benign mammary epithelial cells. The loss of ER-beta resulted in abnormal growth of mammary epithelial cells. We have previously shown that the mRNA expression of the ER-beta gene is almost totally suppressed in breast carcinomas from patients with a poor prognosis. Here we analyzed whether methylation changes in the different promoters of ER-beta are responsible for the loss of expression of the gene. A methylation assay with high specificity and sensitivity was developed, and a panel of breast tissue samples (n = 175) was characterized for methylation status. In contrast to benign breast, more than two-thirds of invasive breast cancers showed a high degree of methylation. Importantly, increased methylation was also detectable in numerous premalignant lesions. By analysis of breast tumors, previously characterized by gene-expression profiling, methylation was predominantly detected in a subgroup of patients with an unfavorable prognosis, suggesting a possible prognostic value of the ER-beta methylation status. We also investigated the structural characteristics of the two ER-beta promoters, which were both found to be closely associated with a second, downstream, localized and opposite-oriented promoter. However, we could not detect endogenous antisense RNA transcribed from these promoters, which may be involved in epigenetic gene silencing. We also failed to induce ER-beta promoter methylation by expressing siRNAs in cell lines. Interestingly, by comparing the promoter sequences of ER-beta with other genes known to be epigenetically inactivated in breast cancers, we identified a sequence motif possibly involved in promoter methylation.
C1 Univ Frankfurt, Dept Gynecol, D-60590 Frankfurt, Germany.
   German Breast Grp, D-63263 Neu Isenburg Frankfurt, Germany.
   Univ Frankfurt, Dept Pathol, D-60590 Frankfurt, Germany.
C3 Goethe University Frankfurt; German Breast Group; Goethe University
   Frankfurt
RP Univ Frankfurt, Dept Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM t.karn@em.uni-frankfurt.de
RI Karn, Thomas/C-7452-2013
OI Karn, Thomas/0000-0002-3264-6573
CR Ahr A, 2002, LANCET, V359, P131, DOI 10.1016/S0140-6736(02)07337-3
   Ahr A, 2001, J PATHOL, V195, P312
   Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509
   Castanotto D, 2002, RNA, V8, P1454, DOI 10.1017/S1355838202021362
   Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Esslimani-Sahla M, 2004, CLIN CANCER RES, V10, P5769, DOI 10.1158/1078-0432.CCR-04-0389
   Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227
   Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   HEILIG R, 2001, SEQUENCING HUMAN CHR, V14
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779
   HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411
   HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736
   Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M
   Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889
   Krop I, 2003, CANCER RES, V63, P2024
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Li LC, 2000, BIOCHEM BIOPH RES CO, V275, P682, DOI 10.1006/bbrc.2000.3363
   Mann MRW, 1999, HUM MOL GENET, V8, P1867, DOI 10.1093/hmg/8.10.1867
   Marignani PA, 2005, J CLIN PATHOL, V58, P15, DOI 10.1136/jcp.2003.015255
   Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281
   Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372
   Myers E, 2004, BRIT J CANCER, V91, P1687, DOI 10.1038/sj.bjc.6602156
   O'Neill MJ, 2005, HUM MOL GENET, V14, pR113, DOI 10.1093/hmg/ddi108
   Ogawa Y, 2002, CYTOGENET GENOME RES, V99, P59, DOI 10.1159/000071575
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Omoto Y, 2001, CANCER LETT, V163, P207, DOI 10.1016/S0304-3835(00)00680-7
   Palmieri C, 2004, CLIN CANCER RES, V10, P2421, DOI 10.1158/1078-0432.CCR-03-0215
   Park BW, 2003, BREAST CANCER RES TR, V80, P79, DOI 10.1023/A:1024406223619
   PARK JH, 1988, MOL CELL BIOL, V8, P2536, DOI 10.1128/MCB.8.6.2536
   Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349
   Rein T, 1998, NUCLEIC ACIDS RES, V26, P2255, DOI 10.1093/nar/26.10.2255
   Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416
   Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101
   Roger P, 2001, CANCER RES, V61, P2537
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Shaw JA, 2002, J PATHOL, V198, P450, DOI 10.1002/path.1230
   Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Speirs V, 1999, CANCER RES, V59, P525
   Steele-Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685-698.2005
   Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272
   Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157
   Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
   Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-1
   Zwart R, 2001, GENE DEV, V15, P2361, DOI 10.1101/gad.206201
NR 57
TC 66
Z9 79
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD DEC
PY 2005
VL 12
IS 4
BP 903
EP 916
DI 10.1677/erc.1.01088
PG 14
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA 996ZW
UT WOS:000234215800014
PM 16322330
OA Bronze
DA 2025-01-12
ER

PT J
AU Brown, BW
   Costello, TJ
   Hwang, SJ
   Strong, LC
AF Brown, BW
   Costello, TJ
   Hwang, SJ
   Strong, LC
TI Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome
SO HUMAN GENETICS
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; SOFT-TISSUE-SARCOMA; MYOTONIC-DYSTROPHY;
   FAMILIAL SYNDROME; BREAST-CANCER; P53 MUTATIONS; ANTICIPATION; NEOPLASMS
AB Genetic anticipation is the increased incidence, earlier onset, or increased severity of a disease in successive generations. Before the biological basis of anticipation had been demonstrated, the phenomenon was thought to be due to sampling bias, epigenetic effects, gene conversion, or recombinant events. Since then, the biologic basis for anticipation in a number of neurodegenerative disorders has been shown to be attributable to trinucleotide repeat instability, with expansion of repeats clearly correlated with an earlier age of onset. Recently, telomere shortening has been suggested as the mechanism for anticipation in the autosomal dominant form of dyskeratosis congenita, attributable to mutations in the TERC gene, leading to dysfunctional telomeres (Vulliamy et al. 2004). However, the pattern of anticipation has been observed in other disorders, including cancers, for which no genetic defect has been identified. In this study, we assess the apparent generation effect on cancer incidence in ten extended families with P53 germline mutation, identified through probands diagnosed with childhood sarcoma.: The probands were from two sets of systernaticalty ascertained sarcoma patients treated at the University of Texas M. D. Anderson Cancer Center between 1944 and 1982. From those overall studies, we have identified ten kindreds having germline P53 mutations in more than one generation. We compared the cancer incidence in members of successive generations of these families with P53 mutations (carriers) and with no P53 mutations (noncarriers). In carriers, cancer incidence increased in succeeding generations; there was no evidence for this effect In noncarriers; however, the noncarrier population was too small to rule it out. The apparent lack of increase in incidence in noncarriers argues against a cohort effect explaining the increase in carriers.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Genet, Unit 209, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center
RP Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Unit 237,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM bwb@mdanderson.org
OI Costello, Tracy/0000-0001-6138-2450
FU NCI NIH HHS [CA57730, CA34936, CA16672] Funding Source: Medline
CR BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5
   Brown BW, 2002, COMPUTATION STAT, V17, P47, DOI 10.1007/s001800200098
   Efron B., 1993, An introduction to the bootstrap
   Evans SC, 1998, HUM GENET, V102, P681, DOI 10.1007/s004390050761
   Fleischer B., 1918, A VONGRAEFES ARCH KL, V96, P91, DOI [10.1007/bf02018704, DOI 10.1007/BF02018704]
   Horwitz M, 1997, LEUKEMIA, V11, P1347, DOI 10.1038/sj.leu.2400707
   Horwitz M, 1996, AM J HUM GENET, V59, P990
   HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779
   Hwang SJ, 2003, AM J HUM GENET, V72, P975, DOI 10.1086/374567
   Kalbfleisch JD, 1980, STAT ANAL FAILURE TI
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747
   LUSTBADER ED, 1992, AM J HUM GENET, V51, P344
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   McInnis MG, 1996, AM J HUM GENET, V59, P973
   MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X
   Mott FW, 1911, LANCET, V1, P1251
   Mott FW, 1910, BRIT MED J, V1910, P1013, DOI 10.1136/bmj.2.2597.1013
   PENROSE LS, 1948, ANN EUGENIC, V14, P125
   *SEER, 2003, PUBL US DAT 1973 200
   STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213
   Trkova M, 2002, J HUM GENET, V47, P381, DOI 10.1007/s100380200055
   Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346
   Wiernik PH, 2001, BRIT J HAEMATOL, V113, P407, DOI 10.1046/j.1365-2141.2001.02773.x
   Yuille MR, 1998, LEUKEMIA, V12, P1696, DOI 10.1038/sj.leu.2401176
NR 25
TC 19
Z9 20
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD DEC
PY 2005
VL 118
IS 3-4
BP 489
EP 498
DI 10.1007/s00439-005-0016-x
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 001NF
UT WOS:000234542900021
PM 16284780
DA 2025-01-12
ER

PT J
AU Ren, MQ
   Pozzi, S
   Bistulfi, G
   Somenzi, G
   Rossetti, S
   Sacchi, N
AF Ren, MQ
   Pozzi, S
   Bistulfi, G
   Somenzi, G
   Rossetti, S
   Sacchi, N
TI Impaired retinoic acid (RA) signal leads to <i>RAR</i>β2 epigenetic
   silencing and RA resistance
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID BREAST-CANCER CELLS; RECEPTOR BETA-2 PROMOTER; TUMOR-SUPPRESSOR GENE;
   NUCLEAR RECEPTORS; RESPONSE ELEMENT; DNA METHYLATION; HISTONE
   MODIFICATIONS; CARCINOMA-CELLS; IN-VIVO; TRANSCRIPTION
AB Resistance to the growth-inhibitory action of retinoic acid (RA), the bioactive derivative of vitamin A, is common in human tumors. One form of RA resistance has been associated with silencing and hypermethylation of the retinoic acid receptor beta 2 gene (RAR beta 2), an RA-regulated tumor suppressor gene. The presence of an epigenetically silent RAR beta 2 correlates with lack of the RA receptor alpha (RAR alpha). Normally, RAR alpha regulates RAR beta 2 transcription by mediating dynamic changes of RAR beta 2 chromatin in the presence and absence of RA. Here we show that interfering with RA signal through RAR alpha (which was achieved by use of a dominant-negative RAR alpha, by downregulation of RAR alpha by RNA interference, and by use of RAR alpha antagonists) induces an exacerbation of the repressed chromatin status of RAR beta 2 and leads to RAR beta 2 transcriptional silencing. Further, we demonstrate that RAR beta 2 silencing causes resistance to the growth-inhibitory effect of RA. Apparently, RAR beta 2 silencing can also occur in the absence of DNA methylation. Conversely, we demonstrate that restoration of RA signal at a silent RAR beta 2 through RAR alpha leads to RAR beta 2 reactivation. This report provides proof of principle that RAR beta 2 silencing and RA resistance are consequent to an impaired integration of RA signal at RAR beta 2 chromatin.
C1 Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
C3 Roswell Park Comprehensive Cancer Center
RP Sacchi, N (通讯作者)，Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St,C&V Bldg,RM 226, Buffalo, NY 14263 USA.
EM nicoletta.sacchi@roswellpark.org
RI Silvia, Pozzi/AAF-9396-2019
CR APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Bean GR, 2005, CANCER EPIDEM BIOMAR, V14, P790, DOI 10.1158/1055-9965.EPI-04-0580
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013
   Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255
   CREUSOT F, 1982, J BIOL CHEM, V257, P2041
   DAMM K, 1993, P NATL ACAD SCI USA, V90, P2089
   DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329
   DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925
   Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johnson BS, 1999, MOL CELL BIOL, V19, P3372
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kikuchi K, 2001, BIOORG MED CHEM LETT, V11, P1215, DOI 10.1016/S0960-894X(01)00177-9
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3
   RISHI AK, 1995, CANCER RES, V55, P4999
   ROMAN SD, 1993, CANCER RES, V53, P5940
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   Toulouse A, 1996, BBA-GENE STRUCT EXPR, V1309, P1, DOI 10.1016/S0167-4781(96)00126-1
   TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
NR 42
TC 56
Z9 61
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD DEC
PY 2005
VL 25
IS 23
BP 10591
EP 10603
DI 10.1128/MCB.25.23.10591-10603.2005
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 986MB
UT WOS:000233452600032
PM 16287870
OA Green Published
DA 2025-01-12
ER

PT J
AU Ruiz-Cortés, ZT
   Kimmins, S
   Monaco, L
   Burns, KH
   Sassone-Corsi, P
   Murphy, BD
AF Ruiz-Cortés, ZT
   Kimmins, S
   Monaco, L
   Burns, KH
   Sassone-Corsi, P
   Murphy, BD
TI Estrogen mediates phosphorylation of histone H3 in ovarian follicle and
   mammary epithelial tumor cells via the mitotic kinase, aurora B
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID BREAST-CANCER CELLS; GENE-EXPRESSION; RECEPTOR-ALPHA; CHROMOSOME
   CONDENSATION; TARGETED DISRUPTION; KNOCKOUT MICE; ACTIVATION; CHROMATIN;
   BETA; PROLIFERATION
AB Cells of the ovarian follicle undergo extensive proliferation and differentiation from the time that the follicle escapes from the primordial state to its acquisition of ovulatory capacity. We examined the dynamic modification of the phosphorylation state of the histone H3 N-terminal tail in granulosa cells during follicular development. In rodent follicles, the granulosa cell H3 phosphorylation on Ser10 peaks during proestrus. This epigenetic mark is induced by both FSH and 17 beta-estradiol (E2), acting independently. E2-induced H3 phosphorylation fails to occur in mice with inactivated alpha-isoform of the nuclear estrogen receptor. E2 induction of histone phosphorylation is attenuated by cell cycle inhibition. Further, E2 induces the activity of the mitotic kinase, Aurora B, in a mammary tumor cell model where mitosis is estrogen receptor-alpha dependent. These results provide evidence for mitotic regulation in follicle development by estrogen and demonstrate a previously undiscovered mechanism for induction of cell proliferation in ovarian and mammary gland cells.
C1 Univ Antioquia, Grp Fisiol & Biotechnol Reprod, Medellin, Colombia.
   Univ Antioquia, Fac Ciencias Agrarias, Medellin, Colombia.
   Univ Montreal, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada.
   Univ Montreal, Fac Med Vet, St Hyacinthe, PQ J2S 7C6, Canada.
   Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France.
   Baylor Coll Med, Dept Biol, Houston, TX 77030 USA.
C3 Universidad de Antioquia; Universidad de Antioquia; Universite de
   Montreal; Universite de Montreal; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Baylor College of
   Medicine
RP Murphy, BD (通讯作者)，Univ Antioquia, Grp Fisiol & Biotechnol Reprod, Medellin, Colombia.
RI Monaco, Lucia/A-4031-2010; Ruiz-Cortes, Zulma Tatiana/GPK-1868-2022;
   Burns, Kathleen/A-3360-2011; Sassone-Corsi, Paolo/H-6182-2011
OI Ruiz-Cortes, Zulma Tatiana/0000-0003-2253-863X; monaco,
   lucia/0000-0002-1986-1711; Murphy, Bruce/0000-0001-7158-3360; Kimmins,
   Sarah/0000-0002-0168-7233; Burns, Kathleen/0000-0003-1620-3761
CR Adamski J, 2004, MOL ENDOCRINOL, V18, P1963, DOI 10.1210/me.2004-0098
   Bhatnagar A S, 1990, J Enzyme Inhib, V4, P179, DOI 10.3109/14756369009040740
   Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486
   Britt KL, 2002, J ENDOCRINOL, V175, P269, DOI 10.1677/joe.0.1750269
   Britt KL, 2001, J STEROID BIOCHEM, V79, P181, DOI 10.1016/S0960-0760(01)00158-3
   Britt KL, 2000, ENDOCRINOLOGY, V141, P2614, DOI 10.1210/en.141.7.2614
   Burns KH, 2002, ENDOCRINOLOGY, V143, P2823, DOI 10.1210/en.143.8.2823
   Burns KH, 2001, ENDOCRINOLOGY, V142, P2742, DOI 10.1210/en.142.7.2742
   Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5
   Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200
   Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002
   DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91
   Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   Dupont S, 2000, DEVELOPMENT, V127, P4277
   Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017
   FREEMAN ME, 1993, PHYSL REPRODUCTION, P613
   Fujita T, 2003, J BIOL CHEM, V278, P26704, DOI 10.1074/jbc.M301031200
   Fuller PJ, 2004, TRENDS ENDOCRIN MET, V15, P122, DOI 10.1016/j.tem.2004.02.005
   Gaben AM, 2004, MOL ENDOCRINOL, V18, P2700, DOI 10.1210/me.2003-0133
   Gevry NY, 2003, MOL ENDOCRINOL, V17, P704, DOI 10.1210/me.2002-0093
   Hamilton A, 2001, ONCOLOGY-NY, V15, P965
   Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092
   Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256
   Hewitt SC, 2003, REPRODUCTION, V125, P143, DOI 10.1530/rep.0.1250143
   Hewitt Sylvia Curtis, 2002, Rev Endocr Metab Disord, V3, P193, DOI 10.1023/A:1020068224909
   Ke YW, 2003, CELL RES, V13, P69, DOI 10.1038/sj.cr.7290152
   Kinyamu HK, 2004, BBA-GENE STRUCT EXPR, V1677, P30, DOI 10.1016/j.bbaexp.2003.09.015
   Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969
   Ljungman M, 2001, MOL PHARMACOL, V60, P785
   Loury R, 2003, METHODS, V31, P40, DOI 10.1016/S1046-2023(03)00086-0
   Marino M, 2003, MOL BIOL CELL, V14, P2583, DOI 10.1091/mbc.E02-09-0621
   Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006
   Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200
   Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007
   Palter SF, 2001, ENDOCR REV, V22, P389, DOI 10.1210/er.22.3.389
   PRICE CA, 1995, J REPROD FERTIL, V103, P63, DOI 10.1530/jrf.0.1030063
   RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223
   Sainsbury R, 2004, BRIT J CANCER, V90, P1733, DOI 10.1038/sj.bjc.6601731
   Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200
   Sharrow KM, 2002, NEUROSCIENCE, V113, P89, DOI 10.1016/S0306-4522(02)00151-3
   Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941
   Wade CNB, 2003, ENDOCRINOLOGY, V144, P832, DOI 10.1210/en.2002-220899
   Wakeling AE, 2000, ENDOCR-RELAT CANCER, V7, P17, DOI 10.1677/erc.0.0070017
   WANG Y, 2004, NOVART FDN SYMP, V17, P163
   Wang Yanming, 2004, Novartis Found Symp, V259, P3
NR 46
TC 26
Z9 30
U1 0
U2 4
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD DEC
PY 2005
VL 19
IS 12
BP 2991
EP 3000
DI 10.1210/me.2004-0441
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 986OV
UT WOS:000233460500009
PM 16020485
OA Bronze
DA 2025-01-12
ER

PT J
AU Whang, YM
   Choi, EJ
   Seo, JH
   Kim, JS
   Yoo, YD
   Kim, YH
AF Whang, YM
   Choi, EJ
   Seo, JH
   Kim, JS
   Yoo, YD
   Kim, YH
TI Hyperacetylation enhances the growth-inhibitory effect of
   <i>all-trans</i> retinoic acid by the restoration of retinoic acid
   receptor β expression in head and neck squamous carcinoma (HNSCC) cells
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE hyperacetylation; growth-inhibitory effect; retinoic acid receptor;
   HNSCC
ID HISTONE DEACETYLASE INHIBITOR; BREAST-CANCER CELLS; IN-VIVO; HUMAN
   NEUROBLASTOMA; RESPONSE ELEMENT; BINDING PROTEIN; GENE-EXPRESSION; H3
   LYSINE-9; CPG ISLANDS; RAR-BETA
AB The chemotherapeutic effects of all-trans-retinoic acid (atRA) are mediated by the retinoic acid receptor beta (RAR beta), but RAR beta expression is reduced in a number of head and neck carcinoma (HNSCC) cells which causes resistance to RA treatment in half the patients with HNSCC. The possible mechanism for the reduced RAR beta expression has been suggested as the methylation of the CpG islands adjacent to the RA response elements (RARE) in the RAR beta promoter and the loss of histone acetylation. The suppressed RAR beta expression can be reactivated by a demethylating agent (5-aza-2'-deoxycytidine, 5-AzaC) or a histone deacetylase inhibitor (trichostatin A, TSA). Therefore, we sought to determine if the restoration of RAR beta activity, or a combination of these drugs, could restore the sensitivity to RA in RAR beta-negative HNSCC cells with an epigenetically methylated RAR beta promoter region. SqCC/Y1 cells resistant to atRA showed methylated and unmethylated forms in the RAR beta promoter region. RAR beta expression of these cells was restored by 5-AzaC or TSA treatment. Also, treatment with TSA and atRA combined synergistically increased the growth-inhibitory effect and highly induced the transcriptional activation of the RAR beta promoter compared to atRA treatment in HNSCC cells. Additionally, TSA alone and the combination 5-AzaC and TSA increased lysine-9 (Lys-9) acetylation and Lys-4 methylation of the first exon at the RAR beta gene, while decreasing the methylation of Lys-9 in the HNSCC cells.
C1 Korea Univ, Coll Med, Genom Res Ctr Lung & Breast Ovarian Canc, Seoul 136705, South Korea.
   Korea Univ, Coll Med, Dept Internal Med, Seoul 136705, South Korea.
   Korea Univ, Coll Med, Brain Korea Program Biomed Sci 21, Seoul 136705, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine); Korea University;
   Korea University Medicine (KU Medicine)
RP Korea Univ, Coll Med, Genom Res Ctr Lung & Breast Ovarian Canc, 126-1,5-Ga Anam Dong, Seoul 136705, South Korea.
EM yhk0215@ns.kumc.or.kr
RI Kim, Tae-You/J-2750-2012
OI Kim, Yeul Hong/0000-0002-2555-2333
CR Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   BENNER SE, 1994, J NATL CANCER I, V86, P140, DOI 10.1093/jnci/86.2.140
   BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0
   Butler LM, 2000, CANCER RES, V60, P5165
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9
   Coffey DC, 2001, CANCER RES, V61, P3591
   Cote S, 1998, ANTI-CANCER DRUG, V9, P743
   CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x
   Ferrara FF, 2001, CANCER RES, V61, P2
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Glick RD, 1999, CANCER RES, V59, P4392
   Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401
   HU L, 1991, CANCER RES, V51, P3972
   KIM YH, 1995, CANCER RES, V55, P5603
   Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879
   LATIF F, 2002, BIOL PHARM BULL, V25, P1298
   LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138
   LOTAN R, 1994, CANCER RES, V54, pS1987
   Lotan R, 1991, Semin Cancer Biol, V2, P197
   LOWE NJ, 1998, RETINOIDS CLIN GUIDE, P1
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465
   Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789
   Pili R, 2001, CANCER RES, V61, P1477
   Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990
   Suh YA, 2002, CANCER RES, V62, P3945
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   TSUYOSHI N, 2001, LAB INVEST, V81, P1049
   Wan HS, 1999, CANCER RES, V59, P3518
   WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135
   Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469
   Youssef EM, 2004, CLIN CANCER RES, V10, P1733, DOI 10.1158/1078-0432.CCR-0989-3
   ZHANG XK, 1994, CANCER RES, V54, P5663
   Zou CP, 2001, ONCOGENE, V20, P6820, DOI 10.1038/sj.onc.1204846
NR 42
TC 13
Z9 17
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
EI 1432-0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD NOV
PY 2005
VL 56
IS 5
BP 543
EP 555
DI 10.1007/s00280-004-0970-3
PG 13
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 970VI
UT WOS:000232340100013
PM 15959780
DA 2025-01-12
ER

PT J
AU Tian, KG
   Jurukovski, V
   Wang, XP
   Kaplan, MH
   Xu, HP
AF Tian, KG
   Jurukovski, V
   Wang, XP
   Kaplan, MH
   Xu, HP
TI Epigenetic regulation of <i>WTH3</i> in primary and cultured
   drug-resistant breast cancer cells
SO CANCER RESEARCH
LA English
DT Article
ID MULTIDRUG-RESISTANT; P-GLYCOPROTEIN; HISTONE DEACETYLASE; DNA
   METHYLATION; TUMOR-CELLS; GENE FAMILY; PROTEIN; EXPRESSION; MECP2;
   OVEREXPRESSION
AB Previous studies showed that the WTH3 gene functioned as a negative regulator during multidrug resistance (MDR) development in vitro. To understand whether this gene is also involved in clinical drug resistance, hypermethylation at its promoter region observed in cultured MDR MCF7/AdrR cells was examined in primary drug-resistant breast cancer epithelial cells isolated from effusions of breast cancer patients. The results showed that this event also occurred in drug-resistant breast cancer epithelial cells and a newly induced drug-resistant cell line, MCF7/inR. Interestingly, we found that a CpG (CpG 23) that was close to the TATA-like box was constantly methylated in the WTH3 promoter of drug-resistant breast cancer epithelial and cultured MDR cells. Mutagenic study suggested that this CpG site had a functional effect on promoter activity. We also discovered that MCF7/AdrR cells treated with trichostatin A, a histone deacetylase inhibitor, exhibited higher WTH3, but lower MDR1, expression. A reverse correlation between WTH3 and MDR1 gene expression was also observed in MCF7/AdrR, and its non-MDR parental cell line, MCF7/WT. This result indicated that both DNA methylation and histone deacetylase could act in concert to inhibit WTH3 and consequently stimulate MDR1 expression. This hypothesis was supported by data obtained from introducing the WTH3 transgene into MDR cell lines, which reduced endogenous MDR1 expression. Therefore, our studies suggested that the behavior of WTH3 in primary drug-resistant breast cancer epithelial cells was similar to that in a model system where epigenetic regulation of the WTH3 gene was linked to the MDR phenotype.
C1 SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.
   N Shore Univ Hosp, N Shore Long Isl Jewish Res Inst, Manhasset, NY USA.
   N Shore Univ Hosp, Dept Med, Div Infect Dis, Manhasset, NY USA.
C3 State University of New York (SUNY) System; Stony Brook University;
   Northwell Health; North Shore University Hospital; Northwell Health;
   North Shore University Hospital
RP SUNY Stony Brook, Dept Biochem & Cell Biol, R474 Life Sci Bldg, Stony Brook, NY 11794 USA.
EM hduffy@notes.cc.sunysb.edu
FU NCI NIH HHS [1R01CA090443-01A2] Funding Source: Medline
CR ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   ANTEQUERA F, 1993, BIRKHAUSER VERLAG, P169
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Desiderato L, 1997, SOMAT CELL MOLEC GEN, V23, P391, DOI 10.1007/BF02673749
   DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521
   Echard A, 2000, MOL BIOL CELL, V11, P3819, DOI 10.1091/mbc.11.11.3819
   Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Gouazé V, 2005, CANCER RES, V65, P3861, DOI 10.1158/0008-5472.CAN-04-2329
   GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0
   GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5
   GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0
   Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602
   Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kaplan MH, 2004, BREAST CANCER RES TR, V83, P171, DOI 10.1023/B:BREA.0000010710.51614.2d
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Kusaba H, 1997, SOMAT CELL MOLEC GEN, V23, P259, DOI 10.1007/BF02674417
   Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828
   MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575
   Mattick JS, 2005, HUM MOL GENET, V14, pR121, DOI 10.1093/hmg/ddi101
   Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830
   ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014
   Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990
   Sakaguchi M, 1999, BRIT J CANCER, V79, P416, DOI 10.1038/sj.bjc.6690065
   Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918
   Shan JD, 2000, GENE, V257, P67, DOI 10.1016/S0378-1119(00)00395-4
   Shan JD, 2002, BBA-MOL CELL RES, V1589, P112, DOI 10.1016/S0167-4889(02)00164-7
   SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497
   Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024
   Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9
   Tian KG, 2005, CANCER RES, V65, P7421, DOI 10.1158/0008-5472.CAN-05-0658
   Vu TH, 2004, HUM MOL GENET, V13, P2233, DOI 10.1093/hmg/ddh244
   Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435
   Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173
   Yuan LM, 1999, CANCER RES, V59, P3215
   ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394
NR 44
TC 19
Z9 21
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2005
VL 65
IS 21
BP 10024
EP 10031
DI 10.1158/0008-5472.CAN-05-1944
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 979TF
UT WOS:000232967000054
PM 16267028
OA Bronze
DA 2025-01-12
ER

PT J
AU Tesiram, YA
   Saunders, D
   Towner, RA
AF Tesiram, YA
   Saunders, D
   Towner, RA
TI Application of proton NMR spectroscopy in the study of lipid metabolites
   in a rat hepatocarcinogenesis model
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Article
DE H-1-NMR spectroscopy; hepatocarcinogenesis; rat; lipid; in vivo
ID MAGNETIC-RESONANCE-SPECTROSCOPY; HUMAN BRAIN-TUMORS; MR SPECTROSCOPY;
   VISIBLE LIPIDS; BREAST-CANCER; LIVER; DESATURASE; DELTA-6-DESATURASE;
   EXPRESSION; GLIOMAS
AB Liver cancer is one of the most common cancers worldwide. Altered lipid metabolism in the liver is a key feature of developing liver nodules and tumors. Methods of analysis vary from the most sophisticated chromatography to the in vivo nuclear magnetic resonance (NMR) spectroscopy. In this study, we present a systematic method for the identification and quantitation of signature signals from lipid metabolites using 1D NMR proton spectroscopy. We assessed lipid metabolites in an epigenetic rat hepatocarcinogenesis model induced by treatment with a choline-deficient diet (CDAA, choline-deficient L-amino acid defined) over a period of 1 year, from the formation of steatosis, to the development of nodules and adenomas. A comparable choline-sufficient (CSAA) diet was used for the controls. The resonances of the methylene protons of the glycerol backbone in phospholipids were used to quantify the total concentration of such compounds. CDAA rat livers were found to have significantly higher levels of phospholipids, when compared to CSAA, throughout the entire carcinogenesis period. The tri-methyl protons of choline compounds serves to quantify total choline, and the vinyl and bis-allyl proton resonances can be used to not only quantify fatty acid concentrations but also to probe the number of double bonds in a fatty acid moiety. Early stages of carcinogenesis indicate a lower degree of double bonds in fatty acyl containing compounds in CDAA rat livers, when compared to CSAA. The results of this study are in agreement with those previously published in the literature on other rat hepatocarcinogenesis models. (c) 2005 Elsevier B.V. All rights reserved.
C1 Oklahoma Med Res Fdn, Free Radical Biol & Aging Res Program, Oklahoma City, OK 73104 USA.
C3 Oklahoma Medical Research Foundation
RP Oklahoma Med Res Fdn, Free Radical Biol & Aging Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.
EM Rheal-Towner@omrf.ouhsc.edu
RI ; Tesiram, Yasvir/B-7332-2016
OI Towner, Rheal/0000-0001-7368-8983; Tesiram, Yasvir/0000-0003-3008-2927
CR Abel S, 2001, CARCINOGENESIS, V22, P795, DOI 10.1093/carcin/22.5.795
   Cooper WA, 2001, MAGNET RESON MED, V45, P1001, DOI 10.1002/mrm.1133
   Delikatny EJ, 2002, CANCER RES, V62, P1394
   Farber E, 1996, CLIN LAB MED, V16, P377
   Ferretti A, 1999, BBA-MOL CELL BIOL L, V1438, P329, DOI 10.1016/S1388-1981(99)00071-2
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Foley LM, 2001, BBA-GEN SUBJECTS, V1526, P230, DOI 10.1016/S0304-4165(01)00128-3
   Gelderblom WCA, 2002, LIPIDS, V37, P869, DOI 10.1007/s11745-002-0973-4
   Griffin JL, 2003, CANCER RES, V63, P3195
   HAGBERG G, 1995, MAGN RESON MED, V34, P242, DOI 10.1002/mrm.1910340216
   Hasumi M, 2002, ANTICANCER RES, V22, P1205
   Kim JK, 2003, BREAST, V12, P179, DOI 10.1016/S0960-9776(03)00012-2
   Kim YC, 1999, BIOCHEM BIOPH RES CO, V266, P1, DOI 10.1006/bbrc.1999.1704
   Kobliakov VA, 2001, BIOCHEMISTRY-MOSCOW+, V66, P603, DOI 10.1023/A:1010294911682
   KUGEL H, 1992, RADIOLOGY, V183, P701, DOI 10.1148/radiology.183.3.1584924
   Kwek JW, 2003, ANN ACAD MED SINGAP, V32, P500
   Lane J, 2003, INT J MOL MED, V12, P253
   LONGO R, 1993, INVEST RADIOL, V28, P297, DOI 10.1097/00004424-199304000-00006
   McKnight TR, 2002, J NEUROSURG, V97, P794, DOI 10.3171/jns.2002.97.4.0794
   Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2
   Moore S, 2005, INT J CANCER, V114, P563, DOI 10.1002/ijc.20773
   Nakae D, 1999, PATHOL INT, V49, P1028, DOI 10.1046/j.1440-1827.1999.00990.x
   Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005
   OTT D, 1993, RADIOLOGY, V186, P745, DOI 10.1148/radiology.186.3.8430183
   SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047
   SIJENS PE, 1995, MAGNET RESON MED, V33, P818, DOI 10.1002/mrm.1910330612
   SMUTS CM, 1994, CORONARY ARTERY DIS, V5, P331, DOI 10.1097/00019501-199404000-00009
   STEWART BW, 2003, WORLD HLTH REPORT
   Tessitore L, 2003, ONCOLOGY-BASEL, V65, P152, DOI 10.1159/000072341
   TOWNER RA, 2005, TOXICOL APPL PHARM
   Yeung DKW, 2002, RADIOLOGY, V225, P190, DOI 10.1148/radiol.2243011519
NR 31
TC 18
Z9 20
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 1879-2618
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD OCT 15
PY 2005
VL 1737
IS 1
BP 61
EP 68
DI 10.1016/j.bbalip.2005.09.006
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 982KH
UT WOS:000233156500008
PM 16230047
DA 2025-01-12
ER

PT J
AU Zheng, YL
   Loffredo, CA
   Alberg, AJ
   Yu, ZP
   Jones, RT
   Perlmutter, D
   Enewold, L
   Krasna, MJ
   Yung, R
   Shields, PG
   Harris, CC
AF Zheng, YL
   Loffredo, CA
   Alberg, AJ
   Yu, ZP
   Jones, RT
   Perlmutter, D
   Enewold, L
   Krasna, MJ
   Yung, R
   Shields, PG
   Harris, CC
TI Less efficient G<sub>2</sub>-M checkpoint is associated with an
   increased risk of lung cancer in African Americans
SO CANCER RESEARCH
LA English
DT Article
ID CELL-CYCLE CHECKPOINTS; WILD-TYPE P53; ATAXIA-TELANGIECTASIA; MUTAGEN
   SENSITIVITY; DNA-DAMAGE; CHROMOSOMAL-ABERRATIONS; CHROMATID DAMAGE;
   X-IRRADIATION; BREAST-CANCER; GENE
AB Cell cycle checkpoints play critical roles in the maintenance of genomic integrity. The inactivation of checkpoint genes by genetic and epigenetic mechanisms is frequent in all cancer types, as a less-efficient cell cycle control can lead to genetic instability and tumorigenesis. In an on-going case-control study consisting of 216 patients with non-small cell lung cancer, 226 population-based controls, and 114 hospital-based controls, we investigated the relationship of gamma-radiation-induced G(2)-M arrest and lung cancer risk. Peripheral blood lymphocytes were cultured for 90 hours, exposed to 1.0 G gamma gamma-radiation, and harvested at 3 hours after gamma-radiation treatment. gamma-Radiation-induced G(2)-M arrest was measured as the percentage of mitotic cells in untreated cultures minus the percentage of mitotic cells in gamma-radiation-treated cultures from the same subject. The mean percentage of gamma-radiation-induced G2-M arrest was significantly lower in cases than in population controls (1.18 versus 1.44, P < 0.01) and hospital controls (1.18 versus 1.40, P = 0.01). When dichotomized at the 50th percentile value in combined controls (population and hospital controls), a lower level of gamma-radiation-induced G(2)-M arrest was associated with an increased risk of lung cancer among African Americans after adjusting for baseline mitotic index, age, gender, and pack-years of smoking [adjusted odd ratio (OR), 2.25; 95% confidence interval (95% CI), 0.97-5.20]. A significant trend of an increased risk of lung cancer with a decreased level of G(2)-M arrest was observed (P-trend = 0.02) among African Americans, with a lowest-versus-highest quartile adjusted OR of 3.74 (95% Cl, 0.98-14.3). This trend was most apparent among African American females (P-trend < 0.01), with a lowest-versus-highest quartile adjusted OR of 11.75 (95% Cl, 1.47-94.04). The results suggest that a less-efficient DNA damage-induced G(2)-M checkpoint is associated with an increased risk of lung cancer among African Americans. Interestingly, we observed a stronger association of DNA damage-induced G(2)-M arrest and lung cancer among African Americans when compared with Caucasians. If replicated, these results may provide clues to the exceedingly high lung cancer incidence experienced by African Americans.
C1 NCI, Human Carcinogenesis Lab, Canc Res Ctr, Bethesda, MD 20892 USA.
   Georgetown Univ, Canc Genet & Epidemiol Program, Washington, DC USA.
   Univ Maryland, Sch Med, Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21201 USA.
   Univ Maryland, Sch Med, Johns Hopkins Med Inst, Dept Pulm Med, Baltimore, MD 21201 USA.
   Univ Maryland, Sch Med, Greenbaum Canc Ctr, Dept Pathol & Surg, Baltimore, MD 21201 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Georgetown University; University System of Maryland; University
   of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine;
   University System of Maryland; University of Maryland Baltimore; Johns
   Hopkins University; Johns Hopkins Medicine; University System of
   Maryland; University of Maryland Baltimore
RP NCI, Human Carcinogenesis Lab, Canc Res Ctr, 37 Convent Dr,Bldg 37,Room 3068, Bethesda, MD 20892 USA.
EM curtis_harris@nih.gov
RI Shields, Peter/I-1644-2012
FU NCI NIH HHS [Z01 BC005480-20, CA73790] Funding Source: Medline
CR Antoccia A, 1997, INT J RADIAT BIOL, V71, P41, DOI 10.1080/095530097144409
   Bache M, 1999, ANTICANCER RES, V19, P1827
   Bailey LR, 1998, CANCER RES, V58, P65
   Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528
   Biros E, 2001, LUNG CANCER, V31, P157, DOI 10.1016/S0169-5002(00)00188-4
   Biros E, 2001, NEOPLASMA, V48, P407
   Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577
   COSMA G, 1993, CANCER EPIDEM BIOMAR, V2, P53
   Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670
   Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217
   Garte S, 1998, CARCINOGENESIS, V19, P1329, DOI 10.1093/carcin/19.8.1329
   Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596
   Gu J, 1999, CARCINOGENESIS, V20, P1465, DOI 10.1093/carcin/20.8.1465
   HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079
   HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   HSU TC, 1989, INT J CANCER, V43, P403, DOI 10.1002/ijc.2910430310
   JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026
   KASTAN MB, 1991, CANCER RES, V51, P6304
   KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988
   KNIGHT RD, 1993, INT J CANCER, V54, P589, DOI 10.1002/ijc.2910540412
   Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882
   KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491
   Kühne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384
   Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900
   LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6
   Martin AM, 2003, HUM HERED, V55, P171, DOI 10.1159/000073201
   Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207
   Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x
   NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X
   PARSHAD R, 1985, P NATL ACAD SCI USA, V82, P5400, DOI 10.1073/pnas.82.16.5400
   Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X
   Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519
   PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D
   Piette J, 2000, PATHOL BIOL, V48, P174
   Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124
   SANFORD KK, 1990, JNCI-J NATL CANCER I, V82, P1050, DOI 10.1093/jnci/82.12.1050
   SCHANTZ SP, 1990, JNCI-J NATL CANCER I, V82, P1773, DOI 10.1093/jnci/82.22.1773
   Shields PG, 2000, J CLIN ONCOL, V18, P2309, DOI 10.1200/JCO.2000.18.11.2309
   SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142
   Smith GCM, 1999, BIOCHEM SOC SYMP, P91
   SPITZ MR, 1995, CANCER EPIDEM BIOMAR, V4, P99
   Tang YM, 2000, PHARMACOGENETICS, V10, P761, DOI 10.1097/00008571-200012000-00001
   TAYLOR AMR, 1989, INT J RADIAT BIOL, V56, P677, DOI 10.1080/09553008914551901
   Weber WW, 1999, MOL DIAGN, V4, P299, DOI 10.1016/S1084-8592(99)80006-X
   Wei QY, 2000, J NATL CANCER I, V92, P1764
   Wu XF, 2005, CANCER RES, V65, P349
   Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681
   Wu XF, 1996, CANCER EPIDEM BIOMAR, V5, P577
   Xu B, 2002, CANCER RES, V62, P4588
   Zhang PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-14
   Zheng YL, 2003, CARCINOGENESIS, V24, P269, DOI 10.1093/carcin/24.2.269
NR 53
TC 36
Z9 38
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2005
VL 65
IS 20
BP 9566
EP 9573
DI 10.1158/0008-5472.CAN-05-1003
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 974BR
UT WOS:000232566800061
PM 16230422
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Ogishima, T
   Shiina, H
   Breault, JE
   Terashima, M
   Honda, S
   Enokida, H
   Urakami, S
   Tokizane, T
   Kawakami, T
   Ribeiro, LA
   Fujime, M
   Kane, CJ
   Carroll, PR
   Igawa, M
   Dahiya, R
AF Ogishima, T
   Shiina, H
   Breault, JE
   Terashima, M
   Honda, S
   Enokida, H
   Urakami, S
   Tokizane, T
   Kawakami, T
   Ribeiro, LA
   Fujime, M
   Kane, CJ
   Carroll, PR
   Igawa, M
   Dahiya, R
TI Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate
   heparanase expression in bladder cancer
SO ONCOGENE
LA English
DT Article
DE heparanase; methylation; epigenetics; bladder cancer
ID HUMAN BREAST-CANCER; MAMMALIAN HEPARANASE; PANCREATIC-CANCER; DNA
   METHYLATION; PROSTATE-CANCER; TUMOR INVASION; GENE; CELLS;
   HYPERMETHYLATION; METASTASIS
AB Heparanase plays a critical role in the degradation of extracellular matrix and cell membrane and is frequently upregulated in malignant tumors. Transcription factor, early growth response 1 (EGR1), is closely associated with inducible transcription of the heparanase gene. We hypothesized that promoter CpG hypomethylation with increased EGR1 expression could determine heparanase expression during the pathogenesis of bladder cancer. Bladder cancer cell lines (J82, T24 and transitional cell carcinoma) significantly restored heparanase expression after 5-Aza-dC treatment. Transfection of EGR1 siRNA with T24 bladder cancer cell line significantly downregulated heparanase expression compared to the control siRNA transfection. In 54 bladder cancer and paired normal bladder samples, heparanase expression was significantly higher in bladder cancer than in normal bladder (P < 0.01). We performed methylation-specific PCR targeting the CpG sites within the core-binding consensus motifs of EGR1 (GGCG) and Sp1 (GGGCGG). Methylation prevalence was significantly higher in normal bladder than in bladder cancer (P < 0.05) and inversely correlated with heparanase expression (P = 0.055). In the total series of bladder cancer and normal bladder samples, the combination of promoter CpG methylation and EGR1 expression regulated heparanase expression in a stepwise manner, where heparanase expression was the lowest in methylation-positive and EGR1-negative samples and the highest in methylation-negative and EGR1-positive samples. To our knowledge, this is the first study demonstrating that increased heparanase expression during the pathogenesis of bladder cancer is due to promoter hypomethylation and transcription factor EGR1.
C1 Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
   Univ Calif San Francisco, San Francisco, CA 94121 USA.
   Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane 6930085, Japan.
   Univ Sao Paulo, Sch Med, Dept Urol, Sao Paulo, Brazil.
   Juntendo Univ, Sch Med, Dept Urol, Tokyo 1130082, Japan.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   University of California System; University of California San Francisco;
   Shimane University; Universidade de Sao Paulo; Juntendo University
RP Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urol.ucsf.edu
FU FIC NIH HHS [R01TW006215] Funding Source: Medline; NCI NIH HHS
   [R01CA1018447] Funding Source: Medline; NIA NIH HHS [R01AG21418] Funding
   Source: Medline; NIDDK NIH HHS [T32DK07790] Funding Source: Medline
CR Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231
   Adamson E, 2003, CANCER BIOL THER, V2, P617
   Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3
   Dahiya R, 1997, INT J CANCER, V72, P762, DOI 10.1002/(SICI)1097-0215(19970904)72:5<762::AID-IJC10>3.0.CO;2-B
   de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525
   Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260
   Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200
   Kanaya T, 2003, ONCOGENE, V22, P2352, DOI 10.1038/sj.onc.1206365
   Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x
   Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427
   Koliopanos A, 2001, CANCER RES, V61, P4655
   Kosir MA, 1997, J SURG RES, V67, P98, DOI 10.1006/jsre.1996.4976
   Marchetti D, 1996, CANCER RES, V56, P2856
   Ogishima T, 2005, CLIN CANCER RES, V11, P1028
   Sasaki M, 2003, BIOCHEM BIOPH RES CO, V309, P305, DOI 10.1016/j.bbrc.2003.08.005
   Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327
   Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056
   Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415
   Simon R, 1998, J PATHOL, V185, P345
   Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
   Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD
   Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662
NR 27
TC 75
Z9 86
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT 13
PY 2005
VL 24
IS 45
BP 6765
EP 6772
DI 10.1038/sj.onc.1208811
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 973MV
UT WOS:000232527800004
PM 16007175
DA 2025-01-12
ER

PT J
AU Calabrese, P
   Mecklin, JP
   Järvinen, H
   Aaltonen, LA
   Tavaré, S
   Shibata, D
AF Calabrese, P
   Mecklin, JP
   Järvinen, H
   Aaltonen, LA
   Tavaré, S
   Shibata, D
TI Numbers of mutations to different types of colorectal cancer -: art. no.
   126
SO BMC CANCER
LA English
DT Article
ID CLONAL EVOLUTION; CELL POPULATIONS; BREAST-CANCER; COLON-CANCER; GENE;
   CARCINOGENESIS; METASTASIS; EXPRESSION; HMLH1; MODEL
AB Background: The numbers of oncogenic mutations required for transformation are uncertain but may be inferred from how cancer frequencies increase with aging. Cancers requiring more mutations will tend to appear later in life. This type of approach may be confounded by biologic heterogeneity because different cancer subtypes may require different numbers of mutations. For example, a sporadic cancer should require at least one more somatic mutation relative to its hereditary counterpart.
   Methods: To better estimate numbers of mutations before transformation, 1,022 colorectal cancers were classified with respect to microsatellite instability (MSI) and germline DNA mismatch repair mutations characteristic of hereditary nonpolyposis colorectal cancer (HNPCC). MSI-cancers were also classified with respect to clinical stage. Ages at cancer and a Bayesian algorithm were used to estimate the numbers of oncogenic mutations required for transformation for each cancer subtype.
   Results: Ages at MSI+ cancers were consistent with five or six oncogenic mutations for hereditary ( HNPCC) cancers, and seven or eight mutations for its sporadic counterpart. Ages at cancer were consistent with seven mutations for sporadic MSI-cancers, and were similar ( six to eight mutations) regardless of clinical cancer stage.
   Conclusion: Different biologic subtypes of colorectal cancer appear to require different numbers of oncogenic mutations before transformation. Sporadic MSI+ cancers may require more than a single additional somatic alteration compared to hereditary MSI+ cancers because the epigenetic inactivation of MLH1 commonly observed in sporadic MSI+ cancers may be a multistep process. Interestingly, estimated numbers of MSI-cancer mutations were similar ( six to eight mutations) regardless of clinical cancer stage, suggesting a propensity to spread or metastasize does not require additional mutations after transformation. Estimates of oncogenic mutation numbers may help explain some of the biology underlying different cancer subtypes.
C1 Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   Univ So Calif, Dept Biol Sci, Program Mol & Computat Biol, Los Angeles, CA 90089 USA.
   Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00029 Helsinki, Finland.
   Jyvaskyla Cent Hosp, FIN-40620 Jyvaskyla, Finland.
   Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland.
   Univ Cambridge, Dept Oncol, Cambridge, England.
C3 University of Southern California; University of Southern California;
   University of Helsinki; Helsinki University Central Hospital; Central
   Finland Central Hospital; University of Cambridge
RP Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
EM petercal@usc.edu; jukka-pekka.mecklin@ksvax9.ksshp.fi;
   heikki.jarvinen@hus.fi; lauri.aaltonen@helsinki.fi; stavare@usc.edu;
   dshibata@usc.edu
RI Mecklin, Jukka-Pekka/AAB-5378-2020; Aaltonen, Lauri/A-5375-2010
OI Mecklin, Jukka-Pekka/0000-0003-4895-2249; Aaltonen,
   Lauri/0000-0001-6839-4286
CR ARMITAGE P, 1954, BRIT J CANCER, V1, P1
   Ashley D J, 1969, J Med Genet, V6, P376, DOI 10.1136/jmg.6.4.376
   Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Calabrese P, 2004, AM J PATHOL, V164, P1337, DOI 10.1016/S0002-9440(10)63220-8
   Cappel WHDTN, 2002, DIS COLON RECTUM, V45, P1588, DOI 10.1097/01.DCR.0000034502.64985.3F
   COOK PJ, 1969, INT J CANCER, V4, P93, DOI 10.1002/ijc.2910040113
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Frank SA, 2005, P NATL ACAD SCI USA, V102, P1071, DOI 10.1073/pnas.0407299102
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herrero-Jimenez P, 2000, MUTAT RES-FUND MOL M, V447, P73, DOI 10.1016/S0027-5107(99)00201-8
   Järvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5
   Kane MF, 1997, CANCER RES, V57, P808
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Luebeck EG, 2002, P NATL ACAD SCI USA, V99, P15095, DOI 10.1073/pnas.222118199
   Malkhosyan SR, 2000, GASTROENTEROLOGY, V119, P598, DOI 10.1053/gast.2000.16154
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Pinsky PF, 2000, J THEOR BIOL, V207, P129, DOI 10.1006/jtbi.2000.2148
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   RENAN MJ, 1993, MOL CARCINOGEN, V7, P139
   Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193
   SAMOWITZ WS, 1995, GASTROENTEROLOGY, V109, P1765, DOI 10.1016/0016-5085(95)90742-4
   *SEER, 2001, SEER STAT DAT INC SE
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701
NR 30
TC 14
Z9 18
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 3
PY 2005
VL 5
AR 126
DI 10.1186/1471-2407-5-126
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 977KZ
UT WOS:000232804000001
PM 16202134
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Francia, G
   Green, SK
   Bocci, G
   Man, S
   Ernmenegger, U
   Ebos, JML
   Weinerman, A
   Shaked, Y
   Kerbel, RS
AF Francia, G
   Green, SK
   Bocci, G
   Man, S
   Ernmenegger, U
   Ebos, JML
   Weinerman, A
   Shaked, Y
   Kerbel, RS
TI Down-regulation of DNA mismatch repair proteins in human and murine
   tumor spheroids: implications for multicellular resistance to alkylating
   agents
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID DRUG-RESISTANCE; HMLH1 EXPRESSION; MSI-LOW; CELLS; OVARIAN; MUTATION;
   DEMETHYLATION; SUPPRESSION; DEFICIENCY; REVERSAL
AB Similar to other anticancer agents, intrinsic or acquired resistance to DNA-damaging chemotherapeutics is a major obstacle for cancer therapy. Current strategies aimed at overcoming this problem are mostly based on the premise that tumor cells acquire heritable genetic mutations that contribute to drug resistance. Here, we present evidence for an epigenetic, tumor cell adhesion-mediated, and reversible form of drug resistance that is associated with a reduction of DNA mismatch repair proteins PMS2 and/or MLH1 as well as other members of this DNA repair process. Growth of human breast cancer, human melanoma, and murine EMT-6 breast cancer cell lines as multicellular spheroids in vitro, which is associated with increased resistance to many chemotherapeutic drugs, including alkylating agents, is shown to lead to a reproducible down-regulation of PMS2, MLH1, or, in some cases, both as well as MHS6, MSH3, and MSH2. The observed downregulation is in part reversible by treatment of tumor spheroids with the DNA-demethylating agent, 5-azacytidine. Thus, treatment of EMT-6 mouse mammary carcinoma spheroids with 5-azacytidine resulted in reduced and/or disrupted cell-cell adhesion, which in turn sensitized tumor spheroids to cispiatin-mediated killing in vitro. Our results suggest that antiadhesive agents might sensitize tumor spheroids to alkylating agents in part by reversing or preventing reduced DNA mismatch repair activity and that the chemosensitization properties of 5-azacytidine may conceivably reflect its role as a potential antiadhesive agent as well as reversal agent for MLH1 gene silencing in human tumors.
C1 Sunnybrook & Womens Coll, Ctr Hlth Sci, Toronto, ON M4N 3M5, Canada.
   Univ Toronto, Toronto, ON, Canada.
C3 University of Toronto; Sunnybrook Research Institute; Sunnybrook Health
   Science Center; University of Toronto
RP Sunnybrook & Womens Coll, Ctr Hlth Sci, S-217 Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM kerbel@srcl.sunnybrook.utoronto.ca
RI Bocci, Guido/AAC-7515-2022
OI Ebos, John/0000-0002-7175-9044; Bocci, Guido/0000-0001-7120-9141
CR Aebi S, 1997, CLIN CANCER RES, V3, P1763
   Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004
   BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0
   Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167
   Chan ATC, 2004, J CLIN ONCOL, V22, P1373, DOI 10.1200/JCO.2004.04.185
   Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645
   Francia G, 2004, MOL CELL BIOL, V24, P6837, DOI 10.1128/mcb.24.15.6837-6849.2004
   Frankel A, 2000, CLIN CANCER RES, V6, P3719
   Fritzell JA, 1997, CANCER RES, V57, P5143
   Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538
   GRAHAM CH, 1994, J NATL CANCER I, V86, P975, DOI 10.1093/jnci/86.13.975
   Green SK, 2004, MOL CANCER THER, V3, P149
   Green SK, 1999, ANTI-CANCER DRUG DES, V14, P153
   Halford SER, 2003, J PATHOL, V201, P389, DOI 10.1002/path.1453
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   JAIN RK, 1989, JNCI-J NATL CANCER I, V81, P570, DOI 10.1093/jnci/81.8.570
   Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369
   KLUNDER I, 1993, EXP CELL RES, V207, P155, DOI 10.1006/excr.1993.1175
   KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294
   KOMBLITH AB, 2002, J CLIN ONCOL, V20, P2441
   KREBEL RS, 1994, COL SPRING HARB S QU, V59, P661
   Man S, 2002, CANCER RES, V62, P2731
   Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003
   Momparler RL, 1997, LEUKEMIA, V11, P175, DOI 10.1038/sj.leu.2400550
   Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635
   PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227
   Plumb JA, 2000, CANCER RES, V60, P6039
   Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276
   RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587
   St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557
   StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285
   StCroix B, 1996, NAT MED, V2, P1204
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497
   Tomlinson I, 2002, J PATHOL, V197, P6, DOI 10.1002/path.1071
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215
NR 37
TC 31
Z9 40
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2005
VL 4
IS 10
BP 1484
EP 1494
DI 10.1158/1535-7163.MCT-04-0214
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 974AS
UT WOS:000232564300004
PM 16227397
OA Bronze
DA 2025-01-12
ER

PT J
AU Liu, HY
   Liu, W
   Wu, YW
   Zhou, Y
   Xue, R
   Luo, C
   Wang, L
   Zhao, W
   Jiang, JD
   Liu, JW
AF Liu, HY
   Liu, W
   Wu, YW
   Zhou, Y
   Xue, R
   Luo, C
   Wang, L
   Zhao, W
   Jiang, JD
   Liu, JW
TI Loss of epigenetic control of <i>Synuclein</i>-γ gene as a molecular
   indicator of metastasis in a wide range of human cancers
SO CANCER RESEARCH
LA English
DT Article
ID MITOTIC CHECKPOINT KINASE; ESTROGEN-RECEPTOR; DNA METHYLATION; CPG
   ISLAND; ABERRANT EXPRESSION; BREAST; PROTEIN; IDENTIFICATION;
   LOCALIZATION; STIMULATION
AB Metastasis is a major contributing factor to poor prognosis in cancer. Reliable and sensitive biomarkers that indicate the development of metastasis of primary tumors would be of great clinical use. In this study, we show that the neuronal protein synuclein-gamma (SNCG) is abnormally expressed in a high percentage (67.5%) of tumor tissues of diversified cancer types, including liver, esophagus, colon, gastric, lung, prostate, cervical, and breast cancer, but rarely expressed in tumor-matched nonneoplastic adjacent tissues (0.6%). Expressions of SNCG protein in different cancer types all display stage-specific patterns of very low expression in stage I and high expression in stages II to IV. Importantly, we observe a strong association between SNCG protein expression in primary tumors with distant metastasis in patients regardless of the cancer type (60.6%, P < 0.001). By performing genomic sequencing and methylation-specific PCR assays, we identify an inclusive demethylation of CpG sites within the CpG island of SNCG gene in every tumor sample (100%) across all cancer types, illustrating a universal loss of the epigenetic control of SNCG gene expression in tumors and further demonstrating that the demethylation of SNCG CpG island is primarily responsible for the aberrant expression of SNCG protein in cancerous tissues. These new findings strongly suggest that reactivation of SNCG gene expression by DNA demethylation is a common critical contributing factor to malignant progression of many solid tumors and its expression in primary carcinomas is an effective molecular indicator of distant metastasis. Our studies also suggest that the methylation status of SNCG gene can be used as a sensitive molecular tool in early detections of tumorigenesis.
C1 Dept Vet Affairs Palo Alto Hlth Care Syst, Res Serv, Palo Alto, CA 94304 USA.
   Chinese Acad Med Sci, Inst Med Biotechnol, Peking Union Med Coll, Beijing 100050, Peoples R China.
   Hosp Nanjing City 2, Nanjing, Peoples R China.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Palo Alto Health Care System; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Peking Union Medical College; Institute of
   Medicinal Biotechnology - CAMS
RP Dept Vet Affairs Palo Alto Hlth Care Syst, Res Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.
EM jiandong.jiang@mssm.edu
RI wu, yiwen/KLY-8477-2024
CR Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Brueckner B, 2004, TRENDS PHARMACOL SCI, V25, P551, DOI 10.1016/j.tips.2004.09.004
   Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9
   BUSEE M, 2004, NEOPLASIA, V6, P813
   Cao DF, 2005, MODERN PATHOL, V18, P752, DOI 10.1038/modpathol.3800363
   Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941
   Chan KYK, 2002, CANCER RES, V62, P4151
   Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, CANCER RES, V60, P4366
   Gonzalez-Gomez P, 2003, BRIT J CANCER, V88, P109, DOI 10.1038/sj.bjc.6600737
   Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880
   Gupta A, 2003, CANCER RES, V63, P664
   INABA S, 2005, IN PRESS BREAST CANC
   Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   Ji HJ, 1997, CANCER RES, V57, P759
   Jia TL, 1999, CANCER RES, V59, P742
   Jiang YF, 2003, CANCER RES, V63, P3899
   Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650
   Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014
   Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792
   Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871
   Lee YF, 2004, CANCER RES, V64, P7201, DOI 10.1158/0008-5472.CAN-04-1673
   LEVENSON VV, 2004, FUTURE MED, V5, P699
   Li ZK, 2004, CANCER-AM CANCER SOC, V101, P58, DOI 10.1002/cncr.20321
   Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012
   Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011
   LU A, 2002, J BIOL CHEM, V12, P12
   Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668
   Müller HM, 2003, CANCER RES, V63, P7641
   Nass SJ, 2000, CANCER RES, V60, P4346
   Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417
   Oltra S, 2005, DIAGN MOL PATHOL, V14, P53, DOI 10.1097/01.pas.0000149876.32376.c0
   Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119
   Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5
   Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166
   Takeda A, 1998, AM J PATHOL, V152, P367
   Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1
   UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282
   Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920
   Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107
   YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141
   Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057
NR 46
TC 127
Z9 157
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2005
VL 65
IS 17
BP 7635
EP 7643
DI 10.1158/0008-5472.CAN-05-1089
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 961JX
UT WOS:000231659500018
PM 16140929
DA 2025-01-12
ER

PT J
AU Fukui, T
   Kondo, M
   Ito, G
   Maeda, O
   Sato, N
   Yoshioka, H
   Yokoi, K
   Ueda, Y
   Shimokata, K
   Sekido, Y
AF Fukui, T
   Kondo, M
   Ito, G
   Maeda, O
   Sato, N
   Yoshioka, H
   Yokoi, K
   Ueda, Y
   Shimokata, K
   Sekido, Y
TI Transcriptional silencing of secreted frizzled related protein 1
   (<i>SFRP1</i>) by promoter hypermethylation in non-small-cell lung
   cancer
SO ONCOGENE
LA English
DT Article
DE chromosome 8p; hypermethylation; non small-cell lung cancer; SFRP1;
   tumor suppressor gene
ID WNT ANTAGONIST SFRP1; COLORECTAL-CANCER; BREAST-CANCER; GENE;
   INACTIVATION; EXPRESSION; CATENIN; ADENOCARCINOMAS; HETEROZYGOSITY;
   MESOTHELIOMA
AB Secreted frizzled related protein 1 (SFRP1) is an antagonist of the transmembrane frizzled receptor, a component of the Wnt signaling pathway, and has been suggested to be a candidate tumor suppressor in several human malignancies. Since SFRP1 is located at chromosome 8p11, where lung cancers also exhibit frequent allelic loss, we hypothesized that the inactivation of SFRP1 is also involved in lung carcinogenesis. To substantiate this, we performed mutational analysis of SFRP1 for 29 nonsmall-cell lung cancer (NSCLC) and 25 small-cell lung cancer (SCLC) cell lines, and expression analysis for the same cell lines. Although somatic mutations were not detected in the coding sequence, downregulation of SFRP1 was observed in 14 (48%) NSCLC and nine (36%) SCLC cell lines. We analysed epigenetic alteration of the SFRP1 promoter region and detected hypermethylation in 15 (52%) of 29 NSCLC cell lines, two (8%) of 25 SCLC cell lines, and 44 (55%) of 80 primary lung tumors. By comparing the methylation status with SFRP1 expression, we found a significant correlation between them. We also performed loss of heterozygosity (LOH) analysis and found that 15 (38%) of 40 informative surgical specimens had LOH in the SFRP1 gene locus. Furthermore, we performed colony formation assay of two NSCLC cell lines (NCI-H460 and NCI-H2009) and found the reduction of colony formation with SFRP1 transfection. In addition, we also detected that SFRP1 inhibits the transcriptional activity of beta-catenin, which is thought to be a downstream molecule of SFRP1, with luciferase reporter assay. Our current studies demonstrated that the SFRP1 gene is frequently downregulated by promoter hypermethylation and suppresses tumor growth activity of lung cancer cells, which suggests that SFRP1 is a candidate tumor suppressor gene for lung cancer.
C1 Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan.
   Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan.
   Nagoya Univ, Sch Med, Dept Resp Med, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University; Nagoya University; Nagoya University
RP Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.
EM ysekido@aichi-cc.jp
RI Fukui, Takayuki/AAR-2292-2021; Yokoi, Kohei/I-7261-2014; Kondo,
   Masashi/I-7378-2014; Sekido, Yoshitaka/P-9756-2015
OI Sekido, Yoshitaka/0000-0002-2428-3848
CR Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   EMI M, 1992, CANCER RES, V52, P5368
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Girard L, 2000, CANCER RES, V60, P4894
   HORII A, 1992, CANCER RES, V52, P6696
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185
   Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254
   Minna JD, 2002, CANCER J, V8, pS41
   Mori S, 2004, CANCER-AM CANCER SOC, V100, P1673, DOI 10.1002/cncr.20164
   Morin Patrice J, 2003, Cancer Treat Res, V115, P169
   Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145
   Polakis P, 2000, GENE DEV, V14, P1837
   Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659
   Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202
   Sekido Y, 2002, CANCER GENET CYTOGEN, V137, P33, DOI 10.1016/S0165-4608(02)00536-8
   Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Toyooka S, 2002, CLIN CANCER RES, V8, P2292
   Uchiyama M, 2003, INT J CANCER, V107, P962, DOI 10.1002/ijc.11493
   Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533
   Wistuba II, 1999, CANCER RES, V59, P1973
   Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291
NR 30
TC 154
Z9 179
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD SEP
PY 2005
VL 24
IS 41
BP 6323
EP 6327
DI 10.1038/sj.onc.1208777
PG 5
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 964JM
UT WOS:000231877100013
PM 16007200
DA 2025-01-12
ER

PT J
AU Banelli, B
   Gelvi, I
   Di Vinci, A
   Scaruffi, P
   Casciano, I
   Allemanni, G
   Bonassi, S
   Tonini, GP
   Romani, M
AF Banelli, B
   Gelvi, I
   Di Vinci, A
   Scaruffi, P
   Casciano, I
   Allemanni, G
   Bonassi, S
   Tonini, GP
   Romani, M
TI Distinct CpG methylation profiles characterize different clinical groups
   of neuroblastic tumors
SO ONCOGENE
LA English
DT Article
DE neuroblastoma; ganglioneuroma; methylation; methylator phenotype
ID RECEPTOR-BETA EXPRESSION; DNA METHYLATION; P73 GENE; PROMOTER
   METHYLATION; COLORECTAL-CANCER; BREAST-CANCER; HYPERMETHYLATION;
   DELTA-NP73; TUMORIGENESIS; PHENOTYPE
AB The hypermethylation of CpG islands within gene promoter regions is an epigenetic phenomenon that is often, but not always, associated with the transcriptional silencing of downstream genes and contributes to carcinogenesis. We have determined the pattern of methylation of several genes involved in distinct biological pathways, including cell proliferation and apoptosis, in neuroblastoma and in the nonmalignant ganglioneuroma. The purpose of this work was to search for epigenetic signatures that could be associated with defined clinical and biological parameters and that, in prospective, could identify specific risk categories among the patients. We have analysed 31 malignant neuroblastoma with or without MYCN amplification and 13 benign ganglioneuroma and we have observed dramatic differences in the methylation pattern of five genes (CASP8, 14.3.3 sigma, Delta N p73, RASSF1A and DCR2) between these tumors indicating that this phenomenon is not tissue-specific and can be considered as cancer-dependent. Furthermore, the methylation pattern of 14.3.3 sigma, RASSF1A and of an intragenic segment of CASP8 was significantly different between MYCN amplified and single copy neuroblastoma suggesting a specific role of epigenetic alterations in aggressive neuroblastoma.
C1 Ist Nazl Ric Canc, IST Genova, Environm Epidemiol & Biostat Lab, I-16132 Genoa, Italy.
C3 University of Genoa; IRCCS AOU San Martino IST
RP Ist Nazl Ric Canc, IST Genova, Environm Epidemiol & Biostat Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.
EM massimo.romani@istge.it
RI Bonassi, Stefano/ABI-6281-2020; Scaruffi, Paola/AAB-3999-2020; Banelli,
   Barbara/Y-1151-2019
OI casciano, ida/0000-0003-1776-670X; scaruffi, paola/0000-0001-9799-1661;
   bonassi, stefano/0000-0003-3833-6717; Banelli,
   Barbara/0000-0003-1505-7141
CR Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224
   Banelli B, 2000, ONCOGENE, V19, P4553, DOI 10.1038/sj.onc.1203807
   Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014
   Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993
   Casciano I, 2002, CELL DEATH DIFFER, V9, P343, DOI 10.1038/sj.cdd.4400992
   Cheung B, 1998, ONCOGENE, V17, P751, DOI 10.1038/sj.onc.1201982
   Corn PG, 1999, CANCER RES, V59, P3352
   Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962
   Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   KALBFLEISCH JD, 1980, STAT ANAL FAILTURE T
   Kawano S, 1999, BLOOD, V94, P1113
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861
   Romani M, 1999, INT J CANCER, V84, P365, DOI 10.1002/(SICI)1097-0215(19990820)84:4<365::AID-IJC6>3.0.CO;2-X
   Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058
   Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P
   Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007
   TONINI GP, 1993, EUR J CANCER, V28, P1000
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   van Noesel MM, 2002, CANCER RES, V62, P2157
   van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898
   Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4
   Widschwendter M, 1997, CANCER RES, V57, P4158
   Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331
NR 32
TC 62
Z9 67
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG 25
PY 2005
VL 24
IS 36
BP 5619
EP 5628
DI 10.1038/sj.onc.1208722
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 956JN
UT WOS:000231296100008
PM 16044164
DA 2025-01-12
ER

PT J
AU Oliva, J
   El Messaoudi, S
   Pellestor, F
   Fuentes, M
   Georget, V
   Balaguer, P
   Cavaillès, V
   Vignon, FO
   Badia, E
AF Oliva, J
   El Messaoudi, S
   Pellestor, F
   Fuentes, M
   Georget, V
   Balaguer, P
   Cavaillès, V
   Vignon, FO
   Badia, E
TI Involvement of HP1α protein in irreversible transcriptional inactivation
   by antiestrogens in breast cancer cells
SO FEBS LETTERS
LA English
DT Article
DE antiestrogen; tamoxifen; heterochromatin protein 1; transcription;
   silencing; breast cancer
ID HISTONE H3 METHYLATION; ZINC FINGER PROTEINS; GENE-EXPRESSION;
   ESTROGENIC RESPONSE; EPIGENETIC CONTROL; KRAB DOMAIN; LYSINE 9; HP1;
   HETEROCHROMATIN; REPRESSION
AB Resistance to 4-hydroxy-tamoxifen (OHT), which appears in breast cancer cells after long-term antiestrogen treatment, may involve irreversible changes of gene expression. We previously developed a MCF-7 derived cell line (MVLN), in which OHT rapidly and irreversibly inactivates the expression of an estrogen-regulated luciferase transgene (Vit-tk-luciferase). In chromatin immunoprecipitation experiments, heterochromatin protein 1 (HP1 alpha) was found to be associated with the Vit-tk-luciferase transgene, only when it was inactivated by OHT treatment. Chimeras composed of either HP1 alpha or the Krupple-associated box (KRAB) module of KOX-1 protein (known to repress gene expression by recruitment of HP1 proteins), fused to the estrogen receptor (ER)-DNA binding domain (DBD) and the androgen receptor (AR)-ligand binding domain (LBD) were generated and appeared as potent transcriptional repressors. In stably transfected MVLN cells, irreversible inactivation of the luciferase transgene expression obtained with HP1 alpha-ER(DBD)AR(LBD) was partial, whereas inactivation obtained with KRAB-ER(DBD)-AR(LBD) was comparable to that obtained with OHT, although with a slower kinetics. Altogether, these data suggest that HP1 alpha is involved in the silencing effects associated with long-term OHT treatments. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 INSERM, U540, F-34090 Montpellier, France.
   Univ Montpellier I, F-34090 Montpellier, France.
   Inst Genet Mol Montpellier, F-34293 Montpellier, France.
   Inst Human Genet, F-34396 Montpellier, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; Universite de Montpellier; Universite de
   Montpellier; Universite de Montpellier
RP INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.
EM badia@montp.inserm.fr
RI Balaguer, Patrick/I-2973-2016; Cavailles, Vincent/Y-5379-2019; Georget,
   Virginie/AAQ-1843-2020; Oliva, Joan/AEB-9056-2022
OI BADIA, Eric/0000-0002-8922-9834; Cavailles, Vincent/0000-0002-7160-3074
CR Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803
   Ayyanathan K, 2000, CANCER RES, V60, P5803
   BADIA E, 1994, CANCER RES, V54, P5860
   Badia E, 1998, BREAST CANCER RES TR, V47, P71, DOI 10.1023/A:1005801005966
   Badia E, 2000, CANCER RES, V60, P4130
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329
   BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608
   Bowie LJ, 1978, METHOD ENZYMOL, V57, P15
   Bramlett KS, 2001, MOL CELL ENDOCRINOL, V183, P19, DOI 10.1016/S0303-7207(01)00636-0
   Cammas F, 2004, GENE DEV, V18, P2147, DOI 10.1101/gad.302904
   Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572
   Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719
   Danzer JR, 2004, DEVELOPMENT, V131, P3571, DOI 10.1242/dev.01223
   de Haan G, 2000, J BIOL CHEM, V275, P13493, DOI 10.1074/jbc.275.18.13493
   DEMIRPENCE E, 1993, J STEROID BIOCHEM, V46, P355, DOI 10.1016/0960-0760(93)90225-L
   Demirpence E, 2002, CANCER RES, V62, P6519
   Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7
   Eissenberg JC, 2003, PROG NUCLEIC ACID RE, V74, P275, DOI 10.1016/S0079-6603(03)01016-X
   Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579
   García-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278
   Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887
   Jordan VC, 1997, JNCI-J NATL CANCER I, V89, P747, DOI 10.1093/jnci/89.11.747
   Kamakaka RT, 2003, CURR BIOL, V13, pR317, DOI 10.1016/S0960-9822(03)00236-7
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x
   LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x
   Li YH, 2003, DEVELOPMENT, V130, P1817, DOI 10.1242/dev.00405
   Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699
   Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200
   Lorenz P, 2001, BIOL CHEM, V382, P637, DOI 10.1515/BC.2001.075
   Ma JY, 2001, CHROMOSOMA, V109, P536, DOI 10.1007/s004120000113
   Ma ZQ, 1999, J STEROID BIOCHEM, V69, P155, DOI 10.1016/S0960-0760(98)00154-X
   Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355
   MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509
   Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150
   Oikemus SR, 2004, GENE DEV, V18, P1850, DOI 10.1101/gad.1202504
   Perrini B, 2004, MOL CELL, V15, P467, DOI 10.1016/j.molcel.2004.06.036
   Perrod S, 2003, CELL MOL LIFE SCI, V60, P2303, DOI 10.1007/s00018-003-3246-x
   PONS M, 1990, BIOTECHNIQUES, V9, P450
   RAAP KW, 1992, NON RADIOACTIVE LABE
   Rabenoelina F, 2002, INT J CANCER, V98, P698, DOI 10.1002/ijc.10252
   Ryan RF, 1999, MOL CELL BIOL, V19, P4366
   SAUNDERS WS, 1993, J CELL SCI, V104, P573
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501
   Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200
   VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R
   Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045
NR 52
TC 8
Z9 11
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD AUG 15
PY 2005
VL 579
IS 20
BP 4278
EP 4286
DI 10.1016/j.febslet.2005.06.060
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 957DX
UT WOS:000231350900013
PM 16051232
DA 2025-01-12
ER

PT J
AU Utsunomiya, T
   Ogawa, K
   Yoshinaga, K
   Ohta, M
   Yamashita, K
   Mimori, K
   Inoue, H
   Ezaki, T
   Yoshikawa, Y
   Mori, M
AF Utsunomiya, T
   Ogawa, K
   Yoshinaga, K
   Ohta, M
   Yamashita, K
   Mimori, K
   Inoue, H
   Ezaki, T
   Yoshikawa, Y
   Mori, M
TI Clinicopathologic and prognostic values of <i>Apolipoprotein D</i>
   alterations in hepatocellular carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE apolipoprotein D; hepatocellular carcinoma; histological grade;
   prognostic factor; methylation
ID MESSENGER-RNA EXPRESSION; BREAST-CANCER; CLINICAL-SIGNIFICANCE;
   GENE-EXPRESSION; GROWTH ARREST; METHYLATION; PROTEIN; HYPERMETHYLATION;
   SUPPRESSION; PROMOTER
AB We previously identified apolipoprotein D (Apo D) as a novel tumor suppressor gene based on the pharmacological unmasking of epigenetic silencing. We analyzed Apo D expression using real-time reverse transcription-PCR and evaluated its expression status based on the clinicopathological parameters of 70 patients with hepatocellular carcinoma (HCC). Immunohistochemical staining was also performed. We determined the methylation status of Apo D gene promoter by methylation-specific PCR (MSP). The Apo D gene-expression in tumor tissue was significantly lower than that in nontumor tissue (p = 0.011). A low Apo D expression significantly correlated with less-differentiated HCC (p = 0.019). Immunohistochemical studies confirmed a decreased Apo D expression in poorly differentiated tumors. The prognosis of patients with a lower Apo D gene-expression was significantly worse than that in those with a higher expression (p = 0.028). The Apo D gene-expression was an independent prognostic factor (relative risk: 2.36, p = 0.018). An MSP assay showed a low-level of methylation in well differentiated HCC and a high-level of methylation in less differentiated tumors. Apo D may be a novel tumor suppressor gene of HCC, and its expression status may be a useful biomarker for predicting the patient outcome. (c) 2005 Wiley-Liss. Inc.
C1 Kyushu Univ, Med Inst Bioregulat, Dept Surg, Beppu, Oita 8740838, Japan.
   Kyushu Univ, Med Inst Bioregulat, Dept Pathol, Beppu, Oita 8740838, Japan.
   Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21218 USA.
   Hiroshima Red Cross Hosp, Dept Surg, Hiroshima, Japan.
   Atom Bomb Survivors Hosp, Hiroshima, Japan.
C3 Kyushu University; Kyushu University; Johns Hopkins University
RP Kyushu Univ, Med Inst Bioregulat, Dept Surg, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.
EM mmroi-i@beppu.kyushu-u.ac.jp
OI Mimori, Koshi/0000-0003-3897-9974
CR Alexander H, 2004, CLIN CANCER RES, V10, P7500, DOI 10.1158/1078-0432.CCR-04-1002
   COX DR, 1972, J R STAT SOC B, V34, P187
   DIEZITZA I, 1994, AM J PATHOL, V144, P310
   Do Carmo S, 2002, J BIOL CHEM, V277, P5514, DOI 10.1074/jbc.M105057200
   Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392
   FRANCONE OL, 1989, J BIOL CHEM, V264, P7066
   Fukai K, 2003, CANCER RES, V63, P8674
   Hall RE, 2004, PROSTATE, V58, P103, DOI 10.1002/pros.10343
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   IZUMI R, 1994, GASTROENTEROLOGY, V106, P720, DOI 10.1016/0016-5085(94)90707-2
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kanai Y, 1997, INT J CANCER, V71, P355
   King KL, 2000, CANCER, V88, P2464, DOI 10.1002/1097-0142(20000601)88:11<2464::AID-CNCR6>3.0.CO;2-W
   Kubo T, 2004, CANCER RES, V64, P5172, DOI 10.1158/0008-5472.CAN-03-3314
   Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100
   Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359
   *LIV CANC STUD GRO, 2000, GEN RUL CLIN PATH ST
   LOPEZBOADO YS, 1994, J BIOL CHEM, V269, P26871
   Masuda T, 2003, CLIN CANCER RES, V9, P5693
   MCCONATH.WJ, 1973, FEBS LETT, V37, P178, DOI 10.1016/0014-5793(73)80453-3
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750
   Ogawa K, 2004, BRIT J CANCER, V91, P282, DOI 10.1038/sj.bjc.6601941
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   Shimada M, 1998, ANN SURG, V227, P80, DOI 10.1097/00000658-199801000-00012
   Utsunomiya T, 2004, J HEPATOL, V41, P399, DOI 10.1016/j.jhep.2004.05.015
   Utsunomiya T, 2002, ARCH SURG-CHICAGO, V137, P181, DOI 10.1001/archsurg.137.2.181
   Utsunomiya T, 2002, CLIN CANCER RES, V8, P2591
   Vázquez J, 2000, GYNECOL ONCOL, V76, P340, DOI 10.1006/gyno.1999.5678
   Wong CM, 2003, CANCER RES, V63, P7646
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
NR 33
TC 22
Z9 22
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 10
PY 2005
VL 116
IS 1
BP 105
EP 109
DI 10.1002/ijc.20986
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 935FW
UT WOS:000229766100016
PM 15756681
DA 2025-01-12
ER

PT J
AU Tsai, KKC
   Chuang, EYY
   Little, JB
   Yuan, ZM
AF Tsai, KKC
   Chuang, EYY
   Little, JB
   Yuan, ZM
TI Cellular mechanisms for low-dose ionizing radiation-induced perturbation
   of the breast tissue microenvironment
SO CANCER RESEARCH
LA English
DT Article
ID PHOSPHOINOSITIDE 3-OH KINASE; MATRIX METALLOPROTEINASES; ALPHA-6-BETA-4
   INTEGRIN; IN-VIVO; CANCER; CELLS; FIBROBLASTS; EXPRESSION; PHENOTYPE;
   APOPTOSIS
AB Radiation exposure is an important form of environmental carcinogen and has been associated with increased risk of breast cancer. Epigenetic events, especially those involving alterations in the breast stromal microenvironment, may play an important role in radiation-induced carcinogenesis but remain not well understood. We here show that human mammary stromal fibroblasts respond to protracted low-dose ionizing radiation exposures by displaying a senescence-like phenotype. Using a three-dimensional coculture system to model the interactions of different mammary cell types with their neighbors and with their environment, we provide a direct experimental proof that ionizing radiation-induced senescence-like fibroblasts significantly perturb the mammary stromal microenvironment, which is highlighted by impaired formation of pseudopodia networks due to marked cytoskeletal alterations in senescence-like fibroblasts and increased extracellular matrix degradation because of the up-regulation of multiple secreted matrix metalloproteinases. Within such a perturbed environment, mammary ductal morphogenesis is completely disrupted and epithelial cells instead grow into enlarged cystic structures, which further develop and become disorganized cell masses on inactivation of cellular death pathways. Breast carcinoma cells growing in such an environment are enabled to fully express their malignant potential as evidenced by the alpha 6 beta 4 integrin/phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway-dependent invasive growth. Our results suggest that ionizing radiation, in addition to causing gene mutations in epithelial cells, can contribute to breast carcinogenesis by perturbing the tissue microenvironment that leads to dysregulated cell-cell and cell-matrix interactions.
C1 Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA.
   NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
RP Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Room 508,Bldg 1,665 Huntington Ave, Boston, MA 02115 USA.
EM zyuan@hsph.harvard.edu
RI Tsai, Kun-Chih/C-1371-2010
OI Tsai, Kelvin/0000-0002-1612-2868
CR Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7
   Atula S, 1997, EXP CELL RES, V235, P180, DOI 10.1006/excr.1997.3676
   Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254
   Barcellos-Hoff MH, 1998, J MAMMARY GLAND BIOL, V3, P165, DOI 10.1023/A:1018794806635
   Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277
   Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291
   Chuang YYE, 2002, CANCER RES, V62, P6246
   Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0
   Ingber DE, 2003, P NATL ACAD SCI USA, V100, P1472, DOI 10.1073/pnas.0530201100
   Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T
   Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491
   Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783
   Krtolica A, 2002, INT J BIOCHEM CELL B, V34, P1401, DOI 10.1016/S1357-2725(02)00053-5
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   MATHON NF, 2004, NAT REV CANCER, V1, P203
   MILLIS AJT, 1992, EXP CELL RES, V201, P373, DOI 10.1016/0014-4827(92)90286-H
   Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101
   Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3
   Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325
   Parmar H, 2002, ENDOCRINOLOGY, V143, P4886, DOI 10.1210/en.2002-220570
   Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635
   Pattingre S, 2004, METHOD ENZYMOL, V390, P17
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rudolph-Owen LA, 1998, CANCER RES, V58, P5500
   Sameni Mansoureh, 2003, Mol Imaging, V2, P159, DOI 10.1162/153535003322556903
   Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9
   Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5
   Shimizu H, 2002, INT J ONCOL, V21, P1073
   Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8
   Toussaint O, 2002, INT J BIOCHEM CELL B, V34, P1415, DOI 10.1016/S1357-2725(02)00034-1
   Tranquillo RT, 1999, BIOCHEM SOC SYMP, V65, P27
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025
   Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023
NR 50
TC 107
Z9 128
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2005
VL 65
IS 15
BP 6734
EP 6744
DI 10.1158/0008-5472.CAN-05-0703
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 950DN
UT WOS:000230837900034
PM 16061655
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Amaar, YG
   Baylink, DJ
   Mohan, S
AF Amaar, YG
   Baylink, DJ
   Mohan, S
TI Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding
   partner and a potential regulator of osteoblast cell proliferation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE protein-protein interaction; yeast two-hybrid screen; small interfering
   RNA; extracellular signalregulated; kinase-1/2 phosphorylation;
   insulin-like growth factor-independent mechanism
ID BREAST-CANCER CELLS; BONE-FORMATION; EPIGENETIC INACTIVATION; RNA
   INTERFERENCE; MAMMALIAN-CELLS; IN-VITRO; GROWTH; INTERACTS; KINASE; BETA
AB Introduction: It has been predicted that the intrinsic growth factor action of insulin-like growth factor binding protein (IGFBP)-5 involves either the binding of IGFBP-5 to a putative receptor to induce downstream signaling pathways and/or intracellular translocation of IGFBP-5 to bind to potential signaling molecules involved in osteoblast cell regulation. This study reports the characterization of isoform. C of the Ras association family 1 (RASSF1C) gene as an interacting partner of IGFBP-5.
   Materials and Methods: IGFBP-5 was used as bait in a yeast two-hybrid screen of a human osteosarcoma cDNA library. Expression levels of RASSF1C were measured by RT-PCR and/or Northern blot. IGFBP-5 effects on ERK phosphorylation were evaluated by immunoblot analysis. The effect of RASSF1C siRNA on cell proliferation was measured by the AlamarBlue assay.
   Results: One of the clones that interacted strongly with the bait under high stringency conditions corresponded to RASSF1C. The interaction between RASSF1C and IGFBP-5 was confirmed by in vitro coimmunoprecipitation studies. Northern blot and RT-PCR analysis showed that RASSF1C was expressed in a variety of osteoblast cell types that produce IGFBP-5. Addition of synthetic RASSF1C-specific small interfering (si) RNA duplex or use of a RASSF1C-specific si-hairpin plasmid caused a decrease in cell number and abolished IGFBP-5-induced extracellular signal-regulated kinase (ERK)-1/2 phosphorylation but had no effect on IGFBP-5-induced increases in alkaline phosphatase (ALP) activity.
   Conclusions: We have shown a novel interaction between IGFBP-5 and RASSF1C. Our findings that silencing of RASSF1C results in the reduction of osteoblast cell proliferation and that IGFBP-5 treatment increases phosphorylation of ERK-1/2 raise the possibility that RASSF1C, a Ras effector, could, in part, contribute to mediating the effects of IGFBP-5 on ERK phosphorylation and, consequently, cell proliferation.
C1 Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA.
   Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA.
   Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA.
   Loma Linda Univ, Dept Physiol, Loma Linda, CA 92350 USA.
C3 Loma Linda University; Loma Linda University; Loma Linda University
RP Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, 11201 Benton St, Loma Linda, CA 92357 USA.
EM Subburaman.Mohan@med.va.gov
FU NIAMS NIH HHS [T32 AR007543, R01 AR031062-21, R01 AR031062, AR07543,
   AR31062] Funding Source: Medline
CR Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200
   ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004
   Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744
   Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200
   Bauss F, 2001, GROWTH HORM IGF RES, V11, P1, DOI 10.1054/ghir.2000.0181
   Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783
   Cobb LJ, 2004, J CELL SCI, V117, P1737, DOI 10.1242/jcs.01028
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Devlin RD, 2002, ENDOCRINOLOGY, V143, P3955, DOI 10.1210/en.2002-220129
   Douziech M, 2003, EMBO J, V22, P5068, DOI 10.1093/emboj/cdg506
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200
   FARLEY JR, 1994, J BONE MINER RES, V9, P497
   FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0
   Harborth J, 2001, J CELL SCI, V114, P4557
   Kuemmerle JF, 2002, J BIOL CHEM, V277, P20563, DOI 10.1074/jbc.M200885200
   Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com
   Lau KHW, 1998, J BONE MINER RES, V13, P1660, DOI 10.1359/jbmr.1998.13.11.1660
   Leirdal M, 2002, BIOCHEM BIOPH RES CO, V295, P744, DOI 10.1016/S0006-291X(02)00736-2
   LINKHART TA, 1991, J BONE MINER RES, V6, P1285
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263
   Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459
   MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424
   Mohan S, 1996, HORM RES, V45, P59, DOI 10.1159/000184833
   MOHAN S, 1999, IGF SYSTEM MOL BIOL, P457
   OH YM, 1993, J BIOL CHEM, V268, P14964
   Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025
   Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200
   Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181
   Richman C, 1999, ENDOCRINOLOGY, V140, P4699, DOI 10.1210/en.140.10.4699
   Rosen CJ, 1998, P SOC EXP BIOL MED, V219, P1
   Salih DAM, 2005, ENDOCRINOLOGY, V146, P931, DOI 10.1210/en.2004-0816
   SAMBROOK J, 1989, MOL CLONING KABORATO
   Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347
   Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200
   Spagnoli A, 2001, J BIOL CHEM, V276, P5533, DOI 10.1074/jbc.M005088200
   Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8
   Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739
   Yin P, 2004, J BIOL CHEM, V279, P32660, DOI 10.1074/jbc.M401378200
NR 42
TC 42
Z9 44
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2005
VL 20
IS 8
BP 1430
EP 1439
DI 10.1359/JBMR.050311
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 948KE
UT WOS:000230713900014
PM 16007340
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Cheung, HW
   Ching, YP
   Nicholls, JM
   Ling, MT
   Wong, YC
   Hui, N
   Cheung, A
   Tsao, SW
   Wang, Q
   Yeun, PW
   Lo, KW
   Jin, DY
   Wang, XH
AF Cheung, HW
   Ching, YP
   Nicholls, JM
   Ling, MT
   Wong, YC
   Hui, N
   Cheung, A
   Tsao, SW
   Wang, Q
   Yeun, PW
   Lo, KW
   Jin, DY
   Wang, XH
TI Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through
   promoter methylation
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE CHFR; nasopharyngeal carcinoma; promoter hypermethylation
ID EPSTEIN-BARR-VIRUS; CELL LINES HNE-1; MITOTIC CHECKPOINT; CENTROSOME
   AMPLIFICATION; HUMAN CANCERS; EXPRESSION; GENE; ESTABLISHMENT;
   HYPERMETHYLATION; INSTABILITY
AB Chromosomal instability (CIN) is a cytogenetic hallmark of human cancers. Increasing evidence suggests that impairment of mitotic checkpoint is causally associated with CIN. CHFR is one of the mitotic checkpoint regulators and it delays chromosome condensation in response to mitotic stress. Epigenetic inactivation of CHFR through promoter CpG hypermethylation may lead to CIN and has been reported in several human cancers. In this study, we investigated the CHFR gene expression in a panel of nasopharyngeal carcinoma (NPC), prostate, ovarian, and breast cancer cell lines. We found that the expression of CHFR mRNA was significantly decreased or undetectable in all eight NPC cell lines as well as three human NPC xenografts, whereas non-malignant nasopharyngeal cell lines and other cancer cell lines tested expressed CHFR at relatively high levels. Hype methylation of CHFR promoter region was also strongly correlated with decreased CHFR expression in NPC cell lines and xenografts. Treatment with a methyltransferase inhibitor, 5-aza-2'-deoxycytidine, led to restoration of CHFR expression in NPC cell lines. More importantly, hypermethylation of CHFR promoter region was detected in 61.1% (22 out of 36) of primary NPC tumors while it was absent in non-malignant tissues. These findings suggest that downregulation of CHFR is a common event in NPC cells which may be due to hypermethylation of the gene promoter region. (c) 2005 Wiley-Liss, Inc.
C1 Univ Hong Kong, Dept Anat, Fac Med, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Biochem, Fac Med, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Pathol, Fac Med, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Surg, Fac Med, Hong Kong, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong; University of Hong Kong; Chinese University of Hong Kong
RP Jin, DY (通讯作者)，Univ Hong Kong, Dept Anat, Fac Med, Canc Biol Grp, 1-F,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.
RI Jin, Dong-Yan/AFL-5026-2022; Tsao, George/C-4422-2009; wang,
   xicheng/IXX-0974-2023; Ching, Yick/C-4244-2009; Jin,
   Dong-Yan/C-4287-2009; /C-4230-2009; Nicholls, John Malcolm/C-4375-2009
OI Jin, Dong-Yan/0000-0002-2778-3530; /0000-0003-3217-1456; Nicholls, John
   Malcolm/0000-0001-7217-7444; CHING, Yick Pang/0000-0002-6461-8358
FU FIC NIH HHS [D43 TW06186] Funding Source: Medline
CR Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374
   Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831
   Bright RK, 1997, CANCER RES, V57, P995
   Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688
   Chaturvedi P, 2002, CANCER RES, V62, P1797
   Cheng RYS, 1998, BRIT J CANCER, V77, P456, DOI 10.1038/bjc.1998.72
   Choo CK, 1999, PROSTATE, V40, P150, DOI 10.1002/(SICI)1097-0045(19990801)40:3<150::AID-PROS2>3.0.CO;2-7
   Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8
   Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161
   GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Honda T, 2004, BRIT J CANCER, V90, P2013, DOI 10.1038/sj.bjc.6601849
   HUANG DP, 1980, INT J CANCER, V26, P127, DOI 10.1002/ijc.2910260202
   HUANG DP, 1989, INT J CANCER, V43, P936, DOI 10.1002/ijc.2910430535
   Hui ABY, 1999, INT J CANCER, V82, P498, DOI 10.1002/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.0.CO;2-S
   Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065
   Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016
   Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   LIN CT, 1990, LAB INVEST, V62, P713
   Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999
   Lo KW, 2000, CANCER RES, V60, P3348
   Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483
   Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094
   MITELMAN F, 1994, CATALOG CHROMOSOME A
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   Niedobitek G, 1996, SEMIN CANCER BIOL, V7, P165, DOI 10.1006/scbi.1996.0023
   Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
   Satoh A, 2003, CANCER RES, V63, P8606
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695
   Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Tsao SW, 2003, EUR J CANCER, V39, P524, DOI 10.1016/S0959-8049(02)00494-X
   Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2
   Wang CZ, 2002, INT J EDUC DEV, V22, P109, DOI 10.1016/S0738-0593(00)00079-1
   Wang XH, 2002, CANCER RES, V62, P1662
   Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293
   Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1
   Wong CM, 2003, CANCER RES, V63, P7646
   YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116
   ZHANG S, 1982, HEREDITAS, V97, P23, DOI 10.1111/j.1601-5223.1982.tb00706.x
NR 42
TC 44
Z9 55
U1 0
U2 10
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD AUG
PY 2005
VL 43
IS 4
BP 237
EP 245
DI 10.1002/mc.20106
PG 9
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 953MG
UT WOS:000231079900007
PM 15937956
DA 2025-01-12
ER

PT J
AU Hu, M
   Yao, J
   Cai, L
   Bachman, KE
   van den Brûle, F
   Velculescu, V
   Polyak, K
AF Hu, M
   Yao, J
   Cai, L
   Bachman, KE
   van den Brûle, F
   Velculescu, V
   Polyak, K
TI Distinct epigenetic changes in the stromal cells of breast cancers
SO NATURE GENETICS
LA English
DT Article
ID HUMAN COLON-CARCINOMA; CPG ISLANDS; ALTERED METHYLATION; PROTEOGLYCAN
   GENE; DNA METHYLATION; HYPOMETHYLATION; EXPRESSION; HIN-1;
   TRANSCRIPTOME; EPIGENOMICS
AB Increasing evidence suggests that changes in the cellular microenvironment contribute to tumorigenesis, but the molecular basis of these alterations is not well understood. Although epigenetic modifications of the neoplastic cells in tumors have been firmly implicated in tumorigenesis(1), it is not known whether epigenetic modifications occur in the non-neoplastic stromal cells. To address this question in an unbiased and genome-wide manner, we developed a new method, methylation-specific digital karyotyping, and applied it to epithelial and myoepithelial cells, stromal fibroblasts from normal breast tissue, and in situ and invasive breast carcinomas. Our analyses showed that distinct epigenetic alterations occur in all three cell types during breast tumorigenesis in a tumor stage- and cell type-specific manner, suggesting that epigenetic changes have a role in the maintenance of the abnormal cellular microenvironment in breast cancer.
C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
   Univ Liege, Lab Biol & Dev Biol, B-4000 Liege, Belgium.
   Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD 21231 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard Medical School; University System of Maryland; University of
   Maryland Baltimore; University of Liege; Johns Hopkins University
RP Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM Kornelia_Polyak@dfci.harvard.edu
RI Polyak, Kornelia/ACJ-5837-2022; Velculescu, Victor/B-3247-2009
OI Cai, Li/0000-0003-3344-337X; Velculescu, Victor/0000-0003-1195-438X
CR ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301
   ADANY R, 1990, BIOCHEM BIOPH RES CO, V171, P1402, DOI 10.1016/0006-291X(90)90841-A
   ADANY R, 1990, J BIOL CHEM, V265, P11389
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Böcker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5
   Cai L, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r51
   Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794
   Dai ZY, 2002, GENOME RES, V12, P1591, DOI 10.1101/gr.197402
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kremenskoy M, 2003, BIOCHEM BIOPH RES CO, V311, P884, DOI 10.1016/j.bbrc.2003.10.078
   Krop I, 2004, MOL CANCER RES, V2, P489
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226
   Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508
   Shi HD, 2002, CANCER RES, V62, P3214
   Shigematsu H, 2005, INT J CANCER, V113, P600, DOI 10.1002/ijc.20622
   Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Wang TL, 2002, P NATL ACAD SCI USA, V99, P16156, DOI 10.1073/pnas.202610899
NR 29
TC 426
Z9 515
U1 2
U2 35
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD AUG
PY 2005
VL 37
IS 8
BP 899
EP 905
DI 10.1038/ng1596
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 950TK
UT WOS:000230880400023
PM 16007089
DA 2025-01-12
ER

PT J
AU Roa, JC
   Anabalón, L
   Roa, I
   Tapia, O
   Melo, A
   Villaseca, M
   Araya, JC
AF Roa, JC
   Anabalón, L
   Roa, I
   Tapia, O
   Melo, A
   Villaseca, M
   Araya, JC
TI Promoter methylation profile in gastric cancer
SO REVISTA MEDICA DE CHILE
LA Spanish
DT Article
DE DNA methylation; promoter regions (Genetics); stomach neoplasms
ID CPG ISLAND METHYLATION; DNA METHYLATION; MICROSATELLITE INSTABILITY;
   GENE HYPERMETHYLATION; BREAST-CANCER; E-CADHERIN; CARCINOMAS;
   EXPRESSION; ADENOCARCINOMAS; EPIGENETICS
AB Background: Promoter genomic DNA methylation is an important inactivation mechanism of tumor suppresor genes. This genetic-molecular pathway for cancer may separate a subset of patients with different prognoses and eventually different responses to specific therapies. Aim: To analyze the methylation pattern of important genes related to different carcinogenic mechanisms in patients with gastric cancer (GC) and the relationship with its morphological features and biological behavior. Material and methods: Forty-seven fresh-frozen GC samples were selected. The methylation-specific PCR (MSP) test was used to analyze promoter methylation status for genes MLH1, CDKN2A (p16), APC CDH1 (Cadherin E) and FHIT. Follow-up and complete morphological features were obtained,for all cases. Results: We found methylation in at least one of the genes studied in 83% of the cases The frequencies of promoter hypemethylation of MLH1, CDKN2A, APC CDH1 and FHIT were 31016, 43%, 46%, 80% y 62%, respectively. We found a relationship between APC methylation and good histological cl differentiation (p=0.03),. CDTH methylation with diffuse type by Lauren and 3 or more metastasic lymph nodes (p < 0.05), FHIT CDKYN2A and CDH1 methylation and female condition (p < 0.04). We also found a non-significant relationship between CDKN2A methylation and better survival (p = 0.07). Conclusions: The high frequency promoter methylation found confirms its importance in gastric carcinogenesis. The finding of alterations in the methylation pattern of genes studied and its association with prognostic factors is a helpful tool in the search for new criteria in clinical and therapeutic decision making.
C1 Univ La Frontera, Fac Med, Dept Anat Patol, Mol Biol Lab, Temuco, Chile.
C3 Universidad de La Frontera
RP Roa, JC (通讯作者)，Univ La Frontera, Fac Med, Dept Anat Patol, Mol Biol Lab, Manuel Montt 112,Codigo Postal 478-1176, Temuco, Chile.
EM jcroa@ufro.cl
RI ARAYA, JUAN/Q-5575-2018; Roa, Juan/K-4749-2014
OI Anabalon, Leonardo/0000-0001-9943-3356; Roa, Juan
   Carlos/0000-0001-8313-8774
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   ARIMIJO R, 1982, NATL CANC I MONOGR, V62, P91
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Esteller M, 2001, CANCER RES, V61, P3225
   Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998
   Graziano F, 2004, CLIN CANCER RES, V10, P2784, DOI 10.1158/1078-0432.CCR-03-0320
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   House MG, 2003, J GASTROINTEST SURG, V7, P1004, DOI 10.1016/j.gassur.2003.08.002
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kang GH, 2003, LAB INVEST, V83, P635, DOI 10.1097/01.LAB.0000067481.08984.3F
   Kawaguchi K, 2004, BRIT J CANCER, V90, P672, DOI 10.1038/sj.bjc.6601601
   Kim H, 2003, J PATHOL, V200, P23, DOI 10.1002/path.1325
   Lee HS, 2003, J PATHOL, V200, P39, DOI 10.1002/path.1288
   Lee JH, 2004, ONCOGENE, V23, P4646, DOI 10.1038/sj.onc.1207588
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Medina E, 2001, REV MED CHILE, V129, P1195
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Oue N, 2003, CANCER SCI, V94, P901, DOI 10.1111/j.1349-7006.2003.tb01373.x
   Roa JC, 2003, REV MED CHILE, V131, P1227
   Roa JC, 2004, REV MED CHILE, V132, P1069
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Rocco A, 2003, J CANCER RES CLIN, V129, P84, DOI 10.1007/s00432-002-0409-3
   Sarbia M, 2004, INT J CANCER, V111, P224, DOI 10.1002/ijc.20212
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Zheng Zhi-Hong, 2003, Acta Genetica Sinica, V30, P103
NR 28
TC 12
Z9 16
U1 0
U2 2
PU SOC MEDICA SANTIAGO
PI SANTIAGO 9
PA BERNARDA MORIN 488 PROVIDENCIA, CASILLA 168 CORREO 55, SANTIAGO 9, CHILE
SN 0034-9887
J9 REV MED CHILE
JI Rev. Medica Chile
PD AUG
PY 2005
VL 133
IS 8
BP 874
EP 880
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 970TH
UT WOS:000232332000002
PM 16163424
DA 2025-01-12
ER

PT J
AU Hodge, DR
   Xiao, WH
   Peng, BJ
   Cherry, PC
   Munroe, DJ
   Farrar, WL
AF Hodge, DR
   Xiao, WH
   Peng, BJ
   Cherry, PC
   Munroe, DJ
   Farrar, WL
TI Enforced expression of superoxide dismutase 2/manganese superoxide
   dismutase disrupts autocrine interleukin-6 stimulation in human multiple
   myeloma cells and enhances dexamethasone-induced apoptosis
SO CANCER RESEARCH
LA English
DT Article
ID NF-KAPPA-B; AP-1 TRANSCRIPTION FACTOR; BREAST-CANCER CELLS;
   GROWTH-FACTOR; CARCINOMA-CELLS; IL-6 FUNCTIONS; TUMOR-CELLS; ACTIVATION;
   PARACRINE; CYTOKINES
AB Autocrine pathways of proliferative and antiapoptotic growth factors represent a serious impediment to the treatment of many types of tumors. In particular, interleukin-6 (IL-6), a pleiotropic cytokine known to play a critical role in the survival and growth of multiple myeloma cells, participates in an autocrine. stimulation loop that serves to inhibit the induction of apoptosis during chemotherapy. Manganese syperoxide dismutase (MnSOD) is an important antioxidant enzyme encoded by the SOD2 gene that attenuates oxidative free radicals in the mitochondria by catalyzing the formation of hydrogen peroxide from superoxide radicals. Transcription factor activity and binding is influenced by the oxidative state of cells, and dysregulation of MnSOD levels can result in abnormal patterns of gene expression. In the human multiple myeloma cell line IM-9, an autocrine IL-6 loop exists, which enables the cell to resist the effects of dexamethasone, a common treatment for multiple myeloma. Here, we show that SOD2 expression is epigenetically silenced in IM-9 cells, and replacement of MnSOD reduces cell proliferation and partially restores susceptibility to dexamethasone. The restoration of MnSOD also serves to decrease the expression levels of IL-6 by reducing the ability of activator protein-1, an important mediator of IL-6 expression in multiple myeloma cells, to bind to its enhancer site. These results show the importance of free radical-mediated dysregulation of autocrine growth factor loops in tumor cells and their effect on cell growth and response to chemotherapy.
C1 NCI, Lab Mol Immunoregulat, Cytokine Mol Mech Sect, Ctr Canc Res, Frederick, MD 21701 USA.
   NCI, Lab Mol Technol, Frederick, MD 21701 USA.
   Sci Applicat Int Corp Frederick, Intramural Res Support Program, Basic Res Program, Frederick, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); Science Applications International Corporation (SAIC)
RP NCI, Lab Mol Immunoregulat, Cytokine Mol Mech Sect, Ctr Canc Res, 1050 Boyles St,Bldg 560,Room 31-76, Frederick, MD 21701 USA.
EM hodje@mail.ncifcrf.gov
RI Xiao, Weihua/N-2775-2013
CR Alonzi T, 1997, IMMUNOBIOLOGY, V198, P144, DOI 10.1016/S0171-2985(97)80035-6
   Bailey S, 1999, ADV EXP MED BIOL, V457, P615
   Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207
   Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3
   CADMAN ED, 1994, J NEUROCHEM, V63, P980
   Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082
   Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234
   Chauhan D, 2000, J BIOL CHEM, V275, P27845
   Cullen JJ, 2003, CANCER RES, V63, P1297
   Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200
   Dubost JJ, 2002, J NEURO-ONCOL, V56, P29, DOI 10.1023/A:1014467804488
   Esteller M, 2001, CANCER RES, V61, P3225
   EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156
   Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200
   Frassanito MA, 2001, BLOOD, V97, P483, DOI 10.1182/blood.V97.2.483
   Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261
   Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7
   Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167
   Haddad JJ, 2002, BRIT J PHARMACOL, V135, P520, DOI 10.1038/sj.bjp.0704467
   HARDIN J, 1994, BLOOD, V84, P3063
   HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x
   JANSSEN YMW, 1993, LAB INVEST, V69, P261
   JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U
   Kiningham KK, 1997, CANCER RES, V57, P5265
   Kyriakis JM, 1999, GENE EXPRESSION, V7, P217
   Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Li ZK, 2001, FREE RADICAL BIO MED, V30, P260, DOI 10.1016/S0891-5849(00)00468-8
   Liu TS, 2004, J BIOL CHEM, V279, P2461, DOI 10.1074/jbc.M307251200
   LOTEM J, 1992, BLOOD, V80, P1750
   Lund P, 2004, CANCER LETT, V206, P85, DOI 10.1016/j.canlet.2003.10.018
   Mates J M, 1999, Front Biosci, V4, pD339
   MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200
   Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261
   Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363
   Okamoto M, 1997, CANCER RES, V57, P141
   Overbergh L, 2003, J Biomol Tech, V14, P33
   PIETSCH T, 1993, NOUV REV FR HEMATOL, V35, P285
   PLUTHERO FG, 1991, ANN NY ACAD SCI, V628, P222, DOI 10.1111/j.1749-6632.1991.tb17249.x
   Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970
   RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289
   RIECKMANN P, 1991, J IMMUNOL, V146, P3462
   Samper E, 2003, AGING CELL, V2, P277, DOI 10.1046/j.1474-9728.2003.00062.x
   Soini Y, 2001, J PATHOL, V195, P156, DOI 10.1002/path.946
   Thabard W, 2001, CYTOKINE, V14, P352, DOI 10.1006/cyto.2001.0911
   Wei P, 1997, ENDOCRINE, V7, P303, DOI 10.1007/BF02801323
   Xiao WH, 2004, CANCER BIOL THER, V3, P1007, DOI 10.4161/cbt.3.10.1141
   Xiao WH, 2004, PROSTATE, V61, P354, DOI 10.1002/pros.20113
   Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X
   Zhang GJ, 2000, J UROLOGY, V163, P1553, DOI 10.1016/S0022-5347(05)67678-1
   Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9
NR 53
TC 31
Z9 36
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2005
VL 65
IS 14
BP 6255
EP 6263
DI 10.1158/0008-5472.CAN-04-4482
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 947HG
UT WOS:000230633400035
PM 16024627
DA 2025-01-12
ER

PT J
AU Kamikihara, T
   Arima, T
   Kato, K
   Matsuda, T
   Kato, H
   Douchi, T
   Nagata, Y
   Nakao, M
   Wake, N
AF Kamikihara, T
   Arima, T
   Kato, K
   Matsuda, T
   Kato, H
   Douchi, T
   Nagata, Y
   Nakao, M
   Wake, N
TI Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an
   early event in the progression of human ovarian cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE genomic imprinting; human ovarian cancer; ZAC; DNA methylation; tumor
   suppressor gene
ID TUMOR-SUPPRESSOR GENE; ZINC-FINGER PROTEIN; NEONATAL DIABETES-MELLITUS;
   CPG BINDING DOMAIN; HISTONE DEACETYLASE; BREAST-CANCER; GROWTH-FACTOR;
   TRANSCRIPTIONAL COACTIVATOR; MICRODISSECTION SYSTEM; CELL-LINES
AB ZAC is a paternally expressed, imprinted gene located on chromosome 6q24, within a region known to harbor a tumor suppressor gene for several types of neoplasia, including human ovarian cancer (HOC). We have failed to identify genetic mutations in the ZAC gene in tumor material. Many imprinted genes contain differentially allele-specific-methylated regions (DMR) and harbor promoter activity that is regulated by the DNA methylation. Aberrant DNA methylation is a common feature of neoplasia and changes in DNA methylation at the ZAC locus have been reported in some cases of HOC. We investigated the DNA methylation and ZAC mRNA expression levels in a larger sample of primary HOC material, obtained by laser capture microdissection. ZAC mRNA expression was reduced in the majority of samples and this correlated with hypermethylation of the ZAC-DMR. Treatment of hypermethylated cells lines with a demethylating agent restored ZAC expression. Our studies indicate that transcriptional silencing of ZAC is likely to be caused by DNA methylation in HOC. Forced expression of ZAC resulted in a reduction in proliferation and marked induction of apoptotic cell death. The ZAC-mediated apoptosis signal is p53-independent and eliminated by inhibitors of caspase 3, 8 and 9. Reduced expression of ZAC would therefore favor tumor progression. As there were no significant differences in either DNA methylation or expression of ZAC mRNA between localized and advanced tumors, our data indicates that loss of ZAC is a relatively early event in HOC. (Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/ suppmat/index.html.) (c) 2005 Wiley-Liss, Inc.
C1 Kyushu Univ, Med Inst Bioregulat, Div Mol & Cell Therapeut, Dept Mol Genet, Beppu, Oita 8740838, Japan.
   Kagoshima Univ, Fac Med, Dept Obstet & Gynecol, Kagoshima 890, Japan.
   Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan.
C3 Kyushu University; Kagoshima University; Kumamoto University
RP Kyushu Univ, Med Inst Bioregulat, Div Mol & Cell Therapeut, Dept Mol Genet, 4546,Tsurumihara, Beppu, Oita 8740838, Japan.
EM nwake@tsurumi.beppu.kyushu-u.ac.jp
CR Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067
   Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200
   ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Arima T, 2001, HUM MOL GENET, V10, P1475, DOI 10.1093/hmg/10.14.1475
   Arima T, 2000, GENOMICS, V67, P248, DOI 10.1006/geno.2000.6266
   Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200
   Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523
   El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200
   Feinberg AP, 2000, CURR TOP MICROBIOL, V249, P87
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4
   Hall JG, 1997, ANNU REV MED, V48, P35
   Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101
   Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499
   Huang SM, 2001, ONCOGENE, V20, P2134, DOI 10.1038/sj.onc.1204298
   Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000
   Inoue K, 2003, VIRCHOWS ARCH, V442, P159, DOI 10.1007/s00428-002-0719-5
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Joyce JA, 1998, J CLIN PATHOL-MOL PA, V51, P185, DOI 10.1136/mp.51.4.185
   Kamiya M, 2000, HUM MOL GENET, V9, P453, DOI 10.1093/hmg/9.3.453
   Kohda T, 2001, GENES CELLS, V6, P237, DOI 10.1046/j.1365-2443.2001.00412.x
   Kohda Y, 2000, KIDNEY INT, V57, P321, DOI 10.1046/j.1523-1755.2000.00824.x
   Kölble K, 2000, J MOL MED-JMM, V78, pB24
   Koy S, 2004, HEAD NECK-J SCI SPEC, V26, P338, DOI 10.1002/hed.10386
   May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285
   NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275
   Pagotto U, 2000, CANCER RES, V60, P6794
   Rozenfeld-Granot G, 2002, ONCOGENE, V21, P1469, DOI 10.1038/sj.onc.1205218
   Singhal S, 2003, CANCER BIOL THER, V2, P291, DOI 10.4161/cbt.2.3.399
   Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814
   SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0
   TAGUCHI T, 1993, CANCER RES, V53, P4349
   Terao Y, 2001, INT J CANCER, V94, P257, DOI 10.1002/ijc.1448
   Theile M, 1996, ONCOGENE, V13, P677
   Ueoka Y, 2000, BRIT J CANCER, V82, P891, DOI 10.1054/bjoc.1999.1016
   Varrault A, 2001, J BIOL CHEM, V276, P18653, DOI 10.1074/jbc.C100095200
   Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835
   WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361
   Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
NR 44
TC 64
Z9 78
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUL 10
PY 2005
VL 115
IS 5
BP 690
EP 700
DI 10.1002/ijc.20971
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 933BC
UT WOS:000229597900004
PM 15751035
DA 2025-01-12
ER

PT J
AU To, MD
   Faseruk, SA
   Gokgoz, N
   Pinnaduwage, D
   Done, SJ
   Andrulis, IL
AF To, MD
   Faseruk, SA
   Gokgoz, N
   Pinnaduwage, D
   Done, SJ
   Andrulis, IL
TI <i>LAF-4</i> is aberrantly expressed in human breast cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE LAF-4; overexpression; proto-oncogene; methylation; breast cancer
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; AF4-RELATED GENE; POOR-PROGNOSIS; INFANT;
   FUSION; MLL; METHYLATION; PROTEIN; AF-4
AB LAF-4, which encodes a nuclear protein with transactivation potential, is fused to the MLL gene in acute lymphoblastic leukemia (ALL). We identified LAF-4 as a gene that is transcriptionally deregulated in breast tumors and thus may have a pathological role in mammary tumorigenesis. In line with the previous finding that LAF-4 expression is tissue specific, we did not detect any LAF-4 mRNA in normal mammary epithelial cell lines. However, 2 of 5 breast cancer cell lines were found to express LAF-4 at both the RNA and protein levels. In 2 of 9 primary tumor-normal pairs, the expression of LAF-4 was clearly elevated in the tumor tissue. Using RNA in situ hybridization, we demonstrated that LAF-4 is expressed in mammary tumor cells but not in normal acini. In a group of 64 primary human breast tumors, we found that LAF-4 was overexpressed in approximately 20% of the cases. Although epigenetic changes may be involved in altered expression of some genes, differences in LAF-4 expression were not associated with DNA methylation of the predicted promoter region. Our results suggest that LAF-4 may be a proto-oncogene that is transcriptionally activated in some cases of breast cancer. (c) 2005 Wiley-Liss, Inc.
C1 Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, Toronto, ON M5G 1X5, Canada.
   Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada.
   Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
C3 University of Toronto; Sinai Health System Toronto; Lunenfeld Tanenbaum
   Research Institute; University of Toronto; University of Toronto
RP Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, 600 Univ Ave,Room 984, Toronto, ON M5G 1X5, Canada.
EM andrulis@mshri.on.ca
RI To, Minh/KFA-7155-2024; Andrulis, Irene/E-7267-2013
OI Done, Susan/0000-0002-1770-988X
CR Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340
   [Anonymous], 2019, An Introduction To Categorical Data Analysis
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Bruch J, 2003, GENE CHROMOSOME CANC, V37, P106, DOI 10.1002/gcc.10187
   Caslini C, 2004, LEUKEMIA, V18, P1064, DOI 10.1038/sj.leu.2403321
   Estable MC, 2002, J BIOMED SCI, V9, P234, DOI 10.1159/000059424
   Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105
   GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A
   Heerema NA, 1999, LEUKEMIA, V13, P679, DOI 10.1038/sj.leu.2401413
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389
   Imamura T, 2002, LEUKEMIA, V16, P2302, DOI 10.1038/sj.leu.2402665
   LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393
   Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734
   ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377
   Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535
   von Bergh ARM, 2002, GENE CHROMOSOME CANC, V35, P92, DOI 10.1002/gcc.10091
NR 17
TC 10
Z9 10
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUL 1
PY 2005
VL 115
IS 4
BP 568
EP 574
DI 10.1002/ijc.20881
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 925WA
UT WOS:000229082800009
PM 15704140
DA 2025-01-12
ER

PT J
AU Schagdarsurengin, U
   Seidel, C
   Ulbrich, EJ
   Kölbl, H
   Dittmer, J
   Dammann, R
AF Schagdarsurengin, U
   Seidel, C
   Ulbrich, EJ
   Kölbl, H
   Dittmer, J
   Dammann, R
TI A polymorphism at codon 133 of the tumor suppressor RASSF1A is
   associated with tumorous alteration of the breast
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE RASSF1A; polymorphism; breast cancer; fibroadenoma
ID K-RAS MUTATIONS; EPIGENETIC INACTIVATION; PROMOTER HYPERMETHYLATION;
   MOLECULAR-GENETICS; DNA METHYLATION; BRCA2 GENE; CANCER; CARCINOMA;
   3P21.3; PROTEIN
AB The tumor suppressor gene RASSF1A is inactivated or mutated in different tumor entities including breast cancer. The frequency of the genomic variants of RASSF1A in patients with breast tumors has not been evaluated. We studied the association between ten nucleotide polymorphisms of RASSF1A and the risk of breast cancer in 178 cases with tumorous alterations of mammary tissue (including 141 carcinomas and 37 fibroadenomas) and 70 controls by SSCP and sequencing. Polymorphisms of RASSF1A were found at codon 28 and codon 133. The distribution of polymorphisms at codon 28 showed no significant difference between the patient groups: 5 of 178 (2.8%) in patients with tumorous alterations and 2 of 70 (2.9%) in control patients. However, the G-T polymorphism (GCT -> TCT; Ala -> Ser) at codon 133, which alters the microtubule association and stabilization domain of RASSFIA, exhibited a different genotype distribution: 29 out of 141 (20.6%) patients with breast carcinoma and 9 out of 37 (24.3%) patients with fibroadenoma harbored mutant T-alleles. However, only in 2 out of 70 (2.9%) controls, the mutant T-allele was detected and therefore the frequency was significantly diminished compared to tumorous alterations (Fisher's exact test: carcinomas vs. controls, p=0.0003; fibroadenoma vs. controls, p=0.001). From five probands with homozygous TT-genotype at codon 133, three were diagnosed with carcinomas and two with fibroadenomas. Our data indicate that the mutant T-allele of RASSFIA at codon 133 is correlated with an increased number of breast tumors.
C1 Univ Halle Wittenberg, Inst Human Genet & Med Biol, AG Tumorgenet & Med Fak, D-06097 Halle Saale, Germany.
   Univ Halle Wittenberg, Univ Klin & Poliklin Gynakol, D-06097 Halle Saale, Germany.
   Univ Mainz, Univ Klin & Frauenklin Geburtschilfe & Frauenkran, D-55101 Mainz, Germany.
C3 Martin Luther University Halle Wittenberg; Martin Luther University
   Halle Wittenberg; Johannes Gutenberg University of Mainz
RP Univ Halle Wittenberg, Inst Human Genet & Med Biol, AG Tumorgenet & Med Fak, Magdeburger Str 2, D-06097 Halle Saale, Germany.
EM reinhard.dammann@medizin.uni-halle.de
RI Dittmer, Juergen/G-1160-2011; Schagdarsurengin, Undraga/AAH-4312-2020
OI Schagdarsurengin, Undraga/0000-0003-0127-4938
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Alle KM, 1998, CLIN CANCER RES, V4, P847
   Blackwood MA, 1998, J CLIN ONCOL, V16, P1969, DOI 10.1200/JCO.1998.16.5.1969
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2003, ONCOGENE, V22, P3806, DOI 10.1038/sj.onc.1206582
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fitzgibbons PL, 1998, ARCH PATHOL LAB MED, V122, P1053
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Hunter CP, 2000, CANCER-AM CANCER SOC, V88, P1193, DOI 10.1002/(SICI)1097-0142(20000301)88:5+<1193::AID-CNCR3>3.0.CO;2-D
   Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124
   Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058
   Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8
   Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538
   Kuzmin I, 2002, CANCER RES, V62, P3498
   Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   Lo KW, 2001, CANCER RES, V61, P3877
   Máthé E, 2004, NAT GENET, V36, P117, DOI 10.1038/ng0204-117
   Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245
   Müller HM, 2003, CANCER RES, V63, P7641
   OLUWOLE SF, 1979, AM J SURG, V137, P786, DOI 10.1016/0002-9610(79)90094-1
   Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192
   Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943
   Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   TENGS TO, 1996, CURR ISSUES PUBLIC H, V2, P13
   Tommasi S, 2005, CANCER RES, V65, P92
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466
   Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Weber BL, 1998, RECENT RESULTS CANC, V152, P49
NR 40
TC 20
Z9 23
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2005
VL 27
IS 1
BP 185
EP 191
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 937SL
UT WOS:000229945700019
PM 15942659
DA 2025-01-12
ER

PT J
AU Hoque, MO
   Rosenbaum, E
   Westra, WH
   Xing, M
   Ladenson, P
   Zeiger, MA
   Sidransky, D
   Umbricht, CB
AF Hoque, MO
   Rosenbaum, E
   Westra, WH
   Xing, M
   Ladenson, P
   Zeiger, MA
   Sidransky, D
   Umbricht, CB
TI Quantitative assessment of promoter methylation profiles in thyroid
   neoplasms
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID CPG ISLAND METHYLATION; PANCREATIC ENDOCRINE NEOPLASMS; INTRAGENIC
   ALLELIC LOSS; TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINES; BREAST-CANCER
   CELLS; MULTIPLE GENES; PROSTATE-CANCER; E-CADHERIN; MICROSATELLITE
   INSTABILITY
AB Context: Cancer-specific molecular markers are needed to supplement the cytopathological assessment of thyroid tumors, because a majority of patients with cytologically indeterminate nodules currently undergo thyroidectomy without a definitive diagnosis.
   Objective: The aim of this study was the quantitative assessment of promoter hypermethylation and its relation to the BRAF mutation in thyroid tumors.
   Design: Quantitative hypermethylation of Rassf1A, TSHR, RAR-beta 2, DAPK, S100, p16, CDH1, CALCA, TIMP3, TGF-beta, and GSTpi was tested on a cohort of 82 benign and malignant thyroid tumors and five thyroid cancer cell lines.
   Setting: The study was conducted at a tertiary research hospital.
   Patients: Patients underwent surgical resection for a thyroid tumor from 2000 to 2003 at our institution.
   Interventions: There were no interventions.
   Main Outcome Measure: Final surgical pathology diagnosis was the main outcome measure.
   Results: Thyroid tumors showed hypermethylation for the followingmarkers: Rassf1A, TSHR, RAR-beta 2, DAPK, CDH1, TIMP3, and TGF-beta. A trend toward multiple hypermethylation was evident in cancer tissues, with hypermethylation of two or more markers detectable in 25% of hyperplasias, 38% of adenomas, 48% of thyroid cancers, and 100% of cell lines. A rank correlation analysis of marker hypermethylation suggests that a subset of these markers is epigenetically modified in concert, which may reflect an organ-specific regulation process. Furthermore, a positive correlation was found between the BRAF mutation and RAR-beta 2, and a negative correlation was found between the BRAF mutation and Rassf1A.
   Conclusions: Methylation-induced gene silencing appears to affect multiple genes in thyroid tissue and increases with cancer progression. Additional markers with better discriminatory power between benign and malignant samples are needed for the diagnostic assessment of cytologically indeterminate thyroid nodules.
C1 Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine;
   Johns Hopkins University; Johns Hopkins Medicine
RP Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.
EM cumbrich@jhmi.edu
OI Hoque, Mohammad Obaidul/0000-0001-6701-9978
FU NCI NIH HHS [CA 095703, CA 96784-01] Funding Source: Medline
CR Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Bandyopadhyay D, 2003, EXP GERONTOL, V38, P1299, DOI 10.1016/j.exger.2003.09.009
   BAYLIN SB, 1986, CANCER RES, V46, P2917
   Begum S, 2004, MODERN PATHOL, V17, P1359, DOI 10.1038/modpathol.3800198
   Boltze C, 2003, PATHOL RES PRACT, V199, P399, DOI 10.1078/0344-0338-00436
   Braakhuis BJM, 2003, CANCER RES, V63, P1727
   Brock MV, 2003, CLIN CANCER RES, V9, P2912
   Cairns P, 2001, CLIN CANCER RES, V7, P2727
   Carling T, 2003, SURGERY, V134, P932, DOI 10.1016/S0039-6060(03)00422-7
   Chan AOO, 2003, ONCOGENE, V22, P924, DOI 10.1038/sj.onc.1206123
   Chen H, 2003, SURGERY, V134, P909
   Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625
   Cohen Y, 2004, CLIN CANCER RES, V10, P2761, DOI 10.1158/1078-0432.CCR-03-0273
   Dammann R, 2003, ONCOGENE, V22, P3806, DOI 10.1038/sj.onc.1206582
   Darnton SJ, 2005, INT J CANCER, V115, P351, DOI 10.1002/ijc.20830
   Doherty GM, 2003, SURGERY, V134, P939
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Elisei R, 1998, CANCER, V83, P2185, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.0.CO;2-4
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fendrich V, 2005, PANCREAS, V30, pE40, DOI 10.1097/01.mpa.0000153325.62192.8a
   GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007
   Graff JR, 1998, CANCER RES, V58, P2063
   Granja F, 2004, CANCER LETT, V209, P129, DOI 10.1016/j.canlet.2003.12.013
   Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763
   Ha PK, 2003, CRIT REV ORAL BIOL M, V14, P363, DOI 10.1177/154411130301400506
   Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099
   *HCIA I, 1996, 1996 NAT LINK STUD 1
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   House MG, 2003, SURGERY, V134, P902, DOI 10.1016/S0039-6060(03)00412-4
   Huang Y, 2003, INT J CANCER, V104, P735, DOI 10.1002/ijc.11006
   Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1
   Ito Y, 2004, ONCOLOGY-BASEL, V67, P397, DOI 10.1159/000082924
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65
   Kato N, 2002, PATHOL INT, V52, P13, DOI 10.1046/j.1440-1827.2002.01310.x
   Kim DH, 2003, CANCER RES, V63, P3743
   Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077
   Kim HP, 2004, BIOCHEM J, V379, P141, DOI 10.1042/BJ20031408
   Kimura ET, 2003, CANCER RES, V63, P1454
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Leotlela PD, 2003, ENDOCR-RELAT CANCER, V10, P437, DOI 10.1677/erc.0.0100437
   Li LC, 2004, BIOCHEM BIOPH RES CO, V321, P455, DOI 10.1016/j.bbrc.2004.06.164
   Moreno-Bueno G, 2003, J PATHOL, V199, P471, DOI 10.1002/path.1310
   Nakatsuka S, 2000, LAB INVEST, V80, P1651, DOI 10.1038/labinvest.3780175
   Nishimura R, 1997, PATHOL INT, V47, P673, DOI 10.1111/j.1440-1827.1997.tb04440.x
   Rocha AS, 2001, J PATHOL, V194, P358, DOI 10.1002/path.905
   Rossi D, 2004, HAEMATOLOGICA, V89, P154
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Schagdarsurengin U, 2002, CANCER RES, V62, P3698
   Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Wild A, 2003, J CLIN ENDOCR METAB, V88, P1367, DOI 10.1210/jc.2002-021027
   Xing M, 2004, J CLIN ENDOCR METAB, V89, P1365, DOI 10.1210/jc.2003-031488
   Xing MZ, 2003, CANCER RES, V63, P2316
   Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242
   Xu XL, 2003, CANCER RES, V63, P4561
   Youssef EM, 2004, CANCER BIOL THER, V3, P82, DOI 10.4161/cbt.3.1.591
NR 65
TC 101
Z9 117
U1 0
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2005
VL 90
IS 7
BP 4011
EP 4018
DI 10.1210/jc.2005-0313
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 943FT
UT WOS:000230339100030
PM 15840741
OA Bronze
DA 2025-01-12
ER

PT J
AU Sharma, D
   Blum, J
   Yang, XW
   Beaulieu, N
   Macleod, AR
   Davidson, NE
AF Sharma, D
   Blum, J
   Yang, XW
   Beaulieu, N
   Macleod, AR
   Davidson, NE
TI Release of methyl CpG binding proteins and histone deacetylase 1 from
   the estrogen receptor α (ER) promoter upon reactivation in ER-negative
   human breast cancer cells
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; CHROMATIN-STRUCTURE; LYSINE
   9; GENE; COMPLEX; DOMAIN; MECP2; METHYLTRANSFERASES; EXPRESSION
AB Estrogen receptor alpha ( ER) is an epigenetically regulated gene. Inhibitors of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) synergistically activate the methylated ER gene promoter in ER-negative MDA-MB-231 human breast cancer cells. Chromatin immunoprecipitation was used to examine the chromatin status and repressor complex associated with silenced ER and changes in the key regulatory factors during reactivation by inhibitors of DNMT (5-aza-2'-deoxycytidine) and HDAC ( trichostatin A). The silencing of ER due to CpG hypermethylation correlates with binding of specific methyl-binding proteins, DNMTs, and HDAC proteins. Inhibition of HDAC activity by trichostatin A results in the accumulation of hyperacetylated core histones. The activation of ER gene expression by 5-aza-2'-deoxycytidine also involves the release of the repressor complex involving various methyl-binding proteins, DNMTs, and HDAC1. HDAC and DNMT inhibitors modulate histone methylation at H3-K9 and H3-K4 to form a more open chromatin structure necessary for reactivation of silenced ER transcription. Together these results impart a better understanding of molecular mechanisms of chromatin remodeling during ER reactivation by DNMT and HDAC inhibitors. These findings will aid in the application of agents targeting epigenetic changes in the treatment of breast cancer.
C1 Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
   MethylGene Inc, Montreal, PQ H45 2A1, Canada.
C3 Johns Hopkins University; Johns Hopkins Medicine; MethylGene Inc
RP Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
EM davidna@jhmi.edu
FU NCI NIH HHS [CA88843] Funding Source: Medline
CR ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3
   Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256
   De Marzo AM, 1999, CANCER RES, V59, P3855
   Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002
   Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lin XH, 2003, CANCER RES, V63, P498
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200
   Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001
   Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799
   Snape A, 2000, Trends Genet, V16, P20, DOI 10.1016/S0168-9525(99)01925-3
   Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8
   Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
NR 57
TC 131
Z9 162
U1 1
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUL
PY 2005
VL 19
IS 7
BP 1740
EP 1751
DI 10.1210/me.2004-0011
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 937UO
UT WOS:000229951500006
PM 15746193
OA Bronze
DA 2025-01-12
ER

PT J
AU Krepulat, F
   Löhler, J
   Heinlein, C
   Hermannstädter, A
   Tolstonog, GV
   Deppert, W
AF Krepulat, F
   Löhler, J
   Heinlein, C
   Hermannstädter, A
   Tolstonog, GV
   Deppert, W
TI Epigenetic mechanisms affect mutant p53 transgene expression in
   <i>WAP-mutp53</i> transgenic mice
SO ONCOGENE
LA English
DT Article
DE transgenic mice; whey acidic protein ( WAP) promoter; mutant p53;
   mammary carcinoma; SV40 T- antigen; epigenetics
ID LARGE T-ANTIGEN; PROTEIN GENE PROMOTER; MATRIX-ATTACHMENT REGIONS;
   BREAST-CANCER PATIENTS; MAMMARY-GLAND; VALPROIC ACID; MOUSE MODEL;
   CELL-DIFFERENTIATION; TUMOR-SUPPRESSOR; HYBRID GENE
AB We describe the construction and phenotypic characterization of 23 whey acidic protein (WAP)-mutp53 transgenic mouse lines. The mutp53-expressing lines showed a mosaic expression pattern for the transgenes, leading to a heterogeneous yet mouse line-specific expression pattern for mutp53 upon induction. Only fewlines were obtained, in which the majority of the induced mammary epithelial cells expressed the mutp53 transgene, most of the transgenic lines did not express mutp53, or expressed the transgene in less than 2% of the induced mammary epithelial cells. Hormone requirements for mutp53 transgene expression from the WAP-promoter differed in high and lowexpressing lines, being low in high expressing lines, and even lower in multiparous mutp53 mice, where persistent expression of the transgene occurred. Repeated induction of mutp53 expression through repeated parturition resulted in the formation of expanding mutp53-expressing foci within the mammary alveolar epithelium. The data suggest that epigenetic mechanisms play a role in modulating the expression of the mutp53 transgene. To support this idea, we crossed a nonexpressing WAP-mutp53 line with a strongly SV40 T-antigen-expressing WAP-T mouse line. In the bitransgenic mice, T-antigen-induced chromatin remodeling led to re-expression of epigenetically silenced mutp53 transgene(s). In these mice, mutp53 expression was much more variable compared to SV40 T-antigen expression, and seemed to depend on the coexpression of SV40 T-antigen. Mutp53 expression in this system thus resembles the situation in many human tumors, where one can observe a heterogeneous expression of mutp53, despite a homogeneous distribution of the p53 mutation in the tumor cells.
C1 Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany.
C3 University of Hamburg; Heinrich Pette Institute
RP Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.
EM wolfgang.deppert@hpi.uni-hamburg.de
CR Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811
   ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299
   Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368
   Bartoli A, 2003, PHARMACOL RES, V48, P111, DOI 10.1016/S1043-6618(03)00079-3
   Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174
   BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836
   BURDON T, 1991, J BIOL CHEM, V266, P6909
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1
   DEPPERT W, 1979, J VIROL, V31, P522, DOI 10.1128/JVI.31.2.522-536.1979
   Deppert W, 2000, J CELL BIOCHEM, P115
   Ebina M, 2001, ONCOGENE, V20, P2579, DOI 10.1038/sj.onc.1204351
   ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0
   FELIX CA, 1993, ONCOGENE, V8, P1203
   FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159
   GOH HS, 1995, CANCER RES, V55, P5217
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Hanash S, 2004, NAT REV CANCER, V4, P638, DOI 10.1038/nrc1414
   Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138
   Hogan B., 1986, MANIPULATING MOUSE E
   HORIO Y, 1994, ONCOGENE, V9, P1231
   JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x
   Jiao JF, 2003, J VIROL, V77, P12720, DOI 10.1128/JVI.77.23.12720-12728.2003
   Klawitz I, 2001, INT J ONCOL, V19, P1325
   Krämer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   KRNACIK MJ, 1995, J BIOL CHEM, V270, P11119, DOI 10.1074/jbc.270.19.11119
   Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5
   Lazar H, 2000, INT J CANCER, V85, P578, DOI 10.1002/(SICI)1097-0215(20000215)85:4<578::AID-IJC21>3.0.CO;2-S
   LI BL, 1994, CELL GROWTH DIFFER, V5, P711
   Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621
   Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691
   LI S, 1994, J BIOL CHEM, V269, P14235
   LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103
   MCKNIGHT RA, 1995, TRANSGENIC RES, V4, P39, DOI 10.1007/BF01976500
   McKnight RA, 1996, MOL REPROD DEV, V44, P179, DOI 10.1002/(SICI)1098-2795(199606)44:2<179::AID-MRD6>3.0.CO;2-K
   MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943
   Milavetz BI, 2002, VIROLOGY, V294, P170, DOI 10.1006/viro.2001.1308
   Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274
   Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081
   PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874
   PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027
   Rahko E, 2003, EUR J CANCER, V39, P447, DOI 10.1016/S0959-8049(02)00499-9
   ROBINSON GW, 1995, DEVELOPMENT, V121, P2079
   SANDGREN EP, 1995, CANCER RES, V55, P3915
   SCHIRMBECK R, 1991, J VIROL, V65, P2578, DOI 10.1128/JVI.65.5.2578-2588.1991
   SCHMITT MK, 1987, VIROLOGY, V156, P268, DOI 10.1016/0042-6822(87)90407-7
   SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x
   Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281
   Seinsoth S, 2003, EMBO REP, V4, P263, DOI 10.1038/sj.embor.embor770
   Sherr CJ, 2000, CANCER RES, V60, P3689
   Sigal A, 2000, CANCER RES, V60, P6788
   Simmons DT, 2004, NUCLEIC ACIDS RES, V32, P1103, DOI 10.1093/nar/gkh236
   Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105
   Smalley MJ, 1998, IN VITRO CELL DEV-AN, V34, P711
   STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X
   TIEMANN F, 1994, ONCOGENE, V9, P1907
   Tolstonog GV, 2000, DNA CELL BIOL, V19, P647, DOI 10.1089/10445490050199054
   TZENG YJ, 1993, ONCOGENE, V8, P1965
   Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418
   Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X
   Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323
   Zgouras D, 2004, BIOCHEM BIOPH RES CO, V316, P693, DOI 10.1016/j.bbrc.2004.02.105
   Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4
   Zhou Q, 2002, BREAST CANCER RES TR, V75, P107, DOI 10.1023/A:1019698807564
NR 64
TC 21
Z9 23
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL
PY 2005
VL 24
IS 29
BP 4645
EP 4659
DI 10.1038/sj.onc.1208557
PG 15
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 942TD
UT WOS:000230304500004
PM 15870706
DA 2025-01-12
ER

PT J
AU Umetani, N
   Mori, T
   Koyanagi, K
   Shinozaki, M
   Kim, J
   Giuliano, AE
   Hoon, DSB
AF Umetani, N
   Mori, T
   Koyanagi, K
   Shinozaki, M
   Kim, J
   Giuliano, AE
   Hoon, DSB
TI Aberrant hypermethylation of <i>ID4</i> gene promoter region increases
   risk of lymph node metastasis in T1 breast cancer
SO ONCOGENE
LA English
DT Article
DE ID4; breast cancer; hypermethylation; lymph node metastasis
ID EPIGENETIC INACTIVATION; DNA METHYLATION; CUTANEOUS MELANOMA;
   EXPRESSION; PROTEINS; CELLS; DIFFERENTIATION; CARCINOMA; DISEASE; ID-1
AB ID4 gene is a member of the inhibitor of DNA-binding ( ID) family, which inhibits DNA binding of basic helix loop-helix transcription factors. Certain human primary breast cancers reportedly have low or no expression of ID4 protein, but its role in carcinogenesis and cancer progression is unknown. To determine its possible role, we examined epigenetic inactivation of ID4 gene by promoter hypermethylation in human breast cell lines and T1 breast cancer tissues. Methylation status of ID4 promoter CpG island was assessed by methylation-specific PCR (MSP); ID4 mRNA level was assessed by quantitative real-time RT-PCR. Of eight cell lines, two were fully methylated, four were partially methylated, and two were not methylated. ID4 mRNA level was suppressed in fully methylated cell lines. ID4 hypermethylation was observed in 16 of 24 (67%) node- positive and seven of 36 (19%) node- negative T1 primary breast cancers matched by patient age and tumor diameter. It was a significant risk factor for nodal metastasis (OR 13.1, P = 0.0004). ID4 mRNA level was suppressed in hypermethylated cancer specimens (P = 0.014). ID4 may play an important suppressive role in tumor progression, and its silencing by hypermethylation may increase the risk of regional lymph node metastasis.
C1 John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   John Wayne Canc Inst, Joyce Eisenberg Keefer Breast Ctr, Santa Monica, CA 90404 USA.
C3 John Wayne Cancer Institute; John Wayne Cancer Institute
RP John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI Hoon, Dave/C-7146-2018
OI Hoon, Dave/0000-0003-1915-3683
CR Barth A, 1997, CANCER-AM CANCER SOC, V79, P1918, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1918::AID-CNCR12>3.0.CO;2-Y
   Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130
   Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160
   Brenin DR, 2001, ANN SURG ONCOL, V8, P432, DOI 10.1007/s10434-001-0432-7
   Carter BA, 2000, AM J CLIN PATHOL, V113, P259, DOI 10.1309/7EF8-F1W7-YVNT-H8H5
   CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
   Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   FISHER ER, 1984, CANCER-AM CANCER SOC, V54, P3002, DOI 10.1002/1097-0142(19841215)54:12<3002::AID-CNCR2820541231>3.0.CO;2-V
   FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0
   Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holland PA, 1996, BRIT J CANCER, V74, P1643, DOI 10.1038/bjc.1996.602
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Itahana Y, 2003, CANCER RES, V63, P7098
   Jen Y, 1996, DEV DYNAM, V207, P235
   Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X
   Jones PA, 1996, CANCER RES, V56, P2463
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Kee Y, 2001, MECH DEVELOP, V109, P341, DOI 10.1016/S0925-4773(01)00576-7
   Lin CQ, 2000, CANCER RES, V60, P1332
   Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000
   Moore KH, 2004, CANCER-AM CANCER SOC, V100, P929, DOI 10.1002/cncr.20035
   PAGLIUCA A, 1995, GENOMICS, V27, P200, DOI 10.1006/geno.1995.1026
   Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091
   Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009
   Shan L, 2003, AM J PATHOL, V163, P2495, DOI 10.1016/S0002-9440(10)63604-8
   Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Takeuchi H, 2003, CANCER RES, V63, P441
   Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135
   Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689
   Umetani N, 2004, ONCOGENE, V23, P8292, DOI 10.1038/sj.onc.1208022
   Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799
   Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092
NR 36
TC 81
Z9 92
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL
PY 2005
VL 24
IS 29
BP 4721
EP 4727
DI 10.1038/sj.onc.1208538
PG 7
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 942TD
UT WOS:000230304500010
PM 15897910
DA 2025-01-12
ER

PT J
AU Wang, YM
   Wang, R
   Wen, DG
   Li, Y
   Guo, W
   Wang, N
   Wei, LZ
   He, YT
   Chen, ZF
   Zhang, XF
   Zhang, JH
AF Wang, Yi-Min
   Wang, Rui
   Wen, Deng-Gui
   Li, Yan
   Guo, Wei
   Wang, Na
   Wei, Li-Zhen
   He, Yu-Tong
   Chen, Zhi-Feng
   Zhang, Xiu-Feng
   Zhang, Jian-Hui
TI Single nucleotide polymorphism in <i>DNA</i> <i>methyltransferase</i>
   <i>3B</i> promoter and its association with gastric cardiac
   adenocarcinoma in North China
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE DNA methyltransferase; Single nucleotide polymorphism; Gastric cardiac
   adenocarcinoma; Susceptibility; Lymphatic metastasis
ID MESSENGER-RNA EXPRESSION; METHYLATION; ESOPHAGEAL; CANCER; RISK;
   SUSCEPTIBILITY; EPIGENETICS; CARCINOMA; DNMT1; 3A
AB AIM: To investigate the association between single nucleotide polymorphism (SNP) in promoter of the DNA methyltransferase 3B (DNMT3B) gene and risk for development and lymphatic metastasis of gastric cardiac adenocarcinoma (GCA).
   METHODS: The hospital based case-control study included 212 GCA patients and 294 control subjects without overt cancer. The DNMT3B SNP was genotyped by PCR and restriction fragment length polymorphism (RFLP) analysis.
   RESULTS: The C/C genotype was not detected in both GCA patients and controls. In control subjects, the frequency of T/T and C/T genotypes was 94.9% and 5.1% respectively, and that of T and C alleles was 97.4% and 2.6%, respectively. The genotype and allelotype distribution in the GCA patients was not significantly different from that in controls (P = 0.34 and 0.33, respectively). When stratified by smoking status and family history of upper gastrointestinal cancer, significant difference in the genotype distribution was not observed between GCA patients and controls. The distribution of DNMT3B genotypes in GCA patients with or without lymphatic metastasis did not show significant difference (P = 0.42).
   CONCLUSION: The distribution of DNMT3B SNP in North China is distinct from that in Caucasians. Although this SNP has been associated with susceptibility to lung, head, neck and breast cancer, it may not be used as a stratification marker to predict susceptibility and lymphatic metastasis of GCA, at least in the population of North China. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
C1 [Wang, Yi-Min; Wen, Deng-Gui; Li, Yan; Guo, Wei; Wang, Na; Wei, Li-Zhen; He, Yu-Tong; Chen, Zhi-Feng; Zhang, Xiu-Feng; Zhang, Jian-Hui] Hebei Med Univ, Hebei Canc Inst, Shijiazhuang 050011, Hebei Province, Peoples R China.
   [Wang, Rui] Hebei Med Univ, Affiliated Hosp 4, Shijiazhuang 050011, Hebei Province, Peoples R China.
C3 Hebei Medical University; Hebei Medical University
RP Zhang, JH (通讯作者)，Hebei Med Univ, Hebei Canc Inst, Jiankanglu 12, Shijiazhuang 050011, Hebei Province, Peoples R China.
EM jianhuizh@hotmail.com
RI wang, yimin/HRD-5082-2023
FU National Natural Science Foundation of China [30371591]; Natural Science
   Foundation of Hebei Province [C20040062]
FX Supported by the National Natural Science Foundation of China, No.
   30371591 and the Natural Science Foundation of Hebei Province, No.
   C20040062
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487
   Liu K, 2003, MOL CELL BIOL, V23, P2709, DOI 10.1128/MCB.23.8.2709-2719.2003
   Miao XP, 2003, CANCER RES, V63, P3987
   Miao XP, 2002, CANCER EPIDEM BIOMAR, V11, P1454
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Paz MF, 2003, CANCER RES, V63, P1114
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Shen HB, 2002, CANCER RES, V62, P4992
   Siewert JR, 1998, BRIT J SURG, V85, P1457
   Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510
   Stolzenberg-Solomon RZ, 2003, CANCER EPIDEM BIOMAR, V12, P1222
   Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009
   Wang L, 2004, INT J ONCOL, V25, P993
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Zhang JH, 2003, CARCINOGENESIS, V24, P905, DOI 10.1093/carcin/bgg019
   Zhang JH, 2003, INT J CANCER, V105, P281, DOI 10.1002/ijc.11067
NR 22
TC 30
Z9 35
U1 0
U2 2
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUN 21
PY 2005
VL 11
IS 23
BP 3623
EP 3627
DI 10.3748/wjg.v11.i23.3623
PG 5
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA V19VD
UT WOS:000208099000029
PM 15962389
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Safar, AM
   Spencer, H
   Su, XB
   Coffey, M
   Cooney, CA
   Ratnasinghe, LD
   Hutchins, LF
   Fan, CY
AF Safar, AM
   Spencer, H
   Su, XB
   Coffey, M
   Cooney, CA
   Ratnasinghe, LD
   Hutchins, LF
   Fan, CY
TI Methylation profiling of archived non-small cell lung cancer: A
   promising prognostic system
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PROMOTER HYPERMETHYLATION; DNA METHYLATION; CLINICAL-IMPLICATIONS;
   MULTIPLE GENES; BREAST-CANCER; SURVIVAL; INACTIVATION; CARCINOMA; ASSAY;
   HEAD
AB Purpose: Enhanced prognostication power is becoming more desirable in clinical oncology. In this study, we explored the prognostic potential of multigene hypermethylation profiling in non-small-cell lung cancer.
   Experimental Design: We evaluated a panel of eight genes (p16, APC, ATM, hMLH1, MGMT DAPK, ECAD, and RASSF1A) using methylation-specific PCR in 105 archived specimens of non-small-cell lung cancer representing all stages of the illness, We analyzed the effect of gene methylation status on outcome individually in a cumulative manner and in a combinatorial approach using recursive partitioning to identify methylation profiles, which affect overall survival.
   Results: In this data set, tumors harboring promoter hypermethylation at two or more genes exhibit similar survival trends to others in the cohort. Using recursive partitioning, three genes (APC, ATM, and RASSF1A) emerged as determinants of prognostic groups. This designation retained its statistical significance even when disease stage and age were entered into a multivariate analysis. Using this approach, patients whose tumors were hypermethylated at APC and those hypermethylated at only ATM (not also at APC or RASSF1A) enjoyed substantially longer 1- and 2-year survival than patients in the remaining groups. In 32 adjacent histologically normal lung tissue specimens, we detected similar methylation abnormalities.
   Conclusion: Assessment of promoter hypermethylation aberrations may facilitate prognostic profiling of lung tumors, but validation in independent data sets is needed to verify these profiles. This system uses material that is abundantly available with linked outcome data and can be used to generate reliable epigenetic determinants.
C1 Univ Arkansas Med Sci, Div Hematol & Oncol, Little Rock, AR 72205 USA.
   Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA.
   US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Central Arkansas Veterans Healthcare System; US Food & Drug
   Administration (FDA)
RP Safar, AM (通讯作者)，Univ Arkansas Med Sci, Div Hematol & Oncol, 4301 W Markham,Slot 508, Little Rock, AR 72205 USA.
EM safarahmedm@uams.edu
OI Spencer, Horace/0000-0001-8176-881X; Cooney, Craig/0000-0003-4279-557X
CR Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3
   Blasiak J, 2000, TOXICOL IN VITRO, V14, P287, DOI 10.1016/S0887-2333(00)00022-9
   Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455
   Breiman L., 1983, CLASSIFICATION REGRE
   Brock MV, 2003, CLIN CANCER RES, V9, P2912
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Conolly RB, 2000, ENVIRON HEALTH PERSP, V108, P919, DOI 10.2307/3454325
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Frenzilli G, 2000, MUTAT RES-GEN TOX EN, V468, P93, DOI 10.1016/S1383-5718(00)00042-5
   González-Quevedo R, 2004, INT J ONCOL, V24, P349
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153
   Liu K, 2003, DIAGN MOL PATHOL, V12, P50, DOI 10.1097/00019606-200303000-00007
   Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144
   Millar DS, 2002, METHODS, V27, P108, DOI 10.1016/S1046-2023(02)00061-0
   Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2
   Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863
   Shedlock AM, 1997, BIOTECHNIQUES, V22, P394, DOI 10.2144/97223bm03
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   THEMEAU TM, 1997, TECHNICAL REPORT SER, V61
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   Toyooka S, 2004, BRIT J CANCER, V91, P771, DOI 10.1038/sj.bjc.6602013
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
   Zöchbauer-Müller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451
NR 28
TC 105
Z9 117
U1 2
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 15
PY 2005
VL 11
IS 12
BP 4400
EP 4405
DI 10.1158/1078-0432.CCR-04-2378
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 934RM
UT WOS:000229725900019
PM 15958624
OA Bronze
DA 2025-01-12
ER

PT J
AU Qian, DZ
   Ren, MQ
   Wei, YF
   Wang, XF
   van de Geijn, FE
   Rasmussen, C
   Nakanishi, O
   Sacchi, N
   Pili, R
AF Qian, DZ
   Ren, MQ
   Wei, YF
   Wang, XF
   van de Geijn, FE
   Rasmussen, C
   Nakanishi, O
   Sacchi, N
   Pili, R
TI In vivo imaging of retinoic acid receptor β2 transcriptional activation
   by the histone deacetylase inhibitor MS-275 in retinoid-resistant
   prostate cancer cells
SO PROSTATE
LA English
DT Article
DE MS-275; retinoic acid receptor; HDAC inhibitor; retinoid resistance;
   prostate cancer
ID RECEPTOR BETA-2 PROMOTER; BREAST-CANCER; TUMOR-GROWTH; ACID; GENE
AB BACKGROUND. In retinoid resistant epithelial tumors, the lack of retinoic acid receptor beta 2 (RAR beta 2) expression due to epigenetic silencing impairs the activation of retinoid target genes including RAR beta 2, and has been associated with the development of cancer. In this study we developed a strategy to monitor the re-activation of RAR beta 2 by chromatin remodeling agents combined with retinoids in real time, and to correlate the RAR beta 2 re-activation with anti-tumor activity.
   METHODS. We selected the RAR beta 2-negative retinoid resistant human prostate carcinoma cell line PC3 and stably transfected it with a luciferase expression vector under the control of a functional segment of RAR beta 2 promoter (pGL2-RAR beta 2-PC3). Then, we used the bioluminescence technology to monitor the reporter gene expression in real time both in vitro and in vivo following combination treatment with the histone deacetylase inhibitor MS-275 and 13-cis retinoic acid (CRA). Based on the effective dose for the RAR beta 2 re-activation, we tested the antitumor activity of this drug combination.
   RESULTS. Following combination treatment with MS-275 and CRA, we observed endogenous RAR beta 2 re-expression, acetylation at the RAR beta 2 promoter level, and synergistic activation of the luciferase reporter gene by real time imaging both in vitro and in vivo. Combination treatment with MS-275 and CRA restored retinoid sensitivity in human prostate carcinoma cell lines, and had a greater inhibitory effect on tumor cell growth than single agents in vitro and in vivo.
   CONCLUSIONS. This study provides evidence that HDAC inhibitors restore retinoid sensitivity in prostate cancer cells, and in vivo real time imaging of RAR beta 2 activation may represent a useful tool to study the pharmacodynamics of combination therapy with HDAC inhibitors and retinoids. (c) 2005 Wiley-Liss. Inc.
C1 Sydneu Kimmel Comprhens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA.
   Nihon Schering KK, Mobare, Japan.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Pili, R (通讯作者)，Sydneu Kimmel Comprhens Canc Ctr Johns Hopkins, 1650 Orleans St,Canc Res Bldg,1M52, Baltimore, MD 21231 USA.
EM rpili@jhmi.edu
RI Qian, David/AAL-3441-2021
CR Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Camacho LH, 2003, J BIOL REG HOMEOS AG, V17, P98
   Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191
   Jenkins DE, 2003, CLIN EXP METASTAS, V20, P733, DOI 10.1023/B:CLIN.0000006815.49932.98
   Li R, 2004, EXP CELL RES, V294, P290, DOI 10.1016/j.yexcr.2003.11.014
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   Pili R, 2001, CANCER RES, V61, P1477
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   VANDEGEIJN FRC, 2002, P AACR, V43, P92
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
NR 18
TC 32
Z9 39
U1 0
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-4137
J9 PROSTATE
JI Prostate
PD JUN 15
PY 2005
VL 64
IS 1
BP 20
EP 28
DI 10.1002/pros.20209
PG 9
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 930XO
UT WOS:000229450600003
PM 15651062
OA Bronze
DA 2025-01-12
ER

PT J
AU Ioannidis, P
   Mahaira, LG
   Perez, SA
   Gritzapis, AD
   Sotiropoulou, PA
   Kavalakis, GJ
   Antsaklis, AI
   Baxevanis, CN
   Papamichail, M
AF Ioannidis, P
   Mahaira, LG
   Perez, SA
   Gritzapis, AD
   Sotiropoulou, PA
   Kavalakis, GJ
   Antsaklis, AI
   Baxevanis, CN
   Papamichail, M
TI CRD-BP/IMP1 expression characterizes cord blood CD34<SUP>+</SUP> stem
   cells and affects <i>c</i>-<i>myc</i> and <i>IGF-II</i> expression in
   MCF-7 cancer cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RNA-BINDING-PROTEIN; HUMAN-BREAST-CANCER; MESSENGER-RNA; GROWTH-FACTOR;
   CRD-BP; GENE-EXPRESSION; SELF-RENEWAL; PROGENITOR CELLS; CODING REGION;
   BONE-MARROW
AB The coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein (CRDBP/IMP1) is an RNA-binding protein specifically recognizing c-myc, leader 3' IGF-II and tau mRNAs, and the H19 RNA. CRD-BP/IMP1 is predominantly expressed in embryonal tissues but is de novo activated and/or over-expressed in various human neoplasias. To address the question of whether CRD-BP/IMP1 expression characterizes certain cell types displaying distinct proliferation and/or differentiation properties (i.e. stem cells), we isolated cell subpopulations from human bone marrow, mobilized peripheral blood, and cord blood, all sources known to contain stem cells, and monitored for its expression. CRD-BP/IMP1 was detected only in cord blood-derived CD34(+) stem cells and not in any other cell type of either adult or cord blood origin. Adult BM CD34(+) cells cultured in the presence of 5'-azacytidine expressed de novo CRD-BP/IMP1, suggesting that epigenetic modifications may be responsible for its silencing in adult non-expressing cells. Furthermore, by applying the short interfering RNA methodology in MCF-7 cells, we observed, subsequent to knocking down CRD-BP/IMP1, decreased c-myc expression, increased IGF-II mRNA levels, and reduced cell proliferation rates. These data 1) suggest a normal role for CRD-BP/IMP1 in pluripotent stem cells with high renewal capacity, like the CB CD34(+) cells, 2) indicate that altered methylation may directly or indirectly affect its expression in adult cells, 3) imply that its de novo activation in cancer cells may affect the expression of c-Myc and insulin-like growth factor II, and 4) indicate that the inhibition of CRD-BP/IMP1 expression might affect cancer cell proliferation.
C1 St Savas Hosp, Canc Immunol Immunotherapy Ctr, Athens 11522, Greece.
   Obstet & Gynecol Univ Clin 1st, Alexandras Matern Hosp, Athens 11521, Greece.
C3 Alexandra Hospital
RP St Savas Hosp, Canc Immunol Immunotherapy Ctr, 171,Alexandras Ave, Athens 11522, Greece.
EM perez@ciic.gr
RI GRITZAPIS, ANGELOS/AAG-9225-2019
OI Sotiropoulou, Peggy/0009-0001-7515-8975; GRITZAPIS,
   ANGELOS/0000-0003-3031-2710
CR ARANDAABREU GE, 1999, J NEUROCHEM, V22, P8827
   Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x
   BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642
   Doyle GA, 2000, CANCER RES, V60, P2756
   El-Osta A, 2004, LEUKEMIA, V18, P233, DOI 10.1038/sj.leu.2403218
   Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317
   Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898
   Gu LJ, 2004, INT J ONCOL, V24, P671
   Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004
   Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015
   Ioannidis P, 2003, INT J CANCER, V104, P54, DOI 10.1002/ijc.10794
   Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512
   Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   KARN J, 1989, ONCOGENE, V4, P773
   Kim DK, 1999, STEM CELLS, V17, P286, DOI 10.1002/stem.170286
   Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093
   LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009
   Liao BS, 2004, J BIOL CHEM, V279, P48716, DOI 10.1074/jbc.M405853200
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746
   Ng YY, 2004, J LEUKOCYTE BIOL, V75, P314, DOI 10.1189/jlb.0603287
   Nielsen J, 1999, MOL CELL BIOL, V19, P1262
   Nielsen J, 2003, BIOCHEM J, V376, P383, DOI 10.1042/BJ20030943
   Oh IH, 2000, BLOOD, V96, P4160, DOI 10.1182/blood.V96.13.4160.h8004160_4160_4168
   OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701
   Piacibello W, 1999, BLOOD, V93, P3736, DOI 10.1182/blood.V93.11.3736.411k01_3736_3749
   PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261
   Puri MC, 2003, P NATL ACAD SCI USA, V100, P12753, DOI 10.1073/pnas.2133552100
   Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838
   Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3
   Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200
   Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200
   Schwartz GN, 1996, STEM CELLS, V14, P337, DOI 10.1002/stem.140337
   Shojaei F, 2004, BLOOD, V103, P2530, DOI 10.1182/blood-2003-09-3209
   Steidl U, 2002, BLOOD, V99, P2037, DOI 10.1182/blood.V99.6.2037
   Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005
   Tanavde VM, 2002, EXP HEMATOL, V30, P816, DOI 10.1016/S0301-472X(02)00818-4
   Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927
   Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104
   YEE D, 1988, CANCER RES, V48, P6691
   Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472
   Zhang JY, 2003, CANCER EPIDEM BIOMAR, V12, P136
NR 44
TC 60
Z9 73
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 20
PY 2005
VL 280
IS 20
BP 20086
EP 20093
DI 10.1074/jbc.M410036200
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 926HH
UT WOS:000229113700079
PM 15769738
OA hybrid
DA 2025-01-12
ER

PT J
AU Martens, JWM
   Nimmrich, I
   Koenig, T
   Look, MP
   Harbeck, N
   Model, F
   Kluth, A
   Bolt-De Vries, J
   Sieuwerts, AM
   Portengen, H
   Gelder, MEM
   Piepenbrock, C
   Olek, A
   Höfler, H
   Kiechle, M
   Klijn, JGM
   Schmitt, M
   Maier, S
   Foekens, JA
AF Martens, JWM
   Nimmrich, I
   Koenig, T
   Look, MP
   Harbeck, N
   Model, F
   Kluth, A
   Bolt-De Vries, J
   Sieuwerts, AM
   Portengen, H
   Gelder, MEM
   Piepenbrock, C
   Olek, A
   Höfler, H
   Kiechle, M
   Klijn, JGM
   Schmitt, M
   Maier, S
   Foekens, JA
TI Association of DNA methylation of phosphoserine aminotransferase with
   response to endocrine therapy in patients with recurrent breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID FIRST-LINE THERAPY; POSTMENOPAUSAL WOMEN; HYPERMETHYLATION; TAMOXIFEN;
   GENE; ANASTROZOLE; GROWTH; LEADS; 14-3-3-SIGMA; PROGRESSION
AB To understand the biological basis of resistance to endocrine therapy is of utmost importance in patients with steroid hormone receptor-positive breast cancer. Not only will this allow us prediction of therapy success, it may also lead to novel therapies for patients resistant to current endocrine therapy. DNA methylation in the promoter regions of genes is a prominent epigenetic gene silencing mechanism that contributes to breast cancer biology. In the current study, we investigated whether promoter DNA methylation could be associated with resistance to endocrine therapy in patients with recurrent breast cancer. Using a microarray-based technology, the promoter DNA methylation status of 117 candidate genes was studied in a cohort of 200 steroid hormone receptor-positive tumors of patients who received the antiestrogen tamoxifen as first-line treatment for recurrent breast cancer. Of the genes analyzed, the promoter DNA methylation status of 10 genes was significantly associated with clinical outcome of tamoxifen therapy. The association of the promoter hypermethylation of the strongest marker, phosphoserine aminotransferase (PSAT1) with favorable clinical outcome was confirmed by an independent quantitative DNA methylation detection method. Furthermore, the extent of DNA methylation of PSAT1 was inversely associated with its expression at the mRNA level. Finally, also at the mRNA level, PSAT1 was a predictor of tamoxifen therapy response. Concluding, our work indicates that promoter hypermethylation and mRNA expression of PSAT1 are indicators of response to tamoxifen-based endocrine therapy in steroid hormone receptor-positive patients with recurrent breast cancer.
C1 Epigenom AG, Dept Biomed Res & Dev & Technol Dev, D-10178 Berlin, Germany.
   Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands.
   Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-8000 Munich, Germany.
   Tech Univ Munich, Inst Pathol, D-8000 Munich, Germany.
   GSF, Inst Pathol, Ctr Hlth & Environm, Neuherberg, Germany.
C3 Erasmus University Rotterdam; Erasmus MC; Technical University of
   Munich; Technical University of Munich; Helmholtz Association;
   Helmholtz-Center Munich - German Research Center for Environmental
   Health
RP Epigenom AG, Dept Biomed Res & Dev & Technol Dev, Praesidentenstr 1, D-10178 Berlin, Germany.
EM sabine.maier@epigenomics.com
RI Harbeck, Nadia/JOZ-6178-2023; Koenig, Thomas/F-6454-2010
OI Model, Fabian/0009-0002-6319-9902
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748
   Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
   Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224
   Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086
   De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785
   Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2001, CANCER RES, V61, P3225
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   FOEKENS JA, 1989, CANCER RES, V49, P5823
   Foekens JA, 2001, CANCER RES, V61, P5407
   Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576
   HAYWARD JL, 1977, CANCER-AM CANCER SOC, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Ludwig B, 2001, CHEMBIOCHEM, V2, P392, DOI 10.1002/1439-7633(20010601)2:6<392::AID-CBIC392>3.0.CO;2-N
   Mardia KV, 1979, Multivariate Analysis
   Martens JWM, 2003, THROMB HAEMOSTASIS, V89, P393
   Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   PERSYN JP, 1980, EUR J CANCER, V16, P1513
   SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221
   Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8
   Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826
   van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8
   Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang HY, 2003, CLIN CANCER RES, V9, P4034
   Yuan YF, 2001, CANCER RES, V61, P5558
NR 36
TC 99
Z9 112
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2005
VL 65
IS 10
BP 4101
EP 4107
DI 10.1158/0008-5472.CAN-05-0064
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 925OI
UT WOS:000229062000017
PM 15899800
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Macaluso, M
   Montanari, M
   Giordano, A
AF Macaluso, M.
   Montanari, M.
   Giordano, A.
TI The regulation of ER-α transcription by pRb2/p130 in breast cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE breast cancer; ER-alpha transcription; pRb2/p130; chromatin remodeling
   enzymes; DNA methylation
AB Breast carcinoma is the most common form of neoplasia in women of the Western world, and the mortality from this disease in women is second only to that of lung cancer, with a means incidence of 10%. Although, several studies have indicated that the development of this fairly heterogeneous disease depends on a great many environmental, socio-economic, hormonal and genetic factors, the pathogenesis of breast cancer remains poorly understood.
   ER-alpha (estrogen-receptor alpha) and its ligand (17 beta-estradiol) play a crucial role in normal breast development and have also been linked to mammary carcinogenesis and clinical outcome in breast cancer patients. The estrogen signaling regulates the growth of some breast tumors, and antiestrogen therapies can effectively block this growth signaling resulting in tumor suppression. However, most tumors eventually develop antiestrogen resistance, and antiestrogen are mostly ineffective in patience with advanced disease. Although several studies have been proposed that epigenetic events could be involved in ER-alpha silencing the mechanisms regulating ER-alpha transcription are poorly understood. Our studies suggested that pRb2/p130-complexes bind to the ER-alpha promoter and could be involved in the transcriptional regulation of the ER-alpha gene by altering chromatin structure and DNA methylation pattern.
C1 Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med,Ctr Biotechnol, Philadelphia, PA 19122 USA.
   Univ Palermo, Dept Oncol, Palermo, Italy.
   Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy.
   Univ Cattolica Sacro Cuore, Ctr Ric Oncol Giovanni XXIII, Ist Patol Gen, I-00168 Rome, Italy.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; University of Palermo; University of Siena; Catholic
   University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Giordano, A (通讯作者)，Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med,Ctr Biotechnol, Philadelphia, PA 19122 USA.
EM giordano@temple.edu
RI Giordano, Antonio/F-1927-2010
OI Giordano, Antonio/0000-0002-5959-016X
CR FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359
   Gustafsson JÅ, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487
   Macaluso M, 2004, TUMORI J, V90, P367, DOI 10.1177/030089160409000401
   Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245
   Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Yang XW, 2001, CANCER RES, V61, P7025
NR 11
TC 8
Z9 10
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD MAY
PY 2005
VL 16
SU 4
BP 20
EP 22
DI 10.1093/annonc/mdi903
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA V43YH
UT WOS:000202969900004
OA Bronze
DA 2025-01-12
ER

PT J
AU Azhikina, TL
   Sverdlov, ED
AF Azhikina, TL
   Sverdlov, ED
TI Study of tissue-specific CpG methylation of DNA in extended genomic loci
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article
DE DNA methylation analysis; bisulfite sequencing; methyl-sensitive PCR
   (MS-PCR); whole-genome approaches; non-methylated genomic sites
   coincidence cloning (NGSCC)
ID REPRESENTATIONAL DIFFERENCE ANALYSIS; X-CHROMOSOME INACTIVATION; HUMAN
   BREAST-CANCER; RESTRICTION ENZYMES; CYTOSINE METHYLATION;
   GAS-CHROMATOGRAPHY; PCR ASSAY; 5-METHYLCYTOSINE; PATTERNS; GENE
AB Modem approaches for studies on genome functioning include investigation of its epigenetic regulation. Methylation of cytosines in CpG dinucleotides is an inherited epigenctic modification that is responsible for both functional activity of certain genomic loci and total chromosomal stability, This review describes the main approaches for studies on DNA methylation. Under consideration are site-specific approaches based on bisulfite sequencing and methyl-sensitive PCR, whole-genome approaches aimed at searching for new methylation hot spots, and also mapping of unmethylated CpG sites in extended genomic loci.
C1 Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia.
C3 Russian Academy of Sciences; Pushchino Scientific Center for Biological
   Research (PSCBI) of the Russian Academy of Sciences; Institute of
   Bioorganic Chemistry of the Russian Academy of Sciences
RP Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117997, Russia.
EM tanya@humgen.siobe.ras.ru
RI Azhikina, Tatyana/X-8411-2018
CR Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810
   ANTEQUERA F, 1984, J BIOL CHEM, V259, P8033
   Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580
   Azhikina T, 2004, MOL GENET GENOMICS, V271, P22, DOI 10.1007/s00438-003-0959-3
   Bianco T, 1999, HUM MUTAT, V14, P289, DOI 10.1002/(SICI)1098-1004(199910)14:4<289::AID-HUMU3>3.0.CO;2-A
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BIRD AP, 1978, J MOL BIOL, V118, P27, DOI 10.1016/0022-2836(78)90242-5
   BURTIS CA, 1970, J CHROMATOGR, V51, P183, DOI 10.1016/S0021-9673(01)96853-0
   CEDAR H, 1979, NUCLEIC ACIDS RES, V6, P2125, DOI 10.1093/nar/6.6.2125
   CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HOTCHKISS RD, 1948, J BIOL CHEM, V175, P315
   Hsieh J, 2000, ANNU REV GENET, V34, P187, DOI 10.1146/annurev.genet.34.1.187
   Huang THM, 1997, CANCER RES, V57, P1030
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaneda A, 2003, ANN NY ACAD SCI, V983, P131, DOI 10.1111/j.1749-6632.2003.tb05968.x
   KUO KC, 1980, NUCLEIC ACIDS RES, V8, P4763, DOI 10.1093/nar/8.20.4763
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0
   MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560
   MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640
   MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0
   Müller K, 2001, J BIOL CHEM, V276, P14271
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   Oakeley EJ, 1999, BIOTECHNIQUES, V27, P744, DOI 10.2144/99274st05
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   PATEL CV, 1987, BIOCHEM BIOPH RES CO, V142, P334, DOI 10.1016/0006-291X(87)90278-6
   Paul CL, 1996, BIOTECHNIQUES, V21, P126
   Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830
   Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253
   RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204
   RAZIN A, 1977, ANAL BIOCHEM, V77, P370, DOI 10.1016/0003-2697(77)90250-0
   RAZIN A, 1977, P NATL ACAD SCI USA, V74, P2725, DOI 10.1073/pnas.74.7.2725
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Rein T, 1997, J BIOL CHEM, V272, P10021
   Rein T, 1998, NUCLEIC ACIDS RES, V26, P2255, DOI 10.1093/nar/26.10.2255
   Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416
   ReynaLopez GE, 1997, MOL GEN GENET, V253, P703, DOI 10.1007/s004380050374
   Rouillard JM, 2001, GENOME RES, V11, P1453, DOI 10.1101/gr.181601
   RUBERY ED, 1971, ANAL BIOCHEM, V42, P149, DOI 10.1016/0003-2697(71)90021-2
   Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058
   SHEID B, 1968, BIOCHEMISTRY-US, V7, P280
   SINGER J, 1979, SCIENCE, V203, P1019, DOI 10.1126/science.424726
   SINGER J, 1979, ANAL BIOCHEM, V94, P297, DOI 10.1016/0003-2697(79)90363-4
   SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P687, DOI 10.1093/nar/18.3.687
   SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987
   STEIGERWALD SD, 1990, NUCLEIC ACIDS RES, V18, P1435, DOI 10.1093/nar/18.6.1435
   Takahashi K, 2001, Genome Inform, V12, P212
   Thomassin H, 2001, EMBO J, V20, P1974, DOI 10.1093/emboj/20.8.1974
   Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284
   VANYUSHIN BF, 1970, NATURE, V225, P948, DOI 10.1038/225948a0
   VANYUSHIN BF, 1968, NATURE, V218, P1066, DOI 10.1038/2181066a0
   VISHER E, 1948, J BIOL CHEM, V176, P703
   WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891
   Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yuan LM, 1999, CANCER RES, V59, P3215
NR 65
TC 14
Z9 22
U1 0
U2 3
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD MAY
PY 2005
VL 70
IS 5
BP 596
EP 603
DI 10.1007/s10541-005-0153-9
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 936ZL
UT WOS:000229894200012
PM 15948713
DA 2025-01-12
ER

PT J
AU Fujii, H
   Gabrielson, E
   Takagaki, T
   Ohtsuji, M
   Ohtsuji, N
   Hino, O
AF Fujii, H
   Gabrielson, E
   Takagaki, T
   Ohtsuji, M
   Ohtsuji, N
   Hino, O
TI Frequent down-regulation of <i>HIVEP2</i> in human breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE breast cancer; HIVEP2; down-regulation; 6q23-24; LOH; real-time RT-PCR
ID ZINC-FINGER PROTEIN; MAJOR HISTOCOMPATIBILITY COMPLEX; TUMOR-SUPPRESSOR
   GENE; ENHANCER-BINDING-PROTEIN; CHROMOSOME 6Q; KAPPA-B; V(D)J
   RECOMBINATION; TRANSCRIPTION FACTOR; POSITIVE SELECTION;
   MOLECULAR-CLONING
AB The HIVEP2 gene, located on 6q23-q24, belongs to a family of genes that encodes large zinc fingers containing transcription factor proteins. Although this gene has been implicated in the regulation of immune responses and cellular proliferation, its functions are largely unknown. In the present study, we investigated HIVEP2 gene abnormalities in microdissected breast cancer tissue. For real-time quantitational RT-PCR analysis of paired normal and tumor tissues, mRNA levels were down-regulated to a maximum of 96%. The overall median expression level in breast cancer (33 cases) was significantly lower than that in normal breast tissue (normalized median value of 4.49 versus 17.68; p &LT; 0.0001). Through full-length 5'-RACE (rapid amplification of cDNA ends) analysis, we identified multiple exons in the 5'-untranslated regions with multiple transcriptional start sites, four of which were located in a large CpG island. No tissue- or cancer-specific usage patterns for the transcription start sites were identified by multiplex RT-PCR analysis. Only faint methylation was detected in the 5' region of the island in normal cells and breast cancer tissue, indicating physiological, aging and no tumor-specific methylation. Mutation screening showed only germline polymorphisms. Thus, down-regulation of the HIVEP2 genes frequently occurs and may be one of the genetic events responsible for breast cancer, and their transcription may be regulated by complex mechanisms involving interactions with other factors and/or by other genetic/epigenetic mechanisms.
C1 Juntendo Univ, Sch Med, Dept Pathol 2, Bunkyo Ku, Tokyo 1138421, Japan.
   Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
C3 Juntendo University; Johns Hopkins University; Johns Hopkins University
RP Fujii, H (通讯作者)，Juntendo Univ, Sch Med, Dept Pathol 2, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.
EM hfujii@med.juntendo.ac.jp
CR Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200
   Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034
   Abe T, 1999, GENE CHROMOSOME CANC, V25, P60, DOI 10.1002/(SICI)1098-2264(199905)25:1<60::AID-GCC9>3.3.CO;2-P
   Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275
   Allen CE, 2002, GENE CHROMOSOME CANC, V35, P287, DOI 10.1002/gcc.10128
   Allen CE, 2000, EXP CELL RES, V260, P346, DOI 10.1006/excr.2000.5029
   BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406
   Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933
   BRADY JP, 1995, J BIOL CHEM, V270, P1221, DOI 10.1074/jbc.270.3.1221
   Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224
   Dörflinger U, 1999, MOL CELL BIOL, V19, P3736
   FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29
   Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4
   Gascoigne NRJ, 2001, NAT IMMUNOL, V2, P989, DOI 10.1038/ni1101-989
   Hicar MD, 2001, GENOMICS, V71, P89, DOI 10.1006/geno.2000.6425
   Hjelmsoe I, 2000, J BIOL CHEM, V275, P913, DOI 10.1074/jbc.275.2.913
   Huang LW, 2000, HUM PATHOL, V31, P367, DOI 10.1016/S0046-8177(00)80252-X
   MAEKAWA T, 1989, J BIOL CHEM, V264, P14591
   Mak CH, 1998, IMMUNOGENETICS, V48, P32, DOI 10.1007/s002510050397
   Makino N, 2001, DNA SEQUENCE, V11, P547, DOI 10.3109/10425170109041340
   MITCHELMORE C, 1991, NUCLEIC ACIDS RES, V19, P141, DOI 10.1093/nar/19.1.141
   MUCHARDT C, 1992, J VIROL, V66, P244, DOI 10.1128/JVI.66.1.244-250.1992
   NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700
   NOMURA N, 1991, J BIOL CHEM, V266, P8590
   Noviello C, 1996, CLIN CANCER RES, V2, P1601
   Oukka M, 2002, MOL CELL, V9, P121, DOI 10.1016/S1097-2765(01)00434-8
   Oukka M, 2004, J EXP MED, V199, P15, DOI 10.1084/jem.20030421
   RON D, 1991, MOL CELL BIOL, V11, P2887, DOI 10.1128/MCB.11.5.2887
   RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707
   Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27
   Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756
   Srikantan V, 1999, INT J CANCER, V84, P331, DOI 10.1002/(SICI)1097-0215(19990621)84:3<331::AID-IJC23>3.0.CO;2-J
   SUDO T, 1992, GENOMICS, V12, P167, DOI 10.1016/0888-7543(92)90423-P
   Takagi T, 2001, NAT IMMUNOL, V2, P1048, DOI 10.1038/ni728
   Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000
   Theile M, 1996, ONCOGENE, V13, P677
   VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971
   Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835
   WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208
   Wu LC, 2002, GENE EXPRESSION, V10, P137, DOI 10.3727/000000002783992479
   WU LC, 1993, NUCLEIC ACIDS RES, V21, P5067, DOI 10.1093/nar/21.22.5067
   Wu LC, 1996, GENOMICS, V35, P415, DOI 10.1006/geno.1996.0380
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Zeller C, 2003, ONCOGENE, V22, P2972, DOI 10.1038/sj.onc.1206474
NR 44
TC 8
Z9 10
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2005
VL 91
IS 2
BP 103
EP 112
DI 10.1007/s10549-004-5779-6
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 922VI
UT WOS:000228867600001
PM 15868437
DA 2025-01-12
ER

PT J
AU Wang, XF
   Qian, DZ
   Ren, MQ
   Kato, Y
   Wei, YF
   Zhang, L
   Fansler, Z
   Clark, D
   Nakanishi, O
   Pili, R
AF Wang, XF
   Qian, DZ
   Ren, MQ
   Kato, Y
   Wei, YF
   Zhang, L
   Fansler, Z
   Clark, D
   Nakanishi, O
   Pili, R
TI Epigenetic modulation of retinoic acid receptor β2 by the histone
   deacetylase inhibitor MS-275 in human renal cell carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER CELLS; 13-CIS-RETINOIC ACID; PROMOTER METHYLATION;
   MULTIPLE GENES; WILMS-TUMOR; HOX GENES; EXPRESSION; GROWTH;
   HYPERMETHYLATION; DNA
AB Purpose: Histone deacetylase (HDAC) inhibitors have been shown to reverse epigenetic repression of certain genes, including retinoic acid receptor beta 2 (RAR beta 2). In this study, we examined whether RAR beta 2 expression is repressed in human renal cell carcinoma (RCC) and whether the HDAC inhibitor MS-275 may revert its epigenetic repression.
   Experimental Design: Six human tumor RCC cell lines were analyzed for RAR beta 2 gene expression and for methylation and acetylation status at the promoter level. Modulation of RAR beta 2 expression and correlation with antitumor activity by combination of MS-275 with 13-cis-retinoic acid (CRA) was assessed in a RAR beta 2-negative RCC cell line.
   Results: RAR beta 2 expression was either strongly present, weakly expressed, or absent in the RCC cell lines analyzed. Methylation-specific PCR indicated that the RAR beta 2 promoter was partially methylated in three of the cell lines. CRA treatment did not inhibit clonogenic growth in the RAR beta 2-negative cell line RCC1.18, whereas MS-275 induced a dose-dependent inhibitory effect. A greater inhibitory effect was observed with combination treatment (MS-275 + CRA). Treatment with MS-275 was associated with histone acetylation at the promoter level and synergistic gene reexpression of RAR beta 2 in combination with CRA. RAR beta 2 reexpression was associated with synergistic induction of the retinoid-responsive gene HOXA5. In vivo, single-agent CRA treatment showed no significant effect, whereas MS-275 and the combination induced a regression of RCC1.18 tumor xenografts. Discontinuation of treatment produced tumor recurrence in MS-275-treated mice, whereas animals treated with the combination remained tumor free.
   Conclusion: The HDAC inhibitor MS-275 seems to revert retinoid resistance due to epigenetic silencing of RAR beta 2 in a human RCC model and has greater antitumor activity in combination with CRA compared with single agents. Thus, the combination of HDAC inhibitors and retinoids may represent a novel therapeutic approach in patients with RCC.
C1 Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
   Nihon Schering KK, Kobe, Hyogo, Japan.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg,1650 Orleans St, Baltimore, MD 21231 USA.
EM piliro@jhmi.edu
RI Qian, David/AAL-3441-2021
CR Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Berg WJ, 1997, INVEST NEW DRUG, V15, P353, DOI 10.1023/A:1005902022076
   Berg WJ, 1999, CLIN CANCER RES, V5, P1671
   Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0
   Cote S, 1998, ANTI-CANCER DRUG, V9, P743
   DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x
   Esteller M, 2002, CANCER RES, V62, P5902
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Guo XJ, 2001, CANCER RES, V61, P2774
   Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoffman AD, 1996, CLIN CANCER RES, V2, P1077
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kuroki T, 2003, CANCER RES, V63, P3724
   Lehmann S, 2001, CLIN CANCER RES, V7, P367
   Li YP, 1997, BLOOD, V90, P306
   Lippman SM, 1997, CANCER CHEMOTHER BIO, V17, P349
   Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179
   Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Pili R, 2001, CANCER RES, V61, P1477
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   Takahashi Y, 2004, EXP CELL RES, V293, P144, DOI 10.1016/j.yexcr.2003.09.024
   Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275
   Van de Geijn Fleur, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P91
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 43
TC 68
Z9 77
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2005
VL 11
IS 9
BP 3535
EP 3542
DI 10.1158/1078-0432.CCR-04-1092
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 922OT
UT WOS:000228848000052
PM 15867257
DA 2025-01-12
ER

PT J
AU Phipps, SMO
   Woodfin, WK
   Tollefsbol, TO
AF Phipps, SMO
   Woodfin, WK
   Tollefsbol, TO
TI The epigenetics of breast carcinogenesis and metastasis
SO CURRENT GENOMICS
LA English
DT Article
DE epigenetics; breast cancer; HDIs; demethylating agents; metastasis;
   telomerase; Bmi-1; stem cells
ID HISTONE DEACETYLASE INHIBITORS; MAMMARY EPITHELIAL-CELLS; DNA
   METHYLATION; TELOMERASE ACTIVITY; CPG ISLAND; CANCER EPIGENETICS; P53
   GENE; GROWTH; BMI-1; TUMORIGENESIS
AB The study of epigenetic regulation of genes involved in breast cancer provides a level of complexity that lends understanding to the factors contributing to this prevalent disease. Recent evidence from studies that employ pharmacological agents such as trichostatin A and/or 5-aza-cytidine to alter epigenetic changes have been shown to reactivate key regulators such as p21 in breast cancer cells or explain silencing mechanisms of p16 that could lead to carcinogenesis. The roles of telomerase and Bmi-1 expression in the cellular processes of senescence, aging, and the maintenance of stem cells are discussed in relation to breast carcinogenesis, the implications of breast cancer stem cells, and the feasibility of these genes as epigenetic targets in cancer therapy.
C1 Univ Alabama, Dept Biol, Birmingham, AL 35294 USA.
   Univ Alabama, Ctr Aging, Birmingham, AL 35294 USA.
   Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Univ Alabama, Dept Biol, 175 Campbell Hall,1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Artandi SE, 2003, BREAST CANCER RES, V5, P37, DOI 10.1186/bcr553
   Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399
   Bender CM, 1998, CANCER RES, V58, P95
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Blagosklonny MV, 2002, MOL CANCER THER, V1, P937
   Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   Devereux TR, 1999, CANCER RES, V59, P6087
   Dimri GP, 2002, CANCER RES, V62, P4736
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516
   Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003
   Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004
   Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678
   Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010
   Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kyo S, 1999, CANCER RES, V59, P5917
   Lai SR, 2005, FRONT BIOSCI-LANDMRK, V10, P1779, DOI 10.2741/1661
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353
   Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303
   Norton JD, 2000, J CELL SCI, V113, P3897
   Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628
   PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102
   Porter DA, 2001, CANCER RES, V61, P5697
   Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Tollefsbol TO, 2001, MED HYPOTHESES, V56, P630, DOI 10.1054/mehy.2000.1241
   van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896
   Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong DJ, 1999, MOL CELL BIOL, V19, P5642
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 55
TC 0
Z9 0
U1 2
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
EI 1875-5488
J9 CURR GENOMICS
JI Curr. Genomics
PD MAY
PY 2005
VL 6
IS 3
BP 129
EP 135
DI 10.2174/1389202053971956
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 930BM
UT WOS:000229390800002
DA 2025-01-12
ER

PT J
AU Dammann, R
   Strunnikova, M
   Schagdarsurengin, U
   Rastetter, M
   Papritz, M
   Hattenhorst, UE
   Hofmann, HS
   Silber, RE
   Burdach, S
   Hansen, G
AF Dammann, R
   Strunnikova, M
   Schagdarsurengin, U
   Rastetter, M
   Papritz, M
   Hattenhorst, UE
   Hofmann, HS
   Silber, RE
   Burdach, S
   Hansen, G
TI CpG island methylation and expression of tumour-associated genes in lung
   carcinoma
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE lung cancer; methylation; tumour-suppressor gene; epigenetics
ID ABERRANT PROMOTER METHYLATION; EPIGENETIC INACTIVATION; SUPPRESSOR GENE;
   BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; BRONCHIAL EPITHELIUM; TISSUE
   INHIBITOR; CELL-LINES; HYPERMETHYLATION; RASSF1A
AB In this study, microarray analysis was used to identify tumour-related genes that were down regulated in lung carcinoma. The promoter sequences of the identified genes were analysed for methylation patterns. In lung cancer cell lines, CpG island methylation was frequently detected for TIMP4 (64 %), SOX18 (73 %), EGF-like domain 7 (56 %), CD105 (71 %), SEMA2 (55 %), RASSF1A (71 %), p16 (56 %) SLIT2 (100 %) and TIMP3 (29 %). Methylation was however rarely observed in cell lines for SLIT3 (18 %) and DLC1 (18 %). In primary lung tumours, methylation of TIMP4 (94 %), SOX18 (100 %), EGF-like domain 7 (100 %), CD105 (69 %), SEMA2 (93 %), DLC1 (61 %), RASSF1A (44 %), p16 (47 %), SLIT2 (100 %) and TIMP3 (13 %) was also detected. Methylation of several CpG islands was frequently found in normal lung tissue of cancer patients and this may have been attributed to epigenetic field defect and/ or infiltrating tumour cells. Interestingly, inactivation of RASSF1A and p16 correlated well with an extended smoking habit (P = 0.02), and exposure to asbestos (P = 0.017) or squamous cell carcinoma (P = 0.011), respectively. These results have identified genes whose aberrant promoter methylation could play a crucial role in the malignancy of lung carcinoma. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Halle Wittenberg, AWG, Tumour Genet Med Fac, D-06097 Halle Saale, Germany.
   Univ Halle Wittenberg, Dept Cardiothorac Surg, D-06097 Halle Saale, Germany.
   Univ Halle Wittenberg, Dept Pediat, D-06097 Halle Saale, Germany.
   Tech Univ Munich, Dept Pediat, D-81664 Munich, Germany.
C3 Martin Luther University Halle Wittenberg; Martin Luther University
   Halle Wittenberg; Martin Luther University Halle Wittenberg; Technical
   University of Munich
RP Dammann, R (通讯作者)，Univ Halle Wittenberg, AWG, Tumour Genet Med Fac, D-06097 Halle Saale, Germany.
EM reinhard.dammann@medizin.uni-halle.de
RI Schagdarsurengin, Undraga/AAH-4312-2020
OI Schagdarsurengin, Undraga/0000-0003-0127-4938
CR Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Çeliker MY, 2001, ONCOGENE, V20, P4337, DOI 10.1038/sj.onc.1204508
   Dallol A, 2002, CANCER RES, V62, P5874
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   Downes M, 2001, TRENDS CARDIOVAS MED, V11, P318, DOI 10.1016/S1050-1738(01)00131-1
   Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev
   Esteller M, 2001, CANCER RES, V61, P3225
   Girard L, 2000, CANCER RES, V60, P4894
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Jüppner H, 1998, P NATL ACAD SCI USA, V95, P11798, DOI 10.1073/pnas.95.20.11798
   Kim DH, 2003, CANCER RES, V63, P3743
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Li CG, 2000, INT J CANCER, V89, P122, DOI 10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M
   Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447
   Lutz JM, 2003, ANN ONCOL, V14, P313, DOI 10.1093/annonc/mdg059
   Mendes-da-Silva P, 2000, J CLIN PATHOL-MOL PA, V53, P184, DOI 10.1136/mp.53.4.184
   Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O
   Ng IOL, 2000, CANCER RES, V60, P6581
   Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   SEIDEL C, INT J CANC
   Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274
   Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X
   Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907
   Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362
   Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245
   Wistuba II, 2000, CLIN CANCER RES, V6, P2604
   Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 43
TC 131
Z9 157
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAY
PY 2005
VL 41
IS 8
BP 1223
EP 1236
DI 10.1016/j.ejca.2005.02.020
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 940RS
UT WOS:000230162300023
PM 15911247
DA 2025-01-12
ER

PT J
AU Garcia, V
   García, JM
   Peña, C
   Silva, J
   Domínguez, G
   Rodríguez, R
   Maximiano, C
   Espinosa, R
   España, P
   Bonilla, F
AF Garcia, V
   García, JM
   Peña, C
   Silva, J
   Domínguez, G
   Rodríguez, R
   Maximiano, C
   Espinosa, R
   España, P
   Bonilla, F
TI The <i>GADD45</i>, <i>ZBRK1</i> and <i>BRCA1</i> pathway:: quantitative
   analysis of mRNA expression in colon carcinomas
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE GADD45; ZBRK1; BRCA1; gene expression; real-time RT-PCR; colon
   carcinomas
ID ZINC-FINGER PROTEIN; BREAST-CANCER; INDUCTION; OCT-1; GENE; REPRESSION;
   REPAIR
AB GADD45 is a growth arrest-associated gene that is induced in response to DNA damage. This gene is a target for coordinate regulation by both ZBRK1 and BRCA1. A sequence within intron 3 of GADD45 supports specific assembly of the ZBRK1/BRCA1 complex. In this study, the relationships between GADD45, ZBRK1, and BRCA1 expression were investigated in colon carcinomas. mRNA expression of these three genes was analysed in 116 colon carcinomas by real-time reverse transcriptase polymerase chain reaction (RT-PCR). Genetic and epigenetic changes that could alter expression of these genes were studied. Possible relationships between expression levels of GADD45, ZBRK1, and BRCA1, and a series of clinicopathological parameters classically associated with poor prognosis, were also examined. ZBRK1 showed a tendency towards underexpression, while GADD45 and BRCA1 were generally overexpressed. A direct relationship between these three genes was observed, with the exception of BRCA1 expression levels, similar to normal tissues, which showed a tendency to be associated with low levels of GADD45 mRNA. Concomitantly altered expression of ZBRK-1 and BRCA1 was associated with GADD45 mRNA expression. Promoter hypermethylation was not observed in GADD45 or BRCA1, and no mutations in GADD45 or ZBRK1 were found in regions involved in the interaction between the GADD45 gene and the ZBRK1 and BRCA1 proteins. No clinicopathological parameter was correlated with altered GADD45 or ZBRK1 expression but there was a statistically significant relationship between BRCA1 levels and the sex of patients. In conclusion, these results suggest that this pathway, involved in the response to DNA damage, is deregulated in colon carcinomas, and concomitantly altered expression of ZBRK1 and BRCA1 has an additive effect on GADD45 regulation. This is the first study in human carcinomas to analyse the relationships between expression of GADD45, ZBRK1, and BRCA1 mRNA. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 Hosp Univ Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain.
   Hosp Virgen Salud, Dept Pathol, Toledo, Spain.
C3 Hospital Puerta de Hierro-Majadahonda; Complejo Hospitalario de Toledo
RP Hosp Univ Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain.
EM felixbv@stnct.cs
RI Garcia, Vanesa/ADJ-1460-2022; Alonso, Constanza/AAE-9102-2021
OI Garcia-Barberan, Vanesa/0000-0002-2531-0203; Pena,
   Cristina/0000-0003-4406-8640; MAXIMIANO ALONSO,
   CONSTANZA/0000-0002-4051-3965
CR Bianco T, 1999, HUM MUTAT, V14, P289, DOI 10.1002/(SICI)1098-1004(199910)14:4<289::AID-HUMU3>3.0.CO;2-A
   Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001
   Deng CX, 2000, BIOESSAYS, V22, P728
   Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200
   FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4
   Garcia JM, 2003, GUT, V52, P1756, DOI 10.1136/gut.52.12.1756
   Garcia V, 2004, J PATHOL, V202, P224, DOI 10.1002/path.1513
   Garcia-Patiño E, 1998, CANCER GENET CYTOGEN, V104, P119, DOI 10.1016/S0165-4608(97)00460-3
   Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2
   Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091
   Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802
   Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759
   KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2
   Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134
   OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379
   Rutter JL, 2003, HUM MUTAT, V22, P121, DOI 10.1002/humu.10238
   Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000
   Sigurdson AJ, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-9
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Somasundaram K, 2003, J CELL BIOCHEM, V88, P1084, DOI 10.1002/jcb.10469
   Takahashi S, 2001, CANCER RES, V61, P1187
   Tan W, 2004, J BIOL CHEM, V279, P55153, DOI 10.1074/jbc.M410926200
   Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706
   Yun JH, 2003, MOL CELL BIOL, V23, P7305, DOI 10.1128/MCB.23.20.7305-7314.2003
   Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7
NR 25
TC 24
Z9 27
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD MAY
PY 2005
VL 206
IS 1
BP 92
EP 99
DI 10.1002/path.1751
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 920YY
UT WOS:000228732600012
PM 15772983
DA 2025-01-12
ER

PT J
AU Helmbold, P
   Altrichter, D
   Klapperstück, T
   Marsch, WC
AF Helmbold, P
   Altrichter, D
   Klapperstück, T
   Marsch, WC
TI Intratumoral DNA stem-line heterogeneity in superficial spreading
   melanoma
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
ID IMAGE CYTOMETRY; CELL CARCINOMA; EPIGENETIC INACTIVATION;
   COLORECTAL-CARCINOMA; CUTANEOUS MELANOMA; GASTRIC-CARCINOMA; CLONAL
   DIVERGENCE; CONSENSUS REPORT; BREAST-CANCER; P53 GENE
AB Background: In primary melanomas, data on the degree of intratumoral heterogeneity to date have been lacking.
   Objective: Our purpose was to investigate intratumoral DNA stem-line heterogeneity in superficial spreading melanoma (SSM).
   Methods: Multiple measuring fields of 54 SSMs (tumor thickness median 1.60 mm) were studied by DNA image cytometry to obtain data on the number of DNA stem lines per tumor, their ploidy characteristics, and intratumoral distribution. Results were compared with standard histopathological criteria.
   Results: Twenty-three of 54 SSMs were found to have two or three distinct proliferating tumor cell stem lines (1.46 ± 0.57 per tumor). Stern lines appeared spatially separated in 22 of 23 SMMs. At least 3 measuring fields per tumor were necessary to identify all stein lines with a likelihood of 95%. DNA heterogeneity correlated with tumor thickness, but occurred in 5 of 19 cases of pT1 melanoma.
   Conclusions. Primary SSMs can be regarded as potentially clonally unstable with a tendency for spatial separation Of tumor cell stem lines.
C1 Univ Halle Wittenberg, Dept Dermatol & Venerol, D-06097 Halle Saale, Saale, Germany.
C3 Martin Luther University Halle Wittenberg
RP Helmbold, P (通讯作者)，Univ Halle Wittenberg, Dept Dermatol & Venerol, Ernst Kromayer Str 5, D-06097 Halle Saale, Saale, Germany.
EM peter.helmbold@medizin.uni-halle.de
CR ALERS JC, 1995, CYTOMETRY, V21, P84, DOI 10.1002/cyto.990210116
   Bamba M, 1998, CANCER, V83, P867, DOI 10.1002/(SICI)1097-0142(19980901)83:5<867::AID-CNCR10>3.0.CO;2-T
   BARRANCO SC, 1994, CANCER RES, V54, P5351
   Bissig H, 1999, AM J PATHOL, V155, P267, DOI 10.1016/S0002-9440(10)65120-6
   BOCKING A, 1995, ANAL CELL PATHOL, V8, P67
   CARDER PJ, 1995, BRIT J CANCER, V71, P215, DOI 10.1038/bjc.1995.46
   Cheng L, 2002, CANCER-AM CANCER SOC, V94, P104, DOI 10.1002/cncr.10151
   Cheng L, 1999, CANCER, V85, P2017, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2017::AID-CNCR20>3.0.CO;2-V
   Chung YJ, 1999, INT J CANCER, V82, P782, DOI 10.1002/(SICI)1097-0215(19990909)82:6<782::AID-IJC2>3.0.CO;2-#
   Diaz-Cano SJ, 2000, LAB INVEST, V80, P279, DOI 10.1038/labinvest.3780033
   Giroud F, 1998, ANAL CELL PATHOL, V17, P201, DOI 10.1155/1998/237659
   Going JJ, 2001, J PATHOL, V194, P406, DOI 10.1002/path.937
   Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642
   Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837
   Hartmann A, 2000, LAB INVEST, V80, P709, DOI 10.1038/labinvest.3780074
   Helmbold P, 2003, NEW ENGL J MED, V348, P1715
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Hu XR, 2002, J EXP MED, V195, P845, DOI 10.1084/jem.20011564
   Klapperstuck T, 1996, CYTOMETRY, V25, P82, DOI 10.1002/(SICI)1097-0320(19960901)25:1<82::AID-CYTO9>3.0.CO;2-G
   Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.97.7.3236
   Lotem M, 2003, CANCER GENET CYTOGEN, V142, P87, DOI 10.1016/S0165-4608(02)00798-7
   Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123
   MICALE MA, 1992, CANCER GENET CYTOGEN, V61, P165, DOI 10.1016/0165-4608(92)90082-J
   Morita R, 1998, J INVEST DERMATOL, V111, P919, DOI 10.1046/j.1523-1747.1998.00458.x
   Nakayama T, 2001, AM J PATHOL, V158, P1371, DOI 10.1016/S0002-9440(10)64088-6
   Paiss T, 2002, J UROLOGY, V167, P718, DOI 10.1016/S0022-5347(01)69133-X
   Perren A, 1998, J PATHOL, V186, P363
   Petersen S E, 1988, Scand J Urol Nephrol Suppl, V110, P213
   Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722
   Rosenthal AN, 2002, INT J CANCER, V99, P549, DOI 10.1002/ijc.10362
   Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3
   Spugnardi M, 2003, CANCER RES, V63, P1639
   SYMMANS WF, 1995, HUM PATHOL, V26, P210, DOI 10.1016/0046-8177(95)90039-X
   Tada M, 1996, INT J CANCER, V67, P447, DOI 10.1002/(SICI)1097-0215(19960729)67:3<447::AID-IJC22>3.0.CO;2-3
   Tollenaar RAEM, 1997, CANCER-AM CANCER SOC, V79, P1304, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1304::AID-CNCR6>3.3.CO;2-V
   YANO H, 1993, HEPATOLOGY, V18, P320, DOI 10.1002/hep.1840180216
NR 36
TC 5
Z9 5
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD MAY
PY 2005
VL 52
IS 5
BP 803
EP 809
DI 10.1016/j.jaad.2004.12.049
PG 7
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA 926JT
UT WOS:000229120200006
PM 15858470
DA 2025-01-12
ER

PT J
AU Strunnikova, M
   Schagdarsurengin, U
   Kehlen, A
   Garbe, JC
   Stampfer, MR
   Dammann, R
AF Strunnikova, M
   Schagdarsurengin, U
   Kehlen, A
   Garbe, JC
   Stampfer, MR
   Dammann, R
TI Chromatin inactivation precedes de novo DNA methylation during the
   progressive epigenetic silencing of the <i>RASSF1A</i> promoter
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; HISTONE H3 METHYLTRANSFERASE; BINDING PROTEIN
   MECP2; CPG ISLAND; BREAST-CANCER; LYSINE 9; DEACETYLASE COMPLEX;
   NEUROSPORA-CRASSA; GENE; TRANSCRIPTION
AB Epigenetic inactivation of the RASSFIA tumor suppressor by CpG island methylation was frequently detected in cancer. However, the mechanisms of this aberrant DNA methylation are unknown. In the RASSFIA promoter, we characterized four Sp1 sites, which are frequently methylated in cancer. We examined the functional relationship between DNA methylation, histone modification, Sp1 binding, and RASSFIA expression in proliferating human mammary epithelial cells. With increasing passages, the transcription of RASSFIA was dramatically silenced. This inactivation was associated with deacetylation and lysine 9 trimethylation of histone H3 and an impaired binding of Sp1 at the RASSFIA promoter. In mammary epithelial cells that had overcome a stress-associated senescence barrier, a spreading of DNA methylation in the CpG island promoter was observed. When the RASSFIA-silenced cells were treated with inhibitors of DNA methyltransferase and histone deacetylase, binding of Sp1 and expression of RASSFIA reoccurred. In summary, we observed that histone H3 deacetylation and H3 lysine 9 trimethylation occur in the same time window as gene inactivation and precede DNA methylation. Our data suggest that in epithelial cells, histone inactivation may trigger de novo DNA methylation of the RASSFIA promoter and this system may serve as a model for CpG island inactivation of tumor suppressor genes.
C1 Univ Halle Wittenberg, AG Tumorgenet Med Fak, D-06097 Halle Saale, Germany.
   Univ Halle Wittenberg, Inst Med Immunol, D-06097 Halle Saale, Germany.
   Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
C3 Martin Luther University Halle Wittenberg; Martin Luther University
   Halle Wittenberg; United States Department of Energy (DOE); Lawrence
   Berkeley National Laboratory
RP Univ Halle Wittenberg, Inst Humangenet & Med Biol, Magdeburger Str 2, D-06097 Halle Saale, Germany.
EM reinhard.dammann@medizin.uni-halle.de
RI Schagdarsurengin, Undraga/AAH-4312-2020
OI Schagdarsurengin, Undraga/0000-0003-0127-4938
CR Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 1997, MOL CELL BIOL, V17, P219, DOI 10.1128/MCB.17.1.219
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731
   Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Müller HM, 2003, CANCER RES, V63, P7641
   Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   Pieper RO, 1996, J BIOL CHEM, V271, P13916, DOI 10.1074/jbc.271.23.13916
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   Stampfer M., 1985, Journal of Tissue Culture Methods, V9, P107
   Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143
   TOMMASI S, 1995, MOL CELL BIOL, V15, P6901
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yan PS, 2003, CANCER RES, V63, P6178
NR 49
TC 105
Z9 128
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAY
PY 2005
VL 25
IS 10
BP 3923
EP 3933
DI 10.1128/MCB.25.10.3923-3933.2005
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 923DB
UT WOS:000228888100008
PM 15870267
OA Green Published
DA 2025-01-12
ER

PT J
AU Zhang, YJ
   Chen, Y
   Ahsan, H
   Lunn, RM
   Chen, SY
   Lee, PH
   Chen, CJ
   Santella, RM
AF Zhang, YJ
   Chen, Y
   Ahsan, H
   Lunn, RM
   Chen, SY
   Lee, PH
   Chen, CJ
   Santella, RM
TI Silencing of <i>glutathione S-transferase P1</i> by promoter
   hypermethylation and its relationship to environmental chemical
   carcinogens in hepatocellular carcinoma
SO CANCER LETTERS
LA English
DT Article
DE epigenetic changes; hepatocellular carcinoma; hypermethylation;
   glutathione S-transferase P1; chemical carcinogens
ID GLUTATHIONE-S-TRANSFERASE; GENE O-6-METHYLGUANINE-DNA METHYLTRANSFERASE;
   ISLAND DNA HYPERMETHYLATION; GSTP1 CPG ISLAND; AFLATOXIN EXPOSURE;
   BREAST-CANCER; HUMAN NEOPLASIA; EXPRESSION; PI; METHYLATION
AB Glutathione S-transferases (GSTs) are a family of isoenzymes that play an important role in protecting cells from cytotoxic and carcinogenic agents. GST pi is encoded by the GSTP1 gene. GSTP1 null mice show an increased risk of skin tumorigenesis induced by carcinogens. GSTP1 is transcriptionally silenced by promoter hypermethylation in several human cancers including hepatocellular carcinoma (HCC). Methylation-specific PCR (MSP) was used to analyze the GSTP1 promoter hypermethylation status of 83 hepatocellular carcinoma tissues from Taiwan. Hypermethylation was detected in 38 of 83 (46%) tumors. GSTP1 expression by immunohistochemical staining of HCC tissue samples was significantly associated with methylation status. The relationship between methylation status and clinical parameters and tumor markers including environmental exposure to aflatoxin B-1(AFB(1)) and polycyclic aromatic hydrocarbons (PAH), measured as DNA adducts, was also investigated. A statistically significant association was found between GSTP1 promoter hypermethylation and the level of AFB(1)-DNA adducts in tumor tissue (OR 2.81, 95% CI 1.03-7.70); a marginally significant association was found for adjacent non-tumor tissue (OR 2.57, 95% CI 0.97-6.80). There was no association between GSTP1 hypermethylation and PAH-DNA adducts in tumor or adjacent non-tumor tissues. These results suggest that epigenetic inactivation of GSTP1 plays an important role in the development of HCC and exposure to environmental carcinogens may be related to altered methylation of genes involved in hepatocarcinogenesis. The mechanism by which environmental exposures induce epigenetic changes in HCC needs further analysis. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.
   NIEHS, Res Triangle Pk, NC USA.
   Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei, Taiwan.
   Natl Taiwan Univ, Coll Med, Dept Surg, Taipei, Taiwan.
C3 Columbia University; National Institutes of Health (NIH) - USA; NIH
   National Institute of Environmental Health Sciences (NIEHS); National
   Taiwan University; National Taiwan University
RP Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 701 W 168th St, New York, NY 10032 USA.
EM rps1@columbia.edu
RI Chen, Chien-Jen/N-4723-2019; Lunn, Ruth/AAP-8848-2021; Liu,
   Tsung-Hao/D-3357-2016; Chen, Yu/KWU-0062-2024
OI Chen, Yu/0000-0002-1519-4894; LEE, PO-HUANG/0000-0001-5831-035X
FU NIEHS NIH HHS [ES09098, ES05116, R01 ES005116, P30 ES009089] Funding
   Source: Medline
CR AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586
   *AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN, P97
   Anzola M, 2003, LIVER INT, V23, P249, DOI 10.1034/j.1600-0676.2003.00834.x
   BANNASCH P, 1986, CARCINOGENESIS, V7, P689, DOI 10.1093/carcin/7.5.689
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   CAIRNS J, 1992, J PATHOL, V166, P19, DOI 10.1002/path.1711660105
   CHEN CJ, 1993, J GASTROEN HEPATOL, V8, P83
   Chen SY, 2002, INT J CANCER, V99, P14, DOI 10.1002/ijc.10291
   COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605
   DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794
   DIILIO C, 1991, CARCINOGENESIS, V12, P1471
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 1998, CANCER RES, V58, P4515
   GILBERT L, 1993, J CLIN ONCOL, V11, P49, DOI 10.1200/JCO.1993.11.1.49
   GROOPMAN JD, 1988, CRC CR REV TOXICOL, V19, P113, DOI 10.3109/10408448809014902
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   Henderson CJ, 1998, CHEM-BIOL INTERACT, V112, P69, DOI 10.1016/S0009-2797(97)00176-2
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   JIANG W, 1992, CANCER RES, V52, P2980
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kondoh N, 2001, INT J ONCOL, V18, P1271
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lunn RM, 1997, CANCER RES, V57, P3471
   MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202
   Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199
   MORROW CS, 1992, J BIOL CHEM, V267, P10544
   Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562
   PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   ROOMI MW, 1985, CANCER RES, V45, P564
   RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475
   SANTELLA RM, 1990, ENVIR SCI R, V39, P291
   SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964
   Silvestrini R, 1997, J NATL CANCER I, V89, P639, DOI 10.1093/jnci/89.9.639
   Tchou JC, 2000, INT J ONCOL, V16, P663
   TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566
   Wachsman JT, 1997, MUTAT RES-FUND MOL M, V375, P1, DOI 10.1016/S0027-5107(97)00003-1
   WILSON VL, 1987, P NATL ACAD SCI USA, V84, P3298, DOI 10.1073/pnas.84.10.3298
   Zhang YJ, 2003, INT J CANCER, V103, P440, DOI 10.1002/ijc.10852
   Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076
   Zhong S, 2002, CLIN CANCER RES, V8, P1087
   Zhou TL, 1997, CANCER RES, V57, P2749
NR 43
TC 81
Z9 88
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD APR 28
PY 2005
VL 221
IS 2
BP 135
EP 143
DI 10.1016/j.canlet.2004.08.028
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 919GS
UT WOS:000228607000003
PM 15808399
DA 2025-01-12
ER

PT J
AU Ahmed-Choudhury, J
   Agathanggelou, A
   Fenton, SL
   Ricketts, C
   Clark, GJ
   Maher, ER
   Latif, F
AF Ahmed-Choudhury, J
   Agathanggelou, A
   Fenton, SL
   Ricketts, C
   Clark, GJ
   Maher, ER
   Latif, F
TI Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced
   binding of p120<SUP>E4F</SUP> to the cyclin A2 promoter
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; EPIGENETIC INACTIVATION; CELL; IDENTIFICATION;
   ASSOCIATION; EXPRESSION; PROTEIN; LUNG; E4F; PROGRESSION
AB Recent advances in the study of RASSFIA, the candidate tumor suppressor gene, indicate a possible role of RASSFIA in cell cycle regulation; however, very little is known regarding molecular mechanisms underlying this control. Using small interfering RNA to knockdown endogenous RASSFIA in the breast tumor cell line 11132 and in the cervical cancer cell line HeLa, we identify that a key player in cell cycle progression, cyclin A2, is concomitantly increased at both protein and mRNA levels. In A549 clones stably expressing RASSFIA, cyclin A2 levels were diminished compared with vector control. A known transcriptional regulator of cyclin A2, p120(E4F) (a repressor of cyclin A2), has been shown previously by our group to interact with RASSFIA. We show that levels of p120(E4F) are not affected by RASSFIA small interfering RNA in HB2 and HeLa cells. However, electrophoretic mobility shift assays indicate that knockdown of endogenous RASSFIA in HB2 and HeLa cells leads to a reduction in the binding capacity of p120(E4F) to the cyclin A2 promoter, whereas in the A549 clone stably expressing RASSFIA the binding capacity is increased. These data are further corroborated in vitro by the luciferase assay and in vivo by chromatin immunoprecipitation experiments. Together, these data identify the cyclin A2 gene as a cellular target for RASSFIA through p120(E4F) and for the first time suggest a transcriptional mechanism for RASSFIA-dependent cell cycle regulation.
C1 Univ Birmingham, Biomed Res Inst, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
   NCI, Dept Cell & Canc Biol, Rockville, MD USA.
C3 University of Birmingham; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI)
RP Univ Birmingham, Biomed Res Inst, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
EM flatif@hgmp.mrc.ac.uk
RI MAHER, EAMONN/A-9507-2008
OI MAHER, EAMONN/0000-0002-6226-6918
FU Breast Cancer Now [1999:98] Funding Source: Medline
CR Agathanggelou A, 2003, CANCER RES, V63, P5344
   BARLAT I, 1995, ONCOGENE, V11, P1309
   Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301
   DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001
   Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397
   Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622
   Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890
   HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079
   Huet X, 1996, MOL CELL BIOL, V16, P3789
   Le Cam L, 2004, MOL CELL BIOL, V24, P6467, DOI 10.1128/MCB.24.14.6467-6475.2004
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   Morrissey C, 2001, CANCER RES, V61, P7277
   Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655
   RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x
   RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620
   Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202
   Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200
   RONG R, 2004, ONCOGENE
   Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250
   Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   Tessari MA, 2003, MOL CELL BIOL, V23, P9104, DOI 10.1128/MCB.23.24.9104-9116.2003
   Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339
NR 30
TC 38
Z9 51
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 1
PY 2005
VL 65
IS 7
BP 2690
EP 2697
DI 10.1158/0008-5472.CAN-04-3593
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 911AB
UT WOS:000227972300029
PM 15805267
OA Bronze
DA 2025-01-12
ER

PT J
AU Shen, DH
   Chan, KYK
   Khoo, US
   Ngan, HYS
   Xue, WC
   Chiu, PM
   Ip, P
   Cheung, ANY
AF Shen, DH
   Chan, KYK
   Khoo, US
   Ngan, HYS
   Xue, WC
   Chiu, PM
   Ip, P
   Cheung, ANY
TI Epigenetic and genetic alterations of <i>p33<SUP>ING1b</SUP></i> in
   ovarian cancer
SO CARCINOGENESIS
LA English
DT Article
ID TUMOR-SUPPRESSOR P33(ING1); DNA METHYLATION; REDUCED EXPRESSION;
   DOWN-REGULATION; P53 EXPRESSION; MELANOMA-CELLS; BREAST-CANCER;
   MESSENGER-RNA; ING1; INHIBITOR
AB p33(ING1b) is a candidate tumor suppressor gene and a nuclear protein. We investigated whether genetic and epigenetic mechanisms affect p33(ING1b) expression in ovarian cancer thus contributing toward its pathogenesis. A total of 111 ovarian cancers collected from Beijing and Hong Kong were used for this study. Weak or negative p33(ING1b) protein expression was demonstrated by immunohistochemistry on tissue microarray in 28/111 cases. Real-time quantitative RT-PCR also showed overall significant reduction of p33(ING1b) mRNA expression (P = 0.0137), with 53.1% (17/32) cases showing 2- to 5-fold reduction and absence of expression. The reduction of mRNA expression in cancer correlated with decreased p33(ING1b) protein expression (P < 0.0001). While no p33(ING1b) mutation was found, allelic loss at the p33(ING1b) locus was demonstrated in 25% (8/32) cases. The allelic loss profiles also showed statistical significant correlation with reduction of p33(ING1b) protein and mRNA expression (P = 0.031 and 0.030). Promoter methylation as assessed by methylation specific PCR was found in 23.9% (21/88) cases analyzed. Bisulfite sequencing results confirmed the p33(ING1b) promoter methylation status of these methylation positive cases. Statistical significant correlation between methylation and mRNA expression (P = 0.006) was demonstrated. Treatment with demethylating drug, 5'-aza-2'-deoxycytidine, resulted in dosage-dependent elevated mRNA expression of p33(ING1b) in ovarian cancer cell lines. This is the first study reporting epigenetic mechanism regulating the p33(ING1b) expression. Our findings support that genetic and epigenetic alteration of p33(ING1b) are likely to contribute towards the pathogenesis of ovarian cancers.
C1 Univ Hong Kong, Hong Kong Jockey Club Clin Res Ctr, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Pathol, SH Ho Fdn, Res Labs Pathol, Hong Kong, Hong Kong, Peoples R China.
   Peking Univ, Peoples Hosp, Dept Pathol, Beijing 100871, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; Peking University
RP Univ Hong Kong, Queen Marys Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM anycheun@hkucc.hku.hk
RI Chan, Kelvin/HGA-3097-2022; Cheung, Annie/C-4230-2009; Ip,
   Philip/AAV-5995-2021; Khoo, Ui/K-2041-2019; Cheung, Annie Nga
   Yin/C-4231-2009; Chan, Kelvin Yuen Kwong/I-4788-2014; Khoo, Ui
   Soon/C-4293-2009
OI Ngan, Hextan Y S/0000-0003-3945-159X; Ip, Philip
   Pun-Ching/0000-0002-0493-9838; Cheung, Annie Nga
   Yin/0000-0002-1584-7568; Chan, Kelvin Yuen Kwong/0000-0002-5272-0005;
   Khoo, Ui Soon/0000-0003-2200-7505
CR Ahluwalia A, 2001, GYNECOL ONCOL, V82, P261, DOI 10.1006/gyno.2001.6291
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Boland D, 2000, HYBRIDOMA, V19, P161, DOI 10.1089/02724570050031202
   Chan KYK, 2002, CANCER RES, V62, P4151
   Chan QKY, 2005, J MOL DIAGN, V7, P8, DOI 10.1016/S1525-1578(10)60003-7
   Chen LS, 2001, CANCER RES, V61, P4345
   Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610
   Cheung KJ, 2002, INT J ONCOL, V20, P1319
   Cheung KJ, 2001, EXP CELL RES, V268, P1, DOI 10.1006/excr.2001.5258
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Feng HC, 2004, GYNECOL ONCOL, V94, P375, DOI 10.1016/j.ygyno.2004.04.019
   FLATAU E, 1984, MOL CELL BIOL, V4, P2098, DOI 10.1128/MCB.4.10.2098
   Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537
   Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415
   Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675
   Gunduz M, 2000, CANCER RES, V60, P3143
   Ito K, 2002, AM J HEMATOL, V69, P141, DOI 10.1002/ajh.10031
   Jäger D, 1999, CANCER RES, V59, P6197
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Krishnamurthy J, 2001, ORAL ONCOL, V37, P222, DOI 10.1016/S1368-8375(00)00081-6
   LI SS, 2005, IN PRESS HISTOPATHOL
   McCluskey LL, 1999, GYNECOL ONCOL, V72, P87, DOI 10.1006/gyno.1998.5235
   Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008
   Nouman GS, 2003, J CLIN PATHOL, V56, P507, DOI 10.1136/jcp.56.7.507
   Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584
   Ohmori M, 1999, AM J HEMATOL, V62, P118
   Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8
   Sanchez-Cespedes M, 2000, GENE CHROMOSOME CANC, V27, P319, DOI 10.1002/(SICI)1098-2264(200003)27:3<319::AID-GCC13>3.0.CO;2-P
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Tallen G, 2004, INT J CANCER, V109, P476, DOI 10.1002/ijc.11715
   Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6
   Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905
   Vieyra D, 2002, CANCER RES, V62, P4445
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Wong YF, 1999, CANCER LETT, V136, P231, DOI 10.1016/S0304-3835(98)00327-9
   Xue WC, 2004, J MOL DIAGN, V6, P326, DOI 10.1016/S1525-1578(10)60528-4
NR 37
TC 38
Z9 44
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD APR
PY 2005
VL 26
IS 4
BP 855
EP 863
DI 10.1093/carcin/bgi011
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 911BR
UT WOS:000227976700018
PM 15677627
OA Bronze
DA 2025-01-12
ER

PT J
AU Henrique, R
   Jerónimo, C
   Hoque, MO
   Carvalho, AL
   Oliveira, J
   Teixeira, MR
   Lopes, C
   Sidransky, D
AF Henrique, R
   Jerónimo, C
   Hoque, MO
   Carvalho, AL
   Oliveira, J
   Teixeira, MR
   Lopes, C
   Sidransky, D
TI Frequent <i>14-3-3</i>σ promoter methylation in benign and malignant
   prostate lesions
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID BREAST-CANCER; MOLECULAR-DETECTION; TUMOR-SUPPRESSOR; SIGMA GENE;
   HYPERMETHYLATION; INACTIVATION; CELLS; LEADS; PCR
AB 14-3-3 sigma is a putative tumor suppressor gene involved in cell cycle regulation and apoptosis following DNA damage. 14-3-3 sigma loss of expression has been reported is several human cancers, including prostate adenocarcinoma and precursor lesions, and promoter hypermethylation has been proposed as the mechanism underlying gene silencing. Here, we investigate the frequency and extent of 14-3-3 sigma promoter methylation in benign and cancerous prostate tissues. We examined tumor tissue from 121 patients with prostate carcinoma (PCa), 39 paired high-grade prostatic intraepithelial neoplasias (HGPIN), 29 patients with benign prostate hyperplasia (BPH), as well as four prostate cancer cell lines using quantitative methylation-specific PCR (QMSP). The percentage of methylated alleles (PMA) was calculated and correlated with clinical and pathological parameters. RT-PCR was performed in the cell lines to assess 14-3-3 sigma mRNA expression. PCa, HGPIN, BPH, and cancer cell lines showed ubiquitous 14-3-3 sigma promoter methylation. However, the PMA of HGPIN was significantly lower than that of PCa or BPH (P < 0.0001), while PCa and BPH did not significantly differ. The PMA did not correlate with any clinicopathological parameter. All prostate cancer cell lines expressed 14-3-3 sigma mRNA. 14-3-3 sigma promoter methylation is a frequent event in prostate tissues and cancer cell lines. Furthermore, there is a progressive accumulation of neoplastic cells with 14-3-3 sigma methylated alleles from HGPIN to PCa, suggesting a role for this epigenetic event in prostate carcinogenesis. However, other mechanisms besides promoter methylation might be required for effective 14-3-3 sigma downregulation.
C1 Portuguese Oncol Inst Porto, Dept Genet, P-4200072 Oporto, Portugal.
   Portuguese Oncol Inst Porto, Dept Pathol, P-4200072 Oporto, Portugal.
   Portuguese Oncol Inst Porto, Dept Urol, P-4200072 Oporto, Portugal.
   Fernando Pessoa Univ, Sch Hlth Sci, Oporto, Portugal.
   Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21205 USA.
C3 Portuguese Institute of Oncology; Portuguese Institute of Oncology;
   Portuguese Institute of Oncology; Universidade Fernando Pessoa; Johns
   Hopkins University
RP Portuguese Oncol Inst Porto, Dept Genet, Rua Dr Antonio Bernardino Almeida, P-4200072 Oporto, Portugal.
EM cjeronimo@hotmail.com
RI Jeronimo, Carmen/H-3284-2013; Lopes Carvalho, Andre/S-7053-2016;
   Henrique, Rui/I-2757-2013; Rodrigues Teixeira, Manuel
   Antonio/E-4885-2011
OI Jeronimo, Carmen/0000-0003-4186-5345; Lopes Carvalho,
   Andre/0000-0001-7214-6402; Henrique, Rui/0000-0003-3171-4666; Rodrigues
   Teixeira, Manuel Antonio/0000-0002-4896-5982; Hoque, Mohammad
   Obaidul/0000-0001-6701-9978
CR Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332
   Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652
   Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Henrique R, 2004, EUR UROL, V46, P660, DOI 10.1016/j.eururo.2004.06.014
   HERMANEK P, 1997, ILLUSTRATED GUIDE TN, P278
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Jerónimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   LIVAK KJ, 1995, PCR METH APPL, V4, P357
   Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   Suzuki H, 2000, CANCER RES, V60, P4353
   Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056
   van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
NR 25
TC 48
Z9 62
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD APR
PY 2005
VL 24
IS 4
BP 264
EP 269
DI 10.1089/dna.2005.24.264
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 915CT
UT WOS:000228275900007
PM 15812243
DA 2025-01-12
ER

PT J
AU Yeo, W
   Wong, N
   Wong, WL
   Lai, PBS
   Zhong, S
   Johnson, PJ
AF Yeo, W
   Wong, N
   Wong, WL
   Lai, PBS
   Zhong, S
   Johnson, PJ
TI High frequency of promoter hypermethylation of RASSF1A in tumor and
   plasma of patients with hepatocellular carcinoma
SO LIVER INTERNATIONAL
LA English
DT Article
DE epigenetic; liver cancer tissues; plasma; promoter methylation; RASSF1A
ID COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER PATIENTS; HEPATITIS-B
   VIRUS; EPIGENETIC INACTIVATION; DNA METHYLATION; CPG ISLAND;
   MICROSATELLITE INSTABILITY; SUPPRESSOR GENES; SERUM; LUNG
AB Purpose: To determine the presence of ras association domain family 1A (RASSF1A) promoter methylation in the tumor tissues and plasma of patients with hepatocellular carcinoma (HCC). Experimental Design: Methylation-specific polymerase chain reaction was used to detect RASSF1A methylation in DNA extracted from HCC tumors and paired plasma samples of 40 patients. The association of RASSF1A hypermethylation in tumor and plasma DNA of HCC patients with clinicopathological characteristics was also analyzed. Results: RASSF1A promoter hypermethylation was detected in 37 of the 40 HCC tissues (92.5%). Of the paired plasma from the 40 HCC patients, aberrant methylation was detected in 17 (42.5%). No RASSF1A methylation was detected in the plasma in the absence of methylation in the corresponding tumor. The presence of RASSF1A promoter hypermethylation in plasma DNA was found to associate with HCC size of >= 4 cm (P=0.035). Conclusion: RASSF1A promoter hypermethylation occurred at a high frequency in HCC. The aberrant methylation was also detectable in over 40% of matched plasma. The latter should be evaluated as a screening tool and/or prognosticator of HCC patients.
C1 Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
   Univ Birmingham, Inst Canc Studies, Canc Res UK, Birmingham, W Midlands, England.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Prince of Wales Hospital; Chinese University of
   Hong Kong; Prince of Wales Hospital; University of Birmingham; Cancer
   Research UK
RP Yeo, W (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.
EM winnieyeo@cuhk.edu.hk
RI LAI, Paul Bo-San/K-8556-2015; Yeo, Winnie/R-4792-2018
OI LAI, Paul Bo-San/0000-0002-9469-6728; Yeo, Winnie/0000-0002-0863-8469
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BEASLEY RP, 1981, LANCET, V2, P1129
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971
   Daigo Y, 1999, CANCER RES, V59, P1966
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Esteller M, 1999, CANCER RES, V59, P67
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Lin YW, 1999, EUR J CANCER, V35, P652, DOI 10.1016/S0959-8049(98)00430-4
   Lo KW, 2001, CANCER RES, V61, P3877
   Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   SCDHAGDARSURENG.U, 2002, CANCER RES, V62, P3698
   Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380
   Silva JM, 1999, CANCER RES, V59, P3251
   Wong IHN, 2004, CLIN CANCER RES, V10, P994, DOI 10.1158/1078-0432.CCR-0378-3
   Wong IHN, 1999, CANCER RES, V59, P71
   Wong IHN, 2000, CLIN CANCER RES, V6, P3516
   Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0
   Wong N, 2002, J HEPATOL, V37, P633, DOI 10.1016/S0168-8278(02)00269-6
   Yan PS, 2003, CANCER RES, V63, P6178
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076
   Zhong S, 2003, CLIN CANCER RES, V9, P3376
NR 32
TC 94
Z9 111
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
J9 LIVER INT
JI Liver Int.
PD APR
PY 2005
VL 25
IS 2
BP 266
EP 272
DI 10.1111/j.1478-3231.2005.01084.x
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 907MI
UT WOS:000227721800010
PM 15780049
DA 2025-01-12
ER

PT J
AU Yeo, W
   Wong, WL
   Wong, N
   Law, BK
   Tse, GM
   Zhong, S
AF Yeo, W
   Wong, WL
   Wong, N
   Law, BK
   Tse, GM
   Zhong, S
TI High frequency of promoter hypermethylation of RASSF1A in tumorous and
   non-tumourous tissue of breast cancer
SO PATHOLOGY
LA English
DT Article
DE breast cancer; epigenetic; promoter methylation
ID HUMAN-CHROMOSOME 3P21.3; CARCINOMA IN-SITU; DOMAIN FAMILY 1A; SUPPRESSOR
   GENE; CPG ISLAND; EPIGENETIC INACTIVATION; DNA METHYLATION; LUNG-CANCER;
   REGION; SERUM
AB Aim: To determine the presence of RASSF1A promoter methylation in tumorous and non-tumorous tissues of breast cancer.
   Methods: Methylation-specific PCR was used to detect RASSF1A methylation in DNA extracted from tumorous and paired non-tumorous tissues of 40 breast cancer patients. The associations of RASSF1A hypermethylation with clinicopathological characteristics in tumorous and non-tumorous breast tissues were analysed.
   Results: RASSF1A promoter hypermethylation was detected in 38 of the 40 breast cancer tissues (95%) and 37 of the paired non-tumorous tissues (92.5%). When compared with the non-tumorous tissues, aberrant methylation was detected to be higher in 24 of the tumorous tissues (60%). The latter was found to be associated with lower histological grade tumours (p=0.048).
   Conclusion: RASSF1A promoter hypermethylation occurred at a high frequency in breast cancer tumorous and non-tumorous tissues; the majority of tumours have a higher level of methylation status when compared with non-tumorous tissues. This supports the notion that RASSF1A methylation is an early and premalignant alteration.
C1 Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Prince of Wales Hospital; Chinese University of
   Hong Kong; Prince of Wales Hospital
RP Yeo, W (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.
EM winnieyeo@cuhk.edu.hk
RI Yeo, Winnie/R-4792-2018
OI Yeo, Winnie/0000-0002-0863-8469; Tse, Gary/0000-0002-9405-9665
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ahuja N, 1998, CANCER RES, V58, P5489
   Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971
   Coleman MP., 1993, TRENDS CANC INCIDENC
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Ejeskär K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297
   Esteller M, 1999, CANCER RES, V59, P67
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fisher B, 2001, SEMIN ONCOL, V28, P400, DOI 10.1053/sonc.2001.26151
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797
   Kurtz J, 2002, EUR J CANCER, V38, P1961, DOI 10.1016/S0959-8049(02)00314-3
   Kuzmin I, 2002, CANCER RES, V62, P3498
   Lee MG, 2001, CANCER RES, V61, P6688
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Lehmann U, 2002, CANCER RES, V62, P6634
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lerman MI, 2000, CANCER RES, V60, P6116
   Lo KW, 2001, CANCER RES, V61, P3877
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   SCDHAGDARSURENG.U, 2002, CANCER RES, V62, P3698
   Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Wong IHN, 2004, CLIN CANCER RES, V10, P994, DOI 10.1158/1078-0432.CCR-0378-3
   Wong N, 2002, J HEPATOL, V37, P633, DOI 10.1016/S0168-8278(02)00269-6
   Zhong S, 2003, CLIN CANCER RES, V9, P3376
NR 35
TC 33
Z9 50
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0031-3025
J9 PATHOLOGY
JI Pathology
PD APR
PY 2005
VL 37
IS 2
BP 125
EP 130
DI 10.1080/00313020500058623
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 920XU
UT WOS:000228729600003
PM 16028839
DA 2025-01-12
ER

PT J
AU Sirchia, SM
   Ramoscelli, L
   Grati, FR
   Barbera, F
   Coradini, D
   Rossella, F
   Porta, G
   Lesma, E
   Ruggeri, A
   Radice, P
   Simoni, G
   Miozzo, M
AF Sirchia, SM
   Ramoscelli, L
   Grati, FR
   Barbera, F
   Coradini, D
   Rossella, F
   Porta, G
   Lesma, E
   Ruggeri, A
   Radice, P
   Simoni, G
   Miozzo, M
TI Loss of the inactive X chromosome and replication of the active x in
   <i>BRCA1</i>-defective and wild-type breast cancer cells
SO CANCER RESEARCH
LA English
DT Article
ID SEX-CHROMATIN; HISTONE H3; DNA METHYLATION; XIST RNA; BRCA1; CARCINOMA;
   HETEROZYGOSITY; GENE; HYPOACETYLATION; ASSOCIATION
AB In females, X chromosome inactivation (XCI) begins with the expression of the XIST gene from the X chromosome destined to be inactivated (Xi) and the coating of XIST RNA in cis. It has recently been reported that this process is supported by the product of the BRCA1 tumor suppressor gene and that BRCAI(-/-) cancers show Xi chromatin structure defects, thus suggesting a role of XCI perturbation in BRCA1-mediated tumorigenesis. Using a combined genetic and epigenetic approach, we verified the occurrence of XCI in BRCA1(-/-) and BRCA1(wt) breast cancer cell lines. It was ascertained that the Xi was lost in all cancer cell lines, irrespective of the BRCA1 status and that more than one active X (Xa) was present. In addition, no epigenetic silencing of genes normally subjected to XCI was observed. We also evaluated XIST expression and found that XIST may be occasionally transcribed also from Xa. Moreover, in one of the BRCA1(wt) cell line the restoring of XIST expression using a histone deacetylase inhibitor, did not lead to XCI. To verify these findings in primary tumors, chromosome X behavior was investigated in a few BRCA1-associated and BRCA1-not associated primary noncultured breast carcinomas and the results mirrored those obtained in cancer cell lines. Our findings indicate that the lack of XCI may be a frequent phenomenon in breast tumorigenesis, which occurs independently of BRCA1 status and XIST expression and is due to the loss of Xi and replication of Xa and not to the reactivation of the native Xi.
C1 Univ Milan, Dipartimento Med Chirurg & Odontoiatria, I-20142 Milan, Italy.
   Ist Nazl Tumori, Dipartimento Med Sperimentale, I-20133 Milan, Italy.
   Ist Fdn Italiana Ric Canc Oncol Mol, I-20133 Milan, Italy.
   Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, Varese, Italy.
   Lab TOMA, Unita Citogenet & Biol Mol, Busto Arsizio, Italy.
C3 University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan;
   University of Insubria
RP Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Via A Rudini 8, I-20142 Milan, Italy.
EM silvia.sirchia@unimi.it
RI Miozzo, Monica/AAC-6401-2022; Sirchia, Silvia/AAB-2620-2019; ruggeri,
   arianna/Q-5101-2018; Grati, Francesca Romana/H-7397-2019; Radice,
   Paolo/O-3119-2013
OI Grati, Francesca Romana/0000-0002-3836-5190; Radice,
   Paolo/0000-0001-6298-4111; porta, giovanni/0000-0001-5260-2415; Lesma,
   Elena/0000-0002-9096-713X; Sirchia, Silvia/0000-0002-6106-3721; Miozzo,
   Monica/0000-0002-6523-4575
CR ALLEN RC, 1992, AM J HUM GENET, V51, P1229
   Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580
   BALAZS M, 1991, CANCER GENET CYTOGEN, V57, P93, DOI 10.1016/0165-4608(91)90194-Y
   Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787
   BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0
   BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M
   CAMARGO M, 1980, HUM GENET, V55, P81, DOI 10.1007/BF00329131
   Canzian F, 1996, CANCER RES, V56, P3331
   Choi Chan, 1998, Journal of Korean Medical Science, V13, P311
   Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773
   Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887
   Deng CX, 2000, BIOESSAYS, V22, P728
   DUTRILLAUX B, 1986, INT J CANCER, V38, P475, DOI 10.1002/ijc.2910380404
   Favy DA, 1999, BIOCHEM BIOPH RES CO, V258, P284, DOI 10.1006/bbrc.1999.0602
   Fehm T, 2002, BREAST CANCER RES TR, V75, P227, DOI 10.1023/A:1019901010758
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   GIAMMARINI A, 1980, CLIN GENET, V18, P103
   Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825
   Giordano SH, 2002, ANN INTERN MED, V137, P678, DOI 10.7326/0003-4819-137-8-200210150-00013
   Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0
   HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663
   Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298
   Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X
   KIMEL VM, 1957, CANCER-AM CANCER SOC, V10, P922, DOI 10.1002/1097-0142(195709/10)10:5<922::AID-CNCR2820100509>3.0.CO;2-7
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6
   LOUPART ML, 1995, GENE CHROMOSOME CANC, V13, P229, DOI 10.1002/gcc.2870130402
   PERRY M, 1972, BRIT J SURG, V59, P731, DOI 10.1002/bjs.1800590912
   Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789
   Piao Z, 2002, GENE CHROMOSOME CANC, V33, P262, DOI 10.1002/gcc.10024
   Roncuzzi L, 2002, CANCER GENET CYTOGEN, V135, P173, DOI 10.1016/S0165-4608(01)00652-5
   Rudas M, 2000, CANCER GENET CYTOGEN, V121, P190, DOI 10.1016/S0165-4608(00)00254-5
   SAVINO A, 1971, ACTA CYTOL, V15, P372
   Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000
   Swerdlow AJ, 2001, ANN HUM GENET, V65, P177, DOI 10.1017/S0003480001008569
   Teixeira MR, 1998, GENE CHROMOSOME CANC, V23, P16, DOI 10.1002/(SICI)1098-2264(199809)23:1<16::AID-GCC3>3.0.CO;2-9
   Tomlinson GE, 1998, CANCER RES, V58, P3237
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Wagner TMU, 1998, INT J CANCER, V77, P354, DOI 10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N
   WANG N, 1990, CANCER GENET CYTOGEN, V46, P271, DOI 10.1016/0165-4608(90)90112-N
   WOLMAN SR, 1995, MODERN PATHOL, V8, P239
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
NR 42
TC 75
Z9 89
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2005
VL 65
IS 6
BP 2139
EP 2146
DI 10.1158/0008-5472.CAN-04-3465
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 905VW
UT WOS:000227600000015
PM 15781624
OA Bronze
DA 2025-01-12
ER

PT J
AU Shinozaki, M
   Hoon, DSB
   Giuliano, AE
   Hansen, NM
   Wang, HJ
   Turner, R
   Taback, B
AF Shinozaki, M
   Hoon, DSB
   Giuliano, AE
   Hansen, NM
   Wang, HJ
   Turner, R
   Taback, B
TI Distinct hypermethylation profile of primary breast cancer is associated
   with sentinel lymph node metastasis
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GENE-EXPRESSION; E-CADHERIN; DNA METHYLATION; EPIGENETIC INACTIVATION;
   PROGNOSTIC-SIGNIFICANCE; CUTANEOUS MELANOMA; RETINOIC ACID; TUMOR SIZE;
   CARCINOMA; SURVIVAL
AB Purpose: Gene promoter region hypermethylation is a significant event in primary breast cancer. However, its impact on tumor progression and potential predictive implications remain relatively unknown.
   Experimental Design: We conducted hypermethylation profiling of 151 primary breast tumors with association to known prognostic factors in breast cancer using methylation-specific PCR for six known tumor suppressor and related genes: RASSF1A, APC, TWIST, CDH1, GSTP1, and RAR-beta 2. Furthermore, correlation with sentinel lymph node (SLN) tumor status was assessed as it represents the earliest stage of metastasis that is readily detected. Hypermethylation for any one gene was identified in 147 (97%) of 151 primary breast tumors. The most frequently hypermethylated gene was RASSF1A (81%).
   Results: Hypermethylation of the CDH1 was significantly associated with primary breast tumors demonstrating lymphovascular invasion (P = 0.008), infiltrating ductal histology (P = 0.03), and negative for the estrogen receptor (P = 0.005), whereas RASSF1A and RAR-beta 2 gene hypermethylation were significantly more common in estrogen receptor-positive (P < 0.001) and human epidermal growth factor receptor 2-positive (P < 0.001) tumors, respectively. In multivariate analysis, hypermethylation of GSTP1 and/or RAR-beta 2 was significantly associated with patients having macroscopic SLN metastasis compared with those with microscopic or no sentinel node metastasis (odds ratio, 4.59; 95% confidence interval, 2.02-10.4; P < 0.001). In paired SLN metastasis, CDH1 was the most frequently methylated gene (90%) and provides evidence in patients corroborating its role in the clinical development of metastasis.
   Conclusion: Hypermethylation profiling of primary breast tumors is significantly associated with known pathologic prognostic factors and may have additional clinical and pathologic utility for assessing patient prognosis and predicting early regional metastasis.
C1 John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   John Wayne Canc Inst, Joyce Eisenberg Keefer Breast Ctr, Div Biostat, Santa Monica, CA 90404 USA.
   John Wayne Canc Inst, Joyce Eisenberg Keefer Breast Ctr, Dept Surg Pathol, Santa Monica, CA 90404 USA.
   St Johns Hlth Ctr, Santa Monica, CA USA.
C3 John Wayne Cancer Institute; John Wayne Cancer Institute; John Wayne
   Cancer Institute
RP John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI Hoon, Dave/C-7146-2018
OI Hoon, Dave/0000-0003-1915-3683
CR Acs G, 2001, AM J CLIN PATHOL, V115, P85
   [Anonymous], 2002, AJCC cancer staging manual, P223, DOI DOI 10.1007/978-1-4757-3656-4
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801
   CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
   Cote RJ, 1999, LANCET, V354, P896, DOI 10.1016/S0140-6736(98)11104-2
   Dowlatshahi K, 1997, CANCER, V80, P1188, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H
   Dragnev KH, 2003, CANCER BIOL THER, V2, pS150
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Esteller M, 2001, CANCER RES, V61, P3225
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   FRAKER LD, 1984, CANCER RES, V44, P5757
   Gottardis MM, 1996, BREAST CANCER RES TR, V38, P85, DOI 10.1007/BF01803787
   HANSEN NM, 2001, CLIN SIGNIFICANCE AX, pA24
   Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016
   Henderson CJ, 1998, CHEM-BIOL INTERACT, V112, P69, DOI 10.1016/S0009-2797(97)00176-2
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Jatoi I, 1999, J CLIN ONCOL, V17, P2334, DOI 10.1200/JCO.1999.17.8.2334
   Key TJ, 2003, BREAST, V12, P412, DOI 10.1016/S0960-9776(03)00145-0
   Kuerer HM, 1998, AM J SURG, V176, P502, DOI 10.1016/S0002-9610(98)00253-0
   LACROIX A, 1980, J CLIN INVEST, V65, P586, DOI 10.1172/JCI109703
   Martinet N, 2000, CANCER RES, V60, P2869
   Mbalaviele G, 1996, CANCER RES, V56, P4063
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   NASSER IA, 1993, HUM PATHOL, V24, P950, DOI 10.1016/0046-8177(93)90108-S
   Nelson WG, 2002, CANCER METAST REV, V21, P3, DOI 10.1023/A:1020110718701
   ROSEN PP, 1981, ANN SURG, V194, P585, DOI 10.1097/00000658-198111000-00006
   Singletary SE, 2002, CLIN CANCER RES, V8, P2835
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Stathopoulou A, 2002, J CLIN ONCOL, V20, P3404, DOI 10.1200/JCO.2002.08.135
   Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5
   Taback B, 2001, CANCER RES, V61, P8845
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yoshida R, 2001, INT J ONCOL, V18, P513
NR 36
TC 128
Z9 146
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2005
VL 11
IS 6
BP 2156
EP 2162
DI 10.1158/1078-0432.CCR-04-1810
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 908EK
UT WOS:000227770000008
PM 15788661
DA 2025-01-12
ER

PT J
AU Fazi, F
   Travaglini, L
   Carotti, D
   Palitti, F
   Diverio, D
   Alcalay, M
   McNamara, S
   Miller, WH
   Lo Coco, F
   Pelicci, PG
   Nervi, C
AF Fazi, F
   Travaglini, L
   Carotti, D
   Palitti, F
   Diverio, D
   Alcalay, M
   McNamara, S
   Miller, WH
   Lo Coco, F
   Pelicci, PG
   Nervi, C
TI Retinoic acid targets DNA-methyltransferases and histone deacetylases
   during APL blast differentiation <i>in vitro</i> and <i>in vivo</i>
SO ONCOGENE
LA English
DT Article
DE acute promyelocytic leukemia; retinoic acid; DNA methylation; histone
   deacetylases; differentiation therapy
ID ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; RECEPTOR-BETA GENE;
   PML/RAR-ALPHA; BREAST-CANCER; MYELOID-LEUKEMIA; RESIDUAL DISEASE;
   METHYLATION; TRANSCRIPTION; CELLS
AB The acute promyelocytic leukemia (PML)-retinoic acid receptor alpha (RAR alpha) fusion product recruits histone deacetylase ( HDAC) and DNA methyltransferase (DNMT) activities on retinoic acid (RA)-target promoters causing their silencing and differentiation block. RA treatment induces epigenetic modi. cations at its target loci and restores myeloid differentiation of APL blasts. Using RA-sensitive and RA-resistant APL cell lines and primary blasts, we addressed the functional relevance of the aberrant methylation status at the RA-target promoter RAR beta 2 and the mechanism by which methylation is reversed by RA. RA decreased DNMT expression and activity, which correlated with demethylation at specific sites on RAR beta 2 promoter/exon-1, and the ability of APL blasts to differentiate in vitro and in vivo. None of these events occurred in an RA-resistant APL cell line containing a PML-RAR alpha defective for ligand binding. The specific contribution of the HDAC and DNMT pathways to the response of APL cells to RA was also tested by inhibiting these enzymatic activities with TSA and/or 5-azacytidine. In RA-responsive and RA-resistant APL blasts, TSA and 5-azacytidine induced specific changes on the chromatin state at RA-target sites, increased the RA effect on promoter activity, endogenous RA-target gene expression and differentiation. These results extend the rationale for chromatin-targeted treatment in APL and RA-resistant leukemias.
C1 Univ Roma La Sapienza, San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy.
   Univ Roma La Sapienza, Dept Histol, I-00128 Rome, Italy.
   Univ Roma La Sapienza, Dept Med Embryol, I-00128 Rome, Italy.
   Univ Roma La Sapienza, Dept Biochem Sci, I-00128 Rome, Italy.
   Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00128 Rome, Italy.
   European Inst Oncol, Milan, Italy.
   IFOM, FIRC, Milan, Italy.
   Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   McGill Univ, Dept Oncol & Med, Montreal, PQ, Canada.
   Univ Roma Tor Vergata, Dept Biopathol, I-00173 Rome, Italy.
C3 Sapienza University Rome; Sapienza University Rome; Sapienza University
   Rome; Sapienza University Rome; Sapienza University Rome; IRCCS European
   Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular
   Oncology; Lady Davis Institute; McGill University; McGill University;
   University of Rome Tor Vergata
RP Nervi, C (通讯作者)，Univ Roma La Sapienza, San Raffaele Biomed Sci Pk Rome, Via Castel Romano 100, I-00128 Rome, Italy.
EM clara.nervi@uniroma1.it
RI Pelicci, Pier/AAL-6572-2020; Travaglini, Lorena/AAA-6245-2020; Alcalay,
   Myriam/B-3182-2016; FAZI, Francesco/K-5304-2018
OI Travaglini, Lorena/0000-0003-0142-6516; CAROTTI,
   Daniela/0000-0001-6273-9749; Alcalay, Myriam/0000-0002-5558-4272; NERVI,
   Clara/0000-0001-9341-0188; PELICCI, PIER GIUSEPPE/0000-0002-5076-2316;
   FAZI, Francesco/0000-0003-2910-7912
CR APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129
   Benedetti L, 1996, BLOOD, V87, P1939
   Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533
   Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7
   Cacciamani T, 2002, GENE, V297, P103, DOI 10.1016/S0378-1119(02)00874-0
   Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CAROTTI D, 1989, NUCLEIC ACIDS RES, V17, P9219, DOI 10.1093/nar/17.22.9219
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547
   COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154
   Cote S, 1998, ANTI-CANCER DRUG, V9, P743
   Côté S, 2002, BLOOD, V100, P2586, DOI 10.1182/blood-2002-02-0614
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481
   Ferrara FF, 2001, CANCER RES, V61, P2
   Glass CK, 2000, GENE DEV, V14, P121
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901
   Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642
   Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x
   He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126
   He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9
   LANOTTE M, 1991, BLOOD, V77, P1080
   Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895
   Lo Coco F, 2002, CANCER RES, V62, P5618
   Lo Coco F, 1999, BLOOD, V94, P12, DOI 10.1182/blood.V94.1.12.413a44_12_22
   LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P
   Mandelli F, 1997, BLOOD, V90, P1014
   MARTIN B, 1992, SKIN PHARMACOL, V5, P57
   Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932
   Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215
   MILLER WH, 1993, BLOOD, V82, P1689
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   MUINDI J, 1992, BLOOD, V79, P299
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nervi C, 1998, BLOOD, V92, P2244
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759
   Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
NR 58
TC 79
Z9 91
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAR 10
PY 2005
VL 24
IS 11
BP 1820
EP 1830
DI 10.1038/sj.onc.1208286
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 905BH
UT WOS:000227542000002
PM 15688037
DA 2025-01-12
ER

PT J
AU Updike, MS
   Davis, ME
   Wang, LS
   Huang, YW
   Wick, M
   Lin, YC
AF Updike, MS
   Davis, ME
   Wang, LS
   Huang, YW
   Wick, M
   Lin, YC
TI Decreased MCF-7 breast cancer cell proliferation by serum from a
   selected line of beef cattle
SO ANTICANCER RESEARCH
LA English
DT Article
DE breast cancer; IGF-I; cattle
ID GROWTH-FACTOR-I; PRO-IGF-I; E-PEPTIDES; TUMOR-CELLS; RECEPTOR;
   TUMORIGENESIS; FIBROBLASTS; EPIGENETICS; PERFORMANCE; SOMATOMEDIN
AB One way to combat or treat breast cancer, the most common cancer among women, is to decrease or prevent proliferation of cancerous cells. Many animal species of agricultural importance have been selected for various growth traits, typically through altered proliferative capacity of some cell types. Previous studies in two lines of cattle divergently selected for serum IGF-I concentration have shown that low IGF-I cattle had increased growth rates and high IGF-I cattle had decreased growth rates. Serum from either the high or low IGF-I lines of cattle were administered to MCF-7 breast cancer cell lines and doubling times were determined. The MCF-7 cells treated with serum from cattle with high serum IGF-I concentrations took 26% longer to double than MCF-7 cells treated with serum from cattle with low serum IGF-I concentrations. In conclusion, model systems employing agricultural animals may provide novel insight into mechanisms of cell proliferation.
C1 Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Anim Sci, OSU Comprehens Canc Ctr, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University System of Ohio; Ohio State
   University
RP Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, Columbus, OH 43210 USA.
EM lin.15@osu.edu
RI Davis, Michael/K-6300-2012; Wick, Macdonald/D-3913-2009
OI Wick, Macdonald/0000-0003-1741-5635; Davis, Mike/0000-0001-7666-4856
FU NCI NIH HHS [CA94718, CA95915] Funding Source: Medline
CR ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315
   BASERGA R, 1995, CANCER RES, V55, P249
   Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BISHOP MD, 1989, J ANIM SCI, V67, P2872, DOI 10.2527/jas1989.67112872x
   Chen DM, 2004, CHINESE J ASTRON AST, V4, P118, DOI 10.1088/1009-9271/4/2/118
   Chen MJ, 2002, GEN COMP ENDOCR, V126, P342, DOI 10.1016/S0016-6480(02)00010-2
   DAVIS ME, 1995, J ANIM SCI, V73, P1927
   Davis ME, 2000, J ANIM SCI, V78, P2305
   Davis ME, 1997, J ANIM SCI, V75, P317
   Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979
   Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133
   Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1
   Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824
   Huynh H, 1996, CANCER RES, V56, P3651
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Johnston D. J., 2001, Proceedings of the Fourteenth Conference of the Association for the Advancement of Animal Breeding and Genetics, Queenstown, New Zealand, 30 July-2 August 2001, P163
   Jones PA, 1996, CANCER RES, V56, P2463
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KAREY KP, 1988, CANCER RES, V48, P4083
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kuo YH, 2003, GEN COMP ENDOCR, V132, P231, DOI 10.1016/S0016-6480(03)00089-3
   Kuo YH, 2002, EXP CELL RES, V280, P75, DOI 10.1006/excr.2002.5628
   Lee AV, 1998, BREAST CANCER RES TR, V47, P295, DOI 10.1023/A:1005915420341
   Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3
   LUNDLARSEN TR, 1977, J ANIM SCI, V44, P189, DOI 10.2527/jas1977.442189x
   Pagan M, 2003, DOMEST ANIM ENDOCRIN, V25, P345, DOI 10.1016/j.domaniend.2003.06.002
   Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075
   Tian XC, 1999, ENDOCRINOLOGY, V140, P3387, DOI 10.1210/en.140.7.3387
   YEE D, 1994, BREAST CANCER RES TR, V32, P85, DOI 10.1007/BF00666209
NR 30
TC 1
Z9 1
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD MAR-APR
PY 2005
VL 25
IS 2A
BP 871
EP 874
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 919BT
UT WOS:000228594000025
PM 15868921
DA 2025-01-12
ER

PT J
AU Mhawech, P
   Benz, A
   Cerato, C
   Greloz, V
   Assaly, M
   Desmond, JC
   Koeffler, HP
   Lodygin, D
   Hermeking, H
   Herrmann, F
   Schwaller, J
AF Mhawech, P
   Benz, A
   Cerato, C
   Greloz, V
   Assaly, M
   Desmond, JC
   Koeffler, HP
   Lodygin, D
   Hermeking, H
   Herrmann, F
   Schwaller, J
TI Downregulation of 14-3-3σ in ovary, prostate and endometrial carcinomas
   is associated with CpG island methylation
SO MODERN PATHOLOGY
LA English
DT Article
DE urological and gynecological carcinomas; 14-3-3 sigma expression; CpG
   methylation
ID TUMOR-SUPPRESSOR GENE; MULTIPLE GENES; TISSUE MICROARRAYS; DNA
   METHYLATION; BREAST-CANCER; LUNG CANCERS; EARLY EVENT; SIGMA GENE;
   HYPERMETHYLATION; EXPRESSION
AB The 14-3-3sigma inhibitor of cell cycle progression has been shown to be target of epigenetic deregulation in many forms of human cancers; however, its role in urological and gynecological cancers has not been studied. Here, we have analyzed the expression of 14- 3- 3sigma, wild- type p53 and mutated p53 in over 300 cases of the most common cancers occurring in the urological and gynecological tracts and its normal counterpart tissue by immunohistochemistry using the multiple tumor tissue microarrays. 14- 3- 3sigma expression was detected in normal epithelia from most organs with sporadic expression in renal tubules and absence in the testis. In contrast to normal tissue, 14- 3- 3sigma expression was lost in 40 - 60% of adenocarcinomas of the breast, ovary, endometrium and prostate. There was no association between 14- 3- 3sigma and wild- type/ mutated p53 expression. By performing methylation- specific PCR, we showed a close association of 14- 3- 3sigma CpG island methylation and low protein expression levels of 14- 3- 3sigma. In addition, a direct link of 14- 3- 3sigma mRNA expression levels to CpG island methylation is demonstrated in two human cancer cell lines. Loss of 14- 3- 3sigma expression due to promoter hypermethylation may represent the most frequent molecular aberration in ovarian, endometrial and prostate adenocarcinomas.
C1 Univ Hosp Geneva, CMU, Div Clin Pathol, Dept Clin Pathol, CH-1211 Geneva 4, Switzerland.
   Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.
   Max Planck Inst Biochem, Div Mol Oncol, D-82152 Martinsried, Germany.
C3 University of Geneva; University of California System; University of
   California Los Angeles; Cedars Sinai Medical Center; Max Planck Society
RP Mhawech, P (通讯作者)，Univ Hosp Geneva, CMU, Div Clin Pathol, Dept Clin Pathol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.
EM pmhawech1@yahoo.com
RI HERRMANN, Francois/B-6710-2011; Schwaller, Juerg/A-3044-2016
OI Herrmann, Francois/0000-0003-1312-1517; Hermeking,
   Heiko/0000-0001-6586-4406
CR Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652
   De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Gasco M, 2002, CANCER RES, V62, P2072
   Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256
   Hengstschläger M, 2003, BIOCHEM BIOPH RES CO, V312, P676, DOI 10.1016/j.bbrc.2003.10.170
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854
   Logsdon CD, 2003, CANCER RES, V63, P2649
   Nakajima T, 2003, PATHOL INT, V53, P353, DOI 10.1046/j.1440-1827.2003.01481.x
   Navari JR, 2000, CLIN CANCER RES, V6, P4026
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098
   Sato N, 2003, CANCER RES, V63, P4158
   Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G
   Spandidos DA, 2000, ANN NY ACAD SCI, V900, P56, DOI 10.1111/j.1749-6632.2000.tb06216.x
   Suzuki H, 2000, CANCER RES, V60, P4353
   Swierczynski SL, 2004, HUM PATHOL, V35, P357, DOI 10.1016/j.humpath.2003.10.012
   Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826
   Visakorpi T, 2003, UROLOGY, V62, P3, DOI 10.1016/S0090-4295(03)00776-3
   Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003
   Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284
   Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4
   Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003
   Yatabe Y, 2002, ONCOGENE, V21, P8310, DOI 10.1038/sj.onc.1206014
NR 36
TC 75
Z9 81
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD MAR
PY 2005
VL 18
IS 3
BP 340
EP 348
DI 10.1038/modpathol.3800240
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 899TN
UT WOS:000227168100005
PM 15257317
OA Bronze
DA 2025-01-12
ER

PT J
AU Mongan, NP
   Gudas, LJ
AF Mongan, NP
   Gudas, LJ
TI Valproic acid, in combination with all-<i>trans</i> retinoic acid and
   5-aza-2′-deoxycytidine, restores expression of silenced
   <i>RAR</i>β<i>2</i> in breast cancer cells
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID HISTONE-DEACETYLASE INHIBITORS; ACUTE PROMYELOCYTIC LEUKEMIA;
   RECEPTOR-BETA GENE; TUMOR-SUPPRESSOR GENE; INDUCED GROWTH ARREST;
   C-ALPHA EXPRESSION; DNA METHYLTRANSFERASE; HDAC INHIBITORS; IN-VITRO;
   APOPTOSIS
AB Epigenetic silencing of tumor suppressor genes has been established as an important process of carcinogenesis. The retinoic acid (RA) receptor 2 (RAR beta 2) gene is one such tumor suppressor gene often silenced during carcinogenesis. The combined use of histone deacetylase and DNA methyltransferase inhibitors has been shown to reverse the epigenetic silencing of numerous growth regulatory genes. Valproic acid (VPA), which has long been used in the treatment of epilepsy, was shown recently to be an effective histone deacetylase inhibitor that can induce differentiation of neoplastically transformed cells. In this study, we show for the first time that VPA, in combination with RA and the DNA methyltransferase inhibitor 5-aza-2 ' deoxycytidine (Aza-dC), can overcome the epigenetic barriers to transcription of a prototypical silenced tumor suppressor gene, RAR beta 2, in human breast cancer cells. Chromatin immunoprecipitation assays show that the combination of VPA, RA, and Aza-dC increases histone acetylation at the silenced RAR beta 2 promoter of MCF-7 breast cancer cells. Furthermore, reverse transcription-PCR analyses reveal cell type-specific effects in the actions of VPA on RAR beta 2 expression in cultured human breast cancer cells. Finally, we show that VPA, in combination with RA and Aza-dC, inhibits the proliferation of both estrogen receptor alpha-positive (MCF-7) and estrogen receptor alpha-negative (MDA-MB-231) breast cancer cell lines. These data suggest that VPA may ultimately be useful in combination therapies in the treatment of human breast cancers.
C1 Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA.
C3 Cornell University; Weill Cornell Medicine
RP Cornell Univ, Weill Med Coll, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.
EM ljgudas@med.cornell.edu
RI Mongan, Nigel/B-7410-2011
OI Mongan, Nigel/0000-0001-5438-1126
FU NCI NIH HHS [R01CA77509] Funding Source: Medline; NIDCR NIH HHS
   [R01DE10389] Funding Source: Medline
CR Andreola F, 2000, BIOCHEM BIOPH RES CO, V279, P920, DOI 10.1006/bbrc.2000.3995
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Bacon CL, 2002, J NEUROCHEM, V83, P12, DOI 10.1046/j.1471-4159.2002.01081.x
   Besag FMC, 2001, THER DRUG MONIT, V23, P694, DOI 10.1097/00007691-200112000-00017
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen CF, 2004, ONCOGENE, V23, P5350, DOI 10.1038/sj.onc.1207682
   Cho YH, 2001, EXP CELL RES, V269, P97, DOI 10.1006/excr.2001.5298
   Cho YH, 1997, J CELL PHYSIOL, V172, P306, DOI 10.1002/(SICI)1097-4652(199709)172:3<306::AID-JCP4>3.0.CO;2-S
   Cinatl J, 1997, ANTI-CANCER DRUG, V8, P958, DOI 10.1097/00001813-199711000-00007
   Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Dietze EC, 2002, MICROSC RES TECHNIQ, V59, P23, DOI 10.1002/jemt.10174
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   El Desoky ES, 2004, EUR J CLIN PHARMACOL, V59, P783, DOI 10.1007/s00228-003-0699-7
   Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783
   Farias EF, 2002, CELL GROWTH DIFFER, V13, P335
   Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925
   Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799
   Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   KIRN MS, 2001, NAT MED, V7, P437
   Kuendgen A, 2004, BLOOD, V104, P1266, DOI 10.1182/blood-2003-12-4333
   Li R, 2004, EXP CELL RES, V294, P290, DOI 10.1016/j.yexcr.2003.11.014
   Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000
   Lin F, 2000, CANCER RES, V60, P3271
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520
   MISTSIADES CS, 2004, P NATL ACAD SCI USA, V101, P540
   Munster PN, 2001, CANCER RES, V61, P8492
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020
   Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004
   Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Stewart DJ, 2003, ANN ONCOL, V14, P766, DOI 10.1093/annonc/mdg216
   Suh YA, 2002, CANCER RES, V62, P3945
   Suzui M, 2004, MOL CANCER THER, V3, P309
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Tang R, 2004, LEUKEMIA, V18, P1246, DOI 10.1038/sj.leu.2403390
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   Tighe AP, 2004, EXP CELL RES, V301, P147, DOI 10.1016/j.yexcr.2004.07.008
   Toma S, 2000, INT J ONCOL, V17, P991
   VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621
   WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002
   Xu XC, 1997, CANCER RES, V57, P4992
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X
NR 68
TC 64
Z9 75
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAR
PY 2005
VL 4
IS 3
BP 477
EP 486
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 905SI
UT WOS:000227589600015
PM 15767557
DA 2025-01-12
ER

PT J
AU Cocchi, L
   Scarcelli, V
   Puliti, A
   Barale, R
   Sbrana, I
AF Cocchi, L
   Scarcelli, V
   Puliti, A
   Barale, R
   Sbrana, I
TI Endogenous sex hormones affect the mutagen-induced chromosome damage by
   altering a caffeine-sensitive checkpoint
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE endogenous hormones; menstrual cycle; mitomycin C; caffeine; sister
   chromatid exchanges (SCE)
ID SISTER-CHROMATID EXCHANGE; BREAST-CANCER RISK; MITOMYCIN-C;
   HUMAN-LYMPHOCYTES; DNA-DAMAGE; CELL-PROLIFERATION; ABERRATIONS;
   ESTRADIOL; MICRONUCLEI; WOMEN
AB In the present study we analysed the effect of endogenous sex hormones on the SCE frequencies induced in vitro by mitomycin C (MMC), a bifunctional alkylating agent producing high chromosome damage and mitotic arrest. The analysis has been performed on lymphocytes obtained at three different phases of menstrual cycle, from women with regular cycle and hormones dosage. At ail phases we further analysed the effect of a post-treatment with caffeine, an agent that it is known to overrride the DNA damage checkpoints.
   After MMC, the cultures obtained at ovulation and luteal phases have SCE frequencies statistically higher than the cultures obtained at the progestogenic phase, showing increases of 15 and 25%, respectively. After caffeine, the MMC treated cultures which were set up at the progestogenic phase show a high potentiation of SCE frequencies (28%) whereas the treated cultures set up at ovulatory and luteal phases show little or no potentiation.
   These findings demonstrate that the endogenous hormones greatly modulate the SCE frequencies induced by the mutagen; they also indicate that hormones action competes with the caffeine effect. Caffeine acts by abrogating the mitotic arrest produced by DNA damage and induced cells with a higher chromosome damage into a premature mitosis. Our findings suggest that endogenous hormones could overcome the checkpoint controls activated in cells after mutagenic exposure. This action may be an epigenetic mechanism relevant in hormone carcinogenesis. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Pisa, Dept Human & Environm Sci, I-56126 Pisa, Italy.
C3 University of Pisa
RP Univ Pisa, Dept Human & Environm Sci, Vian San Guiseppe 22, I-56126 Pisa, Italy.
EM i.sbrana@geog.unipi.it
RI ; PULITI, Aldamaria/K-7866-2016
OI BARALE, Roberto/0000-0003-4161-2241; PULITI,
   Aldamaria/0000-0001-9310-6514
CR Ahmad ME, 2000, MUTAT RES-GEN TOX EN, V466, P109, DOI 10.1016/S1383-5718(99)00230-2
   Beiler JSB, 2003, J NATL MED ASSOC, V95, P930
   Biri A, 2002, MUTAT RES-GEN TOX EN, V521, P113, DOI 10.1016/S1383-5718(02)00217-6
   Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2
   Butler LM, 2000, CANCER CAUSE CONTROL, V11, P451, DOI 10.1023/A:1008956524669
   Carrano AV., 1982, Mutagenicity, new horizons in genetic toxicology, P267
   Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75
   CECCHERINI I, 1988, MUTAGENESIS, V3, P39, DOI 10.1093/mutage/3.1.39
   CECCHERINI I, 1988, MUTAT RES, V208, P183, DOI 10.1016/0165-7992(88)90058-9
   Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243
   Djelic N, 2002, ARCH MED RES, V33, P148, DOI 10.1016/S0188-4409(01)00355-1
   Fischer WH, 2001, MUTAGENESIS, V16, P209, DOI 10.1093/mutage/16.3.209
   Franchitto A, 1998, MUTAGENESIS, V13, P499, DOI 10.1093/mutage/13.5.499
   Hochegger H, 2004, BIOESSAYS, V26, P151, DOI 10.1002/bies.10403
   JOSEPHLERNER N, 1993, MUTAT RES, V300, P247, DOI 10.1016/0165-1218(93)90057-K
   Kaina B, 2004, CYTOGENET GENOME RES, V104, P77, DOI 10.1159/000077469
   Kayikçioglu F, 2000, MUTAT RES-FUND MOL M, V452, P37, DOI 10.1016/S0027-5107(00)00033-6
   Landi S, 1999, MUTAGENESIS, V14, P581, DOI 10.1093/mutage/14.6.581
   Li J J, 1996, Prog Clin Biol Res, V394, P447
   Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40
   Liehr JG, 1997, EUR J CANCER PREV, V6, P3, DOI 10.1097/00008469-199702000-00002
   Lobenhofer EK, 2002, MOL ENDOCRINOL, V16, P1215, DOI 10.1210/me.16.6.1215
   McMurray RW, 2001, PATHOBIOLOGY, V69, P44, DOI 10.1159/000048757
   Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5
   MORALESRAMIREZ P, 1995, SOMAT CELL MOLEC GEN, V21, P33, DOI 10.1007/BF02255820
   PRESTONMARTIN S, 1990, CANCER RES, V50, P7415
   Sarkaria JN, 1999, CANCER RES, V59, P4375
   SBRANA I, 1988, MUTAT RES, V203, P222, DOI 10.1016/0165-1161(88)90150-1
   Stopper H, 2003, MUTAGENESIS, V18, P243, DOI 10.1093/mutage/18.3.243
   Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7
   Terzoudi GI, 2003, MUTAGENESIS, V18, P539, DOI 10.1093/mutage/geg034
   Travis RC, 2003, BREAST CANCER RES, V5, P239, DOI 10.1186/bcr628
   TUCKER JD, 1987, ENVIRON MOL MUTAGEN, V10, P69, DOI 10.1002/em.2850100108
   Yue W, 2003, J STEROID BIOCHEM, V86, P477, DOI 10.1016/S0960-0760(03)00377-7
   Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342
NR 35
TC 2
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD MAR 1
PY 2005
VL 570
IS 2
BP 281
EP 288
DI 10.1016/j.mrfmmm.2004.12.003
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 902TF
UT WOS:000227378700013
PM 15708586
DA 2025-01-12
ER

PT J
AU Iliopoulos, D
   Guler, G
   Han, SY
   Johnston, D
   Druck, T
   McCorkell, KA
   Palazzo, J
   McCue, P
   Baffa, R
   Huebner, K
AF Iliopoulos, D
   Guler, G
   Han, SY
   Johnston, D
   Druck, T
   McCorkell, KA
   Palazzo, J
   McCue, P
   Baffa, R
   Huebner, K
TI Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in
   lung, breast and bladder cancer
SO ONCOGENE
LA English
DT Article
DE CpG island methylation; WWOX; FHIT; methylation patterns; molecular
   markers
ID TUMOR-SUPPRESSOR GENE; ABERRANT PROMOTER METHYLATION; DNA METHYLATION;
   EXPRESSION; HYPERMETHYLATION; INACTIVATION; CARCINOMA; PROTEIN; SERUM;
   FRA16D
AB This study aimed to (a) determine if DNA methylation is a mechanism of WWOX (WW domain containing oxidoreductase) and FHIT ( fragile histidine triad) inactivation in lung, breast and bladder cancers; (b) examine distinct methylation patterns in neoplastic and adjacent tissues and (c) seek correlation of methylation patterns with disease status. Protein expression was detected by immunohistochemistry, and methylation status by methylation-specific PCR (MSP) and sequencing, in lung squamous cell carcinomas and adjacent tissues, invasive breast carcinomas, adjacent tissues and normal mammary tissues and bladder transitional cell carcinomas. Wwox and Fhit expression was reduced in cancers in association with hypermethylation. Differential patterns of WWOX and FHIT methylation were observed in neoplastic vs adjacent non-neoplastic tissues, suggesting that targeted MSP amplification could be useful in following treatment or prevention protocols. WWOX promoter MSP differentiates DNA of lung cancer from DNA of adjacent lung tissue. WWOX and FHIT promoter methylation is detected in tissue adjacent to breast cancer and WWOX exon 1 MSP distinguishes breast cancer DNA from DNA of adjacent and normal tissue. Differential methylation in cancerous vs adjacent tissues suggests that WWOX and FHIT hypermethylation analyses could enrich a panel of DNA methylation markers.
C1 Dept Microbiol Immunol, Philadelphia, PA 19107 USA.
   Dept Pathol, Philadelphia, PA 19107 USA.
   Kimmel Canc Ctr, Dept Urol, Philadelphia, PA 19107 USA.
C3 Thomas Jefferson University
RP Ohio State Univ, Ctr Comprehens Canc, Wiseman Hall,Rm 455C,410 W 12th Ave, Columbus, OH 43210 USA.
EM K_Huebner@mail.jci.tju.edu
RI GULER, GULNUR/I-9887-2013; Iliopoulos, Dimitrios/AAE-9106-2019
OI Makowski, Danika/0009-0003-1500-0097
FU NCI NIH HHS [CA56036, CA77738, N01-CN-15113, N01-CN-15128] Funding
   Source: Medline; NHLBI NIH HHS [T32-HLO7780] Funding Source: Medline
CR Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1
   Bednarek AK, 2000, CANCER RES, V60, P2140
   Bednarek AK, 2001, CANCER RES, V61, P8068
   Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 1999, CANCER RES, V59, P793
   Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.0.CO;2-I
   Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137
   Hennessy BT, 2003, EXPERT OPIN INV DRUG, V12, P1985, DOI 10.1517/13543784.12.12.1985
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937
   Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7
   Ingvarsson S, 1999, CANCER RES, V59, P2682
   Ishii H, 2004, INT J HEMATOL, V79, P238, DOI 10.1532/IJH97.03145
   Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077
   Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096
   Kuroki T, 2002, CANCER RES, V62, P2258
   Maruyama R, 2001, CANCER RES, V61, P8659
   McGregor F, 2002, CANCER RES, V62, P4757
   Müller HM, 2003, CANCER RES, V63, P7641
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Skopelitou AS, 2001, IN VIVO, V15, P169
   SORIA JC, 2000, CANCER RES, V62, P351
   Sozzi G, 1998, CANCER RES, V58, P5032
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Tanaka H, 1998, CANCER RES, V58, P3429
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Yendamuri S, 2003, CANCER RES, V63, P878
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 33
TC 163
Z9 201
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD FEB 24
PY 2005
VL 24
IS 9
BP 1625
EP 1633
DI 10.1038/sj.onc.1208398
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 900ME
UT WOS:000227218200016
PM 15674328
DA 2025-01-12
ER

PT J
AU Kuzmichev, A
   Margueron, R
   Vaquero, A
   Preissner, TS
   Scher, M
   Kirmizis, A
   Ougang, XS
   Brockdorff, N
   Abate-Shen, C
   Farnham, P
   Reinberg, D
AF Kuzmichev, A
   Margueron, R
   Vaquero, A
   Preissner, TS
   Scher, M
   Kirmizis, A
   Ougang, XS
   Brockdorff, N
   Abate-Shen, C
   Farnham, P
   Reinberg, D
TI Composition and histone substrates of polycomb repressive group
   complexes change during cellular differentiation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE methylation; prostate cancer; Ezh2; histone H1
ID METHYLTRANSFERASE ACTIVITY; PROSTATE CARCINOGENESIS; H3
   METHYLTRANSFERASE; LYSINE METHYLATION; BREAST-CANCER; EZH2;
   HETEROCHROMATIN; ENHANCER; PROTEIN; TARGET
AB Changes in the substrate specificities of factors that irreversibly modify the histone components of chromatin are expected to have a profound effect on gene expression through epigenetics. Ezh2 is a histone-lysine methyltransferase with activity dependent on its association with other components of the Polycomb Repressive Complexes 2 and 3 (PRC2/3). Ezh2 levels are increasingly elevated during prostate cancer progression. Other PRC2/3 components also are elevated in cancer cells. Overexpression of Ezh2 in tissue culture promotes formation of a previously undescribed PRC complex, PRC4, that contains the NAD(+)-dependent histone deacetylase SirT1 and isoform 2 of the PRC component Eed. Eed2 is expressed in cancer and undifferentiated embryonic stem (ES) cells but is undetectable in normal and differentiated ES cells. The distinct PRC-s exhibit differential histone substrate specificities. These findings suggest that formation of a transformation-specific PRC complex may have a major role in resetting patterns of gene expression by regulating chromatin structure.
C1 Howard Hughes Med Inst, Div Nucle Acids Enzymol, Dept Biochem, Piscataway, NJ 08854 USA.
   Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Dept Med, Piscataway, NJ 08854 USA.
   Robert Wood Johnson Med Sch, Inst Canc, Piscataway, NJ 08854 USA.
   Hammersmith Hosp, Imperial Coll, X Inactivat Grp,Clin Sci Ctr,Sch Med, MRC, London W12 0NN, England.
   Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53705 USA.
C3 Howard Hughes Medical Institute; Rutgers University System; Rutgers
   University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers University System; Rutgers University New Brunswick;
   Rutgers University Biomedical & Health Sciences; Imperial College
   London; University of Wisconsin System; University of Wisconsin Madison
RP Howard Hughes Med Inst, Div Nucle Acids Enzymol, Dept Biochem, Piscataway, NJ 08854 USA.
EM reinbedf@umdnj.edu
RI Vaquero, Alejandro/ABG-8634-2020; Abate-Shen, Cory/O-2520-2014;
   Margueron, Raphael/B-9996-2015
OI Margueron, Raphael/0000-0002-9093-7977; Reinberg,
   Danny/0000-0003-4288-2016; Farnham, Peggy/0000-0003-4469-7914;
   Brockdorff, Neil/0000-0003-4838-2653; Kirmizis,
   Antonis/0000-0002-3748-8711
FU NCI NIH HHS [CA84294, CA45290, U01 CA084294] Funding Source: Medline;
   NIGMS NIH HHS [GM3712O] Funding Source: Medline
CR Abate-Shen C, 2003, CANCER RES, V63, P3886
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210
   Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634
   Furuyama T, 2004, CURR BIOL, V14, P1812, DOI 10.1016/j.cub.2004.09.060
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999
   Kim MJ, 2002, CANCER RES, V62, P2999
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6
   Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219
   Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202
   Rosenberg MI, 2002, CELL, V109, P447, DOI 10.1016/S0092-8674(02)00732-8
   Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Zhang TF, 2003, ANTICANCER RES, V23, P3735
NR 27
TC 347
Z9 428
U1 0
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 8
PY 2005
VL 102
IS 6
BP 1859
EP 1864
DI 10.1073/pnas.0409875102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 898JK
UT WOS:000227072900013
PM 15684044
OA Green Published
DA 2025-01-12
ER

PT J
AU Alvarez, S
   Diaz-Uriarte, R
   Osorio, A
   Barroso, A
   Melchor, L
   Paz, MF
   Honrado, E
   Rodríguez, R
   Urioste, M
   Valle, L
   Díez, O
   Cigudosa, JC
   Dopazo, J
   Esteller, M
   Benitez, J
AF Alvarez, S
   Diaz-Uriarte, R
   Osorio, A
   Barroso, A
   Melchor, L
   Paz, MF
   Honrado, E
   Rodríguez, R
   Urioste, M
   Valle, L
   Díez, O
   Cigudosa, JC
   Dopazo, J
   Esteller, M
   Benitez, J
TI A predictor based on the somatic genomic changes of the BRCA1/BRCA2
   breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1
   promoter hypermethylation
SO CLINICAL CANCER RESEARCH
LA English
DT Article
AB The genetic changes underlying in the development and progression of familial breast cancer are poorly understood. To identify a somatic genetic signature of tumor progression for each familial group, BRCA1, BRCA2, and non-BRCA1/BRCA2 (BRCAX) tumors, by high-resolution comparative genomic hybridization, we have analyzed 77 tumors previously characterized for BRCA1 and BRCA2 germ line mutations. Based on a combination of the somatic genetic changes observed at the six most different chromosomal regions and the status of the estrogen receptor, we developed using random forests a molecular classifier, which assigns to a given tumor a probability to belong either to the BRCA1 or to the BRCA2 class. Because 76.5% (26 of 34) of the BRCAX cases were classified with our predictor to the BRCA1 class with a probability of > 50%, we analyzed the BRCA1 promoter region for aberrant methylation in all the BRCAX cases. We found that 15 of the 34 BRCAX analyzed tumors had hypermethylation of the BRCA1 gene. When we considered the predictor, we observed that all the cases with this epigenetic event were assigned to the BRCA1 class with a probability of >50%. Interestingly, 84.6% of the cases (11 of 13) assigned to the BRCA1 class with a probability >80% had an aberrant methylation of the BRCA1 promoter. This fact suggests that somatic BRCA1 inactivation could modify the profile of tumor progression in most of the BRCAX cases.
C1 Spanish Natl Canc Ctr, Dept Human Genet, Mol Pathol Programme, Madrid 28029, Spain.
   Spanish Natl Canc Ctr, Canc Epigenet Grp, Mol Pathol Programme, Madrid 28029, Spain.
   Spanish Natl Canc Ctr, Bioinformat Unit, Madrid 28029, Spain.
   Spanish Natl Canc Ctr, Cytogenet Unit, Biotechnol Programme, Madrid 28029, Spain.
   H Santa Creu & Sant Pau, Dept Genet, Barcelona, Spain.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional
   de Investigaciones Oncologicas (CNIO); Centro Nacional de
   Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones
   Oncologicas (CNIO)
RP Spanish Natl Canc Ctr, Dept Human Genet, Mol Pathol Programme, N328029, Madrid 28029, Spain.
EM salvarez@cnio.es
RI Fuentes, Javier/AAG-3465-2021; Cigudosa, Juan/E-4105-2016; Diaz-Uriarte,
   Ramon/M-5517-2013; Osorio, Ana/I-4324-2014; Melchor,
   Lorenzo/H-7221-2015; Valle, Laura/H-8118-2012; Dopazo,
   Joaquin/A-9270-2014; Esteller, Manel/L-5956-2014
OI Diaz-Uriarte, Ramon/0000-0002-6637-9039; diez,
   orland/0000-0001-7339-0570; Osorio, Ana/0000-0001-8124-3984; Honrado
   Franco, Emiliano/0000-0001-5668-4083; Melchor,
   Lorenzo/0000-0002-5322-2817; Valle, Laura/0000-0003-0371-0844; Dopazo,
   Joaquin/0000-0003-3318-120X; Esteller, Manel/0000-0003-4490-6093
CR Alvarez S, 2001, GENE CHROMOSOME CANC, V32, P285, DOI 10.1002/gcc.1192
   Ambroise C, 2002, P NATL ACAD SCI USA, V99, P6562, DOI 10.1073/pnas.102102699
   Blewitt ME, 2008, NAT GENET, V40, P663, DOI 10.1038/ng.142
   *BREAST CANC LINK, 2000, ONCOGENE, V1936, P4170
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Campos B, 2001, ANN ONCOL, V12, P1699, DOI 10.1023/A:1013517313008
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   de la Hoya M, 2002, INT J CANCER, V97, P466, DOI 10.1002/ijc.1627
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576
   Grushko TA, 2004, CLIN CANCER RES, V10, P499, DOI 10.1158/1078-0432.CCR-0976-03
   Gunther EC, 2003, P NATL ACAD SCI USA, V100, P9608, DOI 10.1073/pnas.1632587100
   Harrell F. E., 2001, REGRESSION MODELING, DOI [10.1007/978-1-4757-3462-1, DOI 10.1007/978-1-4757-3462-1]
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100
   Herrero J, 2003, NUCLEIC ACIDS RES, V31, P3461, DOI 10.1093/nar/gkg591
   Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603
   Kirchhoff M, 2000, EUR J HUM GENET, V8, P661, DOI 10.1038/sj.ejhg.5200512
   Kirchhoff M, 1998, CYTOMETRY, V31, P163, DOI 10.1002/(SICI)1097-0320(19980301)31:3<163::AID-CYTO3>3.3.CO;2-1
   Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023
   Nathanson KL, 2001, HUM MOL GENET, V10, P715, DOI 10.1093/hmg/10.7.715
   Ness GO, 2002, AM J MED GENET, V113, P125, DOI 10.1002/ajmg.10593
   Osorio A, 2000, BRIT J CANCER, V82, P1266, DOI 10.1054/bjoc.1999.1089
   Palacios J, 2003, CLIN CANCER RES, V9, P3606
   Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881
   Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14
   Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5
   Tirkkonen M, 1997, CANCER RES, V57, P1222
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wessels LFA, 2002, CANCER RES, V62, P7110
   Zudaire I, 2002, HISTOPATHOLOGY, V40, P547, DOI 10.1046/j.1365-2559.2002.01413.x
NR 32
TC 59
Z9 67
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2005
VL 11
IS 3
BP 1146
EP 1153
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 893SV
UT WOS:000226740400024
PM 15709182
DA 2025-01-12
ER

PT J
AU Fujisawa, K
   Maesawa, C
   Sato, R
   Wada, K
   Ogasawara, S
   Akiyama, Y
   Takeda, M
   Fujita, T
   Otsuka, K
   Higuchi, T
   Suzuki, K
   Saito, K
   Masuda, T
AF Fujisawa, K
   Maesawa, C
   Sato, R
   Wada, K
   Ogasawara, S
   Akiyama, Y
   Takeda, M
   Fujita, T
   Otsuka, K
   Higuchi, T
   Suzuki, K
   Saito, K
   Masuda, T
TI Epigenetic status and aberrant expression of the <i>maspin</i> gene in
   human hepato-biliary tract carcinomas
SO LABORATORY INVESTIGATION
LA English
DT Article
DE histone acetylation; DNA methylation; tumor suppressor gene;
   hepato-biliary tract carcinoma; maspin
ID BREAST-CANCER; DNA METHYLATION; MUTANT P53; CELLS; PROMOTER; SERPIN
AB We examined expression of maspin and the epigenetic status of its gene in 40 primary hepato-biliary tract carcinomas and 11 cell lines originating from hepato-pancreatico- biliary tract carcinomas. Aberrant maspin expression was frequently observed immunohistochemically in biliary tract carcinomas (22/25, 88%) but not in hepatocellular carcinomas (HCCs) (0/15, 0%). Aberrant maspin expression by five pancreatico-biliary tract carcinoma cell lines was closely associated with demethylation at the maspin promoter. Five of six HCC cell lines were maspin-negative and exhibited extensive hypomethylation and hypoacetylation at the maspin promoter. Treatment with 5-aza-2'-deoxycytidine did not activate maspin expression in these five maspin-negative HCC cell lines, whereas treatment with Trichostatin A ( TSA) activated maspin expression in two of them. Treatment with TSA increased histone acetylation in some HCC cell lines. These results suggest that aberrant maspin expression in biliary tract carcinomas is closely associated with demethylation at the promoter region, but that some HCC cell lines additionally require histone acetylation. In addition, the fact that maspin-negative HCC cell lines remain after treatment with TSA suggests the existence of other repressive factors controlling maspin expression.
C1 Iwate Med Univ, Sch Med, Dept Pathol, Morioka, Iwate 0208505, Japan.
   Iwate Med Univ, Sch Med, Dept Surg 1, Morioka, Iwate 0208505, Japan.
   Iwate Med Univ, Sch Med, Dept Internal Med 1, Morioka, Iwate 0208505, Japan.
   Iwate Med Univ, Sch Med, Dept Dermatol, Morioka, Iwate 0208505, Japan.
C3 Iwate Medical University; Iwate Medical University; Iwate Medical
   University; Iwate Medical University
RP Iwate Med Univ, Sch Med, Dept Pathol, Morioka, Iwate 0208505, Japan.
EM chihaya@iwate-med.ac.jp
CR Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Dong M, 2003, J SURG ONCOL, V82, P111, DOI 10.1002/jso.10186
   Fitzgerald M, 2003, NEOPLASIA, V5, P427, DOI 10.1016/S1476-5586(03)80045-3
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Maass N, 2001, CLIN CANCER RES, V7, P812
   Maass N, 2001, J PATHOL, V195, P321
   Maass N, 2001, CLIN BIOCHEM, V34, P303, DOI 10.1016/S0009-9120(01)00220-X
   Machtens S, 2001, INT J CANCER, V95, P337, DOI 10.1002/1097-0215(20010920)95:5<337::AID-IJC1059>3.0.CO;2-1
   Odero-Marah VA, 2003, CANCER BIOL THER, V2, P398, DOI 10.4161/cbt.2.4.471
   Ogasawara S, 2004, ONCOGENE, V23, P1117, DOI 10.1038/sj.onc.1207211
   Ohike N, 2003, CANCER LETT, V199, P193, DOI 10.1016/S0304-3835(03)00390-2
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832
   RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315
   Rougeulle C, 2004, MOL CELL BIOL, V24, P5475, DOI 10.1128/MCB.24.12.5475-5484.2004
   Soejima H, 2004, ONCOGENE, V23, P4380, DOI 10.1038/sj.onc.1207576
   Song SY, 2002, DIGEST DIS SCI, V47, P1831, DOI 10.1023/A:1016409031562
   Sood AK, 2002, CLIN CANCER RES, V8, P2924
   Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500
   Wada K, 2004, J INVEST DERMATOL, V122, P805, DOI 10.1111/j.0022-202X.2004.22308.x
   Weihrauch M, 2000, CANCER-AM CANCER SOC, V88, P1030, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1030::AID-CNCR12>3.3.CO;2-W
   Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535
   Zhang WG, 2002, INT J ONCOL, V20, P1145
   Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 29
TC 30
Z9 35
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2005
VL 85
IS 2
BP 214
EP 224
DI 10.1038/labinvest.3700214
PG 11
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 893LG
UT WOS:000226719900008
PM 15608662
OA Bronze
DA 2025-01-12
ER

PT J
AU Zha, S
   Isaacs, WB
AF Zha, S
   Isaacs, WB
TI A nonclassic CCAAT enhancer element binding protein binding site
   contributes to α-methylacyl-CoA racemase expression in prostate cancer
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID CELL-CYCLE ARREST; REPLICATION-ASSOCIATED PROTEIN; COENZYME-A RACEMASE;
   C/EBP-ALPHA; BREAST-CANCER; GENE; HYPOMETHYLATION; ADIPOGENESIS;
   LOCALIZATION; PROGRESSION
AB alpha-Methylacyl-CoA racemase (AMACR), an enzyme involved in branched-chain fatty acid beta-oxidation that is normally expressed at high levels in human liver, is specifically and consistently overexpressed at both mRNA and protein levels in human prostate cancer and potentially other cancer types. To characterize the mechanisms underlying transcriptional regulation of AMACR at the genetic and epigenetic levels, we performed a series of methylation and reporter assays in prostate cancer tissues and cell lines. The results ruled out altered methylation patterns as the cause of overexpression in prostate cancer cells. However, promoter deletion analysis identified an 8-bp nonclassic CCAAT enhancer element located similar to 80 bp upstream of the transcriptional initiation site that is responsible for AMACR expression in both prostate cancer cell lines and cell lines of liver origin. Deletion or mutation of this element completely abolished AMACR promoter activity. Ectopic expression of CCAAT/enhancer binding protein beta increased luciferase activity driven by a wild-type AMACR promoter sequence but not by the sequence in which the putative CCAAT/enhancer binding protein binding element had been mutated. These results implicate a nonclassic CCAAT enhancer element in the AMACR gene promoter as playing a critical role in the regulation of AMACR gene expression.
C1 Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Johns Hopkins Univ Hosp, Dept Urol, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.
EM wisaacs@jhmi.edu
OI Zha, Shan/0000-0002-6568-1818
CR Amery L, 2000, J LIPID RES, V41, P1752
   CLEUTJENS CBJM, 1993, GENOMICS, V16, P520, DOI 10.1006/geno.1993.1220
   De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004
   Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605
   Ferdinandusse S, 2000, J LIPID RES, V41, P1890
   Ferdinandusse S, 2000, NAT GENET, V24, P188, DOI 10.1038/72861
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097
   Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007
   Jiang Z, 2002, JAMA-J AM MED ASSOC, V287, P3080, DOI 10.1001/jama.287.23.3080-a
   Kaeferstein A, 2003, LEUKEMIA, V17, P343, DOI 10.1038/sj.leu.2402805
   Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3
   Lou J, 2002, CANCER RES, V62, P2220
   Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884
   Mobley JA, 2003, CANCER EPIDEM BIOMAR, V12, P775
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5
   Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662
   Schacherer F, 2001, BIOINFORMATICS, V17, P1053, DOI 10.1093/bioinformatics/17.11.1053
   Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wu FY, 2003, J VIROL, V77, P8893, DOI 10.1128/JVI.77.16.8893-8914.2003
   Wu FY, 2003, J VIROL, V77, P1481, DOI 10.1128/JVI.77.2.1481-1500.2003
   Wu FY, 2002, P NATL ACAD SCI USA, V99, P10683, DOI 10.1073/pnas.162352299
   Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428
   Zha S, 2003, CANCER RES, V63, P7365
   Zha S, 2001, CANCER RES, V61, P8617
   ZHA S, 2004, PROSTATE        1214
NR 30
TC 14
Z9 15
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD FEB
PY 2005
VL 3
IS 2
BP 110
EP 118
DI 10.1158/1541-7786.MCR-04-0178
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 899LB
UT WOS:000227144800006
PM 15755877
DA 2025-01-12
ER

PT J
AU Corcoran, KE
   Patel, PS
   Rameshwar, P
AF Corcoran, KE
   Patel, PS
   Rameshwar, P
TI An <i>in vitro</i> method to select malignant cells from surgical
   biopsies of breast cancer patients
SO BIOLOGICAL PROCEDURES ONLINE
LA English
DT Article
DE bone marrow; cultured, cells; breast neoplasms
ID HEMATOPOIETIC STEM-CELLS; BONE-MARROW; METASTASIS
AB To date, breast cancer (BC) research is mainly studied with cell lines. These cells were passaged multiple times, acquiring phenotypes, additional mutations and epigenetic changes. These changes make the passaged cell lines different from the original malignancy. Thus cell lines, although useful as models could be improved with additional studies with primary BC. It is difficult to obtain malignant cells from breast tissues without contamination from surrounding healthy cells. Selection and expansion of malignant cells from surgical tissues have proved to be daunting tasks. This study describes a reliable and reproducible method for isolating and expanding malignant cells from surgical breast tissues. The method uses co-cultures with BM stroma to select for the cancer cells while the healthy cells undergo rapid cell death. Studies are described to show the cloning efficiencies and sensitivity of the method using surgical samples of varying sizes, different stages of BC, and samples from needle biopsies.
C1 Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA.
   Univ Med & Dent New Jersey Grad Sch Biomed Sci, Interdisciplinary Program, Newark, NJ USA.
   Brookdale Univ Hosp & Med Ctr, Dept Surg, Brooklyn, NY USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences
RP Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, MSB,Rm E-579,185 S Orange Ave, Newark, NJ 07103 USA.
EM rameshwa@umdnj.edu
FU NCI NIH HHS [R01 CA089868] Funding Source: Medline
CR Bonnet D, 2002, J PATHOL, V197, P430, DOI 10.1002/path.1153
   GLUCK S, 1995, CAN J ONCOL, V1, P58
   Kato M, 2003, BREAST CANCER RES, V5, pR144, DOI 10.1186/bcr627
   MANSI JL, 1989, J CLIN ONCOL, V7, P445, DOI 10.1200/JCO.1989.7.4.445
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Rameshwar P, 2001, J NEUROIMMUNOL, V121, P22, DOI 10.1016/S0165-5728(01)00443-X
   Rao G, 2004, CANCER RES, V64, P2874, DOI 10.1158/0008-5472.CAN-03-3121
NR 9
TC 6
Z9 6
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1480-9222
J9 BIOL PROCED ONLINE
JI Biol. Proced. Online
PD JAN 24
PY 2005
VL 7
BP 8
EP 16
DI 10.1251/bpo100
PG 9
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 992YN
UT WOS:000233920000002
PM 15678170
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Maier, S
   Dahlstroem, C
   Haefliger, C
   Plum, A
   Piepenbrock, C
AF Maier, S
   Dahlstroem, C
   Haefliger, C
   Plum, A
   Piepenbrock, C
TI Identifying DNA methylation biomarkers of cancer drug response
SO AMERICAN JOURNAL OF PHARMACOGENOMICS
LA English
DT Article
ID FOLATE CARRIER GENE; HISTONE-DEACETYLASE INHIBITORS;
   ESTROGEN-RECEPTOR-BETA; BREAST-CANCER; CPG ISLANDS; EPIGENETIC
   REGULATION; PROSTATE-CANCER; METHYLTRANSFERASE LEVELS; PROMOTER
   METHYLATION; ABERRANT METHYLATION
AB In the last few years, DNA methylation has become one of the most studied gene regulation mechanisms in carcinogenesis as a result of the cumulative evidence produced by the scientific community. Moreover, advances in the technologies that allow detection of DNA methylation in a variety of analytes have opened the possibility of developing methylation-based tests. A number of studies have provided evidence that specific methylation changes can alter the response to different therapeutic agents in cancer and, therefore, be useful biomarkers. For example, the association of the methylation status of DNA repair genes such as MGMT and MLH1 illustrate the two main mechanisms of response to DNA damaging agents. Loss of methylation of MGMT, and the subsequent increase in gene expression, leads to a reduction in response to alkylating agents as a result of enhanced repair of drug-induced DNA damage. Conversely, the increase in methylation of MLH1 and its resulting loss of expression has been consistently observed in drug-resistant tumor cells. MLH1 encodes a mismatch repair enzyme activated in response to DNA damage; activation of MLH1 also induces apoptosis of tumor cells, and thus loss of its expression leads to resistance to DNA-damaging agents. Other methylation-regulated genes that could serve as biomarkers in cancer therapy include drug transporters, genes involved in microtubule formation and stability, and genes related to hormonal therapy response. These methylation markers have potential applications for disease prognosis, treatment response prediction, and the development of novel treatment strategies.
C1 Epigenom AG, D-10178 Berlin, Germany.
   Epigenom Inc, Seattle, WA USA.
RP Epigenom AG, Kleine Prasidentenstr 1, D-10178 Berlin, Germany.
EM sabine.maier@epigenomics.com
CR Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905
   Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176
   Bach FR, 2003, J MACH LEARN RES, V3, P1, DOI 10.1162/153244303768966085
   Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2
   Balaña C, 2003, CLIN CANCER RES, V9, P1461
   Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025
   Bearzatto A, 2000, CANCER RES, V60, P3262
   Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167
   Chan MF, 2000, CURR TOP MICROBIOL, V249, P75
   Chang HG, 2005, J MOL MED, V83, P132, DOI 10.1007/s00109-004-0596-2
   Chen ZP, 1999, CAN J NEUROL SCI, V26, P104
   Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200
   Christmann M, 2001, INT J CANCER, V92, P123, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.3.CO;2-M
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9
   CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1
   D'Andrea AD, 2003, CELL CYCLE, V2, P290, DOI 10.4161/cc.2.4.413
   Dowell JE, 2004, J CLIN ONCOL, V22, P1353, DOI 10.1200/JCO.2004.01.947
   Duan ZF, 1999, GENE, V229, P75, DOI 10.1016/S0378-1119(99)00042-6
   Duan ZF, 2003, CLIN CANCER RES, V9, P2778
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Efferth T, 2001, BLOOD CELL MOL DIS, V27, P637, DOI 10.1006/bcmd.2001.0427
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2002, CANCER RES, V62, P5902
   Esteller M, 2002, J NATL CANCER I, V94, P26
   Ferreri AJM, 2004, BRIT J HAEMATOL, V126, P657, DOI 10.1111/j.1365-2141.2004.05109.x
   Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732
   Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384
   HERMANN R, 1991, FEBS LETT, V281, P191, DOI 10.1016/0014-5793(91)80391-F
   HSUEH CT, 1994, BIOCHEM PHARMACOL, V47, P1019, DOI 10.1016/0006-2952(94)90413-8
   Izbicka E, 1999, ANTICANCER RES, V19, P1285
   Jaeckle KA, 1998, J CLIN ONCOL, V16, P3310, DOI 10.1200/JCO.1998.16.10.3310
   Jarrard DF, 1998, CANCER RES, V58, P5310
   Johnson Lori, 2002, Clin Colorectal Cancer, V2, P146
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Kantharidis P, 2000, DRUG RESIST UPDATE, V3, P99, DOI 10.1054/drup.2000.0121
   KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110
   KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424
   Koul S, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-16
   Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Li LC, 2000, CANCER RES, V60, P702
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X
   MAIER S, 2004, 40 ANN M AM SOC CLIN, P525
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nass SJ, 2000, CANCER RES, V60, P4346
   Olopade OI, 2003, CANCER CELL, V3, P417, DOI 10.1016/S1535-6108(03)00111-9
   Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1
   Paz MF, 2004, CLIN CANCER RES, V10, P4933, DOI 10.1158/1078-0432.CCR-04-0392
   Plumb JA, 2000, CANCER RES, V60, P6039
   Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002
   PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636
   Reid GK, 2002, CURR OPIN MOL THER, V4, P130
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Rothem L, 2004, J BIOL CHEM, V279, P374, DOI 10.1074/jbc.M309092200
   Sakaeda T, 2003, PHARMACOGENOMICS, V4, P397, DOI 10.1517/phgs.4.4.397.22747
   Sasaki M, 2003, MOL CELL ENDOCRINOL, V202, P201, DOI 10.1016/S0303-7207(03)00084-4
   Satoh A, 2003, CANCER RES, V63, P8606
   Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852
   Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
   Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200
   Yang XW, 2001, CANCER RES, V61, P7025
   Yao XM, 2004, CANCER GENET CYTOGEN, V151, P1, DOI 10.1016/j.cancergencyto.2003.08.021
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
NR 85
TC 53
Z9 66
U1 0
U2 12
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-2203
J9 AM J PHARMACOGENOMIC
JI Am. J. Pharmacogenomics
PY 2005
VL 5
IS 4
BP 223
EP 232
DI 10.2165/00129785-200505040-00003
PG 10
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 963YH
UT WOS:000231842000003
PM 16078859
DA 2025-01-12
ER

PT J
AU Oshiro, MM
   Kim, CJ
   Wozniak, RJ
   Junk, DJ
   Muñoz-Rodríguez, JL
   Burr, JA
   Fitzgerald, M
   Pawar, SC
   Cress, AE
   Domann, FE
   Futscher, BW
AF Oshiro, MM
   Kim, CJ
   Wozniak, RJ
   Junk, DJ
   Muñoz-Rodríguez, JL
   Burr, JA
   Fitzgerald, M
   Pawar, SC
   Cress, AE
   Domann, FE
   Futscher, BW
TI Epigenetic silencing of DSC3 is a common event in human breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ABERRANT CYTOSINE METHYLATION; E-CADHERIN EXPRESSION; DNA METHYLATION;
   DESMOSOMAL CADHERINS; BRCA1 PROMOTER; ADHESION MOLECULES;
   GENE-EXPRESSION; MESSENGER-RNA; CPG ISLAND; DESMOCOLLIN
AB Introduction Desmocollin 3 (DSC3) is a member of the cadherin superfamily of calcium-dependent cell adhesion molecules and a principle component of desmosomes. Desmosomal proteins such as DSC3 are integral to the maintenance of tissue architecture and the loss of these components leads to a lack of adhesion and a gain of cellular mobility. DSC3 expression is down-regulated in breast cancer cell lines and primary breast tumors; however, the loss of DSC3 is not due to gene deletion or gross rearrangement of the gene. In this study, we examined the prevalence of epigenetic silencing of DSC3 gene expression in primary breast tumor specimens.
   Methods We used bisulfite genomic sequencing to analyze the methylation state of the DSC3 promoter region from 32 primary breast tumor specimens. We also used a quantitative real-time RT-PCR approach, and analyzed all breast tumor specimens for DSC3 expression. Finally, in addition to bisulfite sequencing and RT-PCR, we used an in vivo nuclease accessibility assay to determine the chromatin architecture of the CpG island region from DSC3-negative breast cancer cells lines.
   Results DSC3 expression was downregulated in 23 of 32 (72%) breast cancer specimens comprising: 22 invasive ductal carcinomas, 7 invasive lobular breast carcinomas, 2 invasive ductal carcinomas that metastasized to the lymph node, and a mucoid ductal carcinoma. Of the 23 specimens showing a loss of DSC3 expression, 13 (56%) were associated with cytosine hypermethylation of the promoter region. Furthermore, DSC3 expression is limited to cells of epithelial origin and its expression of mRNA and protein is lost in a high proportion of breast tumor cell lines (79%). Lastly, DNA hypermethylation of the DSC3 promoter is highly correlated with a closed chromatin structure.
   Conclusion These results indicate that the loss of DSC3 expression is a common event in primary breast tumor specimens, and that DSC3 gene silencing in breast tumors is frequently linked to aberrant cytosine methylation and concomitant changes in chromatin structure.
C1 Univ Arizona, Arizona Canc Ctr, Dept Pharmacol, Tucson, AZ 85721 USA.
   Univ Arizona, Arizona Canc Ctr, Dept Toxicol, Tucson, AZ USA.
   Univ Arizona, Arizona Canc Ctr, Dept Surg, Tucson, AZ USA.
   Univ Arizona, Arizona Canc Ctr, Dept Cell Biol & Anat, Tucson, AZ USA.
   Univ Iowa, Holden Comprehens Canc Ctr, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA USA.
C3 Arizona Center Cancer Care; University of Arizona; University of
   Arizona; Arizona Center Cancer Care; Arizona Center Cancer Care;
   University of Arizona; University of Arizona; Arizona Center Cancer
   Care; University of Iowa
RP Univ Arizona, Arizona Canc Ctr, Dept Pharmacol, Tucson, AZ 85721 USA.
EM bfutscher@azcc.arizona.edu
RI Cress, Anne/V-6527-2019; Munoz Rodriguez, Jose Manuel/A-7323-2016
OI Cress, Anne/0000-0001-6194-0061; Junk, Damian/0000-0002-9251-3799; Munoz
   Rodriguez, Jose Manuel/0000-0002-4688-6420; Domann,
   Frederick/0000-0002-0489-2179
FU NCI NIH HHS [CA56666, P01 CA056666-090002, T32 CA009213, R01 CA075152,
   P30 CA23074, P30 CA023074, CA65662, R01 CA065662, R01 CA075152-06, R29
   CA073612, R29 CA065662, CA73612, P01 CA056666, T32 CA09213, CA75152, R01
   CA073612, R56 CA073612] Funding Source: Medline; NIEHS NIH HHS [ES07091,
   T32 ES007091] Funding Source: Medline
CR ARNEMANN J, 1993, J CELL SCI, V104, P741
   Bachman KE, 1999, CANCER RES, V59, P798
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Béroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761
   Chidgey MAJ, 1997, DEV DYNAM, V210, P315, DOI 10.1002/(SICI)1097-0177(199711)210:3<315::AID-AJA11>3.0.CO;2-9
   COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381
   Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263
   Dammann R, 2001, CANCER RES, V61, P3105
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Esteller M, 2002, SCIENCE, V297, P1807
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gadhavi PL, 2001, BIOCHEM BIOPH RES CO, V281, P520, DOI 10.1006/bbrc.2001.4375
   Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6
   Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanakawa Y, 2000, J CELL SCI, V113, P1803
   Huang YH, 1999, ARCH BIOCHEM BIOPHYS, V364, P241, DOI 10.1006/abbi.1999.1142
   Johnson GK, 1997, J PERIODONTAL RES, V32, P447, DOI 10.1111/j.1600-0765.1997.tb00557.x
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Klus GT, 2001, INT J ONCOL, V19, P169
   KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9
   KONDO M, 1991, AM J PHYSIOL, V261, pL106, DOI 10.1152/ajplung.1991.261.2.L106
   Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651
   Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415
   Millar DS, 1998, HUM GENET, V103, P228, DOI 10.1007/s004390050810
   Nuber UA, 1996, EUR J CELL BIOL, V71, P1
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721
   Runswick SK, 2001, NAT CELL BIOL, V3, P823, DOI 10.1038/ncb0901-823
   Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0
   Tost J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng050
   TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790
   Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064
   Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996
NR 43
TC 89
Z9 105
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2005
VL 7
IS 5
BP R669
EP R680
DI 10.1186/bcr1273
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 970TJ
UT WOS:000232332200025
PM 16168112
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Sato, N
   Matsubayashi, H
   Fukushima, N
   Goggins, M
AF Sato, N
   Matsubayashi, H
   Fukushima, N
   Goggins, M
TI The chemokine receptor CXCR4 is regulated by DNA methylation in
   pancreatic cancer
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE chemokine receptor; CXCR4; methylation; pancreatic cancer
ID HISTONE DEACETYLASE INHIBITION; BREAST-CANCER; MOLECULAR
   CHARACTERIZATION; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER;
   EPITHELIAL-CELLS; MELANOMA-CELLS; GROWTH-FACTOR; TUMOR-CELLS;
   CPG-ISLANDS
AB Despite the biological and clinical importance of the interaction between the chemokine receptor CXCR4 and its ligand CXCL12 (SDF-1 alpha) in human cancers, little is known about transcriptional regulation of the CXCR,4 gene. Although aberrant hypermethylation in cancer has been described typically in genes with tumor-suppressor properties, this epigenetic alteration has also been observed to affect potential cancer-promoting genes. We now demonstrate that DNA methylation influences CXCR4 expression in human pancreatic cancer. Gene expression profiling and reverse transcription-PCR identified a significant proportion of pancreatic cancer cell lines that displayed little or no CXCR4 mRNA expression. Using methylation-specific PCR, combined bisulfite restriction analysis, and bisulfite sequencing, we found the 5' CpG islands of the CXCR4 gene to be unmethylated in normal pancreas, whereas promoter hypermethylation was detected in 45% (9 of 20) of pancreatic cancer cell lines and in 46% (46 of 100) of primary pancreatic adenocarcinomas. There was a significant inverse correlation between methylation and mRNA expression level of CXCR4 (P = 0.008) in a large panel of pancreatic cancer cell lines. Constitutive as well as inducible expression of CXCR,4 could be restored in methylated cell lines pharmacologically using epigenetic modifying drugs. These findings demonstrate the first evidence for epigenetic regulation of CXCR4 in human cancers, providing new insights into the role of CXCR4/CXCL12 interactions in tumor progression.
C1 Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine
RP Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.
EM mgoggins@jhmi.edu
FU NCI NIH HHS [CA62924] Funding Source: Medline
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Bachelder RE, 2002, CANCER RES, V62, P7203
   Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003
   Barbero S, 2003, CANCER RES, V63, P1969
   Begum NA, 1999, INT J ONCOL, V14, P927
   Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cardones AR, 2003, CANCER RES, V63, P6751
   Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7
   Devine SM, 2004, J CLIN ONCOL, V22, P1095, DOI 10.1200/JCO.2004.07.131
   Dwinell MB, 1999, GASTROENTEROLOGY, V117, P359, DOI 10.1053/gast.1999.0029900359
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685
   Kijima T, 2002, CANCER RES, V62, P6304
   Koshiba T, 2000, CLIN CANCER RES, V6, P3530
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958
   Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031
   Mori T, 2004, MOL CANCER THER, V3, P29
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Murakami T, 2002, CANCER RES, V62, P7328
   Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113
   Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200
   Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100
   Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200
   Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1
   Sato N, 2003, CANCER RES, V63, P3735
   Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267
   Scotton CJ, 2002, CANCER RES, V62, P5930
   Sehgal A, 1998, J SURG ONCOL, V69, P239, DOI 10.1002/(SICI)1096-9098(199812)69:4<239::AID-JSO9>3.0.CO;2-U
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Taichman RS, 2002, CANCER RES, V62, P1832
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X
   Toyota M, 2000, CANCER RES, V60, P4044
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Ueki T, 1997, HEPATOLOGY, V25, P619, DOI 10.1002/hep.510250321
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
NR 42
TC 57
Z9 70
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JAN
PY 2005
VL 4
IS 1
BP 70
EP 76
DI 10.4161/cbt.4.1.1378
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 948RF
UT WOS:000230732700014
PM 15662133
OA Bronze
DA 2025-01-12
ER

PT J
AU Tommasi, S
   Dammann, R
   Zhang, ZQ
   Wang, Y
   Liu, LM
   Tsark, WM
   Wilczynski, SP
   Li, J
   You, N
   Pfeifer, GP
AF Tommasi, S
   Dammann, R
   Zhang, ZQ
   Wang, Y
   Liu, LM
   Tsark, WM
   Wilczynski, SP
   Li, J
   You, N
   Pfeifer, GP
TI Tumor susceptibility of <i>Rassf1a</i> knockout mice
SO CANCER RESEARCH
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; ABERRANT PROMOTER METHYLATION;
   HUMAN-CHROMOSOME 3P21.3; DOMAIN FAMILY 1A; CELL LUNG-CANCER; SUPPRESSOR
   GENE; CPG ISLAND; BREAST-CANCER; CLINICOPATHOLOGICAL FEATURES;
   HEPATOCELLULAR-CARCINOMA
AB The human Ras association domain family 1 (RASSF1) gene is located at 3p21.3 in an area that is believed to harbor at least one important tumor suppressor gene. The two major isoforms of RASSF1, RASSF1A and RASSF1C, are distinguished by alternative N2-terminal exons and the two transcripts initiate in two separate CpG islands. RASSF1A is one of the most frequently inactivated genes described thus far in human solid tumors. Inactivation of RASSF1A most commonly involves methylation of the promoter and CpG island associated with the RASSF1A isoform. In contrast, RASSF1C is almost never inactivated in tumors. Here, we have derived Rassf1a knockout mice in which exon 1-alpha of the Rassf1 gene was deleted, leading to specific loss of Rassf1a but not Rassf1c transcripts. Rassf1a -targeted mice were viable and fertile. Rassf1a(-/-) mice were prone to spontaneous tumorigenesis in advanced age (18-20 months). Whereas only two tumors developed in 48 wild-type mice, six tumors were found in 35 Rassf1a(+/-) mice (P < 0.05) and thirteen tumors were found in 41 Rassf1a(-/-) mice (P < 0.001). The tumors in Rassf1a-targeted mice included lung adenomas, lymphomas, and one breast adenocarcinoma. Rassf1a(-/-) and wild-type mice were treated with two chemical carcinogens, benzo(a)pyrene and urethane, to induce skin tumors and lung tumors, respectively. Rassfla(-/-) and Rassf1a(+/-) mice showed increased tumor multiplicity and tumor size relative to control animals. The data are consistent with the tumor -suppressive role of Rassf1a, which may explain its frequent epigenetic inactivation in human tumors.
C1 City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.
   City Hope Natl Med Ctr, Div Biol, Duarte, CA USA.
   City Hope Natl Med Ctr, Dept Anat Pathol, Duarte, CA USA.
   Univ Halle Wittenberg, Med Fak, Halle An Der Saale, Germany.
   Washington Univ, Sch Med, Dept Surg, St Louis, MO USA.
C3 City of Hope; Beckman Research Institute of City of Hope; City of Hope;
   City of Hope; Martin Luther University Halle Wittenberg; Washington
   University (WUSTL)
RP Pfeifer, GP (通讯作者)，City Hope Natl Med Ctr, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM gpfeifer@coh.org
RI Tommasi, Stefania/J-6732-2012
OI Tommasi, Stella/0000-0001-6897-4985
FU NCI NIH HHS [CA093643, CA88873] Funding Source: Medline
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971
   Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1
   Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Endoh H, 2003, INT J CANCER, V106, P45, DOI 10.1002/ijc.11184
   Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446
   Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119
   Jackson PK, 2004, TRENDS CELL BIOL, V14, P331, DOI 10.1016/j.tcb.2004.05.005
   Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Kuzmin I, 2002, CANCER RES, V62, P3498
   Lee MG, 2001, CANCER RES, V61, P6688
   Lerman MI, 2000, CANCER RES, V60, P6116
   Li J, 2003, NEOPLASIA, V5, P362, DOI 10.1016/S1476-5586(03)80029-5
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Lo KW, 2001, CANCER RES, V61, P3877
   Lusher ME, 2002, CANCER RES, V62, P5906
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   Maruyama R, 2001, CANCER RES, V61, P8659
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Morrissey C, 2001, CANCER RES, V61, P7277
   Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192
   Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097
   Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8
   Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001
   Schagdarsurengin U, 2002, CANCER RES, V62, P3698
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362
   Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381
   TURUSOV VS, 1979, PATHOLOGY TUMORS LAB, V2
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466
   Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349
   Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242
   Yan PS, 2003, CANCER RES, V63, P6178
   Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076
   Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721
   Zhong S, 2003, CLIN CANCER RES, V9, P3376
NR 54
TC 181
Z9 201
U1 1
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2005
VL 65
IS 1
BP 92
EP 98
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 884JF
UT WOS:000226080200013
PM 15665283
DA 2025-01-12
ER

PT J
AU Lewis, CM
   Cler, LR
   Bu, DW
   Zöchbauer-Müller, S
   Milchgrub, S
   Naftalis, EZ
   Leitch, AM
   Minna, JD
   Euhus, DM
AF Lewis, CM
   Cler, LR
   Bu, DW
   Zöchbauer-Müller, S
   Milchgrub, S
   Naftalis, EZ
   Leitch, AM
   Minna, JD
   Euhus, DM
TI Promoter hypermethylation in benign breast epithelium in relation to
   predicted breast cancer risk
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID METHYLATION-SPECIFIC PCR; ABERRANT METHYLATION; DNA METHYLATION;
   MULTIPLE GENES; EPIGENETIC INACTIVATION; LUNG CARCINOMAS; RASSF1A GENE;
   CPG ISLANDS; T-CADHERIN; CELLS
AB Introduction: The tumor suppressor genes RASSF1A, APC, H-cadherin, RARbeta2, and cyclin D2 are methylated more frequently in breast cancer than in adjacent benign tissue. However, it is unclear whether promoter methylation of tumor suppressor genes in benign breast tissue is associated with an increased risk for breast cancer.
   Methods: Promoter hypermethylation was measured in benign and malignant breast samples obtained by fine needle aspiration biopsy from 27 breast cancer patients and 55 unaffected women whose risk of breast cancer had been defined using the Gail, Claus, and BRCAPRO models.
   Results: Cyclin D2 methylation occurred in 57% of tumor samples but not in corresponding benign breast samples and in only one sample from an unaffected patient (P < 0.0001). RARbeta2 methylation occurred in 32% of benign breast samples from cancer patients but only 9% of similar samples from unaffected women (P = 0.002). Promoter methylation of RASSF1A and APC occurred more frequently (70% and 56%, respectively) in unaffected women at high-risk for breast cancer as defined by the Gail model than in low/intermediate risk women (29% and 20%, P = 0.04 and P = 0.03). Of the Gail model risk factors, only number of prior breast biopsies was highly correlated with APC and RASSF1A methylation (P 0.0001 and 0.02, respectively).
   Conclusions: Since cyclin D2 promoter methylation occurs almost exclusively in tumors, it may be possible to exploit it for the early detection of breast cancer. Promoter methylation of APC, RARbeta2, and RASSF1A in benign breast epithelium is associated with epidemiologic markers of increased breast cancer risk.
C1 Univ Texas, SW Med Ctr, Div Surg Oncol, Hamon Ctr Therapeut Oncol Res,Dept Surg, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas Dallas; University of Texas System; University of Texas Dallas;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Dallas; University of Texas
   Southwestern Medical Center Dallas
RP Univ Texas, SW Med Ctr, Div Surg Oncol, Hamon Ctr Therapeut Oncol Res,Dept Surg, 5323 Harry Hines Blvd,E6-222, Dallas, TX 75390 USA.
EM David.Euhus@UTSouthwestern.edu
RI Minna, John/AAB-1036-2022; Zochbauer-Muller, Sabine/B-8399-2012
OI Zochbauer-Muller, Sabine/0000-0002-6777-1729
FU NCI NIH HHS [CA71618] Funding Source: Medline
CR Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227
   Bodian CA, 1996, CANCER, V78, P1024, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1024::AID-CNCR12>3.0.CO;2-4
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5
   Costantino JP, 1999, J NATL CANCER I, V91, P1541, DOI 10.1093/jnci/91.18.1541
   Dammann R, 2001, CANCER RES, V61, P3105
   Dong SM, 2001, CLIN CANCER RES, V7, P1982
   Eads CA, 2001, CANCER RES, V61, P3410
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2001, CANCER RES, V61, P3225
   Euhus D M, 2001, Breast J, V7, P224, DOI 10.1046/j.1524-4741.2001.20012.x
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fowble B, 2001, INT J RADIAT ONCOL, V51, P679, DOI 10.1016/S0360-3016(01)01665-0
   Fredette BJ, 1996, DEVELOPMENT, V122, P3163
   GAIL MH, 1989, JNCI-J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Kang GH, 2003, LAB INVEST, V83, P635, DOI 10.1097/01.LAB.0000067481.08984.3F
   Koller E, 1996, J BIOL CHEM, V271, P30061, DOI 10.1074/jbc.271.47.30061
   Kollias J, 1999, EUR J SURG ONCOL, V25, P584, DOI 10.1053/ejso.1999.0711
   Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109
   Krop I, 2003, CANCER RES, V63, P2024
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586
   RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7
   Rathi A, 2002, CLIN CANCER RES, V8, P3324
   RIES LAG, 1999, SEER PEDIAT MONOGRAP, P1
   Sato M, 1998, HUM GENET, V103, P532
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   SPIEGELMAN D, 1994, J NATL CANCER I, V86, P600, DOI 10.1093/jnci/86.8.600
   To KF, 2002, INT J CANCER, V102, P623, DOI 10.1002/ijc.10783
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787
   Toyooka S, 2002, CANCER RES, V62, P3382
   Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
   Zöchbauer-Müller S, 2003, INT J CANCER, V107, P612, DOI 10.1002/ijc.11458
NR 50
TC 146
Z9 171
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 1
PY 2005
VL 11
IS 1
BP 166
EP 172
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 884TW
UT WOS:000226110300023
PM 15671542
DA 2025-01-12
ER

PT J
AU Prudhomme, S
   Bonnaud, B
   Mallet, F
AF Prudhomme, S
   Bonnaud, B
   Mallet, F
TI Endogenous retroviruses and animal reproduction
SO CYTOGENETIC AND GENOME RESEARCH
LA English
DT Article
ID HUMAN-BREAST-CANCER; HUMAN Y-CHROMOSOME; JAAGSIEKTE SHEEP RETROVIRUS;
   HUMAN PLACENTAL TROPHOBLAST; TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNA
   EXPRESSION; RETRACTED ARTICLE. SEE; DROSOPHILA-MELANOGASTER; HERV-W;
   ENVELOPE PROTEIN
AB Endogenous retroviruses (ERV), as part of the host genetic heritage, are transmissible to the next generation in a Mendelian way. Their abundance in animal genomes and their expression primarily detected in germ cells, embryonic tissues and cancer cell lines, raised the question of their biological significance. This article reviews the possible role of ERVs in the physiology and diseases of animal reproduction, from Drosophila to human. In males, there is no trivial involvement of ERVs in a physiological process. Conversely, a spermatogenesis defect was associated in the human male with HERV-K expression and HERV15-induced chromosomal alteration, leading to cancer and infertility, respectively. In females, the study of insect ERVs (IERV) pointed out the overlap between genetics and virology with the genetic-dependent regulation of ZAM and the non-infectious and infectious life cycles of gypsy. The pattern of ERVs expression in rodent, ovine and human females suggest a hormone-dependent mechanism consistent with the mammalian oestrus cycle regulation. The differentiation of the mammary epithelium and breast tumorigenesis involving the mouse mammary tumour viruses (MMTV) illustrate the intimate connection between endogenous and exogenous retroviruses. Last, as a major site of ERVs transcription, placenta contributed to our understanding of ERVs modulation of neighbouring gene expression. As an interface, i.e. a site of conflicts and exchanges, placenta should resist infection and protect the foetus against the maternal immune system. Retroviral envelopes could theoretically provide such features due to receptor interference, immunosuppression and fusion properties, as shown by the HERV-W envelope involved in the syncytiotrophoblast formation. We conclude with an insight on the evolutionary and epigenetic consequences of the relationships of ERV guests with their animal hosts. Copyright (c) 2005 S. Karger AG, Basel.
C1 Ecole Normale Super Lyon, CNRS Biomerieux, UMR 2142, IFR Biosci Lyon Gerland 128, F-69364 Lyon, France.
C3 Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la
   Recherche Scientifique (CNRS)
RP Ecole Normale Super Lyon, CNRS Biomerieux, UMR 2142, IFR Biosci Lyon Gerland 128, 46 Allee Italie, F-69364 Lyon, France.
EM francois.mallet@ens-lyon.fr
RI Mallet, Francois/G-4812-2014
OI MALLET, Francois/0000-0002-1331-096X
CR Andersson AC, 2002, VIROLOGY, V297, P220, DOI 10.1006/viro.2002.1428
   [Anonymous], WORLD CANC REPORT
   Anway MD, 2001, BIOL REPROD, V65, P1289, DOI 10.1095/biolreprod65.4.1289
   Armbruester V, 2002, CLIN CANCER RES, V8, P1800
   Asch BB, 1996, J MAMMARY GLAND BIOL, V1, P49, DOI 10.1007/BF02096302
   Barbulescu M, 1999, CURR BIOL, V9, P861, DOI 10.1016/S0960-9822(99)80390-X
   Bénit L, 2001, J VIROL, V75, P11709, DOI 10.1128/JVI.75.23.11709-11719.2001
   Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0
   Bi S, 1997, J BIOL CHEM, V272, P30583, DOI 10.1074/jbc.272.48.30583
   Bièche I, 2003, BIOL REPROD, V68, P1422, DOI 10.1095/biolreprod.102.010322
   Blanco P, 2000, J MED GENET, V37, P752, DOI 10.1136/jmg.37.10.752
   Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000
   Blond JL, 1999, J VIROL, V73, P1175, DOI 10.1128/JVI.73.2.1175-1185.1999
   Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794
   Bolander FF, 1998, J MOL ENDOCRINOL, V21, P161, DOI 10.1677/jme.0.0210161
   Boller K, 1997, J VIROL, V71, P4581, DOI 10.1128/JVI.71.6.4581-4588.1997
   BOLLER K, 1993, VIROLOGY, V196, P349, DOI 10.1006/viro.1993.1487
   Borie N, 2002, HEREDITY, V89, P247, DOI 10.1038/sj.hdy.6800135
   Bosch E, 2003, HUM MOL GENET, V12, P341, DOI 10.1093/hmg/ddg031
   BUCHETON A, 1995, TRENDS GENET, V11, P349, DOI 10.1016/S0168-9525(00)89105-2
   Chalvet F, 1999, EMBO J, V18, P2659, DOI 10.1093/emboj/18.9.2659
   COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143
   Conte C, 2002, EMBO J, V21, P3908, DOI 10.1093/emboj/cdf367
   Cross JC, 2003, PLACENTA, V24, P123, DOI 10.1053/plac.2002.0887
   de Parseval N, 2003, J VIROL, V77, P10414, DOI 10.1128/JVI.77.19.10414-10422.2003
   de Parseval N, 1998, J VIROL, V72, P3442, DOI 10.1128/JVI.72.4.3442-3445.1998
   DeHaven JE, 1998, J GEN VIROL, V79, P2687, DOI 10.1099/0022-1317-79-11-2687
   DeMartini JC, 2003, CURR TOP MICROBIOL, V275, P117
   Desset S, 2003, GENETICS, V164, P501
   Dupressoir A, 1997, ONCOGENE, V14, P2951, DOI 10.1038/sj.onc.1201148
   Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003
   Goedert JJ, 1999, CANCER EPIDEM BIOMAR, V8, P293
   Goff SP, 1996, CELL, V86, P691, DOI 10.1016/S0092-8674(00)80141-5
   GOODCHILD NL, 1992, GENE, V121, P287, DOI 10.1016/0378-1119(92)90133-A
   Graham KM, 2000, BIOCHEM BIOPH RES CO, V278, P48, DOI 10.1006/bbrc.2000.3759
   HARAGUCHI S, 1995, P NATL ACAD SCI USA, V92, P3611, DOI 10.1073/pnas.92.8.3611
   Harris JR, 1998, BIOESSAYS, V20, P307, DOI 10.1002/(SICI)1521-1878(199804)20:4<307::AID-BIES7>3.0.CO;2-M
   Herbst H, 1998, APMIS, V106, P216, DOI 10.1111/j.1699-0463.1998.tb01338.x
   Herbst H, 1999, VIRCHOWS ARCH, V434, P11, DOI 10.1007/s004280050298
   Hughes JF, 2001, NAT GENET, V29, P487, DOI 10.1038/ng775
   *IHGSC, 2001, NATURE, V409, P680
   Kaminker J.S., 2002, GENOME BIOL
   Kamp C, 2000, HUM MOL GENET, V9, P2563, DOI 10.1093/hmg/9.17.2563
   KATO N, 1987, J VIROL, V61, P2182, DOI 10.1128/JVI.61.7.2182-2191.1987
   Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657
   KITAMURA M, 1994, INT J CANCER, V58, P836, DOI 10.1002/ijc.2910580615
   Knerr I, 2002, AM J OBSTET GYNECOL, V186, P210, DOI 10.1067/mob.2002.119636
   Kudo Y, 2003, BBA-MOL BASIS DIS, V1638, P63, DOI 10.1016/S0925-4439(03)00043-7
   Landry JR, 2002, MOL BIOL EVOL, V19, P1934, DOI 10.1093/oxfordjournals.molbev.a004017
   Larsson Erik, 1994, Upsala Journal of Medical Sciences, V99, P113
   Le Bouteiller P, 1999, IMMUNOL REV, V167, P233
   Leblanc P, 2000, J VIROL, V74, P10658, DOI 10.1128/JVI.74.22.10658-10669.2000
   Lin L, 1999, PLACENTA, V20, P109, DOI 10.1053/plac.1998.0337
   Lin L, 2000, PLACENTA, V21, P73, DOI 10.1053/plac.1999.0443
   LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480
   LYDEN TW, 1994, BIOL REPROD, V51, P152, DOI 10.1095/biolreprod51.1.152
   Malik HS, 2000, GENOME RES, V10, P1307, DOI 10.1101/gr.145000
   Mangeney M, 2001, J GEN VIROL, V82, P2515, DOI 10.1099/0022-1317-82-10-2515
   Medstrand P, 2001, J BIOL CHEM, V276, P1896, DOI 10.1074/jbc.M006557200
   Mejlumian L, 2002, GENETICS, V160, P201
   Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608
   Nihrane A, 1996, J VIROL, V70, P1882, DOI 10.1128/JVI.70.3.1882-1889.1996
   Nilsson BO, 1999, VIRUS GENES, V18, P115, DOI 10.1023/A:1008004332513
   ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987
   Palmarini M, 2001, J VIROL, V75, P11319, DOI 10.1128/JVI.75.23.11319-11327.2001
   Pantel J, 2000, J BIOL CHEM, V275, P18664, DOI 10.1074/jbc.M001615200
   Pasyukova E, 1997, MOL GEN GENET, V255, P115, DOI 10.1007/s004380050479
   Pelisson A, 2002, INSECT BIOCHEM MOLEC, V32, P1249, DOI 10.1016/S0965-1748(02)00088-7
   PERL A, 1989, NUCLEIC ACIDS RES, V17, P6841, DOI 10.1093/nar/17.17.6841
   Ponferrada VG, 2003, ARCH VIROL, V148, P659, DOI 10.1007/s00705-002-0960-x
   Posnett DN, 2001, IMMUNITY, V15, P503, DOI 10.1016/S1074-7613(01)00211-4
   Sanna E, 2002, EUR J HISTOCHEM, V46, P273
   SAUTER M, 1995, J VIROL, V69, P414, DOI 10.1128/JVI.69.1.414-421.1995
   Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870
   Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759
   Seifarth W, 1998, J VIROL, V72, P8384, DOI 10.1128/JVI.72.10.8384-8391.1998
   Spencer TE, 1999, BIOL REPROD, V61, P1409, DOI 10.1095/biolreprod61.6.1409
   Spencer TE, 2003, J VIROL, V77, P749, DOI 10.1128/JVI.77.1.749-753.2003
   Stoye JP, 2000, NATURE, V403, P715, DOI 10.1038/35001700
   Sun C, 2000, HUM MOL GENET, V9, P2291, DOI 10.1093/oxfordjournals.hmg.a018920
   Tailor CS, 1999, J VIROL, V73, P4470, DOI 10.1128/JVI.73.5.4470-4474.1999
   Tcheressiz S, 2002, MOL GENET GENOMICS, V267, P133, DOI 10.1007/s00438-002-0641-1
   Terzian C, 2001, BMC EVOL BIOL, V1, DOI 10.1186/1471-2148-1-3
   TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457
   Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000
   Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157
   van Regenmortel MHV, 2000, ARCH VIROL, V145, P2227, DOI 10.1007/s007050070053
   VENABLES PJW, 1995, VIROLOGY, V211, P589, DOI 10.1006/viro.1995.1442
   Villareal LP, 1997, J VIROL, V71, P859, DOI 10.1128/JVI.71.2.859-865.1997
   Voisset C, 1999, AIDS RES HUM RETROV, V15, P1529, DOI 10.1089/088922299309810
   Voisset C, 2000, AIDS RES HUM RETROV, V16, P731, DOI 10.1089/088922200308738
   Wang Y, 2001, INT J ONCOL, V18, P1041
   Wang-Johanning F, 2003, CANCER-AM CANCER SOC, V98, P187, DOI 10.1002/cncr.11451
   Wang-Johanning F, 2003, ONCOGENE, V22, P1528, DOI 10.1038/sj.onc.1206241
   Whitmarsh J, 2001, PLOUGHSHARES, V27, P200
NR 95
TC 78
Z9 83
U1 3
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1424-8581
EI 1424-859X
J9 CYTOGENET GENOME RES
JI Cytogenet. Genome Res.
PY 2005
VL 110
IS 1-4
BP 353
EP 364
DI 10.1159/000084967
PG 12
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 953GM
UT WOS:000231064600035
PM 16093687
DA 2025-01-12
ER

PT J
AU Pang, JCS
   Chang, Q
   Chung, YF
   Teo, JGC
   Poon, WS
   Zhou, LF
   Kong, XY
   Ng, HK
AF Pang, JCS
   Chang, Q
   Chung, YF
   Teo, JGC
   Poon, WS
   Zhou, LF
   Kong, XY
   Ng, HK
TI Epigenetic inactivation of DLC-1 in supratentorial primitive
   neuroectodermal tumor
SO HUMAN PATHOLOGY
LA English
DT Article
DE supratentorial primitive neuroectodermal tumor; medulloblastoma; DLC-1;
   hypermethylation; transcriptional silencing; epigenetics
ID COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN HEPATOCELLULAR-CARCINOMA;
   ABERRANT PROMOTER METHYLATION; HUMAN BREAST-CANCER; SUPPRESSOR GENE; RAS
   TRANSFORMATION; CELL-LINES; MEDULLOBLASTOMA; RHO; HYPERMETHYLATION
AB Supratentorial primitive neuroectodermal tumors (SPNETs) and medulloblastomas (MBs) are histologically similar intracranial tumors found in different anatomic locations of the brain. Our group has previously demonstrated that loss of chromosome 8p is a frequent event in MBs. The aim of this study was to evaluate whether DLC-1, a newly identified tumor-suppressor gene on chromosome 8p22, is involved in the turnorigenesis of MBs and the histologically similar SPNETs. We first assessed for alterations of gene expression in microdissected tumors and detected lack of DIG] transcript in 1 of 9 MBs (case M44) and I of 3 SPNETs (case M 1). Neither somatic base substitutions nor homozygous deletion were found in tumors without DLC-1 transcript. We then explored the possibility of hypermethylation of the CpG island in DLC-1 as the mechanism of suppressed expression. Methylation-specific polymerase chain reaction revealed promotor hypermethylation of DLC-1 in M1 but not in M44. Bisulfite sequencing further verified a densely methylated pattern of 35 CpG sites studied in M1 that were not found in normal brain, indicating that inactivation of DLC-1 by hypermethylation is involved in SPNET. Based on this finding, we examined an additional 20 MBs, 8 SPNETs, and 4 MB and 2 SPNET cell lines for hypermethylation of the CpG island of DLC-1, finding that none of these samples exhibited DLC-1 methylation. In conclusion, our results demonstrate that transcriptional silencing of DLC-1 through promoter hypermethylation may contribute to tumorigenesis in a subset of SPNETs, and that loss of DLC-1 expression in MBs may be related to mechanisms other than promoter hypemiethylation, genomic deletion, and mutation. (C) 2005 Elsevier Inc. All rights reserved.
C1 Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   Fudan Univ, Huashan Hosp, Shanghai, Peoples R China.
   Chinese Acad Sci, Inst Biol Sci, Hlth Sci Ctr, Shanghai, Peoples R China.
   Shanghai Med Univ 2, Shanghai, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Prince of Wales Hospital; Fudan University;
   Chinese Academy of Sciences; Shanghai Jiao Tong University
RP Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.
EM hkng@cuhk.edu.hk
RI Poon, Wai/F-1558-2011; Pang, Jesse/H-3549-2013; Ng, Ho/I-3952-2015
OI Chang, Qing/0000-0001-5138-8760; Ng, Ho Keung/0000-0002-2614-2213
CR AVETLOISEAU H, 1999, BRIT J CANCER, V79, P1837
   Chang Q, 2004, INT J CANCER, V109, P309, DOI 10.1002/ijc.11689
   Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200
   Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139
   Dong SM, 2001, J NEUROPATH EXP NEUR, V60, P808, DOI 10.1093/jnen/60.8.808
   Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B
   Frühwald MC, 2001, GENE CHROMOSOME CANC, V30, P38
   Frühwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613
   GAINGASPERO F, 2000, WORLD HLTH ORG CLASS, P129
   Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101
   Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446
   Horiuchi A, 2003, LAB INVEST, V83, P861, DOI 10.1097/01.LAB.0000073128.16098.31
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914
   Lusher ME, 2002, CANCER RES, V62, P5906
   Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1
   Ng IOL, 2000, CANCER RES, V60, P6581
   Nicholson JC, 1999, BRIT J CANCER, V80, P1322, DOI 10.1038/sj.bjc.6690525
   Park SW, 2003, INT J ONCOL, V23, P133
   Paulino AC, 1999, CANCER, V86, P142, DOI 10.1002/(SICI)1097-0142(19990701)86:1<142::AID-CNCR20>3.0.CO;2-Y
   Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z
   POLLACK IF, 1994, NEW ENGL J MED, V331, P1500, DOI 10.1056/NEJM199412013312207
   Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a
   Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449
   QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0
   QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781
   Reardon DA, 1997, CANCER RES, V57, P4042
   RORKE LB, 2000, WHO CLASSIFICATION T, P141
   Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#
   Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23
   Tong CYK, 2001, J NEUROSURG, V95, P9, DOI 10.3171/jns.2001.95.1.0009
   Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4
   Wong CM, 2003, CANCER RES, V63, P7646
   Yin XL, 2002, ONCOGENE, V21, P1461, DOI 10.1038/sj.onc.1205204
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291
   Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064
   Zheng SQL, 2003, MUTAT RES-FUND MOL M, V528, P45, DOI 10.1016/S0027-5107(03)00081-2
   Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246
NR 41
TC 23
Z9 29
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD JAN
PY 2005
VL 36
IS 1
BP 36
EP 43
DI 10.1016/j.humpath.2004.09.021
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 898OU
UT WOS:000227086900007
PM 15712180
DA 2025-01-12
ER

PT J
AU Brooks, WH
AF Brooks, WH
TI Autoimmune disorders result from loss of epigenetic control following
   chromosome damage
SO MEDICAL HYPOTHESES
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHRONIC GRANULOMATOUS-DISEASE;
   POLYMERASE-III TRANSCRIPTION; INACTIVE X-CHROMOSOME;
   ORNITHINE-DECARBOXYLASE; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS;
   BREAST-CANCER; ION CHANNELS; XIST RNA
AB Multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis share common features in typical cases such as: adult onset, central nervous system problems, female predominance, episodes triggered by a variety of stresses, and an autoimmune reaction. At times, the different disorders are found in the same patient or close relatives. These disorders are quite complex but they may share a common mechanism that results in different, tissue-specific consequences based on the cell types in which the mechanism occurs.
   Here, it is hypothesized that DNA damage can Lead to loss of epigenetic control, particularly when the damaged chromatin is distributed unevenly to daughter cells. Expression of genes and pseudogenes that have lost their epigenetic restraints can lead to autoimmune disorders. Loss of control of genes on the X chromosome and loss of control of polyamine expression are discussed as examples of this mechanism. (C) 2004 Elsevier Ltd. All rights reserved.
C1 H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA.
RP Brooks, WH (通讯作者)，H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, SRB-3,12902 Magnolia Dr, Tampa, FL 33612 USA.
EM brookswh@moffitt.usf.edu
CR Alves G, 2000, ANN NY ACAD SCI, V906, P129
   Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016
   Blair HJ, 2000, MAMM GENOME, V11, P710, DOI 10.1007/s003350010141
   Brockdorff N, 1998, CELL MOL LIFE SCI, V54, P104, DOI 10.1007/s000180050129
   Brooks WH, 2002, MED HYPOTHESES, V59, P736, DOI 10.1016/S0306-9877(02)00322-5
   BROOKS WH, 1994, MED HYPOTHESES, V43, P403, DOI 10.1016/0306-9877(94)90016-7
   Brooks WH, 2002, ARTHRITIS RHEUM-US, V46, P1412, DOI 10.1002/art.10194
   Cañizares F, 1999, CLIN CANCER RES, V5, P2035
   Córdoba-Guijarro S, 2000, J EUR ACAD DERMATOL, V14, P409, DOI 10.1046/j.1468-3083.2000.00113.x
   DALESSANDRO E, 1990, AM J MED GENET, V37, P406, DOI 10.1002/ajmg.1320370322
   FURUMITSU Y, 1993, J RHEUMATOL, V20, P1661
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   Ganesan S, 2004, PHILOS T R SOC B, V359, P123, DOI 10.1098/rstb.2003.1371
   GIORGI PP, 1978, NEUROSCI LETT, V10, P335, DOI 10.1016/0304-3940(78)90249-5
   Hobbs CA, 2000, J CELL BIOCHEM, V77, P345, DOI 10.1002/(SICI)1097-4644(20000601)77:3<345::AID-JCB1>3.3.CO;2-G
   Hultborn R, 1997, ANTICANCER RES, V17, P4293
   Kim C, 2001, GENE, V276, P127, DOI 10.1016/S0378-1119(01)00639-4
   Kinne RW, 2001, ARTHRITIS RES, V3, P319, DOI 10.1186/ar322
   KOENIG H, 1989, J NEUROCHEM, V52, P101, DOI 10.1111/j.1471-4159.1989.tb10903.x
   KRAPF F, 1989, CLIN EXP IMMUNOL, V75, P336
   LI JZ, 1989, ARTHRITIS RHEUM-US, V32, P726, DOI 10.1002/anr.1780320610
   Li TH, 2000, NUCLEIC ACIDS RES, V28, P3031, DOI 10.1093/nar/28.16.3031
   Maeda Y, 2002, MOL ENDOCRINOL, V16, P1502, DOI 10.1210/me.16.7.1502
   OrtizRomero PL, 1997, DERMATOLOGY, V195, P280, DOI 10.1159/000245963
   Poduslo JF, 1996, J NEUROCHEM, V66, P1599
   Puri H., 1978, ADV POLYAMINE RES, V2, P359
   RUSSELL DH, 1975, J NEUROBIOL, V6, P267, DOI 10.1002/neu.480060303
   SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5
   Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103
   THOMAS TJ, 1991, J RHEUMATOL, V18, P215
   Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327
   White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547
   Williams K, 1997, CELL SIGNAL, V9, P1, DOI 10.1016/S0898-6568(96)00089-7
NR 33
TC 15
Z9 16
U1 0
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2005
VL 64
IS 3
BP 590
EP 598
DI 10.1016/j.mehy.2004.08.005
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 899IX
UT WOS:000227139200031
PM 15617874
DA 2025-01-12
ER

PT J
AU Soltysova, A
   Altanerova, V
   Altaner, C
AF Soltysova, A
   Altanerova, V
   Altaner, C
TI Cancer stem cells
SO NEOPLASMA
LA English
DT Article
DE stem cells; progenitors; mutation; cancer stem cells; differentiation;
   redifferentiation; resistance; therapy
ID ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; PROGENITOR CELLS; BRAIN-TUMORS;
   IDENTIFICATION; QUIESCENT; SUBPOPULATION; PERSISTENCE; HIERARCHY;
   EXPANSION
AB There is an increasing evidence supporting the cancer stem cell hypothesis. Normal stem cells in the adult organism are responsible for tissue renewal and repair of aged or damaged tissue. A substantial characteristic of stem cells is their ability for self-renewal without loss of proliferation capacity with each cell division. The stem cells are immortal, and rather resistant to action of drugs. They are able to differentiate and form specific types of tissue due to the influence of microenvironmental and some other factors. Stem cells divide asymmetrically producing two daughter cells-one is a new stem cell and the second is progenitor cell, which has the ability for differentiation and proliferation, but not the capability for self-renewal. Cancer stem cells are in many aspects similar to the stem cells. It has been proven that tumor cells are heterogeneous comprising rare tumor initiating cells and abundant non-tumor initiating cells. Tumor initiating cells-cancer stem cells have the ability of self-renewal and proliferation, are resistant to drugs, and express typical markers of stem cells. It is not clear whether cancer stem cells originate from normal stem cells in consequence of genetic and epigenetic changes and/or by redifferentiation from somatic tumor cells to the stem-like cells. Probably both mechanisms are involved in the origin of cancer stem cells. Dysregulation of stem cell self-renewal is a likely requirement for the development of cancer. Isolation and identification of cancer stem cells in human tumors and in tumor cell lines has been successful. To date, the existence of cancer stern cells has been proven in acute and chronic myeloid leukemia, in breast cancer, in brain tumors, in lung cancer and gastrointestinal tumors.
   Cancer stem cell model is also consistent with some clinical observations. Although standard chemotherapy kills most cells in a tumor, cancer stem cells remain viable. Despite the small number of such cells, they might be the cause of tumor reccurrence, sometimes many years after the "successful" treatment of primary tumor. Growth of metastases in distinct areas of body and their cellular heterogeneity might be consequence of cancer stem cell differentiation and/or. dedifferentiation and asymmetric division of cancer stem cells. Further characterization of cancer stem cells is needed in order to find ways to destroy them, which might contribute significantly to the therapeutic management of malignant tumors.
C1 Slovak Acad Sci, Inst Canc Res, Bratislava, Slovakia.
C3 Slovak Academy of Sciences
RP Slovak Acad Sci, Inst Canc Res, Bratislava, Slovakia.
EM exonalt@savba.sk
RI Altaner, Cestmir/F-7057-2018
OI Altaner, Cestmir/0000-0001-6998-0885; Soltysova,
   Andrea/0000-0002-1402-3583
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alison M, 1998, J HEPATOL, V29, P676, DOI 10.1016/S0168-8278(98)80165-7
   Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3
   Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635
   Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282
   Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Demirkazik A, 2002, BIOL BLOOD MARROW TR, V8, P268, DOI 10.1053/bbmt.2002.v8.pm12064364
   Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100
   Frankel MS, 2000, SCIENCE, V287, P1397, DOI 10.1126/science.287.5457.1397
   Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319
   Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062
   Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602
   Hatfield SD, 2005, NATURE, V435, P974, DOI 10.1038/nature03816
   Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100
   Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056
   Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080
   Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100
   Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458
   Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032
   Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Li L, 2003, CANCER RES, V63, P2733
   Nakagawara A, 2004, CANCER LETT, V204, P213, DOI 10.1016/S0304-3835(03)00457-9
   Pecora AL, 2002, BIOL BLOOD MARROW TR, V8, P536, DOI 10.1053/bbmt.2002.v8.pm12434948
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651
   Sherley JL, 2002, STEM CELLS, V20, P561, DOI 10.1634/stemcells.20-6-561
   Singh SK, 2003, CANCER RES, V63, P5821
   Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270
   Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186
   Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219
   TenHaveOpbroek AAW, 1996, CANCER LETT, V101, P211
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tu SM, 2002, LANCET ONCOL, V3, P508, DOI 10.1016/S1470-2045(02)00820-3
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
NR 43
TC 135
Z9 180
U1 0
U2 87
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0028-2685
EI 1338-4317
J9 NEOPLASMA
JI Neoplasma
PY 2005
VL 52
IS 6
BP 435
EP 440
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 995QN
UT WOS:000234119000001
PM 16284686
DA 2025-01-12
ER

PT J
AU Vo, QN
   Kim, WJ
   Cvitanovic, L
   Boudreau, DA
   Ginzinger, DG
   Brown, KD
AF Vo, QN
   Kim, WJ
   Cvitanovic, L
   Boudreau, DA
   Ginzinger, DG
   Brown, KD
TI The <i>ATM</i> gene is a target for epigenetic silencing in locally
   advanced breast cancer
SO ONCOGENE
LA English
DT Article
DE ATM; epigenetics; promoter hypermethylation; breast cancer
ID PROMOTER; MUTATIONS; RADIATION; HYPERMETHYLATION; METHYLATION; WOMEN
AB Several epidemiological studies on ataxia-telangiectasia families indicate that obligate ATM heterozygotes display an elevated risk for developing breast cancer. However, a molecular basis for a potential link between diminished ATM function and sporadic breast malignancy remains elusive. Here, we show that 78% (18 out of a panel of 23) of surgically removed breast tumors (stage II or greater) displayed aberrant methylation of the ATM proximal promoter region as judged by methylation-specific PCR. Aberrant methylation of the ATM promoter was independently confirmed in several tumors by bisulfate sequencing. Moreover, bisulfate sequencing indicated that this region of the genome is subject to dense methylation. Further, we found a highly significant correlation (P = 0.0006) between reduced ATM mRNA abundance, as measured by real-time RT-PCR, and aberrant methylation of the ATM gene promoter. These findings indicate that epigenetic silencing of ATM expression occurs in locally advanced breast tumors, and establish a link at the molecular level between reduced ATM function and sporadic breast malignancy.
C1 Dept Biochem & Mol Biol, New Orleans, LA USA.
   LSU Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA USA.
   Dept Surg, New Orleans, LA USA.
   Dept Pathol, New Orleans, LA USA.
   Univ Calif San Francisco, UCSF Comprehens Canc Ctr, San Francisco, CA 94143 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; University of California System; University
   of California San Francisco; UCSF Medical Center; UCSF Helen Diller
   Family Comprehensive Cancer Center
RP Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245,1600 Archer Rd, Gainesville, FL 32610 USA.
EM kdbrown1@ufl.edu
CR Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3
   Angèle S, 2000, CLIN CANCER RES, V6, P3536
   Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7
   Bebb DG, 1999, BRIT J CANCER, V80, P1979, DOI 10.1038/sj.bjc.6690630
   Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289
   Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785
   Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205
   EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011
   Esteller M, 2001, CANCER RES, V61, P3225
   Fang ZM, 2001, PATHOLOGY, V33, P30
   FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307
   Gueven N, 2003, GENE CHROMOSOME CANC, V38, P157, DOI 10.1002/gcc.10261
   Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kairouz R, 1999, J CLIN PATHOL-MOL PA, V52, P252, DOI 10.1136/mp.52.5.252
   Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485
   Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555
   Shafman TD, 2000, GENE CHROMOSOME CANC, V27, P124, DOI 10.1002/(SICI)1098-2264(200002)27:2<124::AID-GCC2>3.0.CO;2-M
   SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101
   Vo QN, 2002, J CLIN PATHOL, V55, P669, DOI 10.1136/jcp.55.9.669
NR 21
TC 83
Z9 88
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD DEC 16
PY 2004
VL 23
IS 58
BP 9432
EP 9437
DI 10.1038/sj.onc.1208092
PG 6
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 880BT
UT WOS:000225764100015
PM 15516988
DA 2025-01-12
ER

PT J
AU Dickinson, RE
   Dallol, A
   Bieche, I
   Krex, D
   Morton, D
   Maher, ER
   Latif, F
AF Dickinson, RE
   Dallol, A
   Bieche, I
   Krex, D
   Morton, D
   Maher, ER
   Latif, F
TI Epigenetic inactivation of <i>SLIT3</i> and <i>SLIT1</i> genes in human
   cancers
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE SLIT1; SLIT3; methylation; tumours
ID CELL LUNG-CANCER; AXON GUIDANCE; PROMOTER HYPERMETHYLATION; CHROMOSOME
   3P21.3; BREAST CANCERS; HUMAN HOMOLOG; RASSF1A GENE; ALLELIC LOSS;
   TUMOR; METHYLATION
AB In Drosophila, the Slit gene product, a secreted glycoprotein, acts as a midline repellent to guide axonal development during embryogenesis. Three human Slit gene orthologues have been characterised and recently we reported frequent promoter region hypermethylation and transcriptional silencing of SLIT2 in lung, breast, colorectal and glioma cell lines and primary tumours. Furthermore, re-expression of SLIT2 inhibited the growth of cancer cell lines so that SLIT2 appears to function as a novel tumour suppressor gene (TSG). We analysed the expression of SLIT3 (5q35 - 34) and SLIT1 ( 1q23.3 - q24) genes in 20 normal human tissues. Similar to SLIT2 expression profile, SLIT3 is expressed strongly in many tissues, while SLIT1 expression is neuronal specific. We analysed the 50 CpG island of SLIT3 and SLIT1 genes in tumour cell lines and primary tumours for hypermethylation. SLIT3 was found to be methylated in 12 out of 29 ( 41%) of breast, one out of 15 (6.7%) lung, two out of six (33%) colorectal and in two out of (29%) glioma tumour cell lines. In tumour cell lines, silenced SLIT3 associated with hypermethylation and was re-expressed after treatment with 5-aza-2'-deoxycytidine. In primary tumours, SLIT3 was methylated in 16% of primary breast tumours, 35% of gliomas and 38% of colorectal tumours. Direct sequencing of bisulphite-modified DNA from methylated tumour cell lines and primary tumours demonstrated that majority of the CpG sites analysed were heavily methylated. Thus, both SLIT2 and SLIT3 are frequently methylated in gliomas and colorectal cancers, but the frequency of SLIT3 methylation in lung and breast cancer is significantly less than that for SLIT2. We also demonstrated SLIT1 promoter region hypermethylation in glioma tumour lines ( five out of six; 83%), the methylation frequency in glioma tumours was much lower ( two out of 20; 10%). Hence, evidence is accumulating for the involvement of members of the guidance cues molecules and their receptors in tumour development.
C1 Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England.
   Ctr Rene Huguenin, INSERM, E0017, Lab Oncogenet, F-92210 St Cloud, France.
   Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dept Neurosurg, D-01307 Dresden, Germany.
   Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England.
   Univ Birmingham, Canc Res UK Renal Mol Oncol Res Grp, Birmingham B15 2TG, W Midlands, England.
C3 University of Birmingham; Rene Huguenin Hospital; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Technische Universitat
   Dresden; Carl Gustav Carus University Hospital; University of
   Birmingham; University of Birmingham
RP Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England.
EM flatif@hgmp.mrc.ac.uk
RI Krex, Dietmar/E-6833-2014; Dallol, Ashraf/H-8661-2012; MAHER,
   EAMONN/A-9507-2008; Bieche, Ivan/O-7399-2017
OI MAHER, EAMONN/0000-0002-6226-6918; Bieche, Ivan/0000-0002-2430-5429
FU Breast Cancer Now [2001:183] Funding Source: Medline
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Girard L, 2000, CANCER RES, V60, P4894
   Goel A, 2003, CANCER RES, V63, P1608
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9
   Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0
   Kuroki T, 2003, CANCER RES, V63, P3352
   Lerman MI, 2000, CANCER RES, V60, P6116
   Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7
   Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097
   Plump AS, 2002, NEURON, V33, P219, DOI 10.1016/S0896-6273(01)00586-4
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098
   Yuan SSF, 1999, DEV BIOL, V207, P62, DOI 10.1006/dbio.1998.9141
   Yuan WL, 2003, P NATL ACAD SCI USA, V100, P5217, DOI 10.1073/pnas.0730709100
NR 30
TC 120
Z9 142
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD DEC 13
PY 2004
VL 91
IS 12
BP 2071
EP 2078
DI 10.1038/sj.bjc.6602222
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 879OH
UT WOS:000225726600015
PM 15534609
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Jandrig, B
   Seitz, S
   Hinzmann, B
   Arnold, W
   Micheel, B
   Koelble, K
   Siebert, R
   Schwartz, A
   Ruecker, K
   Schlag, PM
   Scherneck, S
   Rosenthal, A
AF Jandrig, B
   Seitz, S
   Hinzmann, B
   Arnold, W
   Micheel, B
   Koelble, K
   Siebert, R
   Schwartz, A
   Ruecker, K
   Schlag, PM
   Scherneck, S
   Rosenthal, A
TI <i>ST18</i> is a breast cancer tumor suppressor gene at human chromosome
   8q11.2
SO ONCOGENE
LA English
DT Article
DE breast cancer; tumor suppressor genes; ST18; chromosome 8q11
ID DNA METHYLATION; ZINC-FINGER; REGION; HETEROZYGOSITY; CARCINOGENESIS;
   IDENTIFICATION; INVOLVEMENT; PARAMETERS; MUTATIONS
AB We have identified a gene, ST18 ( suppression of tumorigenicity 18, breast carcinoma, zinc-finger protein), within a frequent imbalanced region of chromosome 8q11 as a breast cancer tumor suppressor gene. The ST18 gene encodes a zinc-finger DNA-binding protein with six fingers of the C2HC type ( configuration Cys-X-5-Cys-X-12-His-X-4-Cys) and an SMC domain. ST18 has the potential to act as transcriptional regulator. ST18 is expressed in a number of normal tissues including mammary epithelial cells although the level of expression is quite low. In breast cancer cell lines and the majority of primary breast tumors, ST18 mRNA is significantly downregulated. A 160 bp region within the promoter of the ST18 gene is hypermethylated in about 80% of the breast cancer samples and in the majority of breast cancer cell lines. The strong correlation between ST18 promoter hypermethylation and loss of ST18 expression in tumor cells suggests that this epigenetic mechanism is responsible for tumor-specific downregulation. We further show that ectopic ST18 expression in MCF-7 breast cancer cells strongly inhibits colony formation in soft agar and the formation of tumors in a xenograft mouse model.
C1 Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13092 Berlin, Germany.
   Signature Diagnost AG, D-10719 Berlin, Germany.
   Atugen AG, D-13125 Berlin, Germany.
   Univ Potsdam, Inst Biochem & Biol, D-14476 Golm, Germany.
   Humboldt Univ, Charite Hosp, Inst Pathol, D-10117 Berlin, Germany.
   Robert Rossle Hosp, Clin Surg & Surg Oncol, D-13122 Berlin, Germany.
   Univ Hosp Schleswig Holstein, Inst Human Genet, D-24105 Kiel, Germany.
C3 Helmholtz Association; Max Delbruck Center for Molecular Medicine;
   University of Potsdam; Berlin Institute of Health; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; University of Kiel; Schleswig Holstein University Hospital
RP Jandrig, B (通讯作者)，Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13092 Berlin, Germany.
EM jandrig@mdc-berlin.de
RI Siebert, Reiner/A-8049-2010
CR Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S
   Åström AK, 2000, INT J ONCOL, V16, P1107
   Bardet V, 2002, GENE CHROMOSOME CANC, V33, P178, DOI 10.1002/gcc.10014
   Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992
   Böttger V, 1999, J MOL RECOGNIT, V12, P191
   BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S
   Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911
   Dahiya R, 1998, INT J ONCOL, V12, P811
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921
   Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361
   Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065
   Jandrig B, 1996, INT J CANCER, V68, P188, DOI 10.1002/(SICI)1097-0215(19961009)68:2<188::AID-IJC8>3.0.CO;2-U
   Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675
   Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A
   LINDNER W, 1987, INT J PEPT PROT RES, V30, P794
   Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31
   Osborne RJ, 2000, CANCER RES, V60, P3706
   Seitz S, 2000, EUR J CANCER, V36, P1507, DOI 10.1016/S0959-8049(00)00135-0
   Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497
   Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275
   Wang JC, 1999, GENOMICS, V60, P1, DOI 10.1006/geno.1999.5905
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366
   Zhang Y, 1999, CYTOGENET CELL GENET, V87, P115, DOI 10.1159/000015375
NR 26
TC 66
Z9 79
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD DEC 9
PY 2004
VL 23
IS 57
BP 9295
EP 9302
DI 10.1038/sj.onc.1208131
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 878HR
UT WOS:000225638000015
PM 15489893
DA 2025-01-12
ER

PT J
AU Keen, JC
   Garrett-Mayer, E
   Petit, C
   Mack, KM
   Manning, J
   Herman, JG
   Davidson, NE
AF Keen, JC
   Garrett-Mayer, E
   Petit, C
   Mack, KM
   Manning, J
   Herman, JG
   Davidson, NE
TI Epigenetic regulation of protein phosphatase 2A (<i>PP2A</i>),
   lymphotactin (<i>XCL1</i>) and estrogen receptor alpha (<i>ER</i>)
   expression in human breast cancer cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITION; CPG ISLAND; DIFFERENTIAL DISTRIBUTION;
   DNA METHYLTRANSFERASE; GENE-EXPRESSION; METHYLATION; DEMETHYLATION;
   HYPERMETHYLATION; SUPPRESSION; ACTIVATION
AB Absence of the estrogen receptor alpha ( ER) in human breast cancer cells is an indicator of poor prognosis, and predictive of lack of response to hormonal therapy. Previous studies in our laboratory and others have shown that epigenetic regulation, including DNA methylation and histone deacetylation, are common mechanisms leading to ER gene silencing. Through the use of pharmacologic inhibitors, 5-aza 2'deoxycytidine (AZA) and Trichostatin A (TSA), we have shown that alterations in both of these mechanisms results in synergistic reexpression of ER mRNA and functional protein. These alterations may play a larger role in stimulation of cell signaling pathways leading to ER expression. We have utilized newly developed genome wide screening microarray techniques to identify gene(s) contributing to the hormone independent phenotype and AZA/TSA mediated ER expression. From this screen, we identified and confirmed expression of 4 candidate genes (PP2A, XCL1, THY1 and NBC4) as potential regulators of the hormone independent phenotype. Expression of two genes, XCL1 and PP2A, appeared to be correlated with ER expression. PP2A expression was not changed with ER degradation using ICI 182,780 whereas XCL1 expression decreased in the presence of AZA/TSA and ICI 182,780. This suggests that PP2A may be a determinant of ER expression while XCL1 appears to be ER responsive and downstream of ER expression. These gene products may be novel targets to be further explored in the development of new therapeutics for ER negative breast cancer.
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB Room 409, Baltimore, MD 21231 USA.
EM davidna@jhmi.edu
OI Keen, Judith/0000-0002-2894-130X; Garrett-Mayer,
   Elizabeth/0000-0003-4709-0333
CR Abeysinghe HR, 2003, CANCER GENET CYTOGEN, V143, P125, DOI 10.1016/S0165-4608(02)00855-5
   BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7
   BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2
   Bird A, 2001, SCIENCE, V294, P2113, DOI 10.1126/science.1066726
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cao Q, 2001, CANCER GENET CYTOGEN, V129, P131, DOI 10.1016/S0165-4608(01)00442-3
   Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Gopalakrishna R, 1999, CANCER LETT, V136, P143, DOI 10.1016/S0304-3835(98)00315-2
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Rousseau RF, 2003, BLOOD, V101, P1718, DOI 10.1182/blood-2002-08-2493
   Shi HD, 2003, CANCER RES, V63, P2164
   Shi HD, 2002, CANCER RES, V62, P3214
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Van der Velden PA, 2003, INT J CANCER, V106, P472, DOI 10.1002/ijc.11262
   Wang QQ, 2002, J MOL MED, V80, P585, DOI 10.1007/s00109-002-0345-3
   Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200
   Xia DJ, 2002, GENE THER, V9, P592, DOI 10.1038/sj.gt.3301694
   Yan PS, 2003, CANCER RES, V63, P6178
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X
NR 37
TC 29
Z9 37
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD DEC
PY 2004
VL 3
IS 12
BP 1304
EP 1312
DI 10.4161/cbt.3.12.1458
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 918WJ
UT WOS:000228578000031
PM 15662126
OA Bronze
DA 2025-01-12
ER

PT J
AU Hussain, A
   Gutiérrez, MI
   Timson, G
   Siraj, AK
   Deambrogi, C
   Al-Rasheed, M
   Gaidano, G
   Magrath, I
   Bhatia, K
AF Hussain, A
   Gutiérrez, MI
   Timson, G
   Siraj, AK
   Deambrogi, C
   Al-Rasheed, M
   Gaidano, G
   Magrath, I
   Bhatia, K
TI Frequent silencing of fragile histidine triad gene (<i>FHIT</i>) in
   Burkitt's lymphoma is associated with aberrant hypermethylation
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID EXPRESSION INDUCES APOPTOSIS; 5'-CPG ISLAND METHYLATION; BARR-VIRUS
   ASSOCIATION; CARCINOMA CELL-LINES; TUMOR-SUPPRESSOR; BREAST-CANCER;
   PROTEIN EXPRESSION; RNA TRANSCRIPTS; DEFICIENT MICE; FRA3B
AB The fragile histidine triad (FHIT) gene, a potential tumor-suppressor gene, is frequently inactivated in multiple human cancers. However, the FHIT gene remains largely unexplored in Burkitt's lymphoma (BL). Hence, we assessed whether loss of FHIT expression occurs in BL, and, if so, what is the mechanism of such loss. Lack of protein expression was observed in 50% of BL cell lines. Methylation-specific polymerase chain reaction (MSP) showed that 45% of BL cell lines carried aberrantly methylated FHIT alleles. Sequencing of bisulfite-treated DNA confirmed these data and indicated a very high density of methylation in all methylated alleles. Real-time, quantitative reverse-transcription PCR analysis indicated that attenuation of full-length FHIT transcription was correlated with methylation. Sequencing of transcripts illustrated that aberrant transcription resulting in loss of FHIT exons occurred more commonly in BL containing unmethylated FHIT genes. However, such transcripts often coexisted with full-length FHIT transcripts. Not surprisingly, therefore, loss of FHIT protein in BL correlated with CpG island methylation, rather than with aberrant transcription. FHIT methylation also was detected in 31% (16 of 5 1) of the primary BLs examined, including 2 samples whose derived cell lines also manifested FHIT hypermethylation. Aberrant methylation can thus occur in vivo. In summary, this report provides evidence that epigenetic modification frequently results in loss of FHIT expression in BL. (C) 2004 Wiley-Liss, Inc.
C1 KFNCCC, KFSHRC, Riyadh 11211, Saudi Arabia.
   Amadeo Avogadro Univ Eastern Piedmont, Hematol Unit, Dept Med Sci & IRCAD, Novara, Italy.
   Int Network Canc Treatment & Res, Brussels, Belgium.
C3 King Faisal Specialist Hospital & Research Center; University of Eastern
   Piedmont Amedeo Avogadro
RP KFNCCC, KFSHRC, POB 3354,MBC 98-16, Riyadh 11211, Saudi Arabia.
EM gutierrez@kfshrc.edu.sa
RI Siraj, Abdul/IQW-1179-2023; Gutierrez, Margarita/KIC-9718-2024; Gaidano,
   Gianluca/AAW-2773-2021
OI GAIDANO, Gianluca/0000-0002-4681-0151
CR Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t
   Chen PM, 2004, ONCOL REP, V11, P349
   Druck T, 1997, CANCER RES, V57, P504
   Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Ferrer M, 1999, MOL CARCINOGEN, V25, P55, DOI 10.1002/(SICI)1098-2744(199905)25:1<55::AID-MC7>3.0.CO;2-3
   Fong KM, 1997, CANCER RES, V57, P2256
   Gemma A, 1997, CANCER RES, V57, P1435
   GUTIERREZ MI, 1992, BLOOD, V79, P3261
   GUTIERREZ MI, 2004, UNPUB MOD PATHOL
   Hallas C, 1999, CLIN CANCER RES, V5, P2409
   Harada K, 2002, CANCER RES, V62, P5897
   Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157
   Huang LW, 2003, GYNECOL ONCOL, V90, P331, DOI 10.1016/S0090-8258(03)00318-4
   Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937
   Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058
   Ishii H, 2003, FASEB J, V17, P1768, DOI 10.1096/fj.03-0241fje
   Ishii H, 2003, MOL CANCER RES, V1, P940
   Magrath IT, 1997, ANN NY ACAD SCI, V824, P91, DOI 10.1111/j.1749-6632.1997.tb46212.x
   Michael D, 1997, ONCOGENE, V15, P1653
   Murphy GA, 2000, CANCER RES, V60, P2342
   Negrini M, 1996, CANCER RES, V56, P3173
   Noguchi T, 2003, INT J MOL MED, V11, P441
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326
   Peters UR, 1999, ONCOGENE, V18, P79, DOI 10.1038/sj.onc.1202256
   Rossi D, 2003, BRIT J HAEMATOL, V123, P475, DOI 10.1046/j.1365-2141.2003.04644.x
   Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799
   Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489
   Sevignani C, 2003, CANCER RES, V63, P1183
   SHIRAMIZU B, 1991, BLOOD, V77, P1516
   Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771
   Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8
   Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100
   Uehara E, 2003, INT J ONCOL, V23, P693
   Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770
   WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390
   Wu QH, 2003, ULTRASTRUCT PATHOL, V27, P417, DOI 10.1080/01913120390250329
   Xiao GH, 1997, AM J PATHOL, V151, P1541
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898
   Zimonjic DB, 1997, CANCER RES, V57, P1166
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 43
TC 6
Z9 7
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD DEC
PY 2004
VL 41
IS 4
BP 321
EP 329
DI 10.1002/gcc.20099
PG 9
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 869TR
UT WOS:000225007700003
PM 15384174
DA 2025-01-12
ER

PT J
AU Xu, XL
   Yu, J
   Zhang, HY
   Sun, MH
   Gu, J
   Du, X
   Shi, DR
   Wang, P
   Yang, ZH
   Zhu, JD
AF Xu, Xiao-Li
   Yu, Jian
   Zhang, Hong-Yu
   Sun, Meng-Hong
   Gu, Jun
   Du, Xiang
   Shi, Da-Ren
   Wang, Peng
   Yang, Zhen-Hua
   Zhu, Jing-De
TI Methylation profile of the promoter CpG islands of 31 genes that may
   contribute to colorectal carcinogenesis
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID DNA METHYLATION; HYPERMETHYLATION PROFILE; WILMS-TUMOR; E-CADHERIN;
   CANCER; EXPRESSION; ACTIVATION; REGION; INACTIVATION; EPIGENETICS
AB AIM: To establish the methylation profile of the promoter CpG islands of 31 genes that might play etiological roles in colon carcinogenesis.
   METHODS: The methylation specific PCR in conjunction of sequencing verification was used to establish the methylation-profile of the promoter CpG islands of 31 genes in colorectal cancer (n = 65), the neighboring non-cancerous tissues (n = 5), colorectal adenoma (n = 8), and normal mucosa (n = 1). Immunohistochemically, expression of 10 genes was assessed on the home-made tissue microarrays of tissues from 58 patients. The correlation of tumor specific changes with each of clinical-pathologic features was scrutinized with relevant statistic tools.
   RESULTS: In comparison with the normal mucosa of the non-cancer patients, the following 14 genes displayed no tumor associated changes: breast cancer 1, early onset (BRCA1), cadherin 1, type 1, E-cadherin (epithelial) (CDH1), death-associated protein kinase 1 (DAPK1), DNA (cytosine5-)-methyltransferase 1 (DNMT1), melanoma antigen, family A, 1 (directs expression of antigen MZ2-E) (MAGEA1), tumor suppressor candidate 3 (N33), cyclin-dependent kinase inhibitor 1A (p21, Cip1) (p21(WAF1)), cyclin-dependent kinase inhibitor 1B (p27, Kip1) (p27(KIP1)), phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN), retinoic acid receptor, beta (RAR- , Ras association (RalGDS/AF-6) domain family 1 C (RASSF1C), secreted frizzled-related protein 1 (SFRP1), tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) (TIMP3), and von Hippel-Lindau syndrome (VHL). The rest 17 targets exhibited to various extents the tumor associated changes. As changes in methylation of the following genes occurred marginally, their impact on the formation of colorectal cancer were trivial: adenomatous polyposis coli (APC) (8%, 5/65), Ras association (RalGDS/AF-6) domain family 1A (RASSF1A) (3%, 2/65) and cyclin-dependent kinase inhibitor 2A, alternated reading frame (p14(ARF)) (6%, 4/65). The following genes exhibited moderate changes in methylation: O-6methylguanine- DNA methyltransferase (MGMT) (20%, 13/65), mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) (hMLH1) (18%, 12/65), cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (p16(INK4a)) (10%, 10/65), methylated in tumor 1 (MINT1) (15%, 10/65), methylated in tumor 31 (MINT31) (11%, 7/65). The rest changed greatly in the methylation pattern in colorectal cancer (CRC): cyclin A1 (cyclin a1) (100%, 65/65), caudal type homeobox transcription factor 1 (CDX1) (100%, 65/65), RAR-(85%, 55/65), myogenic factor 3 (MYOD1) (69%, 45/65), cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (p15(INK4b)) (68%, 44/65), prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (COX2) (72%, 47/65), cadherin 13, H-cadherin (heart) (CDH13) (65%, 42/65), CAAX box 1 (CXX1) (58%, 38/65), tumor protein p73 (p73) (63%, 41/65) and Wilms tumor 1 (WT1) (58%, 38/65). However, no significant correlation of changes in methylation with any given clinical-pathological features was detected. Furthermore, the frequent changes in methylation appeared to be an early phase event of colon carcinogenesis. The in situ expression of 10 genes was assessed by the immunohistochemical approach at the protein level: CDH1, CDH13, COX2, cyclin A1, hMLH1, MGMT, p14 ARF, p73, RAR-, and TIMP3 genes in the context of the methylation status in colorectal cancer. No clear correlation between the hypermethylation of the promoter CpG islands and the negative expression of the genes was established.
   CONCLUSION: The methylation profile of 31 genes was established in patients with colon cancer and colorectal adenomas, which provides new insights into the DNA methylation mediated mechanisms underlying the carcinogenesis of colorectal cancer and may be of prognostic values for colorectal cancer.
C1 [Yu, Jian; Zhang, Hong-Yu; Gu, Jun; Wang, Peng; Zhu, Jing-De] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Inst Canc, Shanghai 200032, Peoples R China.
   [Xu, Xiao-Li; Sun, Meng-Hong; Du, Xiang; Shi, Da-Ren] Fudan Univ, Canc Hosp, Dept Pathol, Shanghai 200032, Peoples R China.
   [Yang, Zhen-Hua] Fudan Univ, Inst Resp Dis, Zhong Shan Hosp, Shanghai 200032, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Fudan University
RP Zhu, JD (通讯作者)，Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Inst Canc, LN2200-25,Xietu Rd, Shanghai 200032, Peoples R China.
EM zhujingde@yahoo.com
RI Yang, Zhenhua/KIB-8535-2024; sun, meng/JGE-3753-2023
FU National High Technology Research and Development Program of China (863
   Program) [2002AA2Z3352]; Science Foundation of Shanghai Municipal
   Government [02DJ14056, 024119010]; State-Key Laboratory for Oncogenes
   and Related Genes, Shanghai Cancer Institute, Shanghai Jiaotong
   University
FX Supported by the National High Technology Research and Development
   Program of China (863 Program), No. 2002AA2Z3352, the Science Foundation
   of Shanghai Municipal Government, No. 02DJ14056, and the Special Fund
   set up by the State-Key Laboratory for Oncogenes and Related Genes,
   Shanghai Cancer Institute, Shanghai Jiaotong University, This work was
   also supported by the Science Foundation of Shanghai Municipal
   Government to Xiang Du, No. 024119010
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ahuja N, 1998, CANCER RES, V58, P5489
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cai Q, 2002, MOL GENETICS RES HNP
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Cote S, 1997, ANTI-CANCER DRUG, V8, P56
   DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694
   DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149
   DuBois RN, 1999, GUT, V45, P636, DOI 10.1136/gut.45.5.636
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2001, CANCER RES, V61, P3225
   Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515
   Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Issa J., 2001, GENES AFFECTED PROMO
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x
   Jubb AM, 2001, J PATHOL, V195, P111, DOI 10.1002/path.923
   Jubb AM, 2003, ANN NY ACAD SCI, V983, P251, DOI 10.1111/j.1749-6632.2003.tb05980.x
   Kibel AS, 2001, PROSTATE, V48, P248, DOI 10.1002/pros.1104
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036
   Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788
   Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026
   LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564
   Maruyama R, 2001, CANCER RES, V61, P8659
   Müller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   Neibergs HL, 2002, J SURG ONCOL, V80, P204, DOI 10.1002/jso.10131
   Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33
   Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980
   Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0
   Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Toyooka S, 2002, CANCER RES, V62, P3382
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   van Rijnsoever M, 2002, GUT, V51, P797, DOI 10.1136/gut.51.6.797
   Viswanathan M, 2003, INT J CANCER, V105, P41, DOI 10.1002/ijc.11028
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Watanabe T, 2002, ACTA NEUROPATHOL, V104, P357, DOI 10.1007/s00401-002-0549-1
   Yu J, 2003, CELL RES, V13, P319, DOI 10.1038/sj.cr.7290177
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 44
TC 166
Z9 199
U1 0
U2 21
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD DEC 1
PY 2004
VL 10
IS 23
BP 3441
EP 3454
PG 14
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA V19VL
UT WOS:000208099800011
PM 15526363
DA 2025-01-12
ER

PT J
AU Leu, YW
   Yan, PS
   Fan, MY
   Jin, VX
   Liu, JC
   Curran, EM
   Welshons, WV
   Wei, SH
   Davuluri, RV
   Plass, C
   Nephew, KP
   Huang, THM
AF Leu, YW
   Yan, PS
   Fan, MY
   Jin, VX
   Liu, JC
   Curran, EM
   Welshons, WV
   Wei, SH
   Davuluri, RV
   Plass, C
   Nephew, KP
   Huang, THM
TI Loss of estrogen receptor signaling triggers epigenetic silencing of
   downstream targets in breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID HISTONE H3 METHYLTRANSFERASE; CPG-ISLAND METHYLATION; DNA METHYLATION;
   GENE-EXPRESSION; CHROMATIN-STRUCTURE; RNA INTERFERENCE; MAMMALIAN-CELLS;
   ACETYLATION; PATTERNS; TRANSCRIPTION
AB Alterations in histones, chromatin-related proteins, and DNA methylation contribute to transcriptional silencing in cancer, but the sequence of these molecular events is not well understood. Here we demonstrate that on disruption of estrogen receptor (ER) alpha signaling by small interfering RNA, polycomb repressors and histone deacetylases are recruited to initiate stable repression of the progesterone receptor (PR) gene, a known ERalpha target, in breast cancer cells. The event is accompanied by acquired DNA methylation of the PR promoter, leaving a stable mark that can be inherited by cancer cell progeny. Reestablishing ERa signaling alone was not sufficient to reactivate the PR gene; reactivation of the PR gene also requires DNA demethylation. Methylation microarray analysis further showed that progressive DNA methylation occurs in multiple ERa targets in breast cancer genomes. The results imply, for the first time, the significance of epigenetic regulation on ERalpha target genes, providing new direction for research in this classical signaling pathway.
C1 Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.
   Indiana Univ, Sch Med, Bloomington, IN USA.
   Indiana Univ, Ctr Canc, Dept Cellular & Integrat Physiol & Obstet & Genec, Indianapolis, IN USA.
   Univ Missouri, Dept Vet Biomed Sci, Columbus, MS USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Indianapolis; University of Missouri System; University of Missouri
   Columbia
RP Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, 420 W 12th Ave, Columbus, OH 43210 USA.
EM huang-10@medctr.osu.edu
RI Davuluri, Ramana/D-7348-2011; Plass, Christoph/H-7192-2014; Yan,
   Pearlly/E-4339-2011
FU NCI NIH HHS [R01 CA-69065, R01 CA-85289] Funding Source: Medline
CR Aerts JLE, 2002, BBA-GEN SUBJECTS, V1571, P167, DOI 10.1016/S0304-4165(02)00192-7
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731
   Jensen EV, 2003, CLIN CANCER RES, V9, P1980
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 1996, CANCER RES, V56, P2463
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Lynch Catherine A, 2002, Mol Cancer, V1, P2, DOI 10.1186/1476-4598-1-2
   MUTSKOV V, 2004, EMBO J, V1, P1
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Oesterreich S, 2001, CANCER RES, V61, P5771
   Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0
   PFERFER GP, 1990, P NATL ACAD SCI USA, V87, P8252
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X
   Schiff R, 2003, CLIN CANCER RES, V9, p447S
   Schübeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000
   Shi HD, 2003, CANCER RES, V63, P2164
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   TAMARU H, 2003, NAT GENET, V12, P177
   Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   XU X, 2004, GENE, V17, P143
   Yan PS, 2001, CANCER RES, V61, P8375
   Yen PS, 2000, BRIT J CANCER, V82, P514, DOI 10.1054/bjoc.1999.0955
NR 48
TC 161
Z9 189
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2004
VL 64
IS 22
BP 8184
EP 8192
DI 10.1158/0008-5472.CAN-04-2045
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 872CA
UT WOS:000225182300010
PM 15548683
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Saito, T
   Oda, Y
   Kawaguchi, K
   Sugimachi, K
   Yamamoto, H
   Tateishi, N
   Tanaka, K
   Matsuda, S
   Iwamoto, Y
   Ladanyi, M
   Tsuneyoshi, M
AF Saito, T
   Oda, Y
   Kawaguchi, K
   Sugimachi, K
   Yamamoto, H
   Tateishi, N
   Tanaka, K
   Matsuda, S
   Iwamoto, Y
   Ladanyi, M
   Tsuneyoshi, M
TI E-cadherin mutation and Snail overexpression as alternative mechanisms
   of E-cadherin inactivation in synovial sarcoma
SO ONCOGENE
LA English
DT Article
DE E-cadherin; Snail; CpG methylation; mutation; ELF3; synovial sarcoma;
   epithelial-mesenchymal transition
ID EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTIONAL REPRESSOR SNAIL; CPG
   ISLAND METHYLATION; SOFT-TISSUE SARCOMAS; CELL-CELL-ADHESION; SSX FUSION
   TYPE; GENE-EXPRESSION; BREAST-CANCER; GASTRIC-CANCER; BETA-CATENIN
AB We have recently reported frequent E-cadherin gene mutations in synovial sarcoma (SS), suggesting mutational inactivation of E-cadherin as a potential mechanism of spindle cell morphology in SS, a spindle cell sarcoma that shows areas of glandular epithelial differentiaton in some cases (biphasic SS) and only pure spindle cell morphology in most cases (monophasic SS). However, the mechanism of downregulation of E-cadherin in SS remains unknown. To further address this issue, we analysed the mechanisms of E-cadherin silencing in 40 SS. Genetic and epigenetic changes in the E-cadherin gene, and the expression level of its transcriptional repressor Snail were examined by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP), methylation-specific PCR, and real-time quantitative PCR, respectively. Expression of E-cadherin was examined by RT-PCR and immunohistochemistry. We also examined ELF3, a transcription factor associated with epithelial differentiation in SS in a previous cDNA microarray, by RT-PCR. E-cadherin and ELF3 transcripts were detected, respectively, in 27/40 (67.5%) and in 25/40 (62.5%) of SS, and these epithelial-related genes were almost always coexpressed. Hypermethylation of the promoter of the E-cadherin gene was detected in five cases (12.5%) in SS; however, E-cadherin was silenced at mRNA level in only one of the five cases. E-cadherin missense mutations were observed in five cases (12.5%) of SS. In SS, all five cases with E-cadherin missense mutations had the SYT-SSX1 fusion and were monophasic tumors, suggesting a relationship between the SYT-SSX fusion type and E-cadherin missense mutation (P = 0.07). E-cadherin mRNA expression in SS was associated with reduced Snail expression level (P = 0.03). E-cadherin membranous expression was observed in 14/40 (35.0%) of SS, and was also correlated with SYT-SSX1 fusion type and biphasic histology. ELF3 was confirmed to be more highly expressed in biphasic than monophasic SS by real-time quantitative PCR. These results suggest that in SS the loss of E-cadherin expression occurs either by Snail trans-repression or by inactivating mutations. Thus, E-cadherin downregulation is associated with the loss or absence of glandular epithelial differentiation in certain SS.
C1 Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka 8128582, Japan.
   Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
C3 Kyushu University; Kyushu University; Memorial Sloan Kettering Cancer
   Center
RP Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.
EM masazumi@surgpath.med.kyushu-u.ac.jp
RI Ladanyi, Marc/AAG-8585-2019; Tanaka, Kazuhiro/Q-7387-2019; Matsuda,
   Shuichi/CAA-3095-2022
OI Matsuda, Shuichi/0000-0003-0802-1255
FU NCI NIH HHS [CA47179] Funding Source: Medline
CR Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9
   [Anonymous], 2008, ENZINGER WEISSS SOFT
   Antonescu CR, 2000, DIAGN MOL PATHOL, V9, P1, DOI 10.1097/00019606-200003000-00001
   Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0
   Brown DT, 2003, BIOCHEM CELL BIOL, V81, P221, DOI 10.1139/o03-049
   Bukholm IK, 2000, J PATHOL, V190, P15
   BURDSAL CA, 1993, DEVELOPMENT, V118, P829
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x
   Endo K, 2001, J PATHOL, V193, P310, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH816>3.0.CO;2-K
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   Gambarotta G, 1996, ONCOGENE, V13, P1911
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Graff JR, 1998, CANCER RES, V58, P2063
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   Hajra KM, 2002, CANCER RES, V62, P1613
   HENNIG G, 1995, ONCOGENE, V11, P475
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hiraguri S, 1998, CANCER RES, V58, P1972
   Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7
   Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303
   KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L
   Ladanyi M, 2002, CANCER RES, V62, P135
   Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601
   Laskin WB, 2002, ARCH PATHOL LAB MED, V126, P425
   Lee YF, 2003, BRIT J CANCER, V88, P510, DOI 10.1038/sj.bjc.6600766
   Lewis JJ, 2000, J CLIN ONCOL, V18, P2087, DOI 10.1200/JCO.2000.18.10.2087
   Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200
   Machado JC, 1999, LAB INVEST, V79, P459
   Machen SK, 1999, AM J SURG PATHOL, V23, P268, DOI 10.1097/00000478-199903000-00004
   MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623
   MAYER B, 1993, CANCER RES, V53, P1690
   Melki JR, 2000, BLOOD, V95, P3208
   Nagayama S, 2002, CANCER RES, V62, P5859
   Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443
   Noguchi SI, 1997, INT J CANCER, V72, P995
   ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858
   Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419
   OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937
   OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A
   Pérez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200
   Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200
   Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438
   Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1
   Saito A, 1999, JPN J CANCER RES, V90, P993, DOI 10.1111/j.1349-7006.1999.tb00847.x
   Saito T, 2000, J PATHOL, V192, P342, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R
   Saito T, 2002, LAB INVEST, V82, P97, DOI 10.1038/labinvest.3780399
   Saito T, 2002, HISTOPATHOLOGY, V40, P279, DOI 10.1046/j.1365-2559.2002.01345.x
   Saito T, 2001, AM J PATHOL, V159, P2117, DOI 10.1016/S0002-9440(10)63063-5
   Sato H, 1999, HUM PATHOL, V30, P1344, DOI 10.1016/S0046-8177(99)90066-7
   Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132
   SCOTT GK, 1994, J BIOL CHEM, V269, P19848
   Sefton M, 1998, DEVELOPMENT, V125, P3111
   Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6
   SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0
   Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974
   Soares P, 1997, INT J CANCER, V70, P32
   Sugimachi K, 2003, CLIN CANCER RES, V9, P2657
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Trassard M, 2001, J CLIN ONCOL, V19, P525, DOI 10.1200/JCO.2001.19.2.525
   VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M
   Yakushiji T, 2000, J CLIN PATHOL, V53, P525, DOI 10.1136/jcp.53.7.525
   Yoo J, 2002, ARCH PATHOL LAB MED, V126, P33
NR 80
TC 43
Z9 53
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD NOV 11
PY 2004
VL 23
IS 53
BP 8629
EP 8638
DI 10.1038/sj.onc.1207960
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 869MR
UT WOS:000224988800009
PM 15467754
DA 2025-01-12
ER

PT J
AU Khan, S
   Kumagai, T
   Vora, J
   Bose, N
   Sehgal, I
   Koeffler, PH
   Bose, S
AF Khan, S
   Kumagai, T
   Vora, J
   Bose, N
   Sehgal, I
   Koeffler, PH
   Bose, S
TI <i>PTEN</i> promoter is methylated in a proportion of invasive breast
   cancers
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE PTEN; methylation; breast cancer
ID TUMOR-SUPPRESSOR GENE; COWDEN-DISEASE; MUTATIONS; PTEN/MMAC1;
   HYPERMETHYLATION; EPIGENETICS; EXPRESSION
AB The PTEN protein is a negative regulator of the Akt pathway, leading to suppression of apoptosis and increased cell survival. Its role as a tumor-suppressor gene has been adequately substantiated, and homozygous mutations have been demonstrated in familial and sporadic cancers. In breast cancers, expression of PTEN protein is lost/reduced in 38% of cases. Somatic mutations are, however, rarely found. Our study was therefore designed to determine if differential methylation of the PTEN promoter region has a role in the transcriptional inactivation of the gene in invasive breast carcinomas. A total of 44 samples of invasive human breast cancer, 5 breast cancer cell lines and 16 samples of normal human breast tissue from young and elderly women were studied for methylation of the PTEN promoter by methylation-specific PCR and PTEN protein expression by immunohistochemistry. PTEN methylation occurred in 34% of breast cancers, and 60% of these samples were associated with loss of PTEN protein. Analyzed from a different perspective, 34% of breast cancers had reduced expression of PTEN and 60% had a methylated PTEN promoter. None of the breast cancer cell lines and normal breast tissues showed methylation. In summary, methylation of the PTEN promoter leads to PTEN inactivation in a subset of human breast cancers. (C) 2004 Wiley-Liss, Inc.
C1 Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA.
   Cedars Sinai Med Ctr, Dept Hematol Oncol, Los Angeles, CA 90048 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA.
C3 Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP Cedars Sinai Med Ctr, Dept Pathol, South Tower 8732,8400 Beverly Blvd, Los Angeles, CA 90048 USA.
EM BoseS@cshs.org
RI Sehgal, Inderpaul/AAA-8165-2021; Vora, Jaykumar/N-4111-2015
CR Ali IU, 2000, JNCI-J NATL CANCER I, V92, P861, DOI 10.1093/jnci/92.11.861
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940
   Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721
   Bussaglia E, 2000, HUM PATHOL, V31, P312, DOI 10.1016/S0046-8177(00)80244-0
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762
   Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122
   Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756
   Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Freihoff D, 1999, BRIT J CANCER, V79, P754, DOI 10.1038/sj.bjc.6690121
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6
   Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507
   Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563
   Rasheed BKA, 1997, CANCER RES, V57, P4187
   Rhei E, 1997, CANCER RES, V57, P3657
   Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S
   Sato K, 2002, VIRCHOWS ARCH, V440, P160, DOI 10.1007/s004280100499
   Sheng XY, 2002, BIOCHEM BIOPH RES CO, V292, P422, DOI 10.1006/bbrc.2002.6662
   Soria JC, 2002, CLIN CANCER RES, V8, P1178
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Tashiro H, 1997, CANCER RES, V57, P3935
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026
   Wang SI, 1997, CANCER RES, V57, P4183
   Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4
NR 34
TC 98
Z9 116
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 10
PY 2004
VL 112
IS 3
BP 407
EP 410
DI 10.1002/ijc.20447
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 862NA
UT WOS:000224496400007
PM 15382065
DA 2025-01-12
ER

PT J
AU Lee, A
   Kim, Y
   Han, K
   Kang, CS
   Jeon, HM
   Shim, SI
AF Lee, A
   Kim, Y
   Han, K
   Kang, CS
   Jeon, HM
   Shim, SI
TI Detection of tumor markers including carcinoembryonic antigen,
   <i>APC</i>, and <i>cyclin D2</i> in fine-needle aspiration fluid of
   breast
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Article
ID METHYLATION-SPECIFIC PCR; PROMOTER HYPERMETHYLATION; CANCER; DNA;
   EPIGENETICS; EXPRESSION; DIAGNOSIS
AB Context-The traditional triple test for breast cancer diagnosis is physical examination, mammography, and aspiration cytology. However, the accuracy of mammography on young women with nonatrophied breasts is poor compared with that for women older than 50 years, and additional methods for diagnosis of breast cancer are needed.
   Objective.-To investigate whether carcinoembryonic antigen (CEA), CA 15-3, and CA 125 concentrations in breast aspiration fluid are useful as breast cancer biochemical markers and whether APC and cyclin D2 gene promoter hypermethylation could be regarded as a breast cancer molecular marker.
   Design.-CEA, CA 15-3, and CA 125 concentrations were measured, and methylation status of the APC gene promoter 1A and the promoter region of the cyclin D2 gene were analyzed using a methylation-specific polymerase chain reaction assay of ex vivo breast aspiration fluid obtained from 49 samples of excised breast tissue.
   Setting.-The specimens were collected during a 1-year period in the tertiary care teaching hospital in Seoul, Korea.
   Patients.-Forty-nine patients with breast masses were surgically treated. Thirty-four patients had breast cancer, and 15 had benign breast disease.
   Results.-Aspiration fluid CEA concentrations were sig-nificantly higher in breast cancer cases than in cases of benign breast disease (mean, 69.90 ng/mg protein vs 0.68 ng/mg protein, respectively; P < .001). At 90% specificity of the assay (CEA, 2.13 ng/mg protein), the corresponding sensitivity for breast cancer detection was 62%, according to the receiver operating characteristic curve drawn. The APC gene promoter 1A and the promoter region of the cyclin D2 gene were methylated in 42% (14/33) and 70% (23/33) of the breast cancer aspiration fluid samples, respectively. A cumulative incidence of methylation of these 2 genes was 85% (28/33). The APC and cyclin D2 gene promoters were both unmethylated in the aspiration fluids from 19 women with nonmalignant breast disease.
   Conclusions.-Breast aspiration fluid CEA concentration and the methylation of the APC gene promoter 1 A and the promoter region of the cyclin D2 gene can be used as tumor markers to overcome some of the limitations of aspiration cytology. In combination with the mammogram and physical examination, assays for these markers could be used to help determine a definitive diagnosis when cytologic results are suspicious for malignancy.
C1 Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul, South Korea.
   Catholic Univ Korea, Coll Med, Dept Surg, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP St Marys Hosp, Dept Clin Pathol, 62 Youido Dong, Seoul 150713, South Korea.
EM cskang@catholic.ac.kr
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   *CENTR CANC REG, 2003, ANN REP CENTR CANC R
   DEVINE PL, 1995, BREAST CANCER RES TR, V34, P245, DOI 10.1007/BF00689716
   DON SM, 2001, J NATL CANCER I, V93, P858
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   GIULIANO AE, 1994, CURRENT SURG DIAGNOS, P293
   Goessl C, 2000, CANCER RES, V60, P5941
   Goessl C, 2002, J PATHOL, V196, P331, DOI 10.1002/path.1063
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149
   Kim Y, 2003, ANN CLIN LAB SCI, V33, P32
   KUROKI M, 1992, CLIN BIOCHEM, V25, P29, DOI 10.1016/0009-9120(92)80042-F
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Park JW, 2002, J IMMUNOL METHODS, V266, P79, DOI 10.1016/S0022-1759(02)00105-9
   Pathak K A, 1996, J Postgrad Med, V42, P68
   Silverman JF., 1995, Breast J, V1, P3
   Silverman JF, 1997, COMPREHENSIVE CYTOPA, P770
   Stearns V, 1998, BREAST CANCER RES TR, V52, P239, DOI 10.1023/A:1006137619153
   Sundblad AS, 1996, HUM PATHOL, V27, P297, DOI 10.1016/S0046-8177(96)90072-6
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   WANG DY, 1984, EUR J CANCER CLIN ON, V20, P25, DOI 10.1016/0277-5379(84)90030-0
   Zhao YS, 2001, J CLIN ONCOL, V19, P1462, DOI 10.1200/JCO.2001.19.5.1462
NR 25
TC 30
Z9 31
U1 0
U2 2
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
EI 1543-2165
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD NOV
PY 2004
VL 128
IS 11
BP 1251
EP 1256
PG 6
WC Medical Laboratory Technology; Medicine, Research & Experimental;
   Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; Research & Experimental Medicine;
   Pathology
GA 867XC
UT WOS:000224875100009
DA 2025-01-12
ER

PT J
AU Jones, LC
   Tefferi, A
   Idos, GE
   Kumagai, T
   Hofmann, WK
   Koeffler, HP
AF Jones, LC
   Tefferi, A
   Idos, GE
   Kumagai, T
   Hofmann, WK
   Koeffler, HP
TI RARβ2 is a candidate tumor suppressor gene in myelofibrosis with myeloid
   metaplasia
SO ONCOGENE
LA English
DT Article
DE myelofibrosis; CD34+; RAR beta
ID ACID RECEPTOR-BETA; RETINOIC ACID; LUNG-CANCER; BREAST-CANCER;
   EPIGENETIC INACTIVATION; BRONCHIAL EPITHELIUM; COLORECTAL-CARCINOMA;
   PROMOTER METHYLATION; TRANSCRIPTION FACTOR; HOMOZYGOUS DELETION
AB Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem-cell disorder that leads to ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis. The molecular mechanisms underlying the development of this myeloproliferative syndrome are currently unknown. In order to identify tumor suppressor genes that may be involved in the disease process, we performed an analysis for loss of heterozygosity (LOH) in CD34 + cells from 29 patients with MMM. We observed a frequency of allelic loss on chromosomal arm 3p in 24% of cases. Detailed mapping of 3p revealed a distinct region of deletion at 3p24. Among the genes known to map within this region is the retinoic acid receptor-beta (RARbeta2) gene. To determine whether RARbeta2 gene activity is diminished in this disease, we analysed its expression in CD34 + cells from 17 patients with MMM using quantitative PCR. Our results indicate that expression of RARbeta2 is significantly decreased in 100% of patient samples compared to that in CD34+ cells from 10 normal individuals. Since allelic loss at 3p24 occurs in <25% of patients, we investigated the contribution of epigenetic modifications to RARβ2 inactivity. Using methylation-specific PCR, we found hypermethylation of RARβ2 in 16 of 18 patients (89%), while the methylated form of the gene was absent in CD34 + cells from nine normal individuals. Our results suggest that RARβ2 acts as a tumor suppressor gene in MMM and that epigenetic changes are the most significant determinants of RARβ2 gene activity in these patients.
C1 Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA.
   Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA.
   Univ Hosp, Dept Hematol, D-60596 Frankfurt, Germany.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Cedars Sinai Medical Center; Mayo Clinic; Goethe
   University Frankfurt; Goethe University Frankfurt Hospital
RP Jones, LC (通讯作者)，Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 8700 Beverly Blvd,Suite BM-1,Room 109, Los Angeles, CA 90048 USA.
EM letetiajones@yahoo.com
FU NCI NIH HHS [T32-CA-75956] Funding Source: Medline
CR BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0
   Batova A, 1997, CANCER RES, V57, P832
   Bench AJ, 2001, BEST PRACT RES CL HA, V14, P531, DOI 10.1053/beha.2001.0153
   Breems-de Ridder MC, 2000, MOL CELL ENDOCRINOL, V165, P1, DOI 10.1016/S0303-7207(00)00255-0
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   DALY MC, 1993, ONCOGENE, V8, P1721
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2
   Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553
   Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kastner P, 2001, ONCOGENE, V20, P7178, DOI 10.1038/sj.onc.1204757
   Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206
   Kuroki T, 2003, CANCER RES, V63, P3724
   Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302
   Lin F, 2000, CANCER RES, V60, P3271
   LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   MARTYRE MC, 1994, BRIT J HAEMATOL, V88, P9, DOI 10.1111/j.1365-2141.1994.tb04970.x
   Mesa RA, 2000, BLOOD, V96, P3374
   Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0
   Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855
   Prowse AH, 1997, AM J HUM GENET, V60, P765
   Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3
   ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Shimizu T, 2000, CANCER RES, V60, P4544
   Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062
   Tefferi A, 2000, NEW ENGL J MED, V342, P1255, DOI 10.1056/NEJM200004273421706
   Tefferi A, 2001, BRIT J HAEMATOL, V113, P763, DOI 10.1046/j.1365-2141.2001.02796.x
   Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012
   Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1
   Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224
   Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Widschwendter M, 1997, CANCER RES, V57, P4158
   Wistuba II, 2000, CANCER RES, V60, P1949
   Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098
   Xie D, 2000, LEUKEMIA, V14, P805, DOI 10.1038/sj.leu.2401717
   Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624
   Xu XC, 1997, CANCER RES, V57, P4992
   Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 54
TC 37
Z9 40
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD OCT 14
PY 2004
VL 23
IS 47
BP 7846
EP 7853
DI 10.1038/sj.onc.1207510
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 860GX
UT WOS:000224331600010
PM 15361842
DA 2025-01-12
ER

PT J
AU Stone, AR
   Bobo, W
   Brat, DJ
   Devi, NS
   Van Meir, EG
   Vertino, PM
AF Stone, AR
   Bobo, W
   Brat, DJ
   Devi, NS
   Van Meir, EG
   Vertino, PM
TI Aberrant methylation and down-regulation of TMS1/ASC in human
   glioblastoma
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID CASPASE RECRUITMENT DOMAIN; SPECK-LIKE PROTEIN; DNA METHYLATION; HUMAN
   BREAST; ACTIVATING ADAPTER; GLIOMA-CELLS; GENE; CANCER; APOPTOSIS; ASC
AB TMS1/ASC is an intracellular signaling molecule with proposed roles in the regulation of apoptosis, nuclear factor-kappaB activation, and cytokine maturation. Previous studies have shown that TMS1/ASC is silenced by epigenetic means in human breast tumors. in this study, we examined methylation and expression of TMS1/ASC in glioblastoma multiforme (GBM). Whereas normal brain tissue was unmethylated at the TMS1 locus and expressed TMS1 message, 11 of 23 human GBM cell lines exhibited reduced or absent expression of TMS1 that was associated with aberrant methylation of a CpG island in the promoter of the TMS1 gene. Quantitative analysis showed that there was an inverse correlation between the degree of methylation and level of TMS1 expression. Treatment of GBM cell. lines lacking TMS1 expression with the methyltransferase inhibitor 5-aza-2'deoxycytidine resulted in partial demethylation and re-expression of TMS1. Analysis of primary tissues indicated that the TMS1 gene is unmethylated and expressed in normal brain, where its expression is restricted to astrocytes. In contrast, TMS1 was aberrantly methylated in 43% (10 of 23) primary GBM specimens. Tumors that exhibited aberrant methylation of TMS1 generally expressed reduced or absent expression of TMS1 as compared to unmethylated cases. Methylation of TMS1 was not associated with patient age, gender, or treatment status. Although the relationship did not reach statistical significance, there was a trend toward increased overall survival for patients with unmethylated tumors. For one patient, disease progression from astrocytic astrocytoma (World Health Organization grade III) to GBM (World Health Organization grade IV) was associated with selective expansion of TMS1-negative cells. The data suggest a role for the epigenetic silencing of TMS1 in the pathogenesis of human GBM. Methylation of TMS1 may prove to be a useful prognostic marker and/or predictor of patient survival and tumor malignancy.
C1 Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Winship Canc Inst, Dept Pathol, Atlanta, GA USA.
   Emory Univ, Sch Med, Winship Canc Inst, Dept Neurosurg, Atlanta, GA USA.
C3 Emory University; Emory University; Emory University
RP Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, 1365-C Clifton Rd,NE, Atlanta, GA 30322 USA.
EM pvertin@emory.edu
OI Van Meir, Erwin G./0000-0003-2444-7707
FU NCI NIH HHS [CA86335, R01 CA086335, R01 CA077337, CA077337] Funding
   Source: Medline; NINDS NIH HHS [K08 NS042934, NS042934] Funding Source:
   Medline
CR Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Balaña C, 2003, CLIN CANCER RES, V9, P1461
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Chauvet N, 2001, EUR J NEUROSCI, V14, P609, DOI 10.1046/j.0953-816x.2001.01686.x
   Conti B, 1999, MOL BRAIN RES, V67, P46, DOI 10.1016/S0169-328X(99)00034-0
   Conway KE, 2000, CANCER RES, V60, P6236
   Costello J F, 2000, Brain Tumor Pathol, V17, P49, DOI 10.1007/BF02482735
   Costello JF, 2003, FRONT BIOSCI, V8, pS175, DOI 10.2741/1027
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Cuny E, 2002, J NEUROSURG, V96, P294, DOI 10.3171/jns.2002.96.2.0294
   DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   FINE HA, 1994, J NEURO-ONCOL, V20, P111, DOI 10.1007/BF01052722
   Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376
   Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hunter SB, 2003, INT J ONCOL, V23, P857
   Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kikuchi T, 2000, J IMMUNOTHER, V23, P184, DOI 10.1097/00002371-200003000-00002
   Kito T, 2003, J NEUROSURG, V98, P385, DOI 10.3171/jns.2003.98.2.0385
   KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x
   KLEIHUES P, 1997, GLIOBLASTOMA PATHOLO, P29
   Komine C, 2003, BRAIN PATHOL, V13, P176
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835
   Masumoto J, 2001, J HISTOCHEM CYTOCHEM, V49, P1269, DOI 10.1177/002215540104901009
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Moriai R, 2002, ANTICANCER RES, V22, P4163
   Shiohara M, 2002, BIOCHEM BIOPH RES CO, V293, P1314, DOI 10.1016/S0006-291X(02)00384-4
   Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200
   Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154
   Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552
   Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027
NR 40
TC 90
Z9 106
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT
PY 2004
VL 165
IS 4
BP 1151
EP 1161
DI 10.1016/S0002-9440(10)63376-7
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 857IS
UT WOS:000224110400011
PM 15466382
OA Green Published, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Chen, ST
   Lin, SY
   Yeh, KT
   Ku, SJ
   Chan, WL
   Chu, YP
   Chang, JG
AF Chen, ST
   Lin, SY
   Yeh, KT
   Ku, SJ
   Chan, WL
   Chu, YP
   Chang, JG
TI Mutational, epigenetic and expressional analyses of caveolin-1 gene in
   breast cancers
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE breast cancer; caveolin-1 gene; direct sequencing; immunohistochemistry;
   methylation specific PCR
ID TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; DNA METHYLATION;
   PROSTATE-CANCER; PLASMA-MEMBRANE; DOWN-REGULATION; CPG ISLANDS; PROTEIN;
   LINES; KINASE
AB Caveolin-1, an integral membrane protein of caveolae found in many cell types, has been suggested as a candidate tumor suppressor. However, the mechanism underlying caveolin-1 decreased expression is not fully understood. The purpose of this study is to investigate the role of aberrant promoter methylation in the regulation of caveolin-1 gene in breast cancer correlated with clinical findings. We used methylation specific PCR, direct sequencing and immunohistochemistry stain methods to explore the role of caveolin-1 gene in the development of breast cancer. We demonstrated that 14 of 55 cases (25.5%) and 4 of 55 cases (7.3%) had methylated CpG-island on caveolin-1 promoter in cancerous and non-cancerous cells, respectively. The frequency of aberrant promoter methylation of breast cancer tissues was significant higher than non-cancerous tissues (p<0.05). There were four types of methylation pattern of caveolin-1 gene in the breast cancer tissues. No mutation but one polymorphism GAC-->GAT at codon 82 was found in the whole exonic sequences of caveolin-1 gene. The methylation status of caveolin-1 gene had no clear relationship with age, cell grade, stage of tumor, and status of estrogen receptor, p53 and c-erbB2 in the breast cancer tissues. However, in breast tissue with aberrant promoter methylation of caveolin-1 gene, the presence of progesterone receptor showed borderline statistic difference compared to unmethylated promoter (p=0.11). Immunohistochemistry demonstrated that expression of caveolin-1 gene correlated with aberrant promoter methylation status in sporadic breast cancer tissues. Our findings suggest that aberrant promoter methylation of caveolin-1 gene is associated with inactivation of expression. This process occurs in the precancerous stage and may play an important role in the development of breast cancer.
C1 China Med Univ, Dept Mol Med, Taichung, Taiwan.
   Changhua Christian Hosp, Dept Surg, Changhua, Taiwan.
   Taipei Med Univ, Dept Internal Med, Taipei, Taiwan.
   Natl Chung Shing Univ, Dept Comp Sci, Taichung, Taiwan.
   Taipei Inst Pathol, Taipei, Taiwan.
C3 China Medical University Taiwan; Changhua Christian Hospital; Taipei
   Medical University; National Chung Hsing University
RP China Med Univ, Dept Mol Med, 2 Yuh Der Rd, Taichung, Taiwan.
EM d6781@www.crnch.org.tw
RI Chang, Jan-Gowth/C-9544-2009
CR ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bender FC, 2000, CANCER RES, V60, P5870
   Campbell L, 2003, BRIT J CANCER, V89, P1909, DOI 10.1038/sj.bjc.6601359
   Chan TF, 2003, INT J ONCOL, V23, P599
   Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429
   Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#
   Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843
   Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8
   Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172
   Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374
   Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633
   Hayashi K, 2001, CANCER RES, V61, P2361
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hino M, 2003, SURG TODAY, V33, P486, DOI 10.1007/s10595-002-2538-4
   HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H
   HOU MF, 2000, KAOHSIUNG J MED SCI, V16, P411
   Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491
   Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6
   Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930
   Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416
   Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419
   SINGERSAM J, 1992, P NATL ACAD SCI USA, V89, P1413, DOI 10.1073/pnas.89.4.1413
   Smart EJ, 1999, MOL CELL BIOL, V19, P7289
   Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427
   Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690
   Su TH, 1998, INT J CANCER, V76, P216, DOI 10.1002/(SICI)1097-0215(19980413)76:2<216::AID-IJC8>3.3.CO;2-T
   Suzuoki M, 2002, BRIT J CANCER, V87, P1140, DOI 10.1038/sj.bjc.6600619
   Thomas T, 1998, ALZHEIMERS REP, V1, P17
   Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099
   Tsutsui S, 2002, J SURG ONCOL, V79, P216, DOI 10.1002/jso.10079
   Tsutsui S, 2001, Breast Cancer, V8, P194, DOI 10.1007/BF02967508
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X
   Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503
   Yang G, 1999, CANCER RES, V59, P5719
   Yeh KT, 2003, INT J ONCOL, V23, P1001
   Yoo SH, 2003, LUNG CANCER, V42, P195, DOI 10.1016/S0169-5002(03)00287-3
   Zschocke J, 2002, J BIOL CHEM, V277, P38772, DOI 10.1074/jbc.M205664200
NR 45
TC 56
Z9 61
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD OCT
PY 2004
VL 14
IS 4
BP 577
EP 582
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 857GI
UT WOS:000224104000012
PM 15375584
DA 2025-01-12
ER

PT J
AU Butcher, DT
   Mancini-DiNardo, DN
   Archer, TK
   Rodenhiser, DI
AF Butcher, DT
   Mancini-DiNardo, DN
   Archer, TK
   Rodenhiser, DI
TI DNA binding sites for putative methylation boundaries in the
   unmethylated region of the <i>BRCA1</i> promoter
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE DNA methylation; BRCA1; boundaries; Sp1; CTCF; breast cancer
ID TUMOR-SUPPRESSOR GENE; CPG ISLAND METHYLATION; CARCINOMA IN-SITU;
   SPORADIC BREAST; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVITY;
   HOMONUCLEOTIDE TRACTS; MAMMALIAN DEVELOPMENT; COLORECTAL-CANCER;
   CPG/CPNPG MOTIFS
AB Changes in DNA methylation patterns are frequently observed in human cancers and are associated with a decrease in tumor suppressor gene expression. Hypermethylation of the BRCAI promoter has been reported in a portion of sporadic breast tumours that correspond to a reduction in BRCAI transcription and expression. Questions remain concerning the maintenance of methylation free zones in promoter regions of tumor suppressor genes in normal tissues. Sodium bisulfite based analysis of the BRCAI promoter defines a methylation free zone in normal breast tissue that starts 650 bp upstream of the transcription start site and extends for 1.4 kb through most of the BRCAI CpG island. We provide data implicating 2 proteins, SpI and CTCF, in the maintenance of this methylation-free zone. Both of these proteins have been shown to function as methylation boundaries in other genes. Four SpI sites have been identified in the BRCAI promoter by gel shift assays. In vivo binding of SpI has been confirmed at 2 of these sites in the BRCAI promoter and at 2 CTCF sites that flank the unmethylated region. Our data suggest that these DNA binding sites for SpI and CTCF may act as boundary elements that are important in maintaining genomic integrity by delineating the normal methylation free BRCAI promoter. Inactivation or disruption of these boundaries may facilitate an epigenetic "hit", in this case DNA methylation, leading to BRCAI downregulation and contributing to tumorigenesis, particularly the genesis of sporadic breast tumours. (C) 2004 Wiley-Liss, Inc.
C1 London Reg Canc Ctr, Child Hlth Res Inst, London, ON N6A 4L6, Canada.
   Univ Western Ontario, Dept Biochem Paediat & Oncol, London, ON, Canada.
   Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA.
   NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Princeton University; National
   Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP London Reg Canc Ctr, Child Hlth Res Inst, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.
EM drodenhi@uwo.ca
OI Archer, Trevor K/0000-0001-7651-3644
CR Andrews JD, 1996, HUM MOL GENET, V5, P503, DOI 10.1093/hmg/5.4.503
   [Anonymous], 1989, Molecular Cloning, A Laboratory Manual
   Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516
   Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6
   Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cui HM, 2002, CANCER RES, V62, P6442
   Deng CX, 2000, BIOESSAYS, V22, P728
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Filippova GN, 2002, CANCER RES, V62, P48
   Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Greally JM, 1999, P NATL ACAD SCI USA, V96, P14430, DOI 10.1073/pnas.96.25.14430
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637
   JENSEN RA, 1999, NAT GENET, V12, P298
   Jones PA, 1996, CANCER RES, V56, P2463
   Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847
   KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612
   LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   MANCINIDINARDO DN, 2001, ONCOGENE, V20, P5331
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Miyakura Y, 2003, GENE CHROMOSOME CANC, V36, P17, DOI 10.1002/gcc.10134
   Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698
   Nicolás M, 2003, BIOCHEM J, V371, P265, DOI 10.1042/BJ20021166
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530
   Prowse AH, 1997, AM J HUM GENET, V60, P765
   RADFORD DM, 1995, CANCER RES, V55, P3399
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.3.CO;2-V
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Rodenhiser D, 1996, ONCOGENE, V12, P2623
   Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6
   Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796
   Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454
   SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811
   Uno Y, 2001, BIOCHEMISTRY-US, V40, P1787, DOI 10.1021/bi0023596
   Versteeg R, 1997, AM J HUM GENET, V60, P751
   Vos CBJ, 1999, BRIT J CANCER, V81, P1410, DOI 10.1038/sj.bjc.6693372
   Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26
   Yeh A, 2002, GENE CHROMOSOME CANC, V35, P156, DOI 10.1002/gcc.10110
NR 60
TC 52
Z9 59
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 20
PY 2004
VL 111
IS 5
BP 669
EP 678
DI 10.1002/ijc.20324
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 845SD
UT WOS:000223263700004
PM 15252835
OA Bronze
DA 2025-01-12
ER

PT J
AU Bae, YK
   Brown, A
   Garrett, E
   Bornman, D
   Fackler, MJ
   Sukumar, S
   Herman, JG
   Gabrielson, E
AF Bae, YK
   Brown, A
   Garrett, E
   Bornman, D
   Fackler, MJ
   Sukumar, S
   Herman, JG
   Gabrielson, E
TI Hypermethylation in histologically distinct classes of breast cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; E-CADHERIN EXPRESSION; CPG-ISLAND; PROMOTER
   HYPERMETHYLATION; DNA HYPERMETHYLATION; COLORECTAL-CANCER; GENE;
   INACTIVATION; TUMORS; PATTERNS
AB Purpose: A number of different genes are known to be inactivated by aberrant hypermethylation in breast cancer, but it is still unknown to what extent these epigenetic alterations; differ according to specific breast cancer phenotypes. We sought to determine whether the extent of hypermethylation or defined profiles of gene hypermethylation are associated with biological characteristics of breast cancers.
   Experimental Design: We evaluated methylation status of 12 different genes in a series of 109 invasive breast tumors, representing the ductal, lobular, and mucinous histologic subtypes using methylation-specific PCR. Frequencies of methylation were compared across the recognized histologic classes, and multivariate techniques (latent class analysis, factor analysis, recursive partitioning, and hierarchical clustering) were used to seek patterns of methylation for individual genes that distinguish recognized histologic types of breast cancer or define breast cancer phenotypes on a molecular level.
   Results: All 109 cases studied have aberrant methylation of multiple genes (3 to 10 genes per case), demonstrating that gene hypermethylation is pervasive in breast cancer. Lobular cancers and mucinous cancers, which often have relatively low levels of chromosomal changes, have higher overall frequencies of hypermethylation than ductal cancers (49% in lobular and mucinous versus 40% in ductal), but there is a relatively unimodal distribution of methylation frequency for all three histologic types. Only one of the individual genes studied, BRCA1, has a variable frequency of methylation that is significantly dependent on histologic pattern of tumor growth, with a higher frequency of methylation in mucinous cancers than ductal or lobular cancers. Although some trends of histology-specific gene methylation were seen, methylation patterns could not definitively classify breast cancers according to histologic type.
   Conclusions: Although a more comprehensive hypermethylation profile could potentially be useful for breast cancer classification and understanding the biology of this disease, it appears that the hypermethylation patterns across various forms of breast cancer are less distinct than those between breast cancer and cancers of different tissue origins. Furthermore, the relatively unimodal distribution of methylation frequency for all three histologic types does not support there being a distinct CpG island methylator phenotype for breast cancer.
C1 Yeungnam Univ, Coll Med, Dept Pathol, Taegu, South Korea.
   Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA.
   Johns Hopkins Univ, Sch Med, Stanley Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 Yeungnam University; Johns Hopkins University; Johns Hopkins University
RP John Hopkins Canc Ctr, Dept Pathol, 417 N Caroline St, Baltimore, MD 21231 USA.
EM egabriel@jhmi.edu
OI Bae, Young Kyung/0000-0002-6689-9413
CR Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fujii H, 2002, BREAST CANCER RES TR, V76, P255, DOI 10.1023/A:1020808020873
   Garrett ES, 2000, BIOMETRICS, V56, P1055, DOI 10.1111/j.0006-341X.2000.01055.x
   Gonzalgo ML, 1997, CANCER RES, V57, P594
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   GRAFF JR, 1995, CANCER RES, V55, P5195
   HAYASHIZAKI Y, 1993, ELECTROPHORESIS, V14, P251, DOI 10.1002/elps.1150140145
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Huiping C, 1999, BRIT J CANCER, V81, P1103, DOI 10.1038/sj.bjc.6690815
   Krop I, 2003, CANCER RES, V63, P2024
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lehmann U, 2002, CANCER RES, V62, P6634
   Li Z, 2002, CANCER RES, V62, P1939
   McCutcheon AL., 1987, LATENT CLASS ANAL SA
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Shen CY, 2000, CANCER RES, V60, P3884
   Shi HD, 2002, CANCER RES, V62, P3214
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Toyota M, 1999, CANCER RES, V59, P2307
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9
   Yan PS, 2001, CANCER RES, V61, P8375
NR 40
TC 91
Z9 103
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 15
PY 2004
VL 10
IS 18
BP 5998
EP 6005
DI 10.1158/1078-0432.CCR-04-0667
PN 1
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 856XU
UT WOS:000224080200005
PM 15447983
OA Bronze
DA 2025-01-12
ER

PT J
AU Takahashi, T
   Shivapurkar, N
   Riquelme, E
   Shigematsu, H
   Reddy, J
   Suzuki, M
   Miyajima, K
   Zhou, X
   Bekele, BN
   Gazdar, AF
   Wistuba, II
AF Takahashi, T
   Shivapurkar, N
   Riquelme, E
   Shigematsu, H
   Reddy, J
   Suzuki, M
   Miyajima, K
   Zhou, X
   Bekele, BN
   Gazdar, AF
   Wistuba, II
TI Aberrant promoter hypermethylation of multiple genes in gallbladder
   carcinoma and chronic cholecystitis
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CPG-ISLAND METHYLATION; TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER;
   ALLELOTYPING ANALYSIS; DNA METHYLATION; LUNG; EXPRESSION; PATHOGENESIS;
   CELL; RIZ1
AB Purpose: Aberrant methylation of 5' gene promoter regions is an epigenetic phenomenon that is a major mechanism for silencing of tumor suppressor genes in many cancer types. There is limited information about the molecular changes involved in the pathogenesis of gallbladder carcinoma (GBC), including methylation status.
   Experimental Design: We investigated the aberrant promoter methylation profile of 24 known or suspected tumor suppressor genes in 50 GBCs and compared those results with the findings in 25 chronic cholecystitis (CC) specimens without cancer. The methylation-specific polymerase chain reaction and combined restriction analysis methods were used to detect methylation, and the results were confirmed by sequencing of cloned polymerase chain reaction products.
   Results: In GBC, gene methylation frequencies varied from 0% to 80%. Ten genes demonstrated relatively high frequencies of aberrant methylation: SHP1 (80%), 3-OST-2 (72%), CDH13 (44%), P-15(INK4B) (44%), CDH1 (38%), RUNX3 (32%), APC (30%), RIZ1 (26%), P16(INK4A) (24%), and HPP1 (20 %). Eight genes (P73, RARbeta2, SOCS-1, DAPK, DcR2, DcR1, HIN1, and CHFR) showed low frequencies (2-14%) of methylation, and no methylation of the remaining six genes (TIMP-3, P57, RASSF1A, CRBP1, SYK, and NORE1) was detected. In CC, methylation was detected for seven genes: SHP1 (88 %), P15(INK4B) (28 %), 3-OST-2 (12%), CDH1 (12 %), CDH13 (8 %), DcR2 (4 %), and P16(INK4A) (4%) Significantly higher frequencies of methylation in GBC compared with CC were detected for eight genes (3-OST-2, CDH13, CDH1, RUNX3, APC, RIZ1, P16(INK4A), and HPP1). Of those, four genes showed frequent methylation (>30%) in GBCs. The mean methylation index, an expression of the amount of methylated genes by case, was significantly higher in GBC (0.196 +/- 0.013) compared with CC (0.065 +/- 0.008; P < 0.001).
   Conclusions: Our study constitutes the most comprehensive methylation profile report available in GBC and demonstrates that this neoplasm has a distinct pattern of abnormal gene methylation. Whereas gallbladders from healthy individual were not available, our finding of methylation in CC cases without cancer suggests that this phenomenon represents an early event in the pathogenesis of GBC.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA.
   Pontificia Univ Catolica Chile, Dept Pathol Anat, Santiago, Chile.
   Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; Pontificia Universidad Catolica de Chile;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas Dallas
RP Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM iiwistuba@mdanderson.org
RI Gazdar, Adi/F-7496-2010; RIQUELME, ERICK/AAA-6191-2022
OI RIQUELME, ERICK/0000-0002-2696-7995
CR Ajiki T, 1996, GUT, V38, P426, DOI 10.1136/gut.38.3.426
   Bachman KE, 1999, CANCER RES, V59, P798
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497
   Chang HW, 2003, CLIN CANCER RES, V9, P1033
   Corn PG, 1999, CANCER RES, V59, P3352
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Du Y, 2001, CANCER RES, V61, P8094
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2002, CANCER RES, V62, P5902
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Hansel DE, 2003, AM J PATHOL, V163, P217, DOI 10.1016/S0002-9440(10)63645-0
   He LS, 1998, CANCER RES, V58, P4238
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191
   House MG, 2003, ANN SURG ONCOL, V10, P882, DOI 10.1245/ASO.2003.02.014
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lazcano-Ponce EC, 2001, CA-CANCER J CLIN, V51, P349, DOI 10.3322/canjclin.51.6.349
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026
   Matsuda K, 2001, CANCER RES, V61, P5562
   Misra S, 2003, LANCET ONCOL, V4, P167, DOI 10.1016/S1470-2045(03)01021-0
   Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8
   OKA H, 1993, CANCER RES, V53, P1696
   Oka T, 2002, CANCER RES, V62, P6390
   Parwani AV, 2003, MODERN PATHOL, V16, P299, DOI 10.1097/01.MP.0000062656.60581.AA
   Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   Shibata DM, 2002, CANCER RES, V62, P5637
   Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716
   Tang MY, 2004, CLIN CANCER RES, V10, P1041, DOI 10.1158/1078-0432.CCR-0701-3
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2003, CLIN CANCER RES, V9, P3034
   Toyooka S, 2002, CANCER RES, V62, P3382
   Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704
   van Noesel MM, 2002, CANCER RES, V62, P2157
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   WISTUBA II, 1995, CANCER RES, V55, P2511
   Wistuba II, 2002, AM J PATHOL, V160, P2073, DOI 10.1016/S0002-9440(10)61157-1
   Wistuba II, 2001, CANCER RES, V61, P3795
   Wistube II, 2002, BRIT J CANCER, V87, P432, DOI 10.1038/sj.bjc.6600490
   YOSHIDA S, 1995, CANCER RES, V55, P2756
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Young J, 2001, P NATL ACAD SCI USA, V98, P265, DOI 10.1073/pnas.011415298
   Yuan YF, 2001, CANCER RES, V61, P5558
NR 52
TC 95
Z9 106
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 15
PY 2004
VL 10
IS 18
BP 6126
EP 6133
DI 10.1158/1078-0432.CCR-04-0579
PN 1
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 856XU
UT WOS:000224080200021
PM 15447999
OA Bronze
DA 2025-01-12
ER

PT J
AU Dulaimi, E
   Hillinck, J
   Ibanez de Caceres, I
   Al-Saleem, T
   Cairns, P
AF Dulaimi, E
   Hillinck, J
   Ibanez de Caceres, I
   Al-Saleem, T
   Cairns, P
TI Tumor suppressor gene promoter hypermethylation in serum of breast
   cancer patients
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID METHYLATION-SPECIFIC PCR; DNA METHYLATION; CPG ISLAND;
   MOLECULAR-DETECTION; LUNG-CANCER; P16(INK4A); MARKERS; PROTEIN; CELLS;
   EXPRESSION
AB Purpose: Breast cancer is the most common malignancy in American women and the second leading cause of death from cancer. The genetic and epigenetic alterations that initiate and drive cancer can be used as targets for detection of neoplasia in bodily fluids. Tumor cell-specific aberrant promoter hypermethylation can be detected in nipple aspirate and ductal lavage from breast cancer patients. In this study, we examine serum, a more readily accessible bodily fluid known to contain neoplastic DNA from individuals with cancer, for methylation-based detection of breast neoplasia.
   Experimental Design: We examined the promoter methylation status of three normally unmethylated biologically significant cancer genes, PAS association domain family protein 1A (RASSF1A), adenomatous polyposis coli (APC), and death-associated protein kinase (DAP-kinase), by sensitive methylation-specific PCR in 34 breast tumor and paired preoperative serum DNA. The 34 patients comprised 7 ductal carcinoma in situ (CIS), 3 lobular CIS, 5 stage I and 15 stage II to IV invasive ductal carcinomas, and 4 invasive lobular carcinomas. Normal and benign tissue and serum control DNA were also examined to determine the specificity of hypermethylation.
   Results: Hypermethylation of one or more genes was found in 32 of 34 (94%) breast tumor DNA. APC was hypermethylated in 15 of 34 (47%), RASSF1A in 22 of 34 (65%), and DAP-kinase in 17 of 34 (50%) tumors. Twenty-six (76%) of the corresponding serum DNA were positive for promoter hypermethylation, including ductal CIS, lobular CIS, stage I disease, and lobular carcinoma patients. No hypermethylation of APC, RASSF1A, or DAP-kinase was observed in serum DNA from normal healthy women and patients with inflammatory breast disease or nonneoplastic breast tissue specimens. A gene unmethylated in the tumor DNA was always found to be unmethylated in the matched serum DNA (100% specificity).
   Conclusions: Tumor cell specific promoter hypermethylation of APC, RASSF1A, and DAP-kinase is present in ductal CIS, lobular CIS, and all grades and stages of invasive breast cancer. Hypermethylation can be detected by methylation-specific PCR analysis in serum DNA from patients with preinvasive and early-stage breast cancer amenable to cure. If confirmed in additional studies, hypermethylation-based screening of serum, a readily accessible bodily fluid, may enhance early detection of breast cancer.
C1 Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA.
   Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA.
   Chestnut Hill Acad, Philadelphia, PA USA.
C3 Fox Chase Cancer Center; Fox Chase Cancer Center
RP Fox Chase Canc Ctr, Dept Surg Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.
EM Paul.Cairns@fccc.edu
RI IBANEZ DE CACERES, INMACULADA/F-4653-2016
OI IBANEZ DE CACERES, INMACULADA/0000-0001-9805-8486
FU NCI NIH HHS [CA083638] Funding Source: Medline
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Cairns P, 2001, CLIN CANCER RES, V7, P2727
   COUCH FJ, 2001, METABOLIC MOL BASIS, P999
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Greene F., 2002, AJCC cancer staging handbook: From the AJCC cancer staging manual, V6th
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hibi K, 1998, CANCER RES, V58, P1405
   Holst CR, 2003, CANCER RES, V63, P1596
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lehmann U, 2002, CANCER RES, V62, P6634
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Leitch A M, 1999, Surg Oncol Clin N Am, V8, P657
   LEON SA, 1977, CANCER RES, V37, P646
   Müller HM, 2003, CANCER RES, V63, P7641
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Reddy AN, 2003, CANCER RES, V63, P7694
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
NR 33
TC 177
Z9 212
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 15
PY 2004
VL 10
IS 18
BP 6189
EP 6193
DI 10.1158/1078-0432.CCR-04-0597
PN 1
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 856XU
UT WOS:000224080200028
PM 15448006
DA 2025-01-12
ER

PT J
AU Guweidhi, A
   Kleeff, J
   Giese, N
   El Fitori, J
   Ketterer, K
   Giese, T
   Büchler, MW
   Korc, M
   Friess, H
AF Guweidhi, A
   Kleeff, J
   Giese, N
   El Fitori, J
   Ketterer, K
   Giese, T
   Büchler, MW
   Korc, M
   Friess, H
TI Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in
   cell cycle regulation and apoptosis
SO CARCINOGENESIS
LA English
DT Article
ID BCL-X-L; 14-3-3-SIGMA STRATIFIN; DUCTAL ADENOCARCINOMA; BREAST-CANCER;
   EARLY EVENT; BH3 DOMAIN; SIGMA GENE; HUMAN MYT1; PROTEINS; BINDING
AB 14-3-3sigma belongs to the 14-3-3 family of proteins, which are involved in the modulation of diverse signal transduction pathways. Loss of 14-3-3sigma expression has been observed in a number of human cancers, suggesting that it may have a role as a tumor suppressor gene. The aim of the study was to investigate the expression and the functional role of 14-3-3sigma in pancreatic ductal adenocarcinoma (PDAC). Expression of 14-3-3sigma was analyzed using laser capture microdissection (LCM), quantitative real-time-PCR (QRT-PCR), DNA arrays, immunohistochemistry and western blot analysis. The role of 14-3-3sigma in apoptosis and cell cycle regulation was evaluated by western blotting, immunoprecipitation and FACS analysis. By QRT-PCR, 14-3-3sigma mRNA levels were 54-fold increased in pancreatic adenocarcinoma in comparison with normal pancreatic samples and localized in pancreatic cancer cells as determined by LCM. In pancreatic cancer cells, the degree of 14-3-3sigma expression was not decisive for the maintenance of G(2)/M cell cycle checkpoint or induction of apoptosis. Responses to radiation or apoptosis-inducing agents were neither accompanied by a significant 14-3-3sigma accumulation nor by a change in association of 14-3-3sigma with cdc2, bad and bax. In conclusion, the marked over-expression of 14-3-3sigma in PADC together with multiple known genetic and epigenetic alterations of potential 14-3-3sigma interacting partners suggests an important role of aberrant 14-3-3sigma downstream signaling in pancreatic cancer.
C1 Heidelberg Univ, Dept Gen Surg, D-6900 Heidelberg, Germany.
   Heidelberg Univ, Dept Immunol, D-6900 Heidelberg, Germany.
   Dartmouth Coll Sch Med, Dept Med, Lebanon, NH 03756 USA.
   Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Dartmouth College; Dartmouth College
RP Heidelberg Univ, Dept Gen Surg, D-6900 Heidelberg, Germany.
EM helmut_friess@med.uni-heidelberg.de
RI Friess, Helmut/ABO-1348-2022; Buechler, Markus/ABE-3716-2022; Kleeff,
   Jorg/B-2124-2009
OI Kleeff, Jorg/0000-0003-3432-6669
CR AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9
   AITKEN DW, 1992, NUCLEUS-CAMBRIDGE, V14, P3
   Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200
   BEGER HG, 1994, CHIRURG, V65, P246
   Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Chung HJ, 1999, TRENDS PLANT SCI, V4, P367, DOI 10.1016/S1360-1385(99)01462-4
   Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929
   EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713
   Friess H, 2003, CELL MOL LIFE SCI, V60, P1180, DOI 10.1007/s00018-003-3036-5
   Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   Gasco M, 2002, CANCER RES, V62, P2072
   Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256
   Giese NA, 2002, CANCER GENE THER, V9, P432, DOI 10.1038/sj.cgt.7700457
   GUDJONSSON B, 1987, CANCER-AM CANCER SOC, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V
   Guo JC, 2004, ONCOGENE, V23, P71, DOI 10.1038/sj.onc.1206926
   HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040
   Kleeff J, 2000, INT J CANCER, V86, P399, DOI 10.1002/(SICI)1097-0215(20000501)86:3<399::AID-IJC15>3.0.CO;2-G
   Korc M, 1998, Surg Oncol Clin N Am, V7, P25
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346
   Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571
   Logsdon CD, 2003, CANCER RES, V63, P2649
   MARTZOUKOS SH, 1992, ENERG ECON, V14, P3, DOI 10.1016/0140-9883(92)90019-A
   Nakanishi Kozo, 1997, Human Antibodies, V8, P189
   Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866
   Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   RAITANO AB, 1990, PANCREAS, V5, P267, DOI 10.1097/00006676-199005000-00005
   Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9
   Rosenquist M, 2001, PLANT PHYSIOL, V127, P142, DOI 10.1104/pp.127.1.142
   Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200
   Sato N, 2003, CANCER RES, V63, P4158
   Sinha P, 1999, ELECTROPHORESIS, V20, P2952, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H
   Stewart ZA, 1999, J MAMMARY GLAND BIOL, V4, P389, DOI 10.1023/A:1018770417964
   Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376
   Suzuki H, 2000, CANCER RES, V60, P4353
   SWANSON KD, 1992, GENE, V113, P183, DOI 10.1016/0378-1119(92)90394-5
   Türeci Ö, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Ungefroren H, 1998, CANCER RES, V58, P1741
   van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134
   VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45
   Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9
   Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008
   WALDMAN T, 1995, CANCER RES, V55, P5187
   WANG S, 1994, APPL LASER, V14, P3
   Wang WF, 1996, J MOL EVOL, V43, P384
   WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706
   Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0
   Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4
   Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0
   YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3
   Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101
NR 63
TC 67
Z9 100
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD SEP
PY 2004
VL 25
IS 9
BP 1575
EP 1585
DI 10.1093/carcin/bgh159
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 850CM
UT WOS:000223588800004
PM 15073049
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Tzao, C
   Tsai, HY
   Chen, JT
   Chen, CY
   Wang, YC
AF Tzao, C
   Tsai, HY
   Chen, JT
   Chen, CY
   Wang, YC
TI 5′CpG island hypermethylation and aberrant transcript splicing both
   contribute to the inactivation of the <i>FHIT</i> gene in resected
   non-small cell lung cancer
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE FHIT gene; 5 ' CpG hypermethylation; alternative splicing; LOH; NSCLC;
   bronchial lesions
ID BREAST-CANCER; BRONCHIAL LESIONS; DEFICIENT MICE; EXPRESSION; 3P14.2;
   CARCINOMAS; FRA3B; ABNORMALITIES; METHYLATION; ASSOCIATION
AB The relative contribution of promoter hypermethylation and aberrant splicing to the inactivation of the fragile histidine triad (FHIT) gene is unclear. Using genetic and epigenetic analyses, the current investigation examines the loss of protein and mRNA expression, and 5'CpG hypermethylation and allelic imbalance of the FHIT gene in a series of 129 non-small cell lung cancer (NSCLC) samples, in parallel with clinicopathological analyses. We found that 50% of NSCLC patients had aberrant protein expression, which was more frequent in squamous cell carcinomas (SQ)(-) (69%) than in adenocarcinomas (AD) (28%) (P<0.0001). 5'CpG hypermethylation of FHIT was identified in 31% of patients. Abnormally-sized FHIT transcripts were also observed in 24% of patients and were attributed to various exonic deletions, mainly in the region of exons 4-8. Allelic imbalance of the FHIT locus and its correlation with the status of Fhit expression, 5'CpG hypermethylation, and aberrant splicing, indicated that biallelic inactivation of Fhit expression could be induced by 5'CpG hypermethylation of one allele and alternative splicing in the other allele. Moreover, an 83% concordance in the methylation status of FHIT was demonstrated between 12 samples of bronchial precancerous lesions taken before surgery and their matched resected tumours. Our data suggest that FHIT 5'CpG hypermethylation and splicing alterations are both predominant mechanisms involved in the aberrant expression of the FHIT gene, and that FHIT 5'CpG methylation may be potentially used as a supplemental detection marker for NSCLC. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Natl Taiwan Normal Univ, Dept Life Sci, Taipei 116, Taiwan.
   Natl Taiwan Normal Univ, Tri Serv Gen Hosp, Div Thorac Surg, Taipei, Taiwan.
   Taichung Vet Gen Hosp, Dept Pathol, Taichung, Taiwan.
   Taichung Vet Gen Hosp, Div Thorac Surg, Taichung, Taiwan.
C3 National Taiwan Normal University; National Taiwan Normal University;
   Tri-Service General Hospital; Taichung Veterans General Hospital;
   Taichung Veterans General Hospital
RP Natl Taiwan Normal Univ, Dept Life Sci, 88,Sect 4,Tingchou Rd, Taipei 116, Taiwan.
EM t43017@cc.ntnu.edu.tw
RI Wang, Yi-Ching/J-8702-2019
OI Wang, Yi-Ching/0000-0002-7694-2067
CR Ahmadian M, 1997, CANCER RES, V57, P3664
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Burke L, 1998, CANCER RES, V58, P2533
   Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098
   Fong KM, 1997, CANCER RES, V57, P2256
   Garinis GA, 2001, J PATHOL, V193, P55, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH731>3.0.CO;2-#
   Geradts J, 2000, BRIT J CANCER, V82, P1191, DOI 10.1054/bjoc.1999.1062
   Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7
   Ji L, 1999, CANCER RES, V59, P3333
   Mandai M, 1998, EUR J CANCER, V34, P745, DOI 10.1016/S0959-8049(97)10147-2
   Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412
   Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144
   Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456
   Negrini M, 1996, CANCER RES, V56, P3173
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426
   Sozzi G, 1997, CANCER RES, V57, P2121
   Sozzi G, 1998, CANCER RES, V58, P5032
   Sozzi G, 1997, CANCER RES, V57, P5207
   Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8
   Tanaka H, 1998, CANCER RES, V58, P3429
   Tokuchi Y, 1999, GENE CHROMOSOME CANC, V24, P105, DOI 10.1002/(SICI)1098-2264(199902)24:2<105::AID-GCC2>3.3.CO;2-G
   Tseng JE, 1999, CANCER RES, V59, P4798
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 26
TC 21
Z9 27
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2004
VL 40
IS 14
BP 2175
EP 2183
DI 10.1016/j.ejca.2004.06.022
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 860YG
UT WOS:000224379900032
PM 15341994
DA 2025-01-12
ER

PT J
AU Sriuranpong, V
   Mutirangura, A
   Gillespie, JW
   Patel, V
   Amornphimoltham, P
   Molinolo, AA
   Kerekhanjanarong, V
   Supanakorn, S
   Supiyaphun, P
   Rangdaeng, S
   Voravud, N
   Gutkind, JS
AF Sriuranpong, V
   Mutirangura, A
   Gillespie, JW
   Patel, V
   Amornphimoltham, P
   Molinolo, AA
   Kerekhanjanarong, V
   Supanakorn, S
   Supiyaphun, P
   Rangdaeng, S
   Voravud, N
   Gutkind, JS
TI Global gene expression profile of nasopharyngeal carcinoma by laser
   capture microdissection and complementary DNA microarrays
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID EPSTEIN-BARR-VIRUS; SQUAMOUS-CELL CARCINOMAS; PROMOTER HYPERMETHYLATION;
   COLORECTAL-CANCER; BINDING-PROTEIN; HIGH-FREQUENCY; BREAST-CANCER;
   STROMELYSIN 3; MUTATIONS; HEAD
AB A number of genetic and epigenetic changes underlying the development of nasopharyngeal carcinomas have recently been identified. However, there is still limited information on the nature of the genes and gene products whose aberrant expression and activity promote the malignant conversion of nasopharyngeal epithelium. Here, we have performed a genome-wide transcriptome analysis by probing cDNA microarrays with fluorescent-labeled amplified RNA derived from laser capture microdissected cells procured from normal nasopharyngeal epithelium and areas of metaplasia-dysplasia and carcinoma from EBV-associated nasopharyngeal carcinomas. This approach enabled the identification of genes differentially expressed in each cell population, as well as numerous genes whose expression can help explain the aggressive clinical nature of this tumor type. For example, genes indicating cell cycle aberrations (cyclin D2, cyclin B1, activator of S-phase kinase, and the cell cycle checkpoint kinase, CHK1) and invasive-metastatic potential (matrix metalloproteinase 11, v-Ral, and integrin beta(4)) were highly expressed in tumor cells. In contrast, genes under-expressed in tumors included genes involved in apoptosis (B-cell CLL/lymphoma 6, secretory leukocyte protease inhibitor, and calpastatin), cell structure (keratin 7 and carcinoembryonic antigen-related cell adhesion molecule 6), and putative tumor suppressor genes (H-Ras-like suppressor 3, retinoic acid receptor responder 1, and growth arrested specific 8) among others. Gene expression patterns also suggested alterations in the Wnt/beta-catenin and transforming growth factor beta pathways in nasopharyngeal carcinoma. Thus, expression profiles indicate that aberrant expression of growth, survival, and invasion-promoting genes may contribute to the molecular pathogenesis of nasopharyngeal carcinoma. Ultimately, this approach may facilitate the identification of clinical useful markers of disease progression and novel potential therapeutic targets for nasopharyngeal carcinoma.
C1 NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
   NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA.
   Chulalongkorn Univ, Fac Med, Med Oncol Unit, Dept Med, Bangkok 10330, Thailand.
   Chulalongkorn Univ, Fac Med, Genet Unit, Dept Anat, Bangkok 10330, Thailand.
   Chulalongkorn Univ, Fac Med, Dept Otorhinolaryngol, Bangkok 10330, Thailand.
   Chiang Mai Univ, Fac Med, Dept Pathol, Chiang Mai 50000, Thailand.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Dental & Craniofacial Research (NIDCR); National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI); Chulalongkorn
   University; Chulalongkorn University; Chulalongkorn University; Chiang
   Mai University
RP NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.
EM sg39v@nih.gov
RI Gillespie Jr, John/HKM-4991-2023; Gutkind, J./A-1053-2009; Mutirangura,
   Apiwat/C-8197-2009; Amornphimoltham, Walt/AAP-9654-2020; Gutkind, J
   Silvio/J-1201-2016
OI Gutkind, J Silvio/0000-0002-5150-4482
CR AHMAD A, 1986, J SURG ONCOL, V33, P194, DOI 10.1002/jso.2930330310
   Ahmad A, 1998, AM J PATHOL, V152, P721
   Albagli-Curiel O, 2003, ONCOGENE, V22, P507, DOI 10.1038/sj.onc.1206152
   Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685
   Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0
   Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7
   Bassal S, 2001, GENOMICS, V77, P5, DOI 10.1006/geno.2001.6570
   Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29
   Bernard DJ, 2002, MOL ENDOCRINOL, V16, P207, DOI 10.1210/me.16.2.207
   Bolon I, 1997, AM J PATHOL, V150, P1619
   BONNER RF, 1997, SCIENCE WASH DC, V278
   Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174
   Chan ASC, 2000, CANCER RES, V60, P5365
   Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899
   Clark GM, 1997, CANCER RES, V57, P5505
   CVITKOVIC E, 1993, J CLIN ONCOL, V11, P2434, DOI 10.1200/JCO.1993.11.12.2434
   Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559
   Eberwine J, 1996, BIOTECHNIQUES, V20, P584
   EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998
   Feldman AL, 2002, BIOTECHNIQUES, V33, P906, DOI 10.2144/02334mt04
   Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375
   Fung LF, 2000, LIFE SCI, V67, P923, DOI 10.1016/S0024-3205(00)00684-6
   Gildea JJ, 2002, CANCER RES, V62, P982
   HAJNAL A, 1994, ONCOGENE, V9, P479
   Heichman KA, 1998, MOL CELL, V1, P457, DOI 10.1016/S1097-2765(00)80046-5
   Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060
   Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201
   KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370
   Kirikoshi H, 2001, INT J ONCOL, V19, P111
   Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0
   Kummar S, 2002, BRIT J CANCER, V86, P1884, DOI 10.1038/sj.bjc.6600326
   Kwong J, 2002, CLIN CANCER RES, V8, P131
   LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825
   Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703
   Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859
   Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009
   Lo KW, 1996, CANCER RES, V56, P2721
   Lo KW, 2000, CANCER RES, V60, P3348
   Lo KW, 2001, CANCER RES, V61, P3877
   Lo YMD, 1999, CANCER RES, V59, P1188
   López-Ferrer A, 2001, AM J RESP CELL MOL, V24, P22, DOI 10.1165/ajrcmb.24.1.4294
   Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477
   Mutirangura A, 1997, BRIT J CANCER, V76, P770, DOI 10.1038/bjc.1997.460
   Nicholls JM, 1997, J PATHOL, V183, P164
   NIEDOBITEK G, 1991, J PATHOL, V165, P17, DOI 10.1002/path.1711650105
   Opdam FJM, 2000, EUR J CELL BIOL, V79, P308, DOI 10.1078/S0171-9335(04)70034-5
   PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103
   PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355
   PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114
   Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X
   Regauer S, 2000, HUM PATHOL, V31, P1096, DOI 10.1053/hupa.2000.6279
   ROUYER N, 1994, INVAS METAST, V14, P269
   Rubin JS, 2000, J LARYNGOL OTOL, V114, P772
   Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926
   SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2
   Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094
   Soni S, 2003, INT J CANCER, V107, P309, DOI 10.1002/ijc.11366
   Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367
   Taggart CC, 2002, J BIOL CHEM, V277, P33648, DOI 10.1074/jbc.M203710200
   Tokumaru Y, 2003, J NATL CANCER I, V95, P919, DOI 10.1093/jnci/95.12.919
   Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901
   Vokes EE, 1997, LANCET, V350, P1087, DOI 10.1016/S0140-6736(97)07269-3
   Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457
   Xie L, 2000, J CANCER RES CLIN, V126, P400, DOI 10.1007/PL00008488
   Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843
   Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556
   Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911
NR 69
TC 77
Z9 85
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 1
PY 2004
VL 10
IS 15
BP 4944
EP 4958
DI 10.1158/1078-0432.CCR-03-0757
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 845PQ
UT WOS:000223257200007
PM 15297395
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Hochedlinger, K
   Blelloch, R
   Brennan, C
   Yamada, Y
   Kim, MJ
   Chin, L
   Jaenisch, R
AF Hochedlinger, K
   Blelloch, R
   Brennan, C
   Yamada, Y
   Kim, MJ
   Chin, L
   Jaenisch, R
TI Reprogramming of a melanoma genome by nuclear transplantation
SO GENES & DEVELOPMENT
LA English
DT Article
DE cancer; epigenetics; nuclear transfer; reprogramming; pluripotency;
   embryonic stem cells
ID TETRAPLOID EMBRYO COMPLEMENTATION; ACUTE PROMYELOCYTIC LEUKEMIA;
   STEM-CELL; MOUSE ZYGOTES; DONOR CELLS; GERM-LINE; MICE; TUMORS; CANCER;
   GENE
AB We have used nuclear transplantation to test whether the reprogramming activity of oocytes can reestablish developmental pluripotency of malignant cancer cells. We show here that the nuclei of leukemia, lymphoma, and breast cancer cells could support normal preimplantation development to the blastocyst stage but failed to produce embryonic stem (ES) cells. However, a blastocyst cloned from a RAS-inducible melanoma nucleus gave rise to ES cells with the potential to differentiate into multiple cell types in vivo including melanocytes, lymphocytes, and fibroblasts. Chimeras produced from these ES cells developed cancer with higher penetrance, shorter latency, and an expanded tumor spectrum when compared with the donor mouse model. These results demonstrate that the secondary changes of a melanoma nucleus are compatible with a broad developmental potential but predispose mice to melanomas and other malignant tumors on reactivation of RAS. Our findings serve as a paradigm for studying the tumorigenic effect of a given cancer genome in the context of a whole animal.
C1 MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
   MIT, Dept Biol, Cambridge, MA 02142 USA.
   Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Dept Dermatol, Boston, MA 02115 USA.
C3 Massachusetts Institute of Technology (MIT); Whitehead Institute;
   Massachusetts Institute of Technology (MIT); Harvard University; Brigham
   & Women's Hospital; Harvard University; Dana-Farber Cancer Institute;
   Harvard Medical School
RP MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
EM Lynda_Chin@dfci.harvard.edu; jaenisch@wi.mit.edu
RI Chin, Lynda/D-2295-2010; Jaenisch, Rudolf/AEQ-0698-2022; Brennan,
   Cameron/R-7082-2019
OI Yamada, Yasuhiro/0000-0002-2463-1478; Kim, Minjung/0000-0002-5682-6640;
   Brennan, Cameron/0000-0003-4064-8891
FU NCI NIH HHS [R37 CA 84198-04, R01 CA093947, T32 CA009382, R350 CA
   44339-13, R37 CA084198, R01 CA93947, T32 CA09382] Funding Source:
   Medline
CR Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007
   Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6
   Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387
   BRENNAN C, 2004, IN PRESS CANC RES
   Bridge JA, 2002, GENE CHROMOSOME CANC, V33, P310, DOI 10.1002/gcc.10026
   CARLSON DL, 1994, J COMP PATHOL, V111, P197, DOI 10.1016/S0021-9975(05)80051-9
   Chang S, 2003, GENE DEV, V17, P88, DOI 10.1101/gad.1029903
   CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528
   Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788
   Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   Eggan E, 2004, NATURE, V428, P44, DOI 10.1038/nature02375
   Eggan K, 2002, NAT BIOTECHNOL, V20, P455, DOI 10.1038/nbt0502-455
   Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070
   Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902
   Hochedlinger K, 2002, NATURE, V415, P1035, DOI 10.1038/nature718
   Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397
   Hochedlinger K, 2002, CURR OPIN CELL BIOL, V14, P741, DOI 10.1016/S0955-0674(02)00380-0
   Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515
   JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3
   Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KATSUKI M, 1989, MOL BIOL MED, V6, P567
   Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li L, 2003, CANCER RES, V63, P2733
   Liu X, 1997, DEV DYNAM, V209, P85
   Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003
   Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844
   MCKINNELL RG, 1969, SCIENCE, V165, P394, DOI 10.1126/science.165.3891.394
   Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861
   OLSHEN A, 2004, IN PRESS BIOSTATISTI
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5
   Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206
   Sanz MA, 1998, NEW ENGL J MED, V338, P393
   Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787
   STEWART C, 1983, SCIENCE, V221, P760, DOI 10.1126/science.6683871
   Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302
   Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615
   Wakayama T, 2001, MOL REPROD DEV, V58, P376, DOI 10.1002/1098-2795(20010401)58:4<376::AID-MRD4>3.0.CO;2-L
   Wang ZQ, 1997, MECH DEVELOP, V62, P137, DOI 10.1016/S0925-4773(97)00655-2
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
   Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306
NR 52
TC 271
Z9 310
U1 3
U2 18
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD AUG 1
PY 2004
VL 18
IS 15
BP 1875
EP 1885
DI 10.1101/gad.1213504
PG 11
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 843IZ
UT WOS:000223073500009
PM 15289459
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Rüter, B
   Wijermans, PW
   Lübbert, M
AF Rüter, B
   Wijermans, PW
   Lübbert, M
TI DNA methylation as a therapeutic target in hematologic disorders::
   Recent results in older patients with myelodysplasia and acute myeloid
   leukemia
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
DE epigenetics; silencing; quality of life; cytogenetics
ID HISTONE DEACETYLASE; GENE-EXPRESSION; CPG ISLANDS; HYPERMETHYLATION;
   DEMETHYLATION; AZACITIDINE; DECITABINE; INHIBITOR; PHASE;
   5-AZA-2'-DEOXYCYTIDINE
AB DNA methylation provides a major epigenetic code (besides histone modification) of the lineage- and development-specific genes (such as regulators of differentiation in the hematopoietic lineages) that control expression of normal cells. However, DNA methylation is also involved in malignancies because aberrant methylating gene activity occurs during leukemic transformation. Thus, genes such as tumor suppressor genes, growth-regulatory genes, and adhesion molecules are often silenced in various hematopoietic malignancies by epigenetic inactivation via DNA hypermethylation. This inactivation is frequently seen not only in transformed cell lines but also in primary leukemia cells. Because this defect is amenable to reversion by pharmacologic means, agents that inhibit DNA methylation have been developed to specifically target this hypermethylation defect in leukemia and preleukemia cases. The most clinically advanced agents, the azanucleosides 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine), were discovered more than 25 years ago, when their methylation-inhibitory activities, even at low concentrations, became apparent. Although both of these agents, like cytarabine, had been clinically used until then at high doses, the redevelopment of these agents for low-dose schedules has revealed very interesting clinical activities for treating myelodysplasia (MDS) and acute myeloid leukemia (AML). Because these diseases occur mostly in patients over 60 years of age, low-dose schedules with these compounds provide a very promising approach in such patient groups by virtue of their low nonhematologic toxicity profiles. In the present review, we describe the development of treatments that target DNA hypermethylation in MDS and AML, and clinical results are presented. In addition, pharmacologic DNA demethylation may be viewed as a platform for biological modification of malignant cells to become sensitized (or resensitized) to secondary signals, such as differentiating signals (retinoids, vitamin D,) and hormonal signals (eg, estrogen receptor in breast cancer cells, androgen receptor in prostate cancer cells). Finally, an in vitro synergism between the reactivating potency of demethylating agents and inhibitors of histone deacetylation has been tested in several pilot studies of AML and MDS treatment. Finally, gene reactivation by either group of compounds results in therapeutically meaningful reactivation of fetal hemoglobin in patients with severe hemoglobinopathies, extending the therapeutic range of derepressive epigenetic agents to nonmalignant hematopoietic disorders. (C) 2004 The Japanese Society of Hematology.
C1 Univ Freiburg, Med Ctr, Dept Internal Med 1, Div Hematol Oncol, D-79106 Freiburg, Germany.
   Leyenburg Hosp, The Hague, Netherlands.
C3 University of Freiburg
RP Univ Freiburg, Med Ctr, Dept Internal Med 1, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM luebbert@mm11.ukl.uni-freiburg.de
CR BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chan ATC, 2004, J CLIN ONCOL, V22, P1373, DOI 10.1200/JCO.2004.04.185
   Chim CS, 2002, HEMATOL ONCOL, V20, P167, DOI 10.1002/hon.694
   CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1
   DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gore SD, 2002, CLIN CANCER RES, V8, P963
   Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Hiddemann W, 1999, J CLIN ONCOL, V17, P3569, DOI 10.1200/JCO.1999.17.11.3569
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134
   Kornblith AB, 2002, J CLIN ONCOL, V20, P2441, DOI 10.1200/JCO.2002.04.044
   KOSHY H, 1998, BLOOD S, V92, pB306
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Lavelle D, 2003, LEUKEMIA RES, V27, P999, DOI 10.1016/S0145-2126(03)00068-7
   Lehmann U, 2004, ANN HEMATOL, V83, P137, DOI 10.1007/s00277-003-0798-7
   LOWREY CH, 1993, NEW ENGL J MED, V329, P845, DOI 10.1056/NEJM199309163291205
   Lübbert M, 2003, LEUKEMIA, V17, P1762, DOI 10.1038/sj.leu.2403045
   Lübbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x
   Lübbert M, 2000, CURR TOP MICROBIOL, V249, P135
   Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447
   Lyko F, 2004, ELECTROPHORESIS, V25, P1530, DOI 10.1002/elps.200305830
   MILLER KB, 1992, ANN HEMATOL, V65, P162, DOI 10.1007/BF01703109
   Momparler RL, 1997, LEUKEMIA, V11, pS1
   PFEIFER GP, 1988, CANCER LETT, V39, P185, DOI 10.1016/0304-3835(88)90103-6
   PINTO A, 1989, BONE MARROW TRANSPL, V4, P28
   Sakashita K, 2001, J CLIN INVEST, V108, P1195, DOI 10.1172/JCI13030
   Saunthararajah Y, 2003, BLOOD, V102, P3865, DOI 10.1182/blood-2003-05-1738
   SILVERMAN LR, 1993, LEUKEMIA, V7, P21
   Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117
   Trus MR, 2001, BLOOD, V98, p460A
   VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0
   WAHLFORS J, 1992, BLOOD, V80, P2074
   Wijermans PW, 2002, BLOOD, V100, p96A
   Wijermans PW, 1997, LEUKEMIA, V11, P1, DOI 10.1038/sj.leu.2400526
NR 44
TC 51
Z9 57
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0925-5710
EI 1865-3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD AUG
PY 2004
VL 80
IS 2
BP 128
EP 135
DI 10.1532/IJH97.04094
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 852JE
UT WOS:000223750800004
PM 15481440
DA 2025-01-12
ER

PT J
AU Fackler, MJ
   McVeigh, M
   Mehrotra, J
   Blum, MA
   Lange, J
   Lapides, A
   Garrett, E
   Argani, P
   Sukumar, S
AF Fackler, MJ
   McVeigh, M
   Mehrotra, J
   Blum, MA
   Lange, J
   Lapides, A
   Garrett, E
   Argani, P
   Sukumar, S
TI Quantitative multiplex methylation-specific PCR assay for the detection
   of promoter hypermethylation in multiple genes in breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; DNA METHYLATION; IN-SITU; EPIGENETIC
   INACTIVATION; LUNG-CANCER; CPG ISLAND; APC GENE; EXPRESSION;
   HETEROZYGOSITY; RASSF1A
AB If detected early, breast cancer is eminently curable. To detect breast cancer in samples with little cellularity, a high level of sensitivity is needed. Tumor-specific promoter hypermethylation has provided such a valuable tool for detection of cancer cells in biological samples. To accurately assess promoter hypermethylation for many genes simultaneously in small samples, we developed a novel method, quantitative multiplex-methylation-specific PCR (QM-MSP). QM-MSP is highly sensitive (1 in 10(4)-10(5) copies of DNA) and linear over 5 orders of magnitude. For RASSF1A, TWIST, Cyclin D2, and HIN1, we observed significant differences in both the degree (P < 0.003) and incidence (P < 0.02) of hypermethylation between normal and malignant breast tissues. Evaluation of the cumulative hypermethylation of the four genes within each sample revealed a high level of sensitivity (84%) and specificity (89%) of detection of methylation. We demonstrate the application of this technique for detecting hypermethylated RASSF1A, TWIST, Cyclin D2, HIN1, and RARB in 50-1000 epithelial cells collected from breast ducts during endoscopy or by lavage. Such an approach could be used in a variety of small samples derived from different tissues, with these or different biomarkers to enhance detection of malignancy.
C1 Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD 21231 USA.
   Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA.
   Johns Hopkins Univ, Sch Med, Dept Clin Trials & Biometry, Baltimore, MD 21231 USA.
   Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University
RP Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, 1650 Orleans St,Room 410, Baltimore, MD 21231 USA.
EM sukumsa@jhmi.edu
FU NCI NIH HHS [P50CA88843] Funding Source: Medline
CR [Anonymous], 1982, MOL CLONING LAB MANU
   Brock MV, 2003, CLIN CANCER RES, V9, P2912
   Buller A, 2000, MOL DIAGN, V5, P239, DOI 10.2165/00066982-200005030-00011
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Califano J, 1996, CANCER RES, V56, P2488
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Dammann R, 2001, CANCER RES, V61, P3105
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   Dhar S, 2001, CLIN CANCER RES, V7, P3393
   Eads CA, 1999, CANCER RES, V59, P2302
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fackler MJ, 2003, J MAMMARY GLAND BIOL, V8, P75, DOI 10.1023/A:1025735405628
   Goyal J, 1998, CANCER RES, V58, P4782
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harrison J, 1998, ANAL BIOCHEM, V264, P129, DOI 10.1006/abio.1998.2833
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hogg RP, 2002, EUR J CANCER, V38, P1585, DOI 10.1016/S0959-8049(01)00422-1
   Jerónimo C, 2002, UROLOGY, V60, P1131
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lehmann U, 2001, LAB INVEST, V81, P635, DOI 10.1038/labinvest.3780272
   Li B, 2001, CANCER RES, V61, P8014
   Lo YMD, 1999, CANCER RES, V59, P3899
   Melki JR, 1999, CANCER RES, V59, P3730
   Müller HM, 2003, EXPERT REV MOL DIAGN, V3, P443, DOI 10.1586/14737159.3.4.443
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Wang Q, 2003, INT J CANCER, V106, P923, DOI 10.1002/ijc.11333
   Warnecke PM, 2000, CURR OPIN ONCOL, V12, P68, DOI 10.1097/00001622-200001000-00012
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong IHN, 2003, CLIN CANCER RES, V9, P1047
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yunes MJ, 2003, INT J RADIAT ONCOL, V56, P653, DOI 10.1016/S0360-3016(03)00068-3
NR 48
TC 226
Z9 278
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 1
PY 2004
VL 64
IS 13
BP 4442
EP 4452
DI 10.1158/0008-5472.CAN-03-3341
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 834JL
UT WOS:000222407300011
PM 15231653
DA 2025-01-12
ER

PT J
AU Tlsty, TD
   Crawford, YG
   Holst, CR
   Fordyce, CA
   Zhang, JM
   McDermott, K
   Kozakiewicz, K
   Tlsty, TD
AF Tlsty, TD
   Crawford, YG
   Holst, CR
   Fordyce, CA
   Zhang, JM
   McDermott, K
   Kozakiewicz, K
   Tlsty, TD
TI Genetic and epigenetic changes in mammary epithelial cells may mimic
   early events in carcinogenesis
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE human mammary epithelial cells; breast carcinogenesis; genomic
   instability; p16(INK4a); hypermethylation; COX-2
ID CARCINOMA IN-SITU; BREAST-CANCER; PRIMARY TUMORS; GROWTH-FACTOR;
   UP-REGULATION; CPG ISLANDS; LIFE-SPAN; EXPRESSION; INACTIVATION;
   METHYLATION
AB Studies of human mammary epithelial cells from healthy individuals are providing novel insights into how early epigenetic and genetic events affect genomic integrity and fuel carcinogenesis. Key epigenetic changes, such as the hypermethylation of the p16(INK4a) promoter sequences, create a previously unappreciated preclonal phase of tumorigenesis in which a subpopulation of mammary epithelial cells are positioned for progression to malignancy (Romanov et al., 2001, Nature, 409: 633-637; Tlsty et al., 2001, J. Mammary Gland Biol. Neoplasia, 6: 235-243). These key changes precede the clonal outgrowth of premalignant lesions and occur frequently in healthy, disease-free women. Understanding more about these early events should provide novel molecular candidates for prevention and therapy of breast cancer that target the process instead of the consequences of genomic instability. This review will highlight some of the key alterations that have been studied in human mammary epithelial cells in culture and relate them to events observed in vivo and discussed in accompanying reviews in this volume.
C1 Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
   Genentech Inc, Dept Med Oncol, San Francisco, CA 94080 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; University of California San Francisco; Roche Holding; Genentech
RP Tlsty, TD (通讯作者)，Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
EM ttlsty@itsa.ucsf.edu
OI Holst, Charles/0000-0001-8010-1677
CR ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3
   BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249
   BANDYOPADHYAY GK, 1987, J BIOL CHEM, V262, P2750
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004
   BERG JW, 1995, CANCER, V75, P257, DOI 10.1002/1097-0142(19950101)75:1+<257::AID-CNCR2820751311>3.0.CO;2-Y
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Burbano RR, 2000, CANCER GENET CYTOGEN, V119, P62, DOI 10.1016/S0165-4608(99)00175-2
   CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Foster SA, 1996, ONCOGENE, V12, P1773
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124
   GONZALEZZULUETA.M, 1997, CANCER RES, V55, P4531
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Harris RE, 1999, MED HYPOTHESES, V52, P291, DOI 10.1054/mehy.1998.0009
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9
   Herman JG, 1997, CANCER RES, V57, P837
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097
   Huang M, 1998, CANCER RES, V58, P1208
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056
   KAO CY, 1995, CARCINOGENESIS, V16, P531, DOI 10.1093/carcin/16.3.531
   Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962
   KRINFERPOT P, 2001, NATURE, V413, P83
   Liu XH, 1998, CANCER RES, V58, P4245
   LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6
   Luria SE, 1943, GENETICS, V28, P491
   MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289
   Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465
   NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   PANDIS N, 1995, CANCER, V76, P250, DOI 10.1002/1097-0142(19950715)76:2<250::AID-CNCR2820760215>3.0.CO;2-W
   Parry D, 1996, MOL CELL BIOL, V16, P3844
   Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592
   Shim V, 2003, CANCER RES, V63, P2347
   Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391
   Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998
   TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403
   TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441
   Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168
   van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0
   WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3
   Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014
   Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045
NR 52
TC 65
Z9 79
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD JUL
PY 2004
VL 9
IS 3
BP 263
EP 274
DI 10.1023/B:JOMG.0000048773.95897.5f
PG 12
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 872PM
UT WOS:000225219700005
PM 15557799
DA 2025-01-12
ER

PT J
AU Loginov, VI
   Malyukova, AV
   Seryogin, YA
   Hodyrev, DS
   Kazubskaya, TP
   Ermilova, VD
   Garkavtseva, RF
   Kisselev, LL
   Zabarovsky, ER
   Braga, EA
AF Loginov, VI
   Malyukova, AV
   Seryogin, YA
   Hodyrev, DS
   Kazubskaya, TP
   Ermilova, VD
   Garkavtseva, RF
   Kisselev, LL
   Zabarovsky, ER
   Braga, EA
TI Methylation of the promoter region of the <i>RASSF1A</i> candidate tumor
   suppressor gene in primary epithelial tumors
SO MOLECULAR BIOLOGY
LA English
DT Article
DE tumor suppressor gene; DNA methylation; CpG islands; promoter regions;
   RASSF1A; epithelial tumors
ID EPIGENETIC INACTIVATION; DNA METHYLATION; CHROMOSOME 3P; CANCER; LUNG;
   3P21.3
AB The methylation of the promoter CpG island of the RASSF1A tumor suppressor gene in primary tumors of 172 Muscovites with renal cell carcinoma (RCC), breast cancer (BC), or ovarian epithelial tumors (OET) was assayed by means of methylation-specific PCR (MSP) and PCR-based methylation-sensitive restriction enzyme analysis (MSRA). The MSP, MSRA, and previous bisulfite sequencing data correlated significantly with each other (P much less than 10(-6) for Spearman's rank correlation coefficients). By MSP and MSRA, the respective methylation frequencies of the RASSF1A promoter were 86% (25/29) and 94% (50/53) in RCC, 64% (18/28) and 78% (32/41) in BC, and 59% (17/29) and 73% (33/45) in OET. Methylation-sensitive restriction enzymes (HpaII, HhaI, Bsh1236I, AciI) increased the analysis sensitivity and made it possible to establish the methylation status for 18 CpG dinucleotides of the RASSF1A promoter region. With the MSRA data, the density of methylation of the CpG island was estimated at 72% in RCC, 63% in BC, and 58% in OET (the product of the number of CpG dinucleotides and the number of specimens with RASSF1A methylation was taken as 100%). Methylation of the RASSF1A promoter region was observed in 11-35% of the DNA specimens from the histologically normal tissue adjacent to the tumor but not in the peripheral blood DNA of 15 healthy subjects. The RASSF1A methylation frequency showed no significant correlation with the stage, grade, and metastatic potential of the tumor. On the other hand, epigenetic modification of RASSF1A was considerably more frequent than hemizygous or homozygous deletions from the RASSF1A region. These results testify that methylation of the RASSF1A promoter region takes place early in carcinogenesis and is a major mechanism inactivating RASSF1A in epithelial tumors.
C1 State Res Ctr GosNllgenet, Moscow 117545, Russia.
   Russian Acad Med Sci, Blokhin Canc Res Ctr, Moscow 115478, Russia.
   Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia.
   Karolinska Inst, Microbiol & Tumor Biol Ctr, S-17177 Stockholm, Sweden.
   Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden.
C3 Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer
   Research Center; Russian Academy of Sciences; Engelhardt Institute of
   Molecular Biology, RAS; Karolinska Institutet; Karolinska Institutet
RP State Res Ctr GosNllgenet, Moscow 117545, Russia.
EM loginov7@genetika.ru; ebraga@genetika.ru
RI Braga, Eleonora/P-5574-2016; Malyukova, Alena/LUW-9047-2024; Zabarovsky,
   Eugene/A-6645-2010; Loginov, Vytaliy/J-9738-2018
OI Braga, Eleonora/0000-0001-5188-4094; Loginov,
   Vitaly/0000-0003-2668-8096; Malyukova, Alena/0000-0003-0389-4129
CR [Anonymous], 1989, Molecular Cloning, A Laboratory Manual
   Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511
   Braga EA, 2004, MOL BIOL+, V38, P145, DOI 10.1023/B:MBIL.0000023728.57655.34
   Braga EA, 2003, MOL BIOL+, V37, P170, DOI 10.1023/A:1023381218481
   BRAGA EA, 2003, 7 ROS ONK K SBORN MA, P141
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4
   Jain PK, 2003, ANN NY ACAD SCI, V983, P71, DOI 10.1111/j.1749-6632.2003.tb05963.x
   Kanaya T, 2003, ONCOGENE, V22, P2352, DOI 10.1038/sj.onc.1206365
   Kaneda A, 2003, ANN NY ACAD SCI, V983, P131, DOI 10.1111/j.1749-6632.2003.tb05968.x
   Lerman MI, 2000, CANCER RES, V60, P6116
   Li Z, 2002, CANCER RES, V62, P1939
   Patel A, 2003, ANN NY ACAD SCI, V983, P286, DOI 10.1111/j.1749-6632.2003.tb05983.x
   Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097
   Prokhortchouk E, 2002, ONCOGENE, V21, P5394, DOI 10.1038/sj.onc.1205631
   SENCHENKO VN, 2004, IN PRESS ONCOGENE
   Szyf M, 2003, AGEING RES REV, V2, P299, DOI 10.1016/S1568-1637(03)00012-6
   Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362
   *WHO, 1999, INT HIST CLASS TUM H
   *WHO, 1998, INT HIST CLASS TUM H
   *WHO, 1981, INT HIST CLASS TUM, V2
   Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835
NR 30
TC 38
Z9 40
U1 0
U2 5
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0026-8933
EI 1608-3245
J9 MOL BIOL+
JI Mol. Biol.
PD JUL-AUG
PY 2004
VL 38
IS 4
BP 549
EP 560
DI 10.1023/B:MBIL.0000037007.71787.b9
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 849TZ
UT WOS:000223565100010
DA 2025-01-12
ER

PT J
AU Staalesen, V
   Leirvaag, B
   Lillehaug, JR
   Lonning, PE
AF Staalesen, V
   Leirvaag, B
   Lillehaug, JR
   Lonning, PE
TI Genetic and epigenetic changes in <i>p21</i> and <i>p21B</i> do not
   correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil
   in locally advanced breast cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; P53 MUTATIONS;
   NEOADJUVANT TREATMENT; SOMATIC MUTATION; DNA-REPLICATION; WAF1/CIP1
   GENE; CDK INHIBITORS; GROWTH ARREST; IN-VIVO
AB Purpose: The cyclin-dependent kinase inhibitor p21 acts as a main executor of p53-induced growth arrest. Recently, a second transcript, p21B, was found to code for a protein expressing proapoptotic activity. We investigated p21 and p12B for mutations and epigenetic silencing in locally advanced breast cancers treated with doxorubicin or 5-fluorouracil/mitomycin and correlated our findings with treatment response and TP53 status.
   Experimental Design: We used reverse transcription-PCR to analyze p21/p21B mutation status in 73 breast cancer samples. The p21 promoter region was sequenced and analyzed for hypermethylations by methylation-specific PCR. In addition, a selection of patients were analyzed for mutations in the p21B promoter.
   Results: The p21 gene was neither mutated nor silenced by promoter hypermethylation in any of the tumors examined. One patient harbored a novel p21 splice variant in addition to the wild-type transcript. We observed two base substitutions in the p2l transcript, C93A and. G251A, each affecting six patients (8.2%). The G251A variant had not been reported previously. In 12 patients (16.4%), we observed a novel base substitution, T35C, in p21B. All three base substitutions were observed in lymphocyte DNA and therefore considered polymorphisms. The polymorphisms did not correlate with p2l staining index, treatment response to doxorubicin or 5-fluorouracil/mitontycin, or TP53 status.
   Conclusions: Our findings do not suggest that genetic or epigenetic disturbances in p21 or p21B cause resistance to doxorubicin or mitomycin/5-fluorouracil in breast cancer. Future studies should assess potential associations between these novel polymorphisms and breast cancer risk.
C1 Haukeland Univ Hosp, Sect Oncol, Dept Med, N-5021 Bergen, Norway.
   Univ Bergen, Dept Biol Mol, Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of
   Bergen
RP Haukeland Univ Hosp, Sect Oncol, Dept Med, N-5021 Bergen, Norway.
EM per.lonning@helse-bergen.no
OI Lonning, Per Eystein/0000-0002-8890-6303
CR Aas T, 2003, EUR J CANCER, V39, P438, DOI 10.1016/S0959-8049(02)00732-3
   Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811
   Amati B, 2001, NAT CELL BIOL, V3, pE112, DOI 10.1038/35074634
   Balbin M, 1996, J BIOL CHEM, V271, P15782, DOI 10.1074/jbc.271.26.15782
   Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267
   BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0
   Chen B, 2000, CANCER RES, V60, P3290
   Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571
   Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719
   Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697
   DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X
   DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4
   Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546
   Ellis PA, 1997, BRIT J CANCER, V76, P480, DOI 10.1038/bjc.1997.413
   Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161
   Facher EA, 1997, CANCER, V79, P2424, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2424::AID-CNCR19>3.0.CO;2-T
   Furutani M, 1997, CANCER LETT, V111, P191, DOI 10.1016/S0304-3835(96)04509-0
   GAO X, 1995, ONCOGENE, V11, P1395
   Geisler S, 2003, CLIN CANCER RES, V9, P5582
   Geisler S, 2001, CANCER RES, V61, P2505
   GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0
   Harima Y, 2001, INT J MOL MED, V7, P261
   HARPER JW, 1993, CELL, V75, P805
   Hsieh YY, 2001, J CLIN LAB ANAL, V15, P184, DOI 10.1002/jcla.1025
   Ibrahim SO, 2002, ANTICANCER RES, V22, P1445
   Iida S, 1997, ANTICANCER RES, V17, P633
   Kandioler-Eckersberger D, 2000, CLIN CANCER RES, V6, P50
   Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153
   Konishi R, 2000, J DERMATOL SCI, V24, P177, DOI 10.1016/S0923-1811(00)00096-7
   KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491
   Lacombe L, 1996, ONCOL RES, V8, P409
   LI YJ, 1995, ONCOGENE, V10, P599
   Li YJ, 1998, J NEURO-ONCOL, V40, P107, DOI 10.1023/A:1006149021810
   LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210
   Lodén M, 2002, ONCOGENE, V21, P4680, DOI 10.1038/sj.onc.1205578
   Lonning PE, 2004, TRENDS MOL MED, V10, P113, DOI 10.1016/j.molmed.2004.01.005
   Lonning PE, 2003, LANCET ONCOL, V4, P177
   LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0
   LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0
   McKenzie KE, 1997, CLIN CANCER RES, V3, P1669
   Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558
   Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629
   Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191
   Patiño-García A, 1998, PEDIATR RES, V43, P393, DOI 10.1203/00006450-199803000-00014
   Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1
   Schmitt CA, 1999, J PATHOL, V187, P127
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Shih CM, 2000, JPN J CANCER RES, V91, P9, DOI 10.1111/j.1349-7006.2000.tb00854.x
   Terry LA, 1996, MOL CARCINOGEN, V16, P221, DOI 10.1002/(SICI)1098-2744(199608)16:4<221::AID-MC6>3.0.CO;2-I
   Tsai MH, 2002, J CLIN LAB ANAL, V16, P146, DOI 10.1002/jcla.10032
   Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270
   Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032
NR 57
TC 21
Z9 25
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2004
VL 10
IS 10
BP 3438
EP 3443
DI 10.1158/1078-0432.CCR-03-0796
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 823PY
UT WOS:000221626600025
PM 15161699
OA Bronze
DA 2025-01-12
ER

PT J
AU Suzuki, M
   Sunaga, N
   Shames, DS
   Toyooka, S
   Gazdar, AF
   Minna, JD
AF Suzuki, M
   Sunaga, N
   Shames, DS
   Toyooka, S
   Gazdar, AF
   Minna, JD
TI RNA interference-mediated knockdown of DNA methyltransferase 1 leads to
   promoter demethylation and gene re-expression in human lung and breast
   cancer cells
SO CANCER RESEARCH
LA English
DT Article
ID CULTURED-MAMMALIAN-CELLS; DOWN-REGULATION; EPIGENETIC INACTIVATION; CPG
   METHYLATION; INHIBITION; TUMOR; GROWTH; 3P21.3; DNMT1; ESTABLISHMENT
AB DNA methyltransferase 1 (DNMT1) is required to maintain DNA methylation patterns in mammalian cells, and is thought to be the predominant maintenance methyltransferase gene. Recent studies indicate that inhibiting DNMT1 protein expression may be a useful approach for understanding the role of DNA methylation in tumorigenesis. To this end, we used RNA interference to specifically down-regulate DNMT1 protein expression in NCI-H1299 lung cancer and HCC1954 breast cancer cells. RNA interference-mediated knockdown of DNMT1 protein expression resulted in >80% reduction of promoter methylation in RASSF1A, p16(ink4A), and CDH1 in NCI-H1299; and RASSF1A, p16(ink4A), and HPP1 in HCC1954; and re-expression of p16(ink4A), CDH1, RASSF1A, and SEMA3B in NCI-H1299; and p16(ink4A), RASSF1A, and HPP1 in HCC1954. By contrast, promoter methylation and lack of gene expression was maintained when these cell lines were treated with control small interfering RNAs. The small interfering RNA treatment was stopped and 17 days later, all of the sequences showed promoter methylation and gene expression was again dramatically down-regulated, indicating the tumor cells still were programmed for these epigenetic changes. We saw no effects on soft agar colony formation of H1299 cells 14 days after DNMT1 knockdown indicating that either these genes are not functioning as tumor suppressors under these conditions, or that more prolonged knockdown or other factors are also required to inhibit the malignant phenotype. These results provide direct evidence that loss of DNMT1 expression abrogates tumor-associated promoter methylation and the resultant silencing of multiple genes implicated in the pathogenesis of human lung and breast cancer.
C1 Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.
   Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chiba, Japan.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas Dallas;
   University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; Chiba University
RP Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM john.minna@utsouthwestern.edu
RI Gazdar, Adi/F-7496-2010; Minna, John/AAB-1036-2022
OI Shames, David/0000-0002-5900-1177
FU NCI NIH HHS [P50CA70907, CA71618] Funding Source: Medline
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bender CM, 1998, PHARM RES-DORDR, V15, P175, DOI 10.1023/A:1011946030404
   Bender CM, 1998, CANCER RES, V58, P95
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Harborth J, 2001, J CELL SCI, V114, P4557
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466
   Kuroki T, 2003, CANCER RES, V63, P3352
   Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077
   Phelps RM, 1996, J CELL BIOCHEM, P32
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149
   Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001
   Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Toyooka KO, 2002, AM J PATHOL, V161, P629, DOI 10.1016/S0002-9440(10)64218-6
   Toyooka S, 2003, CLIN CANCER RES, V9, P3034
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381
   Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.3.CO;2-I
   Velicescu M, 2002, CANCER RES, V62, P2378
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125
   Zöchbauer-Müller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451
NR 35
TC 145
Z9 182
U1 1
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2004
VL 64
IS 9
BP 3137
EP 3143
DI 10.1158/0008-5472.CAN-03-3046
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 817AN
UT WOS:000221150500028
PM 15126351
OA Bronze
DA 2025-01-12
ER

PT J
AU Pakneshan, P
   Têtu, B
   Rabbani, SA
AF Pakneshan, P
   Têtu, B
   Rabbani, SA
TI Demethylation of urokinase promoter as a prognostic marker in patients
   with breast carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CELL LUNG-CANCER; PLASMINOGEN-ACTIVATOR SYSTEM; TUMOR-SUPPRESSOR GENES;
   DNA METHYLATION; PROSTATE-CANCER; IN-VIVO; INVASION; METASTASIS;
   INHIBITOR; HYPERMETHYLATION
AB Purpose: Urokinase (uPA) is expressed in a number of highly invasive malignancies including breast cancer. Because production of uPA is associated with breast cancer progression and can serve as a useful prognostic marker, the purpose of this study was to examine the role of uPA promoter methylation as an indicator of uPA production in breast cancer patients.
   Experimental Design: We examined the methylation status of the uPA promoter and the levels of uPA expression in normal human breast epithelial cells and several human breast cancer cells by bisulfite sequencing analysis and reverse transcription-PCR. We also analyzed the methylation status of the uPA promoter in surgical biopsy samples from patients with breast cancer of different grades, as determined by the Elston-Ellis histological grading system.
   Results: Expression of uPA mRNA was only detected in the highly invasive estrogen receptor-negative breast cancer cell lines, where the promoter was completely demethylated. In normal and low invasive breast cancer cells, the uPA promoter was methylated, resulting in lack of uPA mRNA expression. Analysis of biopsy samples showed that demethylation of the uPA promoter is associated with malignant transformation. Reverse transcription-PCR analysis revealed that this demethylation of the uPA promoter is directly associated with induction of uPA mRNA expression, which is well known to be associated with poor prognosis in breast cancer patients.
   Conclusions: This study indicated that uPA expression in breast cancer patients is under epigenetic control via methylation of its promoter. Determination of uPA promoter methylation can therefore serve as an early reliable indicator of uPA production in breast cancer patients.
C1 McGill Univ, Ctr Hlth, Dept Med & Oncol, Montreal, PQ H3A 1A1, Canada.
   Univ Laval, Dept Pathol, Quebec City, PQ, Canada.
C3 McGill University; Laval University
RP Rabbani, SA (通讯作者)，McGill Univ, Ctr Hlth, Dept Med & Oncol, 687 Pine Ave W,Room H467, Montreal, PQ H3A 1A1, Canada.
EM shafaat.rabbani@mcgill.ca
OI rabbani, shafaat/0000-0001-5594-3899
CR Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z
   Baylin S, 2001, Dev Biol (Basel), V106, P85
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bearzatto A, 2002, CLIN CANCER RES, V8, P3782
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/bst0300207
   Duffy MJ, 2002, CLIN CHEM, V48, P1194
   DUFFY MJ, 1988, CANCER-AM CANCER SOC, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B
   Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Fujii T, 1999, HEPATO-GASTROENTEROL, V46, P2299
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400
   Harbeck N, 2002, J CLIN ONCOL, V20, P1000, DOI 10.1200/JCO.20.4.1000
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HSU DW, 1995, AM J PATHOL, V147, P114
   Jain PK, 2003, ANN NY ACAD SCI, V983, P71, DOI 10.1111/j.1749-6632.2003.tb05963.x
   Jerónimo C, 2002, UROLOGY, V60, P1131
   Kalebic T, 2003, ANN NY ACAD SCI, V983, P278, DOI 10.1111/j.1749-6632.2003.tb05982.x
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116
   Ma Z, 2001, J CELL SCI, V114, P3387
   Miyake H, 1999, PROSTATE, V39, P123, DOI 10.1002/(SICI)1097-0045(19990501)39:2<123::AID-PROS7>3.0.CO;2-2
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Patel A, 2003, ANN NY ACAD SCI, V983, P286, DOI 10.1111/j.1749-6632.2003.tb05983.x
   Paz MF, 2002, CANCER RES, V62, P4519
   Pedersen AN, 2000, CANCER RES, V60, P6927
   Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393
   Rabbani SA, 1998, INT J ONCOL, V12, P911
   Rabbani SA, 2002, CANCER RES, V62, P2390
   Salden M, 2000, ANN ONCOL, V11, P327, DOI 10.1023/A:1008312801800
   Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Smiraglia DJ, 2003, ANN NY ACAD SCI, V983, P110, DOI 10.1111/j.1749-6632.2003.tb05966.x
   VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699
   Weinstein JN, 2000, NEW ENGL J MED, V343, P1408, DOI 10.1056/NEJM200011093431910
   Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109
   Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407
NR 44
TC 75
Z9 84
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2004
VL 10
IS 9
BP 3035
EP 3041
DI 10.1158/1078-0432.CCR-03-0545
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 818UN
UT WOS:000221270100018
PM 15131040
DA 2025-01-12
ER

PT J
AU Kalantzi, OI
   Hewitt, R
   Ford, KJ
   Cooper, L
   Alcock, RE
   Thomas, GO
   Morris, JA
   McMillan, TJ
   Jones, KC
   Martin, FL
AF Kalantzi, OI
   Hewitt, R
   Ford, KJ
   Cooper, L
   Alcock, RE
   Thomas, GO
   Morris, JA
   McMillan, TJ
   Jones, KC
   Martin, FL
TI Low dose induction of micronuclei by lindane
SO CARCINOGENESIS
LA English
DT Article
ID POLYCYCLIC AROMATIC-HYDROCARBONS; BREAST-CANCER; OXIDATIVE STRESS; COMET
   ASSAY; CELLS; PESTICIDES; DNA; ESTROGENS; HEXACHLOROCYCLOHEXANE;
   STEROIDOGENESIS
AB Environmental contaminants possessing hormonal activity have long been suspected of playing a role in cancer causation. What is unclear is whether such agents elicit their effects through genotoxic and/or epigenetic mechanisms. gamma-Hexachlorocyclohexane (gamma-HCH, lindane) was tested in the 10(-12)-10(-4) M range. Chromosomal damage in MCF-7 breast cells and PC-3 prostate cells was assessed using the cytokinesis block micronucleus assay. Micronuclei (MNi) were scored in 1000 binucleate cells per treatment. Cell viability and cell cycle kinetics were also assessed, along with immunocytochemical and quantitative gene expression analyses of CDKN1A (P21(WAF1/CIP1)), BCL-2 and BAX. Following 24 h treatment, lindane (10(-12)-10(-10) M) induced increases (up to 5-fold) in MNi in both cell lines. Increases in MNi occurred in the absence of DNA single-strand breaks or cytotoxicity and, compared with benzo[a]pyrene and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, at low concentrations. Lindane induced more MNi than the alpha or beta stereoisomers of HCH. Low dose lindane (10(-12)-10(-10) M) significantly elevated the percentage of MCF-7 cells staining positive for Bcl-2 and of PC-3 cells staining positive for Bax. Only high dose lindane (10(-4) M) disrupted cell cycle kinetics with increases in percentage of cells in G(1) and decreases in percentage of cells in G(2)/M. Despite a comparable high dose lindane induction of cell cycle arrest, marked increases in expression of P21(WAF1/CIP1) were observed only in MCF-7 cells, although in PC-3 cells a significant increase (P < 0.0005) in the percentage of cells staining positive for p21(Waf1/Cip1) was seen. These results suggest that 'environmental' concentrations of lindane can induce a number of subtle alterations in breast and prostate cells in the absence of cytotoxicity.
C1 Univ Lancaster, IENS, Dept Biol Sci, Lancaster LA1 4YQ, England.
   Univ Lancaster, IENS, Dept Environm Sci, Lancaster LA1 4YQ, England.
   Royal Lancaster Infirm, Dept Histopathol, Lancaster LA1 4RP, England.
   Environm Res Solut, Witherslack LA11 6SG, Cumbria, England.
C3 Lancaster University; Lancaster University
RP Univ Lancaster, IENS, Dept Biol Sci, Lancaster LA1 4YQ, England.
EM f.martin@lancaster.ac.uk
RI Martin, Francis/J-4585-2019; Jones, Kevin/F-4296-2014; Kalantzi,
   Olga-Ioanna/E-5085-2017
OI Kalantzi, Olga-Ioanna/0000-0002-0466-212X; Jones, Kevin
   Christopher/0000-0001-7108-9776; Morris, James/0000-0001-7713-0004;
   Alcock, Ruth/0000-0002-6079-1022; L Martin, Francis/0000-0001-8562-4944
CR BHUNYA SP, 1992, MUTAT RES, V272, P175, DOI 10.1016/0165-1161(92)90045-N
   Bigsby RM, 1997, CANCER RES, V57, P865
   Breivik K, 1999, SCI TOTAL ENVIRON, V239, P151, DOI 10.1016/S0048-9697(99)00291-0
   Buranatrevedh S, 2001, J ENVIRON HEALTH, V64, P17
   Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75
   Davis C, 2002, MUTAGENESIS, V17, P431, DOI 10.1093/mutage/17.5.431
   Defamie N, 2001, CARCINOGENESIS, V22, P1537, DOI 10.1093/carcin/22.9.1537
   Devoto E, 1998, ARCH ENVIRON HEALTH, V53, P147, DOI 10.1080/00039896.1998.10545976
   Dich J, 1997, CANCER CAUSE CONTROL, V8, P420, DOI 10.1023/A:1018413522959
   FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143
   Feigelson HS, 1996, CARCINOGENESIS, V17, P2279, DOI 10.1093/carcin/17.11.2279
   Fischer WH, 2001, MUTAGENESIS, V16, P209, DOI 10.1093/mutage/16.3.209
   Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P686
   Goldman R, 2001, CANCER RES, V61, P6367
   Grover PL, 2002, CARCINOGENESIS, V23, P1095, DOI 10.1093/carcin/23.7.1095
   *IARC, 1987, MON EV CARC RISKS S7, V1, P220
   Jensen AllanAstrup., 1991, CHEM CONTAMINANTS HU
   Junqueira VBC, 1997, TOXICOLOGY, V117, P199, DOI 10.1016/S0300-483X(96)03580-9
   Khan QA, 2002, MOL CARCINOGEN, V33, P1, DOI 10.1002/mc.10013
   Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706
   Li YF, 1999, SCI TOTAL ENVIRON, V232, P121, DOI 10.1016/S0048-9697(99)00114-X
   Martin FL, 2000, MUTAT RES-GEN TOX EN, V470, P115, DOI 10.1016/S1383-5742(00)00046-6
   Martin FL, 1999, MUTAT RES-GEN TOX EN, V445, P21, DOI 10.1016/S1383-5718(99)00116-3
   Martin FL, 1997, CARCINOGENESIS, V18, P2299, DOI 10.1093/carcin/18.12.2299
   McDuffie HH, 2001, CANCER EPIDEM BIOMAR, V10, P1155
   Meinking TL, 2002, ARCH DERMATOL, V138, P220, DOI 10.1001/archderm.138.2.220
   Mills PK, 2003, J OCCUP ENVIRON MED, V45, P249, DOI 10.1097/01.jom.0000058339.05741.0c
   OBANA H, 1981, B ENVIRON CONTAM TOX, V27, P23, DOI 10.1007/BF01610981
   Oropeza-Hernández LF, 2001, TOXICOL LETT, V124, P91, DOI 10.1016/S0378-4274(01)00383-6
   POOLZOBEL BL, 1994, ENVIRON MOL MUTAGEN, V24, P23, DOI 10.1002/em.2850240105
   Rokhlin OW, 1997, CANCER RES, V57, P1758
   Ronco AM, 2001, TOXICOLOGY, V159, P99, DOI 10.1016/S0300-483X(00)00414-5
   RUPA DS, 1989, HUM GENET, V83, P271, DOI 10.1007/BF00285170
   SAGELSDORFF P, 1983, CARCINOGENESIS, V4, P1267, DOI 10.1093/carcin/4.10.1267
   Simon-Giavarotti KA, 2002, FREE RADICAL RES, V36, P1033, DOI 10.1080/1071576021000028280
   Thomas GO, 1999, CHEMOSPHERE, V39, P1533, DOI 10.1016/S0045-6535(99)00050-8
   Tisch M, 2002, HNO, V50, P920, DOI 10.1007/s00106-001-0621-5
   Trosko James E., 1998, Frontiers in Bioscience, V3, pD208
   Walsh LP, 2000, BIOL REPROD, V63, P1024, DOI 10.1095/biolreprod63.4.1024
   Yared E, 2002, MUTAGENESIS, V17, P345, DOI 10.1093/mutage/17.4.345
NR 40
TC 73
Z9 77
U1 0
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD APR
PY 2004
VL 25
IS 4
BP 613
EP 622
DI 10.1093/carcin/bgh048
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 807EV
UT WOS:000220485700018
PM 14688026
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Ishii, H
   Furukawa, Y
AF Ishii, H
   Furukawa, Y
TI Alterations of common chromosome fragile sites in hematopoietic
   malignancies
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
DE common chromosome fragile sites; FHIT; WWOX
ID TUMOR-SUPPRESSOR GENE; PROMOTER METHYLATION PROFILE; CHRONIC MYELOGENOUS
   LEUKEMIA; 5'-CPG ISLAND METHYLATION; SQUAMOUS-CELL CARCINOMA; HISTIDINE
   TRIAD GENE; FHIT GENE; BREAST-CANCER; CLINICOPATHOLOGICAL FEATURES;
   EXPRESSION
AB Conditions of replication stress affect expression of all common fragile regions, including FRA3B (chromosome 3p14.2), FRA16D (16q23), FRA6E (6q26), FRA7G (7q31.2), and FRAXB (Xp22.3), and a number of cancer cell lines exhibit homozygous deletions in 2 or more common fragile regions. In 1996 the fragile histidine triad (FHIT) gene was isolated from the region encompassing the most active fragile FRA3B locus, and recently the WW domain-containing oxidoreductase gene (WWOX) was identified at FRA16D. These 2 fragile genes are altered or deleted in various epithelial tumors and exhibit tumor suppressor function. Aberration or absence of WWOX expression recently was detected in primary hematopoietic malignancies. The aberration resulted not only from genomic deletions but also possibly from epigenetic modifications associated with expression of fragility. Thus chromosomal aberrations at common fragile sites, in addition to the well-defined hallmark leukemia chromosome translocations, are involved in clinicopathological outcomes of hematopoietic malignancies. (C) 2004 The Japanese Society of Hematology.
C1 Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Kawachi, Tochigi, Japan.
C3 Jichi Medical University
RP Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Kawachi, Tochigi, Japan.
RI Furukawa, Yusuke/Y-1342-2018
OI Furukawa, Yusuke/0000-0002-7249-6418
CR Albitar M, 2001, LEUKEMIA RES, V25, P859, DOI 10.1016/S0145-2126(01)00042-X
   Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843
   Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Bednarek AK, 2000, CANCER RES, V60, P2140
   Bednarek AK, 2001, CANCER RES, V61, P8068
   Carapeti M, 1998, BRIT J CANCER, V78, P601, DOI 10.1038/bjc.1998.547
   Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3
   Chang KW, 2002, J PATHOL, V196, P300, DOI 10.1002/path.1047
   Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200
   Clarkson B, 2003, LEUKEMIA, V17, P1211, DOI 10.1038/sj.leu.2402912
   COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107
   Corbin S, 2002, CANCER RES, V62, P3477
   Croce CM, 1999, CANCER RES, V59, p1778S
   Druker Brian J, 2002, Hematology Am Soc Hematol Educ Program, P111
   GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988
   Hallas C, 1999, CLIN CANCER RES, V5, P2409
   Heerema NA, 1998, CANCER INVEST, V16, P183, DOI 10.3109/07357909809050035
   Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058
   Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584
   Ishii H, 2003, MOL CANCER RES, V1, P940
   Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441
   Iwai T, 1998, CANCER RES, V58, P5182
   Ji L, 1999, CANCER RES, V59, P3333
   Kantarjian HM, 1999, CLIN CANCER RES, V5, P4059
   Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322
   Kuroki T, 2003, CANCER RES, V63, P3724
   Kuroki T, 2002, CANCER RES, V62, P2258
   Lin PM, 1997, BRIT J HAEMATOL, V99, P612, DOI 10.1046/j.1365-2141.1997.4223235.x
   Liu Y, 2002, REPRODUCTION, V123, P341, DOI 10.1530/reprod/123.3.341
   Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844
   Maruyama R, 2001, CANCER RES, V61, P8659
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456
   Noguchi T, 2003, INT J MOL MED, V11, P441
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898
   Peters UR, 1999, ONCOGENE, V18, P79, DOI 10.1038/sj.onc.1202256
   Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4
   Ruiz J, 2001, DIGEST DIS, V19, P324, DOI 10.1159/000050699
   Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8
   Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489
   SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571
   Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771
   Soussi T, 1996, MOL MED TODAY, V2, P32, DOI 10.1016/1357-4310(96)88756-9
   Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6
   Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0
   Tamura G, 2002, HISTOL HISTOPATHOL, V17, P323, DOI 10.14670/HH-17.323
   Tanaka H, 1998, CANCER RES, V58, P3429
   Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100
   Wang Li, 2003, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V11, P153
   Wu QH, 2003, ULTRASTRUCT PATHOL, V27, P417, DOI 10.1080/01913120390250329
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Yendamuri S, 2003, CANCER RES, V63, P878
   YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 56
TC 32
Z9 34
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0925-5710
EI 1865-3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD APR
PY 2004
VL 79
IS 3
BP 238
EP 242
DI 10.1532/IJH97.03145
PG 5
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 821DZ
UT WOS:000221441500006
PM 15168591
DA 2025-01-12
ER

PT J
AU Wada, K
   Maesawa, C
   Akasaka, T
   Masuda, T
AF Wada, K
   Maesawa, C
   Akasaka, T
   Masuda, T
TI Aberrant expression of the maspin gene associated with epigenetic
   modification in melanoma cells
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
DE maspin; melanocytic nevi; melanoma; methylation; serine protease
ID PLASMINOGEN-ACTIVATOR; DNA METHYLATION; BREAST-CANCER; PROMOTER
   METHYLATION; INHIBITION; CARCINOMA; MAMMARY; TUMORS; P53;
   HYPERMETHYLATION
AB Maspin, a mammary serine protease inhibitor, was originally reported to be a tumor suppressor gene in breast and prostate cancers. The expression pattern of the maspin gene differs among cancer types and normal tissue however, and its significance as a tumor suppressor has been questioned. In this study, maspin expression and/or allele-specific methylation status were investigated in five melanoma cell lines and a normal human epidermal melanocyte (NHEM) cell line, and 80 surgically resected tumors (40 melanomas and 40 melanocytic nevi). One (HMV-I) of five melanoma cell lines overexpressed maspin protein whereas the remaining four melanoma cell lines and NHEM did not. The 19 CpG sites of the maspin promoter region were extensively hypomethylated in HMV-I, a maspin-positive cell line, and those of the remaining four melanoma and NHEM cell lines were hypermethylated. Furthermore, maspin-negative cell lines exhibited activation after treatment with 5-aza-2'-deoxycytidine, a DNA demethylating agent. Immunoreactivity for maspin was negative in normal skin melanocytes and 40 melanocytic nevi, but five (12.5%) of 40 melanomas were positive. The methylation status judged by the methylation-specific PCR method was inversely correlated with maspin protein expression in vitro and in vivo. These results suggest that maspin expression in normal skin melanocytes and melanocytic nevi may be repressed in a cell-type-specific manner, whereas maspin is expressed aberrantly in a subset of melanoma cells by epigenetic modification. Further investigations are required to determine the significance of aberrant maspin expression.
C1 Iwate Med Univ, Sch Med, Dept Pathol, Morioka, Iwate 0208505, Japan.
   Iwate Med Univ, Sch Med, Dept Dermatol, Morioka, Iwate 0208505, Japan.
C3 Iwate Medical University; Iwate Medical University
RP Iwate Med Univ, Sch Med, Dept Pathol, Uchimaru 19-1, Morioka, Iwate 0208505, Japan.
EM chihaya@iwate-med.ac.jp
CR Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635
   Biliran H, 2001, CANCER RES, V61, P8676
   Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481
   Christmann M, 2001, INT J CANCER, V92, P123, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.3.CO;2-M
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Costello JF, 2002, NAT GENET, V31, P123, DOI 10.1038/ng0602-123
   DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feng YM, 2002, INT J CANCER, V99, P834, DOI 10.1002/ijc.10422
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6
   Lele SM, 2000, APPL IMMUNOHISTO M M, V8, P32, DOI 10.1097/00022744-200003000-00005
   Maass N, 2001, CLIN CANCER RES, V7, P812
   Maass N, 2001, CLIN BIOCHEM, V34, P303, DOI 10.1016/S0009-9120(01)00220-X
   Machtens S, 2001, INT J CANCER, V95, P337, DOI 10.1002/1097-0215(20010920)95:5<337::AID-IJC1059>3.0.CO;2-1
   McGowen R, 2000, CANCER RES, V60, P4771
   Mohsin SK, 2003, J PATHOL, V199, P432, DOI 10.1002/path.1319
   Reis JS, 2002, VIRCHOWS ARCH, V441, P551, DOI 10.1007/s00428-002-0710-1
   Reis JS, 2001, PATHOL RES PRACT, V197, P817, DOI 10.1078/0344-0338-00165
   Reis JS, 2002, J PATHOL, V197, P272, DOI 10.1002/path.1104
   REISFILHO JS, 2003, MOL MORPHOL, V11, P1
   Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452
   Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669
   SHENG SJ, 1994, J BIOL CHEM, V269, P30988
   Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499
   Shi HY, 2001, CANCER RES, V61, P6945
   Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Sood AK, 2002, CLIN CANCER RES, V8, P2924
   Straume O, 2002, AM J PATHOL, V161, P229, DOI 10.1016/S0002-9440(10)64174-0
   Umekita Y, 2003, HISTOPATHOLOGY, V42, P541, DOI 10.1046/j.1365-2559.2003.01620.x
   Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500
   Worm J, 2000, ONCOGENE, V19, P5111, DOI 10.1038/sj.onc.1203891
   Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhang M, 1997, CELL GROWTH DIFFER, V8, P179
   Zhang WG, 2002, INT J ONCOL, V20, P1145
   Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 45
TC 37
Z9 45
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAR
PY 2004
VL 122
IS 3
BP 805
EP 811
DI 10.1111/j.0022-202X.2004.22308.x
PG 7
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA 809UB
UT WOS:000220660500038
PM 15086568
OA Bronze
DA 2025-01-12
ER

PT J
AU Woo, IS
   Park, MJ
   Choi, SW
   Kim, SJ
   Lee, MA
   Kang, JH
   Hong, YS
   Lee, KS
AF Woo, IS
   Park, MJ
   Choi, SW
   Kim, SJ
   Lee, MA
   Kang, JH
   Hong, YS
   Lee, KS
TI Loss of estrogen receptor-α expression is associated with
   hypermethylation near its ATG start codon in gastric cancer cell lines
SO ONCOLOGY REPORTS
LA English
DT Article
DE estrogen receptor-alpha; methylation; gastric cancer
ID CPG ISLAND; BREAST-CANCER; PROGESTERONE-RECEPTORS; METHYLATION; GENE;
   HETEROZYGOSITY; CARCINOMA; BETA; ADENOCARCINOMA; NEUROBLASTOMA
AB The proportion of gastric cancers positive for estrogen receptor (ER)-alpha expression is reported to be between 0-67%, depending upon the study. The role of ER-a in gastric carcinogenesis is unclear. The ER-a gene is located at chromosome 6q25.1, and the long arm of chromosome 6 has been known as a site with frequent loss of heterozygosity (LOH) in gastric cancer. ER expression is linked to suppression of cell proliferation in vitro. Epigenetic inactivation might explain the loss of ER-a gene expression in gastric cancer. Given there is no information available regarding the methylation status of the ER-a gene promoter region in gastric cancer, we investigated such methylation in 13 gastric cancer cell lines. Western blot analysis, reverse transcription-polymerase chain reaction (PCR), methylation-specific PCR (MS-PCR) and bisulfite sequencing analyses were used. ER-cl protein was not detected in any cell line, although ER-cc mRNA was detected in I of 13 gastric cancer cell lines. MS-PCR and bisulfite sequencing showed all 13 gastric cancer cell lines had methylated CpG regions in their ER-a gene promoters. In conclusion, inactivation of ER-a gene expression in gastric cancer cell lines appears associated with CpG island methylation near the TGA initiation codon of the ER-cc gene.
C1 Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul 137040, South Korea.
   Kyung Hee Univ, Coll Med, Dept Internal Med, Seoul 130701, South Korea.
   Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea.
   Catholic Univ, Catholic Res Inst Med Sci, Div Mol Genet, Seoul 137040, South Korea.
C3 Catholic University of Korea; Kyung Hee University; Seoul National
   University (SNU); Catholic University of Korea
RP Woo, IS (通讯作者)，Catholic Univ Korea, Kangnam St Marys Hosp, Dept Internal Med, Banpo Dong 505, Seoul 137040, South Korea.
EM insookwoo@catholic.ac.kr
RI Park, Jinkyeong/GLV-1649-2022; Lee, Eunkyung/AAG-1192-2019
OI Woo, In Sook/0000-0001-8220-2260
CR Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   Al-Azzawi F, 2002, CLIMACTERIC, V5, P3, DOI 10.1080/713605194
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Chung Je Hyuk, 2002, Cancer Res Treat, V34, P382, DOI 10.4143/crt.2002.34.5.382
   DEVILEE P, 1991, ONCOGENE, V6, P1705
   Eads CA, 2000, CANCER RES, V60, P5021
   GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P218, DOI 10.1159/000132325
   HARRISON JD, 1989, CANCER-AM CANCER SOC, V63, P2148, DOI 10.1002/1097-0142(19890601)63:11<2148::AID-CNCR2820631113>3.0.CO;2-C
   Hosoya Y, 1999, CANCER LETT, V140, P139, DOI 10.1016/S0304-3835(99)00059-2
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Issa JPJ, 1996, CANCER RES, V56, P3655
   IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91
   Karat D, 1999, BRIT J CANCER, V80, P1271, DOI 10.1038/sj.bjc.6690497
   KOHIGASHI K, 1987, Gastroenterologia Japonica, V22, P322
   KUNE GA, 1984, AUST NZ J SURG, V54, P321
   Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831
   Li Q, 1999, CLIN CANCER RES, V5, P1077
   MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740
   MATSUI M, 1991, CANCER, V68, P305, DOI 10.1002/1097-0142(19910715)68:2<305::AID-CNCR2820680216>3.0.CO;2-A
   Matsuyama S, 2002, J CANCER RES CLIN, V128, P319, DOI 10.1007/s00432-002-0336-3
   MCCLENDON JE, 1977, ARCH SURG-CHICAGO, V112, P240
   MENASCE LP, 1993, GENOMICS, V17, P263, DOI 10.1006/geno.1993.1320
   Merup M, 1998, BLOOD, V91, P3397, DOI 10.1182/blood.V91.9.3397.3397_3397_3400
   Otis CN, 2002, INT J SURG PATHOL, V10, P237, DOI 10.1177/106689690201000401
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106
   SAITO S, 1992, CANCER RES, V52, P5815
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Shupnik MA, 1998, J CLIN ENDOCR METAB, V83, P3965, DOI 10.1210/jc.83.11.3965
   Takano N, 2002, CANCER LETT, V176, P129, DOI 10.1016/S0304-3835(01)00739-X
   TOKUNAGA A, 1986, CANCER-AM CANCER SOC, V57, P1376, DOI 10.1002/1097-0142(19860401)57:7<1376::AID-CNCR2820570722>3.0.CO;2-Z
   TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817
   Woo IS, 2002, INT J ONCOL, V20, P527
NR 33
TC 13
Z9 15
U1 0
U2 3
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD MAR
PY 2004
VL 11
IS 3
BP 617
EP 622
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 774DR
UT WOS:000188964900005
PM 14767512
DA 2025-01-12
ER

PT J
AU Sato, N
   Fukushima, N
   Matsubayashi, H
   Goggins, M
AF Sato, N
   Fukushima, N
   Matsubayashi, H
   Goggins, M
TI Identification of <i>maspin</i> and <i>S100P</i> as novel
   hypomethylation targets in pancreatic cancer using global gene
   expression profiling
SO ONCOGENE
LA English
DT Article
DE hypomethylation; maspin; SERPINB5; S100P; microarray
ID TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; DNA METHYLATION; ABERRANT
   METHYLATION; CPG-ISLANDS; EPITHELIAL-CELLS; MULTIPLE GENES; DUCTAL
   ADENOCARCINOMA; PLASMINOGEN-ACTIVATOR; OVARIAN-CARCINOMA
AB DNA hypomethylation is one of the major epigenetic alterations in human cancers. We have previously shown that genes identified as hypomethylated in pancreatic cancer are expressed in pancreatic cancer cell lines, but not in normal pancreatic ductal epithelium and can be reexpressed in nonexpressing cells using 'epigenetic modifying agents' such as DNA methyltransferase inhibitors. To identify additional targets for aberrant hypomethylation in pancreatic cancer, we used oligonucleotide microarrays to screen for genes that displayed expression patterns associated with hypomethylation. This analysis identified a substantial number of candidates including previously reported hypomethylated genes. A subset of eight genes were selected for further methylation analysis, and two cancer-related genes, maspin and S100P, were found to be aberrantly hypomethylated in a large fraction of pancreatic cancer cell lines and primary pancreatic carcinomas. Combined treatment with 5-aza-2'-deoxycytidie and trichostatin A resulted in synergistic induction of maspin and S100P mRNA in MiaPaCa2 cells where both genes were methylated. Furthermore, there was an inverse correlation between methylation and mRNA expression level for maspin and S100P in a large panel of pancreatic cancer cell lines. We also found a significant difference in the methylation patterns of maspin and two previously identified hypomethylated genes (trefoil factor 2 and lipocalin 2) between pancreatic and breast cancer cell lines, suggesting cancer-type specificity for some hypomethylation patterns. Thus, our present results confirm that DNA hypomethylation is a frequent epigenetic event in pancreatic cancer, and suggest that gene expression pro. ling may help to identify potential targets affected by this epigenetic alteration.
C1 Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine
RP Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.
EM mgoggins@jhmi.edu
FU NCI NIH HHS [CA62924, CA90709] Funding Source: Medline
CR Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Da Silva IDCG, 2000, INT J ONCOL, V16, P231
   DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Díaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2001, CANCER RES, V61, P3225
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039
   Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Goggins M, 1999, ANN ONCOL, V10, P4, DOI 10.1023/A:1008307913019
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Gupta A, 2003, CANCER RES, V63, P664
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9
   Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Koltzscher M, 2003, MOL BIOL CELL, V14, P2372, DOI 10.1091/mbc.e02-09-0553
   Liang G, 2002, CANCER RES, V62, P961
   Logsdon CD, 2003, CANCER RES, V63, P2649
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Maass N, 2001, CLIN CANCER RES, V7, P812
   Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349
   Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446
   Mousses S, 2002, CANCER RES, V62, P1256
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7
   Ryu B, 2002, CANCER RES, V62, P819
   Sato N, 2003, CANCER RES, V63, P4158
   Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327
   Sato N, 2003, CANCER RES, V63, P3735
   Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807
   Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Sood AK, 2002, CLIN CANCER RES, V8, P2924
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Ueki T, 2000, CANCER RES, V60, P1835
   Ueki T, 2001, CANCER RES, V61, P8540
   Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109
   Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970
   Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 52
TC 132
Z9 161
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD FEB 26
PY 2004
VL 23
IS 8
BP 1531
EP 1538
DI 10.1038/sj.onc.1207269
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 778BP
UT WOS:000189219500006
PM 14716296
DA 2025-01-12
ER

PT J
AU Dhillon, VS
   Young, AR
   Husain, SA
   Aslam, M
AF Dhillon, VS
   Young, AR
   Husain, SA
   Aslam, M
TI Promoter hypermethylation of <i>MGMT</i>, <i>CDH1</i>, <i>RAR</i>-β and
   <i>SYK</i> tumour suppressor genes in granulosa cell tumours (GCTs) of
   ovarian origin
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE ovarian carcinoma; hypermethylation of MGMT; CDH1; RAR-beta and SYK gene
ID ACID RECEPTOR-BETA; BREAST-CANCER CELLS; RETINOIC ACID; E-CADHERIN;
   MICROSATELLITE INSTABILITY; GASTRIC CARCINOMAS; DNA METHYLATION; CPG
   ISLAND; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; CLINICOPATHOLOGICAL
   FEATURES
AB Ovarian carcinoma (OC) is a leading cause of death among women throughout the world. A number of cancer-associated genes have been shown to be inactivated by hypermethylation of CpG islands during tumorigenesis. We tested the hypothesis that methylation status of MGMT, CDHI, RAR-beta and SYK could be important in the ovarian tumorigenic process and can lead to the gene(s) inactivation. Therefore, we assessed the promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK in 43 ovarian granulosa cell tumours (GCTs) (adult type) using methylation-specific PCR. These tumours are relatively rare, accounting for approximately 3% of all ovarian cancers. Hypermethylation of MGMT (in 14 tumours), CDHI (in nine tumours), RAR-beta (in eight tumours) and SYK (in seven tumours) have been found. Selective loss of RAR-beta and RAR-beta2 mRNA has been found in seven patients, while that of MGMT and SYK in three patients who also show aberrant methylation in promoter region of RAR-beta in addition to MGMT SYK and CDHI genes. Promoter CpG hypermethylation may be an alternative to mutation(s) to inactivate tumour suppressor genes such as MGMT CDH1, RAR-beta and SYK, and this can also be an early event in the pathogenesis of OCs. Moreover, hypermethylation of the MGMT and CDH1, MGMT and RAR-beta and CDHI and RAR-beta promoters occurred concordantly (P < 0.001, 0.0421 and 0.0005 respectively; Fischer's exact test). In addition to this, monosomy 22 and trisomy 14 have also been found in 10 tumours. It is clear from the results that hypermethylation of the promoter region of these tumour suppressor genes, monosomy 22 and trisomy 14, may be critical steps in the tumorigenesis, which consequently play a permissive role for tumour aggressiveness. All these events might play an important role in the early clinical diagnosis of the disease. Our results, therefore, suggest a potential role for epigenetic modification of these critical tumour suppressor genes in pathways relevant to the transformation and differentiation of rare type of ovarian cancer (GCTs).
C1 Royal Prince Alfred Hosp, Dept Mol & Clin Genet, Camperdown, NSW 2050, Australia.
   Jamia Millia Islamia, Cytogenet Lab, Dept Biosci, New Delhi 110025, India.
C3 NSW Health; Royal Prince Alfred Hospital; University of Sydney; Jamia
   Millia Islamia
RP Dhillon, VS (通讯作者)，CSIRO Hlth Sci & Nutr, POB 10041,Gate 13,Kintore Ave, Adelaide, SA 5000, Australia.
EM Varinderpal.Dhillon@csiro.au
RI Dhillon, varinderpal/H-4622-2013; Yusuf, Mohd/AAL-4890-2021
OI Aslam, Mohd/0000-0001-8172-5799
CR [Anonymous], SCIENCE
   Bae SI, 2002, BRIT J CANCER, V86, P1888, DOI 10.1038/sj.bjc.6600372
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x
   Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086
   Corn PG, 2001, CLIN CANCER RES, V7, P2765
   DalCin P, 1997, CANCER GENET CYTOGEN, V99, P129, DOI 10.1016/S0165-4608(97)00210-0
   del Muro XG, 2000, EUR J CANCER, V36, P357
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   Duesberg P, 2000, CANCER GENET CYTOGEN, V119, P83, DOI 10.1016/S0165-4608(99)00236-8
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2
   Esteller M, 2000, CANCER RES, V60, P2368
   Evans MF, 1999, J PATHOL, V189, P53, DOI 10.1002/(SICI)1096-9896(199909)189:1<53::AID-PATH393>3.0.CO;2-U
   Fleisher AS, 1999, CANCER RES, V59, P1090
   GEBERT JF, 1991, ONCOGENE, V6, P1859
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Gras E, 2001, CANCER-AM CANCER SOC, V92, P2829, DOI 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3
   Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x
   Heimann R, 2000, CANCER RES, V60, P298
   Herman JG, 1996, CANCER RES, V56, P722
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Jimi S, 1998, ONCOL RES, V10, P7
   Leung SY, 1999, CANCER RES, V59, P159
   LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9
   Maruyama R, 2001, CANCER RES, V61, P8659
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Nakayama K, 2001, INT J CANCER, V94, P605, DOI 10.1002/ijc.1499
   Oue N, 2002, J PATHOL, V198, P55, DOI 10.1002/path.1170
   Rosas SLB, 2001, CANCER RES, V61, P939
   RUSSEL P, 1989, SURG PATHOLOGY OVARI
   Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339
   SANDBERG AA, 1991, MUTAT RES, V247, P231, DOI 10.1016/0027-5107(91)90019-K
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Speleman F, 1997, GENE CHROMOSOME CANC, V19, P192
   STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61
   Suzuki M, 2000, CANCER GENET CYTOGEN, V122, P55, DOI 10.1016/S0165-4608(00)00269-7
   TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Van den Berghe I, 1999, CANCER GENET CYTOGEN, V112, P46, DOI 10.1016/S0165-4608(98)00249-0
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Xu XC, 1997, CANCER RES, V57, P4992
   XU XC, 1994, CANCER RES, V54, P3580
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Yuan YF, 2001, CANCER RES, V61, P5558
   Zheng Z, 1999, HUM PATHOL, V30, P458, DOI 10.1016/S0046-8177(99)90123-5
NR 55
TC 18
Z9 25
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD FEB 23
PY 2004
VL 90
IS 4
BP 874
EP 881
DI 10.1038/sj.bjc.6601567
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 802DN
UT WOS:000220144300021
PM 14970867
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Li, XR
   Cowell, JK
   Sossey-Alaoui, K
AF Li, XR
   Cowell, JK
   Sossey-Alaoui, K
TI <i>CLCA2</i> tumour suppressor gene in 1p31 is epigenetically regulated
   in breast cancer
SO ONCOGENE
LA English
DT Article
DE CLCA2; tumour suppressor gene; 1p31; breast cancer; epigenetics
ID ACTIVATED CHLORIDE CHANNEL; SPORADIC BREAST; 5-METHYLCYTOSINE RESIDUES;
   DNA HYPERMETHYLATION; ALLELIC IMBALANCE; OVARIAN-CANCER; CHROMOSOME 1P;
   HUMAN HOMOLOG; REGION; METHYLATION
AB The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumorigenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoter-associated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.
C1 Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
C3 Roswell Park Comprehensive Cancer Center
RP Roswell Pk Canc Inst, Dept Canc Genet, 110 C&V Bldg,Elm & Carlton St, Buffalo, NY 14263 USA.
EM khalid.sossey-alaoui@roswellpark.org
OI Cowell, John/0000-0002-2079-5950
FU NCI NIH HHS [CA16056] Funding Source: Medline
CR Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200
   Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1
   ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3
   Dallol A, 2002, CANCER RES, V62, P5874
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   DEANE KHO, 1992, EUR J IMMUNOL, V22, P1165, DOI 10.1002/eji.1830220509
   Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   GRIGG G, 1994, BIOESSAYS, V16, P431, DOI 10.1002/bies.950160612
   Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261
   Gruber AD, 1999, CANCER RES, V59, P5488
   Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562
   Hoff C, 2001, CANCER GENET CYTOGEN, V129, P145, DOI 10.1016/S0165-4608(01)00450-2
   HOGGARD N, 1995, GENOMICS, V30, P233, DOI 10.1006/geno.1995.9882
   HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H
   Lichy JH, 1998, AM J PATHOL, V153, P271, DOI 10.1016/S0002-9440(10)65568-X
   NAGAI H, 1995, CANCER RES, V55, P1752
   Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x
   Roy D, 2003, INT J CANCER, V103, P730, DOI 10.1002/ijc.10895
   Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734
   Sossey-Alaoui K, 2002, GENOMICS, V80, P5, DOI 10.1006/geno.2002.6792
   Sossey-Alaoui K, 2001, INT J MOL MED, V7, P543
   SOULE HD, 1990, CANCER RES, V50, P6075
   Su GF, 1999, GENOMICS, V55, P157, DOI 10.1006/geno.1998.5633
   Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.0.CO;2-0
   Ullrich N, 1997, AM J PHYSIOL-CELL PH, V273, pC1290, DOI 10.1152/ajpcell.1997.273.4.C1290
   White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 38
TC 49
Z9 57
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD FEB 19
PY 2004
VL 23
IS 7
BP 1474
EP 1480
DI 10.1038/sj.onc.1207249
PG 7
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 775HZ
UT WOS:000189035800015
PM 14973555
OA Bronze
DA 2025-01-12
ER

PT J
AU Costa, FF
   Verbisck, NV
   Salim, ACM
   Ierardi, DF
   Pires, LC
   Sasahara, RM
   Sogayar, MC
   Zanata, SM
   Mackay, A
   O'Hare, M
   Soares, F
   Simpson, AJG
   Camargo, AA
AF Costa, FF
   Verbisck, NV
   Salim, ACM
   Ierardi, DF
   Pires, LC
   Sasahara, RM
   Sogayar, MC
   Zanata, SM
   Mackay, A
   O'Hare, M
   Soares, F
   Simpson, AJG
   Camargo, AA
TI Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent
   in breast tumors
SO ONCOGENE
LA English
DT Article
DE ADAM23; methylation; cell adhesion; downregulation; breast tumor
ID DNA METHYLATION; CELL-ADHESION; CPG ISLAND; METALLOPROTEASE DOMAIN;
   MEMBRANE-PROTEINS; SUPPRESSOR GENES; DISINTEGRIN-LIKE; CANCER;
   EXPRESSION; FAMILY
AB Altered cell adhesion is causally involved in tumor progression, and the identification of novel adhesion molecules altered in tumors is crucial for our understanding of tumor biology and for the development of new prognostic and therapeutic strategies. Here, we provide evidence for the epigenetic downregulation in breast tumors of the A Desintegrin And Metalloprotease domain 23 gene ( ADAM 23), a member of a new family of surface molecules with roles in cell - cell adhesion and/or cell matrix interactions. W e examined the mRNA expression and methylation status of the 50 upstream region of the ADAM23 gene in different breast tumor cell lines as well as in primary breast tumors. We found ADAM23 50 hypermethylation in eight out of 12 (66.7%) tumor cell lines and in nine out of 13 (69.2%) primary tumors. Promoter hypermethylation was strongly associated with reductions in both mRNA and protein expression, with a threshold of 40 - 60% of modified CpG dinucleotides being required for the complete silencing of ADAM23 mRNA expression. Treatment of MCF-7 and SKBR-3 cell lines with 5'-Aza-2'-deoxycytidine led to a reactivation of ADAM23 mRNA expression and a marked decrease in the methylation level. It is worth noting that primary breast tumors with a more advanced grade showed a higher degree of methylation, suggesting that the adhesion molecule ADAM23 may be downregulated during the progression of breast cancer.
C1 Ludwig Inst Canc Res, Lab Mol Biol & Genom, BR-01509010 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil.
   Univ Fed Parana, Neurobiol Lab, BR-80060000 Curitiba, Parana, Brazil.
   Univ Coll, Ludwig Inst Canc Res, Breast Canc Lab, London, England.
   Hosp ACCamargo, Dept Patol, Sao Paulo, Brazil.
C3 Ludwig Institute for Cancer Research; Universidade de Sao Paulo;
   Universidade Federal do Parana; University of London; University College
   London; Ludwig Institute for Cancer Research; A.C.Camargo Cancer Center
RP Ludwig Inst Canc Res, Lab Mol Biol & Genom, Rua Prof Antonio Prudente 109,4th Floor, BR-01509010 Sao Paulo, Brazil.
EM anamaria@compbio.ludwig.org.br
RI Costa, Fabricio/M-5309-2017; Soares, Fernando/HLV-7984-2023; Zanata,
   Silvio/AAC-9670-2021; Simpson, Amelia/C-1105-2019; Sogayar, Mari
   Cleide/B-3980-2017; Aranha Camargo, Anamaria/E-9388-2012; Verbisck,
   Newton Valerio/I-1356-2012
OI Sogayar, Mari Cleide/0000-0003-4805-4609; Soares, Fernando
   Augusto/0000-0003-1647-7842; Zanata, Silvio/0000-0003-2818-6954; Aranha
   Camargo, Anamaria/0000-0002-6076-9597; Soares,
   Fernando/0000-0002-1212-9093; Verbisck, Newton
   Valerio/0000-0001-9817-7223
CR Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2
   Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457
   Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5
   CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871
   Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353
   Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693
   HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   McCulloch DR, 2000, MOL CELL ENDOCRINOL, V167, P11, DOI 10.1016/S0303-7207(00)00305-1
   Moss ML, 2001, DRUG DISCOV TODAY, V6, P417, DOI 10.1016/S1359-6446(01)01738-X
   OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063
   Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7
   Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5
   Radice D, 2003, PHARMACOECONOMICS, V21, P383, DOI 10.2165/00019053-200321060-00003
   Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609
   Sagane K, 1998, BIOCHEM J, V334, P93, DOI 10.1042/bj3340093
   Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276
   Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87
   Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717
   WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275
   WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152
   Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714
NR 36
TC 53
Z9 63
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD FEB 19
PY 2004
VL 23
IS 7
BP 1481
EP 1488
DI 10.1038/sj.onc.1207263
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 775HZ
UT WOS:000189035800016
PM 14661055
DA 2025-01-12
ER

PT J
AU Han, SE
   Park, KH
   Lee, G
   Huh, YJ
   Min, BM
AF Han, SE
   Park, KH
   Lee, G
   Huh, YJ
   Min, BM
TI Mutation and aberrant expression of <i>Caveolin-1</i> in human oral
   squamous cell carcinomas and oral cancer cell lines
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE Caveolin-1; mutation; aberrant expression; oral cancer; oral cancer cell
   line
ID HUMAN PROSTATE-CANCER; BREAST-CANCER; GENE FAMILY; PROTEIN-COMPONENT;
   PLASMA-MEMBRANE; IN-VIVO; TYROSINE; TRANSFORMATION; KERATINOCYTES;
   ORGANIZATION
AB Caveolin-1, a tumor suppressor gene, was found to be inactivated by structural abnormalities or epigenetic changes in several types of human cancers. In order to investigate the role of Caveolin-1 in the pathogenesis of human oral squamous cell carcinoma, the exon 1 and 3 sequences of the Caveolin-1 were investigated in 74 oral squamous cell carcinomas and 15 oral cancer cell lines. In addition, Caveolin-1 expression was examined in 15 oral cancer cell lines. Mutations of the Caveolin-1 gene were identified in five cancers (I missense and 4 silent mutations), with all mutations being detected in exon 3. Among the cancers containing the Caveolin-1 mutation, case 53 harbored a missense mutation from Ile (ATT) to Phe (TTT) at codon 141 and two silent mutations at codons 112 and 163 of the Caveolin-1 gene. Cases 27, 44, and 84 had two silent mutations from GAC (Asp) to GAT (Asp) at codon 82, and from CCA (Pro) to CCT (Pro) at codon 132. Case 89 contained three silent mutations at codons 84, 124, and 161. However, mutations of the Caveolin-1 gene were not observed in normal human oral keratinocytes, the human papillomavirus-immortalized oral keratinocytes, and 15 oral cancer cell lines. Despite the intact Caveolin-1 gene, one oral cancer cell line, HEp-2, lacked the caveolin-1 protein. In contrast, two cancer cell lines, KOSCC-25C and -33B, had an insignificant amount of the caveolin-1 protein. These results provide genetic evidence showing that the inactivation of Caveolin-1 by a mutation or by reduced expression may play a role in the pathogenesis of oral cancer.
C1 Seoul Natl Univ, Coll Dent, Dept Oral Biochem, Seoul 110749, South Korea.
   Seoul Natl Univ, Coll Dent, Dent Res Inst, Seoul 110749, South Korea.
   Seoul Natl Univ, Coll Dent, BK21 HLS, Seoul 110749, South Korea.
   Seoul Natl Univ, Coll Dent, IBEC, Seoul 110749, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU)
RP Seoul Natl Univ, Coll Dent, Dept Oral Biochem, 28 Yeonkun Dong, Seoul 110749, South Korea.
EM bmmin@snu.ac.kr
RI Park, Keunchil/ABD-5852-2021; Min, Byung-Moo/F-2854-2012
CR BADLEY JE, 1988, BIOTECHNIQUES, V6, P114
   BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9
   Cui J, 1998, CANCER GENET CYTOGEN, V107, P51, DOI 10.1016/S0165-4608(98)00074-0
   Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0
   Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X
   Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X
   Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172
   GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0
   GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517
   Hayashi K, 2001, CANCER RES, V61, P2361
   Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491
   KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381
   Lee G, 2002, INT J ONCOL, V20, P1151
   Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661
   Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182
   Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823
   MIN BM, 1995, INT J ONCOL, V7, P249
   Mizobuchi S, 2000, JPN J CLIN ONCOL, V30, P423, DOI 10.1093/jjco/hyd114
   Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419
   PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627
   Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0
   Pflug BR, 1999, PROSTATE, V40, P269, DOI 10.1002/(SICI)1097-0045(19990901)40:4<269::AID-PROS9>3.0.CO;2-6
   PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5
   REGEZI JA, 1993, ORAL PATHOLOGY CLIN, P77
   ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z
   SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407
   Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337
   Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448
   Smart EJ, 1999, MOL CELL BIOL, V19, P7289
   Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160
   Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255
   Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4
   Yang G, 1999, CANCER RES, V59, P5719
   Yang G, 1998, CLIN CANCER RES, V4, P1873
   ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155
   Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199
NR 36
TC 45
Z9 53
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2004
VL 24
IS 2
BP 435
EP 440
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 766LK
UT WOS:000188377700024
PM 14719121
DA 2025-01-12
ER

PT J
AU Bahar, A
   Bicknell, JE
   Simpson, DJ
   Clayton, RN
   Farrell, WE
AF Bahar, A
   Bicknell, JE
   Simpson, DJ
   Clayton, RN
   Farrell, WE
TI Loss of expression of the growth inhibitory gene <i>GADD45</i>γ, in
   human pituitary adenomas, is associated with CpG island methylation
SO ONCOGENE
LA English
DT Article
DE GADD45 gamma; CpG island methylation; pituitary adenomas
ID DNA METHYLATION; MAMMALIAN-CELLS; BREAST-CANCER; P16 GENE; TUMORS;
   HYPERMETHYLATION; INACTIVATION; TUMORIGENESIS; PATHOGENESIS; DELETION
AB Inappropriate expression of cell-cycle regulatory genes and/or their protein products are a frequent finding in pituitary tumours; however, genetic changes associated with or responsible for their dysregulation are in general uncommon. In a search for novel genes, and employing eDNA-representational difference analysis, the gene encoding GADD45gamma was recently isolated and identified as being under-represented in pituitary adenomas. GADD45gamma is a member of a family of genes that are induced by DNA damage and function in the negative regulation of cell growth. In this study, we further confirm this initial report that the majority of pituitary adenomas (22 of 33; 67%) do not express GADD45gamma as determined by RT-PCR analysis. Loss of expression was not associated with either loss of heterozygosity or mutations within the coding region of this gene. In marked contrast, epigenetic change, namely methylation of the GADD45gamma genes CpG island, was a frequent finding (19 of 33 adenoma; 58%) and was significantly associated with tumours in which GADD45gamma transcript was not expressed (18 of 22; 82%; P = 0.002). In common with the primary tumours, methylation-associated gene silencing of the GADD45gamma gene was also found in the pituitary tumour cell line AtT20. The treatment of AtT20 cells with the demethylating agent, 5-Aza-2'-deoxycytidine, induced the re-expression of this gene. These findings show that silencing of the GADD45gamma gene in pituitary tumours is primarily associated with methylation of the genes CpG island. Methylation has functional importance since reversal of this epigenetic change in a pituitary-derived cell line is associated with reexpression. Silencing of GADD45gamma, a negative regulator of cell growth, is most likely responsible for conferring a selective growth advantage during tumour evolution and outgrowth.
C1 Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent ST4 7QB, Staffs, England.
C3 University Hospital of North Staffordshire NHS Trust; Keele University
RP Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent ST4 7QB, Staffs, England.
EM w.e.farrell@keele.ac.uk
CR Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798
   Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200
   Bates AS, 1997, J CLIN ENDOCR METAB, V82, P818, DOI 10.1210/jc.82.3.818
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BOGGILD MD, 1994, J CLIN ENDOCR METAB, V78, P387, DOI 10.1210/jc.78.2.387
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Davis JRE, 2001, REPRODUCTION, V121, P363, DOI 10.1530/rep.0.1210363
   Esteller M, 2001, CANCER RES, V61, P3225
   Farrell WE, 2000, FRONT NEUROENDOCRIN, V21, P174, DOI 10.1006/frne.1999.0195
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800
   Frost SJ, 1999, MOL ENDOCRINOL, V13, P1801, DOI 10.1210/me.13.11.1801
   Grigg GW, 1996, DNA SEQUENCE, V6, P189, DOI 10.3109/10425179609008443
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hibberts NA, 1999, CLIN CANCER RES, V5, P2133
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jaffrain-Rea ML, 1999, CLIN ENDOCRINOL, V51, P317
   Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952
   Korabiowska M, 1999, IN VIVO, V13, P483
   Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433
   Ruebel KH, 2001, ENDOCR PATHOL, V12, P281, DOI 10.1385/EP:12:3:281
   Seemann N, 2001, J PATHOL, V193, P491, DOI 10.1002/path.833
   Simpson DJ, 1999, GENE CHROMOSOME CANC, V24, P328
   Simpson DJ, 2002, ONCOGENE, V21, P1217, DOI 10.1038/sj.onc.1205195
   Simpson DJ, 2001, CARCINOGENESIS, V22, P1149, DOI 10.1093/carcin/22.8.1149
   Simpson DJ, 2000, CANCER RES, V60, P1211
   SIMPSON DJ, 1999, CANCER RES, V59, P2703
   Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0
   TERADA T, 1995, ENDOCR PATHOL, V6, P301, DOI 10.1007/BF02738730
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Wan YS, 2000, INT J MOL MED, V6, P683
   Woloschak M, 1997, MOL CARCINOGEN, V19, P221, DOI 10.1002/(SICI)1098-2744(199708)19:4<221::AID-MC1>3.0.CO;2-F
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885
   Zhang W, 2001, INT J ONCOL, V18, P749
   Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262
   Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761
NR 38
TC 75
Z9 84
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 29
PY 2004
VL 23
IS 4
BP 936
EP 944
DI 10.1038/sj.onc.1207193
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 767UV
UT WOS:000188486600009
PM 14647444
DA 2025-01-12
ER

PT J
AU Kadouri, L
   Kote-Jarai, Z
   Easton, DF
   Hubert, A
   Hamoudi, R
   Glaser, B
   Abeliovich, D
   Peretz, T
   Eeles, RA
AF Kadouri, L
   Kote-Jarai, Z
   Easton, DF
   Hubert, A
   Hamoudi, R
   Glaser, B
   Abeliovich, D
   Peretz, T
   Eeles, RA
TI Polyglutamine repeat length in the <i>AIB1</i> gene modifies breast
   cancer susceptibility in <i>BRCA1</i> carriers
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE BRCA1/2; breast cancer risk; AIB1 gene; polymorphism
ID SINGLE NUCLEOTIDE POLYMORPHISM; RECEPTOR COACTIVATOR GENE; CAG REPEAT;
   RISK; ESTROGEN; GROWTH; AMPLIFICATION; OOPHORECTOMY; RAD51
AB Variation in the penetrance estimates for BRCA1 and BRCA2 mutation carriers suggests that other factors may modify cancer risk from specific mutations. One possible mechanism is an epigenetic effect of polymorphisms in other genes. Genes involved in hormonal signal transduction are possible candidates. The AIB1 gene, an estrogen receptor (ER) coactivator, is frequently amplified in breast and ovarian tumors. Variation of a CAG repeat length has been reported within this gene that encodes a polyglutamine repeat in the C-terminus of the protein. Three hundred eleven BRCA1/2 mutation carriers (257 were of Ashkenazi origin) were genotyped for the AIB1 polyglutamine repeat. Relative risks (RR) were estimated using a maximum likelihood approach. The estimated breast cancer (BC) RR per average repeat length adjusted for population type (Ashkenazi vs. non-Ashkenazi) was 1.15 (95% CI 1.02-1.30; p = 0.01) for BRCA1/2 carriers, and 1.25 (95% CI 1.09-1.42; p = 0.001) when analysis was restricted to BRCA1 carriers. RR of BC was 1.17 (95% CI = 0.91-1.74), for individuals with 2 alleles greater than or equal to29 polyglutamine repeats and 0.78 (95% CI = 0.50-1.16) for those with at least I allele of :526 repeats, compared to individuals with the common genotypes 28;28, 28;29 or 28;30. The corresponding BC RR in BRCA1 mutation carriers was 0.55 (95% CI = 0.34-0.90) and 1.29 (95% CI = 0.85-1.96) in those with less than or equal to26 and greater than or equal to29 repeats respectively (p = 0.025). These results indicate significant association of the risk for BC in carriers of BRCA1 mutations with the polyglutamine chain of the AIB1 gene. Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers. (C) 2003 Wiley-Liss, Inc.
C1 Hebrew Univ Jerusalem, Hadassah Med Ctr, Sharett Inst Oncol, IL-91120 Jerusalem, Israel.
   Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England.
   Strangeways Res Lab, Canc Res UK Genet Epidemiol Unit, Cambridge CB1 4RN, England.
   Hebrew Univ Jerusalem, Hadassah Med Ctr, Human Genet Labs, IL-91120 Jerusalem, Israel.
   Royal Marsden NHS Trust, Sutton, Surrey, England.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   University of London; Institute of Cancer Research - UK; University of
   Cambridge; Cancer Research UK; Hebrew University of Jerusalem; Hadassah
   University Medical Center; Royal Marsden NHS Foundation Trust
RP Hebrew Univ Jerusalem, Hadassah Med Ctr, Sharett Inst Oncol, IL-91120 Jerusalem, Israel.
EM luna@hadassah.org.il
RI ; Glaser, Benjamin/F-8411-2017
OI Hamoudi, Rifat/0000-0002-1402-0868; Glaser,
   Benjamin/0000-0003-4711-5000; Eeles, Rosalind/0000-0002-3698-6241
CR Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113
   Bautista S, 1998, CLIN CANCER RES, V4, P2925
   Bouras T, 2001, CANCER RES, V61, P903
   CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181
   David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65
   de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000
   EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703
   EASTON DF, 1995, AM J HUM GENET, V56, P265
   Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297
   Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4
   GUDAS JM, 1995, CANCER RES, V55, P4561
   Haiman CA, 2000, BREAST CANCER RES, V2, P378, DOI 10.1186/bcr82
   Hayashi Y, 1999, ENDOCR J, V46, P279, DOI 10.1507/endocrj.46.279
   Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166
   Jernström H, 2001, MOL GENET METAB, V72, P144, DOI 10.1006/mgme.2000.3130
   Kadouri L, 2001, BRIT J CANCER, V85, P36, DOI 10.1054/bjoc.2001.1777
   Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119
   LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611
   LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0
   Levy-Lahad E, 2001, P NATL ACAD SCI USA, V98, P3232, DOI 10.1073/pnas.051624098
   Patel MS, 2000, J BONE MINER RES, V15, P2231, DOI 10.1359/jbmr.2000.15.11.2231
   Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309
   Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078
   Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366
   Rebbeck TR, 2001, CANCER RES, V61, P5420
   Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158
   Sakakura C, 2000, INT J CANCER, V89, P217
   Shirazi SK, 1998, CLIN GENET, V54, P102
   Spillman MA, 1996, ONCOGENE, V13, P1639
   Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001
   Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5
   Wang WW, 2001, CANCER EPIDEM BIOMAR, V10, P955
   Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097
   Young IE, 2000, J MED GENET, V37, P139, DOI 10.1136/jmg.37.2.139
   Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298
   Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62
NR 40
TC 35
Z9 35
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 20
PY 2004
VL 108
IS 3
BP 399
EP 403
DI 10.1002/ijc.11531
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 754BK
UT WOS:000187282700010
PM 14648706
DA 2025-01-12
ER

PT J
AU Meehan, WJ
   Samant, RS
   Hopper, JE
   Carrozza, MJ
   Shevde, LA
   Workman, JL
   Eckert, KA
   Verderame, MF
   Welch, DR
AF Meehan, WJ
   Samant, RS
   Hopper, JE
   Carrozza, MJ
   Shevde, LA
   Workman, JL
   Eckert, KA
   Verderame, MF
   Welch, DR
TI Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with
   retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone
   deacetylase complex and represses transcription
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MOUSE MAMMARY-TUMOR; N-COR; EPIGENETIC REGULATION; COREPRESSOR COMPLEX;
   INTEGRAL COMPONENT; GENE; INHIBITORS; CELLS; YEAST; MTA1
AB Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis of multiple human and murine cancer cells without inhibiting tumorigenicity. By yeast two-hybrid and co-immunoprecipitation, BRMS1 interacts with retinoblastoma binding protein 1 and at least seven members of the mSin3 histone deacetylase (HDAC) complex in human breast and melanoma cell lines. BRMS1 co-immunoprecipitates enzymatically active HDAC proteins and represses transcription when recruited to a Gal4 promoter in vivo. BRMS1 exists in large mSin3 complex(es) of similar to1.4-1.9 MDa, but also forms smaller complexes with HDAC1. Deletion analyses show that the carboxyl-terminal 42 amino acids of BRMS1 are not critical for interaction with much of the mSin3 complex and that BRMS1 appears to have more than one binding point to the complex. These results further show that BRMS1 may participate in transcriptional regulation via interaction with the mSin3.HDAC complex and suggest a novel mechanism by which BRMS1 might suppress cancer metastasis.
C1 Penn State Univ, Coll Med, Dept Pathol, Jake Gittlen Canc Res Inst, Hershey, PA 17033 USA.
   Penn State Univ, Coll Med, Dept Biochem, Hershey, PA 17033 USA.
   Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA.
   Stowers Inst Med Res, Kansas City, MO 64110 USA.
   Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Natl Fdn Canc Res, Ctr Metastasis Res, Birmingham, AL 35294 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health; Stowers Institute for Medical Research; University of Alabama
   System; University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham
RP Univ Alabama Birmingham, Dept Pathol, 1670 Univ Blvd,Volker Hall G-038, Birmingham, AL 35294 USA.
EM dwelch@path.uab.edu
RI Workman, Joanna/AAV-2256-2020; Welch, Danny/B-7310-2009
OI , William/0000-0003-2481-8985; Verderame, Michael F./0000-0001-7046-0879
FU NCI NIH HHS [P50-CA89019, R01-CA88728] Funding Source: Medline
CR Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7
   Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002
   Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   FATTAEY AR, 1993, ONCOGENE, V8, P3149
   Fu TM, 1996, VIROLOGY, V222, P269, DOI 10.1006/viro.1996.0419
   Hartsough MT, 2001, CANCER RES, V61, P2320
   Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7
   Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0
   HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7
   Hunter KW, 2001, CANCER RES, V61, P8866
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695
   KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993
   Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7
   Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636
   Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889
   Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9
   Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2
   Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001
   Laj A, 1999, MOL CELL BIOL, V19, P6632
   Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200
   Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502
   Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699
   Liotta L.A., 1993, CANCER, P134
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   MILLER BE, 1980, CANCER RES, V40, P3977
   Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121
   Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769
   Paget S., 1989, Cancer Metastasis Rev, V8, P98, DOI 10.1016/S0140-6736(00)49915-0
   Samant RS, 2002, INT J CANCER, V97, P15, DOI 10.1002/ijc.1569
   Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690
   Saunders MM, 2001, CANCER RES, V61, P1765
   Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x
   Seraj MJ, 2000, CANCER RES, V60, P2764
   Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5
   Shevde LA, 2002, EXP CELL RES, V273, P229, DOI 10.1006/excr.2001.5452
   Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967
   TOH Y, 1994, J BIOL CHEM, V269, P22958
   TRAINER DL, 1988, CLIN EXP METASTAS, V6, P185, DOI 10.1007/BF01782479
   VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213
   Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001
   Welch DR, 1998, ENDOCR-RELAT CANCER, V5, P155, DOI 10.1677/erc.0.0050155
   WELCH DR, 1994, ONCOGENE, V9, P255
   Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3
   Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717
   Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0
   Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1
NR 54
TC 142
Z9 174
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 9
PY 2004
VL 279
IS 2
BP 1562
EP 1569
DI 10.1074/jbc.M307969200
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 759DJ
UT WOS:000187722800089
PM 14581478
OA hybrid
DA 2025-01-12
ER

PT J
AU Albini, A
   Benelli, R
   Noonan, DM
   Brigati, C
AF Albini, A
   Benelli, R
   Noonan, DM
   Brigati, C
TI The "chemoinvasion assay": a tool to study tumor and endothelial cell
   invasion of basement membranes
SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE invasion; metastasis; angiogenesis; basement membrane; chemoinvasion
ID BREAST-CANCER METASTASIS; CARCINOMA CELLS; IN-VIVO; MATRIX
   METALLOPROTEINASES; EXTRACELLULAR-MATRIX; PULMONARY METASTASIS;
   QUANTITATIVE ASSAY; GROWTH-FACTOR; E-CADHERIN; EXPRESSION
AB Several genetic and epigenetic factors, both in the cell and in the host, contribute to the progression of tumors towards metastases. The escape of cancer cells from a primary, localized tumor to distant organs transforms a relatively curable pathology to an almost untreatable one. Metastatic lesions are often resistant to cancer therapy because of the progressive phenotypic changes that they have undergone. In this article we will give a bird's eye view on the features of metastatic cells and potential therapeutic targets. In particular, the invasion of basement membranes represents a fundamental step for cell dispersion. Over seventeen years ago we established the Matrigel "chemoinvasion" assay, a useful tool for studying the mechanisms involved in tumor and endothelial cell invasion of basement membranes and for the screening of anti-invasive agents. We will describe the assay and review some of the major results it enabled to obtain.
C1 Ist Nazl Ric Canc, I-16132 Genoa, Italy.
C3 University of Genoa; IRCCS AOU San Martino IST
RP Albini, A (通讯作者)，Ist Nazl Ric Canc, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.
EM adriana.albini@istge.it
RI Benelli, Roberto/AAF-3143-2019; Noonan, Douglas/A-8620-2010; Albini,
   Adriana/HLH-6147-2023
OI Noonan, Douglas/0000-0001-8058-0719; Benelli,
   Roberto/0000-0002-9769-0954; Albini, Adriana/0000-0002-9624-5103
CR Akhtar Nasim, 2002, Angiogenesis, V5, P75, DOI 10.1023/A:1021507031486
   ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004
   ALBINI A, 1987, CANCER RES, V47, P3239
   Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497
   Baruch RR, 2001, CELL BIOL INT, V25, P411, DOI 10.1006/cbir.2000.0647
   Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757
   Brem R, 2001, ANTICANCER RES, V21, P1731
   Brigati C, 2002, CLIN EXP METASTAS, V19, P247, DOI 10.1023/A:1015587423262
   Casey RC, 2003, CLIN EXP METASTAS, V20, P143, DOI 10.1023/A:1022670501667
   Chambers AF, 1995, CANCER METAST REV, V14, P279, DOI 10.1007/BF00690599
   Chao C, 1996, CANCER RES, V56, P4811
   Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469
   Coomber BL, 2003, CLIN EXP METASTAS, V20, P215, DOI 10.1023/A:1022935117193
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2
   Eskens FALM, 2003, EUR J CANCER, V39, P917, DOI 10.1016/S0959-8049(03)00057-1
   Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766
   Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416
   Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145
   Gutheil JC, 2000, CLIN CANCER RES, V6, P3056
   HART IR, 1978, CANCER RES, V38, P3218
   Haseneen NA, 2003, AM J PHYSIOL-LUNG C, V284, pL541, DOI 10.1152/ajplung.00290.2002
   HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6
   Herbst RS, 2000, CLIN CANCER RES, V6, P790
   INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0
   Jiang XN, 2003, J HISTOCHEM CYTOCHEM, V51, P1393, DOI 10.1177/002215540305101101
   Kouvaraki M, 2002, CANCER, V94, P2454, DOI 10.1002/cncr.10505
   Kragh M, 2003, INT J ONCOL, V22, P305
   Kubota S, 1997, INT J CANCER, V70, P106
   KUSAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P1070, DOI 10.1016/0006-291X(91)91529-L
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   LIOTTA LA, 1980, CANCER LETT, V11, P141, DOI 10.1016/0304-3835(80)90105-6
   Luo Jan, 1997, Pathol Oncol Res, V3, P264
   Malinda KM, 2003, METH MOLEC MED, V78, P329
   MATRISIAN LM, 1992, MOL REPROD DEV, V32, P111, DOI 10.1002/mrd.1080320206
   MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U
   MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223
   Mullen P, 2004, METH MOLEC MED, V88, P287
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Noujaim D, 2002, ONCOGENE, V21, P4549, DOI 10.1038/sj.onc.1205552
   Osanai M, 2002, JPN J CANCER RES, V93, P532, DOI 10.1111/j.1349-7006.2002.tb01288.x
   PASSANITI A, 1992, LAB INVEST, V67, P519
   Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.0.CO;2-W
   Sato T, 2004, GYNECOL ONCOL, V92, P47, DOI 10.1016/j.ygyno.2003.09.012
   Scapini P, 2002, J IMMUNOL, V168, P5798, DOI 10.4049/jimmunol.168.11.5798
   Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214
   Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940
   Stevenson D, 2002, ADV EXP MED BIOL, V506, P159
   Strong M, 2003, NUCLEIC ACIDS RES, V31, P7099, DOI 10.1093/nar/gkg924
   Tsunemi T, 2003, CLIN ORTHOP RELAT R, P159, DOI 10.1097/01.blo.0000038050.29678.7e
   Uchiyama A, 1999, BRIT J CANCER, V81, P721, DOI 10.1038/sj.bjc.6690754
   Valente P, 1996, ONCOGENE, V13, P1169
   van Kempen LCL, 2002, CANCER CELL, V2, P251, DOI 10.1016/S1535-6108(02)00157-5
   VINK J, 1994, PIGM CELL RES, V7, P339, DOI 10.1111/j.1600-0749.1994.tb00637.x
   VOROBTSOVA IE, 1993, MUTAT RES, V287, P207, DOI 10.1016/0027-5107(93)90013-6
   VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q
   Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508
   Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4
   Welch DR, 2004, BREAST CANCER RES, V6, P61, DOI 10.1186/bcr736
   Wibulswas A, 2002, ARTHRITIS RHEUM-US, V46, P2059, DOI 10.1002/art.10421
   Yano S, 2003, CANCER SCI, V94, P244, DOI 10.1111/j.1349-7006.2003.tb01428.x
   Yoshinari C, 1999, MELANOMA RES, V9, P223, DOI 10.1097/00008390-199906000-00003
   Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D
   Zang CB, 2000, J CANCER RES CLIN, V126, P33, DOI 10.1007/PL00008462
   Zhu AX, 2003, SEMIN RADIAT ONCOL, V13, P454, DOI 10.1016/S1053-4296(03)00048-1
NR 67
TC 74
Z9 98
U1 0
U2 10
PU U B C PRESS
PI BILBAO
PA UNIV BASQUE COUNTRY, EDITORIAL SERVICES, PO BOX 1397, E-48080 BILBAO,
   SPAIN
SN 0214-6282
J9 INT J DEV BIOL
JI Int. J. Dev. Biol.
PY 2004
VL 48
IS 5-6
SI SI
BP 563
EP 571
DI 10.1387/ijdb.041822aa
PG 9
WC Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology
GA 858GM
UT WOS:000224180300022
PM 15349831
OA Bronze
DA 2025-01-12
ER

PT J
AU Ivanovic, V
   Demajo, M
   Todorovic-Rakovic, N
   Nikolic-Vukosavljevic, D
   Neskovic-Konstantinovic, Z
   Krtolica, K
   Veljkovic, V
   Prljic, J
   Dimitrijevic, B
AF Ivanovic, V
   Demajo, M
   Todorovic-Rakovic, N
   Nikolic-Vukosavljevic, D
   Neskovic-Konstantinovic, Z
   Krtolica, K
   Veljkovic, V
   Prljic, J
   Dimitrijevic, B
TI Localization of recognition site between transforming growth
   factor-β<sub>1</sub> (TGF-β<sub>1</sub>) and TGFβ receptor type II::
   possible implications in breast cancer
SO MEDICAL HYPOTHESES
LA English
DT Article
ID GENE MUTATION; GROWTH-FACTOR-BETA-1; PREDICTION; ANTIBODIES; SEQUENCES;
   TUMORS; COLON
AB Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Boris Kidric Inst Nucl Sci, Lab Radiol & Mol Genet, YU-11001 Belgrade, Serbia.
   Inst Oncol & Radiol Serbia, Belgrade, Serbia.
C3 University of Belgrade; Institute for Oncology & Radiology of Serbia
   (IORS)
RP Boris Kidric Inst Nucl Sci, Lab Radiol & Mol Genet, POB 522, YU-11001 Belgrade, Serbia.
EM vesnai@EUnet.yu
RI Todorovic-Rakovic, Natasa/AAA-4340-2019
OI Todorovic-Rakovic, Natasa/0000-0001-8975-3129
CR Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8
   Barrack ER, 1997, PROSTATE, V31, P61
   Boesen CC, 2002, STRUCTURE, V10, P913, DOI 10.1016/S0969-2126(02)00780-3
   COSIC I, 1986, BIOCHEM BIOPH RES CO, V141, P831, DOI 10.1016/S0006-291X(86)80248-0
   COSIC I, 1987, EUR J BIOCHEM, V170, P247, DOI 10.1111/j.1432-1033.1987.tb13692.x
   COSIC I, 1989, BIOCHIMIE, V71, P333, DOI 10.1016/0300-9084(89)90005-9
   DALAL BI, 1993, AM J PATHOL, V143, P381
   Decensi A, 1998, EUR J CANCER, V34, P999, DOI 10.1016/S0959-8049(97)10170-8
   Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755
   Eder IE, 1996, J UROLOGY, V156, P953, DOI 10.1016/S0022-5347(01)65670-2
   GORSCH SM, 1992, CANCER RES, V52, P6949
   Grainger DJ, 2000, CYTOKINE GROWTH F R, V11, P133, DOI 10.1016/S1359-6101(99)00037-4
   Hoefer M, 1995, CANCER IMMUNOL IMMUN, V41, P302, DOI 10.1007/BF01517218
   IVANOVIC V, 1995, NAT MED, V1, P282, DOI 10.1038/nm0495-282
   Ivanovic V, 2001, JUGOSLAV MED BIOHEM, V20, P81
   IVANOVIC V, 2003, Patent No. 58403
   IVAOVIC V, 1998, ARCH ONCOL, V6, P159
   IVAOVIC V, 2003, EUR J CANCER, V39, P454
   KONG FM, 1995, ANN SURG, V222, P155, DOI 10.1097/00000658-199508000-00007
   Krsmanovic V, 1998, J PEPT RES, V52, P410
   Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363
   LIN HY, 1994, CELL MOL BIOL, V40, P337
   MYEROFF LL, 1995, CANCER RES, V55, P5545
   Pepin MC, 1996, BIOCHEM BIOPH RES CO, V220, P289, DOI 10.1006/bbrc.1996.0398
   Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918
   Robson H, 1996, BRIT J CANCER, V74, P753, DOI 10.1038/bjc.1996.432
   Takenoshita S, 1998, ONCOL REP, V5, P367
   Tomita S, 1999, BREAST CANCER RES TR, V53, P33, DOI 10.1023/A:1006167210269
   Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583
   VELJKOVIC V, 1987, CANCER BIOCHEM BIOPH, V9, P139
   VELJKOVIC V, 1985, IEEE T BIO-MED ENG, V32, P337, DOI 10.1109/TBME.1985.325549
   VELJKOVIC V, 1973, PHYS LETT A, VA 45, P41, DOI 10.1016/0375-9601(73)90497-0
   WALKER RA, 1992, EUR J CANCER, V28A, P641, DOI 10.1016/S0959-8049(05)80116-9
   WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044
   YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2
NR 35
TC 4
Z9 4
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2004
VL 62
IS 5
BP 727
EP 732
DI 10.1016/j.mehy.2003.11.027
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 820HA
UT WOS:000221376900016
PM 15082097
DA 2025-01-12
ER

PT J
AU Arapshian, A
   Bertran, S
   Kuppumbatti, YS
   Nakajo, S
   Mira-y-Lopez, R
AF Arapshian, Alice
   Bertran, Silvina
   Kuppumbatti, Yuvarani S.
   Nakajo, Shigeo
   Mira-y-Lopez, Rafael
TI Epigenetic <i>CRBP</i> downregulation appears to be an evolutionarily
   conserved (human and mouse) and oncogene-specific phenomenon in breast
   cancer
SO MOLECULAR CANCER
LA English
DT Article
AB Background: The cellular retinol binding protein I gene (CRBP) is downregulated in a subset of human breast cancers and in MMTV-Myc induced mouse mammary tumors. Functional studies suggest that CRBP downregulation contributes to breast tumor progression. What is the mechanism underlying CRBP downregulation in cancer? Here we investigated the hypothesis that CRBP is epigenetically silenced through DNA hypermethylation in human and mouse breast cancer.
   Results: Bisulfite sequencing of CRBP in a panel of 6 human breast cancer cell lines demonstrated that, as a rule, CRBP hypermethylation is closely and inversely related to CRBP expression and identified one exception to this rule. Treatment with 5-azacytidine, a DNA methyltransferase inhibitor, led to CRBP reexpression, supporting the hypothesis that CRBP hypermethylation is a proximal cause of CRBP silencing. In some cells CRBP reexpression was potentiated by co-treatment with retinoic acid, an inducer of CRBP, and trichostatin A, a histone deacetylase inhibitor. Southern blot analysis of a small panel of human breast cancer specimens identified one case characterized by extensive CRBP hypermethylation, in association with undetectable CRBP mRNA and protein. Bisulfite sequencing of CRBP in MMTV-Myc and MMTV-Neu/NT mammary tumor cell lines extended the rule of CRBP hypermethylation and silencing (both seen in MMTV-Myc but not MMTV-Neu/NT cells) from human to mouse breast cancer and suggested that CRBP hypermethylation is an oncogene-specific event.
   Conclusion: CRBP hypermethylation appears to be an evolutionarily conserved and principal mechanism of CRBP silencing in breast cancer. Based on the analysis of transgenic mouse mammary tumor cells, we hypothesize that CRBP silencing in human breast cancer may be associated with a specific oncogenic signature.
C1 [Arapshian, Alice; Bertran, Silvina; Kuppumbatti, Yuvarani S.; Mira-y-Lopez, Rafael] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
   [Nakajo, Shigeo] Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Tokyo, Japan.
C3 Icahn School of Medicine at Mount Sinai; Showa University
RP Mira-y-Lopez, R (通讯作者)，Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
EM aa74ny@yahoo.com; silvina.bertran@mssm.edu; ykuppumb@uci.edu;
   nakajo@pharm.showa-u.ac.jp; rafael.mira@mssm.edu
FU National Cancer Institute; NCI [CA54273]; Samuel Waxman Cancer Research
   Foundation; Norman and Rosita Winston Foundation; Chemotherapy
   Foundation
FX We thank the following investigators for reagent gifts: Joyce
   TaylorPapadimitriou (MTSV1-7 cells), Phil Leder (16MB9a and SMF cells),
   Pierre Chambon (mCRBP cDNA) and Winnie Eskild (hCRBP cDNA). Tissue
   samples were provided by the Cooperative Human Tissue Network which is
   funded by the National Cancer Institute. Other investigators may have
   received specimens from the same subjects. This work was supported by
   NCI grant CA54273 to RML, the Samuel Waxman Cancer Research Foundation,
   the Norman and Rosita Winston Foundation and the Chemotherapy
   Foundation.
CR Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   BOK D, 1993, J CELL SCI, P189
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BUSCH C, 1990, METHOD ENZYMOL, V189, P315
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen LI, 2002, J BIOL CHEM, V277, P35411, DOI 10.1074/jbc.M202717200
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522
   ESKILD W, 1988, BIOCHEM BIOPH RES CO, V152, P1504, DOI 10.1016/S0006-291X(88)80456-X
   ESKILD W, 1994, MOL ENDOCRINOL, V8, P732, DOI 10.1210/me.8.6.732
   Esteller M, 2002, CANCER RES, V62, P5902
   Farias EF, 2002, CELL GROWTH DIFFER, V13, P335
   FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903
   Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   KROEPELIEN CF, 1993, ENDOCRINOLOGY, V132, P968, DOI 10.1210/en.132.3.968
   Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475
   Kuppumbatti YS, 2001, ONCOGENE, V20, P7413, DOI 10.1038/sj.onc.1204749
   Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100
   Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295
   Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#
   Morrison AJ, 2003, MOL ENDOCRINOL
   MORRISON BW, 1994, ONCOGENE, V9, P3417
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   NILSSON MHL, 1988, EUR J BIOCHEM, V173, P35, DOI 10.1111/j.1432-1033.1988.tb13963.x
   Rexer BN, 2001, CANCER RES, V61, P7065
   RUBERTE E, 1991, DEVELOPMENT, V111, P45
   RUSH MG, 1991, ENDOCRINOLOGY, V129, P705, DOI 10.1210/endo-129-2-705
   SINGER J, 1979, SCIENCE, V203, P1019, DOI 10.1126/science.424726
   SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x
   THOMPSON JN, 1964, PROC R SOC SER B-BIO, V159, P510, DOI 10.1098/rspb.1964.0017
   Triano EA, 2003, CANCER RES, V63, P3092
   Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674
   Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753
   Xu GX, 2001, J CELL PHYSIOL, V187, P315, DOI 10.1002/jcp.1078
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110
   YLIKOSKI J, 1994, J COMP NEUROL, V349, P596, DOI 10.1002/cne.903490407
NR 42
TC 20
Z9 25
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PY 2004
VL 3
AR 13
DI 10.1186/1476-4598-3-13
PG 12
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA V24VV
UT WOS:000208438800013
PM 15113415
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Sekimata, M
   Homma, Y
AF Sekimata, M
   Homma, Y
TI Sequence-specific transcriptional repression by an MBD2-interacting zinc
   finger protein MIZF
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID CPG-BINDING-PROTEIN; HISTONE DEACETYLASE COMPLEX; BREAST-CANCER CELLS;
   S-TRANSFERASE GENE; HUMAN RB GENE; DNA METHYLATION; MYOGENIC
   DIFFERENTIATION; PARTNER KAISO; PROMOTER; SITE
AB MBD2 is a member of the methyl-CpG-binding protein family that plays an important role in methylated DNA silencing. We have recently identified a novel zinc finger protein, MIZF, as an MBD2-binding partner. To understand the physiological function of MIZF in MBD2-mediated gene silencing, we investigated the DNA-binding properties of MIZF and its potential target genes. Using a cyclic amplification and selection of targets technique, the consensus sequence CGGACGTT, which contains a conserved CGGAC core, was determined as sufficient for MIZF binding. Deletion of individual zinc fingers revealed that five of the seven zinc fingers are required for DNA binding. Reporter assays demonstrated that MIZF represses transcription from the promoter including this DNA sequence. A database search indicated that a variety of human genes, including Rb, contain this sequence in their promoter region. MIZF actually bound to its recognition sequence within the Rb promoter and repressed Rb transcription. These results suggest that MIZF, through its DNA-binding activity, acts as a sequence-specific transcriptional repressor likely involved in MBD2-mediated epigenetic gene silencing.
C1 Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Biomol Sci, Fukushima 9601295, Japan.
C3 Fukushima Medical University
RP Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Biomol Sci, Fukushima 9601295, Japan.
EM matam@fmu.ac.jp
CR Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7
   ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398
   DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291
   DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Feng Q, 2001, GENE DEV, V15, P827
   Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7
   Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127
   Jones BE, 1998, EXTREMOPHILES, V2, P191, DOI 10.1007/s007920050060
   KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350
   Lin XH, 2003, CANCER RES, V63, P498
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   MARTELLI F, 1994, ONCOGENE, V9, P3579
   MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397
   Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063
   Okuyama Y, 1996, FEBS LETT, V397, P219, DOI 10.1016/S0014-5793(96)01178-7
   PARK K, 1994, J BIOL CHEM, V269, P6083
   Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501
   RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413
   SAKAKI T, 1991, PHARMACOGENETICS, V1, P86, DOI 10.1097/00008571-199111000-00005
   SAVOYSKY E, 1994, ONCOGENE, V9, P1839
   Sekimata M, 2001, J BIOL CHEM, V276, P42632, DOI 10.1074/jbc.M107048200
   SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299
   Simpson DJ, 2000, CANCER RES, V60, P1211
   Sowa Y, 1997, CANCER RES, V57, P3145
   Stirzaker C, 1997, CANCER RES, V57, P2229
   SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
NR 41
TC 33
Z9 39
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN
PY 2004
VL 32
IS 2
BP 590
EP 597
DI 10.1093/nar/gkh249
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 774NH
UT WOS:000188989000030
PM 14752047
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Fackler, MJ
   McVeigh, M
   Evron, E
   Garrett, E
   Mehrotra, J
   Polyak, K
   Sukumar, S
   Argani, P
AF Fackler, MJ
   McVeigh, M
   Evron, E
   Garrett, E
   Mehrotra, J
   Polyak, K
   Sukumar, S
   Argani, P
TI DNA methylation of <i>RASSF1A</i>, <i>Hin-1</i>, <i>RAR</i>-β, <i>cyclin
   D2</i> and <i>twist</i> in <i>in situ</i> and invasive lobular breast
   carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE methylation; breast cancer; lobular; ductal; DCIS; LCIS
ID TUMOR-SUPPRESSOR GENE; ACID RECEPTOR-BETA; FREQUENT EPIGENETIC
   INACTIVATION; CANCER CELLS; PROMOTER HYPERMETHYLATION; E-CADHERIN;
   ESTROGEN-RECEPTOR; CPG ISLAND; RETINOID RECEPTORS; SERIAL ANALYSIS
AB Little is known about epigenetic silencing of genes by promoter hypermethylation in lobular breast cancers. The promoter methylation status of 5 cancer-related genes (RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist) was evaluated in 2 types of lobular cancers, in situ (LCIS) and invasive lobular carcinomas (ILC) (n = 32), and compared to ductal in situ (DCIS) and invasive (IDC) breast cancers (n = 71). By using methylation-specific PCR (MSP), 100% of ILC and 69% of LCIS cases were found to have 1 or more hypermethylated genes among the panel of 5 genes (compared to 100% 1 DC and 95% of DCIS). Two or more hypermethylated genes were detected per tumor in 79% of invasive and 61% of in situ lobular carcinomas compared to 81% of IDC and 77% of DCIS. By contrast, DNA from nearly all normal reduction mammoplasty tissues (n = 8) was unmethylated for the 5 genes. The methylation profiles of lobular vs. ductal carcinomas with respect to RASSF1A, Cyclin D2, RARbeta, and Hin-1 genes were similar, suggesting that gene silencing by promoter hypermethylation is likely to be important in both groups of diseases. Distinctly different, Twist was hypermethylated less often in ILC (16%, 3/19 cases) than in IDC (56%, 15/27 cases) (p = 0.01). These results suggest that these 2 types of tumors share many common methylation patterns and some molecular differences. Additional studies might lend further understanding into the etiology and clinical behavior of this tumor type. (C) 2003 Wiley-Liss, Inc.
C1 Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD USA.
   Sidney Kimmel Comprehens Canc Ctr, Div Biostat, Baltimore, MD USA.
   Sidney Kimmel Comprehens Canc Ctr, Dept Pathol, Baltimore, MD USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine; Harvard University; Dana-Farber Cancer Institute
RP Argani, P (通讯作者)，Johns Hopkins Hosp, Dept Pathol, Weinberg Bldg,Room 2242,401 N Broadway, Baltimore, MD 21231 USA.
RI Polyak, Kornelia/ACJ-5837-2022
OI Evron, Ella/0000-0002-1003-5042
FU NCI NIH HHS [P50 CA 88843, P50 CA 89393] Funding Source: Medline
CR Acs G, 2001, AM J CLIN PATHOL, V115, P85
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Dammann R, 2001, CANCER RES, V61, P3105
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Günther K, 2001, J PATHOL, V193, P40, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH745>3.0.CO;2-N
   Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jacobs TW, 2001, AM J SURG PATHOL, V25, P229, DOI 10.1097/00000478-200102000-00011
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Lee MG, 2001, CANCER RES, V61, P6688
   Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0
   Lehmann U, 2002, CANCER RES, V62, P6634
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li CI, 2000, CANCER, V88, P2561, DOI 10.1002/1097-0142(20000601)88:11<2561::AID-CNCR19>3.0.CO;2-X
   Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421
   Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207
   Mercapide J, 2002, MOL CARCINOGEN, V35, P6, DOI 10.1002/mc.10069
   Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461
   Mielnicki LM, 2001, J MAMMARY GLAND BIOL, V6, P169, DOI 10.1023/A:1011356623442
   Nacht M, 1999, CANCER RES, V59, P5464
   Nass SJ, 2000, CANCER RES, V60, P4346
   Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192
   Page D.L., 1987, Diagnostic Histopathology of the Breast
   Porter DA, 2001, CANCER RES, V61, P5697
   Raffo P, 2000, ANTICANCER RES, V20, P1535
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Rosen P.P., 2001, ROSENS BREAST PATHOL
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Verkooijhen HM, 2003, INT J CANCER, V104, P778, DOI 10.1002/ijc.11032
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang XW, 2000, CANCER RES, V60, P6890
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
   Zhang XK, 1996, MUTAT RES-FUND MOL M, V350, P267, DOI 10.1016/0027-5107(95)00102-6
NR 50
TC 210
Z9 238
U1 0
U2 6
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 20
PY 2003
VL 107
IS 6
BP 970
EP 975
DI 10.1002/ijc.11508
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 744GJ
UT WOS:000186619300014
PM 14601057
OA Bronze
DA 2025-01-12
ER

PT J
AU Schor, SL
   Ellis, IR
   Jones, SJ
   Baillie, R
   Seneviratne, K
   Clausen, J
   Motegi, K
   Vojtesek, B
   Kankova, K
   Furrie, E
   Sales, MJ
   Schor, AM
   Kay, RA
AF Schor, SL
   Ellis, IR
   Jones, SJ
   Baillie, R
   Seneviratne, K
   Clausen, J
   Motegi, K
   Vojtesek, B
   Kankova, K
   Furrie, E
   Sales, MJ
   Schor, AM
   Kay, RA
TI Migration-stimulating factor: A genetically truncated onco-fetal
   fibronectin isoform expressed by carcinoma and tumor-associated stromal
   cells
SO CANCER RESEARCH
LA English
DT Article
ID PRE-MESSENGER-RNA; CANCER-PATIENTS DISPLAY; FIBROBLAST MIGRATION;
   BREAST; PHENOTYPE; BEHAVIOR; DOMAIN; MICROENVIRONMENT; HETEROGENEITY;
   ELEMENTS
AB Migration-stimulating factor (MSF) is a 70-kDa motogenic protein previously reported to be expressed by fetal and cancer patient fibroblasts cultured in vitro and present in the serum of breast cancer patients. A 2.2-kb full-length MSF cDNA has been cloned and shown to be a truncated isoform of fibronectin generated from its primary gene transcript by a hitherto unrecognized intron read-through mechanism. MSF cDNA is identical to the 5' end of fibronectin cDNA, up to and including exon III-1a, and terminates in a novel 195-nucleotide 3' sequence. This MSF unique sequence is derived from the intron immediately downstream of exon III-1a in the fibronectin gene and is not found in any previously identified "full-length" fibronectin cDNA. MSF mRNA is 1000-fold less abundant than full-length fibronectin message in fetal fibroblasts and exhibits rapid biphasic decay kinetics previously associated with oncogenes and stress response molecules. MSF recombinant protein exhibits a potent and substratum-dependent motogenic activity, with half-maximal response manifest at 0.1-1.0 pg/ml. This activity is (a) mediated by the IGD amino acid motif; and (b) not expressed by (i.e., cryptic within) full-length fibronectin. In situ hybridization and immunohistochemistry confirm that MSF is expressed by tumor-associated fibroblasts and additionally indicate that it is also expressed by carcinoma cells and tumor-associated vascular endothelial cells. MSF, as a consequence of its potent bioactivities and expression by both stromal and carcinoma cell populations, is well placed to function as an epigenetic effector promoting cancer development.
C1 Univ Dundee, Sch Dent, Unit Cell & Mol Biol, Dundee DD1 4HR, Scotland.
   Masaryk Mem Canc Inst, Brno, Czech Republic.
   Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.
   Univ Dundee, Ninewells Hosp & Med Sch, Dept Cytogenet, Dundee DD1 9SY, Scotland.
C3 University of Dundee; Masaryk Memorial Cancer Institute; University of
   Dundee; University of Dundee
RP Univ Dundee, Sch Dent, Unit Cell & Mol Biol, Dundee DD1 4HR, Scotland.
EM S.L.Schor@dundee.ac.uk
RI Ellis, Ian/AAM-9833-2021
OI Kankova, Katerina/0000-0002-5574-1768; Ellis, Ian/0000-0001-8035-6012;
   Kankova, Katerina/0000-0001-9548-0630; Jones, Sarah/0000-0003-0081-5333
FU NIDDK NIH HHS [1 R01 DK9144-01] Funding Source: Medline
CR Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246
   CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507
   Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5
   CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416
   CLARK RAF, 1988, J BIOL CHEM, V263, P12115
   COCKBURN CG, 1989, THROMB HAEMOSTASIS, V61, P378
   Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x
   Currier JR, 1996, J IMMUNOL, V157, P170
   DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876
   DEBLOCK M, 1993, ANAL BIOCHEM, V215, P86, DOI 10.1006/abio.1993.1558
   DURNING P, 1984, LANCET, V2, P890
   Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133
   ELLIS I, 1992, J CELL SCI, V102, P447
   FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374
   FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018
   FUKAI F, 1993, BIOCHEMISTRY-US, V32, P5746, DOI 10.1021/bi00073a004
   FUKAI F, 1991, J BIOL CHEM, V266, P8807
   GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559
   GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438
   HAGGIE JA, 1987, LANCET, V1, P1455
   HashimotoUoshima M, 1997, J CELL SCI, V110, P2271
   Herasse M, 1999, MOL CELL BIOL, V19, P4047
   Hohenester E, 2002, MATRIX BIOL, V21, P115, DOI 10.1016/S0945-053X(01)00191-3
   Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x
   HUH GS, 1993, MOL CELL BIOL, V13, P5301, DOI 10.1128/MCB.13.9.5301
   Hynes R. O., 1990, FIBRONECTINS
   Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1
   Jedlitschky G, 1999, BIOCHEM J, V340, P837, DOI 10.1042/0264-6021:3400837
   KACZMAREK J, 1994, INT J CANCER, V59, P11, DOI 10.1002/ijc.2910590104
   KNUDSON W, 1989, CIBA F SYMP, V143, P150
   Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558
   Labat-Robert J, 2002, SEMIN CANCER BIOL, V12, P187, DOI 10.1016/S1044-579X(02)00022-6
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499
   Li G, 2003, ONCOGENE, V22, P3162, DOI 10.1038/sj.onc.1206455
   Midulla M, 2000, CANCER RES, V60, P164
   MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0
   MUIR D, 1992, J CELL BIOL, V116, P177, DOI 10.1083/jcb.116.1.177
   NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2
   NORTON PA, 1994, J CELL SCI, V107, P1
   Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1
   PICARDO M, 1991, LANCET, V337, P130, DOI 10.1016/0140-6736(91)90798-T
   SCHOR AM, 1994, INT J CANCER, V59, P25, DOI 10.1002/ijc.2910590107
   Schor AM, 1998, HISTOCHEM J, V30, P849, DOI 10.1023/A:1003437619956
   Schor Seth L., 1994, Progress in Growth Factor Research, V5, P223, DOI 10.1016/0955-2235(94)90007-8
   SCHOR SL, 1985, J CELL SCI, V73, P235
   SCHOR SL, 1985, J CELL SCI, V73, P221
   SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503
   Schor SL, 1999, J CELL SCI, V112, P3879
   SCHOR SL, 1988, J CELL SCI, V90, P391
   SCHOR SL, 1989, IN VITRO CELL DEV B, V25, P737
   SCHOR SL, 1980, J CELL SCI, V41, P159
   SCHOR SL, 1993, SYM SOC EXP BIOL, V47, P235
   Schor SL, 2001, BREAST CANCER RES, V3, P373, DOI 10.1186/bcr325
   Schor SL, 1996, J CELL SCI, V109, P2581
   SCHOR SL, 1987, EXP CELL BIOL, V55, P11
   SCHOR SL, 1988, J CELL SCI, V90, P401
   SCHOR SL, 1986, INT J CANCER, V37, P831, DOI 10.1002/ijc.2910370606
   Schor SL, 1997, PATHOL UPDATE, V4, P75
   Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580
   Staffa A, 1997, J BIOL CHEM, V272, P33394, DOI 10.1074/jbc.272.52.33394
   Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361
   Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0
   WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877
   Zhao QS, 2001, EXP CELL RES, V268, P211, DOI 10.1006/excr.2001.5291
NR 65
TC 85
Z9 107
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2003
VL 63
IS 24
BP 8827
EP 8836
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 757UR
UT WOS:000187580300037
PM 14695199
DA 2025-01-12
ER

PT J
AU Sathyanarayana, UG
   Padar, A
   Huang, CX
   Suzuki, M
   Shigematsu, H
   Bekele, BN
   Gazdar, AF
AF Sathyanarayana, UG
   Padar, A
   Huang, CX
   Suzuki, M
   Shigematsu, H
   Bekele, BN
   Gazdar, AF
TI Aberrant promoter methylation and silencing of laminin-5-encoding genes
   in breast carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HEMIDESMOSOMES; INACTIVATION; EXPRESSION; TUMOR; HYPERMETHYLATION;
   ALPHA-6-BETA-4; INTEGRIN; PROTEINS
AB Purpose: Down-regulation of Laminin-5 (LN5)-encoding genes (LAMA3, LAMB3, and LAMC2) has been reported in various human cancers. However, the mechanism of inactivation was not clearly understood until recently. In this study, we investigated the loss of expression of three LN5-encoding genes in breast cancer cell lines and elucidated the mechanism of silencing of the genes in breast cancer cell lines and tumors.
   Experimental Design: We examined the expression of the three LN5-encoding genes by reverse transcription-PCR in breast cancer cell lines (n = 20). To elucidate the mechanism of silencing, we treated expression negative cell lines (n = 5) with a demethylating agent and examined restoration of expression by reverse transcription-PCR. By using methylation-specific primers designed by us, we validated the methylation status of the promoter regions in breast cancer cell lines using methylation-specific PCR. We additionally studied the methylation patterns in primary breast tumors (n = 74) and correlated the data with clinical parameters.
   Results: We observed varied losses of expression (10-55%) of LN5-encoding genes in breast cancer cell lines. Expression of one or more genes was lost in 65% of breast cancer cell lines. Treatment of expression negative cell lines with demethylating agent restored expression in all cases. Methylation frequencies of LAMA3, LAMB3, and LAMC2 genes in 20 breast cancer cell lines were 40, 5, and 15%, respectively. The concordances between loss of expression and methylation in 20 breast cancer cell lines for the three genes (85-95%) were statistically significant. Nonmalignant breast tissues (n = 30) had very low frequencies of methylation (0-7%). In 74 breast tumors, methylation frequencies LAMA3, LAMB3, and LAMC2 were 44, 4, and 20%, respectively. The differences in methylation frequencies between cell lines and tumors were not statistically significant for all of the three genes. The methylation frequencies of LAMA3 and mean chain methylation index in cell lines and tumors were significantly different from methylation frequencies in nonmalignant tissues, and they were significantly higher in high stage and large size tumors as compared with low-stage and small size tumors. LAMA3 promoter methylation frequency in breast tumors was associated with increased tumor stage (P < 0.001) and tumor size (P < 0.001).
   Conclusions: Our results demonstrate epigenetic inactivation of LN5-encoding genes in breast cancers and association of LAMA3 promoter methylation with increased tumor stage and tumor size. Our findings are of biological interest and potentially of clinical importance.
C1 Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; UTMD Anderson Cancer Center
RP Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM adi.gazdar@utsouthwestem.edu
RI Gazdar, Adi/F-7496-2010
FU NCI NIH HHS [5U01CA8497102] Funding Source: Medline
CR ADAMS JC, 1993, DEVELOPMENT, V117, P1183
   Baker SE, 1996, J CELL SCI, V109, P2509
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BERGSTRAESSER LM, 1995, AM J PATHOL, V147, P1823
   Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Davis TL, 2001, PROSTATE, V46, P240
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Falk-Marzillier J, 1998, BIOCHEM BIOPH RES CO, V251, P49, DOI 10.1006/bbrc.1998.9400
   Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515
   Fleming ID, 1997, AJCC CANC STAGING MA, P171
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Giannelli G, 2001, CLIN EXP METASTAS, V18, P439
   Henning K, 1999, HISTOPATHOLOGY, V34, P305
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   LOCHTER A, 1995, SEMIN CANCER BIOL, V6, P165, DOI 10.1006/scbi.1995.0017
   Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760
   Michelson PH, 2000, J HISTOCHEM CYTOCHEM, V48, P535, DOI 10.1177/002215540004800411
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P2665
   SHAPIRO GI, 1995, CANCER RES, V55, P6200
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Stahl S, 1997, J CELL SCI, V110, P55
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704
NR 25
TC 59
Z9 68
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2003
VL 9
IS 17
BP 6389
EP 6394
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 758QH
UT WOS:000187661300012
PM 14695139
DA 2025-01-12
ER

PT J
AU Bertholon, J
   Wang, Q
   Falette, N
   Verny, C
   Auclair, J
   Chassot, C
   Navarro, C
   Saurin, JC
   Puisieux, A
AF Bertholon, J
   Wang, Q
   Falette, N
   Verny, C
   Auclair, J
   Chassot, C
   Navarro, C
   Saurin, JC
   Puisieux, A
TI <i>Chfr</i> inactivation is not associated to chromosomal instability in
   colon cancers
SO ONCOGENE
LA English
DT Article
DE Chfr; hypermethylation; chromosome instability; breast cancer; colon
   cancer
ID COMPARATIVE GENOMIC HYBRIDIZATION; MITOTIC STRESS CHECKPOINT;
   CELL-LINES; BREAST-CANCER; COLORECTAL-CANCER; CPG ISLAND; CENTROSOME
   AMPLIFICATION; MULTIPLE MUTATIONS; LUNG-CANCER; GENES
AB Numerous observations suggest that chromosome instability is caused by mitotic abnormalities such as errors in the partitioning of chromosomes. Chfr was recently defined as a central component of a new mitotic checkpoint that delays chromosome condensation in response to mitotic stress. Chfr was shown to be frequently inactivated in several human neoplasms, including colon, lung and esophageal cancers. To test whether Chfr inactivation may lead or participate to chromosomal instability (CIN), we analysed the genetic and epigenetic status of the gene in a large panel of primary colon and breast cancers, as well as in colon and breast cancer cell lines displaying either a microsatellite instability or a CIN. Our results confirm that Chfr is frequently inactivated in colon cancers, through a mechanism of hypermethylation of the promoter sequences. In contrast, the loss of Chfr expression appears to be a rare event in breast cancers. Furthermore, our data demonstrate that Chfr inactivation is not associated with CIN in these frequent types of human cancers.
C1 Ctr Leon Berard, INSERM, U590, Unite Oncol Mol, F-69373 Lyon 08, France.
   Fac Pharm Lyon, F-69373 Lyon, France.
   Hop Edouard Herriot, Federat Special Digest, F-69437 Lyon 03, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UNICANCER; Centre Leon Berard; Universite Claude Bernard Lyon 1; CHU
   Lyon
RP Puisieux, A (通讯作者)，Ctr Leon Berard, INSERM, U590, Unite Oncol Mol, 28 Rue Laennec, F-69373 Lyon 08, France.
RI saurin, jean/AAB-4077-2020
OI PUISIEUX, Alain/0000-0002-9938-3798
CR Ahuja N, 1997, CANCER RES, V57, P3370
   Bunz F, 2002, CANCER RES, V62, P1129
   Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8
   Duval A, 2002, ANN GENET-PARIS, V45, P71, DOI 10.1016/S0003-3995(02)01115-2
   Forozan F, 2000, CANCER RES, V60, P4519
   Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611
   Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P
   GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219
   Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x
   Jackson AL, 1998, SEMIN CANCER BIOL, V8, P421, DOI 10.1006/scbi.1998.0113
   KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156
   Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016
   Kytölä S, 2000, GENE CHROMOSOME CANC, V28, P308, DOI 10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999
   Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4
   Luker KE, 2001, CANCER RES, V61, P6540
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X
   Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3
   Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014
   Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065
   Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5
   Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224
   Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296
   Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496
NR 32
TC 30
Z9 36
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD DEC 4
PY 2003
VL 22
IS 55
BP 8956
EP 8960
DI 10.1038/sj.onc.1207078
PG 5
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 750GD
UT WOS:000186982200018
PM 14654793
DA 2025-01-12
ER

PT J
AU Kim, H
   Xu, GL
   Borczuk, AC
   Busch, S
   Filmus, J
   Capurro, M
   Brody, JS
   Lange, J
   D'Armiento, JM
   Rothman, PB
   Powell, CA
AF Kim, H
   Xu, GL
   Borczuk, AC
   Busch, S
   Filmus, J
   Capurro, M
   Brody, JS
   Lange, J
   D'Armiento, JM
   Rothman, PB
   Powell, CA
TI The heparan sulfate proteoglycan <i>GPC3</i> is a potential lung tumor
   suppressor
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
ID GOLABI-BEHMEL-SYNDROME; ABERRANT PROMOTER METHYLATION; GENE-EXPRESSION;
   BREAST-CANCER; BRONCHIAL EPITHELIUM; OVERGROWTH; CELLS; ADENOCARCINOMA;
   ABNORMALITIES; INHIBITION
AB Recently, we used gene expression profiling of lung adenocarcinoma and paired normal tissue from smokers and nonsmokers to identify genes and molecular pathways associated with cigarette smoking and lung carcinogenesis. The gene encoding Glypican 3, a glycosylphosphatidylinositol-linked heparan sulfate proteoglycan, was decreased in lung adenocarcinoma. Within nonmalignant lung, GPC3 expression was decreased in smokers compared with nonsmokers; indicating that expression is associated with cigarette smoking. Microarray results were confirmed using an independent cohort of tumors and nonmalignant lung tissues. Immunohistochemical studies localized Glypican 3 protein expression to the apical surface of lung bronchiolar epithelial cells, potential cells of origin for adenocarcinoma. Northern blot analysis demonstrated expression was absent in all tested non-small cell lung carcinoma lines. Pharmacologic treatment of lung cell lines indicated that GPC3 expression was epigenetically silenced by promoter hypermethylation. Human lung carcinoma tumor cells ectopically expressing GPC3 demonstrated increased apoptosis response when exposed to etoposide and growth inhibition when implanted in nude mice. These findings suggest that GPC3 is a candidate lung tumor suppressor gene whose expression may be regulated by exposure to cigarette smoke and functions to modulate cellular response to exogenous damage.
C1 Columbia Coll Phys & surgeons, Dept Med, New York, NY USA.
   Columbia Coll Phys & surgeons, Dept Pathol, New York, NY USA.
   Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai, Peoples R China.
   Aventis Pharmaceut, Bridgewater, NJ USA.
   Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada.
   Boston Univ, Dept Med, Sch Med, Boston, MA 02215 USA.
C3 Columbia University; Columbia University; Chinese Academy of Sciences;
   Center for Excellence in Molecular Cell Science, CAS; Sanofi-Aventis;
   Sanofi USA; University of Toronto; Sunnybrook Research Institute;
   Sunnybrook Health Science Center; Boston University
RP Powell, CA (通讯作者)，Columbia Univ, Div Pulm Allergy & Crit Care Med, 630 W 168th St,Box 91, New York, NY 10032 USA.
RI BORCZUK, alain/AHA-5172-2022; POWELL, CHARLES/C-8663-2011
OI Brody, Jerome/0000-0002-2824-802X; POWELL, CHARLES/0000-0003-3509-891X
FU NCI NIH HHS [CA77862] Funding Source: Medline; NIEHS NIH HHS [ES00354]
   Funding Source: Medline
CR [Anonymous], IARC MON EV CARC R S
   Baeg GH, 2001, DEVELOPMENT, V128, P87
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
   Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Cano-Gauci DF, 1999, J CELL BIOL, V146, P255
   Chiao E, 2002, DEV BIOL, V243, P185, DOI 10.1006/dbio.2001.0554
   Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795
   DeBaun MR, 2001, MOL GENET METAB, V72, P279, DOI 10.1006/mgme.2001.3150
   DERMER GB, 1982, CANCER-AM CANCER SOC, V49, P881, DOI 10.1002/1097-0142(19820301)49:5<881::AID-CNCR2820490511>3.0.CO;2-7
   Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585
   Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407
   Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712
   Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798
   Girard L, 2000, CANCER RES, V60, P4894
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Khan S, 2001, HISTOL HISTOPATHOL, V16, P71, DOI 10.14670/HH-16.71
   LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992
   Li M, 2001, AM J MED GENET, V102, P161, DOI 10.1002/1096-8628(20010801)102:2<161::AID-AJMG1453>3.0.CO;2-O
   Lin HC, 1999, CANCER RES, V59, P807
   Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669
   MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8
   MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545
   Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322
   Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831
   Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863
   Pellegrini M, 1998, DEV DYNAM, V213, P431, DOI 10.1002/(SICI)1097-0177(199812)213:4<431::AID-AJA8>3.3.CO;2-Z
   Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241
   Powell CA, 2003, AM J RESP CELL MOL, V29, P157, DOI 10.1165/rcmb.2002-0183RC
   Powell CA, 1999, CLIN CANCER RES, V5, P2025
   Reinhold WC, 2003, CANCER RES, V63, P1000
   Rom WN, 2000, AM J RESP CRIT CARE, V161, P1355, DOI 10.1164/ajrccm.161.4.9908012
   Sambrook J., 1989, MOL CLONING LAB MANU, Vsecond
   Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574
   Vock EH, 1999, MUTAT RES-GEN TOX EN, V441, P85, DOI 10.1016/S1383-5718(99)00038-8
   Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675
   Xiang YY, 2001, ONCOGENE, V20, P7408, DOI 10.1038/sj.onc.1204925
   Yan PS, 2001, CANCER RES, V61, P8375
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 41
TC 79
Z9 95
U1 0
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD DEC
PY 2003
VL 29
IS 6
BP 694
EP 701
DI 10.1165/rcmb.2003-0061OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 752PB
UT WOS:000187175400006
PM 12816733
DA 2025-01-12
ER

PT J
AU Ballestar, E
   Paz, MF
   Valle, L
   Wei, S
   Fraga, MF
   Espada, J
   Cigudosa, JC
   Huang, THM
   Esteller, M
AF Ballestar, E
   Paz, MF
   Valle, L
   Wei, S
   Fraga, MF
   Espada, J
   Cigudosa, JC
   Huang, THM
   Esteller, M
TI Methyl-CpG binding proteins identify novel sites of epigenetic
   inactivation in human cancer
SO EMBO JOURNAL
LA English
DT Article
DE ChIP on chip; DNA methylation; epigenetic inactivation; MBD; MeCP2
ID TUMOR-SUPPRESSOR GENES; DNA METHYLATION; HEPATOCELLULAR-CARCINOMA;
   REPRESSES TRANSCRIPTION; CELL-GROWTH; ISLAND; COMPLEX; HYPERMETHYLATION;
   MECHANISM; PROFILE
AB Methyl-CpG binding proteins (MBDs) mediate histone deacetylase-dependent transcriptional silencing at methylated CpG islands. Using chromatin immunoprecitation (ChIP) we have found that gene-specific profiles of MBDs exist for hypermethylated promoters of breast cancer cells, whilst a common pattern of histone modifications is shared. This unique distribution of MBDs is also characterized in chromosomes by comparative genomic hybridization of immunoprecipitated DNA and immunolocalization. Most importantly, we demonstrate that MBD association to methylated DNA serves to identify novel targets of epigenetic inactivation in human cancer. We combined the ChIP assay of MBDs with a CpG island microarray (ChIP on chip). The scenario revealed shows that, while many genes are regulated by multiple MBDs, others are associated with a single MBD. These target genes displayed methylation- associated transcriptional silencing in breast cancer cells and primary tumours. The candidates include the homeobox gene PAX6, the prolactin hormone receptor, and dipeptidylpeptidase IV among others. Our results support an essential role for MBDs in gene silencing and, when combined with genomic strategies, their potential to 'catch' new hypermethylated genes in cancer.
C1 Spanish Natl Canc Ctr, Mol Pathol Programme, Epigenet Lab, Madrid 28029, Spain.
   Spanish Natl Canc Ctr, Biotechnol Programme, Cytogenet Unit, Madrid, Spain.
   Univ Missouri, Sch Med, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Columbia, MO 65203 USA.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional
   de Investigaciones Oncologicas (CNIO); University of Missouri System;
   University of Missouri Columbia
RP Spanish Natl Canc Ctr, Mol Pathol Programme, Epigenet Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.
EM mesteller@cnio.es
RI Espada, Jesús/AAA-3198-2019; Cigudosa, Juan/E-4105-2016; Valle,
   Laura/H-8118-2012; Fraga, Mario/H-7824-2017; Esteller,
   Manel/L-5956-2014; Ballestar, Esteban/ABG-8561-2020
OI Valle, Laura/0000-0003-0371-0844; Espada, Jesus/0000-0002-4202-4938;
   Fraga, Mario/0000-0001-8450-2603; Esteller, Manel/0000-0003-4490-6093;
   Ballestar, Esteban/0000-0002-1400-2440
CR Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200
   Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x
   Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5
   Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Cigudosa JC, 1998, BLOOD, V91, P3007, DOI 10.1182/blood.V91.8.3007.3007_3007_3010
   Clark SJ, 2002, METHODS, V27, P99, DOI 10.1016/S1046-2023(02)00059-2
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Feng Q, 2001, GENE DEV, V15, P827
   Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655
   Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01
   Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249
   Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000
   Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kelly PA, 2002, MOL CELL ENDOCRINOL, V197, P127, DOI 10.1016/S0303-7207(02)00286-1
   Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lefkovits I., 1997, IMMUNOLOGY METHODS M
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598
   Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905
   Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226
   Paz MF, 2003, CANCER RES, V63, P1114
   Perk J, 2002, EMBO J, V21, P5807, DOI 10.1093/emboj/cdf570
   Pethiyagoda CL, 2001, CLIN EXP METASTAS, V18, P391, DOI 10.1023/A:1010930918055
   Prokhortchouk E, 2002, ONCOGENE, V21, P5394, DOI 10.1038/sj.onc.1205631
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102
   Xie D, 2002, INT J ONCOL, V21, P499
   Yan PS, 2002, METHODS, V27, P162, DOI 10.1016/S1046-2023(02)00070-1
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
NR 44
TC 260
Z9 321
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD DEC 1
PY 2003
VL 22
IS 23
BP 6335
EP 6345
DI 10.1093/emboj/cdg604
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 753FP
UT WOS:000187221700016
PM 14633992
OA Green Published
DA 2025-01-12
ER

PT J
AU Hui, ABY
   Lo, KW
   Kwong, J
   Lam, ECW
   Chan, SYY
   Chow, LSN
   Chan, ASC
   Teo, PML
   Huall, DP
AF Hui, ABY
   Lo, KW
   Kwong, J
   Lam, ECW
   Chan, SYY
   Chow, LSN
   Chan, ASC
   Teo, PML
   Huall, DP
TI Epigenetic inactivation of <i>TSLC1</i> gene in nasopharyngeal carcinoma
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE 11q23; promoter hypermethylation; tumor suppressor genes; tumor
   suppressor in lung cancer (TSLC1)
ID COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE;
   CANCER-CELL-LINES; PROMOTER HYPERMETHYLATION; PPP2R1B GENE;
   HETEROZYGOSITY; METHYLATION; ABSENCE; REGION; BREAST
AB Deletion of 11q23 is a common genetic aberration in nasopharyngeal carcinoma (NPC). Multiple candidate tumor suppressor genes (TSG) were mapped to this region but few of them were investigated in NPC. TSLC1 (tumor suppressor in lung cancer) is recently reported to be a putative TSG on 11q23. This gene was found to be inactivated by promoter hypermethylation in non-small cell lung carcinoma (NSCLC), liver cancer, and breast cancer. To study the role of TSLC1 gene in NPC tumorigenesis, we screened for mutations and aberrant methylation of TSLC1 gene in 5 NPC cell lines, 3 NPC xenografts, and 38 primary NPC cases. No somatic mutations of TSLC1 were detected in the NPC samples, but a 9-bp (CCACCACCA) deletion in exon 8 was found in a primary NPC and its corresponding blood sample. Bisulfite sequencing revealed aberrant methylation of TSLC1 promoter in four NPC cell lines. Loss of TSLC1 gene expression was found in two cell lines (HK-1 and CNE-2) with dense methylation. Expression of this gene was restored in these cell lines after treatment with demethylating agent 5-aza-2'-deoxycytidine. Our results showed that silencing of TSLC1 gene expression in NPC was associated with promoter hypermethylation. Promoter hypermethylation of TSLC1 gene was further illustrated in 34.2% (13/38) of primary NPCs. No aberrant promoter methylation was found in any of the four investigated normal nasopharyngeal epithelia. Frequent epigenetic inactivation of TSLC1 gene in NPC suggested that this gene is one of the target tumor suppressor genes of this endemic cancer. (C) 2003 Wiley-Liss, Inc.
C1 Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Inst Mol Oncol, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; Chinese University of Hong Kong
RP Hui, ABY (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.
RI Chan, Ash/JPY-2777-2023; Chan, Sui/B-8875-2015; Kwong,
   Joseph/H-2368-2013
OI Lo, Kwok Wai/0000-0002-3488-6124; Kwong, Joseph/0000-0002-3380-6882
CR Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079
   Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070
   Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8
   Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348
   Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x
   Gabra H, 1996, CANCER RES, V56, P950
   Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001
   Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x
   HUANG DP, 1989, INT J CANCER, V43, P936, DOI 10.1002/ijc.2910430535
   Hui ABY, 1998, CANCER GENET CYTOGEN, V101, P83, DOI 10.1016/S0165-4608(97)00231-8
   Hui ABY, 2002, INT J CANCER, V97, P875, DOI 10.1002/ijc.10066
   Hui ABY, 1996, CANCER RES, V56, P3225
   Hui ABY, 1999, INT J CANCER, V82, P498, DOI 10.1002/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.0.CO;2-S
   Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874
   Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847
   Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934
   Kwong J, 2002, CLIN CANCER RES, V8, P131
   Lo KW, 2000, CANCER RES, V60, P3348
   Lo KW, 2001, CANCER RES, V61, P3877
   LO KW, 1996, CANCER RES, V56, P721
   Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200
   Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153
   Pulido HA, 2000, CANCER RES, V60, P6677
   Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1
NR 24
TC 56
Z9 74
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD DEC
PY 2003
VL 38
IS 4
BP 170
EP 178
DI 10.1002/mc.10156
PG 9
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 751QG
UT WOS:000187078000003
PM 14639656
DA 2025-01-12
ER

PT J
AU Müller, HM
   Widschwendter, A
   Fiegl, H
   Ivarsson, L
   Goebel, G
   Perkmann, E
   Marth, C
   Widschwendter, M
AF Müller, HM
   Widschwendter, A
   Fiegl, H
   Ivarsson, L
   Goebel, G
   Perkmann, E
   Marth, C
   Widschwendter, M
TI DNA methylation in serum of breast cancer patients:: An independent
   prognostic marker
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR DNA; ESOPHAGEAL ADENOCARCINOMA; RANDOMIZED-TRIALS; PLASMA DNA;
   GENE; ASSOCIATION; SURVIVAL; APC; HYPERMETHYLATION; CARCINOGENESIS
AB Changes in the status of DNA methylation are one of the most common molecular alterations in human neoplasia. Because it is possible to detect these epigenetic alterations in the bloodstream of patients, we investigated whether aberrant DNA methylation in patient pretherapeutic sera is of prognostic significance in breast cancer.
   Using MethyLight, a high-throughput DNA methylation assay, we analyzed 39 genes in a gene evaluation. se consisting of 10 sera from metastasized patients, 26 patients with primary breast cancer, and 10 control patients. To determine the prognostic value of genes identified within the gene evaluation set, we finally analyzed pretreatment sera of 24 patients having had no adjuvant treatment (training set) to determine their prognostic value. An independent test set consisting of 62 patients was then used to test the validity of genes and combinations of genes, which in the training set were found to be good prognostic markers.
   In the gene evaluation set we identified five genes (ESR1, APC, HSD17B4, HIC1, and RASSF1A). In the training set, patients with methylated serum DNA for RASSF1A and/or APC had the worst prognosis (P < 0.001). This finding was confirmed by analyzing serum samples from the independent test set (P = 0.007). When analyzing all 86 of the investigated patients, multivariate analysis showed methylated RASSF1A and/or APC serum DNA to be independently associated with poor outcome, with a relative risk for death of 5.7.
   DNA methylation of particular genes in pretherapeutic sera of breast cancer patients, especially of RASSF1A/APC, is more powerful than standard prognostic parameters.
C1 Univ Innsbruck Hosp, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria.
   Univ Innsbruck, Dept Biostat & Documentat, A-6020 Innsbruck, Austria.
C3 Medical University of Innsbruck; University of Innsbruck
RP Widschwendter, M (通讯作者)，Univ Innsbruck Hosp, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria.
EM martin.widschwendter@uibk.ac.at
RI Goebel, Georg/P-6909-2015; Zeimet, Alain/AFK-2441-2022; Fiegl,
   Heidi/K-4445-2017
OI Widschwendter, Martin/0000-0002-7778-8380; Fiegl,
   Heidi/0000-0002-1236-6806
CR Abe O, 1998, LANCET, V352, P930
   Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913
   Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801
   Chen XQ, 1999, CLIN CANCER RES, V5, P2297
   Clarke M, 1998, LANCET, V351, P1451
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Eads CA, 2001, CANCER RES, V61, P3410
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721
   García-Olmo D, 2001, ANN NY ACAD SCI, V945, P265
   Goessl C, 2000, CANCER RES, V60, P5941
   Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817
   Hayes DF, 1998, BREAST CANCER RES TR, V52, P305, DOI 10.1023/A:1006197805041
   Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805
   Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153
   Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lecomte T, 2002, INT J CANCER, V100, P542, DOI 10.1002/ijc.10526
   LEON SA, 1977, CANCER RES, V37, P646
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Shao ZM, 2001, CLIN CANCER RES, V7, P2222
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Silva JM, 2002, ANN SURG ONCOL, V9, P71, DOI 10.1245/aso.2002.9.1.71
   Silva JM, 1999, CANCER RES, V59, P3251
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong IHN, 1999, CANCER RES, V59, P71
NR 32
TC 258
Z9 305
U1 0
U2 22
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2003
VL 63
IS 22
BP 7641
EP 7645
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 746WM
UT WOS:000186770700019
PM 14633683
DA 2025-01-12
ER

PT J
AU Wong, CM
   Lee, JMF
   Ching, YP
   Jin, DY
   Ng, IOL
AF Wong, CM
   Lee, JMF
   Ching, YP
   Jin, DY
   Ng, IOL
TI Genetic and epigenetic alterations of <i>DLC-1</i> gene in
   hepatocellular carcinoma
SO CANCER RESEARCH
LA English
DT Article
ID RHO-GTPASES; RAS TRANSFORMATION; NUCLEOTIDE EXCHANGE; ALLELIC LOSSES;
   BREAST-TUMORS; CDC42 GTPASES; LUNG-CANCER; OVEREXPRESSION; PROTEINS;
   REGION
AB Hepatocellular carcinoma (HCC) is one of the most common fatal cancers in the world. However, the underlying molecular mechanisms contributing to hepatocarcinogenesis are still unclear. A putative tumor suppressor gene, namely DLC-1 (frequently deleted in liver cancer) was identified and mapped at chromosome 8p21.3-22, a recurrently deleted region in human cancers. The gene exerts inhibitory effects on the cell proliferation of HCC cells. In this study, we investigated the biological function, and genetic and epigenetic status of this gene in human HCC. With in vitro GTPase activating proteins activity assay, we established that DLC-1 protein was a GTPase-activating protein specific for RhoA and Cdc42. Deletion of the DLC-1 gene was frequent in human HCC, as revealed by loss of heterozygosity analysis performed on 100 human HCC cases with markers mapped at the DLC-1 locus, and allelic losses ranging from 44% to 50% of the informative cases. However, somatic mutations of the DLC-1 gene were rare. Moreover, with real-time quantitative PCR, we found that DLC-1 mRNA was significantly underexpressed in HCCs when compared with the corresponding nontumorous livers (P < 0.0001). In addition, the CpG island 5' to the DLC-1 gene was methylated in 3 of 7 HCC cell lines and in 6 (24%) of 25 primary HCCs. These data suggest that transcriptional silencing by hypermethylation may contribute to the inactivation of the DLC-1 gene. Taken together, the results of our study suggest that both genetic and epigenetic alterations play an important role in inactivation of the DLC-1 gene in hepatocarcinogenesis.
C1 Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Ng, IOL (通讯作者)，Univ Hong Kong, Dept Pathol, Queen Mary Hosp, Room 127B,Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
RI Ching, Yick/C-4244-2009; WONG, Chun-Ming/A-6739-2009; Jin,
   Dong-Yan/AFL-5026-2022
OI Ng, Irene Oi-lin/0000-0001-7532-2029; CHING, Yick
   Pang/0000-0002-6461-8358; WONG, Chun-Ming/0000-0002-2497-7858
CR Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X
   Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919
   Chan KL, 2002, CANCER, V94, P3179, DOI 10.1002/cncr.10612
   Chan KYK, 2002, CANCER RES, V62, P4151
   CHEN CJ, 1997, J GASTROEN HEPATOL, V12, P294
   Chinen K, 1996, CYTOGENET CELL GENET, V75, P190, DOI 10.1159/000134480
   Ching YP, 2000, GENE, V242, P285, DOI 10.1016/S0378-1119(99)00499-0
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1
   Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510
   FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E
   HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x
   Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A
   Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9
   Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x
   KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0
   Momoi H, 2001, CLIN CANCER RES, V7, P2648
   Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1
   MOSCOW JA, 1994, ONCOGENE, V9, P189
   Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136
   Ng IOL, 2000, CANCER RES, V60, P6581
   NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456
   Osborne RJ, 2000, CANCER RES, V60, P3706
   Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8
   Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.0.CO;2-3
   Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449
   QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0
   QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781
   Rihet S, 2001, J CANCER RES CLIN, V127, P733
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302
   Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621
   SELF AJ, 1995, METHOD ENZYMOL, V256, P67
   SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404
   Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23
   Tamura S, 1997, J HEPATOL, V27, P669, DOI 10.1016/S0168-8278(97)80084-0
   Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4
   Wistuba II, 2001, CANCER RES, V61, P3795
   Wistuba II, 1999, CANCER RES, V59, P1973
   Wong CM, 2002, CLIN CANCER RES, V8, P2266
   Yin XL, 2002, ONCOGENE, V21, P1461, DOI 10.1038/sj.onc.1205204
   Yuan BZ, 1998, CANCER RES, V58, P2196
NR 47
TC 174
Z9 204
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2003
VL 63
IS 22
BP 7646
EP 7651
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 746WM
UT WOS:000186770700020
PM 14633684
DA 2025-01-12
ER

PT J
AU Pu, RT
   Laitala, LE
   Alli, PM
   Fackler, MJ
   Sukumar, S
   Clark, DP
AF Pu, RT
   Laitala, LE
   Alli, PM
   Fackler, MJ
   Sukumar, S
   Clark, DP
TI Methylation profiling of benign and malignant breast lesions and its
   application to cytopathology
SO MODERN PATHOLOGY
LA English
DT Article
DE breast lesions; cyclin D2; fine needle; aspiration biopsy; methylation
   profile; MSP; RAR beta 2; RASSF1A; surgical and cytopathology specimens
ID TUMOR-SUPPRESSOR GENE; CYCLIN D2 EXPRESSION; ABERRANT PROMOTER
   HYPERMETHYLATION; FREQUENT EPIGENETIC INACTIVATION; ACID RECEPTOR-BETA-2
   GENE; RETINOIC ACID; CANCER CELLS; LUNG CARCINOMAS; DNA METHYLATION;
   GASTRIC-CANCER
AB Methylation of tumor suppressor genes has been implicated in breast cancer development. However, methylation profiles of different breast lesions, subtypes of carcinoma in particular, have not been examined in detail. In this study, we use methylation-specific PCR (MSP) to generate gene methylation profiles of different breast lesions and to test the clinical utility of such profiles. We examined the methylation status of three genes, RARbeta2, RASSF1A, and cyclin D2, on 102 samples of breast tissue, from benign (n = 36), to in situ carcinoma (n = 21), to invasive carcinoma (n = 45). We found that almost all cases of invasive carcinoma (96%) contained at least one methylated gene from our panel, whereas gene methylation was less common among benign lesions (42%) and in situ carcinoma (76%). Of the three genes, cyclin D2 methylation was most specific for malignancy because only 1 of 35 benign cases was methylated at this gene (1 case was not informative). The major histologic subtypes of invasive carcinoma show similar methylation profiles in the genes examined. We next performed MSP analysis on archival breast fine-needle aspiration (FNA) biopsy samples and corresponding surgical biopsy specimens and found a high concordance between the two types of specimens. We then analyzed 17 breast FNA biopsy samples with an indeterminate diagnosis. In this setting, MSP had a high specificity (100%) and modest sensitivity (67%) for identifying malignancy.
C1 Johns Hopkins Med Inst, Dept Pathol, Div Cytopathol, Baltimore, MD 21287 USA.
   Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Clark, DP (通讯作者)，Johns Hopkins Med Inst, Dept Pathol, Div Cytopathol, Pathol 406,600 N Wolfe St, Baltimore, MD 21287 USA.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Alvarez-Dolado M, 1999, J NEUROSCI RES, V58, P293, DOI 10.1002/(SICI)1097-4547(19991015)58:2<293::AID-JNR9>3.0.CO;2-H
   Bachman KE, 1999, CANCER RES, V59, P798
   Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Chen GQ, 2002, INT J CANCER, V99, P171, DOI 10.1002/ijc.10304
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Esteller M, 1998, CANCER RES, V58, P4515
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Fischer HN, 2002, ONCOL REP, V9, P1157
   GRAFF JR, 1995, CANCER RES, V55, P5195
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lee MG, 2001, CANCER RES, V61, P6688
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446
   Pu RT, 2003, ACTA CYTOL, V47, P247, DOI 10.1159/000326511
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P2
   Takano Y, 1999, J PATHOL, V189, P194
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
   Yu J, 2003, BRIT J CANCER, V88, P1560, DOI 10.1038/sj.bjc.6600940
NR 36
TC 42
Z9 50
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD NOV
PY 2003
VL 16
IS 11
BP 1095
EP 1101
DI 10.1097/01.MP.0000095782.79895.E2
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 748GQ
UT WOS:000186854500004
PM 14614048
OA Bronze
DA 2025-01-12
ER

PT J
AU Ishii, H
   Vecchione, A
   Furukawa, Y
   Sutheesophon, K
   Han, SY
   Druck, T
   Kuroki, T
   Trapasso, F
   Nishimura, M
   Saito, Y
   Ozawa, K
   Croce, CM
   Huebner, K
   Furukawa, Y
AF Ishii, H
   Vecchione, A
   Furukawa, Y
   Sutheesophon, K
   Han, SY
   Druck, T
   Kuroki, T
   Trapasso, F
   Nishimura, M
   Saito, Y
   Ozawa, K
   Croce, CM
   Huebner, K
   Furukawa, Y
TI Expression of <i>FRA16D</i>/<i>WWOX</i> and <i>FRA3B</i>/<i>FHIT</i>
   genes in hematopoietic malignancies
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID PROMOTER METHYLATION PROFILE; HISTIDINE TRIAD GENE; FHIT GENE;
   CLINICOPATHOLOGICAL FEATURES; CELL CARCINOMA; FRAGILE SITES;
   BREAST-CANCER; LEUKEMIA; WWOX; TRANSCRIPTS
AB The WW domain containing oxidoreductase (WWOX) gene was recently identified as a candidate tumor suppressor gene at a common fragile site, FRA16D. Because the fragile histidine triad (FHIT) gene, a tumor suppressor gene encompassing the most active, common fragile site FRA3B, is frequently deleted in various cancers, we evaluated the expression of WWOX and FHIT in 74 cases of primary hematopoietic neoplasias and 20 leukemia cell lines. Aberration or absence of WWOX transcripts was detected in 51% of the primary cases and 55% of cell lines, and three WWOX nucleotide variants were detected among the leukemia cell lines. FHIT expression was absent or altered in 36% of the primary cases and 15% of cell lines. The occurrence of aberrant FHIT reverse transcription-PCR products correlated significantly with the occurrence of WWOX alterations. Wild-type transcripts of both genes were expressed in normal hematopoiesis along with a small fraction of short transcripts. A DNA blot study showed that WWOX and FHIT genes were deleted in 2 of 18 cases with primary acute leukemias; both genes were not expressed in the 2 cases. Furthermore, treatment of cells with a demethylating or histone acetylating agent in culture resulted in increased expression of WWOX and FHIT mRNA in leukemia cells. Conclusions are that WWOX expression is frequently altered or absent in hematopoietic disorders, often in association with FHIT alterations, and that alterations of these fragile genes may result not only from genomic deletions but also from epigenetic modifications associated with expression of fragility.
C1 Jichi Med Sch, Div Stem Cell Res, Ctr Mol Med, Minami Kawachi, Tochigi 3290498, Japan.
   Chiba Univ, Grad Sch Med, Dept Clin Cell Biol, Chiba, Japan.
   Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
C3 Jichi Medical University; Chiba University; Thomas Jefferson University
RP Ishii, H (通讯作者)，Jichi Med Sch, Div Stem Cell Res, Ctr Mol Med, Minami Kawachi, Tochigi 3290498, Japan.
RI Furukawa, Yusuke/Y-1342-2018
OI Furukawa, Yusuke/0000-0002-7249-6418; Vecchione,
   Andrea/0000-0002-5497-6856
FU NCI NIH HHS [P01 CA77738] Funding Source: Medline
CR Albitar M, 2001, LEUKEMIA RES, V25, P859, DOI 10.1016/S0145-2126(01)00042-X
   Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000
   Ausubel F. M., 1995, CURRENT PROTOCOLS MO
   Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1
   Baffa R, 1998, CANCER RES, V58, P4708
   Bednarek AK, 2000, CANCER RES, V60, P2140
   Bednarek AK, 2001, CANCER RES, V61, P8068
   Carapeti M, 1998, BRIT J CANCER, V78, P601, DOI 10.1038/bjc.1998.547
   Chandra S, 2002, TRANSIT METAL CHEM, V27, P196, DOI 10.1023/A:1013935602736
   Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200
   Drexler HG, 2000, LEUKEMIA RES, V24, P881, DOI 10.1016/S0145-2126(00)00070-9
   Drexler HG, 1998, LEUKEMIA LYMPHOMA, V31, P305, DOI 10.3109/10428199809059223
   GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988
   Hallas C, 1999, CLIN CANCER RES, V5, P2409
   Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0
   Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441
   Iwai T, 1998, CANCER RES, V58, P5182
   Kantarjian HM, 1999, CLIN CANCER RES, V5, P4059
   Kuroki T, 2002, CANCER RES, V62, P2258
   Lin PM, 1997, BRIT J HAEMATOL, V99, P612, DOI 10.1046/j.1365-2141.1997.4223235.x
   MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499
   Maruyama R, 2001, CANCER RES, V61, P8659
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898
   Peters UR, 1999, ONCOGENE, V18, P79, DOI 10.1038/sj.onc.1202256
   Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6
   Tanaka H, 1998, CANCER RES, V58, P3429
   Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100
   Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674
   Yendamuri S, 2003, CANCER RES, V63, P878
   YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 33
TC 61
Z9 72
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD NOV
PY 2003
VL 1
IS 13
BP 940
EP 947
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 747DB
UT WOS:000186789000002
PM 14638866
DA 2025-01-12
ER

PT J
AU Hu, XC
   Wong, IHN
   Chow, LWC
AF Hu, XC
   Wong, IHN
   Chow, LWC
TI Tumor-derived aberrant methylation in plasma of invasive ductal breast
   cancer patients: Clinical implications
SO ONCOLOGY REPORTS
LA English
DT Article
DE p16; E-cadherin; aberrant hypermethylation; plasma; serum CEA levels
ID E-CADHERIN EXPRESSION; DNA METHYLATION; MICROSATELLITE ALTERATIONS; P16
   METHYLATION; LUNG-CANCER; GENE; SERUM; P16(INK4A); PROMOTER;
   INACTIVATION
AB Progressive p16 methylation has been associated with metastasis and invasive phenotypes in many cancers. Loss of E-cadherin (CDH1) function contributes to breast cancer progression by promoting cell proliferation, invasion and metastasis. Using methylation-specific PCR, aberrant hypermethylation of p16 and CDH1 in tumor and plasma was analyzed and correlated with levels of serum protein markers, carcinoembryonic antigen (CEA) and carcinoma antigen 15-3 (CA15.3), in 36 patients with invasive ductal breast cancer. Aberrant p 16 methylation was found in 11% (4/36) of primary tumors and 8% (3/36) of plasma samples. Aberrant CDH1 methylation was detected in 25% (9/36) of primary tumors and 20% (7/36) of plasma samples. p16 and/or CDH1 hypermethylation was found in 31% (11/36) of primary breast carcinomas and 82% (9/11) of breast cancer patients with tumoral methylation showing identical epigenetic changes in plasma. The 25 patients without tumoral methylation did not show epigenetic changes in the plasma. Tumoral p16 methylation was significantly associated with advanced tumor stage (p=0.028; Fisher's exact test), tumor size (p=0.017) and nodal metastasis (p=0.002). However, p16 methylation in plasma was only associated with nodal metastasis (p=0.012). Altogether, aberrant p16 methylation in plasma and elevated serum CEA level were associated with advanced tumor stage (p=0.033), tumor size (p=0.022) and extensive nodal metastasis (p=0.003). With clinical implications, p16 hypermethylation in plasma and/or raised serum CEA levels may prove useful as diagnostic and prognostic markers for breast cancer.
C1 Univ Hong Kong, Med Ctr, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Chow, LWC (通讯作者)，Univ Hong Kong, Med Ctr, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
CR Anker P, 1997, GASTROENTEROLOGY, V112, P1114, DOI 10.1016/S0016-5085(97)70121-5
   Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   BERNS EMJJ, 1995, BRIT J CANCER, V72, P964, DOI 10.1038/bjc.1995.442
   BRENNER AJ, 1995, CANCER RES, V55, P2892
   Brenner AJ, 1996, CLIN CANCER RES, V2, P1993
   Charpin C, 1999, INT J ONCOL, V15, P285
   Chen XQ, 1999, CLIN CANCER RES, V5, P2297
   Chen XQ, 1996, NAT MED, V2, P1033
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Geradts J, 1996, AM J PATHOL, V149, P15
   Gonzalez MA, 1999, J PATHOL, V187, P523, DOI 10.1002/(SICI)1096-9896(199904)187:5<523::AID-PATH296>3.0.CO;2-3
   Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336
   Han AC, 1999, HUM PATHOL, V30, P1035, DOI 10.1016/S0046-8177(99)90220-4
   Hayes D F, 1996, Recent Results Cancer Res, V140, P101
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huiping C, 1999, BRIT J CANCER, V81, P1103, DOI 10.1038/sj.bjc.6690815
   Jahr S, 2001, CANCER RES, V61, P1659
   Ji XD, 1997, CELL GROWTH DIFFER, V8, P773
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Lo YMD, 1999, CANCER RES, V59, P3899
   Maesawa C, 1996, CANCER RES, V56, P3875
   REED JA, 1995, CANCER RES, V55, P2713
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Shaw JA, 2000, CLIN CANCER RES, V6, P1119
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Silva JM, 1999, CANCER RES, V59, P3251
   Sorenson GD, 2000, CLIN CANCER RES, V6, P2129
   Wong IHN, 2000, ANN NY ACAD SCI, V906, P102
   Wong IHN, 1999, CANCER RES, V59, P71
   Wong IHN, 2001, ANN NY ACAD SCI, V945, P36
   Wong IHN, 2001, INT J ONCOL, V18, P633
   Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041
NR 36
TC 41
Z9 43
U1 0
U2 1
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD NOV-DEC
PY 2003
VL 10
IS 6
BP 1811
EP 1815
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 740AT
UT WOS:000186379200023
PM 14534701
DA 2025-01-12
ER

PT J
AU Horiguchi, K
   Tomizawa, Y
   Tosaka, M
   Ishiuchi, S
   Kurihara, H
   Mori, M
   Saito, N
AF Horiguchi, K
   Tomizawa, Y
   Tosaka, M
   Ishiuchi, S
   Kurihara, H
   Mori, M
   Saito, N
TI Epigenetic inactivation of <i>RASSF1A</i> candidate tumor suppressor
   gene at 3p21.3 in brain tumors
SO ONCOGENE
LA English
DT Article
DE 3p21.3; methylation; glioma; medulloblastoma; meningioma; schwannoma
ID PRIMITIVE NEUROECTODERMAL TUMORS; CHROMOSOME 3P; PROMOTER
   HYPERMETHYLATION; CPG ISLAND; LUNG; METHYLATION; BREAST; CELL;
   HETEROZYGOSITY; HYBRIDIZATION
AB The human Ras association domain family 1A (RASS-F1A) gene, recently isolated from the lung and breast tumor suppressor locus 3p21.3, is highly methylated in primary lung, breast, nasopharyngeal and other tumors, and re-expression of RASSF1A suppresses the growth of several types of cancer cells. Epigenetic inactivation of RASSF1A by promoter hypermethylation is also important in the development of several human cancers. The methylation status of the promoter region of RASSF1A was analysed in primary brain tumors and glioma cell lines by methylation-specific polymerase chain reaction. In primary brain tumors, 25 of 46 ( 54.3%) gliomas and five of five (100%) medulloblastomas showed RASSF1A methylation. In benign tumors, only one of 10 (10%) schwannomas and two of 12 (16.7%) meningiomas showed RASSF1A methylation. The RASSF1A promoter region was methylated in all four glioma cell lines. RASSF1A was re-expressed in all methylated cell lines after treatment with the demethylating agent 5-aza-2'-deoxycytidine. Methylation of the promoter CpG islands of the RASSF1A may play an important role in the pathogenesis of glioma and medulloblastoma.
C1 Gunma Univ, Sch Med, Dept Neurosurg, Gunma 3718511, Japan.
   Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan.
C3 Gunma University; Gunma University
RP Horiguchi, K (通讯作者)，Gunma Univ, Sch Med, Dept Neurosurg, 3-39-22 Showa Machi, Gunma 3718511, Japan.
OI Saito, Nobuhito/0000-0001-9756-781X
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968
   Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293
   Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   FULTS D, 1990, CANCER RES, V50, P5784
   Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kanno H, 1997, CANCER RES, V57, P1035
   Kleihues PCW., 2000, WORLD HLTH ORG CLASS
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Lee MG, 2001, CANCER RES, V61, P6688
   Lo KW, 2001, CANCER RES, V61, P3877
   Lusher ME, 2002, CANCER RES, V62, P5906
   Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   Mollerup S, 1999, CANCER RES, V59, P3317
   Morrissey C, 2001, CANCER RES, V61, P7277
   Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362
   Toyooka S, 2001, CANCER RES, V61, P5727
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
   Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835
NR 28
TC 61
Z9 69
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD OCT 30
PY 2003
VL 22
IS 49
BP 7862
EP 7865
DI 10.1038/sj.onc.1207082
PG 4
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 737PD
UT WOS:000186240200017
PM 14586413
DA 2025-01-12
ER

PT J
AU Padar, A
   Sathyanarayana, UG
   Suzuki, M
   Maruyama, R
   Hsieh, JT
   Frenkel, EP
   Minna, JD
   Gazdar, AF
AF Padar, A
   Sathyanarayana, UG
   Suzuki, M
   Maruyama, R
   Hsieh, JT
   Frenkel, EP
   Minna, JD
   Gazdar, AF
TI Inactivation of <i>Cyclin D2</i> gene in prostate cancers by aberrant
   promoter methylation
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID POOR-PROGNOSIS; BREAST-CANCER; CELL-CYCLE; OVEREXPRESSION; D1; D2;
   AMPLIFICATION; PROGRESSION; EXPRESSION; CARCINOMA
AB Purpose: Loss or abnormal expression of Cyclin D2, a crucial cell cycle-regulatory gene, has been described in human cancers; however, data for prostate tumors are lacking. We investigated the epigenetic silencing of Cyclin D2 gene in prostate cancers and correlated the data with clinicopathological features.
   Experimental Design: Cyclin D2 promoter methylation was analyzed in 101 prostate cancer samples by methylation-specific PCR. In addition, we analyzed 32 nonmalignant prostate tissue samples, which included 24 samples of benign disease, benign prostatic hypertrophy, or prostatitis and 7 normal tissues adjacent to cancer. The methylation status of Cyclin D2 was correlated with the methylation of nine other tumor suppressor genes published previously from our laboratory on the same set of samples (R. Maruyama et al., Clin. Cancer Res., 8: 514-519, 2002). The methylation index was determined as a reflection of the methylated fraction of the genes examined.
   Results: The frequency of methylation of Cyclin D2 promoter was significantly higher in prostate cancers (32%) than in nonmalignant prostate tissues (6%; P = 0.004), and it was not age related. Aberrant methylation was present at insignificant levels in peripheral blood lymphocytes (8%). We also compared methylation of cyclin D2 with methylation of nine tumor suppressor genes [published previously from our laboratory (R. Maruyama et al., Clin. Cancer Res., 8: 514-519, 2002)] studied in the same set of samples. The concordances between methylation of Cyclin D2 and the methylation of RARbeta, GSTP1, CDH13, RASSF1A, and APC were statistically significant, whereas methylation of P16, DAPK, FHIT, and CDH1 were not significant. The differences in methylation index between malignant and nonmalignant tissues for all 10 genes were statistically significant (P < 0.0001). Among clinicopathological correlations, the high Gleason score group had significantly greater methylation frequency of Cyclin D2 (42%; P = 0.004). Although the high preoperative serum prostate-specific antigen (PSA) group did not have significantly greater methylation frequency, methylation of Cyclin D2 had higher mean PSA value. Also, the prostate cancers in the high Gleason score group had high mean values of PSA.
   Conclusions: Our results indicate that methylation of Cyclin D2 in prostate cancers correlates with clinicopathological features of poor prognosis. These findings are of biological and potential clinical importance.
C1 Univ Texas, Hamon Ctr Therapeut Oncol Res, SW Med Ctr, Dallas, TX 75390 USA.
   Univ Texas, Simmons Canc Ctr, SW Med Ctr, Dallas, TX 75390 USA.
   Univ Texas, Dept Pathol, SW Med Ctr, Dallas, TX 75390 USA.
   Univ Texas, Dept Urol, SW Med Ctr, Dallas, TX 75390 USA.
   Univ Texas, Dept Internal Med, SW Med Ctr, Dallas, TX 75390 USA.
   Univ Texas, Dept Pharmacol, SW Med Ctr, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas Dallas;
   University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas Dallas
RP Gazdar, AF (通讯作者)，Univ Texas, Hamon Ctr Therapeut Oncol Res, SW Med Ctr, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
RI Gazdar, Adi/F-7496-2010; Minna, John/AAB-1036-2022
FU NCI NIH HHS [U01CA84971] Funding Source: Medline
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Beahrs OH., 1992, AM JOINT COMMITTEE C
   Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321
   BUCKLEY MF, 1993, ONCOGENE, V8, P2127
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Evron E, 2001, CANCER RES, V61, P2782
   Gansauge S, 1997, CANCER RES, V57, P1634
   GILLETT C, 1994, CANCER RES, V54, P1812
   GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4
   GRAMLICH TL, 1994, DIAGN MOL PATHOL, V3, P255, DOI 10.1097/00019606-199412000-00007
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.3.CO;2-1
   KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112
   LUKAS J, 1995, ONCOGENE, V10, P2125
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Michalides RJAM, 1997, ARCH OTOLARYNGOL, V123, P497
   Nakamura S, 1997, PATHOL INT, V47, P421, DOI 10.1111/j.1440-1827.1997.tb04519.x
   Nguyen TT, 2000, PROSTATE, V43, P233
   Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9
   Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310
   SHAPIRO GI, 1995, CANCER RES, V55, P6200
   SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2
   Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0
   Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951
   Takano Y, 1999, J PATHOL, V189, P194
   Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3
   TAM SW, 1994, ONCOGENE, V9, P2663
   Tefilli MV, 1999, UROLOGY, V53, P372, DOI 10.1016/S0090-4295(98)00479-8
   Tsihlias J, 1999, ANNU REV MED, V50, P401
   Zhang PM, 1999, CURR OPIN CELL BIOL, V11, P655, DOI 10.1016/S0955-0674(99)00032-0
NR 33
TC 94
Z9 104
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2003
VL 9
IS 13
BP 4730
EP 4734
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 737CW
UT WOS:000186212000011
PM 14581343
DA 2025-01-12
ER

PT J
AU Keen, JC
   Yan, L
   Mack, KM
   Pettit, C
   Smith, D
   Sharma, D
   Davidson, NE
AF Keen, JC
   Yan, L
   Mack, KM
   Pettit, C
   Smith, D
   Sharma, D
   Davidson, NE
TI A novel histone deacetylase inhibitor, Scriptaid, enhances expression of
   functional estrogen receptor α (ER) in ER negative human breast cancer
   cells in combination with 5-aza 2′-deoxycytidine
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE 5-aza-2 '-deoxycytidine; breast cancer; DNA methylation; estrogen
   receptor alpha; histone acetylation; Scriptaid
ID DNA METHYLATION; IN-VIVO; ACETYLATION; GENE; DEMETHYLATION; ACTIVATION;
   CARCINOMA; CHROMATIN; BIOLOGY; ACID
AB Epigenetic mechanisms, such as DNA methylation and histone deacetylation, may play a role in loss of estrogen receptor a (ER) expression in ER negative human breast cancer cells. Our previous studies showed that pharmacologic inhibition of these mechanisms using the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine (AZA), and the histone deacetylase (HDAC) inhibitor, Trichostatin A (TSA), resulted in expression of functional ER mRNA and protein. Therefore, we sought to characterize the effects of a recently described HDAC inhibitor, Scriptaid, on cell growth and ER expression and function in ER negative human breast cancer cell lines. Scriptaid treatment of three ER negative cell lines, MDA-MB-231, MDA-MB-435 and Hs578t, resulted in significant growth inhibition and increased acetylation of H3 and H4 histone tails. Quantitative Real Time PCR showed 2000-20,000-fold increase of ER mRNA transcript in all three cell lines after 48 h of Scriptaid treatment. Further, dose dependent re-expression of an estrogen responsive gene, the progesterone receptor (PR), indicated that induced ER is functional. As seen with TSA and AZA, Scriptaid and AZA co-treatment was more effective in inducing ER than Scriptaid or AZA alone. In vivo analysis using a xenograft mouse model bearing MDA-MB-231 tumors showed decreased tumor growth following Scriptaid or TSA treatment. Our results indicate that the novel HDAC inhibitor, Scriptaid, inhibits tumor growth in vitro and in vivo and, in conjunction with AZA, acts to re-express functional ER. These data suggest that Scriptaid or related HDAC inhibitors are candidates for further study in breast cancer.
C1 Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Davidson, NE (通讯作者)，Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St,CRB Room 409, Baltimore, MD 21231 USA.
OI Keen, Judith/0000-0002-2894-130X
FU NCI NIH HHS [CA09110, CA88843, CA 78352] Funding Source: Medline
CR Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Bird A, 2001, SCIENCE, V294, P2113, DOI 10.1126/science.1066726
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Butler LM, 2000, CANCER RES, V60, P5165
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Gore SD, 2000, EXPERT OPIN INV DRUG, V9, P2923, DOI 10.1517/13543784.9.12.2923
   Hahm HA, 2001, CLIN CANCER RES, V7, P391
   HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Iwase Hirotaka, 2003, Breast Cancer, V10, P89, DOI 10.1007/BF02967632
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Su GH, 2000, CANCER RES, V60, P3137
   THAIAGALINGAN S, 2003, ANN NY ACAD SCI, V983, P84
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   YAN L, 2001, AACR, V42, P844
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
NR 28
TC 140
Z9 164
U1 1
U2 9
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2003
VL 81
IS 3
BP 177
EP 186
DI 10.1023/A:1026146524737
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 732BG
UT WOS:000185920500001
PM 14620913
DA 2025-01-12
ER

PT J
AU Cavalli, LR
   Urban, CA
   Dai, DQ
   de Assis, S
   Tavares, DC
   Rone, JD
   Bleggi-Torres, LF
   Lima, RS
   Cavalli, IJ
   Issa, JPJ
   Haddad, BR
AF Cavalli, LR
   Urban, CA
   Dai, DQ
   de Assis, S
   Tavares, DC
   Rone, JD
   Bleggi-Torres, LF
   Lima, RS
   Cavalli, IJ
   Issa, JPJ
   Haddad, BR
TI Genetic and epigenetic alterations in sentinel lymph nodes metastatic
   lesions compared to their corresponding primary breast tumors
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; AXILLARY DISSECTION; DNA METHYLATION;
   COLORECTAL-CANCER; C-MYC; CARCINOMA; BIOPSY; LYMPHADENECTOMY; ASSAY;
   ABNORMALITIES
AB The accumulation of genetic and epigenetic changes plays a pivotal role in tumor development and progression. In this study, we investigated these changes using comparative genomic hybridization and bisulfite polymerase chain reaction analysis for CpG island hypermethylation of the following genes: TP16, THBS2, E-Cadherin (ECAD), RARbeta2, MINT1, MINT2, and MINT31 in six paired primary breast tumors and their matched sentinel lymph nodes (SLN). The most frequent chromosomal alterations observed were the following: losses of 6q13similar toq23 and 13q13similar toq32 and gains of 9q31similar toqter, 11p15similar toq21, 12q23similar toqter, and 20q12similar toqter. Gain of 6p21similar topter was observed in the SLN but in none of the primary tumors. Overall, 71% (30/42) of the methylation measurements were identical between the primary tumors and the SLN. Of the six cases, two showed no differences between the primary tumors and SLN, one tumor with 4 of 7 genes hypermethylated in the primary tumor showed loss of all four hypermethylation events in the SLN, and the remaining three tumors showed loss of one methylation event and simultaneous gain of one to two methylation changes in the SLN. This is the first study reporting genetic and epigenetic alterations in breast sentinel lymph nodes compared to their corresponding primary tumors. Characterization of such alterations may lead to identification of initial events associated with the metastatic dissemination process. (C) 2003 Elsevier Inc. All rights reserved.
C1 Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
   Hosp Nossa Senhora Gracas, Dept Oncol, Curitiba, Parana, Brazil.
   Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   Univ Franca, Franca, SP, Brazil.
   Univ Fed Parana, Dept Patol, BR-80060000 Curitiba, Parana, Brazil.
   Univ Fed Parana, Dept Genet, BR-80060000 Curitiba, Parana, Brazil.
C3 Georgetown University; University of Texas System; UTMD Anderson Cancer
   Center; Universidad de Franca; Universidade Federal do Parana;
   Universidade Federal do Parana
RP Haddad, BR (通讯作者)，Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Inst Mol & Human Genet, 3800 Reservoir Rd,M4000, Washington, DC 20007 USA.
RI Tavares, Denise/C-3396-2012; Cavalli, Luciane/J-6100-2012; Urban,
   Cicero/D-1578-2011; Assis, Sonia/N-8274-2013
OI Issa, Jean-Pierre/0000-0003-2258-5030; Cavalli, Luciane
   Regina/0000-0001-5619-9037
CR Bell KA, 2001, FERTIL STERIL, V75, P374, DOI 10.1016/S0015-0282(00)01703-9
   Bernardino J, 1997, GENE CHROMOSOME CANC, V19, P195
   BERNS E, 1995, GENE, V14, P11
   Breslin TM, 2000, J CLIN ONCOL, V18, P3480, DOI 10.1200/JCO.2000.18.20.3480
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X
   Figueiredo BC, 1999, J CLIN ENDOCR METAB, V84, P1116, DOI 10.1210/jc.84.3.1116
   Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4
   Garcia-Manero G, 2002, CLIN CANCER RES, V8, P1897
   Giuliano AE, 1996, J SURG ONCOL, V62, P75, DOI 10.1002/(SICI)1096-9098(199606)62:2<75::AID-JSO1>3.0.CO;2-N
   Giuliano AE, 1997, J CLIN ONCOL, V15, P2345, DOI 10.1200/JCO.1997.15.6.2345
   GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hermsen MAJA, 1998, J PATHOL, V186, P356
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kuukasjarvi T, 1997, CANCER RES, V57, P1597
   LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1
   Lindahl T, 2000, ACTA ONCOL, V39, P319, DOI 10.1080/028418600750013087
   Linderholm B, 1998, J CLIN ONCOL, V16, P3121, DOI 10.1200/JCO.1998.16.9.3121
   Manzotti M, 2001, INT J CANCER, V95, P307, DOI 10.1002/1097-0215(20010920)95:5<307::AID-IJC0153>3.0.CO;2-Q
   Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V
   Ollila D B, 2001, Cancer Control, V8, P407
   PANDIS N, 1992, GENE CHROMOSOME CANC, V5, P235, DOI 10.1002/gcc.2870050310
   PANDIS N, 1995, CANCER, V76, P250, DOI 10.1002/1097-0142(19950715)76:2<250::AID-CNCR2820760215>3.0.CO;2-W
   PANDIS N, 1994, CANCER GENET CYTOGEN, V75, P158, DOI 10.1016/0165-4608(94)90172-4
   Pandis N, 1998, GENE CHROMOSOME CANC, V22, P122, DOI 10.1002/(SICI)1098-2264(199806)22:2<122::AID-GCC6>3.0.CO;2-Z
   Pendas S, 1999, AM SURGEON, V65, P500
   Reintgen Douglas, 2000, Breast J, V6, P299, DOI 10.1046/j.1524-4741.2000.20057.x
   Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755
   Teixeira MR, 1996, BREAST CANCER RES TR, V38, P177, DOI 10.1007/BF01806672
   Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota Minoru, 2002, Methods Mol Biol, V200, P101
   TSUDA H, 1994, CANCER RES, V54, P513
   van Diest PJ, 1999, HISTOPATHOLOGY, V35, P14
   Veronesi U, 1999, JNCI-J NATL CANCER I, V91, P368, DOI 10.1093/jnci/91.4.368
   Veronesi U, 2001, EUR J CANCER, V37, P454, DOI 10.1016/S0959-8049(00)00410-X
   Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0
   WATSON PH, 1991, CANCER RES, V51, P3996
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
NR 41
TC 26
Z9 29
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD OCT 1
PY 2003
VL 146
IS 1
BP 33
EP 40
DI 10.1016/S0165-4608(03)00123-7
PG 8
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 726JC
UT WOS:000185595100006
PM 14499694
DA 2025-01-12
ER

PT J
AU Yan, PS
   Shi, HD
   Rahmatpanah, F
   Hsiau, THC
   Hsiau, AHA
   Len, YW
   Liu, JC
   Huang, THM
AF Yan, PS
   Shi, HD
   Rahmatpanah, F
   Hsiau, THC
   Hsiau, AHA
   Len, YW
   Liu, JC
   Huang, THM
TI Differential distribution of DNA methylation within the <i>RASSF1A</i>
   CpG island in breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID DE-NOVO METHYLATION; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION;
   GENE; CELLS; EXPRESSION; PATTERNS; INACTIVATION; PROGRESSION; MICROARRAY
AB Aberrant DNA methylation of promoter CpG islands is associated with transcriptionally repressive heterochromatin in neoplasia. The dynamics of this epigenetic process in mediating the transition from an active to an inactive state of transcription remains to be elucidated, however. Here, we used the methylation-specific oligonucleotide microarray to map the methylation patterns of a CpG island, located within the promoter and the first exon regions of RASSF1A, in normal breast tissue controls, primary tumors, and breast cancer cell lines. Oligonucleotide pairs, spaced along the CpG island region, were designed to discriminate between methylated and unmethylated alleles of selected sites. The methylation-specific oligonucleotide data indicate that the majority of test samples show widespread methylation in the first exon of RASSF1A. In contrast, the promoter area was usually undermethylated in normal controls and in 32% of the primary tumors tested, whereas the rest of the primary tumors and breast cancer cell lines showed various degrees of methylation in the region. Methylation profiling of individual tumors further suggest that DNA methylation progressively spreads from the first exon into the promoter area of this gene. Functional analysis indicates that increased density of RASSF1A promoter methylation is associated with altered chromatin, marked by a depletion of acetylated histones and methylated histone 3-lysine 4 and an enrichment of methylated histone 3-lysine 9 in the studied area. The combination of these epigenetic modifications may engender a stable silencing of the gene in breast cancer cells. Thus, this study underscores the importance of detailed mapping of methylation patterns within a CpG island locus that may provide insights into the progressive nature of aberrant DNA methylation and its relationship with transcriptional silencing during the neoplastic process.
C1 Ohio State Univ, Med Res Facil, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program,Comprehens Canc Ctr, Columbus, OH 43210 USA.
   Univ Missouri, Sch Med, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Columbia, MO 65203 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University of Missouri System; University
   of Missouri Columbia
RP Huang, THM (通讯作者)，Ohio State Univ, Med Res Facil, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program,Comprehens Canc Ctr, Room 514B,420 W 12th Ave, Columbus, OH 43210 USA.
RI Yan, Pearlly/E-4339-2011
OI Shi, Huidong/0000-0003-1137-3390
FU NCI NIH HHS [R21 CA 94441, R01 CA 69065] Funding Source: Medline
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dammann R, 2001, CANCER RES, V61, P3105
   Esteller M, 2001, CANCER RES, V61, P3225
   Fahrner JA, 2002, CANCER RES, V62, P7213
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Lo KW, 2001, CANCER RES, V61, P3877
   MACLEOD D, 1995, GENE DEV, V8, P2282
   Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199
   Nass SJ, 2000, CANCER RES, V60, P4346
   Nosaka K, 2000, CANCER RES, V60, P1043
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Salem C, 2000, CANCER RES, V60, P2473
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381
   Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
NR 34
TC 93
Z9 113
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2003
VL 63
IS 19
BP 6178
EP 6186
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 732WC
UT WOS:000185967700016
PM 14559801
DA 2025-01-12
ER

PT J
AU Zou, E
   Matsumura, F
AF Zou, E
   Matsumura, F
TI Long-term exposure to β-hexachlorocyclohexane (β-HCH) promotes
   transformation and invasiveness of MCF-7 human breast cancer cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE MCF-7 breast cancer cells; beta-hexachlorocyclohexane (beta-HCH);
   long-term exposure; environmental risk factors c-ErbB2 overexpression
ID MALIGNANT PROGRESSION; ESTROGEN-RECEPTOR; ERBB2 EXPRESSION; CYTOTOXIC
   DRUGS; CARCINOMA CELLS; FOCI FORMATION; RESISTANCE; RISK;
   ORGANOCHLORINES; C-ERBB-2
AB Due to its lipophilicity and persistence, an organochlorine compound, beta-hexachlorocyclohexane (beta-HCH), is known to frequently accumulate in human adipose and breast tissues. An epidemiological study has indicated that exposure to beta-HCH could be one of the significant environmental risk factors for the development of human breast cancers. Additionally, beta-HCH has recently been identified as an environmental estrogen capable of activating estrogen receptor (ER) through a ligand-independent pathway. In the present investigation, we examined the impact of long-term in vitro exposure to beta-HCH on cell transformation and the metastatic potentials of MCF-7 cells. We found that continuous exposure of MCF-7 cells to beta-HCH at 100 nM and 1 muM or to 17-beta-estradiol (E-2) at 1 nM for up to 13 months (33 passages) not only enhanced their transformation tendencies but also promoted their invasiveness. Western blot analysis revealed that beta-HCH induced transformation-related biochemical changes in MCF-7 cells, such as a decline in the levels of ERalpha and p44/42 MAP kinase and a significant increase in expression of c-ErbB2 and MMP-9 levels. In contrast, long-term E-2 treatment resulted in the downregulation of ERalpha and p44/42 MAP kinase and upregulation of MMP-9 only, but no changes in c-ErbB2. Together, these results indicate that these biochemical changes induced by beta-HCH are consistent with the events taking place in these cells to promote the phenotypical expression of transformed cells. Our results provide the in vitro mechanistic basis supporting the hypothesis that beta-HCH is one of the epigenetic risk factors assisting the progression of breast cancer cells to an advanced state of malignancy. (C) 2003 Elsevier Inc. All rights reserved.
C1 Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Matsumura, F (通讯作者)，Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA.
FU NIEHS NIH HHS [ES05707, ES/CA 07284] Funding Source: Medline
CR Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Calle EE, 2002, CA-CANCER J CLIN, V52, P301, DOI 10.3322/canjclin.52.5.301
   Carter WB, 2001, INT J CANCER, V91, P295, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1061>3.0.CO;2-Y
   CLARKE R, 1993, BREAST CANCER RES TR, V24, P227, DOI 10.1007/BF01833263
   CLARKE R, 1994, BREAST CANCER RES TR, V31, P237, DOI 10.1007/BF00666157
   CLARKE R, 1990, ANN ONCOL, V1, P401, DOI 10.1093/oxfordjournals.annonc.a057790
   Enan E, 1998, J BIOCHEM MOL TOXIC, V12, P83, DOI 10.1002/(SICI)1099-0461(1998)12:2<83::AID-JBT3>3.0.CO;2-K
   FAIRCHILD CR, 1991, INT J RADIAT ONCOL, V20, P361, DOI 10.1016/0360-3016(91)90121-J
   FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143
   Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954
   Guttes S, 1998, ARCH ENVIRON CON TOX, V35, P140, DOI 10.1007/s002449900361
   Hatakeyama M, 2002, ENVIRON TOXICOL PHAR, V11, P27, DOI 10.1016/S1382-6689(01)00101-6
   Hatakeyama M, 1999, J BIOCHEM MOL TOXIC, V13, P296, DOI 10.1002/(SICI)1099-0461(1999)13:6<296::AID-JBT2>3.0.CO;2-S
   Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964
   Hunter DJ, 1997, NEW ENGL J MED, V337, P1253, DOI 10.1056/NEJM199710303371801
   Jung D, 1997, J TOXICOL ENV HEALTH, V51, P23, DOI 10.1080/009841097160203
   KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149
   KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589
   Larsen SS, 1999, BREAST CANCER RES TR, V58, P41, DOI 10.1023/A:1006232830161
   LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M
   LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890
   LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783
   Mattison D R, 1992, J Ark Med Soc, V88, P553
   Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E
   MUSSALORAUHAMAA H, 1990, CANCER-AM CANCER SOC, V66, P2124, DOI 10.1002/1097-0142(19901115)66:10<2124::AID-CNCR2820661014>3.0.CO;2-A
   Nahta R, 2002, CANCER RES, V62, P2267
   Newman SP, 2000, ONCOGENE, V19, P490, DOI 10.1038/sj.onc.1203416
   Pink JJ, 1996, CANCER RES, V56, P2321
   SIPILA PE, 1993, EUR J CANCER, V15, P2138
   SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519
   Steinmetz R, 1996, CANCER RES, V56, P5403
   Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686
   Tan M, 1997, CANCER RES, V57, P1199
   vantVeer P, 1997, BMJ-BRIT MED J, V315, P81, DOI 10.1136/bmj.315.7100.81
   WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648
   Woolcott CG, 2001, CANCER CAUSE CONTROL, V12, P395, DOI 10.1023/A:1011289905751
   Wosikowski K, 1997, CLIN CANCER RES, V3, P2405
   YU DH, 1993, CANCER RES, V53, P891
   Zou EM, 2002, ENVIRON TOXICOL PHAR, V11, P71, DOI 10.1016/S1382-6689(01)00100-4
NR 40
TC 43
Z9 48
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD SEP 1
PY 2003
VL 66
IS 5
BP 831
EP 840
DI 10.1016/S0006-2952(03)00394-0
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 721NT
UT WOS:000185323000016
PM 12948864
DA 2025-01-12
ER

PT J
AU Yan, L
   Nass, SJ
   Smith, D
   Nelson, WG
   Herman, JG
   Davidson, NE
AF Yan, L
   Nass, SJ
   Smith, D
   Nelson, WG
   Herman, JG
   Davidson, NE
TI Specific inhibition of DNMT1 by antisense oligonucleotides induces
   re-expression of estrogen receptor α (ER) in ER-negative human breast
   cancer cell lines
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE breast cancer; DNA methylation; DNA methyltransferase 1; estrogen
   receptor alpha; antisense oligonucleotide
ID HISTONE DEACETYLASE INHIBITION; DNA METHYLATION; GENE-EXPRESSION;
   ACTIVATION; THERAPY; COMPLEX
AB Recent studies have shown that changes in epigenetic regulation, such as DNA methylation and histone acetylation, are associated with silencing of the estrogen receptor a (ER) gene in ER-negative human breast cancer cells. Treatment of these cells with the general DNMT inhibitor, 5-aza-2'deoxycytidine, led to reactivation of functional ER protein. This study addresses the hypothesis that specific inhibition of the maintenance DNA methyltransferase, DNMT1, by antisense oligonucleotides (DNMT1 ASO) is sufficient to re-express the ER gene in ER-negative human breast cancer cell lines. MDA-MB-231 and Hs578t cells were transfected with 100 nM and 150 nM DNMT1 ASO respectively for three consecutive days and evidence of DNMT1 downregulation and functional ER re-expression was sought. Significant growth reduction was observed within 48 hr and persisted after 96 hr. DNMT1 expression was blocked after exposure to DNMT1 ASO as detected by RT-PCR, Western blot and enzymatic assay whereas a mutant DNMT1 ASO had little effect. This was associated with enhanced ER mRNA and protein expression and restoration of estrogen responsiveness in MDA-MB-231 cells as demonstrated by the ability of the induced ER protein to elicit ERE-regulated reporter activity from a luciferase reporter construct. Methylation specific PCR showed that the ER CpG island was minimally demethylated, suggesting that other epigenetic events, introduced by specific DNMT1 inhibition, might also be involved in ER re-expression. Our results suggest that specific inhibition of DNMT1 expression alone is sufficient to re-express ERa in human breast cancer cell lines.
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,Room 409, Baltimore, MD 21231 USA.
EM davidna@jhmi.edu
OI Nass, Sharyl/0000-0001-5874-5337
FU NCI NIH HHS [P50CA88843, CA78352] Funding Source: Medline
CR FERGUSON AT, 1995, CANCER RES, V55, P2279
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Nass SJ, 1999, ONCOGENE, V18, P7453, DOI 10.1038/sj.onc.1203138
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Stewart DJ, 2003, ANN ONCOL, V14, P766, DOI 10.1093/annonc/mdg216
   Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 19
TC 79
Z9 97
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD SEP-OCT
PY 2003
VL 2
IS 5
BP 552
EP 556
DI 10.4161/cbt.2.5.469
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 751PN
UT WOS:000187076300016
PM 14614325
OA Bronze
DA 2025-01-12
ER

PT J
AU Oesterreich, S
   Deng, W
   Jiang, S
   Cui, XJ
   Ivanova, M
   Schiff, R
   Kang, KY
   Hadsell, DL
   Behrens, J
   Lee, AV
AF Oesterreich, S
   Deng, W
   Jiang, S
   Cui, XJ
   Ivanova, M
   Schiff, R
   Kang, KY
   Hadsell, DL
   Behrens, J
   Lee, AV
TI Estrogen-mediated down-regulation of E-cadherin in breast cancer cells
SO CANCER RESEARCH
LA English
DT Article
ID MESSENGER-RNA LEVELS; GENE-EXPRESSION; RECEPTOR; PROTEIN; TAMOXIFEN;
   PROMOTER; BETA; TRANSCRIPTION; CARCINOMA; PATHWAY
AB E-cadherin is an important mediator of cell-cell interactions, and has been shown to play a crucial role in breast tumor suppression. Its inactivation occurs through instability at its chromosomal locus and mutations, but also through epigenetic mechanisms such as promoter hypermethylation and transcriptional silencing. We show here that the potent mitogen estrogen causes down-regulation of E-cadherin levels in both normal and tumorigenic breast epithelial cells, and that this down-regulation is reversed by antiestrogens. The reduction in E-cadherin levels is via a decrease in promoter activity and subsequent mRNA levels. Chromatin immunoprecipitation assays revealed that estrogen receptor and corepressors were bound to the E-cadherin promoter, and that overexpression of corepressors such as scaffold attachment factor B resulted in enhanced repression of E-cadherin. We propose that estrogen-mediated down-regulation of E-cadherin is a novel way of reducing E-cadherin levels in estrogen receptor-positive breast cancer.
C1 Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Univ Erlangen Nurnberg, Nikolaus Fiebiger Zentrum Mol Med, D-91054 Erlangen, Germany.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine; University of Erlangen Nuremberg
RP Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Pl,BCM 600, Houston, TX 77030 USA.
EM steffio@breastcenter.tmc.edu
RI Hadsell, Darryl/GPF-9037-2022
OI Ivanova, Margarita/0000-0002-6197-8606; Lee, Adrian/0000-0001-9917-514X
FU NCI NIH HHS [R01 CA97213, KO1 CA77674] Funding Source: Medline
CR Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   BRACKE ME, 1994, CANCER RES, V54, P4607
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Charpentier AH, 2000, CANCER RES, V60, P5977
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   DePasquale JA, 1999, HISTOCHEM CELL BIOL, V112, P341, DOI 10.1007/s004180050415
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758
   Habermann H, 2001, ENDOCRINOLOGY, V142, P359, DOI 10.1210/en.142.1.359
   Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336
   Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595
   Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78
   Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637
   Lauritsen KJ, 2002, ONCOGENE, V21, P7147, DOI 10.1038/sj.onc.1205943
   LIPPONEN P, 1994, J PATHOL, V174, P101, DOI 10.1002/path.1711740206
   MACCALMAN CD, 1994, CLIN EXP METASTAS, V12, P276, DOI 10.1007/BF01753834
   MACCALMAN CD, 1995, DEV GENET, V16, P20, DOI 10.1002/dvg.1020160106
   Nass SJ, 2000, CANCER RES, V60, P4346
   Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858
   Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369
   Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.3.CO;2-5
   OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477
   Pedersen KB, 2002, BRIT J CANCER, V87, P1281, DOI 10.1038/sj.bjc.6600624
   Prins GS, 2001, REPROD FERT DEVELOP, V13, P241, DOI 10.1071/RD00107
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394
   TOWNSON S, 2003, J BIOL CHEM, V26, P26
NR 30
TC 86
Z9 109
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2003
VL 63
IS 17
BP 5203
EP 5208
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 722XD
UT WOS:000185402600006
PM 14500345
DA 2025-01-12
ER

PT J
AU Jhanwar-Uniyal, M
AF Jhanwar-Uniyal, M
TI BRCA1 in cancer, cell cycle and genomic stability
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE BRCA1; breast; cancer; mutations; methylation; review; DNA; repair; cell
   cycle
ID GENE-EXPRESSION PROFILES; SPORADIC BREAST-CANCER; ESTROGEN-RECEPTOR
   GENE; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; OVARIAN-CANCER; CPG
   METHYLATION; PROMOTER REGION; UBIQUITIN LIGASE; GROWTH ARREST
AB The BRCA1 gene was isolated in 1994; germline mutations of this gene are known to confer susceptibility to breast and ovarian cancer in high-risk families. Since its discovery, several mutations have been identified in this gene; these are scattered throughout the gene, and include insertion and deletion frameshifts, base substitutions, and inferred regulatory mutations. It role in the pathogenesis of breast cancer, which accounts for almost 95%, although unproven to date, cannot be ruled out. The functional inactivation of both copies of this gene in sporadic tumor cells does not follow the traditional mode: the loss of function in BRCA1 is not accompanied by underlying mutation of the gene in tumor cells with loss of heterozygosity for the BRCA1 gene. Several studies now suggest that an alternate mechanism of inactivation, involving promoter hypermethylation that results in reduced expression of the gene, may be common to a significant proportion of sporadic breast and ovarian cancers. BRCA1 as a tumor suppressor plays an important role in maintaining genomic stability. BRCA1 has the ability to interact with numerous proteins and to form complexes that are involved in recognizing and subsequently repairing DNA. BRCA1 contains several functional domains that directly or indirectly interact with a variety of proteins via protein-protein interaction; these include tumor suppressors (BRCA2, p53, Rb and ATM), oncogenes (c-Myc, casein kinase II and E2F), DNA damage repair proteins (RAD50 and RAD51), cell cycle regulators (cyclins and cyclin dependent kinases), transcriptional activators and repressors (RNA polymerase II, RHA, histone deacetylase complex and CtIP), DNA damage-sensing complex and mismatch repair proteins (BRCA1-Associated Surveillance Complex; BASC) and signal transducer and activator of transcription (STAT) among others Formation of foci containing BRCA1 by inherited mutations, or epigenetic mechanisms (promoter methylation) in sporadic cancers leads to a loss of DNA repair ability, disrupts the potential to form complexes with other proteins that are crucial for DNA repair pathways. Thus, BRCA1 plays a significant role in maintaining genomic stability and serves as a tumor suppressor in breast cancer tumorigenesis.
C1 Amer Hlth Fdn, Canc Prevent Ctr, Inst Canc Prevent, Valhalla, NY 10595 USA.
C3 American Health Foundation
RP Amer Hlth Fdn, Canc Prevent Ctr, Inst Canc Prevent, 1 Dana Rd, Valhalla, NY 10595 USA.
EM mjhanwar@ifcp.us
FU NCI NIH HHS [CA 17613] Funding Source: Medline
CR Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866
   Archey WB, 2002, ONCOGENE, V21, P7034, DOI 10.1038/sj.onc.1205844
   Arizti P, 2000, MOL CELL BIOL, V20, P7450, DOI 10.1128/MCB.20.20.7450-7459.2000
   Bahar AY, 2001, CANCER-AM CANCER SOC, V92, P440, DOI 10.1002/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O
   Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1
   Bertucci F, 2002, J NATL CANCER I, V94, P1506, DOI 10.1093/jnci/94.19.1506
   Bird A, 1999, SCIENCE, V286, P2287, DOI 10.1126/science.286.5448.2287
   Brown MA, 1996, ONCOGENE, V12, P2507
   Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9
   Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X
   Catteau A, 1999, BRIT J CANCER, V79, P759, DOI 10.1038/sj.bjc.6690122
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200
   Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2
   Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162
   Deng CX, 2000, BIOESSAYS, V22, P728
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8
   Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   GATEI M, 2003, IN PRESS J BIOL CHEM
   Gayther SA, 1997, AM J HUM GENET, V60, P1239
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009
   HEDENFALK I, 1995, NEW ENGL J MED, V344, P539
   Ivanov EL, 1997, CURR BIOL, V7, pR492, DOI 10.1016/S0960-9822(06)00246-6
   Jensen DE, 1999, CANCER LETT, V143, pS13, DOI 10.1016/S0304-3835(99)90004-6
   Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861
   Jhanwar-Uniyal M., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P562
   JHANWARUNIYAL M, 2003, P AM ASSOC CANC RES, V44, P1132
   Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8
   Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798
   Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0
   KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1
   Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266
   Li CI, 2003, J CLIN ONCOL, V21, P28, DOI 10.1200/JCO.2003.03.088
   Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421
   Li CI, 2003, ARCH INTERN MED, V163, P49, DOI 10.1001/archinte.163.1.49
   Liu Y, 2002, CANCER RES, V62, P6357
   Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364
   MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200
   MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002
   MacLeod MC, 1996, MOL CARCINOGEN, V15, P241, DOI 10.1002/(SICI)1098-2744(199604)15:4<241::AID-MC1>3.0.CO;2-J
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Merajver SD, 1995, CLIN CANCER RES, V1, P539
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177
   Neuhausen SL, 1996, AM J HUM GENET, V58, P271
   Oe T, 2001, DEV BIOL, V229, P250, DOI 10.1006/dbio.2000.9968
   Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1
   Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200
   Olopade Olufunmilayo I., 2003, Cancer, V97, P236, DOI 10.1002/cncr.11019
   Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697
   Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998
   Ramus SJ, 2003, CANCER RES, V63, P417
   Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6
   Rohlfs EM, 2000, HUM GENET, V107, P385, DOI 10.1007/s004390000372
   Ruffner H, 1999, MOL CELL BIOL, V19, P4843
   Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398
   Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000
   Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4
   Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6
   Sobol A, 1996, CANCER RES, V56, P3216
   Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379
   Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446
   STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198
   SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811
   Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837
   Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000
   Venkitaraman AR, 1999, SCIENCE, V286, P1100, DOI 10.1126/science.286.5442.1100
   Venkitaraman AR, 2001, J CELL SCI, V114, P3591
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403
   Wang Y, 2000, GENE DEV, V14, P927
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
   Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799
   Williams RS, 2003, J BIOL CHEM, V278, P2630, DOI 10.1074/jbc.M210019200
   Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430
   Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200
   Xian Ma Y, 2003, ONCOGENE, V22, P10
   Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057
   XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259
   Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837
   Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747
NR 93
TC 51
Z9 60
U1 1
U2 14
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD SEP
PY 2003
VL 8
BP S1107
EP S1117
DI 10.2741/1131
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 719VX
UT WOS:000185226700050
PM 12957814
OA Bronze
DA 2025-01-12
ER

PT J
AU Skotheim, RI
   Abeler, VM
   Nesland, JM
   Fosså, SD
   Holm, R
   Wagner, U
   Florenes, VA
   Aass, N
   Kallioniemi, OP
   Lothe, RA
AF Skotheim, RI
   Abeler, VM
   Nesland, JM
   Fosså, SD
   Holm, R
   Wagner, U
   Florenes, VA
   Aass, N
   Kallioniemi, OP
   Lothe, RA
TI Candidate genes for testicular cancer evaluated by <i>in situ</i>
   protein expression analyses on tissue microarrays
SO NEOPLASIA
LA English
DT Article
DE candidate genes; molecular tumorigenesis; protein expression; testicular
   germ cell tumor; tissue microarray
ID GERM-CELL TUMORS; FOCAL ADHESION KINASE; CYTOGENETIC ANALYSIS;
   FACTOR-RECEPTOR; BREAST-CANCER; D2 EXPRESSION; CYCLIN D2; GRB7;
   ASSOCIATION; CARCINOMA
AB By the use of high-throughput molecular technologies, the number of genes and proteins potentially relevant to testicular germ cell tumor (TGCT) and other diseases will increase rapidly. In a recent transcriptional profiling, we demonstrated the overexpression of GRB7 and JUP in TGCTs, and confirmed the reported overexpression of CCND2. We also have recent evidences for frequent genetic alterations of FHIT and epigenetic alterations of MGMT. To evaluate whether the expression of these genes is related to any clinicopathological variables, we constructed a tissue microarray with 510 testicular tissue cores from 279 patients diagnosed with TGCT, covering various histological subgroups and clinical stages. By immunohistochemistry, we found that JUP, GRB7, and CCND2 proteins were rarely present in normal testis, but frequently expressed at high levels in TGCT. Additionally, all premalignant intratubular germ cell neoplaslas were JUP-immunopositive. MGMT and FHIT were expressed by normal testicular tissues, but at significantly lower frequencies in TGCT. Except for CCND2, the expressions of all markers were significantly associated with various TGCT subtypes. In summary, we have developed a high-throughput tool for the evaluation of TGCT markers, and utilized this to validate five candidate genes whose protein expressions were indeed deregulated in TGCT.
C1 Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.
   Norwegian Radium Hosp, Dept Pathol, Oslo, Norway.
   Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
   Univ Basel, Inst Pathol, Basel, Switzerland.
   NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
   VTT Tech Res Ctr Finland, Med Biotechnol Grp, Turku, Finland.
   Univ Turku, Turku, Finland.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Basel; National Institutes of Health (NIH) - USA; NIH National Human
   Genome Research Institute (NHGRI); VTT Technical Research Center
   Finland; University of Turku
RP Lothe, RA (通讯作者)，Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.
RI Wagner, Uwe/Y-4194-2018; Kallioniemi, Olli/H-5111-2011; Kallioniemi,
   Olli/H-4738-2012; Skotheim, Rolf I./H-6192-2017
OI Kallioniemi, Olli/0000-0002-3231-0332; Lothe, Ragnhild
   A./0000-0002-1693-1032; Skotheim, Rolf I./0000-0002-5609-4048
CR Akiyama N, 1997, CANCER RES, V57, P3548
   ATKIN NB, 1982, LANCET, V2, P1349
   Barker N, 2000, BIOESSAYS, V22, P961
   Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H
   DEMEYTS ER, 2003, APMIS, V111, P267
   Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835
   Greenspan DL, 1997, CANCER RES, V57, P4692
   Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200
   Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425
   Heidenreich A, 1998, CANCER, V83, P1002, DOI 10.1002/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.3.CO;2-F
   HENDRY WF, 1980, BRIT J UROL, V52, P38, DOI 10.1111/j.1464-410X.1980.tb02917.x
   HOFMANN MC, 1993, EUR UROL, V23, P38
   Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119
   Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293
   Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469
   Kauraniemi P, 2001, CANCER RES, V61, P8235
   Keegan K, 1996, ONCOGENE, V12, P1537
   Kolligs FT, 2000, GENE DEV, V14, P1319
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Koul Sanjay, 2002, Mol Cancer, V1, P8, DOI 10.1186/1476-4598-1-8
   Kraggerud SM, 2002, CANCER RES, V62, P512
   Kraggerud SM, 2002, GENE CHROMOSOME CANC, V34, P168, DOI 10.1002/gcc.10058
   Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516
   Megason SG, 2002, DEVELOPMENT, V129, P2087
   Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7
   MSOTOFI FK, 1998, WHO INT HISTOLOGICAL
   Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607
   RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405
   RODRIGUEZ E, 1992, CANCER RES, V52, P2285
   Saito T, 2000, UROL INT, V65, P140, DOI 10.1159/000064859
   Schmidt BA, 2001, CANCER RES, V61, P4214
   Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0
   SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x
   Skotheim RI, 2003, APMIS, V111, P136, DOI 10.1034/j.1600-0463.2003.11101181.x
   Skotheim RI, 2002, CANCER RES, V62, P2359
   Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488
   Smith-Sorensen B, 2002, ONCOGENE, V21, P8878, DOI 10.1038/sj.onc.1205978
   STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x
   SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J
   Tanaka S, 1997, CANCER RES, V57, P28
   Thömmes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211
   Torhorst J, 2001, AM J PATHOL, V159, P2249, DOI 10.1016/S0002-9440(10)63075-1
   Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727
   Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942
NR 44
TC 41
Z9 42
U1 0
U2 3
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
   USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD SEP-OCT
PY 2003
VL 5
IS 5
BP 397
EP 404
DI 10.1016/S1476-5586(03)80042-8
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 745ZW
UT WOS:000186722400003
PM 14670177
OA gold, Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU Fitzgerald, M
   Oshiro, M
   Holtan, N
   Krager, K
   Cullen, JJ
   Futscher, BW
   Domann, FE
AF Fitzgerald, M
   Oshiro, M
   Holtan, N
   Krager, K
   Cullen, JJ
   Futscher, BW
   Domann, FE
TI Human pancreatic carcinoma cells activate maspin expression through loss
   of epigenetic control
SO NEOPLASIA
LA English
DT Article
DE histone acetylation; DNA methylation; tumor suppressor gene; cancer;
   gene expression
ID ABERRANT CYTOSINE METHYLATION; SUPPRESSOR GENE MASPIN; DNA METHYLATION;
   HISTONE DEACETYLATION; BREAST-CANCER; HYPERMETHYLATION; ADENOCARCINOMA;
   INHIBITOR; MAMMARY; SERPIN
AB The maspin gene is not expressed in normal human pancreas, but its expression is acquired during human pancreatic carcinogenesis. In other normal human cells and their malignant counterparts, maspin expression is controlled through the epigenetic state of its promoter. In studies presented herein, we used bisulfite genomic sequencing and chromatin immunoprecipitation studies to show that maspin-negative pancreas cells have a methylated maspin promoter, and that the associated H3 and H4 histones are hypoacetylated. In contrast to normal pancreas, four of six human pancreatic carcinoma cell lines investigated displayed activation of maspin expression. This activation of maspin expression in pancreatic carcinoma cells was linked to demethylated promoters and hyperacetylation of the associated H3 and H4 histones. In addition, 5-aza-2'-deoxycytidine treatments activated maspin expression in the two maspin-negative pancreatic carcinoma cell lines, suggesting a causal role for cytosine methylation in the maintenance of a transcriptionally silent maspin gene. Thus, human pancreatic carcinoma cells acquire maspin expression through epigenetic derepression of the maspin locus, and in so doing appear to co-opt a normal cellular mechanism for the regulation of this gene.
C1 Univ Iowa, Med Labs B180, Free Radical & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA 52242 USA.
   Univ Arizona, Bone Marrow Transplant Program, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA.
   Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA.
   Univ Iowa, Dept Surg, Iowa City, IA 52242 USA.
   Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Arizona; Arizona Center Cancer Care;
   University of Arizona; University of Iowa; University of Iowa
RP Domann, FE (通讯作者)，Univ Iowa, Med Labs B180, Free Radical & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA 52242 USA.
OI Domann, Frederick/0000-0002-0489-2179; Cullen,
   Joseph/0000-0002-2222-1328
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Domann FE, 2003, J UROLOGY, V169, P1162, DOI 10.1097/01.ju.0000058368.53821.68
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Logsdon CD, 2003, CANCER RES, V63, P2649
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Maass N, 2001, CLIN CANCER RES, V7, P812
   Maass N, 2001, J PATHOL, V195, P321
   Maass N, 2002, J PATHOL, V197, P273, DOI 10.1002/path.1103
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135
   Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315
   Sager R, 1996, CURR TOP MICROBIOL, V213, P51
   Seftor REB, 1998, CANCER RES, V58, P5681
   Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669
   SHENG SJ, 1994, J BIOL CHEM, V269, P30988
   Son HJ, 2002, PATHOL INT, V52, P508, DOI 10.1046/j.1440-1827.2002.01381.x
   Sood AK, 2002, CLIN CANCER RES, V8, P2924
   Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhang M, 1997, CELL GROWTH DIFFER, V8, P179
   Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 33
TC 41
Z9 47
U1 0
U2 1
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
   USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD SEP-OCT
PY 2003
VL 5
IS 5
BP 427
EP 436
DI 10.1016/S1476-5586(03)80045-3
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 745ZW
UT WOS:000186722400006
PM 14670180
OA Green Accepted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Sarrió, D
   Moreno-Bueno, G
   Hardisson, D
   Sánchez-Estévez, C
   Guo, MZ
   Herman, JG
   Gamallo, C
   Esteller, M
   Palacios, J
AF Sarrió, D
   Moreno-Bueno, G
   Hardisson, D
   Sánchez-Estévez, C
   Guo, MZ
   Herman, JG
   Gamallo, C
   Esteller, M
   Palacios, J
TI Epigenetic and genetic alterations of <i>APC</i> and <i>CDH1</i> genes
   in lobular breast cancer:: Relationships with abnormal E-cadherin and
   catenin expression and microsatellite instability
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE lobular breast cancer; E-cadherin; beta-catenin; APC; mutation;
   methylation; loss of heterozygosity; microsatellite instability
ID ADENOMATOUS-POLYPOSIS-COLI; CARCINOMA IN-SITU; ISLAND METHYLATOR
   PHENOTYPE; INVASION-SUPPRESSOR GENE; FAMILIAL GASTRIC-CANCER; 5' CPG
   ISLAND; ABERRANT METHYLATION; ENDOMETRIAL CANCER; COLORECTAL-CANCER;
   HIGH-FREQUENCY
AB The causes and functional consequences of E-cadherin (E-CD) loss in breast cancer are poorly understood. E-CD loss might act in concert with alterations in the APC/beta-catenin pathway to permit oncogenic beta-catenin signaling. To test this hypothesis, we have analyzed the presence of genetic and epigenetic alterations affecting E-CD (CDHI), APC and beta-catenin (CTNNBI) genes and the immunohistochemical expression of E-CD, beta- and gamma-catenin in a series of 46 infiltrating lobular breast carcinomas (ILCs). Since 80% of ILCs featured complete loss of E-CD expression, we analyzed the molecular alterations responsible for E-CD inactivation in these tumors. We found that 10 of 46 (22%) cases harbored mutations in CDHI, including 1 case with 2 different mutations (1 of which was germline). CDHI was also inactivated by loss of heterozygosity (LOH; 30/41, 73%) and promoter hypermethylation (19/46, 41%). Interestingly, LOH and mutations were also detected in the corresponding in situ lesions of the ILCs, implying that these alterations are early events in lobular cancer tumorogenesis. Additionally, the presence of a polymorphism in the CDHI promoter was found to be inversely correlated with CDHI mutations, but not with E-CD levels. We next examined whether alterations in the APC/beta-catenin pathway also occurred in the same series of ILCs. Although no CTNNBI or APC mutations were detected, promoter methylation (25/46, 52%) and LOH (7/30, 23%) of APC were found. Moreover, methylation of APC and CDHI occurred concordantly. However, beta- and gamma-catenin were severely reduced or absent in 90% of these tumors, implying that alterations in CDHI and APC genes do not promote beta-catenin accumulation in ILC. These molecular alterations were not associated with microsatellite instability. In summary, several different mechanisms (mutations, LOH, methylation) are involved in the frequent CDHI inactivation in invasive and in situ lobular breast cancer. The same tumors also show genetic and epigenetic alterations of APC gene. However, altered CDHI and APC genes do not promote beta-catenin accumulation in this tumor type. (C) 2003 Wiley-Liss, Inc.
C1 Ctr Nacl Invest Oncol, Mol Pathol Program, Lab Breast & Gynecol Canc, Madrid 28029, Spain.
   Hosp Univ La Paz, Dept Pathol, Madrid, Spain.
   Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA.
   Hosp Univ Princesa, Serv Pathol, Madrid, Spain.
   Ctr Nacl Invest Oncol, Mol Pathol Program, Canc Epigenet Grp, Madrid, Spain.
C3 Hospital Universitario La Paz; Johns Hopkins University; Johns Hopkins
   Medicine; Hospital de La Princesa
RP Palacios, J (通讯作者)，Ctr Nacl Invest Oncol, Mol Pathol Program, Lab Breast & Gynecol Canc, C Melchor Fernandez Almagro 3, Madrid 28029, Spain.
RI Zhang, Guojie/B-6188-2014; SARRIO, DAVID/Y-8903-2019; Palacios,
   Jose/AAV-3765-2020; Farre, Xavier/M-9768-2014; Hardisson,
   David/E-2832-2010; Esteller, Manel/L-5956-2014; Moreno-Bueno,
   Gema/K-9354-2016
OI Sarrio, David/0000-0003-4886-8290; Farre, Xavier/0000-0001-8702-4643;
   Hardisson, David/0000-0002-2183-3699; Esteller,
   Manel/0000-0003-4490-6093; Moreno-Bueno, Gema/0000-0002-5030-6687
CR ALDAZ CM, 1995, CANCER RES, V55, P3976
   BAKER N, 2000, BIOESSAYS, V22, P961
   Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D
   Berx G, 1996, ONCOGENE, V13, P1919
   Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321
   Candidus S, 1996, CANCER RES, V56, P49
   Canzian F, 1996, CANCER RES, V56, P3331
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7
   Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   DeLeeuw WJF, 1997, J PATHOL, V183, P404, DOI 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9
   GAMALLO C, 1993, AM J PATHOL, V142, P983
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huiping C, 1999, BRIT J CANCER, V81, P1103, DOI 10.1038/sj.bjc.6690815
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jönsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2
   Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2
   Lei HX, 2002, INT J CANCER, V98, P199, DOI 10.1002/ijc.10176
   Li LC, 2000, CANCER RES, V60, P873
   Machado JC, 1999, LAB INVEST, V79, P459
   MEDEIROS AC, 1994, CANCER EPIDEM BIOMAR, V3, P331
   MOLL R, 1993, AM J PATHOL, V143, P1731
   Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924
   Nass SJ, 2000, CANCER RES, V60, P4346
   Pharoah PDP, 2002, INT J CANCER, V101, P196, DOI 10.1002/ijc.10590
   Porter TR, 2002, ONCOGENE, V21, P1928, DOI 10.1038/sj.onc.1205245
   Rahman N, 2000, BRIT J CANCER, V82, P568
   Salahshor S, 2001, BREAST CANCER RES, V3, P199, DOI 10.1186/bcr295
   Shen CY, 2000, CANCER RES, V60, P3884
   Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Toyota M, 2000, J GASTROENTEROL, V35, P727, DOI 10.1007/s005350070030
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, CANCER RES, V59, P5438
   van de Wetering M, 2001, CANCER RES, V61, P278
   VERHAGE BA, 2000, INT J CANCER, V100, P683
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Vos CBJ, 1997, BRIT J CANCER, V76, P1131, DOI 10.1038/bjc.1997.523
   Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x
   Wu MS, 2002, CANCER-AM CANCER SOC, V94, P1443, DOI 10.1002/cncr.10371
   Yamamoto H, 2002, GENE CHROMOSOME CANC, V33, P322, DOI 10.1002/gcc.10010
   Yang SZ, 2001, INT J ONCOL, V18, P541
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Zysman M, 2002, CANCER RES, V62, P3663
NR 53
TC 170
Z9 188
U1 0
U2 15
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 20
PY 2003
VL 106
IS 2
BP 208
EP 215
DI 10.1002/ijc.11197
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 700BE
UT WOS:000184092100010
PM 12800196
DA 2025-01-12
ER

PT J
AU Villar-Garea, A
   Fraga, MF
   Espada, J
   Esteller, M
AF Villar-Garea, A
   Fraga, MF
   Espada, J
   Esteller, M
TI Procaine is a DNA-demethylating agent with growth-inhibitory effects in
   human cancer cells
SO CANCER RESEARCH
LA English
DT Article
ID ACID RECEPTOR-BETA; CPG ISLAND HYPERMETHYLATION; LUPUS-INDUCING DRUGS;
   PROMOTER HYPERMETHYLATION; LOCAL-ANESTHETICS; BREAST-CANCER;
   CYTO-TOXICITY; METHYLATION; GENE; METHYLTRANSFERASE
AB Methylation-associated silencing of tumor suppressor genes is recognized as being a molecular hallmark of human cancer. Unlike genetic alterations, changes in DNA methylation are potentially reversible. This possibility has attracted considerable attention from a therapeutics standpoint. Nucleoside-analogue inhibitors of DNA methyltransferases, such as 5-aza-2'-deoxycytidine, are able to demethylate DNA and restore silenced gene expression. Unfortunately, the clinical utility of these compounds has not yet been fully realized, mainly because of their side effects. A few non-nucleoside inhibitors of DNA methyltransferases have been reported, including the anti-arrhythmia drug procainamide. Following this need to rind new demethylating agents, we have tested the potential use of procaine, an anesthetic drug related to procainamide. Using the MCF-7 breast cancer cell line, we have found that procaine is a DNA-demethylating agent that produces a 40% reduction in 5-methylcytosine DNA content as determined by high-performance capillary electrophoresis or total DNA enzyme digestion. Procaine can also demethylate densely hypermethylated CpG islands, such as those located in the promoter region of the RARbeta2 gene, restoring gene expression of epigenetically silenced genes. This property may be explained by our finding that procaine binds to CpG-enriched DNA. Finally, procaine also has growth-inhibitory effects in these cancer cells, causing mitotic arrest. Thus, procaine is a promising candidate agent for future cancer therapies based on epigeneties.
C1 Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Mol Pathol Program, Madrid 28029, Spain.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO)
RP Esteller, M (通讯作者)，Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Mol Pathol Program, 3rd Floor,Melchor Fernandez Almagro 3, Madrid 28029, Spain.
RI Espada, Jesús/AAA-3198-2019; Esteller, Manel/L-5956-2014; Fraga,
   Mario/H-7824-2017
OI Espada, Jesus/0000-0002-4202-4938; Villar Garea,
   Ana/0000-0001-8960-1635; Esteller, Manel/0000-0003-4490-6093; Fraga,
   Mario/0000-0001-8450-2603
CR Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   BOLOS V, 2002, J CELL SCI, P499
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CHLEBOWSKI RT, 1982, CANCER TREAT REP, V66, P121
   CORNACCHIA E, 1988, J IMMUNOL, V140, P2197
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   ESPOSITO M, 1990, JNCI-J NATL CANCER I, V82, P677, DOI 10.1093/jnci/82.8.677
   Esteller M, 2001, CANCER RES, V61, P2816
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2002, SCIENCE, V297, P1807
   Esteller M, 2002, CANCER RES, V62, P5902
   Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249
   Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11<1677::AID-ELPS1677>3.0.CO;2-Z
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HIDVEGI EJ, 1980, ONCOLOGY-BASEL, V37, P360, DOI 10.1159/000225470
   JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   JONES PA, 1985, PHARMACOL THERAPEUT, V28, P17, DOI 10.1016/0163-7258(85)90080-4
   Lin XH, 2001, CANCER RES, V61, P8611
   MIZUNO S, 1982, CANCER RES, V42, P4726
   OOHARA I, 1987, J MOL BIOL, V196, P399, DOI 10.1016/0022-2836(87)90700-5
   Paz MF, 2003, CANCER RES, V63, P1114
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   SCHEINBART LS, 1991, J RHEUMATOL, V18, P530
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   THOMAS TJ, 1986, ARTHRITIS RHEUM-US, V29, P638, DOI 10.1002/art.1780290508
   Viale M, 1998, ANTI-CANCER DRUG, V9, P457, DOI 10.1097/00001813-199806000-00013
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   YAU TM, 1980, BRIT J RADIOL, V53, P687, DOI 10.1259/0007-1285-53-631-687
   ZACHARIAS W, 1990, ARTHRITIS RHEUM-US, V33, P366, DOI 10.1002/art.1780330309
NR 36
TC 274
Z9 314
U1 0
U2 21
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2003
VL 63
IS 16
BP 4984
EP 4989
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 715AM
UT WOS:000184948400036
PM 12941824
DA 2025-01-12
ER

PT J
AU Jerónimo, C
   Costa, I
   Martins, MC
   Monteiro, P
   Lisboa, S
   Palmeira, C
   Henrique, R
   Teixeira, MR
   Lopes, C
AF Jerónimo, C
   Costa, I
   Martins, MC
   Monteiro, P
   Lisboa, S
   Palmeira, C
   Henrique, R
   Teixeira, MR
   Lopes, C
TI Detection of gene promoter hypermethylation in fine needle washings from
   breast lesions
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID E-CADHERIN EXPRESSION; DNA METHYLATION; LAVAGE FLUID; CANCER;
   ASPIRATION; CYTOLOGY; CELLS; BENIGN; HEAD; P53
AB Purpose: Fine needle aspiration (FNA) is used widely in diagnostic assessment of breast lesions. However, cytomorphological evaluation depends heavily on the proficiency of cytopathologists. Because epigenetic alterations are frequent and specific enough to potentially augment the accuracy of malignant disease detection, we tested whether hypermethylation analysis of a panel of genes would distinguish benign from malignant breast FNA washings.
   Experimental Design: FNA washings were collected from 123 female patients harboring suspicious mammary lesions. Sodium bisulrite-modified DNA was amplified by methyl-specific PCR (MSP) for CDH1, GSTP1, BRCA1, and RARbeta to detect gene promoter CpG island methylation. Paired samples of 27 breast cancer tissue and 7 fibroadenomas and 12 samples of normal breast tissue, collected post-operatively, were also analyzed. MSP results were compared with conventional cytomorphological diagnosis.
   Results: FNAs were cytomorphologically diagnosed as benign (25 cases), malignant (76 cases), suspicious for malignancy (6 cases), and unsatisfactory (16 cases). Percentages of methylated CDH1, GSTP1, BRCA1, and RARbeta in FNA washings were 60, 52, 32, and 16%, and 65.8, 57.9, 39.5, and 34.2% for benign and malignant lesions, respectively. These differences did not reach statistical significance. In all of the paired benign lesions tested, there was absolute concordance. Sixty-seven percent (18 of 27) of FNA washings displayed hypermethylation patterns identical to malignant paired tissue. No methylation was found in the normal breast samples for any of the genes.
   Conclusions: Detection of gene hypermethylation in FNA washings by MSP analysis is feasible, but the selected gene panel does not discriminate between benign and malignant breast lesions.
C1 Portuguese Oncol Inst, Dept Genet, P-4200072 Oporto, Portugal.
   Portuguese Oncol Inst, Dept Pathol, P-4200072 Oporto, Portugal.
C3 Portuguese Institute of Oncology; Portuguese Institute of Oncology
EM cjeronimo@hotmail.com
RI ; Henrique, Rui/I-2757-2013; Jeronimo, Carmen/H-3284-2013; Rodrigues
   Teixeira, Manuel Antonio/E-4885-2011
OI Palmeira, Carlos/0000-0002-4833-2202; Lisboa,
   Susana/0000-0002-9773-331X; Monteiro, Paula/0000-0002-3482-2307;
   Henrique, Rui/0000-0003-3171-4666; Jeronimo, Carmen/0000-0003-4186-5345;
   Rodrigues Teixeira, Manuel Antonio/0000-0002-4896-5982
CR Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332
   BARROWS GH, 1986, CANCER-AM CANCER SOC, V58, P1493, DOI 10.1002/1097-0142(19861001)58:7<1493::AID-CNCR2820580720>3.0.CO;2-F
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   GARDECKI TIM, 1980, LANCET, V2, P790
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Gudlaugsdottir S, 2000, DIAGN CYTOPATHOL, V22, P268, DOI 10.1002/(SICI)1097-0339(200005)22:5<268::AID-DC2>3.0.CO;2-X
   Hamill J, 2002, ACTA CYTOL, V46, P19, DOI 10.1159/000326710
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   JERONIMO C, 2001, J NCI, V93, P1474
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   LEE KR, 1987, ACTA CYTOL, V31, P281
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li Z, 2002, CANCER RES, V62, P1000
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Rohan TE, 1998, JNCI-J NATL CANCER I, V90, P1262, DOI 10.1093/jnci/90.17.1262
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Saxe A, 2001, AM J SURG, V182, P369, DOI 10.1016/S0002-9610(01)00739-5
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Spafford MF, 2001, CLIN CANCER RES, V7, P607
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Widschwendter M, 2002, CLIN CANCER RES, V8, P17
NR 28
TC 56
Z9 67
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 15
PY 2003
VL 9
IS 9
BP 3413
EP 3417
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 718XW
UT WOS:000185172600025
PM 12960130
DA 2025-01-12
ER

PT J
AU Palmisano, WA
   Crume, KP
   Grimes, MJ
   Winters, SA
   Toyota, M
   Esteller, M
   Joste, N
   Baylin, SB
   Belinsky, SA
AF Palmisano, WA
   Crume, KP
   Grimes, MJ
   Winters, SA
   Toyota, M
   Esteller, M
   Joste, N
   Baylin, SB
   Belinsky, SA
TI Aberrant promoter methylation of the transcription factor genes PAX5 α
   and β in human cancers
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; BREAST-CANCER; COLORECTAL-CANCER; DNA
   METHYLATION; CPG ISLANDS; 5'-CPG ISLAND; LUNG-CANCER; FACTOR BSAP;
   IDENTIFICATION; HYPERMETHYLATION
AB Aberrant methylation of 5'CpG islands is a key epigenetic event in many human cancers. A PCR-based technique of methylated CpG island amplification followed by representational difference analysis was used to identify genes methylated in cancer. Two of the CpG islands identified mapped to the 5' untranslated region of the PAX5 alpha and beta genes. These genes, located on chromosome 9p13, are transcribed from two distinct promoters and form two alternative first exons that are subsequently spliced to the common exons 2-10. The resulting splice variants encode two distinct transcription factors important in cell differentiation and embryonic development. Examination of the methylation status of each gene using methylation-specific PCR revealed that both genes are methylated in similar to65% of breast and lung tumors. Bisulfite sequencing revealed dense methylation patterns within each 5'CpG island, strongly correlating with transcriptional silencing. Expression in cell lines with dense methylation of either the PAX5 alpha or beta promoter region was restored after treatment with the demethylating agent 5-Aza-2'-deoxycytidine. The PAX5 beta gene encodes for the transcription factor B cell-specific activating protein that, in turn, directly regulates CD19, a gene shown to negatively control cell growth. A strong association was observed between PAX5 beta methylation and loss of expression of the CD19 gene demonstrating that inactivation of the PAX5 beta gene likely contributes to neoplastic development by inhibiting growth regulation through effects on CD19 gene expression. Recent studies have demonstrated the importance of PAX5 gene alterations in human cancer. Our results are the first to identify aberrant promoter methylation as a common mechanism for dysregulation of these genes in solid tumors.
C1 Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM 87108 USA.
   Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.
   Spanish Natl Canc Ctr, Mol Pathol Program, Canc Epigenet Lab, Majadahonda 28220, Spain.
   Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA.
   Johns Hopkins Univ, Inst Med, Johns Hopkins Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Lovelace Respiratory Research Institute; Sapporo Medical University;
   Centro Nacional de Investigaciones Oncologicas (CNIO); University of New
   Mexico; Johns Hopkins University; Johns Hopkins Medicine
RP Belinsky, SA (通讯作者)，Lovelace Resp Res Inst, Lung Canc Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.
RI Esteller, Manel/L-5956-2014
OI Esteller, Manel/0000-0003-4490-6093
FU NCI NIH HHS [P50 CA 58184] Funding Source: Medline; NIEHS NIH HHS [R01
   ES 08801] Funding Source: Medline
CR ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589
   Antequera F., 1993, Experientia Supplementum (Basel), V64, P169
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Belinsky SA, 2002, CANCER RES, V62, P2370
   BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704
   Brock GJR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.24.e123
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129
   Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Danbara M, 2002, MOL IMMUNOL, V38, P1161, DOI 10.1016/S0161-5890(02)00003-2
   Du Y, 2001, CANCER RES, V61, P8094
   Esteller M, 1999, CANCER RES, V59, P67
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Gonzalgo ML, 1997, CANCER RES, V57, P594
   Huang THM, 1997, CANCER RES, V57, P1030
   Issa JPJ, 1997, CANCER RES, V57, P1678
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KOCH WM, 1994, ARCH OTOLARYNGOL, V120, P943
   KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662
   LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897
   Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X
   Schafer BW, 1998, GEN PHYSIOL BIOPHYS, V17, P211
   Silva JM, 2002, ANN SURG ONCOL, V9, P71, DOI 10.1245/aso.2002.9.1.71
   STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292
   Stuart ET, 1995, ADV GENET, V33, P255, DOI 10.1016/S0065-2660(08)60336-3
   STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyota M, 1999, CANCER RES, V59, P2307
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P4535
   Ueki T, 2001, CANCER RES, V61, P8540
   URBANEK P, 1994, CELL, V79, P751
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Yan PS, 2001, CANCER RES, V61, P8375
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
   Zou HZ, 2002, CLIN CANCER RES, V8, P188
NR 41
TC 89
Z9 125
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2003
VL 63
IS 15
BP 4620
EP 4625
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 708JB
UT WOS:000184562500049
PM 12907641
DA 2025-01-12
ER

PT J
AU Modena, P
   Testi, MA
   Facchinetti, F
   Mezzanzanica, D
   Radice, MT
   Pilotti, S
   Sozzi, G
AF Modena, P
   Testi, MA
   Facchinetti, F
   Mezzanzanica, D
   Radice, MT
   Pilotti, S
   Sozzi, G
TI UQCRH gene encoding mitochondrial Hinge protein is interrupted by a
   translocation in a soft-tissue sarcoma and epigenetically inactivated in
   some cancer cell lines
SO ONCOGENE
LA English
DT Article
DE EWS; sarcoma; ovarian carcinoma; hinge protein; mitochondrial complex
   III
ID CYTOCHROME-C OXIDOREDUCTASE; 17-KDA SUBUNIT-VI; YEAST UBIQUINOL;
   COMPLEX; EXPRESSION; MUTATIONS; DELETION; SITE
AB We previously reported the identification of a novel zinc-finger gene, designated ZSG, fused to Ewing sarcoma gene (EWS) by a submicroscopic paracentric inversion of 22q12 in a small round cell sarcoma presenting a translocation t(1;22)(p34;q12). We report here the molecular cloning and characterization of the breakpoint in 1p34, which encompasses the gene coding for mitochondrial Hinge protein ubiquinol-cytochrome C reductase hinge gene (UQCRH). All the three breakpoints, two on 22q12 and one in 1p34, interrupt different genes: EWS, ZSG and UQCRH. We determined the genomic structure of UQCRH, characterized its splicing variants and identified a transcribed processed pseudogene. The analysis of UQCRH expression in normal tissues and cancer cell lines revealed absent expression of UQCRH in two ovarian and one breast cancer cell lines and reduced expression in a further breast carcinoma cell line. CpG island methylation upstream exon 1 was detected in all the three cell lines with absent expression. Moreover, treatment with demethylating agent 5-azacytidine restored UQCRH expression in OAW42 ovarian cancer cells. These data provide preliminary evidence of the inactivation of UQCRH gene in cancer either by structural rearrangements or epigenetic mechanisms.
C1 Ist Nazl Tumori, Unit Mol Cytogenet, I-20133 Milan, Italy.
   Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy.
   Ist Nazl Tumori, Unit Mol Therapies, I-20133 Milan, Italy.
C3 Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS
   Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale
   Tumori Milan
RP Sozzi, G (通讯作者)，Ist Nazl Tumori, Unit Mol Cytogenet, Via G Venezian 1, I-20133 Milan, Italy.
RI Modena, Piergiorgio/KIL-6918-2024; Sozzi, Gabriella/G-8259-2011; Testi,
   Maria Adele/D-6994-2017; Mezzanzanica, Delia/C-2607-2017
OI Sozzi, Gabriella/0000-0001-9360-6914; Testi, Maria
   Adele/0000-0002-9462-0336; Mezzanzanica, Delia/0000-0002-9664-6871
CR Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598
   Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848
   CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323
   Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64
   Jones DH, 1997, BIOTECHNIQUES, V23, P132, DOI 10.2144/97231rr01
   KIM CH, 1983, J BIOL CHEM, V258, P3543
   KIM CH, 1989, BIOCHEMISTRY-US, V28, P1439, DOI 10.1021/bi00430a002
   Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010
   LIU AY, 1993, CANCER RES, V53, P2460
   Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762
   Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413
   MUKAI K, 1985, J BIOCHEM, V98, P1417, DOI 10.1093/oxfordjournals.jbchem.a135409
   OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2
   Okazaki M, 1998, BIOCHEM BIOPH RES CO, V243, P131, DOI 10.1006/bbrc.1997.7979
   Rustin P, 2002, NAT GENET, V30, P352, DOI 10.1038/ng0402-352
   Santiard-Baron D, 1999, EXP NEUROL, V158, P206, DOI 10.1006/exnr.1999.7076
   Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439
   SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X
   SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x
   Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849
NR 20
TC 18
Z9 24
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JUL 17
PY 2003
VL 22
IS 29
BP 4586
EP 4593
DI 10.1038/sj.onc.1206472
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 699JX
UT WOS:000184054700015
PM 12881716
OA Bronze
DA 2025-01-12
ER

PT J
AU Yuan, JH
   Luo, RZ
   Fujii, S
   Wang, L
   Hu, W
   Andreeff, M
   Pan, Y
   Kadota, M
   Oshimura, M
   Sahin, AA
   Issa, JP
   Bast, RC
   Yu, YH
AF Yuan, JH
   Luo, RZ
   Fujii, S
   Wang, L
   Hu, W
   Andreeff, M
   Pan, Y
   Kadota, M
   Oshimura, M
   Sahin, AA
   Issa, JP
   Bast, RC
   Yu, YH
TI Aberrant methylation and silencing of <i>ARHI</i>, an imprinted tumor
   suppressor gene in which the function is lost in breast cancers
SO CANCER RESEARCH
LA English
DT Article
ID DE-NOVO METHYLATION; DNA METHYLATION; BRCA1 PROMOTER; CPG ISLAND;
   OVARIAN; HYPERMETHYLATION; EPIGENETICS; EXPRESSION; REPRESSION;
   CARCINOMA
AB ARHI is a maternally imprinted tumor suppressor gene that maps to a site on chromosome 1p31 where loss of heterozygosity has been observed in 40% of human breast and ovarian cancers. ARHI is expressed in normal ovarian and breast epithelial cells, but ARHI expression is lost in a majority of ovarian and breast cancers. Expression of ARHI from the paternal allele can be down-regulated by multiple mechanisms in addition to loss of heterozygosity. This article explores the role of DNA methylation in silencing ARHI expression. There are three CpG islands in the ARHI gene. CpG islands I and II are located in the promoter region, whereas CpG island III is located in the coding region. Consistent with imprinting, we have found that all three CpG islands were partially methylated in normal human breast epithelial cells. Additional confirmation of imprinting has been obtained by studying DNA methylation and ARHI expression in murine A9 cells that carry either the maternal or the paternal copy of human chromosome 1. All three CpG islands were methylated, and ARHI was not expressed in A9 cells that contained the maternal allele. Conversely, CpG islands were not methylated and ARHI was expressed in A9 cells that contained the paternal allele of human chromosome 1. Aberrant methylation was found in several breast cancer cell lines that exhibited decreased ARHI expression. Hypermethylation was detected in 67% (6 of 9) of breast cancer cell lines at CpG island I, 33% (3 of 9) at CpG island II, and 56% (5 of 9) at CpG island III. Hypomethylation was observed in 44% (4 of 9) of breast cancer cell lines at CpG island II. When methylation of CpG islands was studied in 20 surgical specimens, hypermethylation was not observed in CpG island 1, but 3 of 20 cases exhibited hypermethylation in CpG island II (15%), and 4 of 20 cases had hypermethylation in CpG island III (20%). Treatment with 5-aza-2'-deoxycytidine, a methyltransferase inhibitor, could reverse aberrant hypermethylation of CpG island 1, 11 and Ill and partially restore ARHI expression in some, but not all of the cell lines. Treatment with 5-aza-2'-deoxycytidine partially reactivated ARHI expression in cell lines with hypermethylation of CpG islands I and 11 but not in cell lines with partial methylation or hypomethylation of these CpG islands. To test the impact of CpG island methylation on ARHI promoter activity more directly, constructs were prepared with the ARHI promoter linked to a luciferase reporter and transfected into SKBr3 and human embryo kidney 293 cells. Methylation of the entire construct destroyed promoter activity. Selective methylation of CpG island II alone or in combination with CpG island I also abolished ARHI promoter activity. Methylation of CpG I alone partially inhibited promoter activity of ARHI. Thus, hypermethylation of CpG island II in the promoter region of ARHI is associated with the complete loss of ARHI expression in breast cancer cells. Other epigenetic modifications such as hypermethylation in CpG island III may also contribute to the loss of ARHI expression.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   Tottori Univ, Tottori 6838503, Japan.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; Tottori University
RP Yu, YH (通讯作者)，Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 354, Houston, TX 77030 USA.
RI Kadota, Mitsutaka/AAF-2652-2019; Bast, Robert/E-6585-2011
OI Yuan, Jiuhong/0000-0002-0991-1463; Bast, Robert/0000-0003-4621-8462;
   Kadota, Mitsutaka/0000-0002-1674-6697; Issa,
   Jean-Pierre/0000-0003-2258-5030
FU NCI NIH HHS [CA 64602, CA 80957] Funding Source: Medline
CR Bao JJ, 2002, CANCER RES, V62, P7264
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Dong SM, 2001, CLIN CANCER RES, V7, P1982
   Inoue J, 2001, J HUM GENET, V46, P137, DOI 10.1007/s100380170101
   Jones PA, 1996, CANCER RES, V56, P2463
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134
   Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1
   Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165
   Luo RZ, 2001, BBA-GENE STRUCT EXPR, V1519, P216, DOI 10.1016/S0167-4781(01)00226-3
   Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034
   Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465
   OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0
   Pedersen IS, 1999, CANCER RES, V59, P5449
   Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7
   Scelfo RAM, 2002, ONCOGENE, V21, P2564, DOI 10.1038/sj.onc.1205336
   Song SH, 2001, CANCER RES, V61, P4628
   STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   WANG L, 2003, IN PRESS CLIN CANC R
   Yoshioka H, 2001, J HUM GENET, V46, P626, DOI 10.1007/s100380170013
   Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214
NR 28
TC 80
Z9 91
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2003
VL 63
IS 14
BP 4174
EP 4180
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 705DE
UT WOS:000184379800053
PM 12874023
DA 2025-01-12
ER

PT J
AU Chen, CM
   Chen, HL
   Hsiau, THC
   Hsiau, AHA
   Shi, HD
   Brock, GJR
   Wei, SH
   Caldwell, CW
   Yan, PS
   Huang, THM
AF Chen, CM
   Chen, HL
   Hsiau, THC
   Hsiau, AHA
   Shi, HD
   Brock, GJR
   Wei, SH
   Caldwell, CW
   Yan, PS
   Huang, THM
TI Methylation target array for rapid analysis of CpG island hype rmethyl
   ation in multiple tissue genomes
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; DNA METHYLATION;
   HYPERMETHYLATION; EXPRESSION
AB Hypermethylation of multiple CpG islands is a common event in cancer. To assess the prognostic values of this epigenetic alteration, we developed Methylation Target Array (MTA), derived from the concept of tissue microarray, for simultaneous analysis of DNA hypermethylation in hundreds of tissue genomes. in NITA, linker-ligated CpG island fragments were digested with methylation-sensitive endonucleases and amplified with flanking primers. A panel of 468 NITA amplicons, which represented the whole repertoire of methylated CpG islands in 93 breast tumors, 20 normal breast tissues, and 4 breast cancer cell lines, were arrayed on nylon membrane for probe hybridization. Positive hybridization signals detected in tumor amplicons, but not in normal amplicons, were indicative of aberrant hypermethylation in tumor samples. This is attributed to aberrant sites that were protected from methylation-sensitive restriction and were amplified by PCR in tumor samples, while the same sites were restricted and could not be amplified in normal samples. Hypermethylation frequencies of the 10 genes tested in breast tumors and cancer cell lines were 60% for GPC3, 58% for RASSF1A, 32% for 3OST3B, 30% for HOXA5, 28% for uPA, 25% for WT1, 23% for BRCA1, 9% for DAPK1, and 0% for KL. Furthermore, hypermethylation of 5 to 7 loci of these genes was significantly correlated with hormone receptor status, clinical stages, and ages at diagnosis of the patients analyzed. This novel approach thus provides an additional avenue for assessing clinicopathological consequences of DNA hypermethylation in breast cancer.
C1 Univ Missouri, Dept Pathol & Anat Sci, Ellis Fischel Canc Ctr, Columbia, MO 65203 USA.
   Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan.
   Natl Chung Hsing Univ, Inst Biomed, Taichung, Taiwan.
   Univ Glasgow, Div Mol Genet, Glasgow, Lanark, Scotland.
   Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland.
C3 University of Missouri System; University of Missouri Columbia; National
   Chung Hsing University; National Chung Hsing University; University of
   Glasgow; University of Glasgow
RP Univ Missouri, Dept Pathol & Anat Sci, Ellis Fischel Canc Ctr, 115 Business Loop I-70 W, Columbia, MO 65203 USA.
EM huangh@health.missouri.edu
RI Yan, Pearlly/E-4339-2011; Chen, Chuan-Mu/K-7049-2013
OI Shi, Huidong/0000-0003-1137-3390; Chen, Chuan-Mu/0000-0003-2461-9150
FU NCI NIH HHS [R29 CA069065, CA-69065, CA-84701, CA-86305, R01 CA069065]
   Funding Source: Medline
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Beahrs O.H., 1992, MANUAL STAGING CANC, P149
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Brock GJR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.24.e123
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dammann R, 2001, CANCER RES, V61, P3105
   Esteller M, 2001, CANCER RES, V61, P3225
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Lehmann U, 2002, CANCER RES, V62, P6634
   Loeb DM, 2001, CANCER RES, V61, P921
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   SHIRAISHI M, 1995, P NATL ACAD SCI USA, V92, P4229, DOI 10.1073/pnas.92.10.4229
   Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Ueki T, 2000, CANCER RES, V60, P1835
   Xiang YY, 2001, ONCOGENE, V20, P7408, DOI 10.1038/sj.onc.1204925
   Yan PS, 2001, CANCER RES, V61, P8375
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yen PS, 2000, BRIT J CANCER, V82, P514, DOI 10.1054/bjoc.1999.0955
NR 24
TC 77
Z9 120
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUL
PY 2003
VL 163
IS 1
BP 37
EP 45
DI 10.1016/S0002-9440(10)63628-0
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 695KP
UT WOS:000183829900005
PM 12819009
OA Green Published
DA 2025-01-12
ER

PT J
AU Gray, JW
AF Gray, JW
TI Evidence emerges for early metastasis and parallel evolution of primary
   and metastatic tumors
SO CANCER CELL
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; CELLS
AB Tumor progression to metastasis usually is assumed to occur through clonal genomic and epigenetic evolution. However, Schmidt-Kittler et al. (2003) present evidence that challenges this paradigm. They show that genomic aberrations in tumor cells disseminated in the bone marrows of patients with no clinical evidence of metastasis generally do not resemble the aberrations in the primary tumors from which they arose. They interpret this to mean that tumor cells disseminate very early and evolve to metastatic disease independent from the primary tumor. Their model suggests that adjuvant therapies should be targeted to lesions in the disseminated cells rather than lesions found in primary tumors.
C1 Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
   Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
C3 United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; University of California System; University of California
   San Francisco; University of California System; University of California
   San Francisco; UCSF Medical Center; UCSF Helen Diller Family
   Comprehensive Cancer Center
RP Gray, JW (通讯作者)，Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
RI Gray, Joe/AAX-9549-2020
CR Al-Mulla F, 1999, GENE CHROMOSOME CANC, V24, P306, DOI 10.1002/(SICI)1098-2264(199904)24:4<306::AID-GCC3>3.0.CO;2-5
   Bissig H, 1999, AM J PATHOL, V155, P267, DOI 10.1016/S0002-9440(10)65120-6
   Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Hovey RM, 1998, CANCER RES, V58, P3555
   Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494
   Kuukasjarvi T, 1997, CANCER RES, V57, P1597
   Pandis N, 1998, GENE CHROMOSOME CANC, V22, P122, DOI 10.1002/(SICI)1098-2264(199806)22:2<122::AID-GCC6>3.0.CO;2-Z
   Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113
   Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100
   Swartz MA, 1999, BRIT J CANCER, V81, P756, DOI 10.1038/sj.bjc.6690760
NR 11
TC 90
Z9 105
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD JUL
PY 2003
VL 4
IS 1
BP 4
EP 6
DI 10.1016/S1535-6108(03)00167-3
PG 3
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 705CT
UT WOS:000184379000003
PM 12892707
OA Bronze
DA 2025-01-12
ER

PT J
AU Sathyanarayana, UG
   Toyooka, S
   Padar, A
   Takahashi, T
   Brambilla, E
   Minna, JD
   Gazdar, AF
AF Sathyanarayana, UG
   Toyooka, S
   Padar, A
   Takahashi, T
   Brambilla, E
   Minna, JD
   Gazdar, AF
TI Epigenetic inactivation of laminin-5-encoding genes in lung cancers
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HUMAN PROSTATE CARCINOMA; BREAST-CANCER; CELL-LINES; DIFFERENTIAL
   EXPRESSION; ABERRANT METHYLATION; DNA METHYLATION; CPG ISLANDS;
   INTEGRIN; PROMOTER; TUMOR
AB Purpose: We investigated the loss of expression of three laminin-5 (LN5)-encoding genes in lung cancer cell lines and elucidated the mechanism of inactivation of the genes in lung cancer cell lines and tumors.
   Experimental Design: We examined the expression of LN5-encoding genes by reverse transcription-PCR in 49 lung cancer cell lines. To elucidate the mechanism of gene silencing, we treated expression-negative cell lines (two for each gene) with a demethylating agent and examined the restoration of expression by reverse transcription-PCR. We dissected out the methylation patterns of CpG sites unique to the promoter regions of LN5-encoding genes by bisulfite genomic sequencing of expression-negative cell lines. We designed methylation-specific primers and validated the methylation status of the promoter regions in lung cancer cell tines using methylation-specific PCR. We further studied the methylation patterns of primary non-small cell lung cancer [NSCLC (n = 36)], small cell lung cancer [SCLC (n = 26)], and carcinoids (n = 24) tumors.
   Results: We observed frequent losses of expression in NSCLC (20-60%) and SCLC (65-86%) cell lines. Expression of one or more genes was lost in 90% of SCLC cell lines' and 65% of NSCLC cell lines. Treatment of expression-negative cell lines with demethylating agent restored expression in all of the cases. Methylation of LN5-encoding genes was present more frequently in SCLC cell lines (60-80%) than in NSCLC cell lines (15-60%), and at least one gene was methylated in 95% of SCLC and 60% of NSCLC cell lines. The concordances between loss of expression and methylation in 40 lung cancer cell lines for the three genes (90-95%) were statistically significant. Methylation was more frequent in SCLC tumors (58-77%) than in NSCLC tumors (22-42%) and carcinoids (13-33%), and at least one gene was methylated in 92% of SCLC tumors, 47% of NSCLC tumors, and 33% of carcinoids.
   Conclusions: Our results demonstrate frequent epigenetic inactivation of LN5-encoding genes in lung cancers, and these findings are of biological interest and are potentially of clinical importance.
C1 Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
   Aichi Canc Ctr, Div Mol Oncol, Nagoya, Aichi 4648681, Japan.
   Ctr Hosp Reg Univ, Pathol Cellulaire Lab, F-38043 Grenoble, France.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas Dallas; Aichi
   Cancer Center; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes;
   Universite Grenoble Alpes (UGA)
RP Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM adi.gazdar@utsouthwesterm.edu
RI Minna, John/AAB-1036-2022; Gazdar, Adi/F-7496-2010; Brambilla,
   Elisabeth/L-8796-2013; Takahashi, Takashi/I-7262-2014
OI Takahashi, Takashi/0000-0003-0615-7001
FU NCI NIH HHS [5U01CA8497102] Funding Source: Medline
CR Baker SE, 1996, J CELL SCI, V109, P2509
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BERGSTRAESSER LM, 1995, AM J PATHOL, V147, P1823
   Calaluce R, 2001, MOL CARCINOGEN, V30, P119, DOI 10.1002/1098-2744(200102)30:2<119::AID-MC1020>3.0.CO;2-N
   Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R
   COSTANTINI RM, 1990, CANCER RES, V50, P6107
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Davis TL, 2001, PROSTATE, V46, P240
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Falk-Marzillier J, 1998, BIOCHEM BIOPH RES CO, V251, P49, DOI 10.1006/bbrc.1998.9400
   Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Giannelli G, 2001, CLIN EXP METASTAS, V18, P439
   Guo NH, 2000, CANCER RES, V60, P457
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Henning K, 1999, HISTOPATHOLOGY, V34, P305
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Kleinman H K, 2001, Surg Oncol Clin N Am, V10, P329
   Manda R, 2000, BIOCHEM BIOPH RES CO, V275, P440, DOI 10.1006/bbrc.2000.3331
   Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760
   Phelps RM, 1996, J CELL BIOCHEM, P32
   SHAPIRO GI, 1995, CANCER RES, V55, P6200
   Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941
   Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   Toyooka S, 2002, CANCER RES, V62, P3382
   Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704
NR 35
TC 38
Z9 45
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL
PY 2003
VL 9
IS 7
BP 2665
EP 2672
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 700JK
UT WOS:000184108700038
PM 12855645
DA 2025-01-12
ER

PT J
AU Osin, P
   Lu, YJ
   Stone, J
   Crook, T
   Houlston, RS
   Gasco, M
   Gusterson, BA
   Shipley, J
AF Osin, P
   Lu, YJ
   Stone, J
   Crook, T
   Houlston, RS
   Gasco, M
   Gusterson, BA
   Shipley, J
TI Distinct genetic and epigenetic changes in medullary breast cancer
SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE medullary breast cancer; comparative genomic hybridization; genomic
   instability; BRCA1
ID COMPARATIVE GENOMIC HYBRIDIZATION; CARCINOMA IN-SITU; MICROSATELLITE
   INSTABILITY; COLORECTAL CANCERS; BRCA1; MUTATIONS; AMPLIFICATION;
   FEATURES; HYPERPLASIA; LOSSES
AB Genetic instability resulting in chromosome aneuploidy or mismatch repair deficiency characterizes cancer. Medullary carcinoma (MC) of the breast is a specific form of breast cancer with unique clinical, epidemiologic, and prognostic features, suggesting distinctive tumorigenic pathways. To investigate the nature of the genetic changes associated with MC we analyzed a series of 22 tumors. Chromosomal imbalances were assessed by comparative genomic hybridization (CGH) and mismatch repair (MMR) deficiency tested for through assessment of microsatellite instability (MSI) and expression of MLH1 and MSH2 genes. MMR deficiency was detected in only a small proportion of cases. The chromosomal copy number changes showed some similarities to BRCA1-associated tumors. A high level of BRCA1 promoter hypermethylation was detected, suggesting a possible role of this gene in MC development.
C1 Royal Marsden Hosp, Dept Breast Pathol & Cytopathol, London SW3 6JJ, England.
   Inst Canc Res, Sect Mol Carcinognesis, Sutton, Surrey, England.
   Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England.
   St Marys Hosp, Sch Med, Ludwig Inst Canc Res, London, England.
   Univ Glasgow, Western Infirm, Dept Pathol, Glasgow G11 6NT, Lanark, Scotland.
   Azienda Ospedaliera S Croce & Carle, Dept Med Oncol, Cuneo, Italy.
C3 Royal Marsden NHS Foundation Trust; University of London; Institute of
   Cancer Research - UK; University of London; Institute of Cancer Research
   - UK; Ludwig Institute for Cancer Research; Imperial College London;
   University of Glasgow
RP Osin, P (通讯作者)，Royal Marsden Hosp, Dept Breast Pathol & Cytopathol, London SW3 6JJ, England.
RI Houlston, Richard/AFS-5129-2022; gusterson, barry/D-3752-2009
OI Houlston, Richard/0000-0002-5268-0242; Lu, Yong-Jie/0000-0001-6174-6621;
   Shipley, Janet/0000-0001-6748-8678
CR ALDAZ CM, 1995, CANCER RES, V55, P3976
   Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J
   Campos B, 2001, CLIN CHEM LAB MED, V39, P401, DOI 10.1515/CCLM.2001.064
   Eisinger F, 1998, CANCER RES, V58, P1588
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923
   Jensen ML, 1997, HISTOPATHOLOGY, V30, P523
   Lakhani S R, 1999, Breast Cancer Res, V1, P31, DOI 10.1186/bcr10
   Lakhani SR, 2000, CLIN CANCER RES, V6, P782
   LAKHANI SR, 1995, J CLIN PATHOL, V48, P611, DOI 10.1136/jcp.48.7.611
   Lee SC, 2001, AM J CLIN PATHOL, V115, P823
   Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Lu YJ, 1998, CANCER RES, V58, P4721
   *NAT GROUP BREAST, 1995, NHSBSP PUBL, V3
   PEDERSEN L, 1991, BRIT J CANCER, V63, P591, DOI 10.1038/bjc.1991.137
   PEDERSEN L, 1994, EUR J CANCER, V30A, P1792, DOI 10.1016/0959-8049(94)00251-Y
   RIDOLFI RL, 1977, CANCER-AM CANCER SOC, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N
   Schmitt FC, 1999, INT J CANCER, V82, P644, DOI 10.1002/(SICI)1097-0215(19990827)82:5<644::AID-IJC5>3.0.CO;2-S
   Stone JG, 2000, CANCER LETT, V149, P15, DOI 10.1016/S0304-3835(99)00324-9
   Stone JG, 2001, CANCER LETT, V167, P171, DOI 10.1016/S0304-3835(01)00448-7
   TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K
   Tirkkonen M, 1997, CANCER RES, V57, P1222
   WeberHall SR, 1996, CANCER RES, V56, P3220
NR 25
TC 25
Z9 28
U1 0
U2 0
PU WESTMINSTER PUBL INC
PI GLEN HEAD
PA 708 GLEN COVE AVE, GLEN HEAD, NY 11545 USA
SN 1066-8969
J9 INT J SURG PATHOL
JI Int. J. Surg. Pathol.
PD JUL
PY 2003
VL 11
IS 3
BP 153
EP 158
DI 10.1177/106689690301100301
PG 6
WC Pathology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Surgery
GA 706VJ
UT WOS:000184475500001
PM 12894346
DA 2025-01-12
ER

PT J
AU Liu, ZJ
   Maekawa, M
AF Liu, ZJ
   Maekawa, M
TI Polymerase chain reaction-based methods of DNA methylation analysis
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
ID PROMOTER HYPERMETHYLATION; CPG ISLAND; BREAST-CANCER; ESTROGEN-RECEPTOR;
   COLORECTAL-CANCER; HUMAN NEOPLASIA; LUNG-CANCER; GENE; ASSAY; PCR
AB DNA methylation is the main epigenetic modification in humans, and changes in methylation patterns play an important role in tumorigenesis. Hypermethylation of normally unmethylated CpG islands in the promoter regions often occurs in important tumor suppressor genes, DNA repair genes, and metastasis inhibitor genes. The changes of methylation status of various gene promoters seem to be a common feature of malignant cells and these changes can occur early in the progression process. Therefore detection of aberrant promoter hypermethylation of cancer-related genes may be useful for cancer diagnosis or detection of cancer recurrence. The purpose of this review is to provide a summary of the most commonly used techniques for the study of DNA methylation. Current scientific literature involving methylation detection methods was reviewed with an emphasis on polymerase chain reaction (PCR)based detection methods. The current methodologies may be broadly classed into PCR-based methylation assays and non-PCR based methylation assays. The problems and advantages of the different methods for detecting aberrant methylation are discussed. As the number of genes known to be hypermethylated in cancer is growing, the detection of aberrant promoter region methylation will be a promising approach for using DNA-based markers for the early detection of human cancers. Many techniques, especially PCR-based methylation assay techniques, make it practical to use these new methylation biomarkers in early cancer diagnosis. (C) 2003 Elsevier Science (USA). All rights reserved.
C1 Third Mil Med Univ, SW Hosp, Dept Lab Med, Chongqing 400038, Peoples R China.
   Hamamatsu Univ Sch Med, Dept Lab Med, Hamamatsu, Shizuoka 4313192, Japan.
C3 Army Medical University; Hamamatsu University School of Medicine
RP Third Mil Med Univ, SW Hosp, Dept Lab Med, Chongqing 400038, Peoples R China.
EM a65424208@online.cq.cn
OI Maekawa, Masato/0000-0001-9710-5324
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Brock GJR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.24.e123
   Deng DJ, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.3.e13
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Galm O, 2002, GENOME RES, V12, P153, DOI 10.1101/gr.202501
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Havlis J, 2002, J CHROMATOGR B, V781, P373, DOI 10.1016/S1570-0232(02)00499-3
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lo YMD, 1999, CANCER RES, V59, P3899
   Maekawa M, 1999, BIOCHEM BIOPH RES CO, V262, P671, DOI 10.1006/bbrc.1999.1230
   Maekawa M, 2001, CLIN CHEM LAB MED, V39, P121, DOI 10.1515/CCLM.2001.021
   MCCLELLAND M, 1981, NUCLEIC ACIDS RES, V9, P5859, DOI 10.1093/nar/9.22.5859
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MYOHANEN S, 1994, DNA SEQUENCE, V5, P1, DOI 10.3109/10425179409039698
   Nass SJ, 2000, CANCER RES, V60, P4346
   Oakeley EJ, 1999, PHARMACOL THERAPEUT, V84, P389, DOI 10.1016/S0163-7258(99)00043-1
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987
   Toyooka KO, 2002, AM J PATHOL, V161, P629, DOI 10.1016/S0002-9440(10)64218-6
   Wong IHN, 2001, ANN NY ACAD SCI, V945, P36
   Worm J, 2001, CLIN CHEM, V47, P1183
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 40
TC 36
Z9 50
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD JUN 15
PY 2003
VL 317
IS 2
BP 259
EP 265
DI 10.1016/S0003-2697(03)00169-6
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 685ZF
UT WOS:000183294400017
PM 12758266
DA 2025-01-12
ER

PT J
AU Kuroki, T
   Trapasso, F
   Yendamuri, S
   Matsuyama, A
   Alder, H
   Williams, NN
   Kaiser, LR
   Croce, CM
AF Kuroki, T
   Trapasso, F
   Yendamuri, S
   Matsuyama, A
   Alder, H
   Williams, NN
   Kaiser, LR
   Croce, CM
TI Allelic loss on chromosome 3p21.3 and promoter hypermethylation of
   <i>Semaphorin</i> 3<i>B</i> in non-small cell lung cancer
SO CANCER RESEARCH
LA English
DT Article
ID SUPPRESSES TUMOR-FORMATION; BREAST-CANCER; AXON GUIDANCE; GENE;
   EXPRESSION; INACTIVATION; ADENOCARCINOMA; APOPTOSIS; CARCINOMA; MULTIPLE
AB The aim of this study was to evaluate the promoter methylation status and loss of heterozygosity (LOH) of the SEMA3B in non-small cell lung cancers (NSCLCs). We analyzed the methylation status of semaphorin 3B (SEMA3B) promoter and LOH at 3p21.3 in eight NSCLC cell lines and 27 primary tumors. Hypermethylation of SEMA3B was found in 50% of the cell lines and 41% of the primary tumors studied. The presence of hypermethylation was statistically associated with loss of SEMA3B expression in both cell lines (P = 0.02) and primary tumors (P < 0.01). There was no correlation between SEMA3B and tumor stage. On the other hand, the correlation between SEMA3B methylation status and LOH at 3p21.3 was significant (P = 0.02). Notably, 7 of 8 tumors with both hypermethylation and LOH of SEMA3B showed the absence of the expression. Treatment with 5-AZAC restored SEMA3B expression in NSCLC cell line. These results indicate that SEMA3B gene alterations may play a important role in the malignant transformation of NSCLC via a two-bit mechanism, including epigenetic changes and allelic loss, for tumor suppressor gene inactivation.
C1 Thomas Jefferson Univ, Kimmel Canc Inst, Jefferson Med Coll, Philadelphia, PA 19107 USA.
   Hosp Univ Penn, Philadelphia, PA 19104 USA.
C3 Thomas Jefferson University; University of Pennsylvania
RP Thomas Jefferson Univ, Kimmel Canc Inst, Jefferson Med Coll, BLSB Room 1050,233 S 10th St, Philadelphia, PA 19107 USA.
EM croce@calvin.jci.tju.edu
RI Kaiser, Larry/L-7940-2019
OI Yendamuri, Sai/0000-0001-6654-3487
FU NCI NIH HHS [CA56036] Funding Source: Medline
CR Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598
   Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928
   KNUDSON AG, 1985, CANCER RES, V45, P1437
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Mori M, 2000, CANCER RES, V60, P1177
   Mori M, 1999, BRIT J CANCER, V79, P211, DOI 10.1038/sj.bjc.6690035
   Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W
   Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211
   Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120
   Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x
   TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123
   Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Tse C, 2002, CANCER RES, V62, P542
   Wistuba II, 2000, CANCER RES, V60, P1949
   Xiang RH, 2002, CANCER RES, V62, P2637
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
   Zoo YM, 2000, CELL, V102, P363, DOI 10.1016/S0092-8674(00)00041-6
NR 20
TC 94
Z9 103
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2003
VL 63
IS 12
BP 3352
EP 3355
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 691CG
UT WOS:000183586800053
PM 12810670
DA 2025-01-12
ER

PT J
AU Oshiro, MM
   Watts, GS
   Wozniak, RJ
   Junk, DJ
   Munoz-Rodriguez, JL
   Domann, FE
   Futscher, BW
AF Oshiro, MM
   Watts, GS
   Wozniak, RJ
   Junk, DJ
   Munoz-Rodriguez, JL
   Domann, FE
   Futscher, BW
TI Mutant p53 and aberrant cytosine methylation cooperate to silence gene
   expression
SO ONCOGENE
LA English
DT Article
DE methylation; p53; tumor suppressor; azacytidine; breast cancer; maspin
ID HUMAN BREAST CARCINOMAS; CLONAL CHROMOSOME-ABNORMALITIES; HISTONE
   DEACETYLASE COMPLEX; DNA METHYLATION; CELL-LINES; TRANSCRIPTIONAL
   REPRESSION; TUMOR-SUPPRESSOR; BINDING PROTEIN; MASPIN GENE; CANCER
AB p53 is an important transcriptional regulator that is frequently mutated in cancer. Gene-profiling experiments of breast cancer cells infected with wt p53 revealed both MASPIN and desmocollin 3 (DSC3) to be p53-target genes, even though both genes are silenced in association with aberrant cytosine methylation of their promoters. Despite the transcriptional repression of these genes by aberrant DNA methylation, restoration of p53 resulted in the partial reactivation of both genes. This reactivation is a result of wt p53 binding to its consensus DNA-binding sites within the MASPIN and DSC3 promoters, stimulating histone acetylation, and enhancing chromatin accessibility of their promoters. Interestingly, wt p53 alone did not affect the methylation status of either promoter, suggesting that p53 itself can partially overcome the repressive barrier of DNA methylation. Pharmacologic inhibition of DNA methylation with 5-aza-2'-deoxycytidine in combination with restoration of wt p53 status resulted in a synergistic reactivation of these genes to near-normal levels. These results suggest that cancer treatments that target both genetic and epigenetic facets of gene regulation may be a useful strategy towards the therapeutic transcriptional reprogramming of cancer cells.
C1 Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA.
   Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA.
   Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA.
   Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.
C3 Arizona Center Cancer Care; University of Arizona; University of
   Arizona; University of Iowa; University of Iowa
RP Futscher, BW (通讯作者)，Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA.
RI Munoz Rodriguez, Jose Manuel/A-7323-2016
OI Munoz Rodriguez, Jose Manuel/0000-0002-4688-6420; Domann,
   Frederick/0000-0002-0489-2179; Junk, Damian/0000-0002-9251-3799
FU NCI NIH HHS [P30 CA023074] Funding Source: Medline; NIEHS NIH HHS [P30
   ES006694] Funding Source: Medline
CR ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319
   KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879
   Khan J, 1998, CANCER RES, V58, P5009
   Klus GT, 2001, INT J ONCOL, V19, P169
   Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997
   MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Seftor REB, 1998, CANCER RES, V58, P5681
   Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G
   Streuli CH, 2002, BREAST CANCER RES, V4, P137, DOI 10.1186/bcr437
   TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9
   THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402
   TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403
   Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612
   Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517
   Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhao RB, 2000, GENE DEV, V14, P981
   Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 44
TC 79
Z9 94
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JUN 5
PY 2003
VL 22
IS 23
BP 3624
EP 3634
DI 10.1038/sj.onc.1206545
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 687WD
UT WOS:000183399200013
PM 12789271
DA 2025-01-12
ER

PT J
AU Lattimore, BS
   Crabbe, MJC
AF Lattimore, BS
   Crabbe, MJC
TI Expression profiles in the progression of ductal carcinoma in the breast
SO COMPUTATIONAL BIOLOGY AND CHEMISTRY
LA English
DT Article
DE gene expression; ANOVA; mRNA
ID DNA MICROARRAYS; CANCER; PATTERNS; TUMORS; GENES
AB An understanding of the multi-step nature of cancer as it is in the breast, as a series of pivotal genetic/epigenetic modifications is irrefutably a milestone in diagnostics, prognostics and eventually providing a cure. Here we have utilised a variant of analysis of variance (ANOVA) as a model for the identification and tracking of specific mRNA species whose transcription has been significantly altered at each grade in the progression of ductal carcinoma, making it possible to correlate histological progression with the genetic events underlying breast cancer. We show that in the progression of ductal carcinomas, from grade I to 3, there is a reduction in the actual number of mRNA species, which are significantly over or under expressed. We also show that this technique can be employed to generate differential gene expression patterns, whereby the combined expression profile of the tailored spectra of genes in the comparison of each ductal grade is sufficient to render them on clearly separate arms of ail array-wise hierarchical cluster dendrogram. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Univ Reading, Dept Anim & Microbial Sci, Div Cell & Mol Biol, Reading RG6 6AJ, Berks, England.
C3 University of Reading
RP Univ Reading, Dept Anim & Microbial Sci, Div Cell & Mol Biol, Whiteknights, Reading RG6 6AJ, Berks, England.
EM m.j.c.crabbe@rdg.ac.uk
CR Abbott A, 2002, NATURE, V416, P470, DOI 10.1038/416470a
   AGNANTIS NJ, 1994, P 2 EUR C SEN BREAST, P243
   ALLRED DC, 1993, J CELL BIOCHEM, P125
   Amat S, 2002, INT J ONCOL, V20, P791
   Ben-Dor A, 1999, J COMPUT BIOL, V6, P281, DOI 10.1089/106652799318274
   Brazma A, 2000, FEBS LETT, V480, P17, DOI 10.1016/S0014-5793(00)01772-5
   Dudoit S, 2002, STAT SINICA, V12, P111
   DUPONT WD, 1993, CANCER, V71, P1258, DOI 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   GALLAGER HS, 1969, CANCER, V24, P1170, DOI 10.1002/1097-0142(196912)24:6<1170::AID-CNCR2820240615>3.0.CO;2-6
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Kerr MK, 2002, STAT SINICA, V12, P203
   Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954
   King HC, 2001, JAMA-J AM MED ASSOC, V286, P2280, DOI 10.1001/jama.286.18.2280
   Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Roylance R, 1999, CANCER RES, V59, P1433
   SOKAL R, 1995, BIOMETRY PRINCIPLE P, P79
   TABAR L, 1992, RADIOL CLIN N AM, V30, P187
   Thomas JG, 2001, GENOME RES, V11, P1227, DOI 10.1101/gr.165101
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
NR 21
TC 4
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1476-9271
EI 1476-928X
J9 COMPUT BIOL CHEM
JI Comput. Biol. Chem.
PD MAY
PY 2003
VL 27
IS 2
BP 115
EP 120
DI 10.1016/S1476-9271(03)00023-9
PG 6
WC Biology; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science
GA 727AE
UT WOS:000185633100004
PM 12821308
DA 2025-01-12
ER

PT J
AU Byun, DS
   Cho, K
   Ryu, BK
   Lee, MG
   Park, JI
   Chae, KS
   Kim, HJ
   Chi, SG
AF Byun, DS
   Cho, K
   Ryu, BK
   Lee, MG
   Park, JI
   Chae, KS
   Kim, HJ
   Chi, SG
TI Frequent monoallelic deletion of <i>PTEN</i> and its reciprocal
   associatioin with <i>PIk3CA</i> amplification in gastric carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE PTEN; PIK3CA; AKT; gastric cancer; loss of heterozygosity; gene
   amplification
ID TUMOR-SUPPRESSOR GENE; COWDEN-DISEASE; PROSTATE-CANCER; BREAST-CANCER;
   CELL-SURVIVAL; ALLELIC LOSS; MUTATIONS; GROWTH; PTEN/MMAC1; PROTEIN
AB Mutational alterations of PTEN and PIK3CA, which negatively and positively regulate PI3-kinase activity, respectively, have been observed in many types of human cancer. To explore the implication of PTEN and PIK3CA mutations in gastric tumorigenesis, we characterized the expression and mutation status of the genes in 126 gastric tissues and 15 cell lines. Expression of PTEN transcript was abnormally low in 5 of 15 (33%) cell lines and 20 of 55 (36%) primary carcinomas, whereas 0 of 71 noncancerous tissues including 16 benign tumors showed altered expression. Allelotyping analysis using an intragenic polymorphism (IVS4+109) revealed that 14 of 30 (47%) informative cases carried LOH of the gene, which is closely linked to low expression. The LOH rate was significantly higher in advanced tumors [ 12 of 19 (63%)] compared to early-stage tumors [2 of 11 (18%)] and more frequent in poorly differentiated tumors [9 of 13 (69%)] than well- or moderately differentiated tumors [5 of 17 (29%)]. Interestingly, however, none of the LOH tumors carried mutational disruption of the remaining allele, suggesting haploinsufficiency of PTEN in gastric tumorigenesis. Methylation studies revealed that PTEN pseudogene, but not PTEN, is methylated in cell lines and primary tumors, indicating that PTEN is not a target of epigenetic silencing in gastric cancers and that the pseudogene should be considered more carefully in methylation analysis of the PTEN promoter. Genomic amplification of PIK3CA was found in 9 of 15 (60%) cell lines and 20 of 55 (36.4%) primary tumors but in no noncancerous tissues. Furthermore, PIK3CA amplification was predominantly detected in tumors with no PTEN alterations, suggesting that mutations of PTEN and PIK3CA are mutually exclusive events in gastric tumorigenesis. Amplification of PIK3CA was strongly associated with increased expression of PIK3CA transcript and elevated levels of phospho-AKT. Collectively, our data reveal that 13 of 15 (87%) gastric cell lines and 31 of 55 (56%) primary carcinomas harbored either amplification of PIK3CA or abnormal reduction of PTEN. Mutually exclusive alterations of PTEN and PIK3CA also suggest that mutations of either gene could activate the PI3-kinase/AKT signaling pathway, which is directly linked to the malignant progression of gastric tumor cells. (C) 2003 Wiley-Liss, Inc.
C1 Kyung Hee Univ, Coll Med, Dept Pathol, Seoul 130701, South Korea.
   Kyung Hee Univ, Coll Med, Dept Internal Med, Div Gastroenterol, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Kyung Hee Univ, Coll Med, Dept Pathol, Seoul 130701, South Korea.
EM sgchi@khu.ac.kr
RI park, jaeil/AAS-5894-2021
OI PARK, JAE-IL/0000-0002-0737-2654
CR Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633
   Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240
   Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848
   Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2
   Chi SG, 1997, CLIN CANCER RES, V3, P1889
   Choi SW, 1998, ONCOGENE, V17, P2655, DOI 10.1038/sj.onc.1202188
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Dahia PLM, 1997, CANCER RES, V57, P4710
   Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122
   Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479
   Gottschalk AR, 2001, CANCER RES, V61, P2105
   Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200
   Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375
   Guan XY, 2000, CANCER GENET CYTOGEN, V123, P27, DOI 10.1016/S0165-4608(00)00306-X
   Guldberg P, 1997, CANCER RES, V57, P3660
   Han SY, 2000, CANCER RES, V60, P3147
   Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422
   Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143
   Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639
   Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Maxwell GL, 1998, CANCER RES, V58, P2500
   Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052
   Park BJ, 2000, CANCER RES, V60, P3370
   Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563
   Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110
   Rooney PH, 1999, BRIT J CANCER, V80, P862, DOI 10.1038/sj.bjc.6690433
   Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S
   Sato K, 2002, VIRCHOWS ARCH, V440, P160, DOI 10.1007/s004280100499
   Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697
   Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042
   Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199
   Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5
   TAHARA E, 1995, CANCER, V75, P1410, DOI 10.1002/1097-0142(19950315)75:6+<1410::AID-CNCR2820751504>3.0.CO;2-O
   Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614
   Tashiro H, 1997, CANCER RES, V57, P3935
   Teng DHF, 1997, CANCER RES, V57, P5221
   Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881
   Van Gele M, 2001, INT J CANCER, V92, P409, DOI 10.1002/ijc.1209
   VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655
   Wang SI, 1997, CANCER RES, V57, P4183
   Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605
   Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246
   Yustein AS, 1999, CANCER RES, V59, P1437
   Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5
   Zur Hausen A, 2001, GASTROENTEROLOGY, V121, P612, DOI 10.1053/gast.2001.27200
   Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4
NR 56
TC 169
Z9 229
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD APR 10
PY 2003
VL 104
IS 3
BP 318
EP 327
DI 10.1002/ijc.10962
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 649UP
UT WOS:000181226600012
PM 12569555
DA 2025-01-12
ER

PT J
AU Konishi, H
   Sugiyama, M
   Mizuno, K
   Saito, H
   Yatabe, Y
   Takahashi, T
   Osada, H
   Takahashi, T
AF Konishi, H
   Sugiyama, M
   Mizuno, K
   Saito, H
   Yatabe, Y
   Takahashi, T
   Osada, H
   Takahashi, T
TI Detailed characterization of a homozygously deleted region corresponding
   to a candidate tumor suppressor locus at distal 17p13.3 in human lung
   cancer
SO ONCOGENE
LA English
DT Article
DE homozygous deletion; 17p13.3; tumor suppressor gene; lung cancer; LOST1
ID HUMAN-CHROMOSOME 3P21.3; HEPATOCELLULAR-CARCINOMA; EPIGENETIC
   INACTIVATION; MITOTIC CHECKPOINT; BREAST-CANCER; CELL-LINES; IN-VIVO;
   GENE; IDENTIFICATION; P53
AB 17p13.3 is one of the chromosomal regions most frequently affected by allelic loss in a variety of human neoplasms including lung cancer. A number of loss of heterozygosity (LOH) analyses have suggested the existence of a tumor suppressor gene at 17p13.3, distal to the p53 locus at 17p13.1. In the present study, we characterized a homozygous deletion at 17p13.3 in a small cell lung cancer cell line by constructing a bacterial artificial chromosome (BAC) contig and a restriction map surrounding the region, as well as by utilizing publicly available draft sequences. We defined the breakpoint, assigned and analysed two known genes, 14-3-3epsilon. and CRK, and a novel gene LOST1 within or at the end of the homozygous deletion of about 170 kb in size. Marked reduction of LOST1 expression was detected in 69% (11/16) of lung cancer specimens by quantitative real-time RT-PCR, while significant DNA hypermethylation was observed at the 5' end of the LOST1 gene in four of six lung cancer cell lines with negligible LOST1 expression. We also show here that a polymorphic marker D17S1174, which resides within the homozygous deletion, was apparently located in the middle of the minimum LOH region, providing further supportive evidence for the presence of a tumor suppressor gene(s) in this region.
C1 Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   Aichi Canc Ctr Hosp, Dept Anat & Mol Diagnost Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
C3 Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center
RP Takahashi, T (通讯作者)，Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.
RI Takahashi, Takashi/I-7262-2014; Osada, Hirotaka/G-4553-2011; YATABE,
   Yasushi/J-6461-2014
OI Konishi, Hiroyuki/0000-0003-1131-4905; Takahashi,
   Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X
CR BIEGEL JA, 1992, CANCER RES, V52, P3391
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   CAIRNS P, 1994, CANCER RES, V54, P1422
   CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044
   Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687
   COGEN PH, 1992, AM J HUM GENET, V50, P584
   COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340
   FUJIMORI M, 1991, CANCER RES, V51, P89
   Haataja L, 1997, CANCER RES, V57, P32
   Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350
   Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44
   Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584
   Ji L, 2002, CANCER RES, V62, P2715
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421
   Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832
   Konishi H, 1998, ONCOGENE, V17, P2095, DOI 10.1038/sj.onc.1202128
   Konishi H, 2002, CANCER RES, V62, P271
   LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889
   Lerman MI, 2000, CANCER RES, V60, P6116
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   McHale JC, 2000, CYTOGENET CELL GENET, V88, P225, DOI 10.1159/000015556
   Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892
   MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849
   MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341
   Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141
   Oh JJ, 2002, CANCER RES, V62, P3207
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Osada H, 2001, CANCER RES, V61, P8331
   Phillips NJ, 1996, CANCER RES, V56, P606
   POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604
   SAXENA A, 1992, CANCER RES, V52, P6716
   Schultz DC, 1996, CANCER RES, V56, P1997
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557
   STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   TADOKORO K, 1992, ONCOGENE, V7, P1215
   TAKAHASHI T, 1992, CANCER RES, V52, P2340
   Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807
   TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494
   Tamura K, 2002, J HUM GENET, V47, P348, DOI 10.1007/s100380200048
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1
   YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252
   Zhao XT, 2001, CANCER RES, V61, P7383
NR 53
TC 32
Z9 35
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAR 27
PY 2003
VL 22
IS 12
BP 1892
EP 1905
DI 10.1038/sj.onc.1206304
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 657QQ
UT WOS:000181678200016
PM 12660825
DA 2025-01-12
ER

PT J
AU Agathanggelou, A
   Dallol, A
   Zöchbauer-Müller, S
   Morrissey, C
   Honorio, S
   Hesson, L
   Martinsson, T
   Fong, KM
   Kuo, MJ
   Yuen, PW
   Maher, ER
   Minna, JD
   Latif, F
AF Agathanggelou, A
   Dallol, A
   Zöchbauer-Müller, S
   Morrissey, C
   Honorio, S
   Hesson, L
   Martinsson, T
   Fong, KM
   Kuo, MJ
   Yuen, PW
   Maher, ER
   Minna, JD
   Latif, F
TI Epigenetic inactivation of the candidate 3p21.3 suppressor gene
   <i>BLU</i> in human cancers
SO ONCOGENE
LA English
DT Article
DE epigenetic inactivation; 3p21.3 region; human cancers
ID SINGLE NUCLEOTIDE POLYMORPHISM; HUMAN-CHROMOSOME 3P21.3;
   HIPPEL-LINDAU-DISEASE; CHANNEL SUBUNIT GENE; HUMAN LUNG-CANCER; 3P
   ALLELE LOSS; NEUROBLASTOMA TUMORS; RENAL-CARCINOMA; BREAST-CANCER;
   IDENTIFICATION
AB Many distinct regions of 3p show frequent allelic losses in a wide range of tumour types. Previously, the BLU candidate tumour suppressor gene (TSG) encoded by a gene-rich critical deleted region in 3p21.3 was found to be inactivated rarely in lung cancer, although expression was downregulated in a subset of lung tumour cell lines. To elucidate the role of BLU in tumorigenesis, we analysed BLU promoter methylation status in tumour cell lines and detected promoter region hypermethylation in 39% lung, 42% breast, 50% kidney, 86% neuroblastoma and 80% nasopharyngeal (NPC) tumour cell lines. Methylation of the BLU promoter region correlated with the down-regulation of BLU transcript expression in tumour cell lines. Expression was recovered in tumour cell lines treated with 5-aza 2-deoxycytidine. Exogenous expression of BLU in neuroblastoma (SK-N-SH) and NSCLC (NCI-H1299) resulted in reduced colony formation efficiency, in vitro. Furthermore, methylation of the BLU promoter region was detected in primary sporadic SCLC (14%), NSCLC (19%) and neuroblastoma (41%). As frequent methylation of the RASSF1A 3p21.3 TSG has also been reported in these tumour types, we investigated whether BLU and RASSF1A methylation were independent or related events. No correlation was found between hypermethylation of RASSF1A and BLU promoter region CpG islands in SCLC or neuroblastoma. However, there was association between RASSF1A and BLU methylation in NSCLC (P = 0.0031). Our data suggest that in SCLC and neuroblastoma, RASSF1A and BLU methylations are unrelated events and not a manifestation of a regional alteration in epigenetic status, while in NSCLC there may be a regional methylation effect. Together, these data suggest a significant role for epigenetic inactivation of BLU in the pathogenesis of common human cancers and that methylation inactivation of BLU occurs independent of RASSF1A in SCLC and neuroblastoma tumours.
C1 Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
   Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA.
   Univ Gothenburg, Sahlgrenska Hosp Ostra, Dept Clin Genet, S-41685 Gothenburg, Sweden.
   Prince Charles Hosp, Brisbane, Qld 4032, Australia.
   Birmingham Childrens Hosp, Birmingham B4 6NH, W Midlands, England.
   Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   Univ Birmingham, Sch Med, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England.
C3 University of Birmingham; University of Texas System; University of
   Texas Dallas; University of Texas Southwestern Medical Center Dallas;
   University of Gothenburg; Prince Charles Hospital; University of
   Birmingham; University of Hong Kong; Cancer Research UK; University of
   Birmingham
RP Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
EM flatif@hgmp.mrc.ac.uk
RI Fong, Kwun/G-6369-2010; Minna, John/AAB-1036-2022; Hesson,
   Luke/HDM-0311-2022; MAHER, EAMONN/A-9507-2008; Zochbauer-Muller,
   Sabine/B-8399-2012; Martinsson, Tommy/J-4140-2013; Dallol,
   Ashraf/H-8661-2012
OI MAHER, EAMONN/0000-0002-6226-6918; Zochbauer-Muller,
   Sabine/0000-0002-6777-1729; Fong, Kwun/0000-0002-6507-1403; Martinsson,
   Tommy/0000-0002-9403-3123; Dallol, Ashraf/0000-0002-8803-228X
FU NCI NIH HHS [P50 CA70907, CA71618] Funding Source: Medline
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001
   Angeloni D, 2000, MOL CELL PROBE, V14, P53, DOI 10.1006/mcpr.1999.0277
   Angeloni D, 2001, MOL CELL PROBE, V15, P125, DOI 10.1006/mcpr.2000.0341
   Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200
   Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Ejeskär K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297
   FEINSTEIN PG, 1995, GENETICS, V140, P573
   Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8
   Fullwood P, 1999, CANCER RES, V59, P4662
   GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Honorio S, 2001, MOL CELL PROBE, V15, P391, DOI 10.1006/mcpr.2001.0382
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361
   Lerman MI, 2000, CANCER RES, V60, P6116
   Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137
   Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300
   Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421
   Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510
   SEKIDO Y, 1994, ONCOGENE, V9, P1599
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   Wei MH, 1996, CANCER RES, V56, P1487
   Wistuba II, 2000, CANCER RES, V60, P1949
   Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3
   Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 33
TC 82
Z9 95
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR 13
PY 2003
VL 22
IS 10
BP 1580
EP 1588
DI 10.1038/sj.onc.1206243
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 652ZZ
UT WOS:000181411900015
PM 12629521
DA 2025-01-12
ER

PT J
AU Gagnon, J
   Shaker, S
   Primeau, M
   Hurtubise, A
   Momparler, RL
AF Gagnon, J
   Shaker, S
   Primeau, M
   Hurtubise, A
   Momparler, RL
TI Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic
   activity and activation of 14-3-3σ, E-cadherin and tissue inhibitor of
   metalloproteinase 3 expression in human breast carcinoma cells
SO ANTI-CANCER DRUGS
LA English
DT Article
DE 14-3-3 sigma; 5-aza-2 '-deoxycytydine; breast cancer; depsipeptide; DNA
   methylation; E-cadherin; histone deacetylation; TIMP3
ID HISTONE DEACETYLASE INHIBITION; ESTROGEN-RECEPTOR-ALPHA; DNA
   METHYLATION; CANCER-CELLS; FR901228; 5-AZA-2-DEOXYCYTIDINE;
   HYPERMETHYLATION; GENES; PHASE; LUNG
AB Genes that suppress tumorigenesis can be silenced by epigenetic events, such as aberrant DNA methylation and modification of chromatin structure. Inhibitors of DNA methylase and histone deacetylase (HDAC) can potentially reverse these events. The aim of this study was to determine the in vitro antineoplastic activity of 5-aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylase, in combination with depsipeptide (depsi), an inhibitor of HDAC, on human breast carcinoma cells. We observed a synergistic antineoplastic interaction between 5-AZA-CdR and depsi in their capacity to inhibit colony formation of Hs578T and MCF-7 breast carcinoma cells. In order to understand the molecular mechanism of this interaction, we investigated the effect of these drugs on the activation of the 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 (TIMP3) cancer-related genes, which were reported to be silenced by aberrant methylation in many breast tumor cell lines. 14-3-3sigma was reported to produce G(2) cell cycle arrest following DNA damage. E-cadherin and TIMP3 function as suppressors of tumor metastasis. Semi-quantitative RT-PCR was used to determine the effect of the co-administration of 5-AZA-CdR and depsi on four breast carcinoma cell lines for the reactivation of these genes. We observed a synergistic activation of E-cadherin by the combination in Hs578T, MDA-MB-231 and MDA-MB-435 tumor cells. For 14-3-3sigma, we demonstrated an additive to synergistic activation by the combination for Hs578T and MDA-MB-435 tumor cells, respectively. In the MCF-7 tumor cells, the drug combination produced a synergistic activation of TIMP3. The association between the synergistic antineoplastic activity and the synergistic activation of the target genes in this study suggests that the mechanism of anticancer activity of 5-AZA-CdR, in combination with depsi, is probably related to their enhanced activation of different types of tumor suppressor genes that have been silenced by epigenetic events.
C1 Hop St Justine, Ctr Rech Pediat, Montreal, PQ H3T 1C5, Canada.
   Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.
C3 Universite de Montreal; Universite de Montreal
RP Hop St Justine, Ctr Rech Pediat, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.
EM richard.l.momparier@umontreal.ca
RI Momparler, Richard/AAU-6945-2020
OI Momparler, Richard L/0000-0002-9186-6269
CR Andreú T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848
   Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4
   Bachman KE, 1999, CANCER RES, V59, P798
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Beauséjour CM, 2002, BIOCHEM BIOPH RES CO, V293, P1478, DOI 10.1016/S0006-291X(02)00413-8
   Beauséjour CM, 2001, CANCER GENE THER, V8, P669, DOI 10.1038/sj.cgt.7700358
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Lawrence M., 2001, Journal of Mammary Gland Biology and Neoplasia, V6, P169
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P277, DOI 10.1016/0163-7258(85)90052-X
   Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Momparler RL, 2001, LUNG CANCER, V34, pS111
   MOMPARLER RL, 1980, PHARMACOL THERAPEUT, V8, P21, DOI 10.1016/0163-7258(80)90058-3
   Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nass SJ, 2000, CANCER RES, V60, P4346
   Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789
   RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144
   RICHEL DJ, 1991, BRIT J CANCER, V64, P144, DOI 10.1038/bjc.1991.258
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Sacchi S, 1999, CANCER-AM CANCER SOC, V86, P2632, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A
   Sandor V, 2002, CLIN CANCER RES, V8, P718
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   UEDA H, 1994, J ANTIBIOT, V47, P301
   VALERIOTE F, 1975, CANCER CHEMOTH REP 1, V59, P895
   Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8
   Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010
   Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 41
TC 48
Z9 71
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4973
EI 1473-5741
J9 ANTI-CANCER DRUG
JI Anti-Cancer Drugs
PD MAR
PY 2003
VL 14
IS 3
BP 193
EP 202
DI 10.1097/00001813-200303000-00002
PG 10
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 665KF
UT WOS:000182118600002
PM 12634613
DA 2025-01-12
ER

PT J
AU Dallol, A
   Morton, D
   Maher, ER
   Latif, F
AF Dallol, A
   Morton, D
   Maher, ER
   Latif, F
TI <i>SLIT2</i> axon guidance molecule is frequently inactivated in
   colorectal cancer and suppresses growth of colorectal carcinoma cells
SO CANCER RESEARCH
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; CPG ISLAND; BREAST CANCERS; HUMAN HOMOLOG;
   TUMOR; GENE; 3P21.3; LUNG; CHROMOSOME-4; RASSF1A
AB We have shown recently that SLIT2 has tumor suppressor activity and that it is epigenetically silenced in >40% of lung and breast tumors. In this study, we have analyzed the methylation status of SLIT2 in primary colorectal cancers and matching normal colorectal mucosa. SLIT2 promoter region methylation was found in 23 (72%) of 32 primary colorectal cancers. In contrast, normal colorectal mucosa from the same patients exhibited significantly lower levels of SLIT2 promoter region hypermethylation. SLIT2 methylation was reversed and expression restored by treating colorectal tumor cell lines with the demethylating agent 5-aza-2-deoxycytidine. Loss of heterozygosity at D4S1546 marker, which maps within 100 kb of the SLIT2 gene, was observed in 39% of the methylated tumors. Furthermore, SLIT2 epigenetic silencing was independent of ROBO1/p16/RASSFIA hypermethylation. The presence of SLIT2 methylation was also independent of the presence of K-P-AS mutations. Ectopic expression of SLIT2 diminished the ability to form colonies in two colorectal tumor cell lines. In addition, conditioned medium from SLIT2-transfected COS-7 cells reduced cell growth and induced apoptosis in SW48 colorectal tumor cell line. In conclusion, SLIT2 is an excellent candidate tumor suppressor gene for colorectal cancer.
C1 Univ Birmingham, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England.
   Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England.
   Univ Birmingham, Canc Res United Kingdom, Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England.
C3 University of Birmingham; University of Birmingham; Cancer Research UK;
   University of Birmingham
RP Latif, F (通讯作者)，Univ Birmingham, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England.
RI MAHER, EAMONN/A-9507-2008; Dallol, Ashraf/H-8661-2012
OI MAHER, EAMONN/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ba-Charvet KTN, 2001, J NEUROSCI, V21, P4281
   Dallol A, 2002, CANCER RES, V62, P5874
   Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421
   Dammann R, 2001, CANCER RES, V61, P3105
   Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298
   Georgas K, 1999, CYTOGENET CELL GENET, V86, P246, DOI 10.1159/000015351
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jubb AM, 2001, J PATHOL, V195, P111, DOI 10.1002/path.923
   Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211
   Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888
   Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303
   Shivapurkar N, 1999, CANCER RES, V59, P3576
   Shivapurkar N, 1999, CLIN CANCER RES, V5, P17
   Shivapurkar N, 2001, HUM PATHOL, V32, P169, DOI 10.1053/hupa.2001.21560
   Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tse C, 2002, CANCER RES, V62, P542
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748
NR 25
TC 121
Z9 142
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2003
VL 63
IS 5
BP 1054
EP 1058
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 651PC
UT WOS:000181327700024
PM 12615722
DA 2025-01-12
ER

PT J
AU Chang, HW
   Chan, A
   Kwong, DLW
   Wei, WI
   Sham, JST
   Yuen, APW
AF Chang, HW
   Chan, A
   Kwong, DLW
   Wei, WI
   Sham, JST
   Yuen, APW
TI Detection of hypermethylated <i>RIZ1</i> gene in primary tumor, mouth,
   and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of
   nasopharyngeal carcinoma patient
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PROMOTER HYPERMETHYLATION; PROTEIN-KINASE; HIGH-FREQUENCY;
   BREAST-CANCER; DNA; SERUM; HEAD; EXPRESSION; PLASMA; EPIGENETICS
AB Purpose: The aims of this study are to examine the methylation status of the Fn2 RIZ1 gene in nasopharyngeal (NP) tumors and nasopharyngeal carcinoma (NPC) cell lines and to evaluate the clinical value of methylated RIZ1 gene in body fluid samples of NPC patients.
   Experimental design: Methylation status of RIZ1 was evaluated by MSP on CNE-2 and M1 cell lines, 30 tumor biopsies, and their matched body fluid samples, including mouth and throat (M & T) rinsing fluid, NP swabs, plasma, and huffy coat. Normal controls included 8 normal NP biopsies and body fluid samples from 29 healthy volunteers. Sequencing was performed on MSP products from one NP tumor and one M & T rinsing fluid. Transcription of the RIZ1 gene before and after 5-aza-2'-deoxycytidine treatment was examined on CNE-2.
   Results: The methylated RIZ1 gene was detected in both CNE-2 and M1, 18 (60%) NP tumors, but not in any of the normal controls. Of 30 matched body fluid samples, methylated RIZ1 DNA was found in 11(37%) NP swabs, 9 (30%) M & T rinsing fluid, 7 (23%) plasma, and 3 (10%) huffy coat samples. Sequencing analysis confirmed all cytosines to uracils conversion, excluding cytosines in CpG dinucleotides in methylated PCR products. Promoter methylation correlated with loss of RIZ1 mRNA expression, and 5-aza-2'-deoxycytidine treatment restored its expression in CNE-2.
   Conclusion: Our results suggest that promoter hypermethylation of the RIZ1 gene is commonly found in NPC. Its detection in body fluid samples of NPC patients but not in normal controls indicates that it is worth to further evaluate its clinical application in assisting screening of NPC and monitoring recurrence after treatment.
C1 Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Queen Mary Hosp, Dept Surg, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM pwyuen@hkucc.hku.hk
RI Kwong, Dora/C-4295-2009; Wei, William/C-4435-2009
OI wei, william/0000-0002-6281-7126
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BOUCHARD J, 1989, LEUKEMIA RES, V13, P715, DOI 10.1016/0145-2126(89)90061-1
   Canote R, 2002, ONCOL REP, V9, P57
   Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497
   Chang HW, 1999, BLOOD, V93, P1651, DOI 10.1182/blood.V93.5.1651.405k20_1651_1657
   Du Y, 2001, CANCER RES, V61, P8094
   Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730
   Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667
   He LS, 1998, CANCER RES, V58, P4238
   Hickey KP, 1999, BRIT J CANCER, V80, P1803, DOI 10.1038/sj.bjc.6690601
   Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kwong J, 2002, CLIN CANCER RES, V8, P131
   LAU SK, 1991, CYTOPATHOLOGY, V2, P239, DOI 10.1111/j.1365-2303.1991.tb00495.x
   Lo KW, 2001, CANCER RES, V61, P3877
   McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066
   Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035
   Nunes DN, 2000, ORAL ONCOL, V36, P525, DOI 10.1016/S1368-8375(00)00045-2
   Rosas SLB, 2001, CANCER RES, V61, P939
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Shao ZM, 2002, ANTI-CANCER DRUG, V13, P353, DOI 10.1097/00001813-200204000-00003
   Spafford MF, 2001, CLIN CANCER RES, V7, P607
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   STROUN M, 1989, ONCOLOGY-BASEL, V46, P318
   Wong IHN, 1999, CANCER RES, V59, P71
   Wong TS, 2002, CLIN CANCER RES, V8, P433
NR 26
TC 36
Z9 45
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2003
VL 9
IS 3
BP 1033
EP 1038
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 653JA
UT WOS:000181430400016
PM 12631603
DA 2025-01-12
ER

PT J
AU Abdollahi, A
   Pisarcik, D
   Roberts, D
   Weinstein, J
   Cairns, P
   Hamilton, TC
AF Abdollahi, A
   Pisarcik, D
   Roberts, D
   Weinstein, J
   Cairns, P
   Hamilton, TC
TI LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome
   6q24-25, is epigenetically regulated in cancer
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ZINC-FINGER PROTEIN; NEONATAL DIABETES-MELLITUS; SURFACE
   EPITHELIAL-CELLS; DNA METHYLATION; HISTONE DEACETYLASE; CHROMATIN
   STRUCTURE; SPONTANEOUS TRANSFORMATION; IMPRINTED GENES; CPG METHYLATION;
   ACETYLATION
AB LOT1 is a zinc-finger nuclear transcription factor, which possesses anti-proliferative effects and is frequently silenced in ovarian and breast cancer cells. The LOT1 gene is localized at chromosome 6q24-25, a chromosomal region maternally imprinted and linked to growth retardation in several organs and progression of disease states such as transient neonatal diabetes mellitus. Toward understanding the molecular mechanism underlying the loss of LOT1 expression in cancer, we have characterized the genomic structure and analyzed its epigenetic regulation. Genome mapping of LOT1 in comparison with the other splice variants, namely ZAC1 and PLAGL1, revealed that its mRNA (similar to4.7 kb; GenBank(TM) accession number U72621) is potentially spliced using six exons spanning at least 70 kb of the human genome. 5'-RACE (rapid amplification of cDNA ends) data indicate the presence of at least two transcription start sites. We found that in vitro methylation of the LOTI promoter causes a significant loss in its ability to drive luciferase transcription. To determine the nature of in vivo methylation of LOTI, we used bisulfite-sequencing strategies on genomic DNA. We show that in the ovarian and breast cancer cell lines and/or tumors the 5'-CpG island of LOT1 is a differentially methylated region. In these cell lines the ratio of methylated to unmethylated CpG dinucleotides in this region ranged from 31 to 99% and the ovarian tumors have relatively higher cytosine methylation than normal tissues. Furthermore, we show that trichostatin A, a specific inhibitor of histone deacetylase, relieves transcriptional silencing of LOT1 mRNA in malignantly transformed cells. It appears that, unlike DNA methylation, histone deacetylation does not target the promoter, and rather it is indirect and may be elicited by a mechanism upstream of the LOT1 regulatory pathway. Taken together, the data suggest that expression of LOT1 is under the control of two epigenetic modifications and that, in the absence of loss of heterozygosity, the biallelic (two-hit) or maximal silencing of LOT1 requires both processes.
C1 Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, Philadelphia, PA 19111 USA.
C3 Fox Chase Cancer Center
RP Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
EM A_Abdollahi@fccc.edu
FU NCI NIH HHS [CA51228, CA56916, CA83638, CA84242] Funding Source: Medline
CR Abdollahi A, 1997, CANCER RES, V57, P2029
   Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067
   Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034
   Arima T, 2001, HUM MOL GENET, V10, P1475, DOI 10.1093/hmg/10.14.1475
   BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610
   Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523
   Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680
   El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589
   GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592
   GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Herman JG, 1996, CANCER RES, V56, P722
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kamiya M, 2000, HUM MOL GENET, V9, P453, DOI 10.1093/hmg/9.3.453
   Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026
   Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   MARUYAMA K, 1994, GENE, V138, P171
   NAN X, 1998, NATURE, V393
   Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279
   SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155
   Singal R, 2002, J BIOL CHEM, V277, P1897, DOI 10.1074/jbc.M105580200
   Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814
   TESTA JR, 1994, CANCER RES, V54, P2778
   Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096
   Varrault A, 2001, J BIOL CHEM, V276, P18653, DOI 10.1074/jbc.C100095200
   Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
   ZHANG YH, 1993, AM J HUM GENET, V53, P113
NR 51
TC 89
Z9 107
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 21
PY 2003
VL 278
IS 8
BP 6041
EP 6049
DI 10.1074/jbc.M210361200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 648BF
UT WOS:000181129400070
PM 12473647
OA hybrid
DA 2025-01-12
ER

PT J
AU Primeau, M
   Gagnon, J
   Momparler, RL
AF Primeau, M
   Gagnon, J
   Momparler, RL
TI Synergistic antineoplastic action of DNA methylation inhibitor
   5-aza-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on
   human breast carcinoma cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; 5-aza-2'-deoxycytydine; depsipeptide; maspin; gelsolin;
   DNA methylation; histone dcacetylation
ID CHROMOBACTERIUM-VIOLACEUM NO-968; CANCER-CELLS; GELSOLIN EXPRESSION;
   LUNG-CANCER; PHASE-I; 5-AZA-2'-DEOXYCYTIDINE; FR901228; MASPIN;
   CHROMATIN; METHYLTRANSFERASE
AB During tumorigenesis, cancer-related genes can be silenced by aberrant DNA methylation and by changes in chromatin structure. It has been reported that 5-aza-2'-deoxycytidine, a potent inhibitor of DNA methylation, in combination with histone deacetylase inhibitors, can produce a synergistic reactivation of these genes. The aim of our study was to investigate the in vitro antineoplastic activity of 5-aza-2'-deoxycytidine in combination with depsipeptide, a potent histone deacetylase inhibitor, against MDA-MB-231 and MDA-MB-435 human breast carcinoma cell lines. We observed that the combination of 5-aza-2'-deoxycytidine and depsipeptide produced a synergistic antineoplastic effect against these tumor cells as compared to either agent administered alone. We also investigated the effect of this drug combination on the activation of maspin and gelsolin expression. These 2 genes whose function is to suppress tumor metastasis have been reported to be silenced by epigenetic events in breast cancer. Using semi-quantitative RT-PCR, we observed that 5-aza-2'-deoxycytidine in combination with depsipeptide produced a greater reactivation of both maspin and gelsolin as compared to each agent alone. The synergistic interaction between 5-aza-2'-deoxycytidine and depsipeptide on breast carcinoma cell lines provides a rationale to investigate this interesting drug combination in future clinical trials on patients with advanced breast cancer. (C) 2002 Wiley-Liss, Inc.
C1 Hop St Justine, Ctr Rech Pediat, Montreal, PQ H3T 1C5, Canada.
   Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.
C3 Universite de Montreal; Universite de Montreal
RP Momparler, RL (通讯作者)，Hop St Justine, Ctr Rech Pediat, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.
RI Momparler, Richard/AAU-6945-2020
OI Momparler, Richard L/0000-0002-9186-6269
CR ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5
   Asch HL, 1999, BREAST CANCER RES TR, V55, P179
   Asch HL, 1996, CANCER RES, V56, P4841
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255
   CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Fujita H, 2001, INT J CANCER, V93, P773, DOI 10.1002/ijc.1413
   Garber K, 2002, J NATL CANCER I, V94, P874
   HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x
   HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Lee HK, 1999, PROSTATE, V40, P14, DOI 10.1002/(SICI)1097-0045(19990615)40:1<14::AID-PROS2>3.0.CO;2-6
   Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461
   MOMPARLER RL, 1985, LEUKEMIA RES, V9, P1361, DOI 10.1016/0145-2126(85)90123-7
   Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Momparler RL, 2001, LUNG CANCER, V34, pS111
   MOMPARLER RL, 1980, PHARMACOL THERAPEUT, V8, P21, DOI 10.1016/0163-7258(80)90058-3
   MOMPARLER RL, 1984, LEUKEMIA RES, V8, P181, DOI 10.1016/0145-2126(84)90141-3
   Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Rajgolikar G, 1998, BREAST CANCER RES TR, V51, P29, DOI 10.1023/A:1006091014092
   RIVARD GE, 1981, LEUKEMIA RES, V5, P453, DOI 10.1016/0145-2126(81)90116-8
   Sager R, 1996, CURR TOP MICROBIOL, V213, P51
   Seftor REB, 1998, CANCER RES, V58, P5681
   Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669
   SHENG SJ, 1994, J BIOL CHEM, V269, P30988
   UEDA H, 1994, J ANTIBIOT, V47, P301
   UEDA H, 1994, J ANTIBIOT, V47, P315
   UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579
   VALERIOTE F, 1975, CANCER CHEMOTH REP 1, V59, P895
   Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010
   WILSON VL, 1983, CANCER RES, V43, P3493
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970
   Zhu WG, 2001, CANCER RES, V61, P1327
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 44
TC 74
Z9 95
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 10
PY 2003
VL 103
IS 2
BP 177
EP 184
DI 10.1002/ijc.10789
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 625BJ
UT WOS:000179796800010
PM 12455031
OA Bronze
DA 2025-01-12
ER

PT J
AU Honorio, S
   Agathanggelou, A
   Schuermann, M
   Pankow, W
   Viacava, P
   Maher, ER
   Latif, F
AF Honorio, S
   Agathanggelou, A
   Schuermann, M
   Pankow, W
   Viacava, P
   Maher, ER
   Latif, F
TI Detection of <i>RASSF1A</i> aberrant promoter hypermethylation in sputum
   from chronic smokers and ductal carcinoma <i>in situ</i> from breast
   cancer patients
SO ONCOGENE
LA English
DT Article
DE methylation; RASSF1A; sputum; ductal carcinoma in situ
ID FREQUENT EPIGENETIC INACTIVATION; TUMOR-SUPPRESSOR GENE; LUNG-CANCER;
   CPG ISLAND; 3P21.3; REGION; METHYLATION; LOCUS
AB The newly identified 3p21.3 tumour suppressor gene RASSF1A is methylated in the majority of primary lung tumours, lung tumour cell lines and in a variable percentage of breast tumours. To determine the extent of RASSF1A promoter hypermethylation in early lung tumorigenesis, we analysed sputum samples from lung cancer patients and from current and former smokers using a sensitive methylation-specific PCR (MSP) technique. We also analysed RASSF1A promoter region hypermethylation in trios of normal breast/invasive ductal breast carcinoma/ductal carcinoma in situ (DCIS) from breast cancer patients and DCIS without invasive cancer. We found that 50% of small cell lung cancer (SCLC) and 21% of non-small cell lung cancer (NSCLC) patients had RASSF1A methylation, while one of two former smokers and four of 13 current smokers demonstrated RASSF1A methylation in sputum. Furthermore, two of the four current smokers and one former smoker showing RASSF1A methylation in their sputum developed cancer within 12-14 months of bronchoscopy. In our breast cancer trios, RASSF1A promoter hypermethylation was detected in 65% of invasive cancers, in 42% of corresponding DCIS but in none of the normal breast samples. In addition, we found that three out of 10 DCIS without invasive breast cancer also underwent RASSF1A promoter hypermethylation. Our findings suggest that RASSF1A promoter region hypermethylation may be a useful molecular marker for early detection of lung cancer. Furthermore, since RASSF1A promoter hypermethylation was detected in ductal carcinoma in situ, inactivation of RASSF1A may be an early event in breast tumorigenesis.
C1 Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Sch Med, Birmingham B15 2TT, W Midlands, England.
   Univ Marburg, D-35033 Marburg, Germany.
   Krankenhaus Neukolln, Abt Innere Med 3, Schwerpunkt Pneumonol Infektiol, Berlin, Germany.
   Univ Pisa, Dept Oncol, Div Pathol, Pisa, Italy.
C3 University of Birmingham; Philipps University Marburg; University of
   Pisa
RP Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Sch Med, Birmingham B15 2TT, W Midlands, England.
EM flatif@hgmp.mrc.ac.uk
RI Caligo, Adelaide/K-4289-2018; MAHER, EAMONN/A-9507-2008
OI MAHER, EAMONN/0000-0002-6226-6918
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221
   Kuzmin I, 2002, CANCER RES, V62, P3498
   Lee MG, 2001, CANCER RES, V61, P6688
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lerman MI, 2000, CANCER RES, V60, P6116
   Lo KW, 2001, CANCER RES, V61, P3877
   Morrissey C, 2001, CANCER RES, V61, P7277
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Vlacava P, 1999, J PATHOL, V188, P245
NR 17
TC 96
Z9 111
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 9
PY 2003
VL 22
IS 1
BP 147
EP 150
DI 10.1038/sj.onc.1206057
PG 4
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 631KL
UT WOS:000180166900015
PM 12527916
DA 2025-01-12
ER

PT J
AU Asada, K
   Miyamoto, K
   Fukutomi, T
   Tsuda, H
   Yagi, Y
   Wakazono, K
   Oishi, S
   Fukui, H
   Sugimura, T
   Ushijima, T
AF Asada, K
   Miyamoto, K
   Fukutomi, T
   Tsuda, H
   Yagi, Y
   Wakazono, K
   Oishi, S
   Fukui, H
   Sugimura, T
   Ushijima, T
TI Reduced expression of <i>GNA11</i> and silencing of <i>MCT1</i> in human
   breast cancers
SO ONCOLOGY
LA English
DT Article
DE DNA methylation; GNA11; breast cancer; MCT1
ID GONADOTROPIN-RELEASING-HORMONE; REPRESENTATIONAL DIFFERENCE ANALYSIS;
   GENE-EXPRESSION; SUPPRESSOR GENE; METHYLATION; HYPERMETHYLATION;
   IDENTIFICATION; LOCALIZATION; EPIGENETICS; TRANSPORT
AB Alteration in the methylation status of a gene is often associated with its altered expression. Based on a genome scanning technique for differences in CpG methylations, methylation-sensitive representational difference analysis, DNA fragments hypermethylated in a human breast cancer were isolated. A DNA fragment was isolated from intron 1 of guanine-nucleotide-binding protein alpha-11 (GNA11). mRNA expression of GNA11 was shown to be decreased in 10 of 16 breast cancers by RTPCR analysis, and the immunoreactivity of the GNA11 product, Gall subunit of heterotrimeric G-protein, was observed to be reduced in 14 of the 16 cancers by immunohistochemistry. Methylation of a CpG island (CGI) in the 5' region of GNA11 or that of intron 1 did not show a clear correlation with its decreased expression. Another DNA fragment was isolated from a CGI in the 5' upstream region of monocarboxylate transporter 1 (MM), and was methylated in 4 of 20 breast cancers. The CGI was also methylated in a human breast cancer cell line, MDA-MB-231, and quantitative RT-PCR showed that its expression was almost lost in the cell line. By treatment of the cells with a demethylating agent, 5-aza-2'-deoxycytidine, the methylation was removed and the expression was restored. GNA11 is involved in signalling of gonadotropin-releasing hormone receptor, which negatively regulates cell growth. MCT1 is involved in cellular transportation of butyrate, which induces cellular differentiation. Downregulation of these two genes was suggested to be involved in human breast cancers.
C1 Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan.
   Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan.
   Natl Canc Ctr, Dept Surg, Tokyo, Japan.
   Nara Med Univ, Dept Internal Med 3, Nara, Japan.
C3 National Cancer Center - Japan; National Cancer Center - Japan; National
   Cancer Center - Japan; Nara Medical University
RP Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM tushijim@ncc.go.jp
RI Asada, Kiyoshi/AFL-8696-2022; Ushijima, Toshikazu/AAP-5742-2021
OI Ushijima, Toshikazu/0000-0003-3405-7817
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481
   Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Davis T, 2000, CLIN CANCER RES, V6, P4334
   EIDNE KA, 1987, J CLIN ENDOCR METAB, V64, P425, DOI 10.1210/jcem-64-3-425
   Esteller M, 2001, CANCER RES, V61, P3225
   GARCIA CK, 1994, GENOMICS, V23, P500, DOI 10.1006/geno.1994.1532
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Goldman R, 1998, IN VIVO, V12, P43
   GREENBLATT MS, 1994, CANCER RES, V54, P4855
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Hadjiagapiou C, 2000, AM J PHYSIOL-GASTR L, V279, pG775, DOI 10.1152/ajpgi.2000.279.4.G775
   Hohn T, 1996, P NATL ACAD SCI USA, V93, P8334, DOI 10.1073/pnas.93.16.8334
   HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464
   Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278
   Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022
   KIJN JG, 2000, J NATL CANCER I, V92, P903
   Kottler ML, 1997, INT J CANCER, V71, P595, DOI 10.1002/(SICI)1097-0215(19970516)71:4<595::AID-IJC14>3.3.CO;2-L
   Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147
   MILLER WR, 1985, NATURE, V313, P231, DOI 10.1038/313231a0
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Ritzhaupt A, 1998, J PHYSIOL-LONDON, V513, P719, DOI 10.1111/j.1469-7793.1998.719ba.x
   Sambrook J., 1989, Molecular Cloning, V2nd
   Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2
   STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113
   Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940
   Tsubaki J, 2001, J ENDOCRINOL, V169, P97, DOI 10.1677/joe.0.1690097
   Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284
   WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
NR 35
TC 55
Z9 79
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PY 2003
VL 64
IS 4
BP 380
EP 388
DI 10.1159/000070297
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 681TA
UT WOS:000183050400014
PM 12759536
DA 2025-01-12
ER

PT J
AU Buckley, PG
   Mantripragada, KK
   Benetkiewicz, M
   Tapia-Páez, I
   de Ståhl, TD
   Rosenquist, M
   Ali, H
   Jarbo, C
   de Bustos, C
   Hirvelä, C
   Wilén, BS
   Fransson, I
   Thyr, C
   Johnsson, BI
   Bruder, CEG
   Menzel, U
   Hergersberg, M
   Mandahl, N
   Blennow, E
   Wedell, A
   Beare, DM
   Collins, JE
   Dunham, I
   Albertson, D
   Pinkel, D
   Bastian, BC
   Faruqi, AF
   Lasken, RS
   Ichimura, K
   Collins, VP
   Dumanski, JP
AF Buckley, PG
   Mantripragada, KK
   Benetkiewicz, M
   Tapia-Páez, I
   de Ståhl, TD
   Rosenquist, M
   Ali, H
   Jarbo, C
   de Bustos, C
   Hirvelä, C
   Wilén, BS
   Fransson, I
   Thyr, C
   Johnsson, BI
   Bruder, CEG
   Menzel, U
   Hergersberg, M
   Mandahl, N
   Blennow, E
   Wedell, A
   Beare, DM
   Collins, JE
   Dunham, I
   Albertson, D
   Pinkel, D
   Bastian, BC
   Faruqi, AF
   Lasken, RS
   Ichimura, K
   Collins, VP
   Dumanski, JP
TI A full-coverage, high-resolution human chromosome 22 genomic microarray
   for clinical and research applications
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID DNA COPY NUMBER; DERMATOFIBROSARCOMA PROTUBERANS; NEUROFIBROMATOSIS
   TYPE-2; BREAST-CANCER; DELETION; GENE; HYBRIDIZATION; CELLS;
   HUMAN-CHROMOSOME-22; 14-3-3-SIGMA
AB We have constructed the first comprehensive microarray representing a human chromosome for analysis of DNA copy number variation. This chromosome 22 array covers 34.7 Mb, representing 1.1% of the genome, with an average resolution of 75 kb. To demonstrate the utility of the array, we have applied it to profile acral melanoma, dermatofibrosarcoma, DiGeorge syndrome and neurofibromatosis 2. We accurately diagnosed homozygous/heterozygous deletions, amplifications/gains, IGLV/IGLC locus instability, and breakpoints of an imbalanced translocation. We further identified the 14-3-3 eta isoform as a candidate tumor suppressor in glioblastoma. Two significant methodological advances in array construction were also developed and validated. These include a strictly sequence defined, repeat-free, and non-redundant strategy for array preparation. This approach allows an increase in array resolution and analysis of any locus; disregarding common repeats, genomic clone availability and sequence redundancy. In addition, we report that the application of phi29 DNA polymerase is advantageous in microarray preparation. A broad spectrum of issues in medical research and diagnostics can be approached using the array. This well annotated and gene-rich autosome contains numerous uncharacterized disease genes. It is therefore crucial to associate these genes to specific 22q-related conditions and this array will be instrumental towards this goal. Furthermore, comprehensive epigenetic profiling of 22q-located genes and high-resolution analysis of replication timing across the entire chromosome can be studied using our array.
C1 Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden.
   Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden.
   Kantonsspital, Zentrum Labormed, CH-5001 Aarau, Switzerland.
   Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.
   Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
   Mol Staging Inc, New Haven, CT 06511 USA.
   Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 2QQ, England.
C3 Uppsala University; Karolinska Institutet; Karolinska University
   Hospital; Kantonsspital Aarau AG (KSA); Lund University; Skane
   University Hospital; Wellcome Trust Sanger Institute; University of
   California System; University of California San Francisco; UCSF Medical
   Center; UCSF Helen Diller Family Comprehensive Cancer Center; University
   of Cambridge; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital
RP Dumanski, JP (通讯作者)，Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, 3rd Floor,Dag Hammarskjolds Vag 20, S-75185 Uppsala, Sweden.
RI ; Tapia-Paez, Isabel/N-1210-2013
OI Rosenquist, Magnus/0000-0001-7795-9728; Dunham, Ian/0000-0003-2525-5598;
   Bastian, Boris/0000-0003-1836-6062; Dumanski, Jan
   Piotr/0000-0002-1489-1452; Hergersberg, Martin/0000-0003-2073-5429; Diaz
   de Stahl, Teresita/0000-0001-5933-6623; Tapia-Paez,
   Isabel/0000-0002-0535-4233
FU MRC [G9810900] Funding Source: UKRI; Medical Research Council [G9810900]
   Funding Source: Medline
CR Bailey JA, 2002, AM J HUM GENET, V70, P83, DOI 10.1086/338458
   Bastian BC, 2000, CANCER RES, V60, P1968
   Bruder CEG, 2001, HUM MOL GENET, V10, P271, DOI 10.1093/hmg/10.3.271
   Bruder CEG, 1999, HUM GENET, V104, P418, DOI 10.1007/s004390050978
   Bruder CEG, 1999, GENE CHROMOSOME CANC, V25, P184, DOI 10.1002/(SICI)1098-2264(199906)25:2<184::AID-GCC15>3.0.CO;2-B
   COLLINS JE, 1995, NATURE, V377, P367
   Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499
   Dean FB, 2001, GENOME RES, V11, P1095, DOI 10.1101/gr.180501
   Dumanski JP, 1996, NEUROPATH APPL NEURO, V22, P412, DOI 10.1111/j.1365-2990.1996.tb00912.x
   DUMANSKI JP, 1991, GENOMICS, V11, P709, DOI 10.1016/0888-7543(91)90079-T
   DUMANSKI JP, 2002, Patent No. 020008654
   Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031
   FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266
   Fish FS, 1996, DERMATOL SURG, V22, P268, DOI 10.1111/j.1524-4725.1996.tb00318.x
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   Gisselsson D, 1999, HUM GENET, V104, P315, DOI 10.1007/s004390050960
   Ino Y, 1999, J NEUROPATH EXP NEUR, V58, P881, DOI 10.1097/00005072-199908000-00010
   NILSSON K, 1979, EPSTEINBARR VIRUS, P227
   Nishio J, 2001, GENE CHROMOSOME CANC, V30, P305, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1091>3.3.CO;2-I
   O'Brien KP, 1998, GENE CHROMOSOME CANC, V23, P187, DOI 10.1002/(SICI)1098-2264(199810)23:2<187::AID-GCC13>3.3.CO;2-R
   Oskam NT, 2000, INT J CANCER, V85, P336, DOI 10.1002/(SICI)1097-0215(20000201)85:3<336::AID-IJC7>3.3.CO;2-0
   PEDEUTOUR F, 1995, CANCER RES, V55, P2400
   Pedeutour F, 1996, CYTOGENET CELL GENET, V72, P171, DOI 10.1159/000134178
   PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393
   Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524
   RUTGERS EJT, 1992, EUR J SURG ONCOL, V18, P241
   Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421
   Shaikh TH, 2000, HUM MOL GENET, V9, P489, DOI 10.1093/hmg/9.4.489
   Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95
   Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754
   SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76
   Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4
NR 34
TC 102
Z9 117
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 1
PY 2002
VL 11
IS 25
BP 3221
EP 3229
DI 10.1093/hmg/11.25.3221
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 622VR
UT WOS:000179668300011
PM 12444106
OA Bronze
DA 2025-01-12
ER

PT J
AU Lehmann, U
   Celikkaya, G
   Hasemeier, B
   Länger, F
   Kreipe, H
AF Lehmann, U
   Celikkaya, G
   Hasemeier, B
   Länger, F
   Kreipe, H
TI Promoter hypermethylation of the <i>death-associated protein</i> kinase
   gene in breast cancer is associated with the invasive lobular subtype
SO CANCER RESEARCH
LA English
DT Article
ID CPG-ISLAND METHYLATION; POLYMERASE-CHAIN-REACTION; DNA METHYLATION;
   CARCINOMA; AMPLIFICATION; EXPRESSION; SPECIMENS; CELL
AB Expression of death-associated protein (DAP) kinase, a proapoptotic serine/threonine protein kinase, is frequently lost in human tumors. In a study of 134 primary breast cancer specimens hypermethylation of the DAP kinase gene was found in 13% of cases. A highly significant difference (P < 0.001) of DAP kinase inactivation was observed between invasive lobular cancer (n = 19) and invasive ductal cancer (n = 85; 53% versus 9%, respectively). Hypermethylation correlated with loss of RNA expression, estrogen receptor positivity (P < 0.01), and the absence of p53 overexpression (P < 0.01). In contrast to invasive lobular cancer, the in situ-growing precursor lesion lacked epigenetic modification of the DAP kinase promotor by aberrant methylation indicating a potential role in tumor progression. Unlike the DAP kinase gene, hypermethylation of the cyclin D1 and RASSF1A genes did not correlate with a particular histological subtype or to invasiveness. We conclude that different histological subtypes of breast cancer may not only differ concerning specific chromosomal abnormalities and DNA mutations but also with regard to epigenetic inactivation patterns.
C1 Hannover Med Sch, Dept Pathol, Inst Pathol, D-30625 Hannover, Germany.
C3 Hannover Medical School
RP Lehmann, U (通讯作者)，Hannover Med Sch, Dept Pathol, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
OI Laenger, Florian/0000-0003-1191-4855
CR Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Graff JR, 1998, CANCER RES, V58, P2063
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599
   Issa JP, 2000, CURR TOP MICROBIOL, V249, P101
   Kang GH, 2001, CANCER RES, V61, P2847
   Kim DH, 2001, CANCER RES, V61, P3419
   Kissil JL, 1998, MOL MED TODAY, V4, P268, DOI 10.1016/S1357-4310(98)01263-5
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lehmann U, 2001, AM J PATHOL, V159, P2023, DOI 10.1016/S0002-9440(10)63054-4
   Lehmann U, 2001, LAB INVEST, V81, P635, DOI 10.1038/labinvest.3780272
   Lehmann U, 2000, AM J PATHOL, V156, P1855, DOI 10.1016/S0002-9440(10)65059-6
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   RAVEH T, NAT CELL BIOL, V3, P1
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Simpson DJ, 2002, ONCOGENE, V21, P1217, DOI 10.1038/sj.onc.1205195
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   vonWasielewski R, 1997, J HISTOCHEM CYTOCHEM, V45, P1455, DOI 10.1177/002215549704501102
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Wong TS, 2002, CLIN CANCER RES, V8, P433
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 22
TC 68
Z9 75
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2002
VL 62
IS 22
BP 6634
EP 6638
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 616QV
UT WOS:000179315200047
PM 12438260
DA 2025-01-12
ER

PT J
AU Bryan, EJ
   Jokubaitis, VJ
   Chamberlain, NL
   Baxter, SW
   Dawson, E
   Choong, DYH
   Campbell, IG
AF Bryan, EJ
   Jokubaitis, VJ
   Chamberlain, NL
   Baxter, SW
   Dawson, E
   Choong, DYH
   Campbell, IG
TI Mutation analysis of <i>EP300</i> in colon, breast and ovarian
   carcinomas
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE EP300; tumour suppressor; somatic mutations; ovarian cancer; colon
   cancer; breast cancer; cancer cell lines
ID TUMOR-SUPPRESSOR GENE; CHROMOSOME ARM 22Q; NEUROFIBROMATOSIS-2 GENE;
   ALLELIC LOSS; COLORECTAL CANCERS; PROTEIN P300; DNA-DAMAGE; REGION;
   HETEROZYGOSITY; LOCALIZATION
AB The putative tumour suppressor gene EP300 is located on chromosome 22q13 which is a region showing frequent loss of heterozygosity (LOH) in colon, breast and ovarian cancers. We analysed 203 human breast, colon and ovarian primary tumours and cell lines for somatic mutations in EP300. LOH across the EP300 locus was detected in 38% of colon, 36% of breast, and 49% of ovarian primary tumours but no somatic mutations in EP300 were identified in any primary tumour. Analysis of 17 colon, 11 breast, and 11 ovarian cancer cell lines identified truncating mutations in 4 colon cancer cell lines (HCT116, HT29, LIM2405 and LIM2412). We confirmed the presence of a previously reported frameshift mutation in HCT116 at codon 1699 and identified a second frameshift mutation at codon 1468. Bi-allelic inactivation of EP300 was also detected in LIM2405 that harbours an insC mutation at codon 927 as well an insA mutation at codon 1468. An insA mutation at codon 1468 was identified in HT29 and a CGA>TGA mutation at codon 86 was identified in LIM2412. Both these lines were heterozygous across the EP300 locus and western blot analysis confirmed the presence of an apparently wild-type protein. Our study has established that genetic inactivation of EP300 is rare in primary colorectal, breast and ovarian cancers. In contrast, mutations are common among colorectal cancer cell lines with 4/17 harbouring homozygous or heterozygous mutations. The rarity of EP300 mutations among these tumour types that show a high frequency of LOH across 22q13 may indicate that another gene is the target of the loss. It is possible that bi-allelic inactivation of EP300 is not necessary and that haploinsufficiency is sufficient to promote tumorigenesis. Alternatively, silencing of EP300 may be achieved by epigenetic mechanisms such as promoter methylation. (C) 2002 Wiley-Liss, Inc.
C1 Peter MacCallum Canc Inst, Canc Genet Lab, VBCRC, Melbourne, Vic 8006, Australia.
   Sanger Ctr, Hinxton, Cambs, England.
C3 Peter Maccallum Cancer Center; Wellcome Trust Sanger Institute
RP Campbell, IG (通讯作者)，Peter MacCallum Canc Inst, Canc Genet Lab, VBCRC, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.
RI campbell, Ian/F-6006-2011
OI Baxter, Simon/0000-0001-5773-6578; Campbell, Ian/0000-0002-7773-4155
CR Allione F, 1998, INT J CANCER, V75, P181, DOI 10.1002/(SICI)1097-0215(19980119)75:2<181::AID-IJC3>3.0.CO;2-Q
   ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565
   Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0
   Bryan EJ, 2000, INT J CANCER, V87, P798, DOI 10.1002/1097-0215(20000915)87:6<798::AID-IJC6>3.0.CO;2-X
   Bryan EJ, 1996, CANCER RES, V56, P719
   CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589
   Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2
   CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506
   CLIBY W, 1993, CANCER RES, V53, P2393
   Duriez C, 1997, GASTROEN CLIN BIOL, V21, P358
   ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869
   ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418
   Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536
   Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704
   Iida A, 1998, GENE CHROMOSOME CANC, V21, P108, DOI 10.1002/(SICI)1098-2264(199802)21:2<108::AID-GCC5>3.3.CO;2-8
   Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6
   KANAI Y, 1995, JPN J CLIN ONCOL, V25, P1
   Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9
   Lida A, 1997, BRIT J CANCER, V75, P264, DOI 10.1038/bjc.1997.43
   Liu L, 1999, MOL CELL BIOL, V19, P1202
   Miyakawa A, 1998, INT J ONCOL, V13, P705
   MULLENBACH R, 1989, TRENDS GENET, V5, P391
   Muraoka M, 1996, ONCOGENE, V12, P1565
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Rustgi AK, 1995, CANCER GENET CYTOGEN, V84, P24, DOI 10.1016/0165-4608(95)00059-3
   RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207
   Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M
   SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x
   Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000
   TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1016/0270-9139(93)90154-F
   TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147
   YAEGASHI S, 1995, JPN J CANCER RES, V86, P929, DOI 10.1111/j.1349-7006.1995.tb03003.x
   YANA I, 1995, INT J CANCER, V60, P174, DOI 10.1002/ijc.2910600207
   Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4
   Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883
   ZHANG SY, 1994, CANCER RES, V54, P5050
NR 36
TC 62
Z9 83
U1 0
U2 9
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 10
PY 2002
VL 102
IS 2
BP 137
EP 141
DI 10.1002/ijc.10682
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 603QF
UT WOS:000178570600005
PM 12385008
DA 2025-01-12
ER

PT J
AU Dallol, A
   Da Silva, NF
   Viacava, P
   Minna, JD
   Bieche, I
   Maher, ER
   Latif, F
AF Dallol, A
   Da Silva, NF
   Viacava, P
   Minna, JD
   Bieche, I
   Maher, ER
   Latif, F
TI <i>SLIT2</i>, a human homologue of the <i>Drosophila</i> <i>Slit2</i>
   gene, has tumor suppressor activity and is frequently inactivated in
   lung and breast cancers
SO CANCER RESEARCH
LA English
DT Article
ID AXON GUIDANCE; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; CELL
   CARCINOMA; CHROMOSOME-4; DELETIONS; PROTEIN; 3P21.3; RECEPTORS; RASSF1A
AB Slit2 plays a vital role in axon guidance by signaling through Robo receptors. Recent evidence suggests that Slit2 protein may function in other settings because human and Xenopus Slit2 has been shown to inhibit leukocyte chemotaxis. SLIT2 protein is a putative ligand for the ROBO receptors. We recently demonstrated that ROBO1 is inactivated by promoter region hypermethylation in <20% of human cancers; furthermore, tumor suppressor activity has not been shown. Thus, the importance of ROBO1 inactivation in human cancer is uncertain. Therefore, we investigated the status of SLIT2 located at 4p15.2 in lung and breast cancers. Although somatic SLIT2 mutations were not detected, epigenetic inactivation was common. SLIT2 promoter methylation was detected in 59% of breast cancer, 77% of non-small cell lung cancer, and 55% of small cell lung cancer cell lines. In these tumor lines, SLIT2 expression was restored by treatment with a demethylating agent. SLIT2 promoter methylation was detected in 43% of breast cancer, 53% of non-small cell lung cancer, and 36% of small cell lung cancer primary tumors. The majority of methylated tumors demonstrated allelic loss at 4p15.2. In addition, SLIT2 expression was down-regulated in methylated breast tumors, relative to normal control, as demonstrated by quantitative real-time reverse transcription-PCR. Overexpression of SLIT2 suppressed >70% of colony growth in each of three breast tumor lines (with either absent or low SLIT2 expression). Because SLIT2 is primarily a secreted protein, SLIT2-conditioned medium suppressed the growth of several breast cancer lines (with absent or weak SLIT2 expression) by 26-51% but had no significant effect on a breast tumor cell line that expresses normal levels of SLIT2. These findings demonstrate that SLIT2 is frequently inactivated in lung and breast cancer by promoter region hypermethylation and allele loss and is an excellent candidate for the lung and breast tumor suppressor gene previously mapped to 4p15.2.
C1 Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
   Univ Birmingham, CRC, Renal Mol Oncol Res Grp, Birmingham B15 2TG, W Midlands, England.
   Univ Pisa, Dept Oncol, Div Pathol, Pisa, Italy.
   Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Ctr Rene Huguenin, INSERM, Lab Oncogenet, E0017, F-92210 St Cloud, France.
C3 University of Birmingham; University of Birmingham; University of Pisa;
   University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; Rene Huguenin Hospital;
   Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
EM flatif@hgmp.mrc.ac.uk
RI Caligo, Adelaide/K-4289-2018; Minna, John/AAB-1036-2022; Dallol,
   Ashraf/H-8661-2012; MAHER, EAMONN/A-9507-2008; Bieche, Ivan/O-7399-2017
OI Dallol, Ashraf/0000-0002-8803-228X; Fernandes da Silva,
   Nancy/0009-0005-2217-8664; MAHER, EAMONN/0000-0002-6226-6918; Bieche,
   Ivan/0000-0002-2430-5429
FU NCI NIH HHS [P50 CA70907] Funding Source: Medline
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ba-Charvet KTN, 2001, J NEUROSCI, V21, P4281
   Battye R, 2001, J NEUROSCI, V21, P4290, DOI 10.1523/JNEUROSCI.21-12-04290.2001
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bièche I, 2001, CANCER RES, V61, P1652
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298
   Georgas K, 1999, CYTOGENET CELL GENET, V86, P246, DOI 10.1159/000015351
   Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482
   Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598
   Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745
   KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116
   Morrissey C, 2001, CANCER RES, V61, P7277
   Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211
   Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836
   POLASCIK TJ, 1995, CANCER RES, V55, P5396
   Ronca F, 2001, J BIOL CHEM, V276, P29141, DOI 10.1074/jbc.M100240200
   Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888
   Sherwood JB, 2000, GYNECOL ONCOL, V79, P90, DOI 10.1006/gyno.2000.5922
   Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303
   Shivapurkar N, 1999, CANCER RES, V59, P3576
   Shivapurkar N, 1999, CLIN CANCER RES, V5, P17
   Shivapurkar N, 2001, HUM PATHOL, V32, P169, DOI 10.1053/hupa.2001.21560
   Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Tse C, 2002, CANCER RES, V62, P542
   Vlacava P, 1999, J PATHOL, V188, P245
   Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098
   Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748
NR 34
TC 199
Z9 238
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2002
VL 62
IS 20
BP 5874
EP 5880
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 605TP
UT WOS:000178693400039
PM 12384551
DA 2025-01-12
ER

PT J
AU Esteller, M
   Guo, MZ
   Moreno, V
   Peinado, MA
   Capella, G
   Galm, O
   Baylin, SB
   Herman, JG
AF Esteller, M
   Guo, MZ
   Moreno, V
   Peinado, MA
   Capella, G
   Galm, O
   Baylin, SB
   Herman, JG
TI Hypermethylation-associated inactivation of the <i>cellular
   retinol-binding-protein 1</i> gene in human cancer
SO CANCER RESEARCH
LA English
DT Article
ID ACID RECEPTOR-BETA; RETINOIC ACID; BREAST-CANCER; PROMOTER
   HYPERMETHYLATION; LUNG-CANCER; METHYLATION; BINDING; EXPRESSION;
   CHEMOPREVENTION; IDENTIFICATION
AB The effects of retinol (vitamin A) depend on its transport and binding to nuclear receptors. The cellular retinol-binding protein 1 (CRBP1) and the retinoic acid receptor beta2 (RARbeta2) are key components of this process. Loss of CRBP1 expression occurs in breast tumors, but the mechanism is not known. We examined whether CpG island hypermethylation of CRBP1 was responsible for its inactivation in cancer cell lines (n = 36) and primary tumors (n = 553) and its relation to PARbeta2 methylation. Hypermethylation of CRBP1 was common in tumors and cancer cell lines, with the highest frequency in lymphoma and gastrointestinal carcinomas. Hypermethylation correlated with loss of CRBP1 mRNA, and in vitro treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivated CRBP1 expression. CRBP1 methylation appeared in premalignant lesions and frequently occurred with RARbeta2 hypermethylation in the same tumors. Finally, we observed that a higher dietary retinol intake was associated with reduced frequencies of methylation of both genes. Epigenetic disruption of CRBP1 is a common event in human cancer that may have important implications for cancer prevention and treatment using retinoids.
C1 Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA.
   Ctr Nacl Invest Oncol, Mol Pathol Program, Canc Epigenet Lab, Madrid 28220, Spain.
   Univ Autonoma Barcelona, Lab Bioestadist & Epidemiol, Calalonia 08907, Spain.
   Univ Autonoma Barcelona, Inst Catala Oncol, Calalonia 08907, Spain.
   Ciudad Sanitaria Univ Bellvitge LHospitalet, Inst Recerca Oncol, Barcelona 08907, Catalonia, Spain.
   Hosp Duren & Reynals, Inst Catala Oncol, Barcelona 08907, Catalonia, Spain.
C3 Johns Hopkins University; Johns Hopkins Medicine; Autonomous University
   of Barcelona; Autonomous University of Barcelona; Institut Catala
   d'Oncologia; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   Bellvitge University Hospital; Institut Catala d'Oncologia; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i
   Reynals
RP Johns Hopkins Comprehens Canc Ctr, Room 543,1650 Orleans St, Baltimore, MD 21231 USA.
EM hermanji@jhmi.edu
RI Peinado, Miguel A./A-5591-2008; Wang, Haitao/GYV-1262-2022; Esteller,
   Manel/L-5956-2014; Moreno, Victor/A-1697-2010; Capella,
   Gabriel/I-1879-2015
OI Esteller, Manel/0000-0003-4490-6093; Moreno, Victor/0000-0002-2818-5487;
   Peinado, Miguel A./0000-0002-4090-793X; Capella,
   Gabriel/0000-0002-4669-7320
FU NCI NIH HHS [CA88843, CA84986, CA58184] Funding Source: Medline
CR [Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS91
   Anzano MA, 1996, J NATL CANCER I, V88, P123, DOI 10.1093/jnci/88.2.123
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Båvik C, 1997, MECH DEVELOP, V69, P155, DOI 10.1016/S0925-4773(97)00167-6
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3
   Esteller M, 2001, CANCER RES, V61, P2816
   Esteller M, 2001, CANCER RES, V61, P4689
   Esteller M, 2001, CANCER RES, V61, P3225
   Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898
   Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903
   GUDAS LJ, 1994, J BIOL CHEM, V269, P15399
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hong WK, 1995, CLIN CANCER RES, V1, P677
   Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168
   Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475
   Kuppumbatti YS, 2001, ONCOGENE, V20, P7413, DOI 10.1038/sj.onc.1204749
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215
   Ong David E., 1994, P283
   PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216
   Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059
   Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200
   WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Xu XC, 1997, CANCER RES, V57, P4992
NR 31
TC 132
Z9 144
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2002
VL 62
IS 20
BP 5902
EP 5905
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 605TP
UT WOS:000178693400043
PM 12384555
DA 2025-01-12
ER

PT J
AU Zschocke, J
   Manthey, D
   Bayatti, N
   van der Burg, B
   Goodenough, S
   Behl, C
AF Zschocke, J
   Manthey, D
   Bayatti, N
   van der Burg, B
   Goodenough, S
   Behl, C
TI Estrogen receptor α-mediated silencing of caveolin gene expression in
   neuronal cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; HUMAN BREAST-CANCER; DNA-METHYLTRANSFERASE;
   DIFFERENTIAL EXPRESSION; NEUROBLASTOMA-CELLS; SIGNALING PATHWAYS;
   ENDOTHELIAL-CELLS; MOLECULAR-CLONING; TYROSINE KINASE; PLASMA-MEMBRANE
AB Estrogen receptors (ERalpha/ERbeta) are expressed in neuronal cells and exhibit a variety of activities in the central nervous system. ER activity is regulated in a ligand-dependent manner and by co-regulatory factors. Caveolin-1 is a recently identified co-activator of ERalpha mediating the ligand-independent activation of this steroid receptor. Here the influence of ERs on caveolin expression in human neuroblastoma SK-N-MC cells as well as in rodent brain was investigated. We found that ectopic expression of ERalpha in SK-N-MC cells (SK-ERalpha) leads to a ligand-independent transcriptional suppression of caveolin-1/-2 genes. This suppression is specifically mediated by ERalpha and not ERbeta because ERbeta counteracts the observed caveolin-silencing process. Interestingly, decreased caveolin expression in SK-ERalpha is accompanied by changes in the methylation pattern of caveolin promoters. The analysis of selected promoter regions of the human caveolin-1 gene showed that certain CpG dinucleotides were hypermethylated in SK-ERalpha cells, whereas the same sites were unmethylated in control, ERbeta-, and ERalpha/beta co-expressing SK-N-MC cells. Inhibition of DNA methylation or histone deacetylation led to partial re-expression of caveolin-1/-2 genes in SK-ERalpha. In vivo analysis revealed a down-regulation of caveolin-1 expression after long term estrogen exposure in certain regions of the mouse brain. In conclusion, we have shown for the first time that ERalpha and not ERbeta silences caveolin-1/-2 expression in an epigenetic fashion in neuronal cells. The observed mechanism of gene silencing by ERalpha may have implications for the transcriptional regulation of further ERalpha target genes.
C1 Max Planck Inst Psychiat, Neurodegenerat Grp, D-80804 Munich, Germany.
   Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands.
C3 Max Planck Society; Royal Netherlands Academy of Arts & Sciences;
   Hubrecht Institute (KNAW)
RP Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany.
EM chris@mpipsykl.mpg.de
RI Zschocke, Johannes/C-5885-2013
OI Behl, Christian/0000-0001-8453-2378
CR Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387
   Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846
   Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045
   BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7
   Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257
   Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640
   Braun JEA, 2000, J NEUROSCI, V20, P5997, DOI 10.1523/JNEUROSCI.20-16-05997.2000
   Cameron PL, 1997, J NEUROSCI, V17, P9520
   Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429
   Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#
   Davy A, 2000, J NEUROCHEM, V74, P676, DOI 10.1046/j.1471-4159.2000.740676.x
   DRYDEN GL, 1977, SCIENCE, V197, P782, DOI 10.1126/science.887921
   Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8
   Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448
   Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333
   Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810
   Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257
   Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633
   GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619
   GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0
   Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3
   Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485
   Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x
   Jayachandran M, 2001, AM J PHYSIOL-HEART C, V281, pH1327, DOI 10.1152/ajpheart.2001.281.3.H1327
   Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6
   Kamiya K, 1996, EXP CLIN ENDOCR DIAB, V104, P111, DOI 10.1055/s-0029-1211432
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366
   LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693
   Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182
   Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200
   Manthey D, 2001, EUR J BIOCHEM, V268, P4285, DOI 10.1046/j.1432-1327.2001.02346.x
   McEwen BS, 2001, J APPL PHYSIOL, V91, P2785, DOI 10.1152/jappl.2001.91.6.2785
   McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321
   McLachlan JA, 2001, TOXICOL LETT, V120, P161, DOI 10.1016/S0378-4274(01)00295-8
   Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932
   Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718
   Pelligrino DA, 2000, BIOCHEM BIOPH RES CO, V269, P165, DOI 10.1006/bbrc.2000.2206
   Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828
   Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100
   Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533
   Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131
   Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8
   Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551
   Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203
   SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217
   Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6
   Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460
   Spink DC, 1998, CARCINOGENESIS, V19, P291, DOI 10.1093/carcin/19.2.291
   Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255
   Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177
   Turi A, 2001, CELL BIOL INT, V25, P785, DOI 10.1006/cbir.2001.0769
   WRENN CK, 1993, J BIOL CHEM, V268, P24089
   Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631
   ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155
NR 62
TC 58
Z9 67
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 11
PY 2002
VL 277
IS 41
BP 38772
EP 38780
DI 10.1074/jbc.M205664200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 602XK
UT WOS:000178529600097
PM 12138116
OA hybrid
DA 2025-01-12
ER

PT J
AU Liu, LM
   Yoon, JH
   Dammann, R
   Pfeifer, GP
AF Liu, LM
   Yoon, JH
   Dammann, R
   Pfeifer, GP
TI Frequent hypermethylation of the <i>RASSF1A</i> gene in prostate cancer
SO ONCOGENE
LA English
DT Article
DE RASSF1A; methylation; tumor suppressor gene; prostate cancer
ID TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; ANDROGEN RECEPTOR GENE;
   CPG ISLAND; EPIGENETIC INACTIVATION; METHYLATION PATTERNS; BREAST
   CANCERS; LUNG-CANCER; PROGRESSION; PROMOTER
AB Recently, we have cloned and characterized the Ras association domain family 1A gene (RASSF1A) at 3p21.3, from which loss of genetic material is one of the most frequent events in several types of human solid tumors. The CpG island promoter region of this gene is highly methylated in several human cancers, most notably in small cell lung cancer, breast cancer, and renal cell carcinoma. In this study, we have analysed the methylation status of RASSF1A in primary prostate tumors and in the prostate cancer cell line LNCaP. In total, 37 out of 52 tumors (71%) were methylated at the promoter region of RASSF1A. The relative frequency of methylation was higher in more aggressive tumors compared with less malignant tumors. For instance, tumors with a Gleason score of 7-10 (25 out of 30, 83%) were significantly more methylated compared with Gleason 4-6 tumors (11 out of 20, 55%, P=0.032, Fisher's exact test). Coincident with a hypermethylated promoter, transcripts of RASSF1A were missing in LNCaP cells. Expression of RASSF1A was restored with 5-aza-2'-deoxycytidine, a DNA methylation inhibitor. In conclusion, our data suggest that epigenetic inactivation of RASSF1A by methylation is a very common event in prostate cancer and might be involved in the progression of the disease. Testing for RASSF1A methylation should become useful in prostate cancer early detection and diagnosis and might aid prognosis by gauging the potential status of progression.
C1 Beckman Res Inst, City Hope Canc Ctr, Dept Biol, Duarte, CA 91010 USA.
   Univ Halle Wittenberg, Inst Human Genet & Med Biol, D-06097 Halle Saale, Germany.
C3 City of Hope; Beckman Research Institute of City of Hope; Martin Luther
   University Halle Wittenberg
RP Pfeifer, GP (通讯作者)，Beckman Res Inst, City Hope Canc Ctr, Dept Biol, Duarte, CA 91010 USA.
OI yoon, jung-hoon/0000-0002-1624-3635
FU NCI NIH HHS [CA88873] Funding Source: Medline
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Cairns P, 2001, CLIN CANCER RES, V7, P2727
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#
   Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.0.CO;2-5
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Goessl C, 2001, UROLOGY, V58, P335, DOI 10.1016/S0090-4295(01)01268-7
   GUMERLOCK PH, 1991, CANCER RES, V51, P1632
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8
   Kito H, 2001, PROSTATE, V49, P110, DOI 10.1002/pros.1124
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Lee MG, 2001, CANCER RES, V61, P6688
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lerman MI, 2000, CANCER RES, V60, P6116
   Li LC, 2000, CANCER RES, V60, P702
   Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8
   Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3
   Lo KW, 2001, CANCER RES, V61, P3877
   Marcelli M, 2000, CANCER RES, V60, P944
   Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y
   Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190
   Nelson JB, 1997, CANCER RES, V57, P35
   Nwosu V, 2001, HUM MOL GENET, V10, P2313, DOI 10.1093/hmg/10.20.2313
   Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192
   Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916
   Ozen M, 2000, ANTICANCER RES, V20, P1905
   Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903
   PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252
   Rökman A, 2001, CANCER RES, V61, P6038
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Singal R, 2001, CANCER RES, V61, P4820
   Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Wang L, 2001, CANCER RES, V61, P6494
   Wistuba II, 2000, CANCER RES, V60, P1949
   Wu YQ, 2001, CANCER RES, V61, P8651
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
NR 47
TC 125
Z9 157
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD OCT 3
PY 2002
VL 21
IS 44
BP 6835
EP 6840
DI 10.1038/sj.onc.1205814
PG 6
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 599CD
UT WOS:000178315800014
PM 12360410
DA 2025-01-12
ER

PT J
AU Blanchard, F
   Kinzie, E
   Wang, YP
   Duplomb, L
   Godard, A
   Held, WA
   Asch, BB
   Baumann, H
AF Blanchard, F
   Kinzie, E
   Wang, YP
   Duplomb, L
   Godard, A
   Held, WA
   Asch, BB
   Baumann, H
TI FR901228, an inhibitor of histone deacetylases, increases the cellular
   responsiveness to IL-6 type cytokines by enhancing the expression of
   receptor proteins
SO ONCOGENE
LA English
DT Article
DE cytokine receptor; inflammatory mediators; signal transduction; gene
   regulation; cytotoxicity
ID BREAST-CANCER CELLS; ONCOSTATIN-M; DNA METHYLATION; BINDING-PROTEIN;
   UP-REGULATION; TRANSCRIPTIONAL REPRESSION; GELSOLIN EXPRESSION; TARGETED
   DISRUPTION; GROWTH-INHIBITION; SIGNAL TRANSDUCER
AB The related members of the interleukin-6 (IL-6) family of cytokines, leukemia inhibitory factor (LIF), oncostatin M (OSM) and IL-6 are inflammatory mediators that control differentiated cell functions as well as proliferation. The cellular responsiveness to these cytokines is largely determined by the expression of the appropriate receptor proteins. The receptor expression profile for each cell type is established during differentiation and is often altered during oncogenic transformation. Since inhibition of histone deacetylases (HDAC) has the potential to re-activate epigenetically silenced genes, we asked whether inhibition of HDAC enhances the expression of IL-6 cytokine receptors and, thus, increase desirable cytokine responses. We demonstrate that treatment with FR901228 (FR), an HDAC inhibitor, increases the responsiveness to LIF in different cell types, including normal fibroblasts, epithelial cells, macrophages and splenocytes, as well as various tumor cell lines. Depending on the cell type, FR treatment also enhances the responsiveness to OSM and IL-6. These effects involve a transcriptional induction of the cytokine receptor subunits LIFRalpha, OSMRbeta, gp130, or the transcription factor STAT3. FR-specific induction of LIFRalpha occurs independently of de noro protein synthesis and cell proliferation and is mediated in part by the CBP/p300 coactivator. Chromatin immunoprecipitation experiments indicate that the expression of LIFRalpha. and gp130 genes correlates with the level of acetylated histone 3 associated with the receptor promoter regions. The FR-stimulated expression of IL-6-type cytokine receptors in certain tumor cells also provided improved conditions for suppression of cell growth by taking advantage of the growth inhibitory effect of these cytokines.
C1 INSERM, U463, Inst Biol, F-44035 Nantes 01, France.
   Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.
   Roswell Pk Canc Inst, Div Expt Pathol, Buffalo, NY 14263 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive
   Cancer Center
RP Blanchard, F (通讯作者)，INSERM, U463, Inst Biol, 9 Quai Moncousu, F-44035 Nantes 01, France.
RI Blanchard, Frederic/AAS-1930-2021; Blanchard, Frederic/K-8018-2015
OI Duplomb, Laurence/0000-0002-5715-3759; Blanchard,
   Frederic/0000-0003-1055-2573
FU NCI NIH HHS [CA 16056, CA 68612, CA 85580] Funding Source: Medline;
   NIDDK NIH HHS [DK 38866] Funding Source: Medline
CR ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791
   Armenante F, 1999, BIOCHEM BIOPH RES CO, V258, P644, DOI 10.1006/bbrc.1999.0566
   Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313
   Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9
   BAJAJ P, 1993, CANCER LETT, V71, P143, DOI 10.1016/0304-3835(93)90109-M
   Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X
   BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137
   BHUYAN BK, 1992, CANCER RES, V52, P5687
   Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291
   Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200
   Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886
   Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200
   BREITMAN TR, 1990, CANCER RES, V50, P6268
   Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408
   CAMERON DJ, 1980, J IMMUNOL, V124, P708
   Chen B, 2000, CANCER RES, V60, P3290
   Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882
   Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127
   Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200
   Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146
   Kantarjian HM, 1997, LEUKEMIA, V11, P1617, DOI 10.1038/sj.leu.2400796
   Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007
   Kim H, 1999, MOL CELL BIOL, V19, P5326
   Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707
   Klouche M, 1999, J IMMUNOL, V163, P4583
   Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035
   Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357
   Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   Melki JR, 1999, CANCER RES, V59, P3730
   Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461
   Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008
   Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635
   NAIR BC, 1992, SCIENCE, V255, P1432
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003
   Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614
   RICHARDS CD, 1994, CYTOKINE, V6, P40, DOI 10.1016/1043-4666(94)90006-X
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327
   Shin JY, 2000, CANCER RES, V60, P262
   Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120
   Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200
   Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200
   Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957
   WARE CB, 1995, DEVELOPMENT, V121, P1283
   Weidle UH, 2000, ANTICANCER RES, V20, P1471
   Wong HR, 1997, AM J PHYSIOL-LUNG C, V273, pL1, DOI 10.1152/ajplung.1997.273.1.L1
   Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371
   Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407
NR 60
TC 31
Z9 34
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD SEP 12
PY 2002
VL 21
IS 41
BP 6264
EP 6277
DI 10.1038/sj.onc.1205777
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 590NM
UT WOS:000177829000003
PM 12214267
DA 2025-01-12
ER

PT J
AU Frisk, T
   Foukakis, T
   Dwight, T
   Lundberg, J
   Höög, A
   Wallin, G
   Eng, C
   Zedenius, J
   Larsson, C
AF Frisk, T
   Foukakis, T
   Dwight, T
   Lundberg, J
   Höög, A
   Wallin, G
   Eng, C
   Zedenius, J
   Larsson, C
TI Silencing of the <i>PTEN</i> tumor-suppressor gene in anaplastic thyroid
   cancer
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID PHOSPHATASE-ACTIVITY; CELL-LINES; PROSTATE-CANCER; COWDEN-DISEASE;
   PTEN/MMAC1; EXPRESSION; MUTATIONS; CARCINOMA; BREAST; PROTEIN
AB Germline mutations in the tumor-suppressor gene PTEN (MMAC1, TEP1) are found in Cowden syndrome, which predisposes to hamartomas, breast cancer, trichilemmomas, and thyroid tumors of follicular epithelium, PTEN has also been found to be somatically deleted, mutated, and/or silenced in various sporadically occurring cancers such as glioblastoma, breast cancer, kidney cancer, malignant melanoma, and endometrial cancer. Loss or reduction of PTEN protein expression as well as inappropriate subcellular compartmentalization is seen in non-medullary thyroid cancers, However. although allelic loss of the PTEN locus in 10q23.3 is frequently seen, this is not coupled with mutations in the PTEN gene. To approach further the frequency and mechanism behind PTEN silencing, we screened a panel of 87 sporadic thyroid tumors for PTEN mRNA expression, including 14 anaplastic carcinomas, 37 follicular carcinomas, 21 atypical adenomas. and 15 ordinary adenomas. Complete loss of PTEN mRNA expression was evident in six of the tumors, including four anaplastic carcinomas, one widely invasive carcinoma, and one ordinary adenoma. The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors. No association was observed between the expression, loss of heterozygosity, and mutation status in the 33 cases in which these parameters were compared. This indicates that PTEN silencing is a result of a wide variety of epigenetic and/or structural silencing mechanisms rather than a consequence of structural biallelic inactivation of the classical type. Furthermore, the high rate of alterations in the 10q23 region might indicate the presence of an as-yet unknown tumor-suppressor gene with an important role in the development of thyroid tumors. (C) 2002 Wiley-Liss, Inc.
C1 Karolinska Hosp, Dept Mol Med, Endocrine Tumor Unit, SE-17176 Stockholm, Sweden.
   Karolinska Hosp, Dept Surg, S-10401 Stockholm, Sweden.
   Huddinge Univ Hosp, Karolinska Inst, Dept Surg, Ctr MEtab & Endocrinol, Stockholm, Sweden.
   Karolinska Hosp, Dept Pathol & Oncol, S-10401 Stockholm, Sweden.
   Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA.
   Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA.
   Univ Cambridge, CRC Human Canc Genet Res Grp, Cambridge, England.
C3 Karolinska Institutet; Karolinska University Hospital; Karolinska
   Institutet; Karolinska University Hospital; Karolinska Institutet;
   Karolinska Institutet; Karolinska University Hospital; James Cancer
   Hospital & Solove Research Institute; University System of Ohio; Ohio
   State University; James Cancer Hospital & Solove Research Institute;
   University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University of Cambridge
RP Larsson, C (通讯作者)，Karolinska Hosp, Dept Mol Med, Endocrine Tumor Unit, CMM L8-01, SE-17176 Stockholm, Sweden.
RI Foukakis, Theodoros/KJL-9701-2024
OI Eng, Charis/0000-0002-3693-5145; Foukakis,
   Theodoros/0000-0001-8952-9987; Dwight, Trisha/0000-0003-1943-4514
CR Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115
   Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762
   Dahia PLM, 1997, CANCER RES, V57, P4710
   Elisei R, 1998, CANCER, V83, P2185, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.0.CO;2-4
   Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828
   Fujii GH, 1999, ONCOGENE, V18, P1765, DOI 10.1038/sj.onc.1202492
   Furnari FB, 1998, CANCER RES, V58, P5002
   Gimm O, 2000, HUM MOL GENET, V9, P1633, DOI 10.1093/hmg/9.11.1633
   Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7
   Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2
   Hedinger C.E., 1988, Histological typing of thyroid tumours
   Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357
   Li DM, 1997, CANCER RES, V57, P2124
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Lui WO, 2000, CANCER GENET CYTOGEN, V119, P109, DOI 10.1016/S0165-4608(99)00224-1
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052
   Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513
   Rhei E, 1997, CANCER RES, V57, P3657
   Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Teng DHF, 1997, CANCER RES, V57, P5221
   Weng LP, 1999, CANCER RES, V59, P5808
   Weng LP, 2001, HUM MOL GENET, V10, P251, DOI 10.1093/hmg/10.3.251
   Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246
   Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5
NR 28
TC 90
Z9 100
U1 1
U2 11
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 1045-2257
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD SEP
PY 2002
VL 35
IS 1
BP 74
EP 80
DI 10.1002/gcc.10098
PG 7
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 578XT
UT WOS:000177146900009
PM 12203792
DA 2025-01-12
ER

PT J
AU Murata, H
   Khattar, NH
   Kang, Y
   Gu, LY
   Li, GM
AF Murata, H
   Khattar, NH
   Kang, Y
   Gu, LY
   Li, GM
TI Genetic and epigenetic modification of mismatch repair genes
   <i>hMSH2</i> and <i>hMLH1</i> in sporadic breast cancer with
   microsatellite instability
SO ONCOGENE
LA English
DT Article
DE hMSH2; hMLH1; microsatellite instability; hypermethylation; breast
   cancer
ID NONPOLYPOSIS COLORECTAL-CANCER; IN-SITU; PROMOTER HYPERMETHYLATION;
   ENDOMETRIAL CARCINOMAS; CELL-LINES; GASTRIC CARCINOMAS; HIGH-FREQUENCY;
   COLON-CANCER; TUMOR-CELLS; DNA
AB Breast cancer is the most common cancer in women, but its pathogenesis is still unclear. Microsatellite instability (MSI) has been identified in breast cancer cells, suggesting an association with mismatch repair defects. To test this hypothesis, we investigated MSI, protein expression of hMSH2 and hMLH1, as well as genetic and epigenetic modifications of these two genes in 32 sporadic breast tumors. MSI was identified in 15 cases. Immunohistochemistry analysis revealed that all MSI cases but one had lower than normal expression of hMSH2 (nine cases), hMLH1 (12 cases), or both (seven cases). In tumors with MSI, both genetic and epigenetic modifications of these mismatch repair genes were also identified. Eight cases harbored mutations or polymorphisms in hMSH2 and hMLH1, and 10 exhibited hypermethylation in the promoter region of hMLH1. These results suggest that both genetic and epigenetic alterations of hMSH2 and especially of h-MLH1 contribute to genomic instability and tumorigenesis in sporadic breast cancer.
C1 Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Markey Canc Ctr, Lexington, KY 40536 USA.
C3 University of Kentucky
RP Li, GM (通讯作者)，Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Markey Canc Ctr, Suite MS 117,800 Rose St, Lexington, KY 40536 USA.
RI Li, Guo-Min/I-5016-2014
OI Li, Guo-Min/0000-0002-9842-4578
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   ALDAZ CM, 1995, CANCER RES, V55, P3976
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bevilacqua RAU, 2000, INT J CANCER, V87, P200, DOI 10.1002/1097-0215(20000715)87:2<200::AID-IJC7>3.0.CO;2-I
   Boland CR, 1998, CANCER RES, V58, P5248
   CONTEGIACOMO A, 1995, INT J CANCER, V64, P264, DOI 10.1002/ijc.2910640409
   CUI J, 1998, CHUNG HUA I HSUEH I, V15, P348
   Cunningham JM, 1998, CANCER RES, V58, P3455
   DeMarchis L, 1997, CLIN CANCER RES, V3, P241
   Deng GR, 1999, CANCER RES, V59, P2029
   Eshleman James R., 1995, Current Opinion in Oncology, V7, P83
   Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178
   Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2
   Fleisher AS, 1999, CANCER RES, V59, P1090
   Friedrich M, 1999, HISTOCHEM J, V31, P717, DOI 10.1023/A:1003996431044
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fujii Satoshi, 1998, Hiroshima Journal of Medical Sciences, V47, P89
   Grady WM, 2001, CANCER RES, V61, P900
   Gurin CC, 1999, CANCER RES, V59, P462
   Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Herman JG, 2000, CURR TOP MICROBIOL, V249, P35
   Hosoya N, 1998, JPN J CANCER RES, V89, P33, DOI 10.1111/j.1349-7006.1998.tb00476.x
   Jonsson M, 1995, EUR J CANCER, V31A, P2330, DOI 10.1016/0959-8049(95)00447-5
   Kane MF, 1997, CANCER RES, V57, P808
   KATABUCHI H, 1995, CANCER RES, V55, P5556
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8
   Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1
   Leung SY, 1999, CANCER RES, V59, P159
   Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.3.CO;2-I
   Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084
   LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950
   LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48
   Lynch HT, 1999, J MED GENET, V36, P801
   Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533
   PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J
   Paulson TG, 1996, CANCER RES, V56, P4021
   Rosenberg CL, 1997, HUM PATHOL, V28, P214, DOI 10.1016/S0046-8177(97)90109-X
   Rush EB, 1997, ANN SURG ONCOL, V4, P310, DOI 10.1007/BF02303580
   Salvesen HB, 2000, CLIN CANCER RES, V6, P3607
   Scott RJ, 2001, AM J HUM GENET, V68, P118, DOI 10.1086/316942
   Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264
   Shen KL, 2000, J SURG ONCOL, V74, P100, DOI 10.1002/1096-9098(200006)74:2<100::AID-JSO5>3.0.CO;2-O
   Siah SP, 2000, BREAST CANCER RES TR, V60, P135, DOI 10.1023/A:1006315315060
   STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0
   Thibodeau SN, 1998, CANCER RES, V58, P1713
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Thibodeau SN, 1996, CANCER RES, V56, P4836
   Toyama T, 1996, CANCER LETT, V108, P205, DOI 10.1016/S0304-3835(96)04414-X
   Toyama T, 1996, INT J CANCER, V68, P447, DOI 10.1002/(SICI)1097-0215(19961115)68:4<447::AID-IJC8>3.0.CO;2-0
   Vasen HFA, 2001, AM J HUM GENET, V68, P1533, DOI 10.1086/320610
   Walsh T, 1998, J PATHOL, V185, P18, DOI 10.1002/(SICI)1096-9896(199805)185:1<18::AID-PATH41>3.0.CO;2-G
   Weber TK, 1997, CANCER RES, V57, P3798
   YEE CJ, 1994, CANCER RES, V54, P1641
   ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155
NR 57
TC 73
Z9 94
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD AUG 22
PY 2002
VL 21
IS 37
BP 5696
EP 5703
DI 10.1038/sj.onc.1205683
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 584JL
UT WOS:000177463400004
PM 12173039
DA 2025-01-12
ER

PT J
AU Toyooka, KO
   Toyooka, S
   Maitra, A
   Feng, QH
   Kiviat, NC
   Smith, A
   Minna, JD
   Ashfaq, R
   Gazdar, AF
AF Toyooka, KO
   Toyooka, S
   Maitra, A
   Feng, QH
   Kiviat, NC
   Smith, A
   Minna, JD
   Ashfaq, R
   Gazdar, AF
TI Establishment and validation of real-time polymerase chain reaction
   method for <i>CDH1</i> promoter methylation
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; TUMOR-SUPPRESSOR
   GENE; CANCER CELL-LINES; BREAST-CANCER; LUNG-CANCER; ALLELE LOSS;
   CARCINOMAS; DNA; HYPERMETHYLATION
AB Aberrant methylation of the promoter region has emerged as the major mechanism for silencing tumor suppressor genes. However, for some genes, such as E-cadherin (CDH1), methylation and protein expression demonstrate considerable heterogeneity, making correlations difficult. We compared methylation and protein expression status of CDH1 in 56 primary breast carcinomas using semiquantitative assays. Aberrant CDH1 methylation was studied by methylation-specific polymerase chain reaction (MSP) and semiquantitative real-time MSP assays. The Cdh1 expression was investigated by immunostaining on archival formalin-fixed sections from 34 primary carcinomas and their accompanying normal epithelium and preinvasive and metastatic lesions. Membrane-specific Cdh1 expression in the neoplastic cells was quantified by image analysis using an automated cellular imaging system and a continuous score. Aberrant promoter methylation of the CDH1 was present in 24 of 56 (43%) breast carcinomas by MSP assay. There was excellent concordance between the standard MSP assay and the real-time assay (91%, P < 0.0001). The concordance between loss of Cdh1 expression and CDH1 methylation by standard MSP was 71% (P = 0.02). Furthermore, there was a strong correlation between the semiquantitative assays for methylation and protein expression (r = 0.47, P = 0.005). We conclude that promoter methylation of CDH1 significantly correlated with the Cdh1 expression level, demonstrating that epigenetic silencing is a valid pathway for silencing of tumor suppressor genes in primary breast carcinomas.
C1 Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.
   Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas Dallas;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Dallas; University of Texas
   Southwestern Medical Center Dallas; University of Washington; University
   of Washington Seattle
RP Gazdar, AF (通讯作者)，Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
RI Gazdar, Adi/F-7496-2010; Minna, John/AAB-1036-2022
FU NCI NIH HHS [5U01CA8497102] Funding Source: Medline
CR Asgeirsson KS, 2000, EUR J CANCER, V36, P1098, DOI 10.1016/S0959-8049(00)00062-9
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258
   Berx G, 1996, ONCOGENE, V13, P1919
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Eads CA, 1999, CANCER RES, V59, P2302
   Girard L, 2000, CANCER RES, V60, P4894
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Hiraguri S, 1998, CANCER RES, V58, P1972
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Kanai Y, 1997, INT J CANCER, V71, P355
   KATAGIRI A, 1995, BRIT J CANCER, V71, P376, DOI 10.1038/bjc.1995.76
   KNUDSON AG, 1985, CANCER RES, V45, P1437
   Kremmidiotis G, 1998, GENOMICS, V49, P467, DOI 10.1006/geno.1998.5281
   LINDBLOM A, 1993, CANCER RES, V53, P3707
   MAREEL M, 1995, CANCER DETECT PREV, V19, P451
   MOLL R, 1993, AM J PATHOL, V143, P1731
   PIERCEALL WE, 1995, ONCOGENE, V11, P1319
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2
   Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   TSUDA H, 1995, CANCER RES, V55, P3395
   TSUDA H, 1994, CANCER RES, V54, P513
   WANG RYH, 1980, NUCLEIC ACIDS RES, V8, P4777, DOI 10.1093/nar/8.20.4777
   Wang SJ, 2001, AM J CLIN PATHOL, V116, P495
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 39
TC 30
Z9 33
U1 0
U2 4
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2002
VL 161
IS 2
BP 629
EP 634
DI 10.1016/S0002-9440(10)64218-6
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 582DQ
UT WOS:000177334800031
PM 12163387
OA Green Accepted, Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Farias, EF
   Arapshian, A
   Bleiweiss, IJ
   Waxman, S
   Zelent, A
   Mira-y-Lopez, R
AF Farias, EF
   Arapshian, A
   Bleiweiss, IJ
   Waxman, S
   Zelent, A
   Mira-y-Lopez, R
TI Retinoic acid receptor α2 is a growth suppressor epigenetically silenced
   in MCF-7 human breast cancer cells
SO CELL GROWTH & DIFFERENTIATION
LA English
DT Article
ID DIFFERENTIAL EXPRESSION; CARCINOMA CELLS; LUNG-CANCER; BETA GENE;
   NUCLEAR; METHYLATION; INHIBITION; PROTEIN; BINDING; CARCINOGENESIS
AB Retinoic acid (RA) receptor (RAR) beta2 has been shown to be underexpressed in human breast cancer cells, including MCF-7 cells, and recent reports have suggested that hypermethylation of the RARbeta2 promoter and 5'-UTR is the underlying cause. Here we show that RARalpha2 is also underexpressed in MCF-7 breast cancer cells, at both the message and the protein level, relative to normal or nontumorigenic breast epithelial cells. Bisulfite sequencing of the CpG island in the RARalpha2 promoter revealed highly penetrant and uniform cytosine methylation in MCF-7 cells. Pretreatment with the DNA methyltransferase inhibitor, azacytidine, followed by treatment with RA and a histone deacetylase inhibitor, trichostatin A, resulted in partial promoter demethylation and RARalpha2 induction, which strongly suggested that promoter hypermethylation is responsible for RARalpha2 underexpression. We compared the outcome of ectopic expression in MCF-7 cells of matched levels of RARalpha2 and RARbeta2. On the basis of a clonogenic assay, RARalpha2 displayed ligand-dependent growth-suppressive activity similar to that of RAR,62; thus, 10 and 20 nm RA inhibited clonogenic growth by 52 and 80%, respectively, in RARalpha2-transfected cells compared with 75 and 77%, respectively, in RARbeta2-transfected cells. We conclude that the silencing of the RARalpha2 promoter, by hypermethylation may play a contributory role in the dysregulation of RA signaling in mammary tumorigenesis.
C1 Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
   Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA.
   Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Royal Marsden NHS Foundation Trust; University of London;
   Institute of Cancer Research - UK
RP Mira-y-Lopez, R (通讯作者)，Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.
RI Zelent, Arthur/B-3532-2009
OI Zelent, Arthur/0000-0002-7968-9888
FU NCI NIH HHS [CA54273, R01 CA054273] Funding Source: Medline
CR Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520
   Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   DAIRKEE S, 1993, IN VITRO CELL DEV-AN, V29A, P427
   DAWSON MI, 1995, CANCER RES, V55, P4446
   Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783
   Fitzgerald P, 1997, CANCER RES, V57, P2642
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D
   Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073
   Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168
   Khuri FR, 2000, J CLIN ONCOL, V18, P2798, DOI 10.1200/JCO.2000.18.15.2798
   LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x
   LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302
   Li YP, 1997, BLOOD, V90, P306
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116
   Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#
   Mollard R, 2000, INT J DEV BIOL, V44, P457
   Powell BL, 2001, CURR OPIN ONCOL, V13, P8, DOI 10.1097/00001622-200101000-00003
   Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3
   ROMAN SD, 1992, CANCER RES, V52, P2236
   Schneider SM, 2000, CANCER RES, V60, P5479
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   SHEIKH MS, 1994, J BIOL CHEM, V269, P21440
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651
   STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415
   Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1
   Ueki T, 2000, CANCER RES, V60, P1835
   VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624
   Xu XC, 1997, CANCER RES, V57, P4992
   XU XC, 1994, CANCER RES, V54, P3580
   ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x
   Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807
NR 40
TC 40
Z9 51
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 1044-9523
J9 CELL GROWTH DIFFER
JI Cell Growth Differ.
PD AUG
PY 2002
VL 13
IS 8
BP 335
EP 341
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 587YJ
UT WOS:000177671700001
PM 12193472
DA 2025-01-12
ER

PT J
AU Cheng, RYS
   Alvord, WG
   Powell, D
   Kasprzak, KS
   Anderson, LM
AF Cheng, RYS
   Alvord, WG
   Powell, D
   Kasprzak, KS
   Anderson, LM
TI Increased serum corticosterone and glucose in offspring of
   chromium(III)-treated male mice
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE chromium(III); corticosterone; insulin-like growth factor 1;
   insulin-like growth factor binding protein 1; offspring; paternal;
   preconceptional; stress; transgenerational
ID FACTOR BINDING-PROTEINS; GROWTH-FACTOR; CALORIC RESTRICTION;
   EPIDEMIOLOGIC EVIDENCE; BREAST-CANCER; INSULIN; RISK; DIRECTIONS;
   ADENOMAS; TUMORS
AB Preconceptional carcinogenesis occurs in animals and is suspected for humans-for example, after occupational metals exposure. Several characteristics in animal models, including high frequency and non-Mendelian inheritance patterns, have suggested an epigenetic mechanism, possibly involving hormone changes in offspring. To test this hypothesis, we treated male mice with chromium(III) chloride, a preconceptional carcinogen, 2 weeks before mating, in two separate experiments. Their 10-week-old offspring showed highly significant increases in average serum corticosterone and glucose, compared with control offspring. Average serum levels of insulin-like growth factor 1 (IGF1) showed more modest possible increases. A previous microarray experiment identified hepatic insulin-like growth factor binding protein 1 (IGF BP1) gene expression as consistently changed in correlation with serum corticosterone levels. In the present study, hepatic IGF BP1 mRNA correlated with serum IGF1 in male offspring of chromium-treated fathers, but not in controls; serum glucose correlated positively with hepatic IGF BP1 in chromium-group offspring but negatively in controls. These results support the hypothesis that preconceptional exposure effects may alter hormones, metabolism, and control of tissue gene expression, probably through epigenetic mechanisms. Risk of neoplasia may be influenced by these changes.
C1 NCI, Comparat Carcinogenesis Lab, Ctr Canc Res, Frederick, MD 21702 USA.
   NCI, Data Management Serv Inc, Frederick, MD 21702 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI)
RP NCI, Comparat Carcinogenesis Lab, Ctr Canc Res, Bldg 538, Frederick, MD 21702 USA.
EM Andersol@mail.ncifcrf.gov
RI Cheng, Robert/E-9799-2013
OI Cheng, Robert/0000-0003-0287-6439
CR Agrawal AA, 1999, NATURE, V401, P60, DOI 10.1038/43425
   Anderson LM, 2000, ENVIRON HEALTH PERSP, V108, P573, DOI 10.2307/3454549
   ANDERSON LM, 1994, P INT S MAL MED DEV, P129
   ANDERSSON SO, 1995, CANCER EPIDEM BIOMAR, V4, P187
   BAXTER RC, 1995, METABOLISM, V44, P12, DOI 10.1016/0026-0495(95)90215-5
   BENCH G, 2000, METAL IONS BIOL MED, P339
   Bunin G.R., 1992, OCCUPATIONAL ENV REP, P76
   CAMPBELL JH, 1988, PROG BRAIN RES, V73, P535
   Cheng R.Y.S., 2000, Proc Am Assoc Cancer Res, V41, P507
   Feinberg AP, 2000, CURR TOP MICROBIOL, V249, P87
   Frame LT, 1998, ENVIRON HEALTH PERSP, V106, P313
   Huang H, 1997, J ENDOCRINOL, V152, P99, DOI 10.1677/joe.0.1520099
   Hursting SD, 1999, MUTAT RES-GEN TOX EN, V443, P235, DOI 10.1016/S1383-5742(99)00021-6
   Iwasaki T, 1996, INT J RADIAT BIOL, V69, P487, DOI 10.1080/095530096145788
   JANERICH DT, 1989, J CLIN EPIDEMIOL, V42, P151, DOI 10.1016/0895-4356(89)90088-7
   Kari F W, 1999, J Nutr Health Aging, V3, P92
   Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319
   LOKTIONOV A, 1992, CARCINOGENESIS, V13, P19, DOI 10.1093/carcin/13.1.19
   McCarty MF, 1997, MED HYPOTHESES, V48, P297, DOI 10.1016/S0306-9877(97)90098-0
   McKenna IM, 2001, MUTAT RES-GEN TOX EN, V490, P57, DOI 10.1016/S1383-5718(00)00153-4
   NOMURA T, 1987, FUNCTIONAL TERATOGEN, P175
   OLSEN JH, 1991, EUR J CANCER, V27, P958, DOI 10.1016/0277-5379(91)90258-F
   Ortega R, 2001, NUCL INSTRUM METH B, V181, P485, DOI 10.1016/S0168-583X(01)00477-3
   PAVELIC K, 1978, Z KREBSFORSCH KLIN O, V92, P147, DOI 10.1007/BF00312407
   Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7
   Potischman N, 1999, CANCER CAUSE CONTROL, V10, P561, DOI 10.1023/A:1008955110868
   RUGGERI BA, 1989, CANCER RES, V49, P4130
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   Schoen RE, 1999, JNCI-J NATL CANCER I, V91, P1147, DOI 10.1093/jnci/91.13.1147
   Sephton SE, 2000, J NATL CANCER I, V92, P994, DOI 10.1093/jnci/92.12.994
   TOMATIS L, 1992, CARCINOGENESIS, V13, P145, DOI 10.1093/carcin/13.2.145
   TOMATIS L, 1994, JPN J CANCER RES, V85, P443, DOI 10.1111/j.1349-7006.1994.tb02378.x
   TURUSOV VS, 1990, CANCER LETT, V55, P227, DOI 10.1016/0304-3835(90)90123-F
   Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472
   Yu W, 1999, TOXICOL APPL PHARM, V158, P161, DOI 10.1006/taap.1999.8692
NR 35
TC 21
Z9 23
U1 0
U2 1
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD AUG
PY 2002
VL 110
IS 8
BP 801
EP 804
DI 10.1289/ehp.02110801
PG 4
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 583FK
UT WOS:000177395900035
PM 12153762
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Chan, KYK
   Ozçelik, H
   Cheung, ANY
   Ngan, HYS
   Khoo, US
AF Chan, KYK
   Ozçelik, H
   Cheung, ANY
   Ngan, HYS
   Khoo, US
TI Epigenetic factors controlling the <i>BRCA1</i> and <i>BRCA2</i> genes
   in sporadic ovarian cancer
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; MESSENGER-RNA; PROMOTER; METHYLATION; HYPERMETHYLATION;
   EXPRESSION; REGION; IDENTIFICATION; TUMOR
AB Hypermethylation of the BRCA1 promoter has previously been shown to cause reduced mRNA expression in both breast and ovarian cancers. Nothing is yet known of the expression pattern or methylation status of the promoter region of BRCA2 in sporadic ovarian cancer. Whereas our analysis of 30 sporadic ovarian carcinomas showed a statistically significant reduction of BRCA1 mRNA expression (P = 0.001), it also showed, in contrast, overexpression of BRCA2 mRNA (P = 0.002) in tumor compared with nontumor. Hypemlethylation of the BRCA1 promoter highly correlated with decreased BRCA1 expression (P = 0.017). Methylated CpGs at the BRCA2 promoter were either absent or at very low levels in tumor DNA, whereas they were present at high levels in nontumor DNA. Such hypomethylation also correlated with elevated levels of BRCA2 mRNA (P = 0.043) and showed a statistically significant correlation with tumor stage (P = 0.037). This supports the role of methylation in BRCA2 contributing to the pathogenesis of sporadic ovarian cancer. Furthermore, 14 (58.2%) and 9 (56.3%) of all of the cases with aberrant BRCA1 mRNA expression and methylation patterns, respectively, demonstrated opposing mRNA expression and methylation patterns of the BRCA1 and BRCA2 genes within the same cases. Our findings suggest that both genes may be involved in the development of sporadic ovarian cancer.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
   Queen Mary Hosp, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China.
   Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada.
   Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong; University of Toronto; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute
RP Khoo, US (通讯作者)，Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
RI Cheung, Annie/C-4230-2009; Chan, Kelvin/HGA-3097-2022; Khoo,
   Ui/K-2041-2019; Ozcelik, Hilmi/A-3952-2011; Khoo, Ui Soon/C-4293-2009;
   Cheung, Annie Nga Yin/C-4231-2009; Chan, Kelvin Yuen Kwong/I-4788-2014
OI Khoo, Ui Soon/0000-0003-2200-7505; Cheung, Annie Nga
   Yin/0000-0002-1584-7568; Chan, Kelvin Yuen Kwong/0000-0002-5272-0005;
   Ngan, Hextan Y S/0000-0003-3945-159X
CR Beckmann MW, 1996, BRIT J CANCER, V73, P1220, DOI 10.1038/bjc.1996.234
   Bièche I, 1999, ONCOGENE, V18, P5232, DOI 10.1038/sj.onc.1202903
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990
   Dong SM, 2001, CLIN CANCER RES, V7, P1982
   HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343
   Khoo U S, 2000, Hum Mutat, V16, P88, DOI 10.1002/1098-1004(200007)16:1<88::AID-HUMU16>3.0.CO;2-G
   Khoo Ui-Soon, 2002, Hum Mutat, V19, P307, DOI 10.1002/humu.9015
   Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Nakajima T, 2001, INT J CANCER, V94, P208, DOI 10.1002/ijc.1454
   OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0
   Özçelik H, 1998, INT J CANCER, V77, P1
   RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B
   Sharan C, 1999, BIOCHEM BIOPH RES CO, V265, P285, DOI 10.1006/bbrc.1999.1652
   SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Wu K, 2000, J BIOL CHEM, V275, P35548, DOI 10.1074/jbc.M004390200
NR 24
TC 111
Z9 129
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2002
VL 62
IS 14
BP 4151
EP 4156
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 574CU
UT WOS:000176871500040
PM 12124354
DA 2025-01-12
ER

PT J
AU Smith, AJH
   Xian, J
   Richardson, M
   Johnstone, KA
   Rabbitts, PH
AF Smith, AJH
   Xian, J
   Richardson, M
   Johnstone, KA
   Rabbitts, PH
TI Cre-<i>loxP</i> chromosome engineering of a targeted deletion in the
   mouse corresponding to the 3p21.3 region of homozygous loss in human
   tumours
SO ONCOGENE
LA English
DT Article
DE Cre-loxP; Luca region; chromosome 3; deletion; breast cancer; lung
   cancer
ID EMBRYONIC STEM-CELLS; FREQUENT EPIGENETIC INACTIVATION; SUPPRESSOR GENE;
   LUNG-CANCER; ALLELE LOSS; RASSF1A; BREAST; MICE; RECOMBINATION;
   GENERATION
AB Chromosomal deletions are a common feature of epithelial tumours and when further defined by homozygous deletions, are often the location of tumour suppressor genes. Deletions within the short arm of chromosome 3 occur very frequently in human carcinomas: a minimal region of loss at 3p21.3 (the Luca) region has been defined by overlapping homozygous deletions in lung and breast cancer cell lines. Using a rapid strategy for Cre-loxP chromosome engineering, a deletion of approximately 370 kb was created in the mouse germline corresponding to the deleted region at 3p21.3. The deletion when homozygous is embryonic lethal. Heterozygotes develop normally despite being haplo-insufficient for twelve genes including the candidate tumour suppressor gene Rassf1. Because damage to 3p21.3 often occurs very early in the sequence of genetic changes that lead to malignancy, particularly in lung and breast cancer, further genetic damage to these mice will provide the opportunity to model multi-step tumorigenesis of these tumours.
C1 Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland.
   Univ Cambridge, Ctr Mrc, Dept Oncol, Cambridge CB2 2QH, England.
C3 University of Edinburgh; University of Cambridge
RP Smith, AJH (通讯作者)，Univ Edinburgh, Ctr Genome Res, W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.
RI Johnstone, Karen/E-2369-2011
OI Johnstone, Karen/0000-0002-3183-8397
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Chung GTY, 1995, ONCOGENE, V11, P2591
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   HESKETH R, 1997, ONCOGENE TUMOUR SUPP
   Justice MJ, 1997, METHODS, V13, P423, DOI 10.1006/meth.1997.0548
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832
   Lee MG, 2001, CANCER RES, V61, P6688
   LePage DF, 2000, P NATL ACAD SCI USA, V97, P10471, DOI 10.1073/pnas.97.19.10471
   Lerman MI, 2000, CANCER RES, V60, P6116
   Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158
   Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0
   Mitelman F, 1991, CATALOGUE CHROMOSOME
   Morrissey C, 2001, CANCER RES, V61, P7277
   RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376
   Thomas JW, 1998, P NATL ACAD SCI USA, V95, P1114, DOI 10.1073/pnas.95.3.1114
   VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z
   Wistuba II, 2000, CANCER RES, V60, P1949
   Zheng BH, 2000, MOL CELL BIOL, V20, P648, DOI 10.1128/MCB.20.2.648-655.2000
   Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137
NR 27
TC 25
Z9 27
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JUL 4
PY 2002
VL 21
IS 29
BP 4521
EP 4529
DI 10.1038/sj.onc.1205530
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 567GH
UT WOS:000176476700006
PM 12085230
OA Bronze
DA 2025-01-12
ER

PT J
AU Tomizawa, Y
   Kohno, T
   Kondo, H
   Otsuka, A
   Nishioka, M
   Niki, T
   Yamada, T
   Maeshima, A
   Yoshimura, K
   Saito, R
   Minna, JD
   Yokota, J
AF Tomizawa, Y
   Kohno, T
   Kondo, H
   Otsuka, A
   Nishioka, M
   Niki, T
   Yamada, T
   Maeshima, A
   Yoshimura, K
   Saito, R
   Minna, JD
   Yokota, J
TI Clinicopathological significance of epigenetic inactivation of
   <i>RASSF1A</i> at 3p21.3 in stage I lung adenocarcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; SMALL-CELL CARCINOMA; PROMOTER METHYLATION;
   CHROMOSOME 3P21.3; DELETION REGION; BREAST CANCERS; CPG ISLAND; RAS;
   LOCUS; P53
AB Purpose: Chromosome 3p is deleted frequently in various types of human cancers, including lung cancer. Recently, the RASSF1A gene was isolated from the 3p21.3 region homozygously deleted in lung and breast cancer cell lines, and it was shown to be inactivated by hypermethylation of the promoter region in lung cancers. In this study, we investigated the pathogenetic and clinicopathological significances of RASSF1A methylation in the development and/or progression of lung adenocarcinoma.
   Experimental Design: Association of RASSF1A methylation with clinicopathological features, allelic imbalance at 3p21.3, p53 mutations, and K-ras mutations was examined in 110 stage 1 lung adenocarcinomas.
   Results: Thirty-five of 110 (32%) tumors showed RASSF1A methylation. RASSF1A methylation was dominantly detected in tumors with vascular invasion (P = 0.0242) or pleural involvement (P = 0.0305), and was observed more frequently in poorly differentiated tumors than in well (P = 0.0005) or moderately (P = 0.0835) differentiated tumors. Furthermore, RASSF1A methylation correlated with adverse survival by univariate analysis (P = 0.0368; log-rank test) as well as multivariate analysis (P = 0.032,; risk ratio 2.357; 95% confidence interval, 1.075-5.169). The correlation between RASSF1A methylation and allelic imbalance at 3p21.3 was significant (P = 0.0005), whereas the correlation between RASSF1A methylation and p53 mutation was borderline (P = 0.0842). However, there was no correlation or inverse correlation between RASSF1A methylation and K-ras mutation (P = 0.2193).
   Conclusions: These results indicated that epigenetic inactivation of RASSF1A plays an important role in the progression of lung adenocarcinoma, and that RASSF1A hypermethylation appears to be a useful molecular marker for the prognosis of patients with stage I lung adenocarcinoma.
C1 Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan.
   Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan.
   Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Chuo Ku, Tokyo 1040045, Japan.
   Natl Canc Ctr, Thorac Surg Div, Tokyo 1040045, Japan.
   Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan.
   Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
C3 National Cancer Center - Japan; National Cancer Center - Japan; National
   Cancer Center - Japan; National Cancer Center - Japan; Gunma University;
   University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas
RP Yokota, J (通讯作者)，Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.
RI Kohno, Takashi/M-8823-2013; niki, toshiro/K-8917-2012; Minna,
   John/AAB-1036-2022
FU NCI NIH HHS [P50 CA70907, R01 CA71618] Funding Source: Medline
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   [Anonymous], TNM CLASSIFICATION M
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Daigo Y, 1999, CANCER RES, V59, P1966
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194
   Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HIBI K, 1992, ONCOGENE, V7, P445
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877
   Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403
   KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0
   Lerman MI, 2000, CANCER RES, V60, P6116
   Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055
   Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0
   NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0
   NESBITT JC, 1995, ANN THORAC SURG, V60, P466, DOI 10.1016/0003-4975(95)00169-L
   NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#
   Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120
   Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9
   STRAUSS GM, 1995, J CLIN ONCOL, V13, P1265, DOI 10.1200/JCO.1995.13.5.1265
   SUGIO K, 1992, CANCER RES, V52, P2903
   Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   TRAVIS WD, 1995, CANCER-AM CANCER SOC, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Wistuba II, 2000, CANCER RES, V60, P1949
   YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 34
TC 104
Z9 118
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL
PY 2002
VL 8
IS 7
BP 2362
EP 2368
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 571VR
UT WOS:000176740300043
PM 12114441
DA 2025-01-12
ER

PT J
AU Yared, E
   McMillan, TJ
   Martin, FL
AF Yared, E
   McMillan, TJ
   Martin, FL
TI Genotoxic effects of oestrogens in breast cells detected by the
   micronucleus assay and the Comet assay
SO MUTAGENESIS
LA English
DT Article
ID CANCER RISK; ETIOLOGY; AMERICAN; WOMEN; MILK
AB Cumulative exposure to oestrogen has been linked to increased risk of breast cancer. Whilst oestrogens induce cancers in rodent bioassays it is unclear whether the mechanisms involved are genotoxic and/or epigenetic. The cytokinesis block micronucleus (CBMN) and the alkaline single cell-gel electrophoresis `Comet' assays were used to examine MCF-7 cells for chromosomal damage and DNA single-strand breaks (SSBs), respectively. The comet-forming activities of oestrogens were also tested in a 72 h primary culture of cells isolated from freshly expressed breast milk. Micronuclei (MN) were scored in 500 binucleate cells per treatment and SSBs were quantified by comet tail length (CTL) (mum). Effects on mitotic rate (per cent binucleate cells) and cell viability (per cent plating efficiency) were also assessed. beta-Oestradiol, oestrone and oestriol were tested for genotoxicity in the 10(-10)-10(-4) M and 10(-10)-10(-2) M concentration ranges in the CBMN and Comet assays, respectively. beta-Oestradiol, following 24 h treatment but not 120 h treatment, induced increases (up to 3-fold) in MN at a concentration of 10(-9) M. Oestrone induced dose-related increases in MN (up to 5-fold) following both 24 and 120 h treatment, whereas oestriol appeared not to induce MN. All three oestrogens induced dose-related increases in per cent binucleate cells suggesting that they enhance mitotic rate. In the Comet assay both beta-oestradiol and oestrone induced dose-related increases in SSBs (up to 7-fold over control CTL) and were significantly comet-forming (P < 0.0001) at concentrations as low as 10(-9) and 10(-8) M, respectively, whereas oestriol was less genotoxic. All three oestrogens were significantly comet-forming (P < 0.0001) in a primary culture of breast milk cells, suggesting that they can damage the target cells from which breast cancers may eventually arise.
C1 Univ Lancaster, IENS, Dept Biol Sci, Lancaster LA1 4YQ, England.
C3 Lancaster University
RP Martin, FL (通讯作者)，Univ Lancaster, IENS, Dept Biol Sci, Lancaster LA1 4YQ, England.
RI Martin, Francis/J-4585-2019
OI L Martin, Francis/0000-0001-8562-4944
CR ADASHI EY, 1992, REPROD ENDOCRINOLOGY, P181
   BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275
   Bowlin SJ, 1997, INT J EPIDEMIOL, V26, P915, DOI 10.1093/ije/26.5.915
   Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75
   ELBAYOUMY K, 1992, CHEM RES TOXICOL, V5, P585, DOI 10.1021/tx00029a001
   Feigelson HS, 1996, CARCINOGENESIS, V17, P2279, DOI 10.1093/carcin/17.11.2279
   Fischer WH, 2001, MUTAGENESIS, V16, P209, DOI 10.1093/mutage/16.3.209
   GROVER PL, 2002, IN PRESS CARCINOGENE, V23
   Higginson J., 1992, Cambridge Monographs on Cancer Research, Human Cancer, P377
   LEMON HM, 1989, CANCER-AM CANCER SOC, V63, P1685
   Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706
   Lingeman C H, 1979, Recent Results Cancer Res, V66, P1
   Martin FL, 2000, MUTAT RES-GEN TOX EN, V470, P115, DOI 10.1016/S1383-5742(00)00046-6
   Martin FL, 1999, MUTAT RES-GEN TOX EN, V445, P21, DOI 10.1016/S1383-5718(99)00116-3
   Martin FL, 1997, CARCINOGENESIS, V18, P2299, DOI 10.1093/carcin/18.12.2299
   Martin FL, 2001, MUTAGENESIS, V16, P401, DOI 10.1093/mutage/16.5.401
   Martin FL, 2001, MUTAGENESIS, V16, P155, DOI 10.1093/mutage/16.2.155
   Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P
   Pfau W, 1999, CARCINOGENESIS, V20, P545, DOI 10.1093/carcin/20.4.545
   RAMAZZINI B, 1940, MORBIS ARTIFICIUM DI
   Roy D, 1999, MUTAT RES-FUND MOL M, V424, P107, DOI 10.1016/S0027-5107(99)00012-3
   TAYLORPAPADIMIT.J, 1992, CULTURE EPITHELIAL C, P107
   TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254
   Ursin G, 2001, CANCER RES, V61, P3326
   Williams JA, 2000, CANCER RES, V60, P4667
   ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819
NR 26
TC 82
Z9 87
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0267-8357
J9 MUTAGENESIS
JI Mutagenesis
PD JUL
PY 2002
VL 17
IS 4
BP 345
EP 352
DI 10.1093/mutage/17.4.345
PG 8
WC Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Toxicology
GA 574VJ
UT WOS:000176910000013
PM 12110632
OA Bronze
DA 2025-01-12
ER

PT J
AU Dong, Y
   Asch, HL
   Ying, A
   Asch, BB
AF Dong, Y
   Asch, HL
   Ying, A
   Asch, BB
TI Molecular mechanism of transcriptional repression of gelsolin in human
   breast cancer cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE gelsolin; breast cancer; transcriptional regulation; actin cytoskeleton
ID BINDING PROTEIN; RESPONSIVE ELEMENT; GENE-EXPRESSION; DOWN-REGULATION;
   CARCINOMA; APOPTOSIS; KINASE; CREB; PHOSPHORYLATION; DIFFERENTIATION
AB Loss of gelsolin, a tumor suppressor, is one of the most frequently occurring molecular defects, in breast cancers of diverse etiologies and across at least three animal species: human, mouse, and rat. Our previous analysis of breast cancer cells demonstrated that the deficiency is not due to mutation of the gelsolin gene, but instead to epigenetic factors, including decreased transcription of the gene. The study described herein provides the first functional characterization of the human gelsolin promoter and reveals a mechanistic basis for the reduced gelsolin transcription. In reporter gene assays, the gelsolin promoter was less active in low-gelsolin-expressing breast cancer cells. A cis-element mediating this reduced promoter activity was defined as a 27-bp sequence located approximately 135 bp upstream of the transcription start site. Gel shift and supershift assays and Southwestern blotting analysis indicated that activating transcription factor-1 (ATF-1) and a protein of similar to100 kDa may have cancer cell-specific DNA-binding activity to the 27-bp gelsolin cis-element. Although the ATF-1 protein was highly expressed in both benign and tumorigenic breast cells, its DNA-binding activity was selectively abundant in the cancer cells and correlated inversely with the gelsolin mRNA level. Thus, our results suggest a role for ATF-1 in gelsolin promoter silencing in contrast to its transactivating effect on various other promoters. (C) 2002 Elsevier Science (USA).
C1 Roswell Pk Canc Inst, Div Expt Pathol, Buffalo, NY 14263 USA.
C3 Roswell Park Comprehensive Cancer Center
RP Asch, BB (通讯作者)，Roswell Pk Canc Inst, Div Expt Pathol, Buffalo, NY 14263 USA.
OI Dong, Yan/0000-0003-1622-5354
FU NCI NIH HHS [CA72768, CA16056] Funding Source: Medline
CR ANTALIS TM, 1993, GENE, V134, P201, DOI 10.1016/0378-1119(93)90094-J
   Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805
   Asch HL, 1999, BREAST CANCER RES TR, V55, P179
   Asch HL, 1996, CANCER RES, V56, P4841
   Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362
   BOHM M, 1995, CELL GROWTH DIFFER, V6, P291
   BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086
   Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9
   CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212
   Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743
   DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Dong Y, 1999, INT J CANCER, V81, P930, DOI 10.1002/(SICI)1097-0215(19990611)81:6<930::AID-IJC15>3.0.CO;2-A
   Dosaka-Akita H, 1998, CANCER RES, V58, P322
   Geng YJ, 1998, EUR J CELL BIOL, V77, P294, DOI 10.1016/S0171-9335(98)80088-5
   HSUEH YP, 1995, J IMMUNOL, V154, P5675
   Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884
   Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532
   Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294
   Kreisberg JI, 1996, KIDNEY INT, V50, P805, DOI 10.1038/ki.1996.379
   Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X
   KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375
   Lee HK, 1999, PROSTATE, V40, P14, DOI 10.1002/(SICI)1097-0045(19990615)40:1<14::AID-PROS2>3.0.CO;2-6
   LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F
   MASSON N, 1993, NUCLEIC ACIDS RES, V21, P1163, DOI 10.1093/nar/21.5.1163
   Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461
   MORIYA S, 1994, INT J ONCOL, V5, P1347
   MULLAUER L, 1993, ONCOGENE, V8, P2531
   Okuyama Y, 1996, FEBS LETT, V397, P219, DOI 10.1016/S0014-5793(96)01178-7
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Salnikow K, 1997, CANCER RES, V57, P5060
   Small JV, 1998, BBA-MOL CELL RES, V1404, P271, DOI 10.1016/S0167-4889(98)00080-9
   Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j
   Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179
   TANAKA M, 1995, CANCER RES, V55, P3228
   Urnov FD, 2001, J MAMMARY GLAND BIOL, V6, P153, DOI 10.1023/A:1011304606604
   VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95
   Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443
   Winston JS, 2001, BREAST CANCER RES TR, V65, P11, DOI 10.1023/A:1006446108411
   YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409
   Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268
NR 41
TC 36
Z9 40
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
J9 EXP CELL RES
JI Exp. Cell Res.
PD JUN 10
PY 2002
VL 276
IS 2
BP 328
EP 336
DI 10.1006/excr.2002.5534
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 560WM
UT WOS:000176104400019
PM 12027462
DA 2025-01-12
ER

PT J
AU Shi, HD
   Yan, PS
   Chen, CM
   Rahmatpanah, F
   Lofton-Day, C
   Caldwell, CW
   Huang, THM
AF Shi, HD
   Yan, PS
   Chen, CM
   Rahmatpanah, F
   Lofton-Day, C
   Caldwell, CW
   Huang, THM
TI Expressed CpG island sequence tag microarray for dual screening of DNA
   hypermethylation and gene silencing in cancer cells
SO CANCER RESEARCH
LA English
DT Article
ID MOLECULAR CLASSIFICATION; METHYLATION; METHYLTRANSFERASE; INHIBITION
AB We present a novel concept by using expressed CpG island sequence tags (ECISTs) for dual analysis of DNA methylation and gene expression in cancer cells. ECISTs are present in the genome and are DNA fragments expected to be located in the promoter and first exon region of genes. Their GC-rich segments can be used for screening hypermethylated CpG sites in cancer cells, and their exon-containing portions can be used for measuring levels of the corresponding transcripts. A total of 1162 loci met the criteria of ECISTs from an initial screening of 7776 CpG island tags. This ECIST panel was used to analyze the breast cancer cell line MDA-MB-231, which was treated with a demethylating agent. Microarray profile analysis identified 30 methylation-silenced genes, the expression of which could be directly reactivated by demethylation. An additional group of 96 up-regulated genes was also identified but appeared to be downstream from this epigenetic cascade. Thus, this study shows that the ECIST microarray can be used to differentiate the primary and secondary causes of demethylation and provides an effective tool to elucidate the mechanisms of aberrant DNA methylation in cancer.
C1 Univ Missouri, Dept Pathol & Anat Sci, Ellis Fischel Canc Ctr, Columbia, MO 65203 USA.
   Natl Chung Hsing Univ, Dept Zool, Life Sci Coll, Taichung, Taiwan.
   Epigen Inc, Seattle, WA 98101 USA.
C3 University of Missouri System; University of Missouri Columbia; National
   Chung Hsing University
RP Univ Missouri, Dept Pathol & Anat Sci, Ellis Fischel Canc Ctr, 115 Business Loop 1-70 W, Columbia, MO 65203 USA.
EM huangh@health.missouri.edu
RI Yan, Pearlly/E-4339-2011; Chen, Chuan-Mu/K-7049-2013
OI Chen, Chuan-Mu/0000-0003-2461-9150; Shi, Huidong/0000-0003-1137-3390
FU NCI NIH HHS [CA 69065, CA 84701] Funding Source: Medline
CR Ahluwalia A, 2001, GYNECOL ONCOL, V82, P261, DOI 10.1006/gyno.2001.6291
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   Craig JM, 1997, HUM GENET, V100, P472, DOI 10.1007/s004390050536
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Esteller M, 2001, CANCER RES, V61, P3225
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Hsu JY, 2001, CANCER RES, V61, P2852
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007
   Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751
   Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788
   MARUYAMA K, 1994, GENE, V138, P171
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Yan PS, 2001, CANCER RES, V61, P8375
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
NR 28
TC 65
Z9 87
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2002
VL 62
IS 11
BP 3214
EP 3220
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 559RE
UT WOS:000176038500035
PM 12036936
DA 2025-01-12
ER

PT J
AU Kim, WJ
   Vo, QN
   Shrivastav, M
   Lataxes, TA
   Brown, KD
AF Kim, WJ
   Vo, QN
   Shrivastav, M
   Lataxes, TA
   Brown, KD
TI Aberrant methylation of the <i>ATM</i> promoter correlates with
   increased radiosensitivity in a human colorectal tumor cell line
SO ONCOGENE
LA English
DT Article
DE ataxia-telangiectasia; gene silencing; epigenetics
ID DNA MISMATCH REPAIR; ATAXIA-TELANGIECTASIA HETEROZYGOTES;
   IONIZING-RADIATION; BREAST-CANCER; GENE-MUTATIONS; PROTEIN;
   HYPERMETHYLATION; INACTIVATION; EXPRESSION; PHENOTYPE
AB Recent findings suggest that DNA alkylating agents trigger cellular responses that overlap those activated after ionizing radiation. Moreover, activation of these responses is dependent upon a functional mismatch repair (MMR) system. These developments led us to test if MMR-deficient cells may be compromised in their ability to activate appropriate cellular signaling pathways after ionizing radiation. An initial experiment to address this notion was to determine the level of radiosensitivity of several MMR-deficient cell lines derived from patients with Hereditary Non-Polyposis Colorectal Cancer (HNPCC). While two of the three HNPCC lines investigated show levels of radiosensitivity consistent with that displayed by normal human fibroblasts, HCT-116 cells display moderate radio sensitivity compared to the other MMR-deficient lines. This increased sensitivity to ionizing radiation correlates with lowered levels of ATM expression in HCT-116. Analysis of genomic DNA from HCT-116 cells determined that these cells possess aberrant methylation of multiple CpG dinucleotides within the proximal promoter region of the ATM gene. The significance of this finding is underscored by our observations that co-culturing HCT-116 cells with the DNA demethylating agent 5-azacytidine reverses promoter methylation, promotes normal levels of ATM expression, and restores normal radiosensitivity. The proximal ATM promoter is a similar to520 bp region shared with the NPAT gene, and current evidence suggests that this region functions as a bi-directional promoter. We found that, unlike ATM, the methylation status of this intergenic region does not effect the expression of the NPAT gene. In sum, these observations indicate that the ATM gene is a novel target for epigentic silencing through inappropriate methylation of its proximal promoter region.
C1 Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.
   Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; Louisiana State University System;
   Louisiana State University Health Sciences Center New Orleans
RP Brown, KD (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,Room 7101, New Orleans, LA 70112 USA.
CR Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7
   Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871
   Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0
   Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460
   BIGBEE WL, 1989, AM J HUM GENET, V44, P402
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303
   Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223
   Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651
   Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785
   CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0
   Chen XG, 1997, MAMM GENOME, V8, P129, DOI 10.1007/s003359900371
   Costello JF, 1996, CANCER RES, V56, P2405
   Dörk T, 2001, CANCER RES, V61, P7608
   Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384
   Ejima Y, 2000, INT J CANCER, V86, P262, DOI 10.1002/(SICI)1097-0215(20000415)86:2<262::AID-IJC17>3.3.CO;2-9
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fritzell JA, 1997, CANCER RES, V57, P5143
   Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942
   Gnarra JR, 1998, J NATL CANCER I, V90, P1685, DOI 10.1093/jnci/90.22.1685
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 2000, CURR TOP MICROBIOL, V249, P35
   Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764
   Hiraguri S, 1998, CANCER RES, V58, P1972
   Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439
   Kane MF, 1997, CANCER RES, V57, P808
   Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058
   Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545
   Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500
   MORRELL D, 1986, JNCI-J NATL CANCER I, V77, P89
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   PANDITA TK, 1994, MUTAT RES-FUND MOL M, V310, P1, DOI 10.1016/0027-5107(94)90004-3
   Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555
   SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600
   SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101
   Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423
   Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   Xu Y, 1999, ADV IMMUNOL, V72, P179, DOI 10.1016/S0065-2776(08)60020-6
   Yan T, 2001, CANCER RES, V61, P8290
   Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456
   Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319
NR 48
TC 79
Z9 96
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAY 30
PY 2002
VL 21
IS 24
BP 3864
EP 3871
DI 10.1038/sj.onc.1205485
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 556KD
UT WOS:000175847200005
PM 12032824
DA 2025-01-12
ER

PT J
AU Dallol, A
   Forgacs, E
   Martinez, A
   Sekido, Y
   Walker, R
   Kishida, T
   Rabbitts, P
   Maher, ER
   Minna, JD
   Latif, F
AF Dallol, A
   Forgacs, E
   Martinez, A
   Sekido, Y
   Walker, R
   Kishida, T
   Rabbitts, P
   Maher, ER
   Minna, JD
   Latif, F
TI Tumour specific promoter region methylation of the human homologue of
   the <i>Drosophilia Roundabout</i> gene <i>DUTT1</i> <i>(ROBO1)</i> in
   human cancers
SO ONCOGENE
LA English
DT Article
DE methylation; 3p12 tumour suppressor gene; DUTT1/ROBO1
ID RENAL-CELL CARCINOMA; SUPPRESSOR GENE; BREAST-CANCER; LUNG-CANCER;
   CLEAR-CELL; EPIGENETIC INACTIVATION; HOMOZYGOUS DELETION; GUIDANCE
   RECEPTORS; DNA METHYLATION; CHROMOSOME 3P12
AB The human homologue of the Drosophila Roundabout gene DUTT1 (Deleted in U Twenty Twenty) or ROBO1 (Locus Link ID 6091), a member of the NCAM family of receptors, was recently cloned from the lung cancer tumour suppressor gene region 2 (LCTSGR2 or U2020 region) at 3p12. DUTT1 maps within a region of overlapping homozygous deletions characterized in both small cell lung cancer lines (SCLC) and in a breast cancer line. In this report we (a) defined the genomic organization of the DUTT1 gene, (b) performed mutation and expression analysis of DUTT1 in lung, breast and kidney cancers, (c) identified tumour specific promoter region methylation of DUTT1 in human cancers. The gene was found to contain 29 exons and spans at least 240 kb of genomic sequence. The 5' region contains a CpG island, and the poly(A)(+) tail has an atypical 5'-GATAAA-3' signal. We analysed DUTT1 for mutations in lung, breast and kidney cancers, no inactivating mutations were detected by PCR-SSCP. However, seven germline missense changes were found and characterized. DUTT1 expression was not detectable in one out of 18 breast tumour lines analysed by RTPCR. Bisulfite sequencing of the promoter region of DUTT1 gene in the HTB-19 breast tumour cell line (not expressing DUTT1) showed complete hypermethylation of CpG sites within the promoter region of the DUTT1 gene (-244 to +27 relative to the translation start site). The expression of DUTT1 gene was reactivated in HTB-19 after treatment with the demethylating agent 5-aza-2'-deoxycytidine. The same region was also found to be hypermethylated in six out of 32 (19%) primary invasive breast carcinomas and eight out of 44 (18%) primary clear cell renal cell carcinomas (CC-RCC) and in one out of 26 (4%) primary NSCLC tumours. Furthermore 80% of breast and 75% of CC-RCC tumours showing DUTT1 methylation had allelic losses for 3p12 markers hence obeying Knudson's two hit hypothesis. Our findings suggest that DUTT1 warrants further analysis as a candidate for the tumour suppressor gene (TSG) at 3p12, a region defined by hemi and homozygous deletions and functional analysis.
C1 Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
   Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA.
   Univ Leicester, Glenfield Hosp, Breast Canc Res Unit, Leicester, Leics, England.
   Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 232, Japan.
   Univ Cambridge, MRC,Mol Oncol Grp, Dept Oncol, MRC Ctr, Cambridge CB2 2QH, England.
   Univ Birmingham, Sch Med, Res UK Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England.
C3 University of Birmingham; University of Texas System; University of
   Texas Southwestern Medical Center Dallas; University of Texas Dallas;
   University Hospitals of Leicester NHS Trust; University of Leicester;
   Glenfield Hospital; Yokohama City University; MRC Laboratory Molecular
   Biology; University of Cambridge; University of Birmingham
RP Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
EM flatif@hgmp.mrc.ac.uk
RI Minna, John/AAB-1036-2022; Sekido, Yoshitaka/P-9756-2015; Dallol,
   Ashraf/H-8661-2012; MAHER, EAMONN/A-9507-2008
OI Dallol, Ashraf/0000-0002-8803-228X; MAHER, EAMONN/0000-0002-6226-6918;
   Sekido, Yoshitaka/0000-0002-2428-3848
FU NCI NIH HHS [P50 CA 70907] Funding Source: Medline; Breast Cancer Now
   [1999:98] Funding Source: Medline
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   ANGELONI D, 2000, CANC GENETICS TUMOR
   Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8
   GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7
   Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3
   KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7
   Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9
   Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   Lerman MI, 2000, CANCER RES, V60, P6116
   Lott ST, 1998, CANCER RES, V58, P3533
   Lovell M, 1999, CANCER RES, V59, P2182
   LUBINSKI J, 1994, CANCER RES, V54, P3710
   Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137
   Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300
   Mau S, 1996, CANCER RES, V56, P5484
   Morrissey C, 2001, CANCER RES, V61, P7277
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Phelps RM, 1996, J CELL BIOCHEM, P32
   RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312
   Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888
   Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264
   SHUIN T, 1994, CANCER RES, V54, P2852
   Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   Sundaresan V, 1998, MOL CELL NEUROSCI, V11, P29, DOI 10.1006/mcne.1998.0672
   THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2
   Todd S, 1997, CANCER RES, V57, P1344
   Wistuba II, 2000, CANCER RES, V60, P1949
   Wistuba II, 1998, CLIN CANCER RES, V4, P2931
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
NR 42
TC 100
Z9 116
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAY 2
PY 2002
VL 21
IS 19
BP 3020
EP 3028
DI 10.1038/sj.onc.1205421
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 546FM
UT WOS:000175262700009
PM 12082532
DA 2025-01-12
ER

PT J
AU Sirchia, SM
   Ren, MQ
   Pili, R
   Sironi, E
   Somenzi, G
   Ghidoni, R
   Toma, S
   Nicolò, G
   Sacchi, N
AF Sirchia, SM
   Ren, MQ
   Pili, R
   Sironi, E
   Somenzi, G
   Ghidoni, R
   Toma, S
   Nicolò, G
   Sacchi, N
TI Endogenous reactivation of the <i>RARβ2</i> tumor suppressor gene
   epigenetically silenced in breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID ACID RECEPTOR-BETA; HISTONE DEACETYLASE INHIBITORS; TRANS-RETINOIC ACID;
   UP-REGULATION; MCF-7 CELLS; EXPRESSION; METHYLATION; LINES;
   ESTERIFICATION; APOPTOSIS
AB Loss of expression of retinoic acid receptor beta2 (RARbeta2), a potent tumor suppressor gene, is commonly observed during breast carcinogenesis. RARbeta2 silencing can be traced to epigenetic chromatin changes affecting the RARbeta P2 promoter. Here we show that retinoic acid therapy fails to induce RARbeta2 in primary breast tumors, which carry a methylated RARbeta P2 promoter. DNA methylation leads to repressive chromatin deacetylation at RARbeta P2. By inducing an appropriate level of histone reacetylation at RARbeta P2 we could reactivate endogenous RARbeta2 transcription from unmethylated as well as methylated RARbeta P2 in breast cancer cell lines and xenograft tumors, and obtain significant growth inhibition both in vitro and in vivo. This study may have translational implications for breast cancer and other cancers carrying an epigenetically silenced RARbeta P2 promoter.
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
   Univ Milan, San Paolo Univ Hosp, Sch Med, Lab Genet & Biochem, I-20142 Milan, Italy.
   Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy.
   Natl Inst Canc Res, I-16132 Genoa, Italy.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Milan;
   University of Genoa; University of Genoa; IRCCS AOU San Martino IST
RP Sacchi, N (通讯作者)，Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, BBCRB 406,1650 Orleans St, Baltimore, MD 21231 USA.
RI Sirchia, Silvia/AAB-2620-2019
OI Sirchia, Silvia/0000-0002-6106-3721; GHIDONI,
   RICCARDO/0000-0002-6300-5867
CR Andreola F, 2000, BIOCHEM BIOPH RES CO, V279, P920, DOI 10.1006/bbrc.2000.3995
   Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783
   Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2
   Lin F, 2000, CANCER RES, V60, P3271
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295
   Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nervi C, 2001, CANCER RES, V61, P1247
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Rexer BN, 2001, CANCER RES, V61, P7065
   Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sutton LM, 1997, CANCER CHEMOTH PHARM, V40, P335, DOI 10.1007/s002800050666
   SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133
   Toma S, 2000, INT J ONCOL, V17, P991
   Toulouse A, 1996, BBA-GENE STRUCT EXPR, V1309, P1, DOI 10.1016/S0167-4781(96)00126-1
   Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224
   VanLint C, 1996, GENE EXPRESSION, V5, P245
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 1997, CANCER RES, V57, P4158
   Xu XC, 1997, CANCER RES, V57, P4992
NR 34
TC 152
Z9 167
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2002
VL 62
IS 9
BP 2455
EP 2461
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 546GG
UT WOS:000175265000002
PM 11980632
DA 2025-01-12
ER

PT J
AU Zhong, S
   Tang, MW
   Yeo, W
   Liu, CL
   Li, D
   Johnson, PJ
AF Zhong, S
   Tang, MW
   Yeo, W
   Liu, CL
   Li, D
   Johnson, PJ
TI Silencing of <i>GSTP1</i> gene by CpG island DNA hypermethylation in
   HBV-associated hepatocellular carcinomas
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HEPATITIS-B VIRUS; GLUTATHIONE S-TRANSFERASES; BREAST-CANCER CELLS;
   AFLATOXIN EXPOSURE; DRUG-RESISTANCE; P1 GENE; METHYLATION; EXPRESSION;
   PI; HEPATOCARCINOGENESIS
AB Purpose and Experimental Design: Glutathione S-transferases, enzymes that defend cells against damage mediated by oxidant and electrophilic carcinogens, may be critical determinants of cancer pathogenesis. In this report, we assess the role of epigenetic silencing of the GSTP1 gene, a gene encoding the pi-class glutathione S-transferase, in the pathogenesis of hepatitis B virus (HBV)-associated hepatocellular carcinomas (HCC). The cell lines Hep3B, HepG2, and a cohort of 43 HBV-associated HCC tissue specimens and corresponding nontumor tissues were subjected to analysis for GSTP1 epigenetic alteration and expression. GSTP1 "CpG" Island DNA hypermethylation in the liver cell lines, and the tissue specimens were determined by methylation-specific PCR and correlated with expression of the gene using reverse-transcription PCR, immunoblotting, and immunohistochemistry.
   Results: GSTP1 CpG island DNA hypermethylation was detected in 28 of 43 (65.1 %) HCC tissues and 4 of 40 (10 %) corresponding nontumor tissues. GSTP1 protein was absent in those cases showing hypermethylation of the gene. Similarly, DNA from Hep3B and HepG2 cell lines displayed complete GSTP1 hypermethylation in the CpG island, and they failed to express GSTP1 mRNA and the corresponding protein product. Treatment of the cell lines with the DNA methyltransferase Inhibitor 5-aza-deoxycytidine reversed the hypermethylation, and restored GSTP1 mRNA and polypeptide expression.
   Conclusions: These data indicate that epigenetic silencing of GSTP1 gene expression by CpG island DNA hypermethylation is common in human HBV-associated HCC. In addition, somatic GSTP1 inactivation via CpG island hypermethylation may contribute to the pathogenesis of this malignancy.
C1 Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Prince of Wales Hospital
RP Johnson, PJ (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China.
RI Yeo, Winnie/R-4792-2018
OI Yeo, Winnie/0000-0002-0863-8469
CR AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586
   Ban N, 1996, CANCER RES, V56, P3577
   BRECHOT C, 1980, NATURE, V286, P533, DOI 10.1038/286533a0
   Bréchot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321
   CAIRNS J, 1992, J PATHOL, V166, P19, DOI 10.1002/path.1711660105
   Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937
   COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605
   DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794
   DILLIO C, 1991, CARCINOGENESIS, V12, P1471
   Esteller M, 1998, CANCER RES, V58, P4515
   GILBERT L, 1993, J CLIN ONCOL, V11, P49, DOI 10.1200/JCO.1993.11.1.49
   GROOPMAN JD, 1988, CRC CR REV TOXICOL, V19, P113, DOI 10.3109/10408448809014902
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3
   Johnson P., 1994, PRIMARY LIVER CANC, P31
   Kanai Y, 1996, JPN J CANCER RES, V87, P1210, DOI 10.1111/j.1349-7006.1996.tb03135.x
   Kanai Y, 1997, INT J CANCER, V71, P355
   Lee WH, 1997, CANCER EPIDEM BIOMAR, V6, P443
   MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202
   Morgan AS, 1996, CANCER CHEMOTH PHARM, V37, P363, DOI 10.1007/s002800050398
   MORROW CS, 1992, J BIOL CHEM, V267, P10544
   NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   ROBINSON WS, 1992, J GASTROEN HEPATOL, V7, P622, DOI 10.1111/j.1440-1746.1992.tb01497.x
   RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475
   Silvestrini R, 1997, J NATL CANCER I, V89, P639, DOI 10.1093/jnci/89.9.639
   Sun L, 1997, JPN J CANCER RES, V88, P1165, DOI 10.1111/j.1349-7006.1997.tb00345.x
   Tchou JC, 2000, INT J ONCOL, V16, P663
   TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566
   Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555
   Wong IHN, 1999, CANCER RES, V59, P71
   WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891
   Zhong S, 2000, J VIRAL HEPATITIS, V7, P115
   Zhou TL, 1997, CANCER RES, V57, P2749
NR 36
TC 157
Z9 178
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR
PY 2002
VL 8
IS 4
BP 1087
EP 1092
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 540TU
UT WOS:000174946200024
PM 11948118
DA 2025-01-12
ER

PT J
AU Huynh, H
   Chow, PKH
   Ooi, LLP
   Soo, KC
AF Huynh, H
   Chow, PKH
   Ooi, LLP
   Soo, KC
TI A possible role for insulin-like growth factor-binding protein-3
   autocrine/paracrine loops in controlling hepatocellular carcinoma cell
   proliferation
SO CELL GROWTH & DIFFERENTIATION
LA English
DT Article
ID BREAST-CANCER CELLS; II MESSENGER-RNA; HUMAN HEPATOMA; EPIGENETIC
   CHANGES; LIVER; GENE; EXPRESSION; INHIBITION; LINES
AB Hepatocellular carcinoma (HCC) is a common malignancy, but treatment outcomes have generally remained poor. Specific factors important for the pathogenesis of HCC are incompletely understood. Insulin-like growth factors (IGFs) are potent autocrine and paracrine mitogens for liver cancer cell proliferation, and their bioactivity is reduced by IGF-binding protein 3 (IGFBP-3). In the present study, we report that IGFBP-3 protein levels were either undetectable (28.5%) or low (71.5%) in human HCC samples examined compared with matched nonneoplastic liver tissue by Western blotting. IGFBP-3 was localized to nontumor liver cells by immunohistochemistry with greater immunointensity than neoplastic liver cells. Levels of type I receptor (IGF-IR) were found to be low in similar to39% of human HCC samples examined compared with matched nontumor tissues. IGF-II was overexpressed in 32%, whereas IGF-I expression was decreased in 100% of HCC samples. In vitro studies revealed that IGF-I and IGF-II induced HepG2 cell proliferation in a dose-dependent manner. Treatment of HepG2 cells with either human recombinant IGFBP-3 (hrIGFBP-3) or IGF-II antibody led to a significant reduction in cell proliferation. Cotreating these cells with hrIGFBP-3 significantly attenuated the mitogenic activity of IGF-I. IGF-I-induced phosphorylation of IGF-IR beta subunit, IRS-1, mitogen-activated protein kinase, Elk-1, and Akt-1 as well as phosphatidylinositol 3'-kinase activity was significantly attenuated when hepG2 cells were pretreated with hrIGFBP-3. Our data indicate that loss of autocrine/paracrine IGFBP-3 loops may lead to HCC tumor growth and suggest that modulating production of the IGFs, IGFBP-3, and IGF-IR may represent a novel approach in the treatment of HCC.
C1 Natl Canc Ctr Singapore, Mol Endocrinol Lab, Singapore 169610, Singapore.
   Singapore Gen Hosp, Dept Gen Surg, Singapore 169608, Singapore.
   Natl Canc Ctr Singapore, Dept Surg Oncol, Singapore 169610, Singapore.
C3 National Cancer Centre Singapore (NCCS); Singapore General Hospital;
   National Cancer Centre Singapore (NCCS)
RP Natl Canc Ctr Singapore, Mol Endocrinol Lab, 11 Hosp Dr, Singapore 169610, Singapore.
EM cmrhth@nccs.com.sg
RI Ooi, London Lucien/AGK-1395-2022
OI Chow, Pierce/0000-0003-0584-2584
CR ARANY E, 1994, J CLIN ENDOCR METAB, V79, P1871, DOI 10.1210/jc.79.6.1871
   CARIANI E, 1988, CANCER RES, V48, P6844
   CHAN EY, 2000, COCHRANE LIB
   Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x
   Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   HUGUET C, 2000, SURG LIVER BILIARY T
   Huynh H, 1996, CANCER RES, V56, P4865
   Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016
   Huynh H, 1996, CLIN CANCER RES, V2, P2037
   HUYNH HT, 1995, CANCER RES, V55, P2225
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215
   LAI E, 1994, SURG LIVER BILIARY T, P1349
   LAI ECS, 1995, ANN SURG, V221, P291, DOI 10.1097/00000658-199503000-00012
   LEROITH D, 1993, GROWTH REGULAT, V3, P78
   Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   Ng IO, 1998, J GASTROEN HEPATOL, V13, P152, DOI 10.1111/j.1440-1746.1998.tb00630.x
   OH Y, 1993, J BIOL CHEM, V268, P26045
   OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589
   OH YM, 1993, J BIOL CHEM, V268, P14964
   OKUDA K, 1985, CANCER-AM CANCER SOC, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
   ROGLER CE, 1994, J BIOL CHEM, V269, P13779
   Scharf JG, 1998, CARCINOGENESIS, V19, P2121, DOI 10.1093/carcin/19.12.2121
   SU TS, 1989, CANCER RES, V49, P1773
   Takenaka K, 1996, ARCH SURG-CHICAGO, V131, P71
   TSAI TF, 1988, BIOCHEM BIOPH RES CO, V153, P39, DOI 10.1016/S0006-291X(88)81186-0
   Wong IHN, 2000, ANN NY ACAD SCI, V906, P102
NR 28
TC 88
Z9 103
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1044-9523
J9 CELL GROWTH DIFFER
JI Cell Growth Differ.
PD MAR
PY 2002
VL 13
IS 3
BP 115
EP 122
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 539HF
UT WOS:000174863900003
PM 11959812
DA 2025-01-12
ER

PT J
AU Uzawa, K
   Ono, K
   Suzuki, H
   Tanaka, C
   Yakushiji, T
   Yamamoto, N
   Yokoe, H
   Tanzawa, H
AF Uzawa, K
   Ono, K
   Suzuki, H
   Tanaka, C
   Yakushiji, T
   Yamamoto, N
   Yokoe, H
   Tanzawa, H
TI High prevalence of decreased expression of KAI1 metastasis suppressor in
   human oral carcinogenesis
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; KAI1/CD82 GENE-EXPRESSION; PANCREATIC-CANCER;
   PROGNOSTIC FACTOR; PROSTATE-CANCER; DOWN-REGULATION; BREAST-CANCER;
   COLON-CANCER; LYMPH-NODE; ESOPHAGEAL
AB Purpose: KAII was originally identified in prostate cancer as a metastasis suppressor gene. Recent studies have shown a frequent down-regulation of KAII expression in many tumor types, whereas mutation or hypermethylation of the gene is infrequent. The aim of the present study was to examine whether loss of KAII expression that might be caused by genetic or epigenetic alterations could contribute to oral carcinogenesis.
   Experimental Design: We analyzed mutational and methylation status of the KAII gene and both the mRNA and protein level in a series of oral tumors [28 precancerous lesions, 101 primary oral squamous cell carcinomas (OSCCs), and 30 metastatic OSCCs] and OSCC-derived cell lines. We also examined p53 protein expression, which has been reported to be a candidate activator for the KAII gene.
   Results: With the exception of three microsatellite instabilities in the KAII gene, we found no mutations in the coding sequence of the KAII gene, no loss of heterozygosity, and no hypermethylation of the KAII promoter region in all samples investigated. By immunohistochemistry, however, high frequencies of KAII down-regulation were evident not only in the metastatic OSCCs [29 of 30 (97%)] but also in the primary OSCCs [83 of 101 (82%)] and in the precancerous lesions [13 of 28 (46%)]. There was a significant relationship between down-regulation of KAII protein expression and primary tumors associated with lymph node metastases; (P = 0.0115), whereas there was no statistical correlation between p53 status and KAII expression. Taken together, reverse transcription- PCR data were consistent with the protein expression status in 16 patients from whom mRNA was available.
   Conclusions: Our data suggest that whereas loss of KAII protein expression is associated with primary tumors with lymph node metastases, the down-regulation of KAII is an early event in the progression of human oral cancer. The down-regulation of KAII is not associated with either mutation, allelic loss, methylation of the promoter, or p53 regulation.
C1 Chiba Univ, Grad Sch Med, Dept Clin Mol Biol, Chuo Ku, Chiba 2608670, Japan.
   Chiba Univ, Grad Sch Med, Dept Urol, Chiba 2608670, Japan.
   Tokyo Dent Coll, Dept Oral & MaxilloFacial Surg 1, Chiba 2618502, Japan.
C3 Chiba University; Chiba University; Tokyo Dental College
RP Chiba Univ, Grad Sch Med, Dept Clin Mol Biol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.
EM tanzawap@med.m.chiba-u.ac.jp
OI Uzawa, Katsuhiro/0000-0002-7036-0859
CR Adachi M, 1996, CANCER RES, V56, P1751
   Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397
   BOYLE P, 1992, Current Opinion in Oncology, V4, P471
   DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374
   Dong JT, 1997, GENOMICS, V41, P25, DOI 10.1006/geno.1997.4618
   Dong JT, 1996, CANCER RES, V56, P4387
   Duriez C, 2000, ONCOGENE, V19, P2461, DOI 10.1038/sj.onc.1203580
   Friess H, 1998, INT J CANCER, V79, P349, DOI 10.1002/(SICI)1097-0215(19980821)79:4<349::AID-IJC7>3.0.CO;2-V
   GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219
   Geradts J, 1999, AM J PATHOL, V154, P1665, DOI 10.1016/S0002-9440(10)65422-3
   Guo XZ, 1998, CANCER RES, V58, P753
   Guo XZ, 1996, CANCER RES, V56, P4876
   HERMANEK P, 1987, TNM CLASSIFICATION M, P16
   Higashiyama M, 1998, CANCER, V83, P466, DOI 10.1002/(SICI)1097-0142(19980801)83:3<466::AID-CNCR15>3.0.CO;2-U
   Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8
   IMAI T, 1992, J IMMUNOL, V149, P2879
   Jackson P, 2000, CANCER LETT, V157, P169, DOI 10.1016/S0304-3835(00)00483-3
   JOHNSON NW, 1991, ORAL CANC DETECTION, P3
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Lombardi DP, 1999, CANCER RES, V59, P5724
   Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307
   Maurer CA, 1999, SURGERY, V126, P869, DOI 10.1016/S0039-6060(99)70028-0
   Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z
   Nakahara Y, 2001, CANCER LETT, V163, P221, DOI 10.1016/S0304-3835(00)00699-6
   Schindl M, 2000, ANTICANCER RES, V20, P4551
   Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5
   Shinohara T, 2001, CANCER RES, V61, P673
   Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X
   Tagawa K, 1999, JPN J CANCER RES, V90, P970, DOI 10.1111/j.1349-7006.1999.tb00843.x
   Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648
   Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186
   Ueda T, 1996, AM J PATHOL, V149, P1435
   UZAWA K, 1994, INT J CANCER, V58, P814, DOI 10.1002/ijc.2910580611
   UZAWA K, 1995, INT J ONCOL, V7, P895
   WAHI PN, 1971, INT HIST CLASSIFICAT
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yamamoto N, 2001, BRIT J CANCER, V84, P754, DOI 10.1054/bjoc.2000.1656
   Yang XH, 2001, CANCER RES, V61, P5284
   Yang XH, 1997, CANCER LETT, V119, P149, DOI 10.1016/S0304-3835(97)00273-5
   Yu Y, 1997, CLIN CANCER RES, V3, P1045
NR 40
TC 37
Z9 55
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2002
VL 8
IS 3
BP 828
EP 835
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 531EP
UT WOS:000174403300028
PM 11895916
DA 2025-01-12
ER

PT J
AU Chan, MWY
   Chan, LW
   Tang, NLS
   Tong, JHM
   Lo, KW
   Lee, TL
   Cheung, HY
   Wong, WS
   Chan, PSF
   Lai, FMM
   To, KF
AF Chan, MWY
   Chan, LW
   Tang, NLS
   Tong, JHM
   Lo, KW
   Lee, TL
   Cheung, HY
   Wong, WS
   Chan, PSF
   Lai, FMM
   To, KF
TI Hypermethylation of multiple genes in tumor tissues and voided urine in
   urinary bladder cancer patients
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CELL LUNG-CANCER; PROMOTER HYPERMETHYLATION; DNA METHYLATION; HUMAN
   NEOPLASIA; BREAST-CANCER; CARCINOMA; INACTIVATION; EXPRESSION;
   INCREASES; RECEPTOR
AB Purpose: We aimed to investigate the methylation pattern in bladder cancer and assess the diagnostic potential of such epigenetic changes in urine.
   Experimental Design: The methylation status of 7 genes (RARbeta, DAPK, E-cadherin, p16, p15, GSTP1, and MGMT) in 98 cases of bladder transitional cell carcinoma and 4 cases of carcinoma in situ was analyzed by methylation-specific PCR. Twenty-two cases had paired voided urine samples for analysis.
   Results: In transitional cell carcinoma tumor tissues, aberrant methylation was frequently detected in RARbeta (87.8%), DAPK (58.2%), E-cadherin (63.3%), and p16 (26.5%), whereas methylation of p15 (13.3%), GSTP1 (5.1%), and MGMT (5.1%) is not common. No association between methylation status and grading or muscle invasiveness was demonstrated. In 22 paired voided urine samples of bladder cancer, methylation of DAPK, RARbeta, E-cadherin, and p16 could be detected in 45.5%, 68.2%, 59.1%, and 13.6% of the cases, respectively. The sensitivity of methylation analysis (90.9%) was higher than that of urine cytology (45.5%) for cancer detection. Methylation of RARbeta (50%), DAPK (75%), and E-cadherin (50%) was also detected in carcinoma in situ. In 7 normal urothelium samples and 17 normal urine controls, no aberrant methylation was detected except for RARbeta methylation in 3 normal urothelium samples (42.9%) and 4 normal urine samples (23.5%), respectively.
   Conclusions: Our results demonstrated a distinct methylation pattern in bladder cancer with frequent methylation of RARbeta, DAPK, E-cadherin, and p16. Detection of gene methylation in routine voided urine using selected markers appeared to be more sensitive than conventional urine cytology.
C1 Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Prince of Wales Hospital; Chinese University of
   Hong Kong; Prince of Wales Hospital
RP To, KF (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.
RI Tang, Nelson/P-5018-2017; Tong, Joanna/J-9327-2013; Lee,
   Tin-Lap/A-7853-2009; To, Ka Fai/JTT-7693-2023; Chan, Michael/F-9615-2018
OI Lee, Tin-Lap/0000-0002-6654-0988; To, Ka Fai/0000-0003-4919-3707; Tang,
   Nelson/0000-0002-3607-5819; Chan, Michael/0000-0003-0314-2437; Chan,
   Michael/0000-0003-1431-322X; Lo, Kwok Wai/0000-0002-3488-6124
CR Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0
   Cairns P, 2001, CLIN CANCER RES, V7, P2727
   CHAN AS, CANC RES, V60, P5365
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2001, CANCER RES, V61, P3225
   Florl AR, 2000, LAB INVEST, V80, P1513, DOI 10.1038/labinvest.3780161
   Goessl C, 2000, CANCER RES, V60, P5941
   Gonzalgo ML, 1998, CANCER RES, V58, P1245
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kanai Y, 1997, INT J CANCER, V71, P355
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353
   Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302
   Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172
   KNOWLES MA, 1994, CANCER RES, V54, P531
   Lo KW, 1996, CANCER RES, V56, P2721
   MIYAO N, 1993, CANCER RES, V53, P4066
   Muto S, 2000, CANCER RES, V60, P4021
   Nass SJ, 2000, CANCER RES, V60, P4346
   Orlow I, 1999, AM J PATHOL, V155, P105, DOI 10.1016/S0002-9440(10)65105-X
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Salem C, 2000, CANCER RES, V60, P2473
   Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wong IHN, 2000, CLIN CANCER RES, V6, P3516
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 30
TC 248
Z9 283
U1 0
U2 19
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB
PY 2002
VL 8
IS 2
BP 464
EP 470
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 522QN
UT WOS:000173908600021
PM 11839665
DA 2025-01-12
ER

PT J
AU Gitan, RS
   Shi, HD
   Chen, CM
   Yan, PS
   Huang, THM
AF Gitan, RS
   Shi, HD
   Chen, CM
   Yan, PS
   Huang, THM
TI Methylation-specific oligonucleotide microarray: A new potential for
   high-throughput methylation analysis
SO GENOME RESEARCH
LA English
DT Article
ID GENE CPG ISLAND; BREAST-CANCER CELLS; SEQUENCE-ANALYSIS; DNA
   METHYLATION; EXPRESSION; PROMOTER; HYPERMETHYLATION; NEOPLASIA; TUMORS;
   BRCA1
AB Oligonucleotide microarray-based hybridization is an emerging technology for genome-wide detection of DNA variations. We have extended this principle and developed a novel approach, called methylation-specific oligonucleotide (MSO) microarray, for detecting changes of DNA methylation in cancer. The method uses bisulfite-modified DNA as a template for PCR amplification, resulting in conversion of unmethylated cytosine, but not methylated cytosine, into thymine within CpG islands of interest. The amplified product, therefore, may contain a pool of DNA fragments with altered nucleotide sequences due to differential methylation status. A test sample is hybridized to a set of oligonucleotide (19-23 nucleotides in length) arrays that discriminate methylated and unmethylated cytosine at specific nucleotide positions, and quantitative differences in hybridization are determined by fluorescence analysis. A unique control system is also implemented to test the accuracy and reproducibility of oligonucleotides designed for microarray hybridization. This MSC) microarray was applied to map methylated CpG sites within the human estrogen receptor alpha (ERalpha) gene CpG island in breast cancer cell lines, normal fibroblasts, breast tumors, and normal controls. Methylation patterns of the breast cancer cell lines, determined by MSO microarray, were further validated by bisulfite nucleotide sequencing (P <0.001). Tills proof-of-principle study shows that MSC) microarray is a promising technique for mapping methylation changes in multiple CpG island loci and for generating epigenetic profiles In cancer.
C1 Univ Missouri, Sch Med, Ellis Fischel Canc Ctr, Dept Pathol, Columbia, MO 65201 USA.
   Univ Missouri, Sch Med, Ellis Fischel Canc Ctr, Dept Anat Sci, Columbia, MO USA.
C3 University of Missouri System; University of Missouri Columbia;
   University of Missouri System; University of Missouri Columbia
RP Huang, THM (通讯作者)，Univ Missouri, Sch Med, Ellis Fischel Canc Ctr, Dept Pathol, Columbia, MO 65201 USA.
RI Yan, Pearlly/E-4339-2011; Chen, Chuan-Mu/K-7049-2013
OI Chen, Chuan-Mu/0000-0003-2461-9150; Shi, Huidong/0000-0003-1137-3390
FU NCI NIH HHS [CA-69065, R29 CA069065, CA-84701, R01 CA069065] Funding
   Source: Medline
CR Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Costello JF, 1996, CANCER RES, V56, P2405
   Favis R, 2000, ANN NY ACAD SCI, V906, P39
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469
   Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kane MF, 1997, CANCER RES, V57, P808
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788
   Melki JR, 1999, CANCER RES, V59, P3730
   Nguyen TT, 2000, PROSTATE, V43, P233
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pieper RO, 1999, NUCLEIC ACIDS RES, V27, P3229, DOI 10.1093/nar/27.15.3229
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Wen WH, 2000, CANCER RES, V60, P2716
NR 19
TC 235
Z9 310
U1 0
U2 24
PU COLD SPRING HARBOR LAB PRESS
PI PLAINVIEW
PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD JAN
PY 2002
VL 12
IS 1
BP 158
EP 164
DI 10.1101/gr.202801
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 508AN
UT WOS:000173064900017
PM 11779841
OA Green Accepted, hybrid, Green Published
DA 2025-01-12
ER

PT J
AU De Paola, F
   Vecci, AM
   Granato, AM
   Liverani, M
   Monti, F
   Innoceta, AM
   Gianni, L
   Saragoni, L
   Ricci, M
   Falcini, F
   Amadori, D
   Volpi, A
AF De Paola, F
   Vecci, AM
   Granato, AM
   Liverani, M
   Monti, F
   Innoceta, AM
   Gianni, L
   Saragoni, L
   Ricci, M
   Falcini, F
   Amadori, D
   Volpi, A
TI p27/kip I expression in normal epithelium, benign and neoplastic breast
   lesions
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE p27/kip1; benign breast lesions; breast carcinoma
ID DEPENDENT KINASE INHIBITOR; PROGNOSTIC IMPLICATIONS; P27(KIP1)
   EXPRESSION; CANCER PATIENTS; CYCLIN D1; PROTEIN; P27; PROLIFERATION;
   APOPTOSIS; ACCUMULATION
AB The development of cancer in the breast and in other sites is a complex process requiring a number of different genetic and epigenetic alterations. The accumulation of the genetic changes is thought to underlie the progression from precancerous lesions to carcinomas. The expression of p27/kip1 protein, a cyclin-dependent kinase inhibitor, was investigated by immunohistochemistry in normal epithelial specimens, benign alterations, and malignant lesions of the breast. The number of p27/kap1-positive cells ranged from none to more than 98% in the overall series. Wide ranges of p27/kip1-positive cells were consistently observed within each histological category, but the median value progressively decreased in typical hyperplasia and fibroadenoma, with an even more marked reduction in malignant lesions, compared with normal epithelium. Moreover, the percentage of cells expressing p27/ktp1 in tumours was about three times lower in invasive than in in situ lesions and was inversely related to tumour size, but not to lymph node involvement. In conclusion, the degree to which p27 expression is altered in typical hyperplastic lesions and fibroadenomas indicates that the deregulation of p27 may occur very early on during breast cell transformation, but the usefulness of its determination to categorize subgroups of lesions at different risk of evolution remains somewhat doubtful. Copyright (C) 2001 John Wiley Sons, Ltd.
C1 Morgagni Pierantoni Hosp, Dept Oncol, I-47100 Forli, Italy.
   Ist Oncol Romagnolo, Forli, Italy.
   Infermi Hosp, Dept Oncol, Rimini, Italy.
   Infermi Hosp, Dept Clin Pathol, Rimini, Italy.
C3 Hospital of Rimini; Hospital of Rimini
RP Morgagni Pierantoni Hosp, Dept Oncol, Via Forlanini 34, I-47100 Forli, Italy.
EM a.volpi@ousl.fo.it
RI Granato, Anna/AAD-1710-2021; volpi, annalisa/LJL-0565-2024; falcini,
   fabio/W-4345-2018
OI falcini, fabio/0000-0002-0864-6266; Volpi, Annalisa/0000-0002-6791-5542
CR Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581
   AMADORI D, 1993, BREAST CANCER RES TR, V28, P251, DOI 10.1007/BF00666586
   Bast RC, 1996, J CLIN ONCOL, V14, P2843
   Cariou S, 1998, BREAST CANCER RES TR, V52, P29, DOI 10.1023/A:1006154900130
   CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995
   Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227
   Ciaparrone M, 1998, CANCER RES, V58, P114
   Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306
   Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380
   Gillett CE, 1999, J PATHOL, V187, P200, DOI 10.1002/(SICI)1096-9896(199901)187:2<200::AID-PATH228>3.0.CO;2-M
   GOMPEL C, 1976, ATLAS DIAGNOSTIC CYT, P211
   Han S, 1999, BREAST CANCER RES TR, V55, P161
   Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861
   Jordan RCK, 1998, AM J PATHOL, V152, P585
   Katayose Y, 1997, CANCER RES, V57, P5441
   Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9
   Lloyd RV, 1997, AM J PATHOL, V150, P401
   Mommers ECM, 1998, HUM PATHOL, V29, P1539, DOI 10.1016/S0046-8177(98)90028-4
   MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0
   MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0
   PAGANO M, 1997, CANC GENES, P255
   Page D.L., 1987, DIAGNOSTIC HISTOPATH, P120
   POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X
   Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222
   REED SI, 1994, J CELL SCI, P69
   Reed W, 1999, VIRCHOWS ARCH, V435, P116, DOI 10.1007/s004280050408
   Sgambato A, 1997, CLIN CANCER RES, V3, P1879
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1
   Singh SP, 1998, CANCER RES, V58, P1730
   Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5
   St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557
   Tan P, 1997, CANCER RES, V57, P1259
   Tsuchiya A, 1999, J SURG ONCOL, V70, P230, DOI 10.1002/(SICI)1096-9098(199904)70:4<230::AID-JSO6>3.0.CO;2-I
   Volpi A, 2000, BREAST CANCER RES TR, V63, P181, DOI 10.1023/A:1006464426977
   Wu J, 1999, BRIT J CANCER, V79, P1572, DOI 10.1038/sj.bjc.6690250
NR 37
TC 28
Z9 32
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JAN
PY 2002
VL 196
IS 1
BP 26
EP 31
DI 10.1002/path.1011
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 511GH
UT WOS:000173255900004
PM 11748638
DA 2025-01-12
ER

PT J
AU Esteller, M
   Fraga, MF
   Guo, MZ
   Garcia-Foncillas, J
   Hedenfalk, I
   Godwin, AK
   Trojan, J
   Vaurs-Barrière, C
   Bignon, YJ
   Ramus, S
   Benitez, J
   Caldes, T
   Akiyama, Y
   Yuasa, Y
   Launonen, V
   Canal, MJ
   Rodriguez, R
   Capella, G
   Peinado, MA
   Borg, A
   Aaltonen, LA
   Ponder, BA
   Baylin, SB
   Herman, JG
AF Esteller, M
   Fraga, MF
   Guo, MZ
   Garcia-Foncillas, J
   Hedenfalk, I
   Godwin, AK
   Trojan, J
   Vaurs-Barrière, C
   Bignon, YJ
   Ramus, S
   Benitez, J
   Caldes, T
   Akiyama, Y
   Yuasa, Y
   Launonen, V
   Canal, MJ
   Rodriguez, R
   Capella, G
   Peinado, MA
   Borg, A
   Aaltonen, LA
   Ponder, BA
   Baylin, SB
   Herman, JG
TI DNA methylation patterns in hereditary human cancers mimic sporadic
   tumorigenesis
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID NONPOLYPOSIS COLORECTAL-CANCER; PEUTZ-JEGHERS-SYNDROME; AND/OR
   OVARIAN-CANCER; PROMOTER HYPERMETHYLATION; BREAST-CANCER; MOLECULAR
   ANALYSIS; GENE-EXPRESSION; MISMATCH REPAIR; COLON TUMORS; BRCA1
AB Cancer cells have aberrant patterns of DNA methylation including hypermethylation of gene promoter CpG islands and global demethylation of the genome. Genes that cause familial cancer, as well as other genes, can be silenced by promoter hypermethylation in sporadic tumors, but the methylation of these genes in tumors from kindreds with inherited cancer syndromes has not been well characterized. Here, we examine CpG island methylation of 10 genes (hMLH1, BRCA1, APC, LKB1, CDH1, p16(INK4a), p14(ARF), MGMT, GSTP1 and RAR beta2) and 5-methylcytosine DNA content, in inherited (n = 342) and non-inherited (n = 215) breast and colorectal cancers. Our results show that singly retained alleles of germline mutated genes are never hypermethylated in inherited tumors. However, this epigenetic change is a frequent second 'hit', associated with the wild-type copy of these genes in inherited tumors where both alleles are retained. Global hypomethylation was similar between sporadic and hereditary cases, but distinct differences existed in patterns of methylation at non-familial genes. This study demonstrates that hereditary cancers 'mimic' the DNA methylation patterns present in the sporadic tumors.
C1 Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.
   Ctr Nacl Invest Oncol, Mol Pathol Program, Canc Epigenet Lab, Madrid, Spain.
   Ctr Nacl Invest Oncol, Mol Pathol Program, Human Genet Lab, Madrid, Spain.
   Univ Navarra, Clin Univ Pamplona, Lab Biotechnol & Genom, E-31080 Pamplona, Spain.
   Fox Chase Canc Ctr, Mol Genet Lab, Philadelphia, PA 19111 USA.
   Goethe Univ Frankfurt, Dept Internal Med, D-6000 Frankfurt, Germany.
   NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
   Ctr Jean Perrin, Oncol Mol Lab, Clermont Ferrand, France.
   Tokyo Med & Dent Univ, Sch Med, Dept Mol Oncol, Tokyo 113, Japan.
   Hosp Clin San Carlos, Mol Oncol Lab, Madrid, Spain.
   Sch Biol, Dept Biochem, Oviedo, Spain.
   Inst Recerca Oncol, Barcelona, Catalonia, Spain.
   Inst Catala Oncol, Barcelona, Catalonia, Spain.
   Lund Univ, Dept Oncol, Lund, Sweden.
   Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki, Finland.
   Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge, England.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Navarra;
   Fox Chase Cancer Center; Goethe University Frankfurt; National
   Institutes of Health (NIH) - USA; NIH National Human Genome Research
   Institute (NHGRI); UNICANCER; Centre Jean Perrin; Institute of Science
   Tokyo; Tokyo Medical & Dental University (TMDU); Hospital Clinico San
   Carlos; Institut Catala d'Oncologia; Lund University; University of
   Helsinki; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; University of Cambridge
RP Johns Hopkins Oncol Ctr, Room 543,1650 Orleans St, Baltimore, MD 21231 USA.
EM hermanji@jhmi.edu
RI Ramus, Susan/AAG-8352-2019; Trojan, Jörg/C-1616-2009; Garcia-Foncillas,
   Jesus/E-6857-2010; Wang, Haitao/GYV-1262-2022; Peinado, Miguel
   A./A-5591-2008; Esteller, Manel/L-5956-2014; Aaltonen,
   Lauri/A-5375-2010; Fraga, Mario/H-7824-2017; Canal-Villanueva, Maria
   Jesus Fatima/L-1005-2014; Capella, Gabriel/I-1879-2015
OI Hedenfalk, Ingrid/0000-0002-6840-3397; Esteller,
   Manel/0000-0003-4490-6093; Ramus, Susan/0000-0003-0005-7798; Aaltonen,
   Lauri/0000-0001-6839-4286; Peinado, Miguel A./0000-0002-4090-793X;
   Fraga, Mario/0000-0001-8450-2603; J,
   Garcia-Foncillas/0000-0002-7591-8006; Vaurs-Barriere,
   catherine/0000-0001-8654-4292; Canal-Villanueva, Maria Jesus
   Fatima/0000-0002-1639-9672; Capella, Gabriel/0000-0002-4669-7320
CR Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101
   Bai YQ, 1999, INT J CANCER, V82, P512, DOI 10.1002/(SICI)1097-0215(19990812)82:4<512::AID-IJC7>3.0.CO;2-8
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bearzatto A, 2000, CANCER RES, V60, P3262
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   de la Hoya M, 2001, INT J CANCER, V91, P137, DOI 10.1002/1097-0215(20010101)91:1<137::AID-IJC1020>3.0.CO;2-R
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, CANCER RES, V61, P3225
   Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Fraga MF, 2000, ELECTROPHORESIS, V21, P2990, DOI 10.1002/1522-2683(20000801)21:14<2990::AID-ELPS2990>3.0.CO;2-I
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432
   HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kane MF, 1997, CANCER RES, V57, P808
   Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195
   Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1
   Lyko F, 2001, TRENDS GENET, V17, P169, DOI 10.1016/S0168-9525(01)02234-X
   Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0
   Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229
   Myöhänen SK, 1998, CANCER RES, V58, P591
   Nathanson KL, 2001, HUM MOL GENET, V10, P715, DOI 10.1093/hmg/10.7.715
   Osorio A, 2000, BRIT J CANCER, V82, P1266, DOI 10.1054/bjoc.1999.1089
   Peltomäki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735
   Prowse AH, 1997, AM J HUM GENET, V60, P765
   Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585
   Tesoriero A, 1999, AM J HUM GENET, V65, P567, DOI 10.1086/302503
   Trojan J, 1999, AM J GASTROENTEROL, V94, P257
   Vaurs-Barriere C, 2000, J Med Genet, V37, pE32, DOI 10.1136/jmg.37.10.e32
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   Wheeler JMD, 2000, J MED GENET, V37, P588, DOI 10.1136/jmg.37.8.588
NR 41
TC 351
Z9 404
U1 0
U2 33
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2001
VL 10
IS 26
BP 3001
EP 3007
DI 10.1093/hmg/10.26.3001
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 504RU
UT WOS:000172870300005
PM 11751682
OA Bronze
DA 2025-01-12
ER

PT J
AU Yan, PS
   Chen, CM
   Shi, HD
   Rahmatpanah, F
   Wei, SH
   Caldwell, CW
   Huang, THM
AF Yan, PS
   Chen, CM
   Shi, HD
   Rahmatpanah, F
   Wei, SH
   Caldwell, CW
   Huang, THM
TI Dissecting complex epigenetic alterations in breast cancer using CpG
   island microarrays
SO CANCER RESEARCH
LA English
DT Article
ID MOLECULAR CLASSIFICATION; GPC3 GENE; METHYLATION; PATTERNS; CLUSTER
AB It is now clear that aberrant DNA methylation observed in cancer cells is not restricted to a few CpG islands, but affects multiple loci. When this epigenetic event occurs at the 5'-end of the regulatory region of genes, it is frequently associated with transcriptional silencing. To investigate further this widespread event in the tumor genome, we developed a novel microarray containing 7776 short GC-rich tags tethered to glass slide surfaces. This DNA chip was used to study 17 paired tissues of breast tumors and normal controls. Amplicons, representing differential pools of methylated DNA fragments between tumors and normal controls, were cohybridized to the microarray panel. Hypermethylation of multiple CpG island loci was then detected in a two-color fluorescence system. Approximately 1% (on average, 83 loci) of these CpG islands examined were hypermethylated in this patient group. Hierarchical clustering segregated these tumors based on their methylation profiles and identified a group of CpG island loci that corresponds to the hormone-receptor status of breast cancer. This observation was independently confirmed by examining a single locus, the promoter of the human glypican 3 gene, which was predominately hypermethylated in the hormone receptor-negative tumors. Our findings support the notion that hypermethylation of critical CpG island loci influences cancer development and produces distinct epigenetic signatures for particular tumor subtypes.
C1 Univ Missouri, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Sch Med, Columbia, MO 65203 USA.
   Natl Chunghsing Univ, Life Sci Coll, Dept Zool, Taichung, Taiwan.
C3 University of Missouri System; University of Missouri Columbia; National
   Chung Hsing University
RP Huang, THM (通讯作者)，Univ Missouri, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Sch Med, 115 Business Loop I-70 W, Columbia, MO 65203 USA.
RI Yan, Pearlly/E-4339-2011; Chen, Chuan-Mu/K-7049-2013
OI Shi, Huidong/0000-0003-1137-3390; Chen, Chuan-Mu/0000-0003-2461-9150
FU NCI NIH HHS [CA-69065, CA-84701] Funding Source: Medline
CR Ahluwalia A, 2001, GYNECOL ONCOL, V82, P261, DOI 10.1006/gyno.2001.6291
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Ehrlich Melanie, 2000, P273
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Esteller M, 2001, CANCER RES, V61, P3225
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Lin HC, 1999, CANCER RES, V59, P807
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   Veugelers M, 2000, HUM MOL GENET, V9, P1321, DOI 10.1093/hmg/9.9.1321
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
NR 19
TC 210
Z9 281
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD DEC 1
PY 2001
VL 61
IS 23
BP 8375
EP 8380
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 499WX
UT WOS:000172594600005
PM 11731411
DA 2025-01-12
ER

PT J
AU Ravenel, JD
   Broman, KW
   Perlman, EJ
   Niemitz, EL
   Jayawardena, TM
   Bell, DW
   Haber, DA
   Uejima, H
   Feinberg, AP
AF Ravenel, JD
   Broman, KW
   Perlman, EJ
   Niemitz, EL
   Jayawardena, TM
   Bell, DW
   Haber, DA
   Uejima, H
   Feinberg, AP
TI Loss of imprinting of insulin-like growth factor-II (IGF2) gene in
   distinguishing specific biologic subtypes of Wilms tumor
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID BECKWITH-WIEDEMANN-SYNDROME; HUMAN-BREAST CANCER; HUMAN NEUROBLASTOMA;
   EXPRESSION; H19; HETEROZYGOSITY; CHROMOSOME-11; CELLS; RHABDOMYOSARCOMA;
   HEPATOBLASTOMA
AB Background: Loss of imprinting (LOI) of the insulin-like growth factor-II (IGF2) gene, an epigenetic alteration associated with expression of the normally silent maternal allele, was observed first in Wilms tumor. Although LOI has subsequently been detected in most adult tumors, the biologic role of LOI in cancer remains obscure. We analyzed the imprinting status of Wilms tumors with respect to pathologic subtype, stage, and patient's age at diagnosis and examined the expression of genes potentially affected by LOI. Methods: Of 60 Wilms tumors examined, 25 were informative for an ApaI polymorphism in the IGF2 gene, allowing analysis of allele-specific gene expression, and could be classified by pathologic subtype. Gene expression was measured quantitatively by real-time polymerase chain reaction, and pathologic analysis was blinded for genetic status. All statistical tests were two-sided. Results: We observed LOI of IGF2 in nine (90%) of 10 Wilms tumors classified as having a pathologic subtype associated with a later stage of renal development and in only one (6.7%) of 15 Wilms tumors with a pathologic subtype associated with an earlier stage of renal development (P < .001). LOI was associated with a 2.2-fold increase (95% confidence interval [CI] = 1.6-fold to 3.1-fold) in IGF2 expression (P<.001). Children whose Wilms tumors displayed LOI of IGF2 were statistically significantly older at diagnosis (median = 65 months; interquartile range [IQR] = 47-83 months) than children whose tumors displayed normal imprinting (median = 24 months; IQR = 13-35 months; P<.001). Conclusions: These data demonstrate a clear relationship between LOI and altered expression of IGF2 in Wilms tumors and provide a molecular basis for understanding the divergent pathogenesis of this cancer. Analysis of LOI could provide a valuable molecular tool for the classification of Films tumor.
C1 Johns Hopkins Univ, Sch Med, Inst Med Genet, Dept Pathol, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21218 USA.
   Harvard Univ, Sch Med, Charlestown, MA USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; Harvard University; Harvard
   University; Massachusetts General Hospital
RP Johns Hopkins Univ, Sch Med, Inst Med Genet, Dept Pathol, Ross 1064,720 Rutland Ave, Baltimore, MD 21205 USA.
EM afeinberg@jhu.edu
RI Feinberg, Andrew/AAY-7666-2020
OI Perlman, Elizabeth/0000-0001-6853-6221; Broman,
   Karl/0000-0002-4914-6671; Feinberg, Andrew/0000-0002-8364-1991
FU NCI NIH HHS [CA65145] Funding Source: Medline
CR Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Becker R.A., 1988, The New S Language
   BECKWITH J B, 1990, Pediatric Pathology, V10, P1
   BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494
   BRESLOW N, 1988, CANCER RES, V48, P1653
   BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429
   BRUNNER N, 1993, EUR J CANCER, V29A, P562, DOI 10.1016/S0959-8049(05)80152-2
   DoucRasy S, 1996, ONCOGENE, V12, P423
   ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042
   ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325
   Feinberg A. P., 2001, METABOLIC MOL BASES, P525
   FEINBERG AP, 1995, J NATL CANC I MONOGR, V17, P21
   GELATO MC, 1990, J CLIN ENDOCR METAB, V71, P1168, DOI 10.1210/jcem-71-5-1168
   GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0
   Grundy P, 1996, MED PEDIATR ONCOL, V27, P429, DOI 10.1002/(SICI)1096-911X(199611)27:5<429::AID-MPO7>3.0.CO;2-O
   HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109
   Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171
   HEDBORG F, 1994, AM J PATHOL, V145, P802
   Hibi K, 1996, CANCER RES, V56, P480
   HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145
   Jarrard DF, 1995, CLIN CANCER RES, V1, P1471
   KNUDSON AG, 1985, CANCER RES, V45, P1437
   KNUDSON AG, 1972, J NATL CANCER I, V48, P313
   KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989
   LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325
   LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425
   Lee MP, 1997, AM J HUM GENET, V61, P304, DOI 10.1086/514858
   LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365
   LI XR, 1995, ONCOGENE, V11, P221
   MANNENS M, 1990, CANCER RES, V50, P3279
   MAW MA, 1992, CANCER RES, V52, P3094
   Miyagawa K, 1998, NAT GENET, V18, P15, DOI 10.1038/ng0198-15
   Nonomura N, 1997, CANCER RES, V57, P2575
   OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0
   OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701
   PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0
   PRITCHARDJONES K, 2001, GENETIC PREDISPOSITI
   RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0
   RAINIER S, 1995, CANCER RES, V55, P1836
   REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799
   STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433
   Takeda S, 1996, ONCOGENE, V12, P1589
   Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040
   VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070
   VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670
   Wang T, 1999, ANAL BIOCHEM, V269, P198, DOI 10.1006/abio.1999.4022
   YEE D, 1988, CANCER RES, V48, P6691
   ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344
   Zhan SL, 1995, ONCOGENE, V11, P2503
NR 49
TC 139
Z9 156
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD NOV 21
PY 2001
VL 93
IS 22
BP 1698
EP 1703
DI 10.1093/jnci/93.22.1698
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 494MX
UT WOS:000172287400009
PM 11717330
DA 2025-01-12
ER

PT J
AU Du, Y
   Carling, T
   Fang, W
   Piao, Z
   Shen, JC
   Huang, S
AF Du, Y
   Carling, T
   Fang, W
   Piao, Z
   Shen, JC
   Huang, S
TI Hypermethylation in human cancers of the <i>RIZ1</i> tumor suppressor
   gene, a member of a histone/protein methyltransferase superfamily
SO CANCER RESEARCH
LA English
DT Article
ID ZINC-FINGER PROTEIN; CPG ISLANDS; PR DOMAIN; LUNG-CANCER; METHYLATION;
   EXPRESSION; CLONING; DNA; EPIGENETICS; PROMOTER
AB The retinoblastoma protein-interacting zinc finger gene RIZ1 is a tumor suppressor gene and a member of a nuclear histone/protein methyltransferase superfamily. RIZ1 inactivation is commonly found in many types of human cancers and occurs through loss of mRNA expression, frame-shift mutation, chromosomal deletion, and missense mutation. RIZ1 is also a tumor susceptibility gene in mice. We now show that loss of RIZ1 mRNA in human cancers is associated with DNA methylation of its promoter CpG island. Methylation of the RIZ1 promoter strongly correlated with lost or decreased RIZ1 mRNA expression in breast, liver, colon, and lung cancer cell lines as well as in liver cancer tissues. Treatment with the methylation inhibitor 5-aza-2'-deoxycytidine activated RIZ1 mRNA expression in cancer cells. Furthermore, methylation was found in 11 of 25 (44%) breast cancer specimens and 20 of 32 (62%) liver cancer specimens. Our results suggest that DNA methylation is a common mechanism in inactivating the RIZ1 tumor suppressor gene in human liver and breast cancers.
C1 Burnham Inst, La Jolla, CA 92037 USA.
   Univ Uppsala Hosp, Dept Surg, Endocrine Surg Unit, S-75185 Uppsala, Sweden.
   Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan.
C3 Sanford Burnham Prebys Medical Discovery Institute; Uppsala University;
   Uppsala University Hospital; National Taiwan University; National Taiwan
   University Hospital
RP Huang, S (通讯作者)，Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.
OI SHEU, JIN-CHUAN/0000-0002-2503-7139
FU NCI NIH HHS [R01-CA76146] Funding Source: Medline
CR Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0
   BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467
   Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730
   Esteller M, 1999, CANCER RES, V59, P67
   Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K
   Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   He LS, 1998, CANCER RES, V58, P4238
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933
   Jiang GL, 2001, CANCER RES, V61, P1796
   Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984
   Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x
   NIZETIC D, 1994, MAMM GENOME, V5, P801, DOI 10.1007/BF00292017
   Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203
   Piao Z, 2000, CANCER RES, V60, P4701
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V
   SHAPIRO VS, 1995, GENE, V163, P329, DOI 10.1016/0378-1119(95)00420-B
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   Weith A, 1996, CYTOGENET CELL GENET, V72, P114
   Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 31
TC 162
Z9 195
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2001
VL 61
IS 22
BP 8094
EP 8099
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 495AF
UT WOS:000172317500009
PM 11719434
DA 2025-01-12
ER

PT J
AU Xu, XL
   Wu, LC
   Du, FH
   Davis, A
   Peyton, M
   Tomizawa, Y
   Maitra, A
   Tomlinson, G
   Gazdar, AF
   Weissman, BE
   Bowcock, AM
   Baer, R
   Minna, JD
AF Xu, XL
   Wu, LC
   Du, FH
   Davis, A
   Peyton, M
   Tomizawa, Y
   Maitra, A
   Tomlinson, G
   Gazdar, AF
   Weissman, BE
   Bowcock, AM
   Baer, R
   Minna, JD
TI Inactivation of human <i>SRBC</i>, located within the 11p15.5-p15.4
   tumor suppressor region, in breast and lung cancers
SO CANCER RESEARCH
LA English
DT Article
ID DEPRIVATION RESPONSE GENE; CHROMOSOME ARM 11P; KINASE C-DELTA;
   WILMS-TUMOR; SERUM STARVATION; BINDING PROTEIN; OVARIAN-CANCER;
   HETEROZYGOSITY; DELETION; LOCUS
AB A cDNA clone encoding human SRBC [serum deprivation response factor (sdr)-related gene product that binds to c-kinase] was isolated in a yeast two-hybrid screening, with amino acids 1-304 of BRCA1 as the probe. The human SRBC gene (hSRBC) was mapped to chromosome region 11p15.5-p15.4, close to marker D11S1323, at which frequent loss of heterozygosity (LOH) has been observed in sporadic breast, lung, ovarian, and other types of adult cancers as well as childhood tumors. hSRBC-coding region mutations including frame shift and truncation mutations were detected in a few ovarian and lung cancer cell lines. More significantly, the expression of hSRBC protein was down-regulated in a large fraction [30 (70%) of 43] of breast, lung, and ovarian cancer cell lines, whereas strong expression of hSRBC protein was detected in normal mammary and lung epithelial cells. The down-regulation of hSRBC expression in cancer cells was associated with hypermethylation of CpG dinucleotides in its promoter region, and 3 (60%) of 5 primary breast tumors and 11 (79%) of 14 primary lung tumors were also found to be hypermethylated. Treatment of breast cancer MCF7 cells with 5' azacytidine and Trichostatin A resulted in expression of hSRBC, confirming DNA methylation as the mode of inactivation. Oar results suggest that epigenetic or mutational inactivation of hSRBC may contribute to the pathogenesis of several types of human cancers, marking hSRBC as a candidate tumor suppressor gene.
C1 Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.
   Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA.
   Washington Univ, Sch Med, Div Human Genet, Dept Genet Pediat & Med, St Louis, MO 63110 USA.
   Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas; Columbia University; Washington University (WUSTL);
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Minna, JD (通讯作者)，Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
RI Wu, Licun/AAL-9596-2021; Gazdar, Adi/F-7496-2010; Minna,
   John/AAB-1036-2022; Peyton, Michael/A-8728-2008
OI Bowcock, Anne/0000-0001-8691-9090
FU NCI NIH HHS [R01-CA76334, P50 CA70907, CA63176] Funding Source: Medline
CR ALBRECHT S, 1994, CANCER RES, V54, P5041
   ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909
   Baffa R, 1996, CANCER RES, V56, P268
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bepler G, 1998, CANCER DETECT PREV, V22, P14
   BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259
   BURGENER R, 1990, BIOCHEM J, V269, P729, DOI 10.1042/bj2690729
   BYRNE JA, 1993, GENE CHROMOSOME CANC, V8, P104, DOI 10.1002/gcc.2870080207
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Girard L, 2000, CANCER RES, V60, P4894
   Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009
   Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x
   GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396
   GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753
   Gustincich S, 1999, GENOMICS, V57, P120, DOI 10.1006/geno.1998.5733
   HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558
   Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381
   Jansa P, 1998, EMBO J, V17, P2855, DOI 10.1093/emboj/17.10.2855
   Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Karnik P, 1998, HUM MOL GENET, V7, P895, DOI 10.1093/hmg/7.5.895
   Karnik P, 1998, ONCOGENE, V17, P237, DOI 10.1038/sj.onc.1201959
   Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421
   KOUFOS A, 1989, AM J HUM GENET, V44, P711
   Maitra A, 1999, NAT MED, V5, P459, DOI 10.1038/7458
   Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601
   Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6
   NEGRINI M, 1995, CANCER RES, V55, P3003
   OBriant K, 1997, ANTICANCER RES, V17, P3243
   OBriant KC, 1997, GENE CHROMOSOME CANC, V18, P111, DOI 10.1002/(SICI)1098-2264(199702)18:2<111::AID-GCC5>3.0.CO;2-5
   Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2
   Pertsemlidis A, 2000, GENOMICS, V70, P300, DOI 10.1006/geno.2000.6359
   Primiano T, 1996, CARCINOGENESIS, V17, P2297, DOI 10.1093/carcin/17.11.2297
   REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799
   Reid LH, 1997, GENOMICS, V43, P366, DOI 10.1006/geno.1997.4826
   Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239
   Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6
   Sambrook J., 1989, MOL CLONING LAB MANU, Vsecond
   SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102
   TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809
   Tran YK, 1996, CANCER RES, V56, P2916
   VANDAMME B, 1992, CANCER RES, V52, P6646
   VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405
   Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302
   WINQVIST R, 1995, CANCER RES, V55, P2660
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430
   XU X, 2000, THESIS U TEXAS SW ME
NR 52
TC 97
Z9 110
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2001
VL 61
IS 21
BP 7943
EP 7949
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 489VQ
UT WOS:000172013500037
PM 11691816
DA 2025-01-12
ER

PT J
AU Ginger, MR
   Gonzalez-Rimbau, MF
   Gay, JP
   Rosen, JM
AF Ginger, MR
   Gonzalez-Rimbau, MF
   Gay, JP
   Rosen, JM
TI Persistent changes in gene expression induced by estrogen and
   progesterone in the rat mammary gland
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HUMAN CHORIONIC-GONADOTROPIN; BREAST-CANCER RISK; HISTONE DEACETYLASE;
   NEGATIVE REGULATOR; CARCINOGENESIS; PREGNANCY; DIFFERENTIATION;
   PREVENTION; COMPLEX; AGE
AB Epidemiological studies have consistently shown that an early full-term pregnancy is protective against breast cancer. We hypothesize that the hormonal milieu that is present during pregnancy results in persistent changes in the pattern of gene expression in the mammary gland, leading to permanent changes in cell fate that determine the subsequent proliferative response of the gland. To investigate this hypothesis, we have used suppression subtractive hybridization to identify genes that are persistently up-regulated in the glands of E-and progesterone (P)-treated Wistar-Furth rats 28 d after steroid hormone treatment compared with age-matched virgins. Using this approach, a number of genes displaying persistent altered expression in response to previous treatment with E and P were identified. Two markers have been characterized in greater detail: RbAp46 and a novel gene that specifies a noncoding RNA (designated G.B7). Both were persistently up-regulated in the lobules of the regressed gland and required previous treatment with both E and P for maximal persistent expression. RbAp46 has been implicated in a number of complexes involving chromatin remodeling, suggesting a mechanism whereby epigenetic factors responsible for persistent changes in gene expression may be related to the determination of cell fate. These results provide the first support at the molecular level for the hypothesis that hormone-induced persistent changes in gene expression are present in the involuted mammary gland.
C1 Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Rosen, JM (通讯作者)，Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.
FU NCI NIH HHS [P01-CA-64255] Funding Source: Medline
CR Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169
   CHODOSH LA, 1999, CANCER RES, V59, P1765
   GRUBBS CJ, 1983, JNCI-J NATL CANCER I, V70, P209
   GRUBBS CJ, 1985, JNCI-J NATL CANCER I, V74, P927
   GRUBBS CJ, 1988, ANTICANCER RES, V8, P113
   Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047
   Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520
   Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449
   HUGGINS C, 1962, P NATL ACAD SCI USA, V48, P379, DOI 10.1073/pnas.48.3.379
   KELSEY JL, 1991, CA-CANCER J CLIN, V41, P146, DOI 10.3322/canjclin.41.3.146
   Kim YC, 1999, BIOCHEM BIOPH RES CO, V266, P1, DOI 10.1006/bbrc.1999.1704
   Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873
   Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4
   Lipman DJ, 1997, NUCLEIC ACIDS RES, V25, P3580, DOI 10.1093/nar/25.18.3580
   MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209
   Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126
   Medina D, 1999, J NATL CANCER I, V91, P967, DOI 10.1093/jnci/91.11.967
   Medina D, 2001, CANCER LETT, V169, P1, DOI 10.1016/S0304-3835(01)00507-9
   Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299
   MITELMAN F, 2001, DATABASE CHROMOSOME
   MOON RC, 1969, INT J CANCER, V4, P312, DOI 10.1002/ijc.2910040308
   Moss EG, 2000, CURR BIOL, V10, pR436, DOI 10.1016/S0960-9822(00)00528-5
   Müller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1
   Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7
   QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0
   QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507
   ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079
   Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022
   RUSSO IH, 1990, CARCINOGENESIS, V11, P1849, DOI 10.1093/carcin/11.10.1849
   RUSSO IH, 1991, BRIT J CANCER, V64, P481, DOI 10.1038/bjc.1991.335
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.1289/ehp.96104938
   RUSSO IH, 1990, JNCI-J NATL CANCER I, V82, P1286, DOI 10.1093/jnci/82.15.1286
   RUSSO J, 1992, BREAST CANCER RES TR, V23, P211, DOI 10.1007/BF01833517
   Russo J, 2000, J Natl Cancer Inst Monogr, P17
   RUSSO J, 1987, LAB INVEST, V57, P112
   RUSSO J, 1980, AM J PATHOL, V100, P497
   Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718
   Ryan J, 1999, J CELL SCI, V112, P2441
   SINHA DK, 1988, BRIT J CANCER, V57, P390, DOI 10.1038/bjc.1988.88
   Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573
   Sumitomo K, 2000, CANCER LETT, V155, P37, DOI 10.1016/S0304-3835(00)00407-9
   TAY LK, 1981, CARCINOGENESIS, V2, P1327, DOI 10.1093/carcin/2.12.1327
   THIEDE MA, 1986, J BIOL CHEM, V261, P3230
   THORDARSON G, 1995, CARCINOGENESIS, V16, P2847, DOI 10.1093/carcin/16.11.2847
   Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8
   Vermaak D, 1999, MOL CELL BIOL, V19, P5847
   vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598
   WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6
   Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379
   Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
NR 52
TC 91
Z9 100
U1 0
U2 2
PU ENDOCRINE SOC
PI BETHESDA
PA 4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD NOV
PY 2001
VL 15
IS 11
BP 1993
EP 2009
DI 10.1210/me.15.11.1993
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 486MH
UT WOS:000171821200013
PM 11682629
DA 2025-01-12
ER

PT J
AU Mohandas, KM
AF Mohandas, KM
TI Genetic predisposition to cancer
SO CURRENT SCIENCE
LA English
DT Article
ID FAMILIAL ADENOMATOUS POLYPOSIS; NONPOLYPOSIS COLON-CANCER;
   BREAST-CANCER; HEREDITARY CANCER; COLORECTAL-CANCER; INTESTINAL
   NEOPLASIA; SUSCEPTIBILITY GENE; GERMLINE MUTATIONS; RISK NOTIFICATION;
   ONSET
AB Small proportion of cancers develop due to inherited mutations of tumour-suppressor genes, DNA repair genes, and a few recessive genes. Several genes that predispose humans to cancer have been cloned and are used for predictive,genetic testing. Interventions such as total colectomy or mastectomy is used for prevention of inherited cancers. However, genetic screening and prophylactic treatments have profound psychosocial effects on patients and families. The first draft of the human genome project has not revealed new genes responsible for common cancers. There is no single technology at present to detect susceptibly due to different genomic abnormalities such as large deletions, rearrangements, base substitutions, small insertions and deletions, amplification, and epigenetic changes like DNA methylation. More laboratory, clinical and ethical research is needed to understand the true extent of genetic predisposition to cancer.. We also need to study the social implications of genetic screening in our communities with diverse customs and prejudices so that we can provide socially acceptable treatment strategies.
C1 Tata Mem Hosp, Div Digest Dis & Clin Nutr, Bombay 400012, Maharashtra, India.
C3 Tata Memorial Centre (TMC); Tata Memorial Hospital
RP Mohandas, KM (通讯作者)，Tata Mem Hosp, Div Digest Dis & Clin Nutr, Bombay 400012, Maharashtra, India.
CR Andrykowski MA, 1997, J CLIN ONCOL, V15, P2139, DOI 10.1200/JCO.1997.15.5.2139
   BURN J, 1991, J MED GENET, V28, P289, DOI 10.1136/jmg.28.5.289
   CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0
   Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123
   DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8
   EASTON DF, 1989, AM J HUM GENET, V44, P208
   EASTON DF, 1993, AM J HUM GENET, V53, P305
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302
   Futreal PA, 2001, NATURE, V409, P850, DOI 10.1038/35057046
   Gardner E J, 1983, Prog Clin Biol Res, V115, P39
   GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   HARPER PS, 1993, BRIT MED J, V306, P1391, DOI 10.1136/bmj.306.6889.1391
   Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952
   Knudson AG, 1997, J CLIN ONCOL, V15, P3280, DOI 10.1200/JCO.1997.15.10.3280
   LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S
   LEDGER GA, 1995, ANN INTERN MED, V122, P118, DOI 10.7326/0003-4819-122-2-199501150-00008
   LERMAN C, 1991, J CLIN ONCOL, V9, P1275, DOI 10.1200/JCO.1991.9.7.1275
   LEVY DB, 1994, CANCER RES, V54, P5953
   LI F, 1990, J NATL CANCER I, V84, P1156
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   LIU B, 1996, NAT MED, V2, P1169
   LYNCH HT, 1994, WORLD J SURG, V18, P21, DOI 10.1007/BF00348188
   Lynch HT, 2000, J CLIN ONCOL, V18, p19S
   Malik K, 2000, BRIT J CANCER, V83, P1583, DOI 10.1054/bjoc.2000.1549
   MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106
   MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mohandas KM, 1999, FAMILIAL CANCER AND PREVENTION, P321
   MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517
   MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70
   NAROD SA, 1995, AM J HUM GENET, V56, P254
   Nichols KE, 2001, CANCER EPIDEM BIOMAR, V10, P83
   NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730
   Pack SD, 1999, CANCER RES, V59, P5560
   PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
   PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120
   PONDER BAJ, 1994, BRIT MED BULL, V50, P732, DOI 10.1093/oxfordjournals.bmb.a072921
   Rozen P, 1999, GUT, V45, P829, DOI 10.1136/gut.45.6.829
   SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936
   SPIRIO L, 1993, CELL, V75, P1
   Stratakis CA, 2000, J PEDIATR ENDOCR MET, V13, P457
   Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117
   VANDERMEY AGL, 1989, LANCET, V2, P1291
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
   WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Yarosh D, 2001, LANCET, V357, P926, DOI 10.1016/S0140-6736(00)04214-8
   ZHAO B, 1995, PHARMACOGENETICS, V5, P275, DOI 10.1097/00008571-199510000-00002
NR 53
TC 1
Z9 1
U1 0
U2 1
PU CURRENT SCIENCE ASSN
PI BANGALORE
PA C V RAMAN AVENUE, PO BOX 8005, BANGALORE 560 080, INDIA
SN 0011-3891
J9 CURR SCI INDIA
JI Curr. Sci.
PD SEP 10
PY 2001
VL 81
IS 5
BP 482
EP 489
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 476BH
UT WOS:000171206000019
DA 2025-01-12
ER

PT J
AU DiNardo, DNM
   Butcher, DT
   Robinson, DP
   Archer, TK
   Rodenhiser, DI
AF DiNardo, DNM
   Butcher, DT
   Robinson, DP
   Archer, TK
   Rodenhiser, DI
TI Functional analysis of CpG methylation in the <i>BRCA1</i> promoter
   region
SO ONCOGENE
LA English
DT Article
DE BRCA1; methylation; expression; CREB
ID CANCER SUSCEPTIBILITY GENE; SPORADIC BREAST-CANCER; TUMOR-SUPPRESSOR
   GENE; OVARIAN-CANCER; DNA METHYLATION; MESSENGER-RNA; ISLAND; ESTROGEN;
   BINDING; TRANSCRIPTION
AB Understanding the role for DNA methylation in tumorigenesis has evolved from defining the location and extent of methylation in a variety of cancer-related genes to clarifying the functional and site-specific effects of aberrant methylation on gene expression, Our objectives were to characterize the functional effects of DNA methylation in the BRCA1 promoter and to clarify the functional status of the BRCA1 CRE (cAMP response element) motif Luciferase reporter assays confirm that an intact CRE is important for BRCA1 expression in transient transfections. Luciferase activities were decreased in constructs where the CRE recognition sequence was altered and when constructs were methylated in vitro. Gel mobility shift and competition assays identified a DNA-protein complex recognizing the CRE motif that we were able to supershift using CREB-specific antibody. Furthermore this CRE is methylation sensitive, and we localized this methylation effect to a CpG dinucleotide within the BRCA1 CRE motif. The consequences of aberrant DNA methylation at specific transcription factor motifs, along with the multiple mutational events that can occur in a variety of essential genes such as BRCA1, paint a complex picture where both genetic and epigenetic changes contribute to tumour formation.
C1 Univ Western Ontario, London Reg Canc Ctr, London, ON N6A 4L6, Canada.
   Univ Western Ontario, Child Hlth Res Inst, London, ON, Canada.
   Univ Western Ontario, Dept Biochem, London, ON, Canada.
   Univ Western Ontario, Dept Paediat, London, ON, Canada.
   NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario); Western University (University of Western Ontario);
   National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP Rodenhiser, DI (通讯作者)，Univ Western Ontario, London Reg Canc Ctr, Room 4068,790 Commissioners Rd E, London, ON N6A 4L6, Canada.
OI Archer, Trevor K/0000-0001-7651-3644
CR ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560
   Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Hwu WL, 1997, DNA CELL BIOL, V16, P449, DOI 10.1089/dna.1997.16.449
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Issa JPJ, 1996, CANCER RES, V56, P973
   Issa JPJ, 1996, CANCER RES, V56, P3655
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Maesawa C, 1996, CANCER RES, V56, P3875
   Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585
   Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898
   Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063
   Okuse K, 1997, MOL BRAIN RES, V46, P197, DOI 10.1016/S0169-328X(96)00302-6
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Rodenhiser D, 1996, ONCOGENE, V12, P2623
   Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6
   SAKAI T, 1991, AM J HUM GENET, V48, P888
   Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4
   SHATTUCKEIDENS E, 1995, JAMA-J AM MED ASSOC, V273, P535
   Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297
   Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837
   Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994
NR 38
TC 45
Z9 54
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD AUG 30
PY 2001
VL 20
IS 38
BP 5331
EP 5340
DI 10.1038/sj.onc.1204697
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 465DZ
UT WOS:000170575500008
PM 11536045
DA 2025-01-12
ER

PT J
AU Castro-Rivera, E
   Samudio, I
   Safe, S
AF Castro-Rivera, E
   Samudio, I
   Safe, S
TI Estrogen-regulation of cyclin D1 gene expression in ZR-75 breast cancer
   cells involves multiple enhancer elements
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CATHEPSIN-D GENE; TRANSCRIPTION FACTOR SP1; CAMP-RESPONSIVE ELEMENT;
   FACTOR-KAPPA-B; GROWTH-FACTOR; MCF-7 CELLS; PROGESTERONE-RECEPTOR;
   INDEPENDENT ACTIVATION; PHASE PROGRESSION; DEPENDENT KINASES
AB Cyclin D1 gene expression is induced by 17 beta -estradiol (E2) in human breast cancer cells and is important for progression of cells through the G(1) phase of the cell cycle. The mechanism of activation of cyclin D1 is mitogen- and cell context-dependent, and this study describes the role of multiple promoter elements required for induction of cyclin D1 by E2 in estrogen receptor (ER)-positive ZR-75 breast cancer cells. Transcriptional activation of cyclin DI by E2 was dependent, in part, on a proximal cAMP-response element at -66, and this was linked to induction of protein kinase A-dependent pathways. These results contrasted to a recent report showing that induction of cyclin DI by E2 in ER-positive MCF-7 and HeLa cells was due to up-regulation of c-jun and subsequent interaction of c-Jun-ATF-2 with the CRE. Moreover, further examination of the proximal region of the cyclin D1 promoter showed that three GC-rich Spl-binding sites at -143 to -110 were also E2-responsive, and interaction of ER alpha and Sp1 proteins at these sites was confirmed by electromobility shift and chromatin immunoprecipitation assays. Thus, induction of cyclin D1 by E2 in ZR-75 cells is regulated through nuclear ER alpha /Sp1 and epigenetic protein kinase A activation pathways, and our results suggest that this mechanism may be cell context-dependent even among ER-positive breast cancer cell lines.
C1 Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station
RP Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU, College Stn, TX 77843 USA.
EM ssafe@cvm.tamu.edu
RI Samudio, Ismael/JMB-1318-2023; Samudio, Ismael/D-3581-2013
OI Samudio, Ismael/0000-0001-8676-1035
FU NCI NIH HHS [CA76636] Funding Source: Medline; NIEHS NIH HHS [ES09253,
   ES09106] Funding Source: Medline
CR Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297
   Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186
   ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589
   Altucci L, 1996, ONCOGENE, V12, P2315
   ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045
   ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517
   ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743
   AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693
   Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990
   BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218
   BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BUCKLEY MF, 1993, ONCOGENE, V8, P2127
   CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552
   CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203
   D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200
   Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099
   Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981
   ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928
   Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488
   Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b
   Hulit J, 2000, J BIOL CHEM, V275, P21203, DOI 10.1074/jbc.M000321200
   Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245
   Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787
   KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710
   KRISHNAN V, 1994, J BIOL CHEM, V269, P15912
   Kyo S, 1999, CANCER RES, V59, P5917
   Lech JJ, 1996, FUND APPL TOXICOL, V30, P229, DOI 10.1006/faat.1996.0060
   Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000
   Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341
   LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3
   Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753
   Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367
   McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382
   Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261
   MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577
   Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200
   Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338
   Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594
   Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696
   Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508
   Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640
   Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972
   Pipaón C, 1999, MOL CELL BIOL, V19, P2734
   Planas-Silva MD, 1999, CANCER RES, V59, P4788
   PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059
   Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371
   Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569
   Prall OWJ, 1997, J BIOL CHEM, V272, P10882
   Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501
   Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149
   Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217
   Salvatori L, 2000, ENDOCRINOLOGY, V141, P2266, DOI 10.1210/en.141.6.2266
   Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000
   Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994
   Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379
   SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Sherr CJ, 2000, CANCER RES, V60, P3689
   SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1
   Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969
   Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200
   Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882
   Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276
   Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200
   Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044
   WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0
   Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373
   Wang WL, 1998, ARCH BIOCHEM BIOPHYS, V356, P239, DOI 10.1006/abbi.1998.0782
   Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212
   Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861
   WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443
   WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257
   WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097
   Xie W, 2000, ENDOCRINOLOGY, V141, P2439, DOI 10.1210/en.141.7.2439
   Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219
   ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707
   ZWIJSEN RM, 1988, GENE DEV, V12, P3488
   Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6
NR 81
TC 164
Z9 211
U1 0
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 17
PY 2001
VL 276
IS 33
BP 30853
EP 30861
DI 10.1074/jbc.M103339200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 463JG
UT WOS:000170472900037
PM 11410592
OA hybrid
DA 2025-01-12
ER

PT J
AU Hayashi, K
   Yokozaki, H
   Goodison, S
   Oue, N
   Suzuki, T
   Lotan, R
   Yasui, N
   Tahara, E
AF Hayashi, K
   Yokozaki, H
   Goodison, S
   Oue, N
   Suzuki, T
   Lotan, R
   Yasui, N
   Tahara, E
TI Inactivation of retinoic acid receptor β by promoter CpG
   hypermethylation in gastric cancer
SO DIFFERENTIATION
LA English
DT Article
DE retinoic acid receptor-beta; partial methylation; 5-azacytidine; TSA
ID HISTONE DEACETYLASE COMPLEX; CARCINOMA CELL-LINES; HUMAN LUNG-CANCER;
   DNA METHYLATION; BREAST-CANCER; EXPRESSION; GENE; PROTEIN; GROWTH;
   AMPLIFICATION
AB Inactivation of nuclear retinoic acid receptor beta (RAR beta) expression is implicated in tumorigenesis. We hypothesized that loss of RAR beta in gastric cancer cells may occur as a result of multiple factors, including epigenetic modifications which alter RAR beta promoter chromatin structure. We examined hypermethylation of CpG islands present in the RAR beta promoter by methylation-specific PCR and the expression of RAR beta in gastric cancer cell lines and tissues. Three (MKN-28, -45 and -74) out of eight gastric cancer cell lines had a loss of RAR expression associated with promoter methylation. RAR beta expression was retrieved in these cell lines by treatment with 5-azacytidine or by the histone deacetylase inhibitor trichostatin A. Promoter hypermethylation was detected in 64% (7/11) of gastric carcinoma tissues with reduced expression of RAR beta, whereas it was detected in 22% (2/9) of tumors with retained RAR beta expression. To investigate the functions of exogenous RAR beta in gastric cancer cells, we transfected a retroviral RAR beta expression vector (LNS beta) into MKN-28 cells that have hypermethylation of the RAR beta promoter. Overexpression of RAR in MKN-28 cells appeared to regulate the expression of DNA methyltransferase and DNA demethylase and the acetylation of hitone H4. These results suggest that the transcriptional inactivation of the RAR beta by promoter CpG hypermethylation is frequently associated with gastric carcinoma. Our data also suggests that DNA methylation plays a pivotal role in establishing and maintaining an inactive state of RAR beta by rendering the chromatin structure inaccessible to the transcription machinery.
C1 Hiroshima Univ, Sch Med, Dept Pathol 1, Minami Ku, Hiroshima 7348551, Japan.
   Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
C3 Hiroshima University; University of California System; University of
   California San Diego; University of California System; University of
   California San Diego; University of Texas System; UTMD Anderson Cancer
   Center
RP Hayashi, K (通讯作者)，Hiroshima Univ, Sch Med, Dept Pathol 1, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
OI Yokozaki, Hiroshi/0000-0001-5276-3331
FU NCI NIH HHS [p101-CA52051] Funding Source: Medline; NIDCR NIH HHS
   [DE11906] Funding Source: Medline
CR [Anonymous], 1999, JAP CLASS GASTR CARC
   ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325
   BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x
   Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533
   Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481
   Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638
   BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0
   Castillo L, 1997, CLIN CANCER RES, V3, P2137
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015
   Cote S, 1997, ANTI-CANCER DRUG, V8, P56
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   GEBERT JF, 1991, ONCOGENE, V6, P1859
   Gudas Lorraine J., 1994, P443
   Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   JONES PA, 1979, CELL, V20, P1324
   KAMEDA T, 1990, CANCER RES, V50, P8002
   KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MINNUCI S, 1997, MOL CELL BIOL, V17, P6481
   MINUCCI S, 1999, SEMIN CELL DEV BIOL, V9, P158
   MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65
   Myöhänen SK, 1998, CANCER RES, V58, P591
   NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   OCHIAI A, 1985, JPN J CANCER RES, V76, P1064
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   PETER S, 1998, CANCER RES, V58, P5049
   SANO T, 1991, CANCER RES, V51, P2926
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Wan HS, 1999, CANCER RES, V59, P3518
   Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624
   Xu XC, 1997, CANCER RES, V57, P4992
   XU XC, 1994, CANCER RES, V54, P3580
   YANAGIHARA K, 1991, CANCER RES, V51, P381
   YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093
   Zhang XK, 1996, MUTAT RES-FUND MOL M, V350, P267, DOI 10.1016/0027-5107(95)00102-6
NR 51
TC 58
Z9 62
U1 0
U2 4
PU BLACKWELL WISSENSCHAFTS-VERLAG GMBH
PI BERLIN
PA KURFURSTENDAMM 57, D-10707 BERLIN, GERMANY
SN 0301-4681
J9 DIFFERENTIATION
JI Differentiation
PD AUG
PY 2001
VL 68
IS 1
BP 13
EP 21
DI 10.1046/j.1432-0436.2001.068001013.x
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA 478YT
UT WOS:000171377700003
PM 11683489
DA 2025-01-12
ER

PT J
AU Ahluwalia, A
   Yan, P
   Hurteau, JA
   Bigsby, RM
   Jung, SH
   Huang, THM
   Nephew, KP
AF Ahluwalia, A
   Yan, P
   Hurteau, JA
   Bigsby, RM
   Jung, SH
   Huang, THM
   Nephew, KP
TI DNA methylation and ovarian cancer
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE ovarian cancer; methylation; CpG islands; epigenetics; microarrays
ID CPG ISLANDS; DRUG-RESISTANCE; EXPRESSION; GENE; HYPERMETHYLATION;
   CLASSIFICATION; CARCINOMAS; DISPLAY; CELLS; MLH1
AB Objective. The aim of this study was to examine CpG island methylation patterns in ovarian cancer and determine whether epigenetic information can be related to clinical data of patients. CpG island (CpGI) hypermethylation is commonly associated with cancer progression, but little is currently known about the role of methylation in ovarian cancer.
   Methods. Differential methylation hybridization (DMH) analysis at 742 loci was performed to determine methylation signatures for 20 primary epithelial ovarian carcinomas (Stages II, III, and IV adenocarcinomas, serous papillary), 6 ovarian cancer cell lines, and normal ovarian surface epithelial cells.
   Results. Between 23 and 108 methylated CpGIs were seen in the ovarian carcinomas. Fewer (P < 0.05) methylated CpGIs were observed in the ovarian cancer cell lines; however, a number of CpGIs were commonly hypermethylated in both the cell lines and the tumor samples. A methylation signature, consisting of frequently (P < 0.05) methylated CpGIs, was determined for the samples. The observed pattern of methylation in ovarian cancers included several (11) CpGI tags that were previously reported to be hypermethylated in human breast cancer.
   Conclusions. Epigenetic signatures in ovarian cancer were determined using DMH. This proof-of-concept study lays the foundation for genome-wide screening of methylation to examine epi-genotype-phenotype relationships in ovarian cancer. (C) 2001. Academic Press.
C1 Indiana Univ, Sch Med, Bloomington, IN 47405 USA.
   Univ Missouri, Dept Pathol, Ellis Fishcel Canc Ctr, Columbia, MO 65203 USA.
   Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; University of
   Missouri System; University of Missouri Columbia; Indiana University
   System; Indiana University Indianapolis
RP Indiana Univ, Sch Med, 302 Jordan Hall,1001 E 3rd St, Bloomington, IN 47405 USA.
EM knephew@indiana.edu
RI Yan, Pearlly/E-4339-2011
FU NCI NIH HHS [CA27469-18] Funding Source: Medline
CR Alaiya AA, 2000, INT J CANCER, V86, P731, DOI 10.1002/(SICI)1097-0215(20000601)86:5<731::AID-IJC20>3.0.CO;2-A
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   AUERSPERG N, 1984, IN VITRO CELL DEV B, V20, P743
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BAYLIN SB, 1991, CANC CELLS, V3, P363
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103
   KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594
   Lin HC, 1999, CANCER RES, V59, P807
   MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8
   MATSUMURA T, 1989, EXP GERONTOL, V24, P477, DOI 10.1016/0531-5565(89)90054-5
   MATSUMURA T, 1989, EXP CELL RES, V184, P148, DOI 10.1016/0014-4827(89)90373-X
   McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328
   McCluskey LL, 1999, GYNECOL ONCOL, V72, P87, DOI 10.1006/gyno.1998.5235
   Melki JR, 1999, CANCER RES, V59, P3730
   Milde-Langosch K, 1998, INT J CANCER, V79, P61, DOI 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K
   Myöhänen SK, 1998, CANCER RES, V58, P591
   Plumb JA, 2000, CANCER RES, V60, P6039
   Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Samimi G, 2000, CLIN CANCER RES, V6, P1415
   Schmutte C, 1998, BIOL CHEM, V379, P377
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Taverna P, 2000, CANCER CHEMOTH PHARM, V46, P507, DOI 10.1007/s002800000186
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P5438
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214
NR 38
TC 75
Z9 82
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD AUG
PY 2001
VL 82
IS 2
BP 261
EP 268
DI 10.1006/gyno.2001.6291
PG 8
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA 463ZY
UT WOS:000170508600008
PM 11531277
DA 2025-01-12
ER

PT J
AU Silva, J
   Domínguez, G
   Silva, JM
   García, JM
   Gallego, I
   Corbacho, C
   Provencio, M
   España, P
   Bonilla, F
AF Silva, J
   Domínguez, G
   Silva, JM
   García, JM
   Gallego, I
   Corbacho, C
   Provencio, M
   España, P
   Bonilla, F
TI Analysis of genetic and epigenetic processes that influence p14ARF
   expression in breast cancer
SO ONCOGENE
LA English
DT Article
DE allelic losses; p14ARF; breast cancer; hypermethylation; overexpression;
   mutations
ID CELL LUNG-CANCER; TUMOR-SUPPRESSOR GENE; INK4A/ARF LOCUS; STABILIZES
   P53; CYCLE ARREST; P19(ARF); METHYLATION; P16(INK4A); INACTIVATION;
   MUTATIONS
AB The INK4a/ARF locus encodes two unrelated cell cycle-regulatory proteins that both function in tumor suppression, p16INK4a and p14ARF. In human tumors including breast cancer, alterations affecting selectively p14ARF have been poorly analysed. We have performed a comprehensive analysis of the inactivation mechanisms (mutation, homozygous and hemizygous deletion, and promoter hypermethylation) in a large series of 100 primary breast carcinomas. RT-PCR showed expression variable of the p14ARF transcript, with 17% demonstrating overexpression and 26% demonstrating decreased expression. No detectable alterations were observed in the majority of cases with overexpressed p14ARF mRNA, but 77% of tumors with decreased expression presented at least one of these genetic/ epigenetic alterations. Nevertheless, a statistically significant correlation was observed between decreased p14ARF expression and several poor prognostic parameters.
C1 Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain.
   Clin Puerta Hierro, Dept Pathol, E-28035 Madrid, Spain.
   Hosp Santa Cristina, Dept Pathol, E-28009 Madrid, Spain.
C3 Clinica Veterinaria Puerta de Hierro; Hospital Puerta de
   Hierro-Majadahonda; Hospital Puerta de Hierro-Majadahonda; Clinica
   Veterinaria Puerta de Hierro
RP Bonilla, F (通讯作者)，Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain.
RI Provencio, Mariano/ABE-8586-2020; Gallego, Ignacio/GZK-5910-2022
OI Provencio Pulla, Mariano/0000-0001-6315-7919; Provencio,
   Mariano/0000-0001-9053-9197
CR Brenner AJ, 1996, CLIN CANCER RES, V2, P1993
   Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5
   Esteller M, 2000, CANCER RES, V60, P129
   FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541
   Gazzeri S, 1998, CANCER RES, V58, P3926
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Herranz M, 1999, LEUKEMIA, V13, P808, DOI 10.1038/sj.leu.2401409
   Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P
   Iwato M, 2000, CANCER RES, V60, P2113
   Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3
   Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N
   Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197
   Markl IDC, 1998, CANCER RES, V58, P5348
   OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379
   QUELLE DE, 1995, CELL, V83, P993
   Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669
   Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457
   Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   STONE S, 1995, CANCER RES, V55, P2988
   Takemoto S, 2000, BLOOD, V95, P3939
   Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937
   Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501
   Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4
   Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
NR 26
TC 44
Z9 54
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JUL 27
PY 2001
VL 20
IS 33
BP 4586
EP 4590
DI 10.1038/sj.onc.1204617
PG 5
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 456GN
UT WOS:000170074900017
PM 11494155
DA 2025-01-12
ER

PT J
AU Yuan, YF
   Mendez, R
   Sahin, A
   Dai, JL
AF Yuan, YF
   Mendez, R
   Sahin, A
   Dai, JL
TI Hypermethylation leads to silencing of the <i>SYK</i> gene in human
   breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; DNA METHYLATION; HISTONE DEACETYLASE; PROMOTER
   HYPERMETHYLATION; SPORADIC BREAST; CPG ISLANDS; PROTEIN; INACTIVATION;
   EPIGENETICS; INHIBITION
AB A number of cancer-associated genes have been shown to be inactivated by hypermethylation of CpG islands during breast tumorigenesis. SYK, a candidate tumor suppressor, has been found not expressed in a subset of breast cancer cell lines, but the mechanism by which SYK is silenced is unclear, In this study, we examined the 5 ' CpG island methylation status of the SYK gene in breast cancer cell lines and primary breast cancer tissues. We found SYK 5 ' CpG hypermethylation in 30% (6/20) of breast cancer cell lines, and the aberrant methylation status was strongly associated with loss of SYK gene expression. Treatment of cells with a methylation inhibitor, 5-aza-2 ' -deoxycytidine, led to a reactivation of SYK expression in SYK-negative cells, as detected by reverse transcription-PCR, Using methylation-specific PCR, we demonstrated that SYK is hypermethylated in 32% (12/37) of unselected breast tumors, whereas all of the matched neighboring normal breast tissues exhibited unmethylated DNA status, We concluded that SYK is frequently inactivated through an epigenetic pathway in breast cancer. Because SYK: has been shown to function as a tumor suppressor, and its loss of expression in breast cancer has been correlated with tumor invasiveness, the aberrant SYK methylation is responsible for the loss of expression and may consequently play a permissive role for tumor aggressiveness.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Dai, JL (通讯作者)，Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.
OI Yuan, Yunfei/0000-0003-2467-3683
FU NCI NIH HHS [5P30 CA16672-25] Funding Source: Medline
CR Ahuja N, 1998, CANCER RES, V58, P5489
   ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x
   Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086
   Corn PG, 1999, CANCER RES, V59, P3352
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   FLUCK M, 1995, BIOCHEM BIOPH RES CO, V213, P273, DOI 10.1006/bbrc.1995.2126
   GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Herman JG, 1996, CANCER RES, V56, P722
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Jones PA, 1996, CANCER RES, V56, P2463
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8
   Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1
   Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nass SJ, 2000, CANCER RES, V60, P4346
   RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Yang XW, 2000, CANCER RES, V60, P6890
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
NR 32
TC 109
Z9 154
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2001
VL 61
IS 14
BP 5558
EP 5561
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 451YN
UT WOS:000169830500039
PM 11454707
DA 2025-01-12
ER

PT J
AU Maitra, A
   Wistuba, II
   Washington, C
   Virmani, AK
   Ashfaq, R
   Milchgrub, S
   Gazdar, AF
   Minna, JD
AF Maitra, A
   Wistuba, II
   Washington, C
   Virmani, AK
   Ashfaq, R
   Milchgrub, S
   Gazdar, AF
   Minna, JD
TI High-resolution chromosome 3p allelotyping of breast carcinomas and
   precursor lesions demonstrates frequent loss of heterozygosity and a
   discontinuous pattern of allele loss
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID CELL LUNG-CANCER; HOMOZYGOUS DELETION; FHIT GENE; EPIGENETIC
   INACTIVATION; SUSCEPTIBILITY GENE; TUMOR; REGION; 3P21.3;
   IDENTIFICATION; EXPRESSION
AB We performed high-resolution allelotyping for loss of heterozygosity (LOH) analysis on microdissected samples from 45 primary breast cancers, 47 mammary preneoplastic epithelial foci, and 18 breast cancer cell Lines, using a panel of 27 polymorphic chromosome 3p markers. Allele loss in some regions of chromosome 3p was detected in 39 of 45 (87%) primary breast tumors. The 3p21.3 region had the highest frequency of LOH (69%), followed by 3p22-24 (61%), 3p21.2-21.3 (58%), 3p25 (48%), 3p14.2 (45%), 3p14.3 (41%), and 3p12 (35%). Analysis of all of the data revealed at least nine discrete intervals showing frequent allele loss: D3S1511-D3S1284 (U2020/DUTT1 region centered on D3S1274 with a homozygous deletion), D3S1300-D3S1234 [fragile histidine triad (FHIT)/FRA3B region centered on D3S1300 with a homozygous deletion], D3S1076-D3S1573, D3S4624/ Luca2.1-D3S4597/P1.5, D3S1478-D3S1029, D3S1029 (with a homozygous deletion), D3S1612-D3S1537, D3S1233-D3S1597, and D3S1597-telomere; it is more than likely that additional localized regions of LOH not examined in this study also exist on chromosome 3p. In multiple cases, there was discontinuous allele loss at several 3p sites in the same tumor. Twenty-one of 47 (45%) preneoplastic lesions demonstrated 3p LOH, including 12 of 13 (92%) ductal carcinoma in situ, 2 of 7 (29%) apocrine metaplasia, and 7 of 25 (28%) usual epithelial hyperplasia. The 3p21.3 region had the highest frequency of LOH in preneoplastic breast epithelium (36%), followed by 3p21.2-21.3 (20%), 3p14.2/FHIT region (11%), 3p25 (10%), and 3p22-24 (5%). In 39 3p loci showing LOH in both the tumor and accompanying preneoplasia, 34 (87%) showed loss of the same parental allele (P = 1.2 x 10(-6), cumulative binomial test). In addition, when 21 preneoplastic samples showing LOH were compared to their accompanying cancers, 67% were clonally related, 20% were potentially clonally related but were divergent, and 13% were clonally unrelated. Overall this demonstrated the high likelihood of clonal relatedness of the preneoplastic foci to the tumors. We conclude that: chromosome 3p allele loss is a common event in breast carcinoma pathogenesis; involves multiple, localized sites that often show discontinuous LOH with intervening markers retaining heterozygosity; and is seen in early preneoplastic stages, which demonstrate clonal relatedness to the invasive cancer.
C1 Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.
   Pontificia Univ Catolica Chile, Dept Pathol, Santiago, Chile.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas Dallas;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Dallas; University of Texas
   Southwestern Medical Center Dallas; Pontificia Universidad Catolica de
   Chile
RP Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM john.minna@utsouthwestern.edu
RI Gazdar, Adi/F-7496-2010; Minna, John/AAB-1036-2022
FU NCI NIH HHS [R01 CA071618, CA71618] Funding Source: Medline
CR Ahmadian M, 1997, CANCER RES, V57, P3664
   Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193
   Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481
   BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Campiglio M, 1999, CANCER RES, V59, P3866
   Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937
   CHEN LC, 1994, CANCER RES, V54, P3021
   DALY MC, 1993, ONCOGENE, V8, P1721
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   DIETRICH CU, 1995, INT J CANCER, V60, P49, DOI 10.1002/ijc.2910600107
   Driouch K, 1998, CANCER RES, V58, P2081
   DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303
   EASTON DF, 1995, AM J HUM GENET, V56, P265
   Euhus DM, 1999, J SURG RES, V83, P13, DOI 10.1006/jsre.1998.5549
   Euhus DM, 1999, CANCER CYTOPATHOL, V87, P372, DOI 10.1002/(SICI)1097-0142(19991225)87:6<372::AID-CNCR8>3.0.CO;2-5
   Fondon JW, 1998, P NATL ACAD SCI USA, V95, P7514, DOI 10.1073/pnas.95.13.7514
   Forozan F, 2000, CANCER RES, V60, P4519
   Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748
   Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.0.CO;2-I
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Hao XP, 2000, CANCER RES, V60, P18
   Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892
   Huang CS, 1999, CANCER RES, V59, P4870
   HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558
   Ingvarsson S, 1999, CANCER RES, V59, P2682
   Kholodnyuk I, 1997, GENE CHROMOSOME CANC, V18, P200, DOI 10.1002/(SICI)1098-2264(199703)18:3<200::AID-GCC6>3.3.CO;2-3
   KOK K, 1994, CANCER RES, V54, P4183
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Lerman MI, 2000, CANCER RES, V60, P6116
   Li MM, 1996, AM J PATHOL, V149, P229
   Matsumoto S, 1997, GENE CHROMOSOME CANC, V20, P268
   Matsumoto S, 2000, CANCER LETT, V152, P63, DOI 10.1016/S0304-3835(99)00431-0
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988
   O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697
   OCONNELL P, 1994, BREAST CANCER RES TR, V32, P5, DOI 10.1007/BF00666201
   Ong ST, 1997, GENE CHROMOSOME CANC, V20, P16, DOI 10.1002/(SICI)1098-2264(199709)20:1<16::AID-GCC3>3.0.CO;2-C
   Osborne RJ, 2000, CANCER RES, V60, P3706
   Pandis N, 1997, GENE CHROMOSOME CANC, V18, P241, DOI 10.1002/(SICI)1098-2264(199704)18:4<241::AID-GCC1>3.3.CO;2-7
   Petersson C, 1997, INT J CANCER, V70, P282, DOI 10.1002/(SICI)1097-0215(19970127)70:3<282::AID-IJC6>3.3.CO;2-F
   RADFORD DM, 1995, CANCER RES, V55, P3399
   Roche J, 1996, ONCOGENE, V12, P1289
   Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489
   SATO T, 1991, CANCER RES, V51, P5794
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Shen CY, 2000, CANCER RES, V60, P3884
   SIEGEL S, 1956, NONPARAMETRIC STAT, P36
   SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329
   Thiagalingam S, 1996, CANCER RES, V56, P2936
   Turker MS, 1999, CANCER RES, V59, P1837
   Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Washington C, 2000, AM J PATHOL, V157, P323, DOI 10.1016/S0002-9440(10)64543-9
   Wei MH, 1996, CANCER RES, V56, P1487
   WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023
   WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160
   Wistuba II, 2000, CANCER RES, V60, P1949
   Wistuba II, 2000, GENE CHROMOSOME CANC, V28, P359, DOI 10.1002/1098-2264(200008)28:4<359::AID-GCC1>3.0.CO;2-N
   Wistuba II, 1998, CLIN CANCER RES, V4, P2931
   Wistuba II, 1998, JAMA-J AM MED ASSOC, V279, P1554, DOI 10.1001/jama.279.19.1554
   Wistuba II, 1997, CANCER RES, V57, P3154
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
NR 69
TC 117
Z9 135
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUL
PY 2001
VL 159
IS 1
BP 119
EP 130
DI 10.1016/S0002-9440(10)61679-3
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 448XM
UT WOS:000169655300016
PM 11438460
OA Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU Nakayama, T
   Watanabe, M
   Yamanaka, M
   Hirokawa, Y
   Suzuki, H
   Ito, H
   Yatani, R
   Shiraishi, T
AF Nakayama, T
   Watanabe, M
   Yamanaka, M
   Hirokawa, Y
   Suzuki, H
   Ito, H
   Yatani, R
   Shiraishi, T
TI The role of epigenetic modifications in retinoic acid receptor β2 gene
   expression in human prostate cancers
SO LABORATORY INVESTIGATION
LA English
DT Article
ID HISTONE DEACETYLASE COMPLEX; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION;
   CPG ISLANDS; METHYLATION; CHROMATIN; DNA; CARCINOGENESIS; ACETYLATION;
   PROMOTER
AB The retinoic acid receptor (RAR) beta gene is a putative tumor suppressor gene on chromosome 3p24, where a high incidence of loss of heterozygosity is detected in many types of tumors. Retinoic acid suppresses cancer cell growth through binding to RARs, especially RAR beta, indicating a critical role in mediating anticancer effects. Selective loss or down-regulation of RAR beta mRNA and protein has been reported in prostate cancers (PCas), although the mechanisms remain unclear. We investigated the role of epigenetic modification in RAR beta2 gene silencing. Aberrant methylation was detected in 11 of 14 (79%) primary PCas. 9 of 10 (90%) hormone-refractory PCas, and 2 of 4 (50%) PCa cell lines, but not in any normal prostate samples. Chromatin immunoprecipitation assay showed that all RAR beta2-negative cells (LNCaP, PC3, and DU145) were hypoacetylated at both histones H3 and H4. After exposure to 5-aza-2 ' -deoxycytidine treatment, Trichostatin A and all-trans retinoic acid induced partial demethylation, increased accumulation of acetylated histones, and markedly restored the expression of RAR beta2 in RAR beta2-negative cells. These data suggest that the RAR beta2 gene may be one of the frequently silenced genes by epigenetic modifications in PCa.
C1 Mie Univ, Fac Med, Dept Pathol 2, Tsu, Mie 514, Japan.
   Chiba Univ, Sch Med, Dept Urol, Chiba 260, Japan.
C3 Mie University; Chiba University
RP Watanabe, M (通讯作者)，Mie Univ, Fac Med, Dept Pathol 2, 2-174 Edobashi, Tsu, Mie 514, Japan.
OI Watanabe, Masatoshi/0000-0002-9423-0901
CR Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Baust C, 1996, INT J CANCER, V67, P409, DOI 10.1002/(SICI)1097-0215(19960729)67:3<409::AID-IJC16>3.0.CO;2-2
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Goldsworthy SM, 1999, MOL CARCINOGEN, V25, P86, DOI 10.1002/(SICI)1098-2744(199906)25:2<86::AID-MC2>3.0.CO;2-4
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hayes AJ, 2000, BRIT J CANCER, V83, P1154, DOI 10.1054/bjoc.2000.1437
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.3.CO;2-1
   JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116
   Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nelson JB, 1997, CANCER RES, V57, P35
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059
   Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Saitoh S, 2000, AM J HUM GENET, V66, P1958, DOI 10.1086/302917
   Shin JY, 2000, CANCER RES, V60, P262
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379
   Xu XC, 1997, CANCER RES, V57, P4992
NR 37
TC 102
Z9 111
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD JUL
PY 2001
VL 81
IS 7
BP 1049
EP 1057
DI 10.1038/labinvest.3780316
PG 9
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 453JR
UT WOS:000169913200015
PM 11454993
OA Bronze
DA 2025-01-12
ER

PT J
AU Kurose, K
   Zhou, XP
   Araki, T
   Cannistra, SA
   Maher, ER
   Eng, C
AF Kurose, K
   Zhou, XP
   Araki, T
   Cannistra, SA
   Maher, ER
   Eng, C
TI Frequent loss of PTEN expression is linked to elevated phosphorylated
   Akt levels, but not associated with p27 and cyclin D1 expression, in
   primary epithelial ovarian carcinomas
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID TUMOR-SUPPRESSOR PTEN/MMAC1; BANNAYAN-ZONANA-SYNDROME; BREAST-CANCER
   FAMILIES; PROTEIN-KINASE-B; COWDEN-DISEASE; PHOSPHATASE-ACTIVITY;
   GERMLINE MUTATIONS; ALLELIC IMBALANCE; PROSTATE-CANCER; THYROID-TUMORS
AB PTEN (MMAC1/TEP1), a tumor suppressor gene on chromosome subband 10q23.3, is variably mutated and/or deleted in a variety of human cancers. Germline mutations in PTEN, which encode a dual-specificity phosphatase, have been implicated in at least two hamartoma tumor syndromes that exhibit some clinical overlap, Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Among several series of ovarian cancers, the frequency of loss of heterozygosity (LOH) of markers nanking and within PTEN, is similar to 30 to 50%, and the somatic intragenic PTEN mutation frequency is < 10%. In this study, we screened primary adenocarcinomas of the ovary for LOH of polymorphic markers within and flanking the PTEN gene and for intragenic mutations of the PTEN gene and compared them to PTEN expression using immunohistochemistry. Furthermore, we sought to detect the expression of the presumed downstream targets of PTEN, such as P-Akt, p27, and cyclin D1 by immunohistochemistry. LOH at 10q23 was observed in 29 of 64 (45%) cases. Of the 117 samples, 6 somatic intragenic PTEN mutations, 1 germline mutation, and 1 novel polymorphism were found in 7 (6%) patients. Immunostaining of 49 ovarian cancer samples revealed that 13 (27%) were PTEN immunostain-negative, 25 (51%) had reduced staining, and the rest (22%) were PTEN expression-positive. Among the 44 informative tumors assessed for 10q23 LOH and PTEN immunostaining, there was an association between 10q23 LOH and decreased or absent staining (P = 0.0317). Of note, there were five (11%) tumors with neither mutation nor deletion that exhibited no PTEN expression and 10 (25%) others without mutation or deletion but had decreased PTEN expression. Among the 49 tumors available for immunohistochemistry, 28 (57%) showed P-Akt-positive staining, 24 (49%) had decreased p27 staining, and cyclin D1 was overexpressed in 35 (79%) cases. In general, P-Akt expression was inversely correlated with PTEN expression (P = 0.0083). These data suggest that disruption of PTEN by several mechanisms, allelic loss, intragenic mutation, or epigenetic silencing, all contribute to epithelial ovarian carcinogenesis, and that epigenetic silencing is a significant mechanism. The Akt pathway is prominently involved, but clearly not in all cases. Surprisingly, despite in vitro demonstration that p27 and cyclin D1 lies downstream of PTEN and Akt, there was no correlation between p27 and cyclin D1 expression and PTEN or P-Akt status. Thus, in vivo, although PTEN and Akt play a prominent role in ovarian carcinogenesis, p27 and cyclin D1 might not be the primary downstream targets. Alternatively, these observations could also suggest that pathways involving other than Akt, p27 and cyclin D1 that Lie downstream of PTEN play roles in ovarian carcinogenesis.
C1 Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA.
   Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA.
   Ohio State Univ, Div Human Genet, Dept Internal Med, Columbus, OH 43210 USA.
   Nippon Med Sch, Dept Obstet & Gynecol, Tokyo 113, Japan.
   Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA.
   Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham, W Midlands, England.
   Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 1TN, England.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; Nippon Medical School; Harvard
   University; Harvard Medical School; Beth Israel Deaconess Medical
   Center; University of Birmingham; University of Cambridge; CRUK
   Cambridge Institute
RP Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 420 W 12th Ave,Room 690C TMRF, Columbus, OH 43210 USA.
EM eng-1@medctr.osu.edu
RI ; MAHER, EAMONN/A-9507-2008
OI Eng, Charis/0000-0002-3693-5145; MAHER, EAMONN/0000-0002-6226-6918
FU NCI NIH HHS [P30 CA016058, P30CA116058] Funding Source: Medline
CR Berchuck A, 1998, CLIN OBSTET GYNECOL, V41, P157, DOI 10.1097/00003081-199803000-00022
   Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633
   Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240
   Carroll BT, 1999, J MED GENET, V36, P94
   Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227
   Cheyney IW, 1999, CANCER RES, V59, P2318
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CLIBY W, 1993, CANCER RES, V53, P2393
   Coffer PJ, 1998, BIOCHEM J, V335, P1
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185
   Dahia PLM, 1997, CANCER RES, V57, P4710
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756
   Eng C, 1998, J CLIN ENDOCR METAB, V83, P4310, DOI 10.1210/jc.83.12.4310
   Eng C, 1998, AM J HUM GENET, V62, P1020, DOI 10.1086/301847
   Eng C, 1998, INT J ONCOL, V12, P701
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Furnari FB, 1998, CANCER RES, V58, P5002
   Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7
   Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389
   Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143
   Kurose K, 1999, AM J HUM GENET, V64, P308, DOI 10.1086/302207
   Kurose K, 2000, GENE CHROMOSOME CANC, V29, P166, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1025>3.3.CO;2-D
   Lachyankar MB, 2000, J NEUROSCI, V20, P1404
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Li DM, 1997, CANCER RES, V57, P2124
   Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li J, 1998, CANCER RES, V58, P5667
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Marsh DJ, 1997, CANCER RES, V57, P5017
   Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6
   Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461
   Maxwell GL, 1998, GYNECOL ONCOL, V70, P13, DOI 10.1006/gyno.1998.5039
   Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924
   Obata K, 1998, CANCER RES, V58, P2095
   Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151
   PEJOVIC T, 1995, ANN MED, V27, P73, DOI 10.3109/07853899509031940
   Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X
   Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3
   PIVER MS, 1991, SEMIN ONCOL, V18, P177
   Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222
   Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110
   Saito M, 2000, INT J CANCER, V85, P160, DOI 10.1002/(SICI)1097-0215(20000115)85:2<160::AID-IJC2>3.3.CO;2-X
   Sakurada A, 1997, JPN J CANCER RES, V88, P1025, DOI 10.1111/j.1349-7006.1997.tb00324.x
   Sano T, 1999, CANCER RES, V59, P1820
   SATO T, 1991, CANCER RES, V51, P5118
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614
   Tashiro H, 1997, CANCER RES, V57, P3935
   Teng DHF, 1997, CANCER RES, V57, P5221
   Weng LP, 1999, CANCER RES, V59, P5808
   Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237
   Werner M, 1996, HISTOCHEM CELL BIOL, V105, P253, DOI 10.1007/BF01463928
   Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246
   Yokomizo A, 1998, INT J ONCOL, V13, P101
   Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5
   Zhou XP, 1999, INT J CANCER, V84, P150, DOI 10.1002/(SICI)1097-0215(19990420)84:2<150::AID-IJC10>3.0.CO;2-#
   Zhou XP, 2000, HUM MOL GENET, V9, P765, DOI 10.1093/hmg/9.5.765
NR 68
TC 222
Z9 268
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUN
PY 2001
VL 158
IS 6
BP 2097
EP 2106
DI 10.1016/S0002-9440(10)64681-0
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 439VN
UT WOS:000169138400026
PM 11395387
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Chen, LS
   Matsubara, N
   Yoshino, T
   Nagasaka, T
   Hoshizima, N
   Shirakawa, Y
   Naomoto, P
   Isozaki, H
   Riabowol, K
   Tanaka, N
AF Chen, LS
   Matsubara, N
   Yoshino, T
   Nagasaka, T
   Hoshizima, N
   Shirakawa, Y
   Naomoto, P
   Isozaki, H
   Riabowol, K
   Tanaka, N
TI Genetic alterations of candidate tumor suppressor <i>ING1</i> in human
   esophageal squamous cell cancer
SO CANCER RESEARCH
LA English
DT Article
ID SPORADIC BREAST-CANCER; P33(ING1); HYBRIDIZATION; METHYLATION; CARCINOMA
AB Overexpression of ING1, a candidate tumor suppressor gene, efficiently blocks cell growth or induces apoptosis in different experimental systems. ING1 maps to chromosome 13q33-34, and because loss of the terminal region of chromosome 13q has been implicated in esophageal squamous cell cancer (ESCC), we examined ESCC for genetic alterations of ING1. Among 31 informative cases of ESCC, 58.9% of the tumors showed allelic loss at chromosome 13q33-34, and we detected four tumor-specific missense nucleotide changes. These alterations were found within the PHD finger domain and nuclear localization motif of the LNG1 and may be functionally involved in the development of ESCC. Because immunohistochemical study revealed that all of the ESCC samples showed loss of ING1 protein expression, genetic or epigenetic alterations that abrogate the normal function of ING1 may contribute to esophageal squamous cell carcinogenesis.
C1 Okayama Univ, Sch Med, Dept Pathol, Okayama 7008558, Japan.
   Okayama Univ, Sch Med, Dept Surg 1, Okayama 7008558, Japan.
   Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada.
   Univ Calgary, So Alberta Canc Res Ctr, Calgary, AB T2N 4N1, Canada.
C3 Okayama University; Okayama University; University of Calgary;
   University of Calgary
RP Matsubara, N (通讯作者)，Okayama Univ, Sch Med, Dept Surg 1, 2-5-1 Shikata Cho, Okayama 700, Japan.
RI Shirakawa, Yasuhiro/B-2351-2011
OI Nagasaka, Takeshi/0000-0002-4236-350X
CR AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4
   Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014
   Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539
   Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415
   Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675
   Garkavtsev I, 1999, NAT GENET, V23, P373, DOI 10.1038/15566
   Gunduz M, 2000, CANCER RES, V60, P3143
   Helbing CC, 1997, CANCER RES, V57, P1255
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152
   Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000
   Pack SD, 1999, GENE CHROMOSOME CANC, V25, P160, DOI 10.1002/(SICI)1098-2264(199906)25:2<160::AID-GCC12>3.0.CO;2-U
   SHIBAGAKI I, 1994, CANCER RES, V54, P2996
   Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905
   Yoshino T, 2000, AM J SURG PATHOL, V24, P688, DOI 10.1097/00000478-200005000-00007
NR 18
TC 76
Z9 87
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2001
VL 61
IS 11
BP 4345
EP 4349
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 438KA
UT WOS:000169051100012
PM 11389058
DA 2025-01-12
ER

PT J
AU Demary, K
   Wong, L
   Liou, JS
   Faller, DV
   Spanjaard, RA
AF Demary, K
   Wong, L
   Liou, JS
   Faller, DV
   Spanjaard, RA
TI Redox control of retinoic acid receptor activity: A novel mechanism for
   retinoic acid resistance in melanoma cells
SO ENDOCRINOLOGY
LA English
DT Article
ID DNA-BINDING ACTIVITY; HUMAN BREAST-CANCER; GLUCOCORTICOID-RECEPTOR;
   ESTROGEN-RECEPTOR; OXIDATIVE STRESS; IN-VITRO; DIFFERENTIATION;
   INDUCTION; GROWTH; COACTIVATORS
AB Retinoic acid (RA) slows growth and induces differentiation of tumor cells through activation of RA receptors (RARs). However, melanoma cell lines display highly variable responsiveness to RA, which is a poorly understood phenomenon. By using Northern and Western blot analyses, we show that RA-resistant A375 and RA-responsive S91 melanoma cells express comparable levels of major components of BAR-signaling pathways. However, A375 cells have substantially higher intracellular reactive oxygen species (ROS) levels than S91 cells. Lowering ROS levels in A375 cells through hypoxic culture conditions restores RAR-dependent trans-activity, which could be further enhanced by addition of the antioxidant N-acetyl-cysteine. Hypoxia also enhances RAR activity in the moderately RA-responsive C32 cells, which have intermediate ROS levels. Conversely, increasing oxidative stress in highly RA-responsive S91 and B16 cells, which have low ROS levels, by treatment with H2O2 impairs RAR activity. Consistent with these observations, RA more potently inhibited the proliferation of hypoxic A375 cells than that of normoxic cells. Oxidative states diminish, whereas reducing conditions enhance, DNA binding of retinoid X receptor/RAR heterodimers in vitro, providing a molecular basis for the observed inverse correlation between activity and ROS levels. The redox state of melanoma cells provides a novel, epigenetic control mechanism of RAR activity and RA resistance.
C1 Boston Univ, Sch Med, Ctr Canc Res, Dept Otolaryngol, Boston, MA 02118 USA.
   Boston Univ, Sch Med, Ctr Canc Res, Dept Med, Boston, MA 02118 USA.
C3 Boston University; Boston University
RP Boston Univ, Sch Med, Ctr Canc Res, Dept Otolaryngol, 715 Albany St R903, Boston, MA 02118 USA.
EM rspan@bu.edu
RI Demary, Kristian/AAB-9989-2019
FU NCI NIH HHS [CA-50459] Funding Source: Medline
CR ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682
   ALLEN RG, 1991, P SOC EXP BIOL MED, V196, P117
   CastroObregon S, 1996, FEBS LETT, V381, P93, DOI 10.1016/0014-5793(96)00088-9
   Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9
   Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602
   Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035
   HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505
   Iwase H, 1998, ONCOLOGY-BASEL, V55, P11, DOI 10.1159/000055254
   Liang XS, 1998, MOL CELL ENDOCRINOL, V146, P151, DOI 10.1016/S0303-7207(98)00161-0
   Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000
   LOTAN R, 1978, JNCI-J NATL CANCER I, V60, P1035, DOI 10.1093/jnci/60.5.1035
   Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164
   Makishima M, 1998, BLOOD, V91, P4715, DOI 10.1182/blood.V91.12.4715.412k07_4715_4726
   MCBURNEY MW, 1993, CANCER INVEST, V11, P590, DOI 10.3109/07357909309011677
   McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7
   MOON RC, 1992, CANCER DETECT PREV, V16, P73
   Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481
   Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73
   Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363
   PEMRICK SM, 1994, LEUKEMIA, V8, P1797
   Rosenthal MA, 1998, AM J CLIN ONCOL-CANC, V21, P352, DOI 10.1097/00000421-199808000-00007
   Schadendorf D, 1995, Recent Results Cancer Res, V139, P183
   Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1
   SILVA CM, 1989, J BIOL CHEM, V264, P6638
   SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839
   Sondak VK, 1999, CANCER J, V5, P41
   Spanjaard RA, 1997, CANCER RES, V57, P5122
   Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990
   SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587
   TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328
   Westin S, 2000, ADV PHARMACOL, V47, P89
NR 33
TC 42
Z9 51
U1 0
U2 7
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2001
VL 142
IS 6
BP 2600
EP 2605
DI 10.1210/en.142.6.2600
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 435VP
UT WOS:000168903100055
PM 11356710
OA Bronze
DA 2025-01-12
ER

PT J
AU Burbee, DG
   Forgacs, E
   Zöchbauer-Müller, S
   Shivakumar, L
   Fong, K
   Gao, BN
   Randle, D
   Kondo, M
   Virmani, A
   Bader, S
   Sekido, Y
   Latif, F
   Milchgrub, S
   Toyooka, S
   Gazdar, AF
   Lerman, MI
   Zabarovsky, E
   White, M
   Minna, JD
AF Burbee, DG
   Forgacs, E
   Zöchbauer-Müller, S
   Shivakumar, L
   Fong, K
   Gao, BN
   Randle, D
   Kondo, M
   Virmani, A
   Bader, S
   Sekido, Y
   Latif, F
   Milchgrub, S
   Toyooka, S
   Gazdar, AF
   Lerman, MI
   Zabarovsky, E
   White, M
   Minna, JD
TI Epigenetic inactivation of RASSF14 in lung and breast cancers and
   malignant phenotype suppression
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID HUMAN-CHROMOSOME 3P21.3; BRONCHIAL EPITHELIUM; ALLELE LOSS; CELL-LINES;
   TUMOR; GENE; IDENTIFICATION; ABNORMALITIES; METHYLATION; DNA
AB Background: The recently identified RASSF1 locus is located within a 120-kilobase region of chromosome 3p21.3 that frequently undergoes allele loss in lung and breast cancers. We explored the hypothesis that RASSF1 encodes a tumor suppressor gene for lung and breast cancers. Methods: We assessed expression of two RASSF1 gene products, RASSF1A and RASSF1C, and the methylation status of their respective promoters in 27 non-small-cell lung cancer (NSCLC) cell lines, in 107 resected NSCLCs, in 47 small-cell Lung cancer (SCLC) cell lines, in 22 breast cancer cell lines, in 39 resected breast cancers, in 104 nonmalignant lung samples, and in three breast and lung epithelial cultures, We also transfected a lung cancer cell line that lacks RASSF1A expression with vectors containing RASSF1A complementary DNA to determine whether exogenous expression of RASSF1A would affect in vitro growth and in vivo tumorigenicity of this cell line. Ail statistical tests were two-sided. Results: RASSF1A messenger RNA was expressed in nonmalignant epithelial cultures but not in 100% of the SCLC, in 65% of the NSCLC, or in 60% of the breast cancer lines. By contrast, RASSF1C was expressed in all nonmalignant cell cultures and in nearly all cancer cell lines. RASSF1A promoter hypermethylation was detected in 100% of SCLC, in 63% of NSCLC, in 63% of breast cancer lines, in 30% of primary NSCLCs, and in 39% of primary breast tumors but in none of the nonmalignant lung tissues, RASSF1A promoter hypermethylation in resected NSCLCs was associated with impaired patient survival (P =.046), Exogenous expression of RASSF1A in a cell line lacking expression decreased in vitro colony formation and in vivo tumorigenicity. Conclusion: RASSF1A is a potential tumor suppressor gene that undergoes epigenetic inactivation in lung and breast cancers through hypermethylation of its promoter region.
C1 Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   Prince Charles Hosp, Dept Thorac Med, Brisbane, Qld 4032, Australia.
   Univ Birmingham, Dept Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England.
   NCI, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA.
   Karolinska Inst, Stockholm, Sweden.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas Dallas; University of Texas System; University of Texas Dallas;
   University of Texas Southwestern Medical Center Dallas; Prince Charles
   Hospital; University of Birmingham; Science Applications International
   Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH)
   - USA; NIH National Cancer Institute (NCI); Karolinska Institutet
RP Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM John.Minna@UTSouthwestern.edu
RI Fong, Kwun/G-6369-2010; Sekido, Yoshitaka/P-9756-2015; Zabarovsky,
   Eugene/A-6645-2010; Kondo, Masashi/I-7378-2014; Minna,
   John/AAB-1036-2022; Gazdar, Adi/F-7496-2010; Zochbauer-Muller,
   Sabine/B-8399-2012
OI Sekido, Yoshitaka/0000-0002-2428-3848; Fong, Kwun/0000-0002-6507-1403;
   Zochbauer-Muller, Sabine/0000-0002-6777-1729
FU NCI NIH HHS [CA71443, R01 CA071443, N01CO56000, R01 CA071443-14, R01
   CA071618, P50CA70907, P50 CA070907, CA71618] Funding Source: Medline
CR [Anonymous], 1989, Molecular Cloning, A Laboratory Manual
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   CHEN JY, 1993, ONCOGENE, V8, P2159
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Claudio PP, 2000, CANCER RES, V60, P372
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Fong KM, 1997, CANCER RES, V57, P2256
   Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Geradts J, 1999, CLIN CANCER RES, V5, P791
   HENNAN JG, 1996, P NATL ACAD SCI USA, V93, P9821
   Hurley JH, 1997, PROTEIN SCI, V6, P477
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Lerman MI, 2000, CANCER RES, V60, P6116
   Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710
   ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766
   Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863
   Phelps RM, 1996, J CELL BIOCHEM, P32
   ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518
   Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9
   SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4
   Tanaka H, 1998, CANCER RES, V58, P3429
   UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x
   Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439
   Wei MH, 1996, CANCER RES, V56, P1487
   Wistuba II, 2000, CANCER RES, V60, P1949
   Wistuba II, 2000, CLIN CANCER RES, V6, P2604
   Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349
   Wistuba II, 1999, CLIN CANCER RES, V5, P991
   Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 36
TC 648
Z9 747
U1 2
U2 25
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD MAY 2
PY 2001
VL 93
IS 9
BP 691
EP 699
DI 10.1093/jnci/93.9.691
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 428KJ
UT WOS:000168460600012
PM 11333291
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Fischer, WH
   Keiwan, A
   Schmitt, E
   Stopper, H
AF Fischer, WH
   Keiwan, A
   Schmitt, E
   Stopper, H
TI Increased formation of micronuclei after hormonal stimulation of cell
   proliferation in human breast cancer cells
SO MUTAGENESIS
LA English
DT Article
ID DNA-DAMAGE; HUMAN-LYMPHOCYTES; ESTRADIOL; CYCLE; DIETHYLSTILBESTROL;
   GENOTOXICITY; INDUCTION; ESTROGEN; INVITRO
AB The carcinogenicity of sex hormones is considered to be the result of a combination of genotoxic and epigenetic modes of action, For estrogens, genotoxic activities include DNA damage by reactive metabolites and indirect genotoxicity by redox cycling and production of reactive oxygen species, Here, we present data on the induction of micronuclei in estrogen receptor-positive (MCF-7) and -negative (MDA) human breast cancer cell lines treated with estradiol to support an additional mechanism of chromosomal damage. MCF-7 cells, but not MDA cells, treated with estradiol in the picomolar concentration range showed an increase in micronucleus formation which correlated with the estradiol-induced cell proliferation. Addition of the specific estradiol-receptor antagonist hydroxytamoxifen suppressed the estradiol-induced formation of micronuclei in MCF-7 cells, Increased frequencies were also seen after normalization of the data to the number of cell divisions by additional treatment of the cells with cytochalasin B, Thus, formation of micronuclei was not due to the chromosomal damaging activity of estradiol, The induced genomic damage may be explained by a hormone-specific forcing of responsive cells through the cell cycle, thereby overriding checkpoints operating under homeostatic control of the fell cycle.
C1 Univ Wurzburg, Dept Toxicol, D-97078 Wurzburg, Germany.
C3 University of Wurzburg
RP Stopper, H (通讯作者)，Univ Wurzburg, Dept Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.
CR Ahmad ME, 2000, MUTAT RES-GEN TOX EN, V466, P109, DOI 10.1016/S1383-5718(99)00230-2
   BANDUHN N, 1985, MUTAT RES, V156, P199, DOI 10.1016/0165-1218(85)90065-5
   BLACKBURN GM, 1974, CANCER RES, V34, P2015
   Boos G, 2000, TOXICOL LETT, V116, P7, DOI 10.1016/S0378-4274(00)00192-2
   COIBION M, 1989, ANTICANCER RES, V9, P475
   Eckert I, 1996, TOXICOL IN VITRO, V10, P637, DOI 10.1016/S0887-2333(96)00035-5
   EPSTEIN RJ, 1988, CANCER RES, V48, P297
   FENECH M, 1993, MUTAT RES, V285, P35, DOI 10.1016/0027-5107(93)90049-L
   FENECH M, 1992, ENVIRON MOL MUTAGEN, V19, P27, DOI 10.1002/em.2850190106
   Kiefer F, 1998, TOXICOL LETT, V96-7, P131, DOI 10.1016/S0378-4274(98)00059-9
   Klotz DM, 1996, ENVIRON HEALTH PERSP, V104, P1084, DOI 10.2307/3433121
   Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425
   Payne J, 2000, SCI TOTAL ENVIRON, V248, P51, DOI 10.1016/S0048-9697(99)00479-9
   Roy D, 1999, MUTAT RES-FUND MOL M, V424, P107, DOI 10.1016/S0027-5107(99)00012-3
   Schuler M, 1998, ENVIRON MOL MUTAGEN, V31, P263, DOI 10.1002/(SICI)1098-2280(1998)31:3<263::AID-EM8>3.0.CO;2-L
   Schwartz JL, 1996, RADIAT RES, V146, P139, DOI 10.2307/3579585
   Suganuma M, 1999, CANCER RES, V59, P5887
   Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4
   WHEELER WJ, 1986, MUTAT RES, V171, P31, DOI 10.1016/0165-1218(86)90006-6
   Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342
NR 20
TC 26
Z9 28
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0267-8357
J9 MUTAGENESIS
JI Mutagenesis
PD MAY
PY 2001
VL 16
IS 3
BP 209
EP 212
DI 10.1093/mutage/16.3.209
PG 4
WC Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Toxicology
GA 432EA
UT WOS:000168678200005
PM 11320145
DA 2025-01-12
ER

PT J
AU Eads, CA
   Lord, RV
   Wickramasinghe, K
   Long, TI
   Kurumboor, SK
   Bernstein, L
   Peters, JH
   DeMeester, SR
   DeMeester, TR
   Skinner, KA
   Laird, PW
AF Eads, CA
   Lord, RV
   Wickramasinghe, K
   Long, TI
   Kurumboor, SK
   Bernstein, L
   Peters, JH
   DeMeester, SR
   DeMeester, TR
   Skinner, KA
   Laird, PW
TI Epigenetic patterns in the progression of esophageal adenocarcinoma
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; CPG ISLAND HYPERMETHYLATION; HUMAN BREAST-CANCER;
   DNA METHYLATION; BARRETTS-ESOPHAGUS; PROMOTER HYPERMETHYLATION;
   GASTRIC-CANCER; MULTIPLE GENES; TUMORIGENESIS; INACTIVATION
AB Esophageal adenocarcinoma (EAC) arises after normal squamous mucosa undergoes metaplasia to specialized columnar epithelium (intestinal metaplasia or Barrett's esophagus), which can then ultimately progress to dysplasia and subsequent malignancy. Epigenetic studies of this model have thus far been limited to the DNA methylation analysis of a few genes. In this study, we analyzed a panel of 20 genes using a quantitative, high-throughput methylation assay, MethyLight. Ne used this broader approach to gain insight into concordant methylation behavior between genes and to generate epigenomic fingerprints for the different histological stages of EAC. Our study included a total of 104 tissue specimens from 51 patients with different stages of Barrett's esophagus and/or associated adenocarcinoma. We screened 84 of these samples with the full panel of 20 genes and found distinct classes of methylation patterns in the different types of tissue. The most informative genes,were those with an intermediate frequency of significant hypermethylation [ranging from 15% (CDKN2A) to 60% (MGMT) of the samples]. This group could be further subdivided into three classes, according to the absence (CDKN2A, ESRI, and MYODI) or presence (CALCA, MGMT, and TIMP3) of methylation in normal esophageal mucosa and stomach, or the infrequent methylation of normal esophageal mucosa accompanied by methylation in all normal stomach samples (APC). The other genes were less informative, because the frequency of hypermethylation was below 5% (ARF, CDH1, CDKN2B, GSTP1, MLH1, PTGS2, and THBS1), completely absent (CTNNB1, RBI, TGFBR2, and TYMS1), or ubiquitous (H1C1 and MTHFR), regardless of tissue type. Each class undergoes unique epigenetic changes at different steps of disease progression of EAC, suggesting a step-wise loss of multiple protective barriers against CpG island hypermethylation. The aberrant hypermethylation occurs at many different loci in the same tissues, suggestive of an overall deregulation of methylation control in EAC tumorigenesis. However, we did not find evidence for a distinct group of tumors with a CpG island methylator phenotype. Finally,we found that normal and metaplastic tissues from patients with evidence of associated dysplasia or cancer had a significantly higher incidence of hypermethylation than similar tissues from patients with no further progression of their disease. The fact that the samples from these two groups of patients were histologically indistinguishable, yet molecularly distinct, suggests that the occurrence of such hypermethylation may provide a clinical tool to identify patients with premalignant Barrett's who are at risk for further progression.
C1 Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Surg, Los Angeles, CA 90089 USA.
   Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.
   Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA.
   Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; University of Southern California
RP Laird, PW (通讯作者)，Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Surg, Room 6418,1441 Eastlake Ave, Los Angeles, CA 90089 USA.
RI DeMeester, Tom/A-4333-2009; LAIRD, PETER W/G-8683-2012
OI LAIRD, PETER W/0000-0001-9117-3641; Lord, Reginald V
   N/0000-0001-7475-492X
FU NCI NIH HHS [R01 CA 75090, R01 CA075090] Funding Source: Medline
CR Bachman KE, 1999, CANCER RES, V59, P798
   Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Beck S, 1999, NAT BIOTECHNOL, V17, P1144, DOI 10.1038/70651
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cheng P, 1997, BRIT J CANCER, V75, P396, DOI 10.1038/bjc.1997.64
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO;2-U
   Eads CA, 1999, CANCER RES, V59, P2302
   Eads CA, 2000, CANCER RES, V60, P5021
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 2000, CANCER RES, V60, P129
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Hakkarainen M, 1996, INT J CANCER, V69, P471, DOI 10.1002/(SICI)1097-0215(19961220)69:6<471::AID-IJC9>3.3.CO;2-A
   Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2
   Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161
   Jankowski JA, 1999, AM J PATHOL, V154, P965, DOI 10.1016/S0002-9440(10)65346-1
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146
   Klump B, 1998, GASTROENTEROLOGY, V115, P1381, DOI 10.1016/S0016-5085(98)70016-2
   Kornblau SM, 1999, LEUKEMIA LYMPHOMA, V35, P283, DOI 10.3109/10428199909145731
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   LARSEN F, 1993, HUM MOL GENET, V2, P775, DOI 10.1093/hmg/2.6.775
   Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663
   LIVAK KJ, 1995, PCR METH APPL, V4, P357
   Melki JR, 1999, CANCER RES, V59, P3730
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Pereira P, 1999, ONCOL REP, V6, P597
   PETERS JH, 1994, J THORAC CARDIOV SUR, V108, P813, DOI 10.1016/S0022-5223(94)70178-4
   Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   SAKAMOTO S, 1990, FAMILIAL ADENOMATOUS, P315
   Salem C, 2000, CANCER RES, V60, P2473
   SHIBATA D, 1992, AM J PATHOL, V141, P539
   SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P687, DOI 10.1093/nar/18.3.687
   Stirzaker C, 1997, CANCER RES, V57, P2229
   STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R
   Tchou JC, 2000, INT J ONCOL, V16, P663
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P5438
   Ueki T, 2000, CANCER RES, V60, P1835
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wong DJ, 1997, CANCER RES, V57, P2619
   Zhuang ZP, 1996, CANCER RES, V56, P1961
   Zimmermann KC, 1999, CANCER RES, V59, P198
NR 48
TC 449
Z9 500
U1 0
U2 31
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2001
VL 61
IS 8
BP 3410
EP 3418
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 424CR
UT WOS:000168215000032
PM 11309301
DA 2025-01-12
ER

PT J
AU Yan, L
   Yang, XW
   Davidson, NE
AF Yan, L
   Yang, XW
   Davidson, NE
TI Role of DNA methylation and histone acetylation in steroid receptor
   expression in breast cancer
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE breast cancer; DNA methylation; histone acetylation; steroid receptor
ID HMLH1 PROMOTER HYPERMETHYLATION; ESTROGEN-RECEPTOR; CPG ISLAND; EARLY
   EVENT; GENE-EXPRESSION; DE-NOVO; DEACETYLASE; CELLS; METHYLTRANSFERASE;
   DEMETHYLATION
AB DNA methylation is an epigenetic modification that is associated with transcriptional silencing of gene expression in mammalian cells. Hypermethylation of the promoter CpG islands contributes to the loss of gene function of several tumor related genes, including estrogen receptor a (ER) and progesterone receptor (PR). Gene expression patterns are also heavily influenced by changes in chromatin structure during transcription. Indeed both the predominant mammalian DNA methyltransferase (DNMT1), and the histone deacetylases (HDACs) play crucial roles in maintaining transcriptionally repressive chromatin by forming suppressive complexes at replication foci. These new findings suggest that epigenetic changes might play a crucial role in gene inactivation in breast cancer. Further, inhibition of DNA methylation and histone deacetylation might be a therapeutic strategy in breast cancer, especially for those cancers with ER and PR negative phenotypes.
C1 Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Johns Hopkins Oncol Ctr, 1650 Orleans St, Baltimore, MD 21231 USA.
EM davidna@jhmi.edu
FU NCI NIH HHS [CA78352, P50CA88843, 2-T32CA09110] Funding Source: Medline
CR Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Carducci MA, 1996, CLIN CANCER RES, V2, P379
   CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842
   COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143
   DOVER GJ, 1985, BLOOD, V66, P527
   Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2
   Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0
   GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802
   Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519
   Heerdt BG, 1999, CANCER RES, V59, P1584
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Jaenisch R, 1998, CIBA F SYMP, V214, P200
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895
   Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038
   MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037
   MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428
   McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040
   MIELNICKI LM, 2001, J MAM GLAND BIOL NEO, V6
   Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nass SJ, 1999, ONCOGENE, V18, P7453, DOI 10.1038/sj.onc.1203138
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   PETERSEN OW, 1987, CANCER RES, V47, P5748
   PIVA R, 1992, BIOCHEM BIOPH RES CO, V183, P996, DOI 10.1016/S0006-291X(05)80289-X
   PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x
   Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684
   READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   RICKETTS D, 1991, CANCER RES, V51, P1817
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003
   Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732
   Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945
   TUCKER MS, 1997, MUTAT RES, V386, P119
   Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621
   Weidle UH, 2000, ANTICANCER RES, V20, P1471
   WEIGEL RJ, 1993, CANCER RES, V53, P3472
   Wong DJ, 1999, MOL CELL BIOL, V19, P5642
   WYNGAERT V, 1998, FEBS LETT, V426, P283
   Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8
   Yang XW, 2000, CANCER RES, V60, P6890
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279
NR 73
TC 71
Z9 105
U1 0
U2 6
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
EI 1573-7039
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD APR
PY 2001
VL 6
IS 2
BP 183
EP 192
DI 10.1023/A:1011308707512
PG 10
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 456QF
UT WOS:000170093200004
PM 11501578
DA 2025-01-12
ER

PT J
AU Widschwendter, M
   Berger, J
   Müller, HM
   Zeimet, AG
   Marth, C
AF Widschwendter, M
   Berger, J
   Müller, HM
   Zeimet, AG
   Marth, C
TI Epigenetic downregulation of the retinoic acid receptor-β2 gene in
   breast cancer
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE retinoic acid receptor beta 2; breast cancer; methylation; epigenetic;
   carcinogenesis; chemoprevention
ID LUNG-CANCER; UP-REGULATION; CELL-LINES; DIFFERENTIAL EXPRESSION; BETA
   EXPRESSION; DNA HYPERMETHYLATION; PROMOTER METHYLATION; 9-CIS-RETINOIC
   ACID; EPITHELIAL-CELLS; CARCINOMA-CELLS
AB A growing body of evidence supports the hypothesis that the retinoic acid receptor,beta2 (RAR-beta2)(3) gene is a tumor suppressor gene which induces apoptosis and that the chemopreventive and therapeutic effects of retinoids are due to induction of RAR-beta2. During breast cancer progression, RAR-beta2 is reduced or even lost. It is known from studies of other tumor-suppressor genes that methylation of the 5'-region is the cause of loss of expression. Several groups demonstrated that this is also true for the RAR-beta2 in breast cancer by treating breast cancer cell lines with a demethylating agent and examining expression of the RAR-beta2 gene in response to a challenge with retinoic acid. Studies using sodium bisulfite genomic sequencing as well as methylation specific PCR showed that a number of breast cancer cell lines as well as breast cancer tissue showed signs of methylation. The RAR-beta2 gene was unmethylated in non-neoplastic breast tissue as well as in other normal tissues. A combination of retinoic acid with demethylating agents as well as with histone deacetylase inhibitors acts synergistically to inhibit growth. This review presents data that suggest that treatment of cancer patients with demethylating agents followed by retinoic acid may offer a new therapeutic modality. Both the time of commencement of chemoprevention and the choice of substances that are able either to prevent de novo methylation or to reverse methylation-caused gene silencing may be important considerations.
C1 Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria.
C3 University of Innsbruck
RP Widschwendter, M (通讯作者)，Univ Innsbruck, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria.
EM martin.widschwendter@uklibk.ac.at
OI Widschwendter, Martin/0000-0002-7778-8380
CR ANZANO MA, 1994, CANCER RES, V54, P4614
   Anzano MA, 1996, J NATL CANCER I, V88, P123, DOI 10.1093/jnci/88.2.123
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen XQ, 1999, CLIN CANCER RES, V5, P2297
   Ciolino HP, 2000, BRIT J CANCER, V83, P333, DOI 10.1054/bjoc.2000.1269
   Cote S, 1997, ANTI-CANCER DRUG, V8, P56
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x
   Esteller M, 1999, CANCER RES, V59, P67
   Fanjul AN, 1996, CANCER RES, V56, P1571
   Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Herbert BS, 2001, JNCI-J NATL CANCER I, V93, P39, DOI 10.1093/jnci/93.1.39
   HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727
   Hong WK, 1995, CLIN CANCER RES, V1, P677
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Lantry LE, 1999, CARCINOGENESIS, V20, P343, DOI 10.1093/carcin/20.2.343
   LEE XH, 1995, EXP CELL RES, V218, P296, DOI 10.1006/excr.1995.1158
   Liang GN, 2000, CANCER RES, V60, P4907
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   López-Otín C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116
   Mielnicki LM, 2001, J MAMMARY GLAND BIOL, V6, P169, DOI 10.1023/A:1011356623442
   Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295
   MOON RC, 1983, CANCER RES, V43, P2469
   Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697
   Palmisano WA, 2000, CANCER RES, V60, P5954
   PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216
   Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3
   Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597
   Salem C, 2000, CANCER RES, V60, P2473
   Shang YF, 1999, ONCOGENE, V18, P6725, DOI 10.1038/sj.onc.1203084
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Silva JM, 1999, CANCER RES, V59, P3251
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651
   Sporn MB, 2000, JNCI-J NATL CANCER I, V92, P780, DOI 10.1093/jnci/92.10.780
   SPORN MB, 1979, FED PROC, V38, P2528
   Srivastava RK, 1999, CLIN CANCER RES, V5, P1892
   SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133
   Toyota M, 2000, ELECTROPHORESIS, V21, P329, DOI 10.1002/(SICI)1522-2683(20000101)21:2<329::AID-ELPS329>3.0.CO;2-9
   URNOV FD, 2001, J MAMMARY GLAND BIOL, V6, pR20
   VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4
   Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Widschwendter M, 1997, INT J CANCER, V71, P497
   WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 1997, CANCER RES, V57, P4158
   Widschwendter M, 1999, BRIT J CANCER, V79, P204, DOI 10.1038/sj.bjc.6690034
   Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956
   Wong IHN, 1999, CANCER RES, V59, P71
   Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656
   Xu XC, 1999, CANCER RES, V59, P2477
   Xu XC, 1999, J NATL CANCER I, V91, P1317, DOI 10.1093/jnci/91.15.1317
   Xu XC, 1997, CANCER RES, V57, P4992
   XU XC, 1994, CANCER RES, V54, P3580
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
   ZHANG XK, 1994, CANCER RES, V54, P5663
NR 68
TC 62
Z9 69
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD APR
PY 2001
VL 6
IS 2
BP 193
EP 201
DI 10.1023/A:1011360724350
PG 9
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 456QF
UT WOS:000170093200005
PM 11501579
DA 2025-01-12
ER

PT J
AU Salisbury, JL
AF Salisbury, JL
TI The contribution of epigenetic changes to abnormal centrosomes and
   genomic instability in breast cancer
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE aneuploidy; centrosome; centriole; cell cycle; cell polarity;
   chromosomal instability
ID SPINDLE POLE BODY; SMALL-MOLECULE INHIBITOR; SEA-URCHIN EGGS;
   CELL-CYCLE; GENETIC INSTABILITY; TARGETED DISRUPTION; DNA METHYLATION;
   MAMMALIAN-CELLS; BRCA1; DUPLICATION
AB The centrosome is the major microtubule organizing center of the cell and as such it plays an important role in cytoskeletal organization and in the formation of the bipolar mitotic spindle. Centrosome defects, characterized by abnormal size, number, and microtubule nucleation capacity, are distinguishing features of most high grade breast tumors and have been implicated as a possible cause for the loss of tissue architecture and the origin of mitotic abnormalities seen in solid tumors in general. Centrosome defects arise through uncoupling of centriole duplication and the cell cycle as a result of either genetic alterations or through physical or chemical perturbation of centrosome function. Centrosomes manifest unique epigenetic properties whereby positional or structural information can be propagated through somatic cell lineages by way of nongenetic pathways. Because aberrant centrosome function can result in chromosomal instability, these properties may have important implications for the origin of malignant breast tumors.
C1 Mayo Clin & Mayo Fdn, Tumor Biol Program, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Salisbury, JL (通讯作者)，Mayo Clin & Mayo Fdn, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.
OI Salisbury, Jeffrey/0000-0001-9257-4578
FU NCI NIH HHS [CA72836] Funding Source: Medline
CR Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0
   ALBRECHTBUEHLER G, 1979, EXP CELL RES, V120, P111, DOI 10.1016/0014-4827(79)90542-1
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948
   BEISSON J, 1965, P NATL ACAD SCI USA, V53, P275, DOI 10.1073/pnas.53.2.275
   Beisson J, 1999, BIOL CELL, V91, P367, DOI 10.1016/S0248-4900(99)80097-5
   BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7
   Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168
   Boveri T., 1907, JENA Z NATURW, V43, P1
   Boveri T., 1914, Zur Frage der Entstehung maligner Tumoren
   Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C
   BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107
   Bullitt E, 1997, CELL, V89, P1077, DOI 10.1016/S0092-8674(00)80295-0
   Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276
   Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515
   Chang P, 2000, NAT CELL BIOL, V2, P30, DOI 10.1038/71350
   Chial HJ, 1999, BIOL CELL, V91, P439, DOI 10.1016/S0248-4900(99)80085-9
   Chial HJ, 1999, P NATL ACAD SCI USA, V96, P10200, DOI 10.1073/pnas.96.18.10200
   Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3
   Compton DA, 1999, SCIENCE, V286, P913, DOI 10.1126/science.286.5441.913
   Deng CX, 2000, BIOESSAYS, V22, P728
   Ding DQ, 1998, J CELL SCI, V111, P701
   Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81
   Duesberg P, 1999, SCIENCE, V284, P2091
   Feinberg AP, 2000, CURR TOP MICROBIOL, V249, P87
   Frankel J, 1989, PATTERN FORMATION CI, P314
   Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744
   Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2
   Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851
   Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983
   Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975
   Karsenti E, 1999, NAT CELL BIOL, V1, pE62, DOI 10.1038/11031
   KARSENTI E, 1986, TRENDS BIOCHEM SCI, V11, P460, DOI 10.1016/0968-0004(86)90247-1
   KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0
   KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599
   Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817
   LANGE BMH, 1995, J CELL BIOL, V130, P919, DOI 10.1083/jcb.130.4.919
   Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X
   Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.97.7.3236
   Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7
   Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950
   Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226
   MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3
   Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398
   Marshall WF, 1999, CURR BIOL, V9, pR218, DOI 10.1016/S0960-9822(99)80133-X
   Marshall WF, 2000, CURR OPIN CELL BIOL, V12, P119, DOI 10.1016/S0955-0674(99)00065-4
   Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126
   Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2
   Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971
   MAZIA D, 1960, J BIOPHYS BIOCHEM CY, V7, P1, DOI 10.1083/jcb.7.1.1
   McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200
   Mettler FA, 1996, CANCER, V77, P903, DOI 10.1002/(SICI)1097-0142(19960301)77:5<903::AID-CNCR15>3.0.CO;2-7
   Mielnicki LM, 2001, J MAMMARY GLAND BIOL, V6, P169, DOI 10.1023/A:1011356623442
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mogensen MM, 2000, J CELL SCI, V113, P3013
   Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460
   Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069
   Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4
   PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075
   Perera FP, 2000, JNCI-J NATL CANCER I, V92, P602, DOI 10.1093/jnci/92.8.602
   Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317
   Pihan GA, 1998, CANCER RES, V58, P3974
   Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0
   SATO C, 1983, J CELL BIOL, V96, P776, DOI 10.1083/jcb.96.3.776
   Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797
   SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256
   Schatten H, 2000, CELL BIOL INT, V24, P611, DOI 10.1006/cbir.2000.0537
   Schatten H, 1998, EUR J CELL BIOL, V75, P9, DOI 10.1016/S0171-9335(98)80041-1
   Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014
   Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243
   Shureiqi Imad, 1999, Current Opinion in Oncology, V11, P408, DOI 10.1097/00001622-199909000-00016
   Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9
   SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025
   SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873
   SLUDER G, 1989, CELL MOTIL CYTOSKEL, V13, P264, DOI 10.1002/cm.970130405
   Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291
   SONNEBORN T M, 1975, Annee Biologique, V14, P565
   STUBBLEFIELD E, 1967, ORIGIN FATE CELL ORG, P175
   Tanaka T, 1999, CANCER RES, V59, P2041
   Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5
   VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z
   Wang CN, 1998, APPL ACOUST, V53, P35, DOI 10.1016/S0003-682X(97)00042-X
   WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN, P232
   WILSON EB, 1925, CELL DEV HEREDITY, P1232
   Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6
   Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9
   Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932
   Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496
NR 92
TC 25
Z9 27
U1 0
U2 0
PU KLUWER ACADEMIC/PLENUM PUBL
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD APR
PY 2001
VL 6
IS 2
BP 203
EP 212
DI 10.1023/A:1011312808421
PG 10
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 456QF
UT WOS:000170093200006
PM 11501580
DA 2025-01-12
ER

PT J
AU Fang, W
   Piao, Z
   Buyse, IM
   Simon, D
   Sheu, JC
   Perucho, M
   Huang, S
AF Fang, W
   Piao, Z
   Buyse, IM
   Simon, D
   Sheu, JC
   Perucho, M
   Huang, S
TI Preferential loss of a polymorphic <i>RIZ</i> allele in human
   hepatocellular carcinoma
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE RIZ (PRDM2); polymorphisms; hepatoma
ID ZINC-FINGER PROTEIN; PR DOMAIN; GENE; EXPRESSION; DELETION; CANCER;
   HETEROZYGOSITY; TUMORIGENESIS; EPIGENETICS; PRODUCT
AB The RIZ(PRDM2) locus commonly undergoes loss of heterozygosity (LOH) and maps within the minimal deleted region on 1p36 in hepatocellular carcinoma (HCC). Although peptide-altering mutations of RIZ are rare in HCC, the RIZ1 product is commonly lost in HCC and has tumour suppressive activities. Here, we analysed RIZ gene mutations and LOH in HCC, breast cancer, familial melanoma, colon cancer, and stomach cancer. We found 7 polymorphisms but no mutations. By analysing the Pro704-deletion polymorphism, we detected LOH of RIZ in 31 of 79 (39%) informative HCC cases, 11 of 47 (23%) colon cancer cases, 8 of 43 (19%) breast cancer cases, 8 of 66 (12%) stomach cancer cases. Importantly, loss of the Pro704(+) allele was found in 74% of the 31 LOH positive HCC cases (P < 0.01), indicating a preferential loss and hence a stronger tumour suppressor role for this allele compared to the P704(-) allele. In addition, the Pro704(+) allele was found to be more common in Asians (0.61) than Gaucasians (0.42) (P = 0.0000), suggesting an interesting link between gene polymorphisms and potential differences in tumour incidence between racial groups. (C) 2001 Cancer Research Campaign http.//www.bjcancer.com.
C1 Burnham Inst, Program Oncogenes & Tumor Suppressor Genes, La Jolla, CA 92037 USA.
   MCP Hahnemann Sch Med, Dept Pathol, Philadelphia, PA 19109 USA.
   Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
C3 Sanford Burnham Prebys Medical Discovery Institute; Drexel University;
   National Taiwan University; National Taiwan University Hospital
RP Huang, S (通讯作者)，Burnham Inst, Program Oncogenes & Tumor Suppressor Genes, La Jolla, CA 92037 USA.
OI SHEU, JIN-CHUAN/0000-0002-2503-7139; Perucho, Manuel/0000-0002-2169-2662
FU NCI NIH HHS [R01-CA76146] Funding Source: Medline
CR Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697
   BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102
   BARDI G, 1993, CANCER RES, V53, P1895
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467
   Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497
   Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730
   Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K
   GENUARDI M, 1989, AM J HUM GENET, V45, P73
   Hammond C, 1999, HEPATOLOGY, V29, P1479, DOI 10.1002/hep.510290513
   He LS, 1998, CANCER RES, V58, P4238
   Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933
   Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Lin YW, 1999, EUR J CANCER, V35, P652, DOI 10.1016/S0959-8049(98)00430-4
   Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984
   Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x
   Piao Z, 2000, CANCER RES, V60, P4701
   Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.3.CO;2-2
   Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.0.CO;2-3
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V
   SHAPIRO VS, 1995, GENE, V163, P329, DOI 10.1016/0378-1119(95)00420-B
   SIMON D, 1991, ONCOGENE, V6, P765
   Weith A, 1996, CYTOGENET CELL GENET, V72, P114
   1995, CANC INC MORT CAL DE
NR 28
TC 28
Z9 33
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAR 23
PY 2001
VL 84
IS 6
BP 743
EP 747
DI 10.1054/bjoc.2000.1667
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 416MH
UT WOS:000167784400002
PM 11259086
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Matsumura, T
   Makino, R
   Mitamura, K
AF Matsumura, T
   Makino, R
   Mitamura, K
TI Frequent down-regulation of E-cadherin by genetic and epigenetic changes
   in the malignant progression of hepatocellular carcinomas
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID INVASION-SUPPRESSOR GENE; HUMAN PROSTATE-CANCER; BETA-CATENIN GENE; P53
   GENE; TYROSINE PHOSPHORYLATION; CPG METHYLATION; BREAST-CANCER;
   CELL-ADHESION; ALLELIC LOSS; EXPRESSION
AB E-cadherin mediates cell-cell adhesion by associating with catenins, Loss of E-cadherin function by genetic or epigenetic alteration of the E-cadherin gene (CDH1) leads to tumorigenesis. To study the involvement of E-cadherin dysfunction in liver tumorigenesis, we examined the allelic loss and methylation of 5'-CpG sites of CDH1 in hepatocellular carcinomas (HCCs), Loss of heterozygosity (LOH) of CDH1 and adjacent 16q22-23 loci was observed in 13 of 30 (43%) HCCs, Methylation of the 5'-CpG of CDH1 was analyzed by Southern blot hybridization, and hypermethylation was observed in 8 of the 24 (33%) HCCs examined. The amount of E-cadherin mRNA was analyzed by RNase protection assay, and a decrease in E-cadherin mRNA was observed in 10 of the 23 cases examined. A reduction in E-cadherin was found in 10 of 21 HCCs using immunoblot analysis. The amount of E-cadherin was comparable. to that of E-cadherin mRNA. Down-regulation of E-cadherin was common in cases with LOW but rare in cases with methylated promoter. These results suggest that hypermethylation of the CDH1 promoter is present in a small cell population in the tumor, thus the methylation status is liable to vary according to individual cell condition, Hypermethylation was observed in early stage HCCs, whereas LOH was found frequently in more malignant tumors. Down-regulation of E-cadherin is closely related to the progression of HCCs and is stably induced by LOH of CDH1.
C1 Showa Univ, Sch Med, Dept Internal Med 2, Shinagawa Ku, Tokyo 1428666, Japan.
C3 Showa University
RP Makino, R (通讯作者)，Showa Univ, Sch Med, Dept Internal Med 2, Shinagawa Ku, Hatanodai 1-5-8, Tokyo 1428666, Japan.
CR BECKER KF, 1994, CANCER RES, V54, P3845
   Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D
   Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321
   CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205
   de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847
   Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0
   El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001
   FUJIMORI M, 1991, CANCER RES, V51, P89
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246
   Hermanek P., 1987, TNM CLASSIFICATION M, V4th
   HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0
   Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9
   Kanai Y, 1997, INT J CANCER, V71, P355
   Li LC, 2000, CANCER RES, V60, P873
   Makino R, 2000, MUTAT RES-FUND MOL M, V452, P83, DOI 10.1016/S0027-5107(00)00056-7
   Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G
   MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703
   Miyoshi Y, 1998, CANCER RES, V58, P2524
   MOLL R, 1993, AM J PATHOL, V143, P1731
   MURAKAMI Y, 1991, CANCER RES, V51, P5520
   ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858
   ODA T, 1992, CANCER RES, V52, P3674
   Osada T, 1996, HEPATOLOGY, V24, P1460, DOI 10.1002/hep.510240627
   Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734
   Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394
   SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791
   UMBAS R, 1992, CANCER RES, V52, P5104
   Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
NR 38
TC 134
Z9 152
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR
PY 2001
VL 7
IS 3
BP 594
EP 599
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 418GT
UT WOS:000167883100023
PM 11297254
DA 2025-01-12
ER

PT J
AU Tamada, H
   Kitazawa, R
   Gohji, K
   Kitazawa, S
AF Tamada, H
   Kitazawa, R
   Gohji, K
   Kitazawa, S
TI Epigenetic regulation of human bone morphogenetic protein 6 gene
   expression in prostate cancer
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE bone morphogenetic protein 6 promoter; prostate cancer; methylation;
   epigenesis; in situ hybridization
ID CARCINOMA CELL-LINE; DNA METHYLATION; SUPPRESSOR GENE; MESSENGER-RNA;
   TRANSCRIPTION FACTORS; CPG METHYLATION; BREAST-CANCER; MOUSE;
   DIFFERENTIATION; IDENTIFICATION
AB Bone morphogenetic proteins (BMPs), belonging to the transforming growth factor-beta (TGF-beta) superfamily, are multifunctional molecules that regulate bone induction and organ development. Among BMPs, BMP-6 has been shown to be overexpressed in prostate cancer and is speculated to be associated with bone-forming skeletal metastasis. We investigated the regulatory mechanism of the BMP-6 gene expression in prostate cancer cell lines DU-145, LNCaP, PC-3, and PC-3M with regard to the methylation status of the CpG island in the 5' Banking region of the human BMP-6 gene. By sequence-specific analysis of methylated cytosines, we show here that the methylation status of the CpG loci around the Sp1 site of the BMP-6 promoter is related to its steady-state expression and an alternative splicing of messenger RNA (mRNA) in prostate cancer cell lines. Furthermore, a study of clinical cases of benign and malignant prostate lesion by in situ hybridization showed that BMP-6 expression was high at both primary and secondary sites in cases of advanced cancer with metastasis. Demethylation of the CPG loci around the Spl binding site was shown in cases with high BMP-6 expression by sequencing analysis of the methylated cytosine from paraffin-embedded materials, Our results suggested that during cancer progression, besides inactivation of tumor suppressor genes by hypermethylation, activation of certain genes like BMP-6 by selective demethylation was a common epigenetic event giving a variable character to the invading and metastasizing cancer cells.
C1 Kobe Univ, Sch Med, Dept Pathol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan.
   Osaka Med Coll, Dept Urol, Takatsuki, Osaka 569, Japan.
C3 Kobe University; Osaka Medical & Pharmaceutical University
RP Kitazawa, S (通讯作者)，Kobe Univ, Sch Med, Dept Pathol 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
RI Kitazawa, Sohei/E-5602-2010
OI Kitazawa, Sohei/0000-0002-7466-7356
CR Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658
   Barnes J, 1995, WORLD J UROL, V13, P337
   BENTLEY H, 1992, BRIT J CANCER, V66, P1159, DOI 10.1038/bjc.1992.427
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010
   BOSTWICK DG, 1994, AM J CLIN PATHOL, V102, pS38
   CAREY DE, 1995, J BONE MINER RES, V10, P401
   Chen J., 1995, Random Operators and Stochastic Equations, V3, P235
   Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D
   DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Galter D, 1999, EUR J NEUROSCI, V11, P2444, DOI 10.1046/j.1460-9568.1999.00667.x
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Grimsrud CD, 1999, J BONE MINER RES, V14, P475, DOI 10.1359/jbmr.1999.14.4.475
   Hamdy FC, 1997, CANCER RES, V57, P4427
   HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Honda Y, 1997, CALCIFIED TISSUE INT, V60, P297, DOI 10.1007/s002239900232
   Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115
   Jarrard DF, 1998, CANCER RES, V58, P5310
   JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6
   JONES CM, 1991, DEVELOPMENT, V111, P531
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KAIGHN ME, 1979, INVEST UROL, V17, P16
   Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787
   Kitazawa S, 2000, LAB INVEST, V80, P275, DOI 10.1038/labinvest.3780031
   Kitazawa S, 1999, HISTOCHEM CELL BIOL, V111, P7, DOI 10.1007/s004180050327
   Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7
   Knittel T, 1997, EXP CELL RES, V232, P263, DOI 10.1006/excr.1997.3504
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Leung SY, 1999, CANCER RES, V59, P159
   Lou W, 1999, CANCER RES, V59, P2329
   LYONS KM, 1990, DEVELOPMENT, V109, P833
   LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657
   Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764
   Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446
   MICHALOWSKY LA, 1989, MOL CELL BIOL, V9, P885, DOI 10.1128/MCB.9.3.885
   Nelson JB, 1997, CANCER RES, V57, P35
   NICOLSON GL, 1984, CANCER METAST REV, V3, P25, DOI 10.1007/BF00047691
   PERRETCATIPOVIC M, 1999, MON SER INT SOC ADOL, V1, P75
   Raida M, 1999, INT J CANCER, V83, P38, DOI 10.1002/(SICI)1097-0215(19990924)83:1<38::AID-IJC8>3.3.CO;2-2
   Rennie PS, 1998, CANCER METAST REV, V17, P401, DOI 10.1023/A:1006121219097
   Rickard DJ, 1998, J CLIN INVEST, V101, P413, DOI 10.1172/JCI119880
   Schmutte C, 1998, BIOL CHEM, V379, P377
   STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951
   STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305
   Tamada H, 1998, BBA-GENE STRUCT EXPR, V1395, P247, DOI 10.1016/S0167-4781(97)00191-7
   Thompson PA, 1998, CANCER EPIDEM BIOMAR, V7, P37
   URIST MR, 1984, P NATL ACAD SCI-BIOL, V81, P371, DOI 10.1073/pnas.81.2.371
   URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986
   VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2
   Verkaik NS, 1999, INT J CANCER, V80, P439
   Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
NR 58
TC 36
Z9 43
U1 0
U2 3
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2001
VL 16
IS 3
BP 487
EP 496
DI 10.1359/jbmr.2001.16.3.487
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 405KC
UT WOS:000167157700008
PM 11277266
OA Bronze
DA 2025-01-12
ER

PT J
AU Yang, QF
   Mori, I
   Shan, L
   Nakamura, M
   Nakamura, Y
   Utsunomiya, H
   Yoshimura, G
   Suzuma, T
   Tamaki, T
   Umemura, T
   Sakurai, T
   Kakudo, K
AF Yang, QF
   Mori, I
   Shan, L
   Nakamura, M
   Nakamura, Y
   Utsunomiya, H
   Yoshimura, G
   Suzuma, T
   Tamaki, T
   Umemura, T
   Sakurai, T
   Kakudo, K
TI Biallelic inactivation of retinoic acid receptor β2 gene by epigenetic
   change in breast cancer
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID UP-REGULATION; CELL-LINES; EXPRESSION; CARCINOMA;
   5-AZA-2'-DEOXYCYTIDINE; ISOTRETINOIN; SENSITIVITY; PREVENTION;
   APOPTOSIS; PROMOTER
AB A growing body of evidence supports the hypotheses that retinoic acid receptor beta2 (RAR beta2) is a tumor suppressor gene. Although the loss of RAR beta2 expression has been reported in many malignant tumors, including breast cancer, the molecular mechanism is still poorly understood. We hypothesized that loss of RAR beta2 activity could result from multiple factors, including epigenetic modification and loss of heterozygosity (LOH), Using methylation-specific polymerase chain reaction and LOH analysis, we found that biallelic inactivation via epigenetic changes of both maternal and paternal alleles, or epigenetic modification of one allele combined with genetic loss of the remaining allele, could completely suppress RAR beta2 expression in breast cancer. Thus, it is possible that substantial numbers of human cancers arise through suppressor gene silencing via epigenetic mechanisms that inactivate both alleles. Because of this, chromatin-remodeling drugs may provide a novel strategy for cancer prevention and treatment.
C1 Wakayama Med Coll, Dept Pathol 2, Wakayama 6410012, Japan.
   Wakayama Med Coll, Dept Surg, Wakayama 6410012, Japan.
   NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA.
C3 Wakayama Medical University; Wakayama Medical University; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
RP Yang, QF (通讯作者)，Wakayama Med Coll, Dept Pathol 2, 811-1 Kimiidera, Wakayama 6410012, Japan.
RI Nakamura, Yasushi/J-5143-2014
OI Yang, Qifeng/0000-0003-0576-8513
CR BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x
   Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172
   Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481
   Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Cote S, 1998, ANTI-CANCER DRUG, V9, P743
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312
   Holländer GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118
   HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KANE MF, 1997, CANCER RES, V57, P5556
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kraemer Kenneth H., 1992, Journal of Dermatology (Tokyo), V19, P715
   LIPPMAN SM, 1998, J NATL CANCER I, V85, P1492
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059
   Qiu HM, 2000, GENE CHROMOSOME CANC, V28, P196, DOI 10.1002/(SICI)1098-2264(200006)28:2<196::AID-GCC8>3.0.CO;2-L
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651
   SPORN MB, 1979, FED PROC, V38, P2528
   SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656
   Xu XC, 1999, CANCER RES, V59, P2477
   Xu XC, 1997, CANCER RES, V57, P4992
NR 29
TC 53
Z9 58
U1 0
U2 0
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD JAN
PY 2001
VL 158
IS 1
BP 299
EP 303
DI 10.1016/S0002-9440(10)63969-7
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 390XV
UT WOS:000166325800034
PM 11141504
OA Green Accepted, Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Ma, DQ
   Huang, H
   Moscow, JA
AF Ma, DQ
   Huang, H
   Moscow, JA
TI Down-regulation of reduced folate carrier gene (RFC1) expression after
   exposure to methotrexate in ZR-75-1 breast cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE antifolates; drug resistance; gene expression
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; MULTIPLE PROMOTERS; TRANSPORT; RESISTANCE;
   LINE; POLYGLUTAMATES; HETEROGENEITY; MECHANISM; MUTATION
AB Methotrexate (MTX) is administered in intervals of one week or longer in the treatment of cancer and autoimmune disease. Early studies suggested that daily MTX administration was associated with decreased effectiveness and increased toxicity, leading to schedules of administration that include periodic intervals of rest during chronic MTX therapy. We hypothesized that these observations may be the result of the down-regulation of the reduced folate carrier, the major route of cellular uptake of both MTX and the endogenous folates, after MTX exposure. We exposed folate-depleted ZR-75-1 breast cancer cells to low-dose MTX in the presence of hypoxanthine, adenosine and thymidine. After 72 h, the initial rate of MTX uptake had decreased to 22% of the Day 0 value. Western blot analysis showed down-regulation of RFC1 protein expression, and Northern blot analysis showed a corresponding decrease in RFC1 RNA levels. Using an RT-PCR assay, we found that levels of RNA transcripts containing each of the three RFC1 5' noncoding exons were decreased after exposure to MTX, suggesting that MTX exposure causes transcriptional downregulation of RFC1. Promoter-reporter construct assays demonstrated decreased activity of RFC1 promoter elements upstream of these exons after MTX exposure. Preexposure of the ZR-75-1 cells to 5-azacytine, a DNA methylation inhibitor, further decreased MTX uptake rather than reverse the inhibition of RFC1 activity, indicating that RFC1 downregulation after MTX exposure is not the result of methylation of the RFC1 promoter. In summary, these studies demonstrate that MTX exposure can downregulate RFC1 expression and activity. These acute, inducible, epigenetic changes in RFC1 expression may ultimately be molded into the more permanent genetic changes that result in the transport-mediated MTX resistance that have been observed in MTX-resistant cell lines. (C) 2000 Academic Press.
C1 Univ Kentucky, Dept Pediat, Lexington, KY 40502 USA.
C3 University of Kentucky
RP Moscow, JA (通讯作者)，740 S Limestone,Room J457, Lexington, KY 40502 USA.
OI ma, deqin/0000-0002-8581-6345
CR ACUTE BGL, 1965, JAMA-J AM MED ASSOC, V194, P187
   BADR MZ, 1987, DRUG NUTR INTERACT, V5, P43
   BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974
   COWAN KH, 1984, J BIOL CHEM, V259, P793
   DAHL MGC, 1972, BRIT MED J, V1, P654, DOI 10.1136/bmj.1.5801.654
   DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687
   FISHER GA, 1960, BIOCHEM PHARMACOL, V11, P1233
   FLINTOFF WF, 1980, BIOCHEMISTRY-US, V18, P4321
   GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007
   Gong MK, 1999, GENE, V233, P21, DOI 10.1016/S0378-1119(99)00166-3
   Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494
   Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013
   Guo W, 1999, CLIN CANCER RES, V5, P621
   HENDERSON GB, 1984, J BIOL CHEM, V259, P1526
   HENDERSON GB, 1980, J BIOL CHEM, V255, P4829
   Jansen G, 1997, ADV ENZYME REGUL, V37, P59, DOI 10.1016/S0065-2571(96)00012-X
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Moscow JA, 1998, LEUKEMIA LYMPHOMA, V30, P215
   MOSCOW JA, 1995, BIOCHEM PHARMACOL, V49, P1069, DOI 10.1016/0006-2952(95)98503-2
   MOSCOW JA, 1995, CANCER RES, V55, P3790
   Moscow JA, 1997, INT J CANCER, V72, P184, DOI 10.1002/(SICI)1097-0215(19970703)72:1<184::AID-IJC26>3.0.CO;2-I
   OHNUMA T, 1985, CANCER RES, V45, P1815
   PIZZO PA, 1989, PRINCIPLES PRACTICE
   SIROTNAK FM, 1968, CANCER RES, V28, P75
   Tolner B, 1998, GENE, V211, P331, DOI 10.1016/S0378-1119(98)00123-1
   VENDITTI JM, 1964, CANCER RES, V24, P1457
   WHITEHEAD VM, 1990, BLOOD, V76, P44
   Zhang L, 1998, CLIN CANCER RES, V4, P2169
   Zhang L, 1998, BIOCHEM J, V332, P773, DOI 10.1042/bj3320773
   Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873
NR 31
TC 14
Z9 16
U1 0
U2 1
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 29
PY 2000
VL 279
IS 3
BP 891
EP 897
DI 10.1006/bbrc.2000.4019
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 391ZJ
UT WOS:000166385900024
PM 11162445
DA 2025-01-12
ER

PT J
AU Grant, DJ
   Bell, DA
AF Grant, DJ
   Bell, DA
TI Bilirubin UDP-glucuronosyltransferase <i>1A1</i> gene polymorphisms::
   Susceptibility to oxidative damage and cancer?
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE liver enzymes; bilirubin; antioxidants; DNA damage; carcinogenesis
ID CORONARY-ARTERY DISEASE; GILBERTS-SYNDROME; SERUM BILIRUBIN;
   LIPID-PEROXIDATION; REACTIVE OXYGEN; NEONATAL HYPERBILIRUBINEMIA;
   SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYMES; MISSENSE MUTATION; ACTIVE
   METABOLITE
AB The UDP-glucuronosyltransferase 1A1 (UCT1A1) gene product catalyzes the glucuronidation of serum bilirubin as part of normal heme catabolism. Recently, TA repeat polymorphisms containing five, six, seven, and eight TA dinucleotides in a putative TATA box in the promoter region of the UGT1A1 gene have been described. TA repeat number modulates UGT1A1 transcriptional activity and the quantity of enzyme available to conjugate serum bilirubin. Serum bilirubin is a known antioxidant, and low serum bilirubin has been associated with increased risk for coronary artery disease and inhibition of reactive oxygen species (ROS)-induced damage to erythrocytes in vitro. We hypothesize that the UGT1A1 TA repeals or other functional polymorphisms resulting in lower serum bilirubin levels may be predictive of genetic susceptibility to oxidative damage and cancer. Exposure-related or endogenous production of ROS may impact the integrity of cellular macromolecules and infrastructure, lead to DNA base changes or chromosomal aberrations, and induce toxicity or apoptosis. ROS damage to lipoproteins may be a factor in formation of atherogenic plaques in coronary heart disease. Thus, cellular oxidative stress could contribute to tumorigenesis through mutagenic or epigenetic pathways, and higher serum bilirubin levels should inhibit this process. No definitive studies have been performed, but in a small prospective study of colon cancer, serum bilirubin levels were observed to be lower in these cases. Another study has suggested a link between UGT1A1 alleles, estrogen metabolism, and risk in breast cancer. Epidemiologic studies examining variation in ROS metabolism, ROS damage, bilirubin, and cancer risk will demonstrate the value of this hypothesis. Published 2000 Wiley-Liss, Inc.(dagger).
C1 Natl Inst Environm Hlth Sci, Lab Computat Biol & Risk Assessment, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP Natl Inst Environm Hlth Sci, Lab Computat Biol & Risk Assessment, C3-03,POB 12233, Res Triangle Pk, NC 27709 USA.
RI Bell, Douglas/C-7687-2019
OI Bell, Douglas/0000-0001-7700-0840
CR Akaba K, 1998, BIOCHEM MOL BIOL INT, V46, P21
   Ambrosone CB, 1999, CANCER RES, V59, P602
   Ando Y, 1998, ANN ONCOL, V9, P845, DOI 10.1023/A:1008438109725
   AONO S, 1995, LANCET, V345, P958, DOI 10.1016/S0140-6736(95)90702-5
   Ashok BT, 1999, EXP GERONTOL, V34, P293, DOI 10.1016/S0531-5565(99)00005-4
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Belanger S, 1997, BIOL NEONATE, V71, P233
   Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170
   BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802
   Brierley CH, 1996, ADV ENZYME REGUL, V36, P85, DOI 10.1016/0065-2571(95)00006-2
   CEBALLOSPICOT I, 1992, MUTAT RES, V275, P281, DOI 10.1016/0921-8734(92)90032-K
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Ciotti M, 1998, BBA-MOL BASIS DIS, V1407, P40, DOI 10.1016/S0925-4439(98)00030-1
   Ciotti M, 1999, BIOCHEM BIOPH RES CO, V260, P199, DOI 10.1006/bbrc.1999.0453
   Ciotti M, 1996, BIOCHEMISTRY-US, V35, P10119, DOI 10.1021/bi960584a
   Dailly E, 1998, BIOCHEM BIOPH RES CO, V248, P303, DOI 10.1006/bbrc.1998.8960
   Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67
   DENNERY PA, 1995, FREE RADICAL BIO MED, V19, P395, DOI 10.1016/0891-5849(95)00032-S
   Doré S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445
   Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5
   Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729
   FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504
   GRANT DJ, 1998, AM SOC HUMAN GENETIC, V63, pA212
   Guillemette C, 2000, CANCER RES, V60, P950
   HALAMEK LP, 1997, NEONATAL PERINATAL M, P1345
   Hall D, 1999, PHARMACOGENETICS, V9, P591, DOI 10.1097/00008571-199910000-00006
   Hammerman C, 1998, CLIN CHEM, V44, P2551
   HARMAN D, 1992, ANN NY ACAD SCI, V673, P126, DOI 10.1111/j.1749-6632.1992.tb27444.x
   HO NK, 1992, BAILLIERE CLIN HAEM, V5, P131, DOI 10.1016/S0950-3536(11)80038-7
   Ho YS, 1998, ENVIRON HEALTH PERSP, V106, P1219, DOI 10.2307/3433989
   HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551
   Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250
   HUSSAIN SP, 1994, ONCOGENE, V9, P2277
   Iyer L, 1998, J CLIN INVEST, V101, P847, DOI 10.1172/JCI915
   JANSEN PLM, 1992, HEPATOLOGY, V15, P532, DOI 10.1002/hep.1840150328
   KO WF, 1994, J NATL CANCER I, V86, P1874, DOI 10.1093/jnci/86.24.1874
   Koiwai O, 1996, HUM MOL GENET, V5, P645, DOI 10.1093/hmg/5.5.645
   KOIWAI O, 1995, HUM MOL GENET, V4, P1183, DOI 10.1093/hmg/4.7.1183
   Lampe JW, 1999, PHARMACOGENETICS, V9, P341, DOI 10.1097/00008571-199906000-00009
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Loft S, 1997, J MOL MED-JMM, V75, P67, DOI 10.1007/s001090050089
   Loft S, 1999, MUTAT RES-GEN TOX EN, V441, P11, DOI 10.1016/S1383-5718(99)00034-0
   Madhavan M, 1997, ATHEROSCLEROSIS, V131, P107, DOI 10.1016/S0021-9150(97)06088-7
   Maruo Y, 1999, PEDIATRICS, V103, P1224, DOI 10.1542/peds.103.6.1224
   Matés JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6
   MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112
   Mireles LC, 1999, PEDIATR RES, V45, P355, DOI 10.1203/00006450-199903000-00011
   Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8
   Monaghan G, 1999, J PEDIATR-US, V134, P441, DOI 10.1016/S0022-3476(99)70201-5
   Natarajan V, 1998, ENVIRON HEALTH PERSP, V106, P1205, DOI 10.2307/3433987
   RAUTALAHTI M, 1994, ANN MED, V26, P435, DOI 10.3109/07853899409148366
   RITTER JK, 1992, J BIOL CHEM, V267, P3257
   Romero FJ, 1998, ENVIRON HEALTH PERSP, V106, P1229, DOI 10.2307/3433990
   Schwertner HA, 1998, ATHEROSCLEROSIS, V136, P383, DOI 10.1016/S0021-9150(97)00232-3
   SCHWERTNER HA, 1994, CLIN CHEM, V40, P18
   Siow RCM, 1999, CARDIOVASC RES, V41, P385, DOI 10.1016/S0008-6363(98)00278-8
   STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864
   Wasserman E, 1997, ANN ONCOL, V8, P1049, DOI 10.1023/A:1008261821434
   Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017
   Yesilkaya A, 1998, INT J CLIN LAB RES, V28, P230, DOI 10.1007/BF02874114
   Zucker SD, 1999, HEPATOLOGY, V30, p498A
NR 61
TC 28
Z9 29
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD DEC
PY 2000
VL 29
IS 4
BP 198
EP 204
DI 10.1002/1098-2744(200012)29:4<198::AID-MC1001>3.3.CO;2-B
PG 7
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 390DW
UT WOS:000166281300002
PM 11170257
DA 2025-01-12
ER

PT J
AU Conway, KE
   McConnell, BB
   Bowring, CE
   Donald, CD
   Warren, ST
   Vertino, PM
AF Conway, KE
   McConnell, BB
   Bowring, CE
   Donald, CD
   Warren, ST
   Vertino, PM
TI <i>TMS1</i>, a novel proapoptotic caspase recruitment domain protein, is
   a target of methylation-induced gene silencing in human breast cancers
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; B-CELL LYMPHOMA; NF-KAPPA-B; DNA METHYLATION;
   HISTONE DEACETYLASE; CPG ISLAND; EXPRESSION; APOPTOSIS; KINASE;
   HYPERMETHYLATION
AB Gene silencing associated with aberrant methylation of promoter region CpG islands is an acquired epigenetic alteration that serves as an alternative to genetic defects in the inactivation of tumor suppressor and other genes in human cancers. The hypothesis that aberrant methylation plays a direct causal role in carcinogenesis hinges on the question of whether aberrant methylation is sufficient to drive gene silencing. To identify downstream targets of methylation-induced gene silencing, we used a human cell model in which aberrant CpG island methylation is induced by ectopic expression of DNA methyltransferase, Here we report the isolation and characterization of TMS1 (target of methylation-induced silencing), a novel CpG Island-associated gene that becomes hypermethylated and silenced in cells overexpressing DNA cytosine-5-methyltransferase-1, We also show that TMS1 is aberrantly methylated and silenced in human breast cancer cells. Forty percent (11 of 27) of primary breast tumors exhibited aberrant methylation of TMS1, TMS1 is localized to chromosome 16p11.2-12.1 and encodes a 22-kDa predicted protein containing a COOH-terminal caspase recruitment domain, a recently described protein interaction motif found in apoptotic signaling molecules. Ectopic expression of TMS1 induced apoptosis in 293 cells and inhibited the survival of human breast cancer cells. The data suggest that methylation-mediated silencing of TMS1 confers a survival advantage by allowing cells to escape from apoptosis, supporting a new role for aberrant methylation in breast tumorigenesis.
C1 Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Howard Hughes Med Inst, Atlanta, GA 30322 USA.
C3 Emory University; Emory University; Emory University; Emory University;
   Howard Hughes Medical Institute
RP Vertino, PM (通讯作者)，Winship Canc Inst, Dept Radiat Oncol, Room B5119,1365-B Clifton Rd NE, Atlanta, GA 30322 USA.
OI Bowring, Claire/0000-0003-4219-4117
FU NCI NIH HHS [1RO1-CA77337, F32-CA83289] Funding Source: Medline
CR Bachman KE, 1999, CANCER RES, V59, P798
   Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361
   Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8
   HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640
   Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560
   Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353
   Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172
   Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835
   McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pan HC, 1997, CANCER SURV, V29, P305
   Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857
   Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5
   WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891
   Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767
NR 36
TC 229
Z9 264
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2000
VL 60
IS 22
BP 6236
EP 6242
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 375ZD
UT WOS:000165432600005
PM 11103776
DA 2025-01-12
ER

PT J
AU Baldwin, RL
   Nemeth, E
   Tran, H
   Shvartsman, H
   Cass, I
   Narod, S
   Karlan, BY
AF Baldwin, RL
   Nemeth, E
   Tran, H
   Shvartsman, H
   Cass, I
   Narod, S
   Karlan, BY
TI <i>BRCA1</i> promoter region hypermethylation in ovarian carcinoma:: A
   population-based study
SO CANCER RESEARCH
LA English
DT Article
ID SPORADIC BREAST-CANCER; DNA METHYLATION; GENE; MUTATIONS; P53;
   HETEROZYGOSITY; SEQUENCE; PROTEIN; PCR
AB There is a clear association between germ-line BRCA1 mutations and inherited ovarian cancer; however, the association between BRCA1 mutations and sporadic ovarian cancer remains ambiguous. The frequency of BRCA1 promoter hypermethylation as an epigenetic means of BRCA1 inactivation was determined for a large, population-based cohort of ovarian cancer patients. BRCA1 promoter hypermethylation was determined by methylation-specific restriction digestion of tumor DNA, followed by Southern blot analysis and confirmed by methylation-specific PCR, BRCA1 promoter hypermethylation was observed in 12 of 98 ovarian tumors. BRCA1 methylation status of the primary tumor was conserved in six recurrent tumors after interim chemotherapy. None of the 12 tumors with BRCA1 promoter hypermethylation demonstrated BRCA1 protein expression by immunohistochemistry. BRCA1 methylation was only seen in ovarian cancer patients without a family history suggestive of a breast/ovarian cancer syndrome. Therefore, the 12 BRCA1 methylated tumors represented 15% (12 of 81) of the sporadic cancers analyzed in this study. Although the clinical significance of BRCA1 promoter hypermethylation Is yet to be determined, promoter hypermethylation may be an alternative to mutation in causing the inactivation of the BRCA1 tumor suppressor gene in sporadic ovarian cancer.
C1 Cedars Sinai Med Ctr, Burns & Allen Res Inst, Div Gynecol Oncol, Los Angeles, CA 90048 USA.
   Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
   Ctr Res Womens Hlth, Toronto, ON, Canada.
C3 Cedars Sinai Medical Center; University of California System; University
   of California Los Angeles
RP Cedars Sinai Med Ctr, Dept Obstet & Gynecol, 8700 Beverly Blvd,Suite 160W, Los Angeles, CA 90048 USA.
EM baldwin@cshs.org
RI Németh, Eszter/JQW-0374-2023; Narod, Steven/AAA-6112-2022
CR Brown MA, 1996, ONCOGENE, V12, P2507
   CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589
   Casey G, 1996, ONCOGENE, V13, P1971
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Dobrovic A, 1997, CANCER RES, V57, P3347
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   ECCLES DM, 1992, ONCOGENE, V7, P2069
   ESTRELLER M, 2000, JNCI-J NATL CANCER I, V92, P564
   Foster KA, 1996, CANCER RES, V56, P3622
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   GRUIS NA, 1993, BRIT J CANCER, V68, P308, DOI 10.1038/bjc.1993.333
   Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298
   Herman JG, 1996, CANCER RES, V56, P722
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Karlan BY, 1999, AM J OBSTET GYNECOL, V180, P917, DOI 10.1016/S0002-9378(99)70663-0
   LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0
   LEE JH, 1990, CANCER RES, V50, P2724
   Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226
   MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0
   Rhei E, 1998, CANCER RES, V58, P3193
   RISINGER JI, 1993, CANCER RES, V53, P5100
   SATO T, 1991, CANCER RES, V51, P5118
   Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029
   STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61
   Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001
   Takahashi H, 1996, CANCER RES, V56, P2738
   TAKAHASHI H, 1995, CANCER RES, V55, P2998
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8
   Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264
   Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994
   YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405
NR 36
TC 286
Z9 307
U1 2
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2000
VL 60
IS 19
BP 5329
EP 5333
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 362HG
UT WOS:000089772100003
PM 11034065
DA 2025-01-12
ER

PT J
AU Stampfer, MR
   Yaswen, P
AF Stampfer, MR
   Yaswen, P
TI Culture models of human mammary epithelial cell transformation
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE immortality; senescence; conversion; telomerase; TGF beta
ID HUMAN BREAST-CANCER; GROWTH-FACTOR-BETA; CARCINOMA IN-SITU; TELOMERASE
   ACTIVITY; P53 GENE; MALIGNANT TRANSFORMATION; HUMAN FIBROBLASTS; MOUSE
   TELOMERASE; DEFINED MEDIUM; LINE HMT-3522
AB Human pre-malignant breast diseases, particularly ductal carcinoma in situ (DCIS)(3) already display several of the aberrant phenotypes found in primary breast cancers, including chromosomal abnormalities, telomerase activity, inactivation of the p53 gene, and overexpression of some oncogenes. Efforts to model early breast carcinogenesis in human cell cultures have largely involved studies of in vitro transformation of normal finite lifespan human mammary epithelial cells (HMEC) to immortality and malignancy. We present a model of HMEC immortal transformation consistent with the known in vivo data. This model includes a recently described, presumably epigenetic process, termed conversion, which occurs in cells that have overcome stringent replicative senescence and are thus able to maintain proliferation with critically short telomeres. The conversion process involves reactivation of telomerase activity, and acquisition of good uniform growth in the absence and presence of TGF beta. We propose that overcoming the proliferative constraints set by senescence, and undergoing conversion, represent key rate-limiting steps in human breast carcinogenesis, and occur during early stage breast cancer progression.
C1 Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
C3 United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; University of California System; University of California
   Berkeley
RP Stampfer, MR (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,70A-1118, Berkeley, CA 94720 USA.
FU NCI NIH HHS [CA-24844] Funding Source: Medline
CR Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675
   BAND V, 1990, CANCER RES, V50, P7351
   Band V, 1998, INT J ONCOL, V12, P499
   BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520
   Bednarek AK, 1997, CLIN CANCER RES, V3, P11
   BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Briand P, 1996, CANCER RES, V56, P2039
   BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578
   CHU CT, 2000, P AM ASSOC CANC RES, V41, P534
   CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108
   CLARK R, 1988, CANCER RES, V48, P4689
   Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703
   COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994
   Dairkee SH, 1997, CANCER RES, V57, P1590
   DIELLA F, 1993, LIFE SCI ADV BIOCH, V12, P47
   Done SJ, 1998, CANCER RES, V58, P785
   Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306
   FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411
   Fujii H, 1996, CANCER RES, V56, P1493
   FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493
   Gao QS, 1996, CANCER RES, V56, P3129
   Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Gollahon LS, 1996, ONCOGENE, V12, P715
   Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Holt SE, 1996, MOL CELL BIOL, V16, P2932
   Iacopetta B, 1998, CLIN CANCER RES, V4, P1597
   KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156
   Landberg G, 1997, CANCER RES, V57, P549
   LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833
   Li Z, 1998, CANCER RES, V58, P5271
   Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986
   Mokbell K, 1999, BREAST, V8, P208, DOI 10.1054/brst.1999.0034
   MOYRET C, 1994, EXP CELL RES, V215, P380, DOI 10.1006/excr.1994.1355
   Nawaz S, 1997, AM J CLIN PATHOL, V107, P542
   NIELSEN KV, 1994, CANCER GENET CYTOGEN, V78, P189, DOI 10.1016/0165-4608(94)90089-2
   Nijjar T, 1999, CANCER RES, V59, P5112
   PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323
   PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064
   PIERCE JH, 1991, ONCOGENE, V6, P1189
   Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020
   Poremba C, 1998, INT J ONCOL, V12, P641
   PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818
   Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477
   ROGALLA P, 1994, CANCER GENET CYTOGEN, V77, P19, DOI 10.1016/0165-4608(94)90143-0
   Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V
   RUSSO J, 1993, CRIT REV ONCOGENESIS, V4, P403
   Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458
   SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283
   SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425
   SHAY JW, 1993, ONCOGENE, V8, P1407
   Shpitz B, 1999, BREAST CANCER RES TR, V58, P65, DOI 10.1023/A:1006394209922
   Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173
   SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435
   SOULE HD, 1990, CANCER RES, V50, P6075
   Stampfer M., 1985, Journal of Tissue Culture Methods, V9, P107
   Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391
   STAMPFER MR, 1993, J CELL PHYSIOL, V155, P210, DOI 10.1002/jcp.1041550127
   STAMPFER MR, UNPUB CANC RES
   STAMPFER MR, 1992, TRANSFORMATION HUMAN, P117
   STAMPFER MR, 1988, BREAST CANCER CELLUL, P1
   Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8
   TAIT L, 1990, CANCER RES, V50, P6087
   TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403
   TEIXEIRA MR, 1995, INT J CANCER, V63, P63, DOI 10.1002/ijc.2910630113
   Tsao JI, 1997, CLIN CANCER RES, V3, P627
   WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3
   WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468
   WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687
   Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089
   WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257
NR 74
TC 40
Z9 46
U1 0
U2 2
PU KLUWER ACADEMIC/PLENUM PUBL
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD OCT
PY 2000
VL 5
IS 4
BP 365
EP 378
DI 10.1023/A:1009525827514
PG 14
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 407FZ
UT WOS:000167262700004
PM 14973382
DA 2025-01-12
ER

PT J
AU Rice, JC
   Ozcelik, H
   Maxeiner, P
   Andrulis, I
   Futscher, BW
AF Rice, JC
   Ozcelik, H
   Maxeiner, P
   Andrulis, I
   Futscher, BW
TI Methylation of the BRCA1 promoter is associated with decreased BRCA1
   mRNA levels in clinical breast cancer specimens
SO CARCINOGENESIS
LA English
DT Article
ID SPORADIC BREAST; CPG ISLAND; DNA METHYLATION; OVARIAN-CANCER; GENE;
   EXPRESSION; CARCINOMAS; REGION; GROWTH; CELLS
AB Functional inactivation of BRCA1 is an important mechanism involved in breast cancer pathogenesis. Mutation is often responsible for BRCA1 inactivation in familial breast cancer, but is not responsible for the decreased levels of BRCA1 seen in a subset of sporadic breast cancer patients. To determine if aberrant cytosine methylation of the BRCA1 promoter is associated with decreased BRCA1 gene expression in human breast cancer, high resolution bisulfite sequence analysis was used to analyze the cytosine methylation status of the BRCA1 promoter in 21 axillary node negative breast cancer patients with known levels of BRCA1 expression. Aberrant cytosine methylation of the BRCA1 promoter was detected in three of 21 patient specimens, These three specimens also expressed the lowest levels of BRCA1. Results from this analysis show that aberrant cytosine methylation of the BRCA1 promoter is directly correlated with decreased levels of BRCA1 expression in human breast cancer, and suggest that epigenetic silencing may be one mechanism of transcriptional inactivation of BRCA1 in sporadic mammary carcinogenesis.
C1 Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
   Samuel Lunenfeld Res Inst, Ctr Canc Genet, Tucson, AZ 85724 USA.
   Mt Sinai Hosp, Dept Pathol & Lab Med, Tucson, AZ 85724 USA.
   Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada.
   Canc Care Ontario, Toronto, ON, Canada.
   Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA.
C3 University of Arizona; University of Toronto; University of Toronto;
   Cancer Care Ontario; University of Arizona; Arizona Center Cancer Care
RP Futscher, BW (通讯作者)，Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
RI Rice, Judd/B-7806-2009; Andrulis, Irene/E-7267-2013; Ozcelik,
   Hilmi/A-3952-2011
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   COSTELLO JF, 1994, J BIOL CHEM, V269, P17228
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Herman JG, 1997, CANCER RES, V57, P837
   Holt JT, 1998, NAT GENET, V19, P102
   Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298
   KLEMPNAUER KH, 1993, ONCOGENE, V8, P111
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839
   Özçelik H, 1998, INT J CANCER, V77, P1
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0
   Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057
   Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994
   Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249
NR 31
TC 187
Z9 215
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD SEP
PY 2000
VL 21
IS 9
BP 1761
EP 1765
DI 10.1093/carcin/21.9.1761
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 352FU
UT WOS:000089204500018
PM 10964110
OA Bronze
DA 2025-01-12
ER

PT J
AU Krämer, F
   White, K
   Kubbies, M
   Swisshelm, K
   Weber, BHF
AF Krämer, F
   White, K
   Kubbies, M
   Swisshelm, K
   Weber, BHF
TI Genomic organization of claudin-1 and its assessment in hereditary and
   sporadic breast cancer
SO HUMAN GENETICS
LA English
DT Article
ID TIGHT-JUNCTION STRANDS; INTEGRAL MEMBRANE-PROTEINS; SEPTATE JUNCTIONS;
   EPITHELIAL-CELLS; FREEZE-FRACTURE; CPG ISLANDS; HUMAN DNA; OCCLUDIN;
   GENE; PERMEABILITY
AB Human claudin-1 is an integral protein component of tight junctions, a structure controlling cell-to-cell adhesion and, consequently, regulating paracellular and transcellular transport of solutes across human epithelia and endothelia. Recently, a claudin-1 (CLDN1) cDNA has been isolated from human mammary epithelial cells (HMECs). CLDN1 expression in HMECs, in contrast to low or undetectable levels of expression in a number of breast tumors and breast cancer cell lines, points to CLDN1 as a possible tumor-suppressor gene. In order to evaluate the CLDN-1 gene in sporadic and hereditary breast cancer, we have characterized its genomic organization and have screened the four coding exons for somatic mutations in 96 sporadic breast carcinomas and for germline mutations in 93 breast cancer patients with a strong family history of breast cancer. In addition, we have compared the 5'-upstream sequences of the human and murine CLDN1 genes to identify putative promoter sequences and have examined both the promoter and coding regions of the human gene in the breast cancer cell lines showing decreased CLDN1 expression. In the sporadic tumors and hereditary breast cancer patients, we have found no evidence to support the involvement of aberrant CLDN1 in breast tumorigenesis. Likewise, in the breast cancer cell lines, no genetic alterations in the promoter or coding sequences have been identified that would explain the loss of CLDN1 expression. Other regulatory or epigenetic factors may be involved in the downregulation of this gene during breast cancer development.
C1 Univ Wurzburg, Inst Humangenet, D-97074 Wurzburg, Germany.
   Roche Pharmaceut Res, Dept Cell Analyt, Penzberg, Germany.
   Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
C3 University of Wurzburg; Roche Holding; University of Washington;
   University of Washington Seattle
RP Weber, BHF (通讯作者)，Univ Wurzburg, Inst Humangenet, Hubland, D-97074 Wurzburg, Germany.
OI Weber, Bernhard H.F./0000-0002-8808-7723
CR Anderson JM, 1999, CURR BIOL, V9, pR922, DOI 10.1016/S0960-9822(00)80105-0
   Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031
   BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8
   Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891
   Cochand-Priollet B, 1998, ULTRASTRUCT PATHOL, V22, P413
   COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782
   Fenton SE, 1996, J BIOL CHEM, V271, P30870, DOI 10.1074/jbc.271.48.30870
   FUJIMOTO K, 1995, J CELL SCI, V108, P3443
   Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391
   FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777
   Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539
   Furuse M, 1996, J CELL SCI, V109, P429
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Hofferbert S, 2000, GENET COUNSEL, V11, P127
   Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X
   Inai T, 1999, EUR J CELL BIOL, V78, P849, DOI 10.1016/S0171-9335(99)80086-7
   IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171
   LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M
   LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103
   McCarthy KM, 1996, J CELL SCI, V109, P2287
   Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511
   Mullin JM, 1997, J EXP ZOOL, V279, P484, DOI 10.1002/(SICI)1097-010X(19971201)279:5<484::AID-JEZ11>3.0.CO;2-8
   ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766
   PENOTTI FE, 1991, J THEOR BIOL, V150, P385, DOI 10.1016/S0022-5193(05)80436-9
   Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991
   PRICE JE, 1990, CANCER RES, V50, P717
   Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397
   Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103
   Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425
   SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165
   SWIFT JG, 1983, J SUBMICR CYTOL PATH, V15, P799
   Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8
   Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13
   Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0
   WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834
   Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399
   WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X
NR 39
TC 137
Z9 151
U1 0
U2 5
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD SEP
PY 2000
VL 107
IS 3
BP 249
EP 256
DI 10.1007/s004390000375
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 361WK
UT WOS:000089747100008
PM 11071387
DA 2025-01-12
ER

PT J
AU Freeman, JW
AF Freeman, JW
TI Loss of TGF-β signaling in epithelial-derived tumors:: Mechanisms and
   biological consequences
SO JOURNAL OF CLINICAL LIGAND ASSAY
LA English
DT Article
DE TGF-beta; TGF-beta receptors; Smads; growth regulation; cell cycle; gene
   regulation; tumorigenicity; cancer
ID GROWTH-FACTOR-BETA; II RECEPTOR GENE; BREAST-CANCER-CELLS; NONPOLYPOSIS
   COLORECTAL-CANCER; COLON-CARCINOMA CELLS; MICROSATELLITE INSTABILITY;
   PANCREATIC-CANCER; SMAD PROTEINS; PROSTATE-CANCER; MUTATION COMMON
AB The purpose of this article is to review current knowledge of the role that loss in transforming growth factor beta (TGF-beta) signaling has on the tumorgenicity of epithelial derived tumors. The mechanisms responsible for loss in TGF-beta signaling are also summarized. Loss in response to TGF-beta is one of the hallmarks of tumor progression. Loss in TGF-beta signaling provides cells with a selective growth advantage by diminishing the expression of cyclin-dependent kinase inhibitors, circumventing cell cycle checkpoints, and promoting cell survival, The loss of TGF-beta signaling is mediated by a variety of mechanisms. These include mutations that inactivate TGF-beta receptors and Smads, expression of oncoproteins ski and sno that inactivate Smad complexes, over-expression of antagonistic Smads, and epigenetic events that down regulate TGF-beta receptor expression. A further understanding of these mechanisms may lead to the development of therapeutic strategies that restore TGF-beta signaling.
C1 Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM freemanjw@uthscsa.edu
CR Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8
   Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269
   Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527
   ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367
   ARTEAGA CL, 1988, CANCER RES, V48, P3898
   ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4
   Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5
   Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1
   Barrack ER, 1997, PROSTATE, V31, P61
   Chen TP, 1998, CANCER RES, V58, P4805
   Christian JL, 1999, BIOESSAYS, V21, P382, DOI 10.1002/(SICI)1521-1878(199905)21:5<382::AID-BIES5>3.0.CO;2-V
   Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.0.CO;2-E
   Engel ME, 1998, J CELL BIOCHEM, P111
   Grady WM, 1998, CANCER RES, V58, P3101
   Grady WM, 1999, CANCER RES, V59, P320
   Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161
   HOWELL GM, 1993, CANCER METAST REV, V12, P275, DOI 10.1007/BF00665958
   HURTA RAR, 1995, J CELL BIOCHEM, V57, P543, DOI 10.1002/jcb.240570319
   Iacopetta BJ, 1998, J PATHOL, V184, P390
   Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355
   KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002
   Kim DH, 1997, J BIOL CHEM, V272, P688
   Kim IY, 1996, CLIN CANCER RES, V2, P1255
   Kim YS, 1999, ARCH PHARM RES, V22, P1, DOI 10.1007/BF02976427
   Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909
   Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171
   Koyama M, 1999, MUTAT RES-GENOMICS, V406, P71, DOI 10.1016/S1383-5726(99)00003-5
   Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7
   LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644
   Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196
   Lynch HT, 1999, J MED GENET, V36, P801
   MacKay SLD, 1998, ANN SURG, V227, P781, DOI 10.1097/00000658-199806000-00001
   MACKAY SLD, 1995, ANN SURG, V221, P767, DOI 10.1097/00000658-199506000-00015
   MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642
   Moses H.L., 1991, CIBA F SYMP, V157, P66
   MYEROFF LL, 1995, CANCER RES, V55, P5545
   Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369
   Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x
   Orimo H, 1998, MUTAT RES-GENOMICS, V382, P115, DOI 10.1016/S1383-5726(98)00003-X
   Ottini L, 1998, ONCOGENE, V16, P2767, DOI 10.1038/sj.onc.1201816
   PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772
   Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865
   Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919
   Reiss M, 1997, ONCOL RES, V9, P447
   ROBERTS AB, 1990, PHILOS T R SOC B, V327, P145, DOI 10.1098/rstb.1990.0050
   ROBERTS AB, 1991, CANCER CELL-MON REV, V3, P19
   ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81
   Rozenblum E, 1997, CANCER RES, V57, P1731
   Salahshor S, 1999, BRIT J CANCER, V81, P190, DOI 10.1038/sj.bjc.6690676
   Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309
   Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537
   Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771
   SUN LZ, 1994, J BIOL CHEM, V269, P26449
   Togo G, 1996, CANCER RES, V56, P5620
   TWARDZIK DR, 1989, JNCI-J NATL CANCER I, V81, P1182, DOI 10.1093/jnci/81.15.1182
   Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y
   Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118
   WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044
   Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716
   Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989
   WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   WU SP, 1993, CELL GROWTH DIFFER, V4, P115
   ZHAO J, 1995, CANCER RES, V55, P6181
   Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3
   Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258
NR 70
TC 2
Z9 2
U1 0
U2 1
PU CLINICAL LIGAND ASSAY SOC, INC
PI WAYNE
PA 3139 S WAYNE RD, WAYNE, MI 48184 USA
SN 1081-1672
EI 1546-1653
J9 J CLIN LIGAND ASSAY
JI J. Clin. Ligand Assay
PD FAL
PY 2000
VL 23
IS 3
BP 239
EP 244
PG 6
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 390XC
UT WOS:000166324200008
DA 2025-01-12
ER

PT J
AU Rice, JC
   Futscher, BW
AF Rice, JC
   Futscher, BW
TI Transcriptional repression of <i>BRCA1</i> by aberrant cytosine
   methylation, histone hypoacetylation and chromatin condensation of the
   <i>BRCA1</i> promoter
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID CLONAL CHROMOSOME-ABNORMALITIES; EPIGENETIC GENE INACTIVATION; HUMAN
   BREAST CARCINOMAS; CPG-BINDING-PROTEIN; DNA METHYLATION; CELL-LINES;
   ACETYLATION; EXPRESSION; ISLAND; MECP2
AB BRCA1 expression is repressed by aberrant cytosine methylation in sporadic breast cancer, We hypothesized that aberrant cytosine methylation of the BRCA1 promoter was associated with the transcriptionally repressive effects of histone hypoacetylation and chromatin condensation. To address this question, we developed an in vitro model of study using normal cells and sporadic breast cancer cells with known levels of BRCA1 transcript to produce a 1.4 kb 5-methylcytosine map of the BRCA1 5' CpG island, While all cell types were densely methylated upstream of -728 relative to BRCA1 transcription start, all normal and BRCA1 expressing cells were non-methylated downstream of -728 suggesting that this region contains the functional BRCA1 5' regulatory region. In contrast, the non-BRCA1 expressing UACC3199 cells were completely methylated at all 75 CpGs. Chromatin immunoprecipitations showed that the UACC3199 cells were hypoacetylated at both histones H3 and H4 in the BRCA1 promoter compared to non-methylated BRCA1 expressing cells. The chromatin of the methylated UACC3199 BRCA1 promoter was inaccessible to DNA-protein interactions. These data indicate that the epigenetic effects of aberrant cytosine methylation, histone hypoacetylation and chromatin condensation act together in a discrete region of the BRCA1 5' CpG island to repress BRCA1 transcription in sporadic breast cancer.
C1 Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
   Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA.
C3 University of Arizona; Arizona Center Cancer Care; University of Arizona
RP Futscher, BW (通讯作者)，Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
RI Rice, Judd/B-7806-2009
FU NCI NIH HHS [3P30CA23074-19, P30 CA023074] Funding Source: Medline; PHS
   HHS [65662] Funding Source: Medline
CR ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3
   BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177
   Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807
   COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Godde JS, 1996, J BIOL CHEM, V271, P24325, DOI 10.1074/jbc.271.40.24325
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085
   MUMMANENI P, 1993, J BIOL CHEM, V268, P552
   MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788
   Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   RICE JC, 2000, IN PRESS CARCINOGENE, V21
   Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H
   THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402
   TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403
   Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096
   Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5
   Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612
   Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711
   Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994
   Yates PA, 1999, J BIOL CHEM, V274, P36357, DOI 10.1074/jbc.274.51.36357
   Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249
NR 35
TC 72
Z9 81
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD SEP 1
PY 2000
VL 28
IS 17
BP 3233
EP 3239
DI 10.1093/nar/28.17.3233
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 350AU
UT WOS:000089078900006
PM 10954590
OA Green Published
DA 2025-01-12
ER

PT J
AU Park, YK
   Park, HR
   Chi, SG
   Kim, CJ
   Sohn, KR
   Koh, JS
   Kim, CW
   Yang, WI
   Ro, JY
   Ahn, KW
   Joo, M
   Kim, YW
   Lee, J
   Yang, MH
   Unni, KK
AF Park, YK
   Park, HR
   Chi, SG
   Kim, CJ
   Sohn, KR
   Koh, JS
   Kim, CW
   Yang, WI
   Ro, JY
   Ahn, KW
   Joo, M
   Kim, YW
   Lee, J
   Yang, MH
   Unni, KK
TI Overexpression of p53 and rare genetic mutation in mesenchymal
   chondrosarcoma
SO ONCOLOGY REPORTS
LA English
DT Article
DE p53; mesenchymal chondrosarcoma; immunohistochemistry; PCR-SSCP
ID SOFT-TISSUE SARCOMAS; BREAST-CANCER; EXPRESSION; PROTEIN; ASSOCIATION;
   ABNORMALITIES; TUMORIGENESIS; ACCUMULATION; MECHANISMS; ONCOGENE
AB Mesenchymal chondrosarcoma is extremely rare and accounts for less than 2% of all chondrosarcomas. The pathogenesis and the molecular genetic events which contribute to the development of mesenchymal chondrosarcoma are not well elucidated, due in part to the lack of sufficient tumor tissue available. To characterize the involvement of the p53 gene abnormality in this disease, we analyzed expression and sequence alteration of p53 by immunohistochemical analysis of the protein expression and quantitative DNA/PCR and PCR-SSCP assays of the gene in 33 paraffin-embedded tissue specimens. Immunohistochemical analysis demonstrated that 19 (61.3%) of 31 had nuclear overexpression of p53 while 7 (22.6%) showed cytoplasmic expression. The remaining 5 (16.1%) were negative for p53 staining. The nuclear positivity of p53 was observed within a range of 22-64% (mean 37.3%) of tumor cells and showed a positive staining in mesenchymal components as well as chondroid components. Quantitative DNA/PCR analysis revealed that 6 (18.2%) of the 33 specimens carried significantly reduced or undetectably low levels of p53 indicating the genomic deletion of the gene in these tumors. In contrast, however, DNA/PCR-SSCP analysis failed to detect any types of mutations resulting in amino acid substitution within exons 5-9 regions of the gene. Taken together, our data suggests that genetic alteration of p53 is a relatively rare event in mesenchymal chondrosarcomas but substantial fraction of this type of tumors carries abnormal overexpression of p53, which might result from as yet unidentified epigenetic mechanism(s).
C1 Korean Soc Pathologists, Bone & Soft Tissue Study Grp, Seoul, South Korea.
   Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Park, YK (通讯作者)，Kyung Hee Univ Hosp, Dept Pathol, Dongdaemoon Ku, 1 Hoeki Dong, Seoul 130702, South Korea.
RI Kim, Chul-Woo/F-7008-2011
CR ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200
   ANDREASSEN A, 1993, CANCER RES, V53, P468
   BAKER SJ, 1990, CANCER RES, V50, P7717
   CHI SG, 1997, CLIN CANCER RES, V3, P18889
   CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476
   COUGHLAN B, 1995, HUM PATHOL, V26, P620, DOI 10.1016/0046-8177(95)90166-3
   CZERNIAK B, 1990, J HISTOCHEM CYTOCHEM, V38, P463, DOI 10.1177/38.4.1969431
   DOBASHI Y, 1993, DIAGN MOL PATHOL, V2, P257
   FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531
   GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442
   HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B
   MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716
   MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262
   MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863
   NAKASHIMA Y, 1986, CANCER-AM CANCER SOC, V57, P2444, DOI 10.1002/1097-0142(19860615)57:12<2444::AID-CNCR2820571233>3.0.CO;2-K
   OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0
   Oshiro Y, 1998, CANCER, V83, P2324, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2324::AID-CNCR12>3.0.CO;2-U
   Park Hye-Rim, 1995, Journal of Korean Medical Science, V10, P360
   RUBIO MP, 1993, CANCER RES, V53, P3465
   SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565
   Shi XB, 1996, DIAGN MOL PATHOL, V5, P271, DOI 10.1097/00019606-199612000-00008
   SIMMS WW, 1995, CANCER-AM CANCER SOC, V76, P223, DOI 10.1002/1097-0142(19950715)76:2<223::AID-CNCR2820760210>3.0.CO;2-4
   STRATTON MR, 1990, ONCOGENE, V5, P1297
   Terek RM, 1998, DIAGN MOL PATHOL, V7, P51, DOI 10.1097/00019606-199802000-00009
   THORP TG, 1993, SCI HORTIC-AMSTERDAM, V53, P85, DOI 10.1016/0304-4238(93)90140-L
   TOGUCHIDA J, 1992, CANCER RES, V52, P6196
   UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41
   WADAYAMA B, 1993, BRIT J CANCER, V68, P1134, DOI 10.1038/bjc.1993.493
NR 30
TC 16
Z9 20
U1 0
U2 1
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD SEP-OCT
PY 2000
VL 7
IS 5
BP 1041
EP 1047
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 342LC
UT WOS:000088645200021
PM 10948336
DA 2025-01-12
ER

PT J
AU Melki, JR
   Vincent, PC
   Brown, RD
   Clark, SJ
AF Melki, JR
   Vincent, PC
   Brown, RD
   Clark, SJ
TI Hypermethylation of E-cadherin in leukemia
SO BLOOD
LA English
DT Article
ID INVASION-SUPPRESSOR GENE; BLOOD STEM-CELLS; DNA METHYLATION; CPG
   METHYLATION; PROSTATE-CANCER; BREAST-CANCER; EXPRESSION; CARCINOMAS;
   PROMOTER; DIFFERENTIATION
AB E-cadherin gene is often termed a "metastasis suppressor" gene because the E-cadherin protein can suppress tumor cell invasion and metastasis, Inactivation of the E-cadherin gene occurs in undifferentiated solid tumors by both genetic and epigenetic mechanisms; however, the role of E-cadherin in hematologic malignancies is only now being recognized. E-cadherin expression is essential for erythroblast and normoblast maturation, yet expression is reduced or absent in leukemic blast cells. This study examined the messenger RNA (mRNA) and protein expression of the E-cadherin gene in bone marrow and blood samples from normal donors and patients with leukemia. We found that all normal donor samples expressed E-cadherin mRNA, whereas both samples of acute myelogenous leukemia and chronic lymphocytic leukemia had a significant reduction or absence of expression. However, normal blast counterparts expressed only a low level of E-cadherin surface protein. Sodium bisulphite genomic sequencing was used to fully characterize the methylation patterns of the CpG island associated with the E-cadherin gene promoter in those samples with matched DNA. All of the normal control samples were essentially unmethylated; however, 14 of 18 (78%) of the leukemia samples had abnormal hypermethylation of the E-cadherin CPG island. In fact both alleles of the E-cadherin gene were often hypermethylated. We conclude the E-cadherin gene is a common target for hypermethylation in hematologic malignancies. (C) 2000 by The American Society of Hematology.
C1 CSIRO, Mol Sci Sydney Lab, N Ryde, NSW 1670, Australia.
   Royal Prince Alfred Hosp, Kanematsu Labs, Camperdown, NSW 2050, Australia.
   Univ Sydney, Fac Med, Sydney, NSW 2006, Australia.
   Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2050, Australia.
C3 Commonwealth Scientific & Industrial Research Organisation (CSIRO);
   University of Sydney; NSW Health; Royal Prince Alfred Hospital;
   University of Sydney; University of Sydney; NSW Health; Royal Prince
   Alfred Hospital
RP Clark, SJ (通讯作者)，CSIRO, Mol Sci Sydney Lab, POB 184, N Ryde, NSW 1670, Australia.
RI Clark, Susan/B-2272-2008
OI Clark, Susan/0000-0001-5925-5030
CR ARMEANU S, 1995, J CELL BIOL, V131, P243, DOI 10.1083/jcb.131.1.243
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Buhring HJ, 1996, LEUKEMIA, V10, P106
   Clark S. J., 1997, P151
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Fliedner TM, 1998, STEM CELLS, V16, P361, DOI 10.1002/stem.160361
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   HENNIG G, 1995, ONCOGENE, V11, P475
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hiraguri S, 1998, CANCER RES, V58, P1972
   HOLLIDAY R, 1990, PHILOS T R SOC B, V326, P329, DOI 10.1098/rstb.1990.0015
   ISSA JP, 1997, LEUKEMIA S1, V11, P7
   Jankowski JA, 1997, PROG NUCLEIC ACID RE, V57, P187, DOI 10.1016/S0079-6603(08)60281-0
   Ji XD, 1997, CELL GROWTH DIFFER, V8, P773
   Kanai Y, 1997, INT J CANCER, V71, P355
   Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727
   Melki JR, 1999, CANCER RES, V59, P3730
   Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932
   Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415
   Paul R, 1997, BRIT J UROL, V79, P37, DOI 10.1111/j.1464-410X.1997.tb00799.x
   Saito Y, 1998, INT J ONCOL, V12, P293
   Stirzaker C, 1997, CANCER RES, V57, P2229
   To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233
   Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8
   Warnecke PM, 1999, MOL CELL BIOL, V19, P164
   Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
NR 32
TC 139
Z9 158
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 15
PY 2000
VL 95
IS 10
BP 3208
EP 3213
PG 6
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 312PE
UT WOS:000086951000030
PM 10807790
DA 2025-01-12
ER

PT J
AU Schwienbacher, C
   Gramantieri, L
   Scelfo, R
   Veronese, A
   Calin, GA
   Bolondi, L
   Croce, CM
   Barbanti-Brodano, G
   Negrini, M
AF Schwienbacher, C
   Gramantieri, L
   Scelfo, R
   Veronese, A
   Calin, GA
   Bolondi, L
   Croce, CM
   Barbanti-Brodano, G
   Negrini, M
TI Gain of imprinting at chromosome 11p15: A pathogenetic mechanism
   identified in human hepatocarcinomas
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID BECKWITH-WIEDEMANN-SYNDROME; DEPENDENT KINASE INHIBITOR; METHYLATED CPG
   ISLAND; WILMS-TUMOR; BREAST-CANCER; GENE; EXPRESSION; P57(KIP2);
   RELAXATION; TISSUE
AB Genomic imprinting is a reversible condition that causes parental-specific silencing of maternally or paternally inherited genes. Analysis of DNA and RNA from 52 human hepatocarcinoma samples revealed abnormal imprinting of genes located at chromosome 11p15 in 51% of 37 informative samples. The most frequently detected abnormality was gain of imprinting, which led to loss of expression of genes present on the maternal chromosome. As compared with matched normal liver tissue, hepatocellular carcinomas showed extinction or significant reduction of expression of one of the alleles of the CDKN1C. SLU2A1L, and IGF2 genes. Loss of maternal-specific: methylation at the KvDMR1 locus in hepatocarcinoma correlated with abnormal expression of CDKN1C and IGF2, suggesting a function for KvDMR1 as a long-range imprinting center active in adult tissues. These results point to the role of epigenetic mechanisms leading to loss of expression of imprinted genes at chromosome region 11p15 in human tumors.
C1 Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy.
   Univ Bologna, Dipartimento Med Interna & Gastroenterol, I-40100 Bologna, Italy.
   Thomas Jefferson Univ, Kimmel Canc Ctr, Kimmerl Canc Inst, Philadelphia, PA 19107 USA.
C3 University of Ferrara; University of Bologna; Thomas Jefferson
   University
RP Negrini, M (通讯作者)，Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Via Luigi Borsari 46, I-44100 Ferrara, Italy.
RI Calin, George/E-9390-2011; Veronese, Angelo/I-4292-2019; Gramantieri,
   Laura/J-3862-2019; NEGRINI, Massimo/J-2377-2016; Gramantieri,
   Laura/K-8603-2016
OI NEGRINI, Massimo/0000-0002-0007-1920; Veronese,
   Angelo/0000-0002-1451-1392; Gramantieri, Laura/0000-0002-5187-9559;
   Calin, George/0000-0001-6704-5615
FU Telethon [E.0653] Funding Source: Medline
CR Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027
   BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395
   Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881
   Cooper PR, 1998, GENOMICS, V49, P38, DOI 10.1006/geno.1998.5221
   Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260
   Dao D, 1998, HUM MOL GENET, V7, P597, DOI 10.1093/hmg/7.4.597
   Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171
   Henry I., 1993, European Journal of Human Genetics, V1, P19
   Hu RJ, 1997, GENOMICS, V46, P9, DOI 10.1006/geno.1997.4981
   Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6
   LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639
   Lee MP, 1998, CANCER RES, V58, P4155
   Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181
   MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650
   Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026
   Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209
   NEGRINI M, 1995, CANCER RES, V55, P3003
   OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0
   OKeefe D, 1997, AM J HUM GENET, V61, P295, DOI 10.1086/514854
   Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021
   RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0
   Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147
   Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6
   SCHROEDER WT, 1987, AM J HUM GENET, V40, P413
   Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873
   SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0
   SLATTER RE, 1994, J MED GENET, V31, P749, DOI 10.1136/jmg.31.10.749
   Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064
   STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433
   STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090
   SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52
   SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332
   TAKODORO K, 1991, NUCLEIC ACIDS RES, V19, P6967
   TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159
   WILLIAMS J, 1990, LANCET, V335, P283
   Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631
   YEE D, 1988, CANCER RES, V48, P6691
   Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0
NR 38
TC 77
Z9 91
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 9
PY 2000
VL 97
IS 10
BP 5445
EP 5449
DI 10.1073/pnas.090087497
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 313KH
UT WOS:000086998500080
PM 10779553
OA Green Published
DA 2025-01-12
ER

PT J
AU Yan, PS
   Perry, MR
   Laux, DE
   Asare, AL
   Caldwell, CW
   Huang, THM
AF Yan, PS
   Perry, MR
   Laux, DE
   Asare, AL
   Caldwell, CW
   Huang, THM
TI CpG island arrays: An application toward deciphering epigenetic
   signatures of breast cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GENE-EXPRESSION PATTERNS; DNA; METHYLATION; MICROARRAY; SEQUENCES
AB CpG island hypermethylation is a frequent epigenetic event in cancer. We have recently developed an array-based method, called differential methylation hybridization (DMH), allowing for a genome-wide screening of CpG island hypermethylation in breast cancer cell lines (T, H-M. Huang et al., Hum. Mol. Genet., 8: 359-470, 1999), In the present study, DMH was applied to screen 28 paired primary breast tumor and normal samples and to determine whether patterns of specific epigenetic alterations correlate with pathological parameters in the. patients analyzed, Amplicons, representing a pool of methylated CpG DNA derived from these samples, were used as hybridization probes in an array panel containing 1104 CpG island tags. close to 9% of these tags exhibited extensive hypermethylation in the majority of breast tumors relative to their normal controls, whereas others had little or no detectable changes. Pattern analysis in a subset of CpG island tags revealed that CpG island hypermethylation is associated with histological grades of breast tumors. Poorly differentiated tumors appeared to exhibit more hypermethylated CpG islands than their moderately or well-differentiated counterparts (P = 0.041). This early finding lays the groundwork for a population-based DMH. study and demonstrates the need to develop a database for examining large-scale methylation data and for associating specific epigenetic signatures with clinical parameters in breast cancer.
C1 Univ Missouri, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Sch Med, Columbia, MO 65203 USA.
   Univ Missouri, Ellis Fischel Canc Ctr, Dept Hlth Management & Informat, Sch Med, Columbia, MO 65203 USA.
C3 University of Missouri System; University of Missouri Columbia;
   University of Missouri System; University of Missouri Columbia
RP Univ Missouri, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Sch Med, 115 Business Loop I-70 W, Columbia, MO 65203 USA.
EM Huangh@health.missouri.edu
RI Yan, Pearlly/E-4339-2011
OI Laux, Douglas/0000-0001-6499-3708; Asare, Adam/0000-0002-9299-3518
FU NCI NIH HHS [CA-69065] Funding Source: Medline
CR *AM JOINT COMM CAN, 1989, MAN STAG CANC, P93
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43
   Brock GJR, 1997, HUM MOL GENET, V6, P451, DOI 10.1093/hmg/6.3.451
   Craig JM, 1997, HUM GENET, V100, P472, DOI 10.1007/s004390050536
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   DeRisi J, 1996, NAT GENET, V14, P457
   Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8
   Hernandez R, 1997, CYTOGENET CELL GENET, V76, P196, DOI 10.1159/000134548
   Huang THM, 1997, CANCER RES, V57, P1030
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4
   VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484
   Yen PS, 2000, BRIT J CANCER, V82, P514, DOI 10.1054/bjoc.1999.0955
NR 19
TC 128
Z9 180
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR
PY 2000
VL 6
IS 4
BP 1432
EP 1438
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 307BL
UT WOS:000086633500033
PM 10778974
DA 2025-01-12
ER

PT J
AU Sirchia, SM
   Ferguson, AT
   Sironi, E
   Subramanyan, S
   Orlandi, R
   Sukumar, S
   Sacchi, N
AF Sirchia, SM
   Ferguson, AT
   Sironi, E
   Subramanyan, S
   Orlandi, R
   Sukumar, S
   Sacchi, N
TI Evidence of epigenetic changes affecting the chromatin state of the
   retinoic acid receptor β2 promoter in breast cancer cells
SO ONCOGENE
LA English
DT Article
DE breast cancer; DNA methylation; chromatin remodeling; retinoic acid
   receptor (RAR)beta
ID ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE COMPLEX; EMBRYONAL
   CARCINOMA-CELLS; PLZF-RAR-ALPHA; DNA METHYLATION; EXPRESSION; GENE;
   TRANSCRIPTION; ACETYLATION; ACTIVATION
AB Retinoic acid (RA)-resistance in breast cancer cells has been associated with irreversible loss of retinoic acid receptor beta, RAR beta, gene expression. Search of the causes affecting RAR beta gene activity has been oriented at identifying possible differences either at the level of one of the RAR beta promoters, RAR beta 2, or at regulatory factors. We hypothesized that loss of RAR beta 2 activity occurs as a result of multiple factors, including epigenetic modifications, which can pattern RAR beta 2 chromatin state. Using methylation-specific PCR, we found hypermethylation at RAR beta 2 in a significant proportion of both breast cancer cell lines and primary breast tumors. Treatment of cells with a methylated RAR beta 2 promoter, by means of the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR), led to demethylation within RAR beta 2 and expression of RAR beta indicating that DNA methylation is at least one factor, contributing to RAR beta inactivity. However, identically methylated promoters can differentially respond to RA, suggesting that RAR beta 2 activity may be associated to different repressive chromatin states. This supposition is supported by the finding that the more stable repressive RAR beta 2 state in the RA-resistant MDA-MB-231 cell line can be alleviated by the HDAC inhibitor, trichostatin A (TSA), with restoration of RA-induced RAR beta transcription. Thus, chromatin-remodeling drugs might provide a strategy to restore RAR beta activity, and help to overcome the hurdle of RA-resistance In breast cancer.
C1 Univ Milan, Dept Biol, I-20133 Milan, Italy.
   Univ Milan, Hosp San Paolo, Lab Human Genet, Milan, Italy.
   Johns Hopkins Univ, Ctr Oncol, Breast Canc Program, Baltimore, MD 21205 USA.
   Inst Nazl Studio & Cura Tumori, Milan, Italy.
C3 University of Milan; University of Milan; Johns Hopkins University;
   Johns Hopkins Medicine; Fondazione IRCCS Istituto Nazionale Tumori Milan
RP Sacchi, N (通讯作者)，Univ Milan, Dept Biol, Via Celoria 26, I-20133 Milan, Italy.
RI Sirchia, Silvia/AAB-2620-2019; Orlandi, Rosaria/C-1182-2017
OI Sirchia, Silvia/0000-0002-6106-3721; Orlandi,
   Rosaria/0000-0002-0533-9041
CR Baust C, 1996, INT J CANCER, V67, P409, DOI 10.1002/(SICI)1097-0215(19960729)67:3<409::AID-IJC16>3.0.CO;2-2
   Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013
   Cote S, 1997, ANTI-CANCER DRUG, V8, P56
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680
   Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961
   Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200
   Formantici C, 1999, J PATHOL, V187, P424, DOI 10.1002/(SICI)1096-9896(199903)187:4<424::AID-PATH259>3.0.CO;2-0
   Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901
   Gudas Lorraine J., 1994, P443
   Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642
   He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126
   HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134
   KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1
   LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302
   Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Minna JD, 1997, J NATL CANCER I, V89, P602, DOI 10.1093/jnci/89.9.602
   Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303
   Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   ROMAN SD, 1992, CANCER RES, V52, P2236
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005
   SHAO ZM, 1994, INT J ONCOL, V4, P849
   Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679
   SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839
   SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133
   TOULOUSE A, 1997, BBA, V1309, P1
   Tsou HC, 1998, EXP CELL RES, V245, P221, DOI 10.1006/excr.1998.4268
   VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068
   VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4
   Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435
   Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621
   WIESCHWENDTNER M, 1997, CANCER RES, V17, P4158
   Xu XC, 1997, CANCER RES, V57, P4992
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
NR 46
TC 186
Z9 202
U1 0
U2 14
PU STOCKTON PRESS
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAR 16
PY 2000
VL 19
IS 12
BP 1556
EP 1563
DI 10.1038/sj.onc.1203456
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 297XN
UT WOS:000086108100008
PM 10734315
DA 2025-01-12
ER

PT J
AU Domann, FE
   Rice, JC
   Hendrix, MJC
   Futscher, BW
AF Domann, FE
   Rice, JC
   Hendrix, MJC
   Futscher, BW
TI Epigenetic silencing of maspin gene expression in human breast cancers
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
ID CLONAL CHROMOSOME-ABNORMALITIES; DNA METHYLATION; CPG ISLAND;
   CARCINOMAS; SERPIN; AMPLIFICATION; PROMOTER; DISEASE; TUMORS; SITES
AB Maspin is a tumor suppressor whose expression is lost in many advanced breast cancers, Maspin has been shown to inhibit cell motility, invasion and metastasis; however, its precise role in normal mammary epithelium remains to be elucidated. Although expression of maspin mRNA is low or absent in most human breast cancer cells, the maspin gene is rarely re-arranged or deleted, We hypothesized that aberrant cytosine methylation and chromatin condensation of the maspin promoter participates in the silencing of maspin expression during neoplastic progression. To test this hypothesis, we compared cultured normal human mammary epithelial cells (HMECs) to 9 cultured human breast cancer cell lines, HMECs expressed maspin mRNA and displayed a completely non-methylated maspin gene promoter with an open chromatin structure, In contrast, 7 of 9 breast cancer cell lines had no detectable maspin expression and 6 of these 7 maspin-negative breast cancer cell lines also displayed an aberrant pattern of cytosine methylation of the maspin promoter. Interestingly, the maspin promoter was completely methylated in maspin-negative normal peripheral blood lymphocytes, This indicates that the maspin promoter is not a functional CpG island and that cytosine methylation of this region may contribute to normal tissue-restricted gene expression. Chromatin accessibility studies with MCF-7 cells, which lack maspin expression and have a methylated maspin promoter, showed a closed chromatin structure compared with HMECs, Moreover, maspin gene expression could be re-activated in MCF-7 cells by treatment with 5-aza-2'-deoxycytidine, a DNA demethylating agent, Thus, aberrant cytosine methylation and heterochromatinization of the maspin promoter may silence maspin gene expression, thereby contributing to the progression of human mammary cancer. (C) 2000 Wiley-Liss, Inc.
C1 Univ Iowa, Coll Med, Dept Radiol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA.
   Iowa Canc Ctr, Iowa City, IA 52242 USA.
   Univ Arizona, Dept Pharmacol, Tucson, AZ USA.
   Univ Arizona, Bone Marrow Transplant Program, Tucson, AZ USA.
   Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA.
   Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Arizona; University of Arizona;
   Arizona Center Cancer Care; University of Arizona; University of Iowa
RP Domann, FE (通讯作者)，Univ Iowa, Coll Med, Dept Radiol, Free Rad & Radiat Biol Program, B-180 Med Labs, Iowa City, IA 52242 USA.
RI Rice, Judd/B-7806-2009
OI Domann, Frederick/0000-0002-0489-2179
FU NCI NIH HHS [CA65562, CA73612, CA75681] Funding Source: Medline
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   GRAFF JR, 1995, CANCER RES, V55, P5195
   GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832
   Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Sager R, 1996, CURR TOP MICROBIOL, V213, P51
   Seftor REB, 1998, CANCER RES, V58, P5681
   Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499
   Stirzaker C, 1997, CANCER RES, V57, P2229
   THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402
   TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403
   Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612
   Zhang M, 1997, CELL GROWTH DIFFER, V8, P179
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 22
TC 160
Z9 176
U1 0
U2 3
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 15
PY 2000
VL 85
IS 6
BP 805
EP 810
DI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 290DM
UT WOS:000085661000012
PM 10709100
OA Bronze
DA 2025-01-12
ER

PT J
AU Ge, K
   Duhadaway, J
   Sakamuro, D
   Wechsler-Reya, R
   Reynolds, C
   Prendergast, GC
AF Ge, K
   Duhadaway, J
   Sakamuro, D
   Wechsler-Reya, R
   Reynolds, C
   Prendergast, GC
TI Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and
   reflect deficits in programmed cell death capacity
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
ID C-MYC AMPLIFICATION; PROGNOSTIC FACTOR; CANCER; GENE; PROTEIN; DNA
AB Oncogenic activation of MYC occurs often in breast carcinoma and is associated with poor prognosis. Loss or inactivation of mechanisms that restrain MYC may therefore be involved in tumor progression. In this study, we show that the MYC-interacting adaptor protein BINI is frequently missing in malignant breast cells and that this loss is functionally significant. BINI was expressed in normal and benign cells and tissues but was undetectable in 6/6 estrogen receptor-positive or estrogen receptor-negative carcinoma cell lines examined. Similarly, complete or partial losses of BIN I were documented in 30/50 (60%) cases of malignant breast tissue analyzed by immuno-histochemistry or RT-PCR. Abnormalities in the organization of the BINI gene were apparent in only a minority of these cases, suggesting that most losses were due to epigenetic causes. Nevertheless, they were functionally significant because ectopic BINI induced programmed cell death in malignant cells lacking endogenous BINI but had no effect on the viability of benign cells. We propose that loss of BINI may contribute to breast cancer progression by eliminating a mechanism that restrains the ability of activated MYC to drive cell division inappropriately. (C) 2000 Wiley-Liss, Inc.
C1 Dupont Pharmaceut, Glenolden Lab, Glenolden, PA 19036 USA.
   Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
   Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 DuPont; The Wistar Institute; University of Pennsylvania
RP Dupont Pharmaceut, Glenolden Lab, 500 S Ridgeway Ave, Glenolden, PA 19036 USA.
EM george.c.prendergast@dupontpharma.com
RI Ge, Kai/H-2810-2019; Sakamuro, Daitoku/AGI-9632-2022
OI Ge, Kai/0000-0002-7442-5138
FU NCI NIH HHS [CA10851] Funding Source: Medline
CR ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995
   BERNS EMJJ, 1992, CANCER RES, V52, P1107
   BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504
   CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991
   DAVIS AR, 1996, CURRENT PROTOCOLS HU
   Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670
   Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Kerangueven F, 1997, CANCER RES, V57, P5469
   Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585
   Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205
   PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124
   Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727
   PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A
   Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69
   Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725
   SCHWARTZ LM, 1995, CELL DEATH
   SHIOZAWA M, 1990, GENE, V87, P299, DOI 10.1016/0378-1119(90)90317-K
   WATSON PH, 1993, J NATL CANCER I, V85, P902, DOI 10.1093/jnci/85.11.902
   Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566
   WechslerReya R, 1997, CANCER RES, V57, P3258
   WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453
NR 22
TC 80
Z9 95
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD FEB 1
PY 2000
VL 85
IS 3
BP 376
EP 383
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 271HP
UT WOS:000084588400014
PM 10652430
DA 2025-01-12
ER

PT J
AU Santarius, T
   Kirsch, M
   Nikas, DC
   Imitola, J
   Black, PM
AF Santarius, T
   Kirsch, M
   Nikas, DC
   Imitola, J
   Black, PM
TI Molecular analysis of alterations of the p18<SUP><i>INK4</i>c</SUP> gene
   in human meningiomas
SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
LA English
DT Article
DE immunohistochemistry; loss of heterozygosity; meningioma; mutation; p18;
   tumour suppressor gene
ID ALLELIC LOSS; BREAST-CANCER; P18 GENES; INHIBITOR; DELETIONS;
   IDENTIFICATION; CHROMOSOME; TUMORS; 1P32; 19Q
AB Meningiomas are common primary brain tumours frequently presenting with deleted and/or mutated NF2 gene located on 22q.1p has been reported as the second most commonly deleted chromosomal region in these neoplasms. A new member of the INK4 family of CDK inhibitors, the p18(INK4c) gene, has recently been mapped to this chromosomal arm. By virtue of its structural and functional similarities with the p16 gene, p18 has been implicated as a tumour suppressor gene in a variety of cancers. In this paper 40 human meningiomas were analysed for loss of heterozygosity (LOH) at the p18 locus, mutations and inactivating methylation of the p18 gene. LOH at D1S193, D1S463 and D1S211 microsatellite marker loci mapped to 1p32 was detected in 13 of 35 (37%), four of 20 (20%), and six of 24 (25%) tumour samples, respectively. One sample presented with homozygous deletion at D1S193. Mutational analysis using single stranded conformational polymorphism (SSCP) and direct sequencing did not detect any missense mutation but revealed a novel silent mutation, G to T, at coding nucleotide 435. Analysis of HgaI, BsaHI, ScrFI and Eco0109I restriction sites of p18 exon 1 revealed absence of inactivating methylation. Immunohistochemistry with p18 monoclonal antibody detected presence of cytoplasmic p18 staining in 21 of 22 examined samples. One sample did not stain and was shown to carry homozygous deletion at D1S193. Despite the high frequency of LOH at 1p32 microsatellite markers, the lack of genetic and epigenetic aberrations in the p18 gene together with the presence of p18 protein in all but one meningioma samples argues against the role of p18 as a tumour suppressor gene important for meningioma development.
C1 Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Neurosurg Labs, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Brain Tumor Ctr, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Surg, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Birmingham Heartlands Hosp, Dept ENT, Birmingham B9 5ST, W Midlands, England.
   Univ Birmingham, Queen Elizabeth Hosp, Dept Neurosurg, Birmingham B15 2TH, W Midlands, England.
   Tech Univ Dresden, Carl Gustav Carus Univ Klinikum, Neurochirurg Klin, D-8027 Dresden, Germany.
C3 Harvard University; Boston Children's Hospital; Harvard University;
   Brigham & Women's Hospital; Harvard University; Brigham & Women's
   Hospital; Harvard University; Harvard Medical School; Dana-Farber Cancer
   Institute; University of Birmingham; Heart of England NHS Foundation
   Trust; University of Birmingham; Technische Universitat Dresden
RP Black, PM (通讯作者)，Childrens Hosp, Dept Neurosurg, 300 Longwood Ave, Boston, MA 02115 USA.
RI Kirsch, Matthias/F-2824-2014
OI Santarius, Thomas/0000-0002-1416-9566
FU NINDS NIH HHS [1F05NS10174-01] Funding Source: Medline
CR BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411
   Blais A, 1998, BIOCHEM BIOPH RES CO, V247, P146, DOI 10.1006/bbrc.1998.8497
   GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939
   HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S
   HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945
   Iolascon A, 1996, GENE CHROMOSOME CANC, V15, P217, DOI 10.1002/(SICI)1098-2264(199604)15:4<217::AID-GCC3>3.0.CO;2-4
   JIMENEZLARA AM, 1992, CANCER GENET CYTOGEN, V63, P174
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Kawamata N, 1996, CANCER, V77, P570
   Kleihues P., 1993, HISTOLOGICAL TYPING
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011
   Lapointe J, 1996, CANCER RES, V56, P4586
   LONGSTRETH WT, 1993, CANCER, V72, P639, DOI 10.1002/1097-0142(19930801)72:3<639::AID-CNCR2820720304>3.0.CO;2-P
   LOPEZGINES C, 1993, CANCER GENET CYTOGEN, V70, P74, DOI 10.1016/0165-4608(93)90135-9
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   REIFENBERGER J, 1994, AM J PATHOL, V145, P1175
   Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#
   RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207
   SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722
   Smith DB, 1996, J INFECT DIS, V173, P727, DOI 10.1093/infdis/173.3.727
   Sulman EP, 1998, CANCER RES, V58, P3226
   VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047
   WELLENREUTHER R, 1995, AM J PATHOL, V146, P827
   YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405
   Zhu JG, 1996, ONCOGENE, V12, P1417
NR 28
TC 23
Z9 28
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0305-1846
J9 NEUROPATH APPL NEURO
JI Neuropathol. Appl. Neurobiol.
PD FEB
PY 2000
VL 26
IS 1
BP 67
EP 75
DI 10.1046/j.1365-2990.2000.00219.x
PG 9
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA 293HN
UT WOS:000085846200008
PM 10736068
DA 2025-01-12
ER

PT J
AU Graff, JR
   Gabrielson, E
   Fujii, H
   Baylin, SB
   Herman, JG
AF Graff, JR
   Gabrielson, E
   Fujii, H
   Baylin, SB
   Herman, JG
TI Methylation patterns of the E-cadherin 5′ CpG island are unstable and
   reflect the dynamic, heterogeneous loss of E-cadherin expression during
   metastatic progression
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INVASION-SUPPRESSOR FUNCTION; CARCINOMA IN-SITU; CANCER CELL-LINES;
   BREAST-CANCER; CHROMATIN STRUCTURE; DNA METHYLATION; TRANSCRIPTION
   FACTORS; TUMOR-CELLS; NUDE-MICE; GENE
AB Metastatic progression of most common epithelial tumors involves a heterogeneous, transient loss of expression of the homotypic cell adhesion protein, E-cadherin, rather than the uniform loss of a functional protein resulting from coding region mutation. Indeed, whereas E-cadherin loss may promote invasion, reexpression may facilitate cell survival within metastatic deposits. The mechanisms underlying such plasticity are unclear. We now show that the heterogeneous loss of E-cadherin expression in primary human breast cancers reflects a heterogeneous pattern of promoter region methylation, which begins early prior to invasion. In cultured human tumor cells, such heterogeneous methylation is dynamic, varying from allele to allele and shifting in relation to the tumor microenvironment. Following invasion in vitro which favors diminished E-cadherin expression, the density of promoter methylation markedly increased. When these cells were cultured as spheroids, which requires homotypic cell adhesion, promoter methylation decreased dramatically, and E-cadherin was reexpressed, These data show that the methylation associated with E-cadherin loss in human breast cancer is heterogeneous and unstable and suggest that such epigenetic plasticity may contribute to the dynamic, phenotypic heterogeneity that drives metastatic progression.
C1 Johns Hopkins Univ, Ctr Comprehens Canc, Baltimore, MD 21231 USA.
   Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Graff, JR (通讯作者)，Eli Lilly & Co, Lilly Res Labs, Lilly Corp Ctr, Drop Code 0546, Indianapolis, IN 46285 USA.
EM graff_jeremy@lilly.com
CR Bachman KE, 1999, CANCER RES, V59, P798
   Batsché E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BECKER KF, 1994, CANCER RES, V54, P3845
   Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x
   BOGHAERT ER, 1991, INT J CANCER, V47, P610, DOI 10.1002/ijc.2910470422
   Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515
   Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656
   Fujii H, 1996, CANCER RES, V56, P5260
   Graff JR, 1998, CANCER RES, V58, P2063
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596
   Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595
   HENNIG G, 1995, ONCOGENE, V11, P475
   HEPPNER GH, 1984, CANCER RES, V44, P2259
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459
   Ji XD, 1997, CELL GROWTH DIFFER, V8, P773
   Jones PA, 1996, CANCER RES, V56, P2463
   Kanai Y, 1997, INT J CANCER, V71, P355
   Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953
   Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1
   Lapidus RG, 1998, CANCER RES, V58, P2515
   LING V, 1984, J CELL PHYSIOL, P99
   Liteplo R G, 1985, Basic Life Sci, V33, P285
   MAREEL M, 1995, CANCER DETECT PREV, V19, P451
   MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623
   Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446
   MOLL R, 1993, AM J PATHOL, V143, P1731
   NICOLSON GL, 1987, CANCER RES, V47, P1473
   OKA H, 1993, CANCER RES, V53, P1696
   PASSANITI A, 1992, INT J CANCER, V51, P318, DOI 10.1002/ijc.2910510224
   Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433
   PIERCEALL WE, 1995, ONCOGENE, V11, P1319
   RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98
   Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394
   SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365
   St Croix Brad, 1997, Current Opinion in Oncology, V9, P549
   StCroix B, 1996, NAT MED, V2, P1204
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   TALMADGE JE, 1982, SCIENCE, V217, P361, DOI 10.1126/science.6953592
   TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G
   VANDENBOSSCHE GMR, 1994, INT J CANCER, V57, P73, DOI 10.1002/ijc.2910570114
   VandenBroecke C, 1996, CLIN EXP METASTAS, V14, P282, DOI 10.1007/BF00053902
   Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4
   VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M
   VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z
   Vos CBJ, 1997, BRIT J CANCER, V76, P1131, DOI 10.1038/bjc.1997.523
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
NR 55
TC 313
Z9 374
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 28
PY 2000
VL 275
IS 4
BP 2727
EP 2732
DI 10.1074/jbc.275.4.2727
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 280XA
UT WOS:000085128000068
PM 10644736
OA hybrid
DA 2025-01-12
ER

PT J
AU Rakitsky, VN
   Koblyakov, VA
   Turusov, VS
AF Rakitsky, VN
   Koblyakov, VA
   Turusov, VS
TI Nongenotoxic (epigenetic) carcinogens: Pesticides as an example. A
   critical review
SO TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS
LA English
DT Article
DE carcinogenicity; genotoxicity; tumor promotion; hepatocarcinogenic
   pesticides; endocrine disruptors; peroxisome proliferators; goitrogenic
   pesticides
ID CELL-PROLIFERATION; GENETIC TOXICITY; RISK ASSESSMENT; BREAST-CANCER;
   RAT; RECEPTOR; HUMANS; CHLOROTHALONIL; EXPRESSION; RELEVANCE
AB The following groups of pesticides are considered in this review by supposed mechanisms of their carcinogenicity: hepatocarcinogenic pesticides, pesticides - peroxisome proliferators, pesticides as endocrine disrupters, goitrogenic pesticides, pesticides producing sustained cell proliferation and some others. With very rare exceptions, pesticides do not react with DNA directly and the mechanisms of their carcinogenicity are, in general, similar to those of other nongenotoxic (epigenetic) carcinogens, namely: promotion of spontaneous initiation, cytotoxicity with sustained cell proliferation, oxidative stress, formation of activated receptors and some others. Genotoxicity of pesticides varies from its complete absence (propiconazol as an example) to a very pronounced one (captafol) with reminaing compounds in between. These two compounds demonstrate full correlation between genotoxicity and carcinogenicity (or their absence). Many pesticides give positive results in some tests for genotoxicity but these results are frequently controversial, not readily reproducible, or obtained only at toxic dose levels. The weak genotoxicity of the majority of pesticides is easily explainable by their rather severe testing before their introduction into practical use. The above mechanisms are threshold-based and therefore pesticides are regulated through NOEL/safety factor. There exist examples of lack of correlation between genotoxicity and carcinogenicity: some pesticides are genotoxic (although not strongly) but noncarcinogenic, others are considered as nongenotoxic but are strongly carcinogenic (chlorothalonil, acetochlor). The general scheme of the promoters' effect is presented in which an important role is attributed to the cytochrome P-450 induction (some pesticides are the cytochrome P-450 inducers), formation of reactive oxygen species and peroxitome proliferation. Teratogenesis Carcinog. Mutagen. 20:229-240, 2000. (C) 2000 Wiley-Liss, Inc.
C1 NN Blokhin Russian Canc Res Ctr, Moscow 115478, Russia.
   FF Erisman Moscow Res Inst Hyg, Moscow, Russia.
C3 N.N. Blokhin Russian Cancer Research Center; Erisman Federal Scientific
   Centre of Hygiene
RP NN Blokhin Russian Canc Res Ctr, Kashirskoe Shosse 24, Moscow 115478, Russia.
RI Rakitskii, V.N./O-8022-2015
OI Rakitskii, V.N./0000-0002-9959-6507
CR [Anonymous], 1991, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, V53, P179, DOI DOI 10.7705/BIOMEDICA.V25I3.1358,335-345
   ASHBY J, 1994, HUM EXP TOXICOL, V13, pS1, DOI 10.1177/096032719401300201
   Ashby J, 1996, HUM EXP TOXICOL, V15, P702, DOI 10.1177/096032719601500902
   ATTERVIL CK, 1997, TEN, V4, P69
   BRUSICK DJ, 1994, MUTAT RES, V317, P133, DOI 10.1016/0165-1110(94)90021-3
   CAPEN C, 1998, IARC SCI PUBLICATION, V147
   Cattley R.C., 1995, CIIT ACTIVITIES, V15, P1
   Cattley RC, 1998, REGUL TOXICOL PHARM, V27, P47, DOI 10.1006/rtph.1997.1163
   Cherpak V V, 1971, Vrach Delo, V10, P136
   COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890
   DYBING E, 1995, 24 IARC, P55
   FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143
   *FAO WHO, 1988, 862 FAOWHO, P35
   *FAO WHO, 1986, 782 FAOWHO, P51
   Gujaeva EL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P929
   *IARC, 1995, 24 IARC, P1
   JOHNSON DC, 1992, P SOC EXP BIOL MED, V199, P42, DOI 10.3181/00379727-199-43326
   Kaskevich L M, 1973, Vrach Delo, V6, P128
   Koblyakov VA, 1998, BIOCHEMISTRY-MOSCOW+, V63, P885
   LASH LH, 1990, DRUG METAB DISPOS, V18, P50
   LAU SS, 1990, TOXICOLOGY, V64, P291, DOI 10.1016/0300-483X(90)90122-W
   Lee SF, 1996, FREE RADICAL BIO MED, V21, P437, DOI 10.1016/0891-5849(96)00040-8
   LOESER E, 1983, FOOD CHEM TOXICOL, V21, P825, DOI 10.1016/0278-6915(83)90219-3
   MASUI T, 1986, JPN J CANCER RES, V77, P854
   MELICK RL, 1996, ENV HLTH PERSPECT S1, V104, P123
   Morozova OV, 1997, EXP TOXICOL PATHOL, V49, P483, DOI 10.1016/S0940-2993(97)80144-3
   NELSON JA, 1974, BIOCHEM PHARMACOL, V23, P447, DOI 10.1016/0006-2952(74)90436-5
   Potapov AI, 1998, REGUL TOXICOL PHARM, V28, P79, DOI 10.1006/rtph.1998.1245
   PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269
   SCRIBNER JD, 1981, CARCINOGENESIS, V2, P1235, DOI 10.1093/carcin/2.12.1235
   SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001
   TAKAGI A, 1990, CANCER LETT, V53, P33, DOI 10.1016/0304-3835(90)90007-K
   TENNANT MK, 1994, J TOXICOL ENV HEALTH, V43, P183, DOI 10.1080/15287399409531914
   TENNANT MK, 1994, J TOXICOL ENV HEALTH, V43, P197, DOI 10.1080/15287399409531915
   TOMATIS L, 1974, Z KREBSFORSCH KLIN O, V82, P25, DOI 10.1007/BF00304381
   TOMATIS L, 1994, JPN J CANCER RES, V85, P443, DOI 10.1111/j.1349-7006.1994.tb02378.x
   Turusov V. S., 1998, Voprosy Onkologii (St. Petersburg), V44, P468
   TURUSOV VS, 1973, J NATL CANCER I, V51, P983, DOI 10.1093/jnci/51.3.983
   TURUSOV VS, 1997, P 1 WORLD C SPONT AN, P19
   Umemura T, 1998, DRUG CHEM TOXICOL, V21, P57, DOI 10.3109/01480549809017851
   Vettorazzi G, 1995, TERATOGEN CARCIN MUT, V15, P313, DOI 10.1002/tcm.1770150608
   WELCH RM, 1969, TOXICOL APPL PHARM, V14, P358, DOI 10.1016/0041-008X(69)90117-3
   Wilkinson CF, 1996, REGUL TOXICOL PHARM, V24, P69, DOI 10.1006/rtph.1996.0065
   Williams GM, 1996, EXP TOXICOL PATHOL, V48, P189, DOI 10.1016/S0940-2993(96)80041-8
   Williams GM, 1997, CANCER LETT, V117, P175, DOI 10.1016/S0304-3835(97)00229-2
   WILSON NH, 1990, TOXICOL LETT, V53, P155, DOI 10.1016/0378-4274(90)90113-Z
   Wiltse J, 1996, MUTAT RES-REV GENET, V365, P3, DOI 10.1016/S0165-1110(96)90009-3
   WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648
   Xie HQ, 1997, J CELL BIOL, V137, P203, DOI 10.1083/jcb.137.1.203
   YAMASAKI H, 1992, TOXICOL LETT, V64-5, P597, DOI 10.1016/0378-4274(92)90237-E
   Yamasaki H, 1996, MUTAT RES-FUND MOL M, V353, P47, DOI 10.1016/0027-5107(95)00241-3
NR 51
TC 72
Z9 82
U1 0
U2 34
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-3211
J9 TERATOGEN CARCIN MUT
JI Teratogenesis Carcinog. Mutagen.
PY 2000
VL 20
IS 4
BP 229
EP 240
DI 10.1002/1520-6866(2000)20:4<229::AID-TCM5>3.0.CO;2-M
PG 12
WC Oncology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity; Toxicology
GA 339TT
UT WOS:000088494500005
PM 10910473
DA 2025-01-12
ER

EF